Cadmium

TOXICOLOGICAL PROFILE FOR
CADMIUM
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service
Agency for Toxic Substances and Disease Registry
September 2012
CADMIUM ii
DISCLAIMER
Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic
Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human
Services.
CADMIUM iii
UPDATE STATEMENT
A Toxicological Profile for Cadmium, Draft for Public Comment was released in September 2008. This
edition supersedes any previously released draft or final profile.
Toxicological profiles are revised and republished as necessary. For information regarding the update
status of previously released profiles, contact ATSDR at:

Division of Toxicology and Human Health Sciences (proposed)
Environmental Toxicology Branch (proposed)
1600 Clifton Road NE
Mailstop F-62
Atlanta, Georgia 30333
CADMIUM iv
This page is intentionally blank.

CADMIUM
C v
FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects
information for the toxic substances each profile describes. Each peer-reviewed profile identifies and
reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is
also presented but is described in less detail than the key studies. The profile is not intended to be an
exhaustive document; however, more comprehensive sources of specialty information are referenced.
The profiles focus on health and toxicologic information; therefore, each toxicological profile begins with
a public health statement that describes, in nontechnical language, a substance's relevant toxicological
properties. Following the public health statement is information concerning levels of significant human
exposure and, where known, significant health effects. A health effects summary describes the adequacy
of information to determine a substance's health effects. ATSDR identifies data needs that are significant
to protection of public health.
Each profile:
(A) Examines, summarizes, and interprets available toxicologic information and

epidemiologic evaluations on a toxic substance to ascertain the levels of significant human
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) Determines whether adequate information on the health effects of each substance is
available or being developed to determine levels of exposure that present a significant risk to
human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identifies toxicologic testing needed to identify the types or levels of
exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are federal, state, and local health professionals;
interested private sector organizations and groups; and members of the public.
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been
peer-reviewed. Staff of the Centers for Disease Control and Prevention and other federal scientists also
have reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel
and was made available for public review. Final responsibility for the contents and views expressed in
this toxicological profile resides with ATSDR.
Christopher J. Portier, Ph.D.
Assistant Administrator


CCADMIUM v
C
*Legislative Background
The toxicological profiles are developed under the Comprehensive Environmental Response,
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section
104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related
authorities” of the statute. This includes the preparation of toxicological profiles for hazardous
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the
most significant potential threat to human health, as determined by ATSDR and the EPA. Section
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile
for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for
substances not found at sites on the National Priorities List, in an effort to “…establish and maintain
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA
Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise
necessary to support the site-specific response actions conducted by ATSDR.
CADMIUM vii
QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation
of available toxicologic and epidemiologic information on a substance. Health care providers treating
patients potentially exposed to hazardous substances will find the following information helpful for fast
answers to often-asked questions.
Primary Chapters/Sections of Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating
patients about possible exposure to a hazardous substance. It explains a substance’s relevant
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of
the general health effects observed following exposure.
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets,
and assesses the significance of toxicity data to human health.
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length
of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are
reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical
setting. Please refer to the Public Health Statement to identify general health effects observed
following exposure.
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health
issues:
Section 1.6 How Can (Chemical X) Affect Children?
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7 Children’s Susceptibility
Section 6.6 Exposures of Children
Other Sections of Interest:

Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center

Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) Fax: (770) 488-4178
E-mail: [email protected] Internet: http://www.atsdr.cdc.gov
The following additional material can be ordered through the ATSDR Information Center:
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an

exposure history and how to conduct one are described, and an example of a thorough exposure
history is provided. Other case studies of interest include Reproductive and Developmental
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide
Toxicity; and numerous chemical-specific case studies.
CADMIUM viii
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene

(prehospital) and hospital medical management of patients exposed during a hazardous materials
incident. Volumes I and II are planning guides to assist first responders and hospital emergency
department personnel in planning for incidents that involve hazardous materials. Volume III—
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease,
injury, and disability related to the interactions between people and their environment outside the
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational
diseases and injuries, responds to requests for assistance by investigating problems of health and
safety in the workplace, recommends standards to the Occupational Safety and Health
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains
professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue,
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch,
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998
• Phone: 800-35-NIOSH.
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on
human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive,
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Referrals
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics
in the United States to provide expertise in occupational and environmental issues. Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976
• FAX: 202-347-4950 • e-mail: [email protected] • Web Page: http://www.aoec.org/.
The American College of Occupational and Environmental Medicine (ACOEM) is an association of

physicians and other health care providers specializing in the field of occupational and
environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk
Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.
CADMIUM ix
CONTRIBUTORS
CHEMICAL MANAGER(S)/AUTHOR(S):
Obaid Faroon, Ph.D. DVM

Annette Ashizawa, Ph.D.
Scott Wright, M.S.
Pam Tucker, M.D.
Kim Jenkins, B.A.
ATSDR, Division of Toxicology and Human Health Sciences (proposed), Atlanta, GA
Lisa Ingerman, Ph.D., DABT

Catherine Rudisill, B.S.
SRC Inc. (formerly known as Syracuse Research Corporation), North Syracuse, NY
THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1. Health Effects Review. The Health Effects Review Committee examines the health effects
chapter of each profile for consistency and accuracy in interpreting health effects and classifying
end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each
profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Environmental Toxicology Branch (proposed) reviews data needs
sections to assure consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.
CADMIUM x

CADMIUM xi
PEER REVIEW
A peer review panel was assembled for cadmium. The panel consisted of the following members:
1. Maryka H. Bhattacharyya, Ph.D., Senior Biochemist, Biosciences Division (BIO), Argonne

National Laboratory, Lemont, Illinois 60439,
2. Masayuki Ikeda, Ph.D., M.D., Professor, Kyoto Industrial Health Association, Kyoto, Japan
604-8472, and
3. Zahir A Shaikh, Ph.D., Professor of Pharmacology and Toxicology, Director of the Center for
Molecular Toxicology, University of Rhode Island, Kingston, Rhode Island 02881.
These experts collectively have knowledge of cadmium’s physical and chemical properties,
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and
quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation,
and Liability Act, as amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer
reviewers' comments and determined which comments will be included in the profile. A listing of the
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their
exclusion, exists as part of the administrative record for this compound.
The citation of the peer review panel should not be understood to imply its approval of the profile's final
content. The responsibility for the content of this profile lies with the ATSDR.
CADMIUM xii

CADMIUM xiii
CONTENTS
DISCLAIMER .............................................................................................................................................. ii
UPDATE STATEMENT ............................................................................................................................. iii
FOREWORD ................................................................................................................................................ v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS.................................................................... vii
CONTRIBUTORS ....................................................................................................................................... ix
PEER REVIEW ........................................................................................................................................... xi
CONTENTS............................................................................................................................................... xiii
LIST OF FIGURES .................................................................................................................................. xvii
LIST OF TABLES ..................................................................................................................................... xix
1. PUBLIC HEALTH STATEMENT .......................................................................................................... 1

1.1 WHAT IS CADMIUM? ................................................................................................................. 2
1.2 WHAT HAPPENS TO CADMIUM WHEN IT ENTERS THE ENVIRONMENT? .................... 2
1.3 HOW MIGHT I BE EXPOSED TO CADMIUM? ........................................................................ 3
1.4 HOW CAN CADMIUM ENTER AND LEAVE MY BODY? ..................................................... 4
1.5 HOW CAN CADMIUM AFFECT MY HEALTH? ...................................................................... 4
1.6 HOW CAN CADMIUM AFFECT CHILDREN?.......................................................................... 5
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO CADMIUM? ..................... 6
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED
TO CADMIUM? ............................................................................................................................ 7
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO
PROTECT HUMAN HEALTH? ................................................................................................... 7
1.10 WHERE CAN I GET MORE INFORMATION? .......................................................................... 8
2. RELEVANCE TO PUBLIC HEALTH ................................................................................................. 11

2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO CADMIUM IN THE
UNITED STATES ....................................................................................................................... 11
2.2 SUMMARY OF HEALTH EFFECTS ......................................................................................... 12
2.3 MINIMAL RISK LEVELS (MRLs) ............................................................................................ 15
3. HEALTH EFFECTS .............................................................................................................................. 45

3.1 INTRODUCTION ........................................................................................................................ 45
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE ..................................... 45
3.2.1 Inhalation Exposure .............................................................................................................. 47
3.2.1.1 Death .............................................................................................................................. 47
3.2.1.2 Systemic Effects............................................................................................................. 50
3.2.1.3 Immunological and Lymphoreticular Effects ................................................................ 94
3.2.1.4 Neurological Effects ...................................................................................................... 95
3.2.1.5 Reproductive Effects ...................................................................................................... 97
3.2.1.6 Developmental Effects ................................................................................................... 99
3.2.1.7 Cancer .......................................................................................................................... 100
3.2.2 Oral Exposure...................................................................................................................... 105
3.2.2.1 Death ............................................................................................................................ 105
3.2.2.2 Systemic Effects........................................................................................................... 106
3.2.2.3 Immunological and Lymphoreticular Effects .............................................................. 169
3.2.2.4 Neurological Effects .................................................................................................... 169
3.2.2.5 Reproductive Effects .................................................................................................... 170
3.2.2.6 Developmental Effects ................................................................................................. 174
3.2.2.7 Cancer .......................................................................................................................... 177
CADMIUM xiv
3.2.3 Dermal Exposure ................................................................................................................. 181

3.2.3.1 Death ............................................................................................................................ 181
3.2.3.2 Systemic Effects........................................................................................................... 181
3.2.3.3 Immunological and Lymphoreticular Effects .............................................................. 182
3.2.3.4 Neurological Effects ........................................................................................................ 184
3.2.3.5 Reproductive Effects ....................................................................................................... 184
3.2.3.6 Developmental Effects .................................................................................................... 184
3.2.3.7 Cancer .......................................................................................................................... 184
3.3 GENOTOXICITY ...................................................................................................................... 184
3.4 TOXICOKINETICS ................................................................................................................... 191
3.4.1 Absorption ........................................................................................................................... 192
3.4.1.1 Inhalation Exposure ..................................................................................................... 192
3.4.1.2 Oral Exposure .............................................................................................................. 193
3.4.1.3 Dermal Exposure ......................................................................................................... 196
3.4.2 Distribution ......................................................................................................................... 198
3.4.2.2 Oral Exposure .............................................................................................................. 198
3.4.2.3 Dermal Exposure ......................................................................................................... 200
3.4.3 Metabolism.......................................................................................................................... 200
3.4.4 Elimination and Excretion................................................................................................... 200
3.4.4.2 Oral Exposure .............................................................................................................. 201
3.4.4.3 Dermal Exposure ......................................................................................................... 202
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models ........... 203
3.4.5.1 Summary of Cadmium PBPK Models............................................................................. 204
3.4.5.2 Cadmium PBPK Model Comparison ........................................................................... 204
3.4.5.3 Discussion of Cadmium Models .................................................................................. 206
3.5 MECHANISMS OF ACTION ................................................................................................... 216
3.5.1 Pharmacokinetic Mechanisms ............................................................................................. 216
3.5.2 Mechanisms of Toxicity ...................................................................................................... 220
3.5.3 Animal-to-Human Extrapolations ....................................................................................... 223
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS ........................... 224
3.7 CHILDREN’S SUSCEPTIBILITY ............................................................................................ 225
3.8 BIOMARKERS OF EXPOSURE AND EFFECT ..................................................................... 230
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Cadmium ....................................... 231
3.8.2 Biomarkers Used to Characterize Effects Caused by Cadmium ......................................... 234
3.9 INTERACTIONS WITH OTHER CHEMICALS ..................................................................... 238
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE ............................................ 240
3.11 METHODS FOR REDUCING TOXIC EFFECTS ................................................................ 241
3.11.1 Reducing Peak Absorption Following Exposure ............................................................. 241
3.11.2 Reducing Body Burden ................................................................................................... 243
3.11.3 Interfering with the Mechanism of Action for Toxic Effects .......................................... 244
3.12 ADEQUACY OF THE DATABASE ..................................................................................... 246
3.12.1 Existing Information on Health Effects of Cadmium ...................................................... 246
3.12.2 Identification of Data Needs ............................................................................................ 248
3.12.3 Ongoing Studies .............................................................................................................. 258
4. CHEMICAL AND PHYSICAL INFORMATION .............................................................................. 261

4.1 CHEMICAL IDENTITY............................................................................................................ 261
4.2 PHYSICAL AND CHEMICAL PROPERTIES......................................................................... 261
CADMIUM xv
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL .......................................................... 267

5.1 PRODUCTION .......................................................................................................................... 267
5.2 IMPORT/EXPORT .................................................................................................................... 273
5.3 USE ............................................................................................................................................ 273
5.4 DISPOSAL ................................................................................................................................. 274
6. POTENTIAL FOR HUMAN EXPOSURE ......................................................................................... 277

6.1 OVERVIEW ............................................................................................................................... 277
6.2 RELEASES TO THE ENVIRONMENT ................................................................................... 281
6.2.1 Air ....................................................................................................................................... 282
6.2.2 Water ................................................................................................................................... 287
6.2.3 Soil ...................................................................................................................................... 288
6.3 ENVIRONMENTAL FATE ...................................................................................................... 290
6.3.1 Transport and Partitioning................................................................................................... 290
6.3.2 Transformation and Degradation ........................................................................................ 295
6.3.2.1 Air ................................................................................................................................ 295
6.3.2.2 Water ............................................................................................................................ 295
6.3.2.3 Sediment and Soil ........................................................................................................ 295
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT .................................. 295
6.4.1 Air ....................................................................................................................................... 296
6.4.2 Water ................................................................................................................................... 297
6.4.3 Sediment and Soil ............................................................................................................... 298
6.4.4 Other Environmental Media ................................................................................................ 300
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE ........................................ 305
6.6 EXPOSURES OF CHILDREN .................................................................................................. 319
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES .............................................. 323
6.8 ADEQUACY OF THE DATABASE ........................................................................................ 324
6.8.1 Identification of Data Needs ............................................................................................... 324
6.8.2 Ongoing Studies .................................................................................................................. 328
7. ANALYTICAL METHODS................................................................................................................ 333

7.1 BIOLOGICAL MATERIALS .................................................................................................... 333
7.2 ENVIRONMENTAL SAMPLES .............................................................................................. 335
7.3 ADEQUACY OF THE DATABASE ........................................................................................ 338
7.3.1 Identification of Data Needs ............................................................................................... 338
7.3.2 Ongoing Studies .................................................................................................................. 342
8. REGULATIONS, ADVISORIES, AND GUIDELINES..................................................................... 345
9. REFERENCES .................................................................................................................................... 351
10. GLOSSARY ...................................................................................................................................... 425
APPENDICES
A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS ............................................................. A-1
B. USER’S GUIDE .................................................................................................................................. B-1
C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS ...................................................................... C-1
D. INDEX ................................................................................................................................................ D-1
CADMIUM xvi

CADMIUM xvii
LIST OF FIGURES
2-1. Combined Chronic Oral Cadmium Intakes (μg/kg/day) and Inhalation Cadmium Exposures
(μg/m3) that Achieve a Urinary Cadmium Excretion of 0.5 μg/g Creatinine at Age 55 Years
Predicted by the Cadmium Pharmacokinetic Model and the International Commission on
Radiological Protection (ICRP) Human Respiratory Tract Model .................................................... 24
2-2. Estimates of the UCD10 from Environmental Exposure Dose-Response Studies............................... 40
2-3. Urinary Cadmium (µg/g creatinine) and Renal Cortex Cadmium Concentration (µg/g wet
tissue) Predicted by the Cadmium Pharmacokinetic Model .............................................................. 42
3-1. Levels of Significant Exposure to Cadmium - Inhalation .................................................................. 69
3-2. Levels of Significant Exposure to Cadmium - Oral ......................................................................... 131
3-3. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a

Hypothetical Chemical Substance.................................................................................................... 205
3-4. A Schematic Representation of the Nordberg-Kjellström Model..................................................... 207
3-5. A Schematic Representation of the Shank Model ............................................................................ 212
3-6. Existing Information on Health Effects of Cadmium ....................................................................... 247
6-1. Frequency of NPL Sites with Cadmium Contamination .................................................................. 278
6-2. Frequency of NPL Sites with Cadmium Compounds Contamination .............................................. 279
CADMIUM xviii

CADMIUM xix
LIST OF TABLES
2-1. Summary of Human Studies Finding Dose-Response Relationships Between Biomarkers of

Renal Dysfunction and Cadmium Exposure ...................................................................................... 33
2-2. Selected Benchmark Dose Estimations of Urinary Cadmium Levels Associated with Increases
in the Prevalence of Low Molecular Weight Proteinuria................................................................... 36
2-3. Selected Studies of Dose-Response Relationship for Cadmium-Induced Low Molecular Weight
Proteinuria .......................................................................................................................................... 39
3-1. Levels of Significant Exposure to Cadmium - Inhalation .................................................................. 51
3-2. Comparison of Lung Effects Across Intermediate-Duration Inhalation Studies ................................ 78
3-3. Severity of Respiratory Effects in Rats and Mice Exposed to Cadmium Oxide for 13 Weeks .......... 79
3-4. Summary of Occupational Exposure Studies Examining Renal Effects ............................................ 87
3-5. Guidelines for Interpreting β2-microglobulin Levels ......................................................................... 91
3-6. Levels of Significant Exposure to Cadmium - Oral ......................................................................... 107
3-7. Summary of Human Studies Examining Renal Effects .................................................................... 149
3-8. Benchmark Dose Estimations of Urinary Cadmium Levels (µg/g Creatinine) ................................ 161
3-9. Levels of Significant Exposure to Cadmium - Dermal..................................................................... 183
3-10. Genotoxicity of Cadmium In Vivo.................................................................................................. 185
3-11. Genotoxicity of Cadmium In Vitro ................................................................................................. 188
3-12. Assumed Model Parameters and Some Physiologic Parameters for the Nordberg-Kjellström
Model ............................................................................................................................................. 208
3-13. Estimated Parameters, Rate of Uptake, Rate Constants, and Biological Half-Lives in Selected
Mouse Organs After Subcutaneous and Oral Administrations of 109CdCI2 ................................... 215
3-14. Ongoing Studies on Cadmium ........................................................................................................ 259
4-1. Chemical Identity of Cadmium and Compounds ............................................................................. 262
4-2. Physical and Chemical Properties of Cadmium and Compounds .................................................... 264
5-1. Facilities that Produce, Process, or Use Cadmium ........................................................................... 268
5-2. Facilities that Produce, Process, or Use Cadmium Compounds ....................................................... 270
6-1. Releases to the Environment from Facilities that Produce, Process, or Use Cadmium.................... 283
CADMIUM xx
6-2. Releases to the Environment from Facilities that Produce, Process, or Use Cadmium
Compounds ...................................................................................................................................... 285
6-3. Mean Concentrations of Cadmium for FDA’s Total Diet Study Market Baskets 2006-1 through
2008-4 .............................................................................................................................................. 302
6-4. Geometric Mean and Selected Percentile Blood Concentrations (μg/L) of Cadmium in the
U.S. Population from 1999 to 2008 ................................................................................................. 306
6-5. Geometric Mean and Selected Percentile Urine Concentrations (Creatinine Corrected) (μg/g
Creatinine) of Cadmium in the U.S. Population from 1999 to 2008................................................ 309
6-6. Geometric Mean and Selected Percentile Urine Concentrations (μg/L) of Cadmium in the
U.S. Population from 1999 to 2008 ................................................................................................. 312
6-7. Blood Cadmium Concentrations, Geometric Means, Adjusted Proportional Change in Means,
and 95th Percentiles in New York City Adults in Population Subgroups........................................ 316
6-8. Occupations with Potential Exposure to Cadmium and Cadmium Compounds .............................. 318
6-9. Estimated Number of Workers Potentially Exposed to Various Chemicals in the Workplace in
1981–1983........................................................................................................................................ 320
6-10. Ongoing Studies on Cadmium ........................................................................................................ 329
7-1. Analytical Methods for Determining Cadmium in Biological Materials ......................................... 336
7-2. Analytical Methods for Determining Cadmium in Environmental Samples .................................... 339
7-3. Ongoing Analytical Methods Studies on Cadmium ......................................................................... 343
8-1. Regulations, Advisories, and Guidelines Applicable to Cadmium .................................................. 347

CADMIUM 1
1. PUBLIC HEALTH STATEMENT
This public health statement tells you about cadmium and the effects of exposure to it.
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the
nation. These sites are then placed on the National Priorities List (NPL) and are targeted for long-term
federal clean-up activities. Cadmium has been found in at least 1,014 of the 1,669 current or former NPL
sites. Although the total number of NPL sites evaluated for this substance is not known, the possibility
exists that the number of sites at which cadmium is found may increase in the future as more sites are
evaluated. This information is important because these sites may be sources of exposure and exposure to
this substance may be harmful.
When a substance is released either from a large area, such as an industrial plant, or from a container,
such as a drum or bottle, it enters the environment. Such a release does not always lead to exposure. You
can be exposed to a substance only when you come in contact with it. You may be exposed by breathing,
eating, or drinking the substance, or by skin contact.
If you are exposed to cadmium or cadmium compounds, many factors will determine whether you will be
harmed. These factors include the dose (how much), the duration (how long), and how you come in
contact with it. You must also consider any other chemicals you are exposed to and your age, sex, diet,
family traits, lifestyle, and state of health.
CADMIUM 2
1.1 WHAT IS CADMIUM?
Description Metal found in the earth’s crust, associated with zinc, lead, and copper
ores.
Pure cadmium is a soft, silver-white metal. Cadmium chloride and

cadmium sulfate are soluble in water.
Uses
• Manufacturing Most cadmium used in the United States is extracted as a byproduct
during the production of other metals such as zinc, lead, or copper.
Cadmium is also recovered from used batteries.
• Consumer Cadmium is used for the following:

products • batteries (83%)
• pigments (8%)
• coatings and platings (7%)
• stabilizers for plastics (1.2%)
• nonferrous alloys, photovoltaic devices, and other uses (0.8%)
For more information on the properties and uses of cadmium, see Chapters 4 and 5.
1.2 WHAT HAPPENS TO CADMIUM WHEN IT ENTERS THE ENVIRONMENT?
Sources Cadmium is emitted to soil, water, and air by non-ferrous metal mining
and refining, manufacture and application of phosphate fertilizers, fossil
fuel combustion, and waste incineration and disposal.
Cadmium can accumulate in aquatic organisms and agricultural crops.
Fate
• Air Cadmium (as oxide, chloride, and sulfate) will exist in air as particles or
vapors (from high temperature processes). It can be transported long
distances in the atmosphere, where it will deposit (wet or dry) onto soils
and water surfaces.
• Soil Cadmium and its compounds may travel through soil, but its mobility
depends on several factors such as pH and amount of organic matter,
which will vary depending on the local environment. Generally,
cadmium binds strongly to organic matter where it will be immobile in
soil and be taken up by plant life, eventually, entering the food supply.
• Water Cadmium exists as the hydrated ion or as ionic complexes with other
inorganic or organic substances. Soluble forms migrate in water.
Insoluble forms of cadmium are immobile and will deposit and absorb
to sediments.
CADMIUM 3
1.3 HOW MIGHT I BE EXPOSED TO CADMIUM?
Food and In the United States, for nonsmokers the primary source of cadmium
smoking—primary exposure is from the food supply. In general, leafy vegetables such as
sources of lettuce and spinach, potatoes and grains, peanuts, soybeans, and
exposure sunflower seeds contain high levels of cadmium, approximately 0.05–
0.12 mg cadmium/kg.
Tobacco leaves accumulate high levels of cadmium from the soil.
The national geometric mean blood cadmium level for adults is

0.38 μg/L. A geometric mean blood cadmium level of 1.58 μg/L for New
York City smokers has been reported. The amount of cadmium
absorbed from smoking one pack of cigarettes per day is about 1–
3 μg/day. Direct measurement of cadmium levels in body tissues
confirms that smoking roughly doubles cadmium body burden in
comparison to not smoking.
Air Except for people living near cadmium-emitting industries, inhalation of

cadmium is not expected to be a major concern.
Water Elevated cadmium levels in water sources in the vicinity of cadmium-

emitting industries (historical and current) have been reported. Aquatic
organisms will accumulate cadmium, possibly entering the food supply.
People who fish in local waters as a means of food should be cautious
and abide by any advisories.
Occupational Highest risk of exposure from processes involving heating cadmium-

exposure containing materials such as smelting and electroplating. Risk will vary
depending on the workplace.
Major route of exposure is through inhalation of dust and fumes or

incidental ingestion from contaminated hands, food, or cigarettes.
Exposure can be controlled through personal protective equipment,

good industrial hygiene practices, and control and reduction of cadmium
emissions.
In Chapter 6, you can find more information on how you might be exposed to cadmium.
CADMIUM 4
1.4 HOW CAN CADMIUM ENTER AND LEAVE MY BODY?
Enter your body

• Inhalation About 5–50% of the cadmium you breathe will enter your body through
your lungs.
• Ingestion A small amount of the cadmium in food and water (about 1–10%) will
enter your body through the digestive tract. If you do not have enough
iron or other nutrients in your diet, you are likely to take up more
cadmium from your food than usual.
• Dermal contact Virtually no cadmium enters your body through your skin.
Leave your body Most of the cadmium that enters your body goes to your kidney and liver
and can remain there for many years. A small portion of the cadmium
that enters your body leaves slowly in urine and feces.
Your body can change most cadmium to a form that is not harmful, but
too much cadmium can overload the ability of your liver and kidney to
change the cadmium to a harmless form.
More information on how cadmium enters and leaves the body is found in Chapter 3.
1.5 HOW CAN CADMIUM AFFECT MY HEALTH?
This section looks at studies concerning potential health effects in animal and human studies.
Workers
• Inhalation Breathing air with very high levels of cadmium can severely damage the
lungs and may cause death.
Breathing air with lower levels of cadmium over long periods of time (for
years) results in a build-up of cadmium in the kidney, and if sufficiently
high, may result in kidney disease.
Laboratory animals
• Inhalation Damage to the lungs and nasal cavity has been observed in animals
exposed to cadmium.
CADMIUM 5
Humans
• Oral Eating food or drinking water with very high cadmium levels severely
irritates the stomach, leading to vomiting and diarrhea, and sometimes
death.
Eating lower levels of cadmium over a long period of time can lead to a
build-up of cadmium in the kidneys. If the build-up of cadmium is high
enough, it will damage the kidneys.
Exposure to lower levels of cadmium for a long time can also cause bones
to become fragile and break easily.
Laboratory animals
• Oral Kidney and bone effects have also been observed in laboratory animals
ingesting cadmium.
Anemia, liver disease, and nerve or brain damage have been observed in
animals eating or drinking cadmium. We have no good information on
people to indicate what cadmium levels people would need to eat or drink
to result in these diseases, or if they would occur at all.
Cancer Lung cancer has been found in some studies of workers exposed to
cadmium in the air and studies of rats that breathed in cadmium.
The U.S. Department of Health and Human Services (DHHS) has

determined that cadmium and cadmium compounds are known human
carcinogens. The International Agency for Research on Cancer (IARC)
has determined that cadmium is carcinogenic to humans. The EPA has
determined that cadmium is a probable human carcinogen.
More information on how cadmium can affect your health is found in Chapters 2 and 3.
1.6 HOW CAN CADMIUM AFFECT CHILDREN?
This section discusses potential health effects in humans from exposures during the period from
conception to maturity at 18 years of age.
CADMIUM 6
Effects in children The health effects seen in children from exposure to toxic levels of
cadmium are expected to be similar to the effects seen in adults (kidney
and lung damage).
Harmful effects on child development or behavior have not generally been

seen in populations exposed to cadmium, but more research is needed.
A few studies in animals indicate that younger animals absorb more

cadmium than adults. Animal studies also indicate that the young are
more susceptible than adults to a loss of bone and decreased bone
strength from exposure to cadmium.
Cadmium is found in breast milk and a small amount will enter the infant’s
body through breastfeeding. The amount of cadmium that can pass to the
infant depends on how much exposure the mother may have had.
Birth defects We do not know whether cadmium can cause birth defects in people.
Studies in animals exposed to high enough levels of cadmium during

pregnancy have resulted in harmful effects in the young. The nervous
system appears to be the most sensitive target. Young animals exposed
to cadmium before birth have shown effects on behavior and learning.
There is also some information from animal studies that high enough
exposures to cadmium before birth can reduce body weights and affect
the skeleton in the developing young.
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO CADMIUM?
Do not smoke Cadmium accumulates in tobacco leaves. The national geometric mean
tobacco products blood cadmium level for adults is 0.376 μg/L. Mean blood cadmium levels
for heavy smokers have been reported as high as 1.58 μg/L.
Good occupational Occupational exposure can be controlled through personal protective

hygiene equipment, good industrial hygiene practices, and control and reduction of
cadmium emissions.
Children can be exposed to cadmium through parents who work in

cadmium-emitting industries. Therefore, good hygiene practices such as
bathing and changing clothes before returning home may help reduce the
cadmium transported from the job to the home.
Avoid cadmium Check and obey local fishing advisories before consuming fish or shellfish
contaminated areas from local waterways.
and food
Avoid hazardous waste sites.
CADMIUM 7
Proper disposal of Dispose of nickel-cadmium batteries properly. Many states have laws in
cadmium- effect that ban the disposal of batteries as municipal waste. Recycle old
containing products batteries whenever possible.
Contact your local waste and recycling authority on how to properly

dispose of paints and coatings.
Handle properly Do not allow children to play with batteries. If mishandled, batteries could
rupture.
Children may also swallow small nickel-cadmium batteries.
If your doctor finds that you have been exposed to significant amounts of cadmium, ask whether your
children might also be exposed. Your doctor might need to ask you state health department to investigate.
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO

CADMIUM?
Detecting exposure Cadmium can be measured in blood, urine, hair, or nails. Urinary
cadmium has been shown to accurately reflect the amount of cadmium in
the body.
Measuring exposure The amount of cadmium in your blood shows your recent exposure to
cadmium. The amount of cadmium in your urine shows both your recent
and your past exposure.
Cadmium levels in hair or nails are not as useful as an indication of when

or how much cadmium you may have taken in, partly because cadmium
from outside of your body may attach to the hair or nails.
Tests are also available to measure the amount of cadmium inside your
liver and kidneys.
More information on how cadmium can be measured in exposed humans is presented in Chapters 3 and 7.
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO

PROTECT HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health. Regulations
can be enforced by law. The EPA, the Occupational Safety and Health Administration (OSHA), and the
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic
substances. Recommendations provide valuable guidelines to protect public health, but cannot be
enforced by law. The Agency for Toxic Substances and Disease Registry (ATSDR) and the National
CADMIUM 8
Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop
recommendations for toxic substances.
Regulations and recommendations can be expressed as “not-to-exceed” levels. These are levels of a toxic
substance in air, water, soil, or food that do not exceed a critical value. This critical value is usually based
on levels that affect animals; they are then adjusted to levels that will help protect humans. Sometimes
these not-to-exceed levels differ among federal organizations because they used different exposure times
(an 8-hour workday or a 24-hour day), different animal studies, or other factors.
Recommendations and regulations are also updated periodically as more information becomes available.
For the most current information, check with the federal agency or organization that provides it.
Recommendations and regulations are also updated periodically as more information becomes available.
For the most current information, check with the federal agency or organization that provides it. Some
regulations and recommendations for cadmium include the following:
Drinking water The EPA has determined that exposure to cadmium in drinking water at a
concentration of 0.04 mg/L for up to 10 days is not expected to cause any
adverse effects in a child.
The EPA has determined that lifetime exposure to 0.005 mg/L cadmium in
drinking water is not expected to cause any adverse effects.
Consumer products The FDA has determined that cadmium levels in bottled water should not
exceed 0.005 mg/L.
3
Workplace air OSHA set a legal limit of 5 μg/m cadmium in air averaged over an 8-hour
work day.
More information on governmental rules regarding cadmium can be found in Chapter 8.
1.10 WHERE CAN I GET MORE INFORMATION?
If you have any more questions or concerns, please contact your community or state health or
environmental quality department, or contact ATSDR at the address and phone number below.
CADMIUM 9
ATSDR can also tell you the location of occupational and environmental health clinics. These clinics
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous
substances.
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You may
request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the toll-free information and technical
assistance number at 1-800-CDCINFO (1-800-232-4636), by e-mail at [email protected], or by writing
to:

Division of Toxicology and Human Health Sciences (proposed)
1600 Clifton Road NE
Mailstop F-62
Atlanta, GA 30333
Fax: 1-770-488-4178
Organizations for-profit may request copies of final Toxicological Profiles from the following:
National Technical Information Service (NTIS)

5285 Port Royal Road
Springfield, VA 22161
Phone: 1-800-553-6847 or 1-703-605-6000
Web site: http://www.ntis.gov/
CADMIUM 10

CADMIUM 11
2. RELEVANCE TO PUBLIC HEALTH
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO CADMIUM IN THE UNITED

STATES
Cadmium occurs in the earth’s crust at a concentration of 0.1–0.5 ppm and is commonly associated with
zinc, lead, and copper ores. It is also a natural constituent of ocean water with average levels between
<5 and 110 ng/L, with higher levels reported near coastal areas and in marine phosphates and
phosphorites. The cadmium concentration of natural surface water and groundwater is usually <1 μg/L.
Surface soil concentrations will depend on several factors such as its mobility, natural geochemistry, and
magnitude of contamination from sources such as fertilizers and atmospheric deposition. Natural
emissions of cadmium to the environment can result from volcanic eruptions, forest fires, generation of
sea salt aerosols, or other natural phenomena.
In the environment, cadmium exists in only one oxidation state (+2) and does not undergo oxidation-
reduction reactions. In surface water and groundwater, cadmium can exist as the hydrated ion or as ionic
complexes with other inorganic or organic substances. Soluble forms of cadmium can migrate in water.
Insoluble forms of cadmium will settle and adsorb to sediments. Cadmium’s fate in soil depends on
several factors such as pH of the soil and the availability of organic matter. Generally, cadmium will bind
strongly to organic matter and this will, for the most part, immobilize it. However, cadmium’s behavior
in soil will vary depending on the environmental conditions. It is not likely that cadmium will undergo
significant transformation in the atmosphere. It will exist in particulate form and sometimes vapor form
(emitted from high temperature processes) where it will undergo atmospheric transport and eventually
deposit onto soils and surface waters.
Non-ferrous metal mining and refining, manufacture and application of phosphate fertilizers, fossil fuel
combustion, and waste incineration and disposal are the main anthropogenic sources of cadmium in the
environment. Except for those who live near cadmium-emitting industries, inhalation of cadmium in the
ambient air may occur, but is not a major source of exposure. Water sources near cadmium-emitting
industries, both with historic and current operations, have shown a marked elevation of cadmium in water
sediments and aquatic organisms. Concentrations of cadmium in these polluted waters have ranged from
<1.0 to 77 μg/L. For the U.S. population, cadmium exposure through the drinking water supply is of
minor concern. Cadmium from polluted soil and water can accumulate in plants and organisms, thus
entering the food supply.
CADMIUM 12
In the United States, the largest source of cadmium exposure for nonsmoking adults and children is
through dietary intake. The estimated daily intakes of cadmium in nonsmoking adult males and females
living in the United States are 0.35 and 0.30 μg Cd/kg/day, respectively. Females generally absorb
greater amounts of cadmium in the gastrointestinal tract. In general, leafy vegetables such as lettuce and
spinach and staples such as potatoes and grains contain relatively high values of cadmium. Peanuts,
soybeans, and sunflower seeds have naturally high levels of cadmium. People who regularly consume
shellfish and organ meats (liver and kidney) have increased cadmium exposure.
Mean values of cadmium in the blood and urine of the U.S. population were reported in the National
Health and Nutrition Examination Survey (NHANES) 1999–2008. Blood cadmium tends to reflect recent
exposures and urinary cadmium reflects cumulative cadmium exposure and body burden (particularly,
kidney cadmium levels). The 20 years or older age group had geometric mean levels of blood and urine
cadmium that were slightly higher than the younger age groups (0.376 µg/L in blood and 0.232 μg/L in
urine). Females (0.331 μg/L in blood and 0.191 μg/L in urine) had slightly higher blood and urine
cadmium levels than males (0.299 μg/L in blood and 0.179 μg/L in urine).
Smoking greatly increases exposure to cadmium, as tobacco leaves naturally accumulate high amounts of
cadmium. It has been estimated that tobacco smokers are exposed to 1.7 μg cadmium per cigarette, and
about 10% is inhaled when smoked. A geometric mean blood cadmium level for a heavy smoker has
been reported as high as 1.58 μg/L, compared to the estimated national mean of 0.38 μg/L for all adults.
Nonsmokers may also be exposed to cadmium in cigarettes via second-hand smoke.
2.2 SUMMARY OF HEALTH EFFECTS
Since the early 1950s, when the hazards of occupational cadmium exposure were recognized, a large
amount of information has been generated concerning the toxic effects of cadmium exposure in humans
and laboratory animals. Toxicological properties of cadmium are similar for the several different salts
and oxides of cadmium that have been investigated, although differences in absorption and distribution
lead to different effect levels. For inhalation exposure, particle size and solubility in biological fluids (in
contrast to solubility in water) appear to be the more important determinants of the toxicokinetics. For
oral exposure, most experimental studies have used soluble cadmium, which exists as the Cd+2 ion
regardless of the initial salt. Absorption appears to be similar for cadmium ion and cadmium complexed
with proteins in food, except for a few specific types of foods such as Bluff oysters and seal meat. Also,
poorly soluble cadmium pigments may be absorbed to a lesser extent than soluble cadmium ion. For the
CADMIUM 13
general population, dietary exposure to cadmium is the most likely route of exposure. There is an
extensive database on the toxicity of cadmium in environmentally exposed populations and in cadmium
workers; however, most of these studies were focused on the presumed sensitive targets. These sensitive
targets of cadmium toxicity are the kidney and bone following oral exposure and kidney and lung
following inhalation exposure. Studies in animals support the identification of these sensitive targets and
provide some suggestive evidence that the developing organisms may also be a sensitive target. There is
also evidence to suggest that cadmium is a human carcinogen. Other effects that have been observed in
humans and/or animals include reproductive toxicity, hepatic effects, hematological effects, and
immunological effects.
The earliest indication of kidney damage in humans is an increased excretion of low molecular weight
proteins, particularly β2-microglobulin, human complex forming glycoprotein (pHC) (also referred to as
α1-microglobulin), and retinol binding protein; increased urinary levels of intracellular enzymes such as
N-acetyl-β-glucosaminidase (NAG); and increased excretion of calcium and metallothione. Numerous
studies of cadmium workers and populations living in areas with low, moderate, or high cadmium
pollution have found significant associations between urinary cadmium levels and biomarker levels or
significant increases in the prevalence of abnormal biomarker levels. At higher exposure levels,
decreases in glomerular filtration rate, increased risk of renal replacement therapy (dialysis or kidney
transplantation), and significant increases in the risk of deaths from renal disease have been observed.
The sensitivity of the kidney to cadmium is related to its distribution in the body and de novo synthesis of
metallothionein in the kidney. In the blood, cadmium is bound to metallothionein and is readily filtered at
the glomerulus and reabsorbed in the proximal tubule. Within the tubular cells, the metallothionein is
degraded in lysosomes and free cadmium is released; the synthesis of endogenous metallothionein by the
tubular cells is then stimulated. However, when the total cadmium content in the renal cortex reaches
between 50 and 300 μg/g wet weight, the amount of cadmium not bound to metallothionein becomes
sufficiently high to cause tubular damage. Free cadmium ions may inactivate metal-dependent enzymes,
activate calmodulin, and/or damage cell membranes through activation of oxygen species. Because the
toxicity of cadmium is dependent on its concentration in the kidney, adverse effects in humans are
typically not observed after shorter durations.
Acute inhalation exposure to cadmium at concentrations above about 5 mg/m3 may cause destruction of
lung epithelial cells, resulting in pulmonary edema, tracheobronchitis, and pneumonitis in both humans
and animals. A single, high-level cadmium exposure can result in long-term impairment of lung function.
At the cellular level, catalase, superoxide dismutase, non-protein sulfhydryl, glucose-6-phosphate
CADMIUM 14
dehydrogenase, and glutathione peroxidase are decreased in response to cadmium lung insults. The
respiratory response to cadmium is similar to the response seen with other agents that produce oxidative
damage. There typically is an alveolar pneumocyte type 2 cell hyperplasia in response to type 1 cell
damage and necrosis. Longer-term inhalation exposure at lower levels also leads to decreased lung
function and emphysema in cadmium workers. Some tolerance to cadmium-induced lung irritation
develops in exposed humans and animals, and respiratory function may recover after cessation of
cadmium exposure. Another effect of long-term inhalation cadmium exposure is damage to the olfactory
function and nasal epithelium. Lung damage has also been seen in a few studies of oral cadmium
exposure in rats, but the lung effects are likely to be related to liver or kidney damage and subsequent
changes in cellular metabolism.
Prolonged inhalation or ingestion exposure of humans to cadmium at levels causing renal dysfunction can
lead to painful and debilitating bone disease in individuals with risk factors such as poor nutrition; the
occurrence of these bone effects in elderly Japanese women exposed to high levels of cadmium in rice
and water was referred to as Itai-Itai disease. Decreases in bone mineral density, increases in the risk of
fractures, and increases in the risk of osteoporosis have also been observed in populations living in
cadmium-polluted areas. An association between bone effects and cadmium exposure has also been
observed in populations exposed to higher levels of cadmium, but not living in cadmium polluted areas.
Similar effects have also been observed in young rats orally exposed to cadmium. Animal data strongly
suggest that cadmium exposure results in increases in bone turnover and decreases in mineralization
during the period of rapid bone growth. Although animal studies suggest that these effects are due to
direct damage to the bone, it is likely that renal damage resulting in the loss of calcium and phosphate and
alteration in renal metabolism of vitamin D would compound these effects.
There are few human data on developmental effects from exposure to cadmium. Some studies indicate
that maternal cadmium exposure may cause decreased birth weight in humans, but most of these studies
are of limited use because of weaknesses in the study design and lack of control for confounding factors.
A number of other studies did not find a significant relationship between maternal cadmium levels and
newborn body weight. In animals, cadmium has been shown to be a developmental toxin by the
inhalation, oral, and parenteral routes. Decreased fetal weight, skeletal malformations, and delayed
ossification are produced by relatively high maternal doses (1–20 mg/kg/day) due to placental toxicity,
interference with fetal metabolism, and damage to the maternal liver. Neurodevelopmental effects have
been observed at lower doses. Impaired performance on neurobehavioral tests were observed in the
offspring of rats exposed to 0.02 mg/m3 or ≥0.04 mg/kg/day.
CADMIUM 15
The results of occupational exposure studies examining the possible association between cadmium
exposure and an increased risk of lung cancer are inconsistent, with some studies finding significant
increases in lung cancer deaths and other studies not finding increases. Interpretation of the results of
many of the studies is complicated by inadequate controls for confounding factors such as co-exposure
with other metal carcinogens and smoking, small number of lung cancer deaths, and the lack of
significant relationships between cadmium exposure and duration. For prostate cancer, initial studies in
European workers indicated an elevation in prostate cancer, but subsequent investigations found either no
increases in prostate cancer or increases that were not statistically significant. Strong evidence from
animal studies exists that cadmium inhalation can cause lung cancer, but only in rats. Most oral studies in
laboratory animals have not found significant increases in cancer incidence. The Department of Health
and Human Services concluded that there were sufficient human and animal data to conclude that
cadmium is a known human carcinogen; likewise, IARC classified cadmium as carcinogenic to humans
(Group 1). The EPA has classified cadmium as a probable human carcinogen by inhalation (Group B1),
based on its assessment of limited evidence of an increase in lung cancer in humans and sufficient
evidence of lung cancer in rats.
2.3 MINIMAL RISK LEVELS (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for cadmium. An
MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs are
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive
health effect(s) for a specific duration within a given route of exposure. MRLs are based on
noncancerous health effects only and do not consider carcinogenic effects. MRLs can be derived for
acute, intermediate, and chronic duration exposures for inhalation and oral routes. Appropriate
methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990d),
uncertainties are associated with these techniques. Furthermore, ATSDR acknowledges additional
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs. As an
example, acute inhalation MRLs may not be protective for health effects that are delayed in development
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic
CADMIUM 16
bronchitis. As these kinds of health effects data become available and methods to assess levels of
significant human exposure improve, these MRLs will be revised.
The database on the toxicity of cadmium in humans and animals following inhalation or oral exposure is
extensive. Target organs are similar among species and, in general, toxicokinetic properties after oral and
inhalation exposures are similar. Most of the human data involve chronic inhalation exposure of workers
or chronic dietary exposure of the general population or populations living in cadmium-polluted areas.
Several approaches for characterizing cadmium exposure have been used in these studies. Occupational
exposure studies have used current air concentrations or have estimated cumulative exposure based on
historical and current monitoring data. Some epidemiology studies have estimated cumulative intake
based on the levels of cadmium in rice, in populations where rice has been the dominant source of oral
exposure to cadmium. However, most studies (particularly oral studies) have used urinary cadmium
levels as a biomarker of exposure. As discussed in greater detail in Section 3.8.1, urinary cadmium levels
correlate with cadmium body burden and cadmium concentration in kidney (a critical target organ for
chronic exposure). The relationship between renal and urinary cadmium appears to be nearly linear at
chronic intakes and kidney burdens that do not produce nephrotoxicity (i.e., elimination half-time is
independent of dose). However, at high kidney cadmium burdens, associated with renal damage (>50 μg
Cd/g cortex), the elimination half-time increases with increasing severity of renal damage. Linearity in
the dose-urinary excretion relationship also does not appear to apply following an acute high exposure to
cadmium. The Nordberg-Kjellström model (described in detail in Section 3.4.5.3) is a multicompartment
pharmacokinetic model that can be used to estimate cadmium intakes (inhalation and oral exposure)
associated with a given urinary cadmium level and/or kidney cadmium burden. The model has been
extensively evaluated for predicting dose-kidney-urinary cadmium relationships within the linear range of
the dose-urinary cadmium relationship.
Inhalation MRLs
Acute-Duration Inhalation MRL
• An MRL of 3x10-5 mg Cd/m3 (0.03 μg Cd/m3) has been derived for acute-duration inhalation
exposure (<14 days) to cadmium.
The acute toxicity of airborne cadmium, particularly cadmium oxide fumes, was first recognized in the
early 1920s and there have been numerous case reports of cadmium workers dying after brief exposures
to presumably high concentrations of cadmium fumes (European Chemicals Bureau 2007). The initial
CADMIUM 17
symptoms, similar to those observed in metal fume fever, are usually mild but rapidly progress to severe
pulmonary edema and chemical pneumonitis. Persistent respiratory effects (often lasting years after the
exposure) have been reported in workers surviving these initial effects. There are limited monitoring data
for these human reports; however, Elinder (1986b) estimated that an 8-hour exposure to 1–5 mg/m3 would
be immediately dangerous.
Animal studies support the findings in humans that acute exposure to cadmium results in lung damage.
Single exposures to approximately 1–10 mg Cd/m3 as cadmium chloride or cadmium oxide resulted in
interstitial pneumonitis, diffuse alveolitis with hemorrhage, focal interstitial thickening, and edema
(Boudreau et al. 1989; Buckley and Bassett 1987b; Bus et al. 1978; Grose et al. 1987; Hart 1986;
Henderson et al. 1979; Palmer et al. 1986). Repeated exposure to 6.1 mg Cd/m3 1 hour/day for 5, 10, or
15 days resulted in emphysema in rats (Snider et al. 1973). Lower concentrations of 0.4–0.5 mg Cd/m3 as
cadmium oxide for 2–3 hours (Buckley and Bassett 1987b; Grose et al. 1987) or 0.17 mg Cd/m3 as
cadmium chloride 6 hours/day for 10 days (Klimisch 1993) resulted in mild hypercellularity and increases
in lung weight. Alveolar histiocytic infiltration and focal inflammation and minimal fibrosis in alveolar
septa were observed in rats exposed to 0.088 mg Cd/m3 as cadmium oxide 6.2 hours/day, 5 days/week for
2 weeks (NTP 1995); in similarly exposed mice, histiocytic infiltration was observed at 0.088 mg Cd/m3
(NTP 1995). At similar concentrations (0.19 or 0.88 mg Cd/m3as cadmium chloride), decreases in
humoral immune response were observed in mice exposed for 1–2 hours (Graham et al. 1978;
Krzystyniak et al. 1987). Other effects that have been reported in animals acutely exposed to cadmium
include erosion of the stomach, decreased body weight gain, and tremors in rats exposed to 132 mg Cd/m3
as cadmium carbonate for 2 hours (Rusch et al. 1986) and weight loss and reduced activity in rats exposed
to 112 mg Cd/m3 as cadmium oxide for 2 hours (Rusch et al. 1986).
The NTP (1995) study was selected as the basis of an acute duration inhalation MRL. In this study,
groups of five male and five female F344 rats were exposed to 0, 0.1, 0.3, 1, 3, or 10 mg cadmium
oxide/m3 (0, 0.088, 0.26, 0.88, 2.6, or 8.8 mg Cd/m3) 6.2 hours/day, 5 days/week for 2 weeks. The mean
median aerodynamic diameter (MMAD) of the cadmium oxide particles was 1.5 μm with a geometric
standard deviation of 1.6–1.8. The animals were observed twice daily and weighed on days 1, 8, and at
termination. Other parameters used to assess toxicity included organ weights (heart, kidney, liver, lungs,
spleen, testis, and thymus) and histopathological examination (gross lesions, heart, kidney, liver, lungs,
tracheobronchial lymph nodes, and nasal cavity and turbinates). All rats in the 8.8 mg Cd/m3 group died
by day 6; no other deaths occurred. A slight decrease in terminal body weights was observed at 2.6 mg
Cd/m3; however, the body weights were within 10% of control weights. Significant increases in relative
CADMIUM 18
and absolute lung weights were observed at 0.26 (males only), 0.88, and 2.6 mg Cd/m3. Histological
alterations were limited to the respiratory tract and consisted of alveolar histiocytic infiltrate and focal
inflammation and minimal fibrosis in alveolar septa at ≥0.088 mg Cd/m3, necrosis of the epithelium lining
alveolar ducts at ≥0.26 mg Cd/m3, tracheobronchial lymph node inflammation at ≥0.88 mg Cd/m3,
degeneration of the nasal olfactory epithelium at 0.88 mg Cd/m3, and inflammation and metaplasia of the
nasal respiratory epithelium at 2.6 mg Cd/m3.
The lowest-observed-adverse-effect level (LOAEL) of 0.088 mg Cd/m3 was selected as the point of
departure for derivation of the MRL; benchmark dose analysis was considered; however, the data were
not suitable for benchmark dose analysis because the data do not provide sufficient information about the
shape of the dose-response relationship below the 100% response level. The LOAELHEC was calculated
using the equations below.
LOAELHEC = LOAELADJ x RDDR
The duration-adjusted LOAEL (LOAELADJ) was calculated as follows:
LOAELADJ = 0.088 mg Cd/m3 x 6.2 hours/24 hours x 5 days/7 days

LOAELADJ = 0.016 mg Cd/m3
The regional deposited dose ratio (RDDR) for the pulmonary region of 0.617 was calculated with EPA’s
RDDR calculator (EPA 1994a) using the final body weight of 0.194 kg for the male rats exposed to
0.088 mg Cd/m3, the reported MMAD of 1.5 μm and the midpoint of the reported range of geometric
standard deviations (1.7).
LOAELHEC = 0.016 mg Cd/m3 x 0.617

LOAELHEC = 0.01 mg Cd/m3
The LOAELHEC was divided by an uncertainty factor of 300 (10 for the use of a LOAEL, 3 for
extrapolation from animals to humans with dosimetric adjustments, and 10 for human variability)
resulting in an acute-duration inhalation MRL of 3x10-5 mg Cd/m3 (0.03 μg Cd/m3).
CADMIUM 19
Intermediate-Duration Inhalation MRL
There are no studies examining the intermediate-duration toxicity of inhaled cadmium in humans;
however, numerous animal studies have identified several targets of cadmium toxicity. Increases in the
number of bronchioalveolar macrophages, alveolar histiocytic infiltration, degeneration or metaplasia in
the larynx, and proliferations have been observed in rats and mice exposed to 0.022 mg Cd/m3 as
cadmium oxide or cadmium chloride (Glaser et al. 1986; NTP 1995; Prigge 1978a). At higher
concentrations (>0.88 mg Cd/m3), marked inflammation and fibrosis was observed in lungs of rats
(Kutzman et al. 1986; NTP 1995). In general, these studies did not identify no-observed-adverse-effect
levels (NOAELs) for lung effects. The NTP (1995) study also found significant increases in the
incidence of inflammation of the nasal respiratory epithelium in rats exposed to 0.22 mg Cd/m3 and
degeneration of the nasal olfactory epithelium in mice exposed to 0.088 mg Cd/m3. The NTP (1995)
study did not find any histological alterations in non-respiratory tract tissues, alterations in urinalysis
parameters, or changes in blood pressure (rats only) in rats or mice. Prigge (1978a, 1978b) reported
increases in hemoglobin and hematocrit levels in rats continuously exposed to ≥0.052 mg Cd/m3;
however, this effect was not observed in the NTP (1995) studies. Reproductive effects (increased
duration of estrous cycle and decreased spermatid counts) have also been observed at higher
concentrations (0.88–1 mg Cd/m3) (Baranski and Sitarek 1987; NTP 1995).
The studies by Baranski (1984, 1985) provide suggestive evidence that the developing organism is also a
sensitive target of cadmium toxicity. Significant alterations in performance on neurobehavioral tests were
observed in the offspring of rats exposed to 0.02 mg Cd/m3 as cadmium oxide 5 hours/day, 5 days/week
for 5 months prior to mating, during a 3-week mating period, and during gestation days 1–20. No other
studies examined neurodevelopmental end points following inhalation exposure. However, the
identification of neurodevelopmental effects as a sensitive target of cadmium toxicity is supported by
several intermediate-duration animal studies finding neurodevelopmental effects including alterations in
motor activity and delays in the development of sensory motor coordination reflexes (Ali et al. 1986;
Baranski 1985; Desi et al. 1998; Nagymajtenyi et al. 1997). Other developmental effects observed in the
inhalation studies included decreases in fetal body weight in the fetuses of rats exposed to 1.7 or 0.581 mg
Cd/m3 (NTP 1995; Prigge 1978b) and mice exposed to 0.4 mg Cd/m3 (NTP 1995).
Based on the available animal data, the LOAEL of 0.022 mg Cd/m3 for lung and larynx effects in mice
(NTP 1995) and the LOAEL of 0.02 mg Cd/m3 for neurodevelopmental effects (Baranski 1984, 1985)
were evaluated as possible points of departure for the intermediate-duration inhalation MRL for cadmium.
CADMIUM 20
The LOAEL of 0.022 mg Cd/m3 identified in the NTP (1995) mouse study was considered as the point of
departure for the MRL because the NTP study provided more study details and information on particle
size distribution. Because an MRL based on this LOAEL (LOAELHEC of 1 μg Cd/m3) would be lower
than the chronic-duration inhalation MRL based on human data, an intermediate-duration inhalation MRL
was not derived.
Chronic-Duration Inhalation MRL
• An MRL of 0.01 μg Cd/m3 has been derived for chronic-duration inhalation exposure (≥1 year) to
cadmium.
Numerous studies examining the toxicity of cadmium in workers have identified the respiratory tract and
the kidney as sensitive targets of toxicity. A variety of respiratory tract effects have been observed in
cadmium workers including respiratory symptoms (e.g., dyspnea, coughing, wheezing), emphysema, and
impaired lung function. However, many of these studies did not control for smoking, and thus, the role of
cadmium in the induction of these effects is difficult to determine. Impaired lung function was reported
in several studies that controlled for smoking (Chan et al. 1988; Cortona et al. 1992; Davison et al. 1988;
Smith et al. 1976); other studies have not found significant alterations (Edling et al. 1986). The observed
alterations included an increase in residual volume in workers exposed to air concentrations of cadmium
fumes ranging from 0.008 (in 1990) to 1.53 mg/m3 (in 1975) (mean urinary cadmium level in the workers
was 4.3 μg/L) (Cortona et al. 1992); alterations in several lung function parameters (e.g., forced
expiratory volume, transfer factor, transfer coefficient) in workers exposed to 0.034–0.156 mg/m3
(Davison et al. 1988); and decreased force vital capacity in workers exposed to >0.2 mg/m3 (Smith et al.
1976). Additionally, Chan et al. (1988) found significant improvements in several parameters of lung
function of workers following reduction or cessation of cadmium exposure.
The renal toxicity of cadmium in workers chronically exposed to high levels of cadmium is well
established. Observed effects include tubular proteinuria (increased excretion of low molecular weight
proteins), decreased resorption of other solutes (increased excretion of enzymes such as NAG, amino
acids, glucose, calcium, inorganic phosphate), evidence of increased glomerular permeability (increased
excretion of albumin), increased kidney stone formation, and decreased glomerular filtration rate (GFR).
The earliest sign of cadmium-induced kidney damage is an increase in urinary levels of low molecular
weight proteins (particularly, β2-microglobulin, retinol binding protein, and pHC) in cadmium workers,
as compared to levels found in a reference group of workers or the general population (Bernard et al.
1990; Chen et al. 2006a, 2006b; Chia et al. 1992; Elinder et al. 1985a; Falck et al. 1983; Jakubowski et al.
CADMIUM 21
1987, 1992; Järup and Elinder 1994; Järup et al. 1988; Shaikh et al. 1987; Toffoletto et al. 1992;
Verschoor et al. 1987). Although increases in the excretion of low molecular weight proteins are not
diagnostic of renal damage (Bernard et al. 1997; Järup et al. 1998b), tubular proteinuria is considered an
adverse effect because it is an early change in a sequence of events which ultimately may result in
compromised renal function (Bernard et al. 1997). Most investigators consider a 10% cadmium-
associated increase in the prevalence of abnormal levels of renal biomarkers (urinary β2-microglobulin,
retinol binding protein, pHC) to be indicative of cadmium-induced renal disease in the population.
However, there is less consensus on the low molecular protein level regarded as elevated or abnormal
(cut-off point).
Several biomarkers of tubular damage have been used in occupational exposure studies; these include
β2-microglobulin, retinol binding protein, NAG, and pHC. Of these biomarkers, which differ in their
sensitivities to detect tubular damage, β2-microglobulin is the most widely used in occupational exposure
studies. In healthy humans, urinary β2-microglobulin levels are <300 μg/24 hours (approximately
300 μg/g creatinine). Four studies have estimated the prevalence of abnormal urinary β2-microglobulin
levels among cadmium workers using cut-off levels of 187–380 μg/g creatinine (Chen et al. 2006a;
Elinder et al. 1985a; Jakubowski et al. 1987; Järup and Elinder 1994). The prevalence of abnormal
urinary β2-microglobin levels was 10% among workers with urinary cadmium levels of 1.5 (≥60 years of
age) or 5 (<60 years of age) μg/g creatinine (β2-microglobulin cut-off level of 220 μg/g creatinine) (Järup
and Elinder 1994), 25% among workers with urinary cadmium levels of 2–5 μg/g creatinine (cut-off level
of 300 μg/g creatinine) (Elinder et al. 1985a), 40% among workers with urinary cadmium levels of 5–
10 μg/g creatinine (cut-off level of 187 μg/g creatinine) (Chen et al. 2006a), and 10% among workers
with urinary cadmium levels of 10–15 μg/g creatinine (cut-off level of 380 μg/g creatinine (Jakubowski et
al. 1987). A 10% prevalence of abnormal β2-microglobulin levels (cut-off level of 300 μg/g creatinine)
was also observed in workers with a cumulative blood cadmium level of 300 μg-years/L (30 years of
10 μg/L) (Jakubowski et al. 1992) or blood cadmium level of 5.6 μg/L (cumulative exposure of
691 μg-years/m3) (Järup et al. 1988).
Most of the studies reporting respiratory effects expressed cadmium exposure as air concentrations;
however, these air concentrations may not be indicative of cadmium exposure over time. For example, in
the Cortona et al. (1992) study, cadmium levels of 0.030 mg/m3 were measured in 1990 in one foundry; in
1976, the cadmium levels in this foundry were 1.53 mg/m3. Cortona et al. (1992) also reported cadmium
body burden data; the mean urinary cadmium level in the workers was 4.3 μg/L (roughly equivalent to
4 μg/g creatinine). Renal effects have been observed at similar cadmium burdens. Most studies have
CADMIUM 22
reported renal effects in workers with urinary cadmium levels of ≥5 μg/g creatinine; Järup and Elinder
(1994) found an increased prevalence of low molecular weight proteinuria in workers ≥60 years of age
with mean urinary cadmium of 1.5 μg/g creatinine. The air concentration that would result in this urinary
cadmium level would be considered a LOAEL. However, cadmium in the workplace air was not the only
source of cadmium. The workers were also exposed to other sources of cadmium (e.g., cadmium in the
diet); both sources contributed to the renal cadmium burden. Thus, in order to calculate a chronic-
duration inhalation MRL from the LOAEL identified in the Järup and Elinder (1994) study, the workers’
other sources of cadmium need to be taken into consideration; this information was not reported in the
study.
An alternative approach would be to use environmental exposure studies to establish a point of departure
for the urinary cadmium-renal response relationship and pharmacokinetic models (ICRP 1994; Kjellström
and Nordberg 1978) to predict cadmium air concentrations. As described in greater detail in the chronic
oral MRL section, a meta-analysis of available environmental exposure studies was conducted to estimate
an internal dose (urinary cadmium expressed as μg/g creatinine) corresponding to a 10% excess risk of
low molecular weight proteinuria (urinary cadmium dose, UCD10). For the inhalation MRL, the meta-
analysis also included dose-response data from three occupational exposure studies (Chen et al. 2006a,
2006b; Järup and Elinder 1994; Roels et al. 1993). Analysis of the environmental exposure studies
resulted in an estimation of a urinary cadmium level that would result in a 10% increase in the prevalence
of β2-microglobulin proteinuria (1.34 μg/g creatinine); the 95% lower confidence limit on this value was
0.5 μg/g creatinine. The UCD10 values from the occupational exposure studies were 7.50 μg/g creatinine
for the European cohorts (Järup and Elinder 1994; Roels et al. 1993) and 4.58 μg/g creatinine for the
Chinese cohort (Chen et al. 2006a, 2006b). Because the dose-response analysis using the European
environmental exposure studies provided the lowest UCD10, it was selected for derivation of the chronic-
duration inhalation MRL; the 95% lower confidence limit on this value (UCDL10) of 0.5 μg/g creatinine
was used as the point of departure for the MRL.
Deposition and clearance of inhaled cadmium oxide and cadmium sulfide particles were modeled using
the ICRP Human Respiratory Tract Model (ICRP 1994). The ICRP model simulates deposition,
retention, and absorption of inhaled cadmium particles of specific aerodynamic diameters, when specific
parameters for cadmium clearance are used in the model (ICRP 1980). Cadmium-specific parameters
represent categories of solubility and dissolution kinetics in the respiratory tract (e.g., slow, S; moderate,
M; or fast, F). Cadmium compounds are classified as follows: oxides and hydroxides, S; sulfides, halides
and nitrates, M; all other, including chloride salts, F.
CADMIUM 23
Inhalation exposures (μg/m3) to cadmium oxide or cadmium sulfide aerosols having particle diameters of
1, 5, or 10 μg (AMAD) were simulated using the ICRP model. Predicted mass transfers of cadmium from
the respiratory tract to the gastrointestinal tract (i.e., mucociliary transport) and to blood (i.e., absorption)
were used as inputs to the gastrointestinal and blood compartments of the Nordberg-Kjellström
pharmacokinetic model (Kjellström and Nordberg 1978) to simulate the kidney and urinary cadmium
levels that correspond to a given inhalation exposure.
As illustrated in Figure 2-1, an airborne cadmium concentration of 1.8–2.4 μg/m3 as cadmium oxide or
1.2–1.4 μg/m3 as cadmium sulfide would result in a urinary cadmium level of 0.5 μg/g creatinine,
assuming that there was no dietary source of cadmium. This assumption is not accurate because the diet
is a significant contributor to the cadmium body burden. Thus, inhalation exposures were combined with
ingestion intakes to estimate an internal dose in terms of urinary cadmium. The age-weighted average
intakes of cadmium in non smoking males and females in the United States are 0.35 and 0.30 μg
Cd/kg/day, respectively (0.32 μg/kg/day for males and females combined) (estimated from data in
Choudhury et al. 2001). Based on the relationship predicted between chronic inhalation exposures to
cadmium sulfide (activity median aerodynamic diameter [AMAD]=1 μm) and oral intakes that yield the
same urinary cadmium level (Figure 2-1), exposure to an airborne cadmium concentration of 0.1 μg/m3
and a dietary intake of 0.3 μg/kg/day would result in a urinary cadmium level of 0.5 μg/g creatinine.
Dividing this cadmium air concentration (0.1 μg Cd/m3) by an uncertainty factor of 3 for human
variability and a modifying factor of 3 results in chronic-duration inhalation MRL of 0.01 μg Cd/m3. The
uncertainty factor of 3 for human variability was used to account for the possible increased sensitivity of
diabetics (Åkesson et al. 2005; Buchet et al. 1990) and the modifying factor of 3 was used to account for
the lack of adequate human data, which could be used to compare the relative sensitivities of the
respiratory tract and kidneys. Although based on exposure to cadmium sulfide, the MRL would be
protective of exposure to cadmium oxide; the pharmacokinetic models predict that exposure to 0.1 μg/m3
as cadmium oxide (AMAD=1 μm) in combination with a dietary intake of 0.3 μg/kg/day would result in a
urinary cadmium level of 0.4 μg/g creatinine.
CADMIUM 24
Figure 2-1. Combined Chronic Oral Cadmium Intakes (μg/kg/day) and Inhalation
Cadmium Exposures (μg/m3) that Achieve a Urinary Cadmium Excretion of
0.5 μg/g Creatinine at Age 55 Years Predicted by the Cadmium
Pharmacokinetic Model and the International Commission on
Radiological Protection (ICRP) Human Respiratory
Tract Model*
2.5
2.0
CdO (1 μm)
CdO (5 μm)
Air (μg/m )
3
1.5
CdO (10 μm)
1.0
0.5
0.0
0.0 0.1 0.2 0.3 0.4
Oral (μg Cd/kg/day)
2.5
2.0
CdS (1 μm)
CdS (5 μm)
Air (μg/m )
3
1.5
CdS (10 μm)
1.0
0.5
0.0
0.0 0.1 0.2 0.3 0.4
Oral (μg Cd/kg/day)
*The upper panel shows simulations of inhalation exposures to cadmium oxide (AMAD=1, 5, or 10 μm); the lower
panel shows simulations of inhalation cadmium sulfide aerosols.
CADMIUM 25
Oral MRLs
Acute-Duration Oral MRL
There are no reliable studies on the acute toxicity of cadmium in humans; animal studies have identified
several targets of toxicity. High exposures (>10 mg Cd/kg/day) to cadmium chloride administered via
gavage or drinking water resulted in increases in hematological (increased hemoglobin, hematocrit, and
erythrocytes, anemia), liver (focal necrosis and degeneration), kidney (focal necrosis of tubular
epithelium), intestine (necrosis, hemorrhage, ulcers), stomach (gastritis, necrosis), neurological
(decreased motor activity), and testicular (atrophy and necrosis, loss of spermatogenic elements) effects
and decreases in body weight in rats and mice (Andersen et al. 1988; Basinger et al. 1988; Bomhard et al.
1987; Borzelleca et al. 1989; Dixon et al. 1976; Kotsonis and Klaassen 1977; Machemer and Lorke 1981;
Sakata et al. 1988; Shimizu and Morita 1990). The NOAELs for these effects ranged from 1.12 to
65.6 mg Cd/kg/day.
Developmental effects have been observed at lower cadmium doses. Delayed ossification of the sternum
and ribs was observed in the offspring of rats administered 2 mg Cd/kg/day via gavage on gestation
days 7–16; at 40 mg Cd/kg/day, fused lower limbs, decreased number of live fetuses, and increased
resorptions were observed (Baranski 1985). A significant increase in malformations was observed in the
offspring of rats administered 18.39 mg Cd/kg/day on gestation days 6–15 (Machemer and Lorke 1981);
no developmental effects were observed in the offspring of rats administered 12.5 mg Cd/kg/day via
drinking water on gestation days 6–15 (Machemer and Lorke 1981).
Although the Baranski (1985) study identified the lowest LOAEL (2 mg Cd/kg/day) following acute-
duration exposure, this study was not considered suitable for derivation of an MRL. The investigators
noted that “a retarded process of ossification of the sternum and ribs was observed after exposure to
cadmium at any of the doses used.” However, the data were not shown and the statistical significance of
the finding was not reported. Additionally, an intermediate-duration study conducted earlier by this
investigator (Baranski et al. 1983) did not find delays in ossification in the offspring of rats administered
up to 4 mg Cd/kg/day for 5 weeks prior to mating, during the 3-week mating period, and throughout
gestation.
CADMIUM 26
Because of the amount of uncertainty associated with the most sensitive end point, an acute-duration oral
MRL was not derived.
Intermediate-Duration Oral MRL
• An MRL of 0.5 μg Cd/kg/day has been derived for intermediate-duration oral exposure (15–
364 days) to cadmium.
There are limited data on the toxicity of cadmium in humans following intermediate-duration exposure.
Numerous animal studies have examined the systemic, immunological, neurological, reproductive, and
developmental toxicity of cadmium. The most sensitive systemic effect following intermediate-duration
oral exposure to cadmium appears to be damage to growing bone. Exposure to 0.2 mg Cd/kg/day as
cadmium chloride in drinking water for 3–12 months resulted in decreases in bone mineral density,
impaired mechanical strength of the lumbar spine, tibia, and femur bones, increased bone turnover, and
increased incidence of deformed or fractured lumbar spine bone in young female rats (3 weeks of age at
study initiation) (Brzóska and Moniuszko-Jakoniuk 2005d; Brzóska et al. 2004b, 2005a, 2005b, 2005c,
2010); similar findings were observed in young male rats exposed to 0.5 mg Cd/kg/day for up to
12 months (Brzóska and Moniuszko-Jakoniuk 2005a, 2005b). Decreases in bone strength were also
observed in young rats exposed to 0.8 mg Cd/kg/day as cadmium chloride in drinking water for 4 weeks
(Ogoshi et al. 1989); however, no skeletal effects were observed in adult or elderly female rats exposed to
doses >20 mg Cd/kg/day for 4 weeks (Ogoshi et al. 1989). Decreases in bone calcium were observed in
mice undergoing repeated pregnancy/lactation periods (Bhattacharyya et al. 1988b) or ovariectomized
mice (Bhaattacharyya et al. 1988c); these changes were not observed in groups not under physiological
stress.
Renal effects have been observed at higher doses than the skeletal effects. Vesiculation of the proximal
tubules was observed in rats exposed to 1.18 mg Cd/kg/day as cadmium chloride in drinking water for
40 weeks (Gatta et al. 1989). At approximately 3–8 mg Cd/kg/day, proteinuria, tubular necrosis, and
decreased renal clearance were observed in rats (Cha 1987; Itokawa et al. 1974; Kawamura et al. 1978;
Kotsonis and Klaassen 1978; Prigge 1978a). Liver necrosis and anemia (Cha 1987; Groten et al. 1990;
Kawamura et al. 1978) were observed at similar cadmium doses.
Immunological effects have been observed in studies of monkeys, rats, and mice. The observed effects
include increases in cell-mediated immune response in monkeys exposed to 5 mg Cd/kg/day as cadmium
chloride in the diet for 10 weeks (Chopra et al. 1984), decreased humoral immune response in mice
CADMIUM 27
exposed to 2.8 mg Cd/kg/day as cadmium chloride in drinking water for 3 weeks (Blakley 1985), and
greater susceptibility to lymphocytic leukemia virus in mice exposed to 1.9 mg Cd/kg/day as cadmium
chloride in drinking water for 280 days (Blakley 1986).
Neurological effects observed in rats include decreases in motor activity at 3.1 or 9 mg Cd/kg/day
(Kotsonis and Klaassen 1978; Nation et al. 1990) and increased passive avoidance at 5 mg Cd/kg/day
(Nation et al. 1984). Reproductive effects (necrosis and atrophy of seminiferous tubules, decreased sperm
count and motility) were observed in rats exposed to 8–12 mg Cd/kg/day (Cha 1987; Saxena et al. 1989).
A number of developmental effects have been observed in the offspring of rats exposed to cadmium
during gestation and lactation. Decreases in glomerular filtration rates and increases in urinary fractional
excretion of phosphate, magnesium, potassium, sodium, and calcium were observed in 60-day-old
offspring of rats administered via gavage 0.5 mg Cd/kg/day on gestation days 1–21 (Jacquillet et al.
2007). Neurodevelopmental alterations have also been observed at the low maternal doses. Delays in the
development of sensory motor coordination reflexes and increased motor activity were observed at
0.706 mg Cd/kg/day (gestation days 1–21) (Ali et al. 1986), decreased motor activity at 0.04 mg
Cd/kg/day (5–8 weeks of pre-gestation exposure, gestation days 1–21) (Baranski et al. 1983), decreased
ambulation and rearing activity and altered ECG at 14 mg Cd/kg/day (gestation days 5–15, lactation days
2–28, postnatal days 1–56) (Desi et al. 1998) or 7 mg Cd/kg/day (F2 and F3 generations) (Nagymajtenyi et
al. 1997) have been observed. Decreases in pup body weight were observed at ≥5 mg Cd/kg/day
(Baranski 1987; Gupta et al. 1993; Kostial et al. 1993; Pond and Walker 1975) and decreases in fetal body
weight or birth weight were observed at ≥2.4 mg Cd/kg/day (Petering et al. 1979; Sorell and Graziano
1990; Webster 1978; Sutou et al. 1980). Another commonly reported developmental effect was
alterations in hematocrit levels or anemia in the offspring of animals exposed to ≥1.5 mg Cd/kg/day
(Baranski 1987; Kelman et al. 1978; Webster 1978). Increases in the occurrence of malformations or
anomalies is limited to a study by Sutou et al. (1980), which reported a significant delay in ossification in
rats exposed to 10 mg Cd/kg/day.
The animal studies identify several sensitive targets of toxicity following intermediate-duration exposure
to cadmium; these include skeletal mineralization in young female rats exposed for at least 3 months to
0.2 mg Cd/kg/day (Brzóska and Moniuszko-Jakoniuk 2005d; Brzóska et al. 2004b, 2005a, 2005b, 2005c),
decreased glomerular filtration in young rats exposed during gestation to maternal doses of 0.5 mg
Cd/kg/day (Jacquillet et al. 2007), and neurodevelopmental effects following gestational exposure to
0.04 mg Cd/kg/day (Baranski et al. 1983). Although the Baranski et al. (1983) study reported the lowest
CADMIUM 28
LOAEL, it was not selected as the principal study for derivation of an intermediate-duration MRL. For
locomotor activity, a significant decrease in activity was observed in female offspring exposed to 0.04,
0.4, and 4 mg Cd/kg/day, as compared to controls; however, no significant differences were found
between the cadmium groups despite the 100-fold difference in doses. Locomotor activity was also
decreased in males exposed to 0.4 or 4 mg Cd/kg/day. For the rotorod test, a significant decrease in the
length of time the rat stayed on the rotorod was observed in males exposed to 0.04 and 0.4 mg Cd/kg/day,
but not to 4 mg Cd/kg/day and in females exposed to 0.4 and 4 mg Cd/kg/day; no differences between the
cadmium groups were observed in the males and females. The results were not well described and the
investigators did not explain the lack of dose-response of the effects or the discrepancy between genders.
The skeletal effects observed in young rats exposed to cadmium during the period of rapid skeletal growth
and mineralization was selected as the critical effect. The Brzóska and associate study (Brzóska and
Moniuszko-Jakoniuk 2005d; Brzóska et al. 2005a, 2005c) was selected as the principal study. In this
study, groups of 40 3-week-old female Wistar rats were exposed to 0, 1, 5, or 50 mg Cd/L as cadmium
chloride in drinking water for 12 months. The investigators noted that cadmium intakes were 0.059–
0.219, 0.236–1.005, and 2.247–9.649 mg Cd/kg/day in the 1, 5, and 50 mg/L groups, respectively. Using
cadmium intake data presented in a figure, cadmium intakes of 0.2, 0.5, and 4 mg Cd/kg/day were
estimated. Bone mineral density, bone mineral concentration, and mineralization area of the lumbar
spine, femur, and total skeleton (bone mineral density only) were assessed after 3, 6, 9, or 12 months of
exposure. The mechanical properties of the femur and tibia were evaluated after 12 months of exposure.
Markers for bone resorption (urinary and serum levels of C-terminal cross-linking telopeptide of type I
collagen [CTX]) and bone formation (serum osteocalcin, total alkaline phosphatase, and cortical bone and
trabecular bone alkaline phosphatase), and serum and urinary levels of calcium were also measured at 3,
6, 9, and 12 months.
No significant alterations in body weight gain or food and water consumption were observed. Significant
decreases in total skeletal bone mineral density was observed at ≥0.2 mg Cd/kg/day; the decrease was
significant after 3 months in the 4 mg Cd/kg/day group, after 6 months in the 0.5 mg Cd/kg/day group,
and after 9 months in the 0.2 mg Cd/kg/day group. Significant decreases in whole tibia and diaphysis
bone mineral density were observed at ≥0.2 mg Cd/kg/day after 12 months of exposure. At 0.2 mg
Cd/kg/day, bone mineral density was decreased at the proximal and distal ends of the femur after
6 months of exposure; diaphysis bone mineral density was not affected. At 0.5 mg Cd/kg/day, bone
mineral density was decreased at the femur proximal and distal ends after 3 months of exposure and
diaphysis bone mineral density after 6 months of exposure. At 4 mg Cd/kg/day decreases in femoral
CADMIUM 29
proximal, distal, and diaphysis bone mineral density were decreased after 3 months of exposure.
Similarly, bone mineral density was significantly decreased in the lumbar spine in the 0.2 and 0.5 mg
Cd/kg/day groups beginning at 6 months and at 3 months in the 4 mg Cd/kg/day group. Significant
decreases in the mineralization area were observed in the femur and lumbar spine of rats exposed to 4 mg
Cd/kg/day; lumbar spine bone mineral area was also affected at 0.5 mg Cd/kg/day. Significant decreases
in tibia weight and length were observed at 4 mg Cd/kg/day. In tests of the mechanical properties of the
tibia diaphysis, significant alterations in ultimate load, yield load, and displacement at load were observed
at ≥0.2 mg Cd/kg/day; work to fracture was also significantly altered at 4 mg Cd/kg/day. In the
mechanical properties compression tests of the tibia, significant alterations were observed in ultimate
load, ultimate load, and stiffness at 0.2 mg Cd/kg/day; displacement at yield and work to fracture at
≥0.5 mg Cd/kg/day; and displacement at ultimate at 4 mg Cd/kg/day. Multiple regression analysis
showed that the cadmium-induced weakness in bone mechanical properties of the tibia was primarily due
to its effects on bone composition, particularly the non-organic components, organic components, and the
ratio of ash weight to organic weight. The mechanical properties of the femur were strongly influenced
by the bone mineral density (at the whole bone and diaphysis). A significant decrease in femur length
was observed at 6 months of exposure to ≥0.2 mg Cd/kg/day; however, decreases in length were not
observed at other time points in the 0.2 or 0.5 mg Cd/kg/day groups. Femur weight was significantly
decreased at 4 mg Cd/kg/day. In tests of mechanical properties of the femur (neck and distal portions),
decreases in yield load, ultimate load, displacement at ultimate, work to fracture (neck only), and stiffness
(distal only) were observed at ≥0.2 mg Cd/kg/day. For the femoral diaphysis, significant alterations were
observed for yield load, displacement at yield, and stiffness at ≥0.2 mg Cd/kg/day. Significant decreases
in osteocalcin concentrations were observed in all cadmium groups during the first 6 months of exposure,
but not during the last 6 months. Decreases in total alkaline phosphatase levels at 4 mg Cd/kg/day,
trabecular bone alkaline phosphatase at 0.2 mg Cd/kg/day, and cortical bone alkaline phosphatase at 4 mg
Cd/kg/day were observed. CTX was decreased at ≥0.2 mg Cd/kg/day. Total urinary calcium and
fractional excretion of calcium were increased at ≥0.2 mg Cd/kg/day.
At the lowest dose tested, 0.2 mg Cd/kg/day, a number of skeletal alterations were observed including
decreases in bone mineral density in the lumbar spine, femur, and tibia, alterations in the mechanical
properties of the femur and tibia, decreases in osteocalcin levels, decreases in trabecular bone alkaline
phosphatase, and decreases in CTX. Of these skeletal end points, the decrease in bone mineral density
was selected as the critical effect because Brzóska et al. (2005a, 2005c) demonstrated that the bone
mineral density was a stronger predictor of femur and tibia strength and the risk of fractures. As
discussed in greater detail in Appendix A, available continuous models in the EPA Benchmark Dose
CADMIUM 30
Software (version 1.4.1c) were fit to data for changes in bone mineral density of the femur and lumbar
spine in female rats resulting from exposure to cadmium in the drinking water for 6, 9, or 12 months
(Brzóska and Moniuszko-Jakoniuk 2005d). The benchmark dose (BMD) and the 95% lower confidence
limit (BMDL) is an estimate of the doses associated with a change of 1 standard deviation from the
control. The BMDLsd1 derived from the best fitting models for each dataset ranged from 0.05 to 0.17 mg
Cd/kg/day. The BMDLsd1 of 0.05 mg Cd/kg/day estimated from the 9-month lumbar spine data set was
selected as the point of departure for the MRL. In young female rats, the process of intense bone
formation occurs during the first 7 months of life (the first 6 months of exposure in this study); thereafter,
the increase in bone mineral density slows. In the lumbar spine of the control group, the changes in bone
mineral density at 3–6 months, 6–9 months, and 9–12 months were 15, 4, and 1%, respectively. Thus, the
9-month data may best reflect the effect of cadmium on bone mineral density during the period of rapid
skeletal growth. The lumbar spine data was selected over the femur data set because trabecular bone,
which is abundant in the spine, appears to be more susceptible to cadmium toxicity than cortical bone.
The BMDLsd1 was divided by an uncertainty factor of 100 (10 for extrapolation from animals to humans
and 10 for human variability) resulting in an intermediate-duration oral MRL of 0.5 μg Cd/kg/day.
Chronic-Duration Oral MRL
• An MRL of 0.1 μg/kg/day has been derived for chronic-duration oral exposure (≥1 year) to
cadmium.
The database examining the chronic toxicity of cadmium following oral exposure is extensive. Although
there are some chronic studies in animals, the majority of the studies in the chronic database examine the
relationship between urinary cadmium levels (or cumulative cadmium intake) and adverse health effects
in the general population or in populations living in cadmium polluted areas. A variety of health effects
have been observed including skeletal defects (osteoporosis, increased bone fractures, decreased bone
mineral density), kidney dysfunction, and alterations in reproductive hormone levels. These
environmental exposure studies strongly support the identification of bone and kidney as the most
sensitive targets of chronic cadmium toxicity.
Bone effects, particularly osteomalacia and/or osteoporosis and increased bone fractures, were first
reported in Japanese women living in areas with heavy cadmium contamination. Chronic cadmium
exposure has been shown to play a role in this disorder, referred to as Itai-Itai disease; however, other
factors such as multiple pregnancies, poor nutrition (low calories, calcium, protein, vitamin D, and iron
intakes), and low zinc levels in food also play important roles in the etiology. Although a conclusive role
CADMIUM 31
of cadmium in Itai-Itai has not been established, several other studies have found bone defects. Observed
bone effects include increased risk of bone fractures in postmenopausal women with urinary cadmium
levels of >1 μg/day (approximately >0.7 μg Cd/g creatinine; Staessen et al. 1999), individuals (>50 years
of age) with urinary cadmium levels of >2 μg/g creatinine (Alfvén et al. 2004), and men and women
(>40 years of age) with urinary cadmium levels of 9.20 and 12.86 μg/g creatinine, respectively (Wang et
al. 2003); increased risk of osteoporosis in men (>60 years of age) with urinary cadmium levels of
≥1.5 μg/g creatinine (Alfvén et al. 2000), in males and females with urinary cadmium levels of ≥10 μg/g
creatinine (Jin et al. 2004b), in males and females (>40 years of age) with urinary cadmium levels of
9.20 and 12.86 μg/g creatinine, respectively (Wang et al. 2003), and women with renal tubular damage
(urinary NAG ≥12 IU/g creatinine) (Chen et al. 2011); and decreased bone mineral density in women
with urinary cadmium levels of >0.6 μg/g creatinine (Schutte et al. 2008), postmenopausal women with
urinary cadmium levels of >20 μg/g creatinine (Nordberg et al. 2002), postmenopausal women with
median urinary cadmium levels of 1.1 µg/g creatinine (Engström et al. 2009), and men with urinary
cadmium levels of ≥2 µg/g creatinine (Trzcinka-Ochocka et al. 2010).
Evidence of renal dysfunction in environmentally exposed populations include increases in deaths from
renal dysfunction in residents living in cadmium polluted areas of Japan (Arisawa et al. 2001, 2007b;
Iwata et al. 1991a, 1991b; Matsuda et al. 2002; Nakagawa et al. 1993; Nishijo et al. 1995, 2004a, 2006),
increases in renal replacement therapy which is indicative of severe renal dysfunction (Hellström et al.
2001), and increases in the excretion of biomarkers of renal dysfunction in association with increased
cadmium intake, increased renal cadmium concentrations, increased blood cadmium levels, and/or
increased urinary cadmium concentrations (Bandara et al. 2010; Buchet et al. 1990; Cai et al. 1990, 1992,
1998, 2001; Ferraro et al. 2010; Hayano et al. 1996; Honda et al. 2010; Horiguchi et al. 2004, 2010;
Hwangbo et al. 2011; Ishizaki et al. 1989; Izuno et al. 2000; Järup et al. 2000; Jin et al. 2002, 2004a,
2004c; Kawada et al. 1992; Kido and Nogawa 1993; Kobayashi et al. 2002a, 2009b; Monzawa et al.
1998; Nakadaira and Nishi 2003; Nakashima et al. 1997; Nogawa et al. 1989; Noonan et al. 2002;
Nordberg et al. 1997; Olsson et al. 2002; Oo et al. 2000; Osawa et al. 2001; Roels et al. 1981b; Suwazono
et al. 2006; Teeyakasem et al. 2007; Trzcinka-Ochocka et al. 2004; Uno et al. 2005; Yamanaka et al.
1998; Wu et al. 2001). The urinary excretion of several biomarkers have been shown to increase due to
cadmium-related alterations in kidney function; these biomarkers include low molecular weight proteins
(e.g., β2-microglobulin, pHC, retinol binding protein), intracellular tubular enzymes (e.g., NAG), amino
acids, high molecular weight proteins (e.g., albumin), metallothionein, and electrolytes (e.g., potassium,
sodium, calcium). Although the more severe renal effects have been observed in populations living in
highly contaminated areas (e.g., decreased glomerular filtration rate), alterations in the above biomarkers
CADMIUM 32
have been observed in areas not considered to be cadmium polluted. Alterations in these biomarker levels
appear to be the most sensitive indicator of cadmium toxicity. Many of the studies examining biomarkers
have reported significant correlations between urinary cadmium levels and biomarker levels. However,
these correlations do not provide insight into exposure levels associated with renal dysfunction. In this
MRL analysis, attention was given to dose-response studies examining the derived quantitative
relationships between cadmium exposure and the prevalence of abnormal biomarker levels. As discussed
in the inhalation MRL section, a 10% increase in the prevalence of abnormal biomarker levels
(particularly β2-microglobulin, pHC, or retinol binding protein) in association with increasing cadmium
exposure is generally considered to be indicative of cadmium-associated renal dysfunction in populations.
However, when examining the prevalence of abnormal levels, careful consideration should be given to the
response criterion (cut-off level) used in the study. A wide range of cut-off levels have been used in the
environmental exposure studies. For β2-microglobulin, the most commonly used biomarker, the cut-off
values ranged from 283 to 1,129 μg/g creatinine. A summary of environmental studies finding significant
dose-response associations between urinary cadmium (or cumulative cadmium intake) and the prevalence
of abnormal levels of urinary biomarkers of renal dysfunction is presented in Table 2-1. The adverse
effect levels range from urinary cadmium levels of 1 μg/g creatinine (Järup et al. 2000) to 9.51 μg/g
creatinine (Jin et al. 2004a).
The adverse effect levels for renal effects were similar to those observed for skeletal effects. Because the
renal effects database is stronger, it was used for derivation of a chronic-duration oral MRL for cadmium.
Several approaches were considered for derivation of the MRL: (1) NOAEL/LOAEL approach using a
single environmental exposure study finding an increased prevalence of abnormal renal effect biomarker
levels, (2) selection of a point of departure from a published benchmark dose analysis, or (3) selection of
a point of departure based on an analysis of the dose-response functions from a number of environmental
exposure studies.
In the first approach, all studies in which individual internal doses for subjects were estimated based on
urinary cadmium were considered. The Järup et al. (2000) study is selected as the principal study because
it identified the lowest adverse effect level (Table 2-1). In this study, 1,021 individuals living near a
nickel-cadmium battery factory (n=799) or employed at the factory (n=222) were examined. The mean
urinary cadmium concentrations were 0.81 μg/g creatinine in men and 0.65 μg/g creatinine in women. A
significant association was found between urinary cadmium concentrations and urinary pHC levels, after
adjustment for age; the association remained statistically significant after removal of the cadmium
workers from the analysis. The investigators estimated that a urinary cadmium level of 1 μg/g creatinine
CADMIUM 33
Table 2-1. Summary of Human Studies Finding Dose-Response Relationships

Between Biomarkers of Renal Dysfunction and Cadmium Exposure
Adverse
effect level
Effect (urinary
Population biomarker Response criterion cadmium) Reference
a
General population (Japan) Total prt 157.4 μg/g creat. (M) 2.4 μg/g creat. Suwazono et
158.5 μg/g creat. (F) al. 2006
β2M 507 μg/g creat. (M)
400 μg/g creat. (F)
NAG 8.2 μg/g creat. (M)
8.5 μg/g creat. (F)
General population β2M 283 μg/24 hours 1.92 μg/g Buchet et al.
b
(Belgium) RBP 338 μg/24 hours creat. 1990
NAG 3-6 IU/24 hours
amino acid 357 mg α-N/24 hours
calcium 4-9 mmol/24 hours
Residents in cadmium- β2M 355 μg/g creat. (M <45 years) 4–7.99 μg/g Cai et al.
c
polluted area (China) >2,500 μg/g creat. (M ≥45 years) creat. 1998
500 μg/g creat. (F)
Residents in cadmium- β2M 300 μg/g creat. ≥5 μg/g creat. Jin et al.
polluted area (China) RBP 300 μg/g creat. 2002
albumin 15 mg/g creat.
Residents in cadmium- β2M 800 μg/g creat. 9.51 μg/g Jin et al.
polluted area (China) NAG 15 U/g creat. creat. 2004a
albumin 20 mg/g creat.
Residents in cadmium- β2M 800 μg/g creat. 2–4 μg/g Nordberg et
c
polluted area (China) creat. al. 1997
Residents in cadmium- β2M 1,000 μg/g creat. 6.9 μg/g creat. Cai et al.
polluted area (Japan) 2001
Residents in cadmium- β2M 1,000 μg/g creat. (M,F) Cadmium Nogawa et
polluted area (Japan) intake: al. 1989;
150 μg/day Kido and
Nogawa
1993
Residents in cadmium- β2M 1,129 μg/g creat. (M) 4–4.9 μg/g Ishizaki et al.
c
polluted area (Japan) 1,059 μg/g creat. (F) creat. 1989;
Hayano et al.
1996
CADMIUM 34
Table 2-1. Summary of Human Studies Finding Dose-Response Relationships

Between Biomarkers of Renal Dysfunction and Cadmium Exposure
Adverse
effect level
Effect (urinary
Population biomarker Response criterion cadmium) Reference
Residents in cadmium- β2M 400 μg/g creat. 6–10 μg/g Teeyakasem
polluted area (Thailand) creat. et al. 2007
d
Residents in cadmium- pHC 7.1 mg/g creat. (M) 1 μg/g creat. Järup et al.
polluted area (includes 5.3 mg/g creat. (F) 2000
occupationally exposed
subjects (Sweden)
a
Mean urinary cadmium level
b
>10% prevalence of abnormal β2-microglobulin, retinal binding protein, amino acid, and calcium values at 3.05,
2.87, 2.74, 4.29, or 1.92 μg/24 hours, respectively.
c
Urinary cadmium level associated with an approximate doubling of prevalence of abnormal β2-microglobulin levels
d
The European Chemicals Bureau (2007) recalculated this value (using raw data from Järup et al. 2000) to account
for differences in age of the reference population and study population; based on these recalculations, a doubling of
the probability of abnormal pHC values would occur at 2.62 μg/g creatinine for the total population and a 0.5 μg/g
creatinine for the environmentally exposed population.
AAP = alanine aminopeptidase; β2M = β2-microglobulin; creat. = creatinine; F = female; M = male; NAG = N-acetyl-
β-glucosaminidase; pHC = human complex-forming glycoprotein, also referred to as α1M; RBP = retinol binding
protein
CADMIUM 35
would be associated with a 10% increase in the prevalence of abnormal pHC levels above background
prevalence (approximately a 10% added risk). However, the European Chemicals Bureau (2007)
recalculated the probability of HC proteinuria because the reference population and the study population
were not matched for age (40 versus 53 years, respectively). They estimated that the probability of HC
proteinuria (13%) would be twice as high as the reference population at a urinary cadmium concentration
of 0.5 μg/g creatinine.
The second approach involves the evaluation of eight published benchmark dose analyses. The
benchmark doses and the lower 95% confidence interval of the benchmark dose (BMDL) for low
molecular weight proteinuria are presented in Table 2-2 (benchmark doses and BMDLs for all effect
parameters are presented in Table 3-8 in the toxicological profile). The BMDL values corresponding to a
10% increase in the prevalence of low molecular weight proteinuria above background (excess risk)
ranged from 0.7 μg/g creatinine (Uno et al. 2005) to 9.9 μg/g creatinine (Kobayashi et al. 2006). Both
studies examined populations living in non-cadmium polluted areas of Japan and used β2-microglobulin
as the effect biomarker. The large difference in cut-off values (233 versus 784 μg/g creatinine) likely
contributed to the order of magnitude difference in BMDLs. The BMDL10 of 0.7 μg/g creatinine is
supported by the Suwazono et al. (2006) benchmark dose analysis, which found a similar BMDL10
(0.81 μg/g creatinine) using pHC as the effect biomarker. The Uno et al. (2005) study examined 410 men
and 418 women (aged 40–59 years) living in three areas of Japan without any known environmental
cadmium pollution. Mean urinary cadmium concentrations were 1.3 and 1.6 μg/g creatinine in men and
women, respectively. Cut-off levels for β2-microglobulin were 233 and 274 μg/g creatinine in males and
females; these values represent the 84% upper limit values calculated from the target population assuming
a log normal distribution.
The third approach involved a meta-analysis of selected environmental exposure dose-response studies.
Studies were selected for inclusion in this analysis based on the following qualitative criteria: (1) the
study measured urinary cadmium as indicator of internal dose; (2) the study measured reliable indicators
of low molecular weight (LMW) proteinuria; (3) a dose-response relationship was reported in sufficient
detail so that the dose-response function could be reproduced independently; (4) the study was of
reasonable size to have provided statistical strength to the estimates of dose-response model parameters
(i.e., most studies selected included several hundred to several thousand subjects); and (5) major co-
variables that might affect the dose-response relationship (e.g., age, gender) were measured or constrained
by design and included in the dose-response analysis. No attempt was made to weight selected studies for
quality, statistical power, or statistical uncertainty in dose-response parameters. Studies using a cut-off
CADMIUM 36
Table 2-2. Selected Benchmark Dose Estimations of Urinary Cadmium

Levels Associated with Increases in the Prevalence of
Low Molecular Weight Proteinuria
Study Effect Response BMD 5% BMR 10% BMR

population biomarker criterion model BMD BMDL BMD BMDL Reference
General pHC 6.8 mg/g creat. Profile 0.63 (F) 0.49 (F) 1.05 (F) 0.81 (F) Suwazono
population (95% cut-off)a likelihood et al. 2006
(Sweden) method
Residents in β2M 507 μg/g creat. (M) Quantal 1.5 (M) 1.2 (M) 3.1 (M) 2.5 (M) Shimizu et
cadmium- 400 μg/g creat. (F) linear 1.4 (F) 1.1 (F) 2.9 (F) 2.3 (F) al. 2006
polluted and (84% cut-off)b model
non-polluted 994 μg/g creat. (M) 2.3 (M) 1.8 (M) 4.7 (M) 3.7 (M)
areas (Japan)
784 μg/g creat. (F) 1.7 (F) 1.4 (F) 3.5 (F) 2.9 (F)
(95% cut-off)c
Residents in β2M 915.5 µg/g creat. Profile 4.0 (M) 3.5 (M) Not calculated Suwazono
cadmium- (M) likelihood 4.0 (F) (3.7 )F) et al. 2011b
pollutedd and 897.1 µg/g creat. method
nonpolluted (F)
areas (Japan) (95% cut-off)e
General β2M 507 μg/g creat. (M) Log- 2.9 (M) 2.4 (M) 5.0 (M) 4.0 (M) Kobayashi
population 400 μg/g creat. (F) logistic 3.8 (F) 3.3 (F) 6.6 (F) 5.5 (F) et al. 2006
(Japan) (84% cut-off)f model
994 μg/g creat. (M) 6.4 (M) 4.5 (M) 10.2 (M) 7.1 (M)
784 μg/g creat. (F) 8.7 (F) 7.3 (F) 12.0 (F) 9.9 (F)
(95% cut-off)g
General β2M 492 µg/g creat. (M) Multiple 3.0 (M) 2.7 (M) 5.0 (M) 4.6 (M) Kobayashi
population 407 µg/g creat. (F) logistic 3.4 (F) 3.2 (F) 5.7 (F) 5.4 (F) et al. 2008a
(Japan) (84% cut-off)h model
965 µg/g creat. (M) 4.9 (M) 4.5 (M) 7.4 (M) 6.8 (M)
798 µg/g creat. (F) 5.9 (F) 5.6 (F) 8.6 (F) 8.1 (F)
(97.5% cut-off)i
General β2M 708 µg/g creat. (M) Profile 3.4 (M) 2.6 (M) Not calculated Suwazono
population 415 µg/g creat. (F) likelihood 1.7 (F) 1.4 (F) et al. 2011c
(Japan) (95% cut-off)j method
CADMIUM 37
Table 2-2. Selected Benchmark Dose Estimations of Urinary Cadmium

Levels Associated with Increases in the Prevalence of
Low Molecular Weight Proteinuria

General β2M 233 μg/g creat. (M) Quantal 0.5 (M) 0.4 (M) 1.0 (M) 0.7 (M) Uno et al.
population 274 μg/g creat. (F) linear 0.9 (F) 0.8 (F) 1.8 (F) 1.3 (F) 2005
(Japan) (84% cut-off)k model
Residents in β2M 800 μg/g creat. Quantal 5.86 (M) 4.74 (M) Jin et al.
cadmium (95% cut-off)l linear 9.98 (F) 8.47 (F) 2004c
highly, or RBP 0.300 mg/g creat. logistic 5.99 (M) 4.87 (M)
moderately (95% cut-off)l regression 9.03 (F) 7.63 (F)
polluted area model
(China)
a th
95 percentile of effect biomarkers on the “hypothetical” control distribution at a urinary cadmium level of zero.
b
84% upper limit values from a group of 424 males and 1,611 females who did not smoke and lived in three different
cadmium nonpolluted areas.
c
d
Same population of residents living in polluted area as Shimizu et al. (2006).
e th
95 percentile calculated by benchmark model at no cadmium exposure (urinary cadmium equal to zero), adjusted
to mean age.
f
84% upper limit value of the target population of people who have not smoked.
g
h th
84 percentile level in subjects from nonpolluted areas.
i th
97.5 percentile level in subjects from nonpolluted areas.
j th
to mean age.
k
84% upper limit value of the target population.
l
95% upper limit value from a control group 98 males and 155 females living in a cadmium nonpolluted area.
BMD = benchmark dose; BMDL = benchmark dose low; BMR = benchmark response; β2M = β2-microglobulin;
creat. = creatinine; F = female; M = male; NAG = N-acetyl-β-D-glucosaminidase;
NAG-B = N-acetyl-β-D-glucosaminidase’s isoform B; RBP = retinol binding protein
CADMIUM 38
value for β2-microglobulin of ≥1,000 μg/g creatinine were eliminated from the analysis based on the
conclusions of Bernard et al. (1997) that urinary β2-microglobulin levels of 1,000–10,000 μg/g creatinine
were indicative of irreversible tubular proteinuria, which may lead to an age-related decline in GFR.
Additionally, an attempt was made to avoid using multiple analyses of the same study population.
The individual dose-response functions from each study were implemented to arrive at estimates of the
internal dose (urinary cadmium expressed as μg/g creatinine) corresponding to probabilities of 10%
excess risk of low molecular weight proteinuria (urinary cadmium dose, UCD10). Estimates were derived
from the seven environmental exposure studies listed in Table 2-3. When available, male and female data
were treated separately; thus, 11 dose-response relationships were analyzed. For studies that did not
report the UCD10, the value was estimated by iteration of the reported dose response relationship for
varying values of urinary cadmium, until an excess risk of 10% was achieved:
P(d ) − P(0)
ER =
1 − P ( 0)
where ER is the excess risk, P(d) is the probability of low molecular weight proteinuria associated with a
given internal (i.e., urinary cadmium) dose, and P(0) is the background probability (i.e., the probability
predicted by the dose-response model when urinary cadmium was zero). For studies that reported the
dose-response relationship graphically, but did not report the actual dose-response function, a function
was derived by least squares fitting based on data from a digitization of the graphic.
Aggregate UCD10 estimates and the estimates stratified by location (i.e., Europe, Japan, China) are
presented in Figure 2-2. The lowest UCD10 (1.34 μg/g creatinine) was estimated from the European
database and the 95% lower confidence limit on this UCD10 (UCDL10) of 0.5 μg/g creatinine was
considered as a potential point of departure for the MRL.
Points of departure selected using the three different approaches are similar: 0.5 μg/g creatinine from the
Järup et al. (2000) study (using the European Chemicals Bureau 2007 recalculation), 0.7 μg/g creatinine
from the Uno et al. (2005) benchmark dose analysis, and 0.5 μg/g creatinine from the dose-response
analysis. The third approach (meta-analysis of environmental exposure studies) was selected for the
derivation of the MRL because it uses the whole dose-response curves from several studies rather than
data from a single study.
CADMIUM 39
Table 2-3. Selected Studies of Dose-Response Relationship for Cadmium-

Induced Low Molecular Weight Proteinuria
Dose- UCD10
Effect Response response (μg/g
Reference Population Number biomarker criterion model creat.)
a
Buchet et al. General population 1,699 M β2M 283 μg/24 hours Logistic 2.51 M
1990 (Belgium) 2,080 F 1.44 F
Suwazono et al. General population 790 F pHC 3.6 U/g creat. Logistic 0.81
2006 (Sweden)
Järup et al. 2000 Residents in 1,465 pHC 7.1 mg/g creat. M Logistic 0.6
cadmium polluted M,F 5.3 mg/g creat. F
area (Sweden)
Kobayashi et al. General population 1,114 M β2M 507 μg/g creat. M Log-logistic 5.0 M
2006 (Japan) 1,664 F 400 μg/g creat. F 6.6 F
Shimizu et al. Residents in 1,865 M β2M 507 μg/g creat. M Log-logistic 5.1 M
2006 cadmium polluted 1,527 F 400 μg/g creat. F 4.2 F
and non-polluted
areas (Japan)
Jin et al. 2004c Residents in 790 M,F β2M 800 μg/g creat. Logistic 9.5 M
cadmium polluted 15.4 F
or non-polluted
area (China)
b
Wu et al. 2001 Residents in 247 M,F β2M 800 μg/g creat. M Linear 3.75
cadmium polluted 900 μg/g creat. F
area (China)
a
Digitized from Figure 2 in Lauwerys et al. 1991
b
Digitized from Figure 2 in Wu et al. 2001
β2M = β2-microglobulin; creat. = creatinine; F = female; M = male; pHC = human complex-forming glycoprotein (also
referred to as α1-microglobulin); UCD10 = urinary cadmium level corresponding to a probability of 10% excess risk of
low molecular weight proteinuria
CADMIUM 40
Figure 2-2. Estimates of the UCD10 from Environmental Exposure Dose-Response

Studies*
18
UCD10 (μg/g creatinine)
16
(3)
14
Gen, Europe
12
Gen, Japan
10
Gen, China
8 (4) (11)
Gen, Europe, Japan
6 (9)
Gen, All
4 (4)
2
0
0 1 2 3 4 5 6
*Estimates of urinary cadmium concentrations (μg/g creatinine) associated with a 10% excess risk of urinary
β2-microglobulin (UCD10) using data from European, Japanese, and Chinese studies. For the aggregate of studies
(plot #4), the mean (-), median (▪), and 95% confidence intervals (CI) on the median are shown. All other plots show
the mean and 95% CI on the mean. Numbers in parenthesis are the number of estimates of the UCD10.
CADMIUM 41
The UCDL10 of 0.5 μg/g creatinine was transformed into estimates of chronic cadmium intake (expressed
as μg Cd/kg/day) that would result in the UCDL10 at age 55 (approximate age of peak cadmium
concentration in the renal cortex associated with a constant chronic intake; Figure 2-3). The dose
transformations were achieved by simulation using a modification of the Nordberg-Kjellström model
(Kjellström and Nordberg 1978). The following modifications (Choudhury et al. 2001; Diamond et al.
2003) were made to the model: (1) the equations describing intercompartmental transfers of cadmium
were implemented as differential equations in Advanced Computer Simulation Language (acslXtreme,
version 2.4.0.9); (2) growth algorithms for males and females and corresponding organ weights
(O’Flaherty 1993) were used to calculate age-specific cadmium concentrations from tissue cadmium
masses; (3) the cadmium concentration in renal cortex (RC, μg/g) was calculated as follows:
K
RC = 1.5 ⋅
KW
where K is the age-specific renal cadmium burden (μg) and KW is the age-specific kidney wet weight (g)
(Friberg et al. 1974).
(4) the rate of creatinine excretion (e.g., Crur, g creatinine/day) was calculated from the relationship
between lean body mass (LBM) and Crur; and (5) absorption of ingested cadmium was assumed to be
5% in males and 10% in females. The rate of creatinine excretion (e.g., Crur, g creatinine/day) was
estimated from the relationship between LBM (kg) and Crur:
LBM = 27.2 ⋅ Crur + 8.58
where the constants 27.2 and 8.58 are the sample size-weighted arithmetic mean of estimates of these
variables from eight studies reported in (Forbes and Bruining 1976). Lean body mass was estimated as
follows (ICRP 1981):
LBM = BW ⋅ 0.85,adult females

LBM = BW ⋅ 0.88,adult males
where the central tendency for adult body weight for males and females were assumed to be 70 and 58 kg
for adult European/American males and females, respectively.
CADMIUM 42
Figure 2-3. Urinary Cadmium (µg/g creatinine) and Renal Cortex Cadmium
Concentration (µg/g wet tissue) Predicted by the Cadmium
Pharmacokinetic Model*
*Shown is a simulation of peak renal cadmium concentration (at age 55) in females based on a chronic intake of
0.33 µg Cd/kg/day.
CADMIUM 43
Dose units expressed as cadmium intake (μg/kg/day), urinary cadmium excretion (μg/g creatinine), or
kidney tissue cadmium (μg/g cortex) were interconverted by iterative pharmacokinetic model simulations
of constant intakes for the life-time to age 55 years, the age at which renal cortex cadmium concentrations
are predicted to reach their peak when the rate of intake (μg/kg/day) is constant.
The dietary cadmium intakes which would result in urinary cadmium levels of 1.34 and 0.5 μg/g
creatinine (UCD10 and UCDL10) are 0.97 and 0.33 μg/kg/day in females and 2.24 and 0.70 μg/kg/day in
males. The dietary concentration associated with the UCDL10 in females (0.33 μg/kg/day) was divided by
an uncertainty factor of 3 for human variability resulting in a chronic-duration oral MRL of 0.1 μg/kg/day
(1x10-4 mg Cd/kg/day). The UCD is based on several large-scale environmental exposure studies that
likely included sensitive subpopulations; however, there is concern that individuals with diabetes may be
especially sensitive to the renal toxicity of cadmium (Åkesson et al. 2005; Buchet et al. 1990) and
diabetics were excluded from a number of the human studies, and thus, an uncertainty factor of 3 was
used.
The urinary cadmium point of departure used as the basis of the MRL (0.5 μg/g creatinine) is
approximately 2-fold higher than the geometric mean urinary cadmium concentrations in the United
States, which is 0.247 μg/g creatinine for adults 20 years and older (CDC 2011). The MRL of
0.1 μg/kg/day is lower than the estimated age-weighted cadmium intake of 0.3 μg/kg/day (estimated from
data in Choudhury et al. 2001). Because this intake is derived from the cadmium dietary exposure model
which estimates food cadmium concentrations from national survey data and food consumption patterns,
it should not be considered a precise value. A better comparison would be between the mean urinary
cadmium concentration in adults living in the United States (0.247 μg/g creatinine) and the MRL
expressed as a urinary cadmium concentration (0.2 μg/g creatinine).
CADMIUM 44

CADMIUM 45
3. HEALTH EFFECTS
3.1 INTRODUCTION
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and
other interested individuals and groups with an overall perspective on the toxicology of cadmium. It
contains descriptions and evaluations of toxicological studies and epidemiological investigations and
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
The form of cadmium and the route of exposure can greatly affect the absorption and distribution of
cadmium to various target sites, and therefore, the concentration at the target site and the severity of the
observed effect. The mechanism of action, however, involves the cadmium cation’s effect on the target
site, and the cation is the same regardless of the anionic species. For inhaled cadmium compounds, the
size of the cadmium particle (i.e., fume or aerosol) can also affect the absorption and distribution. For
oral exposures, cadmium chloride is most often tested in animal studies because of its high water
solubility and the resulting high concentrations of cadmium delivered to target sites. Studies on cadmium
bound to metallothionein are also of interest because cadmium-metallothionein complexes may have
different toxic profiles and are found in relatively high levels in organ meats (e.g., liver and kidney).
Cadmium oxide and cadmium carbonate, which are relatively insoluble in water (but may dissolve at
gastric pH), appear to be similar in absorption and toxicity to soluble cadmium. There are fewer studies
available on other forms of cadmium including insoluble forms in water such as cadmium sulfide (a
yellow pigment) and cadmium selenium sulfide (a red pigment), and a soluble form, cadmium sulfate,
which is less soluble in a closed air system where there is a limited amount of dissolved carbon dioxide.
Chapter 4 lists the chemical and physical properties of several cadmium compounds.
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE
To help public health professionals and others address the needs of persons living or working near
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation,
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive,
developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure
periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).
CADMIUM 46
3. HEALTH EFFECTS
Levels of significant exposure for each route and duration are presented in tables and illustrated in
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.
LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress
or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death,
or those whose significance to the organism is not entirely clear. ATSDR acknowledges that a
considerable amount of judgment may be required in establishing whether an end point should be
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be
insufficient data to decide whether the effect is indicative of significant dysfunction. However, the
Agency has established guidelines and policies that are used to classify these end points. ATSDR
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is
considered to be important because it helps the users of the profiles to identify levels of exposure at which
major health effects start to appear. LOAELs or NOAELs should also help in determining whether or not
the effects vary with dose and/or duration, and place into perspective the possible significance of these
effects to human health.
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and
figures may differ depending on the user's perspective. Public health officials and others concerned with
appropriate actions to take at hazardous waste sites may want information on levels of exposure
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no
adverse effects (NOAELs) have been observed. Estimates of levels posing minimal risk to humans
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of cadmium are
indicated in Tables 3-1 and 3-6 and Figures 3-1 and 3-2. Because cancer effects could occur at lower
exposure levels, Figure 3-1 also shows a range for the upper bound of estimated excess risks, ranging
from a risk of 1 in 10,000 to 1 in 10,000,000 (10-4 to 10-7), as developed by EPA.
A User's Guide has been provided at the end of this profile (see Appendix B). This guide should aid in
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
CADMIUM 47
3. HEALTH EFFECTS
3.2.1 Inhalation Exposure
The information in this section on health effects of inhalation exposure to cadmium in humans is derived
from studies of workers exposed to cadmium fume or dusts in industries such as smelting, battery
manufacturing, soldering, and pigment production. Adverse effects of human exposure to cadmium were
first established among workers in a cadmium battery factory (Friberg 1950). Workers are exposed
occupationally to cadmium primarily by inhalation of fumes or dust. Some gastrointestinal tract exposure
may also occur when dust is removed from the lungs by mucociliary clearance and subsequently
swallowed, or by ingestion of dust on hands, cigarettes, or food (Adamsson et al. 1979). In experiments
with animals, some ingestion may also occur from inhalation exposures by mucociliary clearance or from
animal grooming. The primary form of cadmium in occupational exposures is cadmium oxide.
Experimental studies in laboratory animals have used cadmium oxide, cadmium chloride, and
occasionally other forms of cadmium such as cadmium sulfide and cadmium sulfate. In general, the
different forms of cadmium have similar toxicological effects by the inhalation route, although
quantitative differences may exist from different absorption and distribution characteristics, particularly
for the less soluble cadmium pigments such as cadmium sulfide and cadmium selenium sulfide (Buckley
and Bassett 1987b; Klimisch 1993; Oldiges and Glaser 1986; Oldiges et al. 1989; Rusch et al. 1986).
Smokers inhale cadmium, but studies of cadmium exposure in the general population are considered in
Section 3.2.2 because the primary route of exposure for the general population is through the diet. Also,
the many other toxic compounds in cigarette smoke make it difficult to attribute specific adverse effects
of smoking to the inhalation of cadmium.
3.2.1.1 Death
Numerous studies have shown that acute inhalation exposure to cadmium can cause death in humans and
animals. In humans, several fatal inhalation exposures have occurred in occupational accidents. During
the acute exposure, the general symptoms are relatively mild but, within a few days following exposure,
severe pulmonary edema and chemical pneumonitis develop, leading to death due to respiratory failure
(Beton et al. 1966; Lucas et al. 1980; Patwardhan and Finckh 1976; Seidal et al. 1993). The cadmium
concentration in air was not measured in these cases of accidental death in humans. However, the lung
concentrations of cadmium in the men who died from these accidental acute exposures were measured.
In micrograms of cadmium per gram wet weight (w/w) of lung tissue (μg/g), Patwardhan and Finckh
(1976) reported 1.5 μg/g, Beton et al. (1966) reported 2.5 μg/g, Barrett et al. (1947) reported 3.5 μg/g, and
Lucas et al. (1980) reported 4.7 μg/g. Based upon estimates of the percentage of inhaled cadmium fume
CADMIUM 48
3. HEALTH EFFECTS
that would be retained in the lungs, Barrett et al. (1947) calculated an exposure of 2,500 minutes x mg/m3
in air would be fatal to humans. Beton et al. (1966) used a similar technique to estimate that an exposure
to cadmium oxide in air of 8.63 mg/m3 for 5 hours led to the fatal deaths of the five workers with
cadmium lung burdens of 2.5 μg/g. The lower lung concentrations reported by Patwardhan and Finckh
(1976) prompted Elinder (1986b) to estimate that an exposure of 1–5 mg/m3 for 8 hours could be
immediately dangerous. These estimates of air concentrations, however, are based on a number of
uncertain assumptions concerning the duration of exposure and the retention of cadmium in the human
lung being similar to that found in animal studies (Barrett et al. 1947; Elinder 1986b). No studies on
deaths in humans from intermediate inhalation exposures were found. In a study on chronic exposures,
Friberg (1950) attributes the deaths of 2 workers to exposure to cadmium dust in the air averaging 6.8 mg
Cd/m3 (range 3–15 mg/m3). One worker was 57 years old at death (after 14 years of exposure to the dust)
and the other was 60 years old at death (after 25 years of exposure to the dust). A detailed postmortem
evaluation for the 60-year-old worker showed the presence of emphysema and the occurrence of hyaline
casts in renal tubules, as well as slight nephrotic changes. Pneumonia was the direct cause of death as an
acute complication of chronic bronchitis and pulmonary emphysema. The exposure estimate of 6.8 mg
Cd/m3 is from only six samples taken in 1946. The conditions in earlier years were thought to be similar,
but this exposure value is, at best, a very rough approximation of the actual exposures spanning 34 years.
Acute inhalation of cadmium oxide fumes has also led to death in rats, mice, rabbits, guinea pigs, dogs,
and monkeys, with the mortality rate apparently being directly proportional to the product of the duration
of exposure and the concentration of inhaled cadmium (Barrett et al. 1947). The most reliable LC50
(lethal concentration, 50% kill) (at 7 days) established by this study was 500 minute-mg cadmium
oxide/m3 for rats, equivalent to a 15-minute exposure to 30 mg Cd/m3 (Barrett et al. 1947). Rusch et al.
(1986) demonstrated high mortality rates in the Sprague-Dawley rat from a 2-hour exposure to cadmium
fumes at 112 mg Cd/m3 (25 of 32 died within 1 week). A 2-hour exposure to a different form of
cadmium, cadmium carbonate, at 132 mg Cd/m3 resulted in considerably lower mortality (3 of 22 died by
day 30). No deaths resulted from a 2-hour exposure to cadmium sulfide at 99 mg Cd/m3 or cadmium
selenium sulfide (cadmium red pigment) at 97 mg Cd/m3. Grose et al. (1987) reported 2 out of 36 rats
died from a 2-hour, nose-only inhalation exposure to only 0.45 mg Cd/m3 of cadmium oxide dusts, but the
statistical significance of this low rate of mortality was not reported. A 3-day, 1-hour/day exposure to
cadmium chloride aerosol at 61 mg Cd/m3 resulted in the death of 17 of 18 rats exposed (Snider et al.
1973). In another study, no deaths were observed in rats from a cadmium yellow (cadmium sulfide)
pigment exposure 6 hours/day for 10 days at 6.29 mg Cd/m3 (Klimisch 1993). Thus, it appears that in
acute exposures, the relatively more soluble cadmium chloride, cadmium oxide fume, and cadmium
CADMIUM 49
3. HEALTH EFFECTS
carbonate compounds are more toxic than the relatively less soluble cadmium sulfide compounds
(Klimisch 1993; Rusch et al. 1986). Rusch et al. (1986) attribute this difference to higher lung absorption
and retention times for the more soluble compounds, and greater mucociliary clearance for the less-
soluble pigments. Glaser et al. (1986), however, demonstrated that toxicity does not strictly correlate
with solubility, and that solubility of cadmium oxide in biological fluids may be greater than its solubility
in water. In hamsters, Henderson et al. (1979) reported that a 30-minute exposure to 10.1 mg Cd/m3 from
cadmium chloride resulted in the death of 3 of 30 animals by day 6 postexposure. In rabbits, Friberg
(1950) reported an LC50 (by day 14) from a 4-hour exposure to cadmium metal dusts at 28.4 mg Cd/m3.
Barrett et al. (1947) also reported LC50 values for cadmium oxide fume of 940 mg Cd/m3 for a 14-minute
exposure in the monkey, 46.7 mg/m3 for a 15-minute exposure in the mouse, 204 mg Cd/m3 for a
15-minute exposure in the guinea pig, and 230 mg Cd/m3 for a 15-minute exposure in the dog. However,
the authors report that these LC50 values are only approximations because of insufficiencies in the data or
the small numbers of animals used.
At longer durations of exposure, lower concentrations cause lethality in rats. Cadmium oxide dust
resulted in the deaths of 100% of the females at 1 mg Cd/m3 for 5 hours/day, 5 days/week for 20 weeks,
(Baranski and Sitarek 1987), and of 5 of 12 female rats at only 0.105 mg Cd/m3 22 hours/day,
7 days/week for 63 days (Oldiges and Glaser 1986). Continuous inhalation exposure to cadmium oxide
dust at 0.105 mg Cd/m3 (i.e., 24 hours/day) for 63 days resulted in 5 of 12 deaths in female rats (Prigge
1978a). Five of 54 males died from a cadmium chloride exposure to 1.06 mg Cd/m3 for 62 days,
5 days/week, 6 hours/day (Kutzman et al. 1986). Kutzman et al. (1986) determined that the concentration
times hours of exposure to produce 50% mortality in rats was 390 mg-hour/m3 (males) and 489 mg-
hour/m3 (females). Takenaka et al. (1983) reported that cadmium chloride at 0.0508 mg Cd/m3
23 hours/day, 7 days/week for 18 months resulted in the death of 5 of 40 male rats.
Oldiges et al. (1989) evaluated the long-term effects in rats of inhaling cadmium as either cadmium
chloride, cadmium sulfate, cadmium sulfide, or cadmium oxide. Rats were exposed to aerosols in nearly
continuous exposures of 22 hours/day, 7 days/week for 18 months. An observation period of 12 months
followed the exposure period. Oldiges et al. (1989) recorded mortality as exceeding 25% of the test
animals during the exposure period or 75% of the test animals during the observation period. If either
25 or 75% mortality occurred, the exposure period or the observation period, respectively, was
terminated. The results showed that cadmium chloride at 0.030 mg Cd/m3 was lethal to >75% of the male
and female rats by 12 months of exposure; cadmium oxide dusts at 0.090 mg Cd/m3 were lethal for >25%
of the males by 7 months and 25% of the females by 11 months of exposure; cadmium oxide fume at the
CADMIUM 50
3. HEALTH EFFECTS
highest dose of 0.03 mg Cd/m3 did not result in >25% mortality during exposure or 75% during the
postexposure period; cadmium sulfate at 0.090 mg Cd/m3 was lethal for >25% of the males during the
exposure and for >75% of the females by 14 months following exposure; and cadmium sulfide at
0.090 mg Cd/m3 was not lethal during the exposure period but was lethal to >75% of the males and
females by 12 months postexposure. In these chronic studies, cadmium's lethal effects differed among the
chemical forms in the following order from most to least toxic: cadmium chloride>cadmium sulfate ≈
cadmium oxide dust>cadmium sulfide, but lethality still occurred from all forms of cadmium. Oldiges
and Glaser (1986) report that in their chronic studies and at the doses tested, cadmium toxicity appeared
to be more related to the long-term lung retention of the bioavailable amounts of cadmium than to a
simple function of solubility in water. Representative LOAEL and LC50 values for lethality in each
species and duration category are recorded in Table 3-1 and are plotted in Figure 3-1.
3.2.1.2 Systemic Effects
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each
species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.
Respiratory Effects. In humans, inhalation exposure to high levels of cadmium oxide fumes or dust
is intensely irritating to respiratory tissue, but symptoms can be delayed. During and immediately after
(up to 2 hours) an acute exposure for 5 hours of 8.63 mg/m3, Beton et al. (1966) reported that there were
few symptoms of toxicity limited to coughing and slight irritation of the throat and mucosa. From 4 to
10 hours postexposure, influenza-like symptoms began to appear, including cough, tight chest, pain in
chest on coughing, dyspnea, malaise, ache, chilling, sweating, shivering, and aching pain in back and
limbs. From 8 hours to 7 days postexposure, more advanced stages of pulmonary response included
severe dyspnea and wheezing, chest pain and precordial constriction, persistent cough, weakness and
malaise, anorexia, nausea, diarrhea, nocturia, abdominal pain, hemoptysis, and prostration. Acute,
high-level exposures can be fatal (see Section 3.2.1.1), and those who survive may have impaired lung
function for years after a single acute exposure. A 34-year-old worker exposed to cadmium fume from
soldering for 1 hour (dose not determined) had persistent impaired lung function when examined 4 years
following the exposure (Barnhart and Rosenstock 1984). Initial symptoms were dyspnea, cough,
myalgia, and fever. An initial chest X-ray revealed infiltrates. Townshend (1982) reports the case of a
male welder who developed acute cadmium pneumonitis from a single exposure (dose not determined).
Nine years after the exposure, this worker continued to show signs of progressive pulmonary fibrosis and
Table 3-1 Levels of Significant Exposure to Cadmium - Inhalation
CADMIUM
Exposure/ LOAEL
Duration/
a Frequency Reference
Key to Species NOAEL Less Serious Serious
(Route)
Figure (Strain) System (mg/m³) (mg/m³) (mg/m³) Chemical Form Comments
ACUTE EXPOSURE
Death
1 Human 5 hr Beton et al. 1966
8.63 M (5 male workers died
(occup) after a 5 hour exposure) CdO fume
8.63
2 Rat 10-15 min Barrett et al. 1947

30 (LC50 at 7 days)
(NS)
CdO fume
30
3 Rat 6.2 hr/d

8.8 (100% mortality by day 6) NTP 1995
(Fischer- 344) 5 d/wk
CdO
8.8
2 wk
3. HEALTH EFFECTS
1020
4 Rat 2 hr Rusch et al. 1986

112 (25/32 died within 1
(Sprague- week)
Dawley) CdO fume
112
13
5 Rat 3d Snider et al. 1973

1 hr/d 61 M (17/18 died within 3
(Sprague- days)
Dawley) CdCl2
61
17
6 Mouse 6.2 hr/d

5 d/wk 8.8 (100% mortality by day 7) NTP 1995
(B6C3F1)
CdO
8.8
2 wk
1023
7 Rabbit 4 hr Friberg 1950

28.4 (LC50 at 14 days)
(NS)
Cd metal dust
28.4
24
51
Table 3-1 Levels of Significant Exposure to Cadmium - Inhalation (continued)
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
Systemic
8 Rat 1 hr Boudreau et al. 1989
Resp 5 M (pulmonary edema,
(Long- Evans) enzyme changes CdCl2
associated with type 2
cell hyperplasia)
5
28
9 Rat 3 hr Buckley and Bassett 1987b

Resp 0.4 M (mild hypercellularity at 4.6 M (persistent focal
(Wistar) the bronchoalveolar interstitial thickening, CdO dust
junction and in adjacent increased collagen,
alveoli) general hypercellularity)
3. HEALTH EFFECTS
0.4 4.6
29
Bd Wt 0.4 M 4.6 M (15% decreased body

weight)
0.4
4.6
10 Rat 1 hr Bus et al. 1978

Resp 6.5 M (severe pneumonitis)
(Sprague-
CdCl2
6.5
Dawley)
30
Bd Wt 6.5 M (10.8% decreased body

weight)
6.5
11 Rat 2 hr Grose et al. 1987

Resp 0.45 M 4.5 M (moderate to severe
(Sprague- pneumonitis, CdCl2
0.45
Dawley) hemorrhage, edema)

4.5
34
Bd Wt 4.5 M (20% decreased body

weight)
4.5
52
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
12 Rat 2 hr Grose et al. 1987

Resp 0.45 M (significant increased 4.5 M (severe pneumonitis,
(Sprague- absolute and relative hyperplasia of type 2
Dawley) CdO dust
lung weight) cells and fibroblasts)
0.45 4.5
35
Bd Wt 0.45 M
0.45
13 Rat 1-6 wk Hart 1986

5 d/wk Resp 1.6 M (interstitial pneumonitis)
(Lewis)
CdO dust
1.6
3 hr/d
36
3. HEALTH EFFECTS
14 Rat 10 d Klimisch 1993 No histopathological
6 hr/d Bd Wt 0.17 M
(Wistar) examination.
CdCl2
0.17
38
15 Rat 10 d Klimisch 1993 No histopathological

6 hr/d Bd Wt 6.29 M
(Wistar) examination.
CdS
6.29
39
16 Rat 6.2 hr/d NTP 1995

Resp 0.88 F (degeneration of nasal 8.8 (marked necrosis of
(Fischer- 344) 5 d/wk olfactory epithelium) alveolar ducts)
2 wk CdO
0.88 8.8
b
0.088 (alveolar histiocytic
infiltrate and focal
inflammation in alveolar
septa)
0.088
1017
Hepatic 2.6
2.6
Renal 2.6
2.6
53
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
17 Rat 2 hr Palmer et al. 1986

Resp 6 M (alveolar type 1 cell
(Sprague- damage and necrosis)
Dawley) CdCl2
6
40
Endocr 6M
6
Bd Wt 6M
6
18 Rat 2 hr Rusch et al. 1986

Gastro 132 (erosions of the stomach)
(Sprague-
CdCO3
132
Dawley)
3. HEALTH EFFECTS
41
19 Rat 5, 10, or Snider et al. 1973

15 d Resp 6.1 M (emphysema)
(Sprague-
CdCl2
6.1
Dawley) 1 hr/d
45
20 Rat 3d
1 hr/d Resp 61 M (pulmonary hemorrhage) Snider et al. 1973
(Sprague-
CdCl2
61
Dawley)
46
21 Mouse 6.2 hr/d NTP 1995

5 d/wk Resp 0.88 (fibrosis and
(B6C3F1) inflammation around the
2 wk CdO
alveolar ducts, necrosis
of the alveolar duct
epithelium)
0.88
0.088 (histiocytic infiltrates)

0.088
1022
Hepatic 2.6
2.6
Renal 2.6
2.6
54
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
22 Hamster 30 min Henderson et al. 1979

Resp 1.1 (moderate increase in 10.1 (severe pneumonitis)
(Golden PMN, 2-fold increase in CdCl2
10.1
Syrian) acid phosphatase)

1.1
47
23 Rabbit 2 hr Grose et al. 1987

Resp 4.5 M (mild, multifocal
(New interstitial pneumonitis)
Zealand) CdCl2
4.5
48
24 Rabbit 2 hr
3. HEALTH EFFECTS
Resp 0.45 M (increase in alveolar 4.5 M (multifocal interstitial Grose et al. 1987
(New macrophages) pneumonitis)
Zealand) CdO dust
0.45 4.5
49
Bd Wt 0.45 M (unspecified decrease in

body weight)
0.45
Immuno/ Lymphoret
25 Mouse 2 hr Graham et al. 1978
0.11 F 0.19 F (decreased humoral
(Swiss) immune response) CdCl2
0.11
0.19
53
26 Mouse 60 min Krzystyniak et al. 1987

0.88 F (reduction in spleen
(C57BI/6) lymphocyte viability CdCl2
[35%], numbers, and
humoral response (75%)]
0.88
54
INTERMEDIATE EXPOSURE
Death
27 Rat 20 wk Baranski and Sitarek 1987
5 d/wk 1 F (13/13 died by week 20)
(Wistar)
CdO dusts
1
5 hr/d
58
55
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
28 Rat 62 d Kutzman et al. 1986

2.13 M (100% mortality by day
(Fischer 344) 5 d/wk 45)
6 hr/d CdCl2
2.13
62
29 Rat 6 mo Oldiges et al. 1989

40 hr/wk 0.09 (> 75% mortality by
(Wistar) 11-12 months CdCl2
postexposure)
0.09
65
30 Rat 6 mo
3. HEALTH EFFECTS
0.27 (> 75% mortality by Oldiges et al. 1989
(Wistar) 40 hr/wk
21-23 months CdS
postexposure)
0.27
67
31 Rat 63d Prigge 1978a

24 hr/d 0.105 F (5/12 died)
(Wistar)
CdO dust
0.105
68
Systemic
32 Rat 20 wk
5 d/wk Bd Wt 0.16 F 1 F (30-50% decreased body Baranski and Sitarek 1987
(Wistar) weight gain) CdO dusts
0.16
5 hr/d
1
71
33 Rat 30 d Glaser et al. 1986 No histopathology

7 d/wk Resp 0.105 M (increased total
(Wistar) bronchoalvelolar examination.
22 hr/d CdCl2
macrophage numbers,
leukocytes, and
macrophage cytotoxicity)
0.105
72
Hemato 0.105 M (45% increase in WBC)

0.105
56
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
34 Rat 30 d Glaser et al. 1986 No histopathology

22 hr/d CdO dust
macrophage numbers,
leukocytes, and
0.098
73
Hemato 0.098 M (45% increase in WBC)

0.098
35 Rat 30 d Glaser et al. 1986 No histopathological

22 hr/d CdS
3. HEALTH EFFECTS
macrophage numbers,
leukocytes, and
1.034
74
Hemato 1.034 M
1.034
Bd Wt 1.034 M
1.034

Resp 1.06 M (marked fibrosis with
(Fischer 344) 5 d/wk significant increase in
6 hr/d CdCl2
collagen)
1.06
78
Bd Wt 0.33 1.06 (14% decreased body 2.13 (42-51% decreased body

weight) weight)
0.33
1.06 2.13
57
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
37 Rat 6.33 hr/d NTP 1995

Resp 0.022 F (epithelial degeneration 0.88 (marked inflammation
(Fischer- 344) 5 d/wk in the larynx) and moderate fibrosis in
13 wk CdO
interstitium around
0.022
alveolar ducts and

0.22 (Inflammation of nasal terminal bronchioles)
respiratory epithelium)
0.88
0.22
1018
Cardio 0.88
0.88
Gastro 0.88
0.88
Hemato 0.88
3. HEALTH EFFECTS
0.88
Hepatic 0.88
0.88
Renal 0.88
0.88
Bd Wt 0.88
0.88
38 Rat 4 wks Oberdorster et al. 1994

Resp 0.1 M
(Fischer 344) 5 d/wk
CdCl2
0.1
6 hr/d
79
58
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
39 Rat 63 or 90 d Prigge 1978a

24 hr/d Resp 0.025 F (proliferations, histiocytic
(Wistar) cell granulomas) CdO dust
0.025
82
Hemato 0.052 F (increased hemoglobin

and hematocrit)
0.052
Hepatic 0.105 F
0.105
Renal 0.105 F
0.105
Bd Wt 0.105 F (11% decrease in body
3. HEALTH EFFECTS
weight)
0.105
Metab 0.105 F (decreased blood pH and

pO2, increased pCO2)
0.105
40 Rat 21 d Prigge 1978b

Gd 1-21 Resp 0.204 F (77% increased lung
(Wistar) relative weight)
24 hr/d CdCl2
0.204
83
Hemato 0.204 F (8% increased

hemoglobin, 5%
increased hematocrit )
0.204
Hepatic 0.581 F
0.581
Renal 0.581 F
0.581
Bd Wt 0.394 F
0.394
59
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
41 Rat 21 d Prigge 1978b

Gd 1-21 Resp 0.204 F (70% increased lung
(Wistar) relative weight)
24 hr/d CdCl2
0.204
84
Hemato 0.581 F (increased hemoglobin

[12%], hematocrit [12%],
total biliurin [2-fold])
0.581
Hepatic 0.581 F
0.581
Renal 0.581 F
3. HEALTH EFFECTS
0.581
Bd Wt 0.394 F (12% decreased

maternal weight gain)
0.394

5 d/wk Resp 0.088 M (Degeneration of nasal
(B6C3F1) olfactory epithelium)
13 wk CdO
0.088
0.022 (alveolar histiocytic

infiltrates and squamous
metaplasia of the larynx)
0.022
1024
Cardio 0.88
0.88
Gastro 0.88
0.88
Hepatic 0.88
0.88
Renal 0.88
0.88
Bd Wt 0.88
0.88
60
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
43 Mouse 4 wks Oberdorster et al. 1994

5 d/wk Resp 0.1 M (increased neutrophils,
(BALB/c) LDH and
6 hr/d CdCl2
beta-glucuronidase;
pulmonary inflammation)
0.1
86
44 Rabbit 9 mo Friberg 1950

21 d/mo Resp 4 (chronic pneumonia,
(NS) emphysema)
3 hr/d Cd metal dust
4
87
Hemato 4 (eosinophilia, lower
3. HEALTH EFFECTS
hemoglobin)
4
Renal 4 (proteinuria)
4
45 Rabbit 7 mo Friberg 1950

23 d/mo Resp 5.6 (emphysema)
(NS)
Cd metal dust
5.6
3 hr/d
88
Renal 5.6 (proteinuria in 6/10

surviving to the end of
exposure)
5.6
46 Rabbit 4-6 wk Johansson et al. 1984

5 d/wk Resp 0.4 M (lung interstitial
(NS) inflammation, type 2 cell
6 hr/d CdCl2
hyperplasia)
0.4
89
61
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
Reproductive
47 Rat 5 hr/d Baranski 1984
5 d/wk 0.16 F
(Wistar)
CdO
0.16
5 mo
premating,
mating, Gd
1-20
1026

5 d/wk 1 F (increased duration of
(Wistar) estrous cycle)
5 hr/d CdO dusts
1
97
3. HEALTH EFFECTS
1.06 M (
(Fischer 344) 5 d/wk t
6 hr/d CdCl2
1.06
98
50 Rat 6.33 hr/d NTP 1995

0.22 M 0.88 M (decreased spermatid
(Fischer- 344) 5 d/wk counts CdO
0.22
13 wk
0.22 F
0.22
0.88
0.88 F (increased estrous cycle

length)
0.88
1019
Developmental
51 Rat 5 hr/d Baranski 1984
5 d/wk 0.02 F (altered performance on
(Wistar) neurobehavioral tests)
5 mo CdO
premating, 0.02
mating, Gd
1-20
1027
62
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
52 Rat 4-5 mo Baranski 1985

5 d/wk 0.02 (altered performance on 0.16 (decreased pup viability)
(Wistar) neurobehavioral tests) CdO dusts
0.16
5 hr/d
0.02
100
53 Rat 6.27 hr/d NTP 1995

7 d/wk 0.4 F 1.7 F (decreased fetal body
(Sprague- weight and reduced CdO
0.4
Dawley) Gd 4-19
ossification)
1.7
1021
54 Rat 21 d
3. HEALTH EFFECTS
0.581 (9% decreased fetal body Prigge 1978b
(Wistar) Gd 1-21
24 hr/d weight, 12% increase in CdCl2
fetal alkaline
phosphatase)
0.581
101

7 d/wk 0.04 F 0.4 F (decreased fetal body
(Swiss) weight) CdO
0.04
Gd 4-17
0.4
1025
Cancer
40 hr/wk 0.09 (CEL: lung
(Wistar) bronchioalveolar CdCl2
adenomas,
adenocarcinomas, and
squamous cell
carcinomas)
0.09
103
CHRONIC EXPOSURE
Death
57 Human 1-34 yr
5 d/wk 6.8 M (2 fatalities from 14 years Friberg 1950
8 hr/d or 25 years of exposure Cd dust
to Cd dust)
(occup)
63
6.8
106
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
58 Rat 413-455 d Oldiges and Glaser 1986

7 d/wk 0.095 M (6/20 died)
(Wistar)
CdSO4
0.095
22 hr/d
108

7 d/wk 0.03 M (>75% mortality by 12
(Wistar) months postexposure)
22 hr/d CdCl2
0.03
109

7 d/wk 0.09 (more than 25% died
(Wistar) after 7 months [M] and
22 hr/d CdO dust
3. HEALTH EFFECTS
11 months [F] of
exposure)
0.09
110

7 d/wk 0.09 (>75% mortality after 12
(Wistar) months postexposure)
22 hr/d CdS
0.09
112

7 d/wk 0.09 M (>25% mortality by 14
(Wistar) months of exposure)
22 hr/d CdSO4
0.09
0.09 F (>75% by 11 months

postexposure)
0.09
113
Systemic
63 Human c
Renal 0.0001 F Buchet et al. 1990; Jarup et al.
0.0001
2000; Suwazono et al. 2006

1035 form not specified
64
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
64 Human 4-24 yr Edling et al. 1986

5 d/wk Resp 0.025
CdO fume
0.025
8 hr/d
(occup)
129
65 Human 30 yr
5 d/wk Renal 0.033 0.067 (pronounced proteinuria) Elinder et al. 1985b
CdO fume
0.033 0.067
8 hr/d
(occup)
131
66 Human 30 yr Falck et al. 1983
3. HEALTH EFFECTS
5 d/wk Renal 0.0153 M 0.0379 M (100% incidence of
proteinuria in the cohort CdO fume
0.0153
8 hr/d
exposed to this level for
(occup) 21 years)
0.0379
132
67 Human 30 yr Jarup et al. 1988

5 d/wk Renal 0.017 0.023 (9.2% incidence of
proteinuria) CdO dust
0.017
8 hr/d
(occup) 0.023
138
68 Human 30 yr Mason et al. 1988

5 d/wk Renal 0.0367 M
form not specified
0.0367
8 hr/d
(occup)
150
69 Human 30 yr Thun et al. 1989

5 d/wk Renal 0.027
CdO dust or fume
0.027
8 hr/d
(occup)
169
65
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
70 Rat 18 mo Takenaka et al. 1983

7 d/wk Resp 0.0134 M (adenomatous
(Wistar) hyperplasia in the
23 hr/d CdCl2
bronchoalveolar area)
0.0134
174
Bd Wt 0.0508 M
0.0508
Cancer
71 Human 6 mo - 43 yr Stayner et al. 1992
7 d/wk 0.1 M (CEL: 50-111 lung
8 hr/d cancer deaths per 1000 CdO dust or fumes
workers; 45 year
(occup) exposure)
3. HEALTH EFFECTS
0.1
209

7 d/wk 0.03 (CEL: lung
(Wistar) bronchioalveolar
22 hr/d CdCl2
adenomas,
squamous cell
carcinomas)
0.03
210

22 hr/d CdO dust
adenomas,
squamous cell
carcinomas)
0.03
211
66
CADMIUM
Exposure/ LOAEL
Duration/
(Route)

22 hr/d CdO fume
adenomas,
adenocarcinomas)
0.03
212

22 hr/d CdS
adenomas,
squamous cell
3. HEALTH EFFECTS
carcinomas)
0.09
213

(Wistar) bronchio-alveolar
22 hr/d CdSO4
adenomas,
adenocarcinomas,
squamous cell
carcinomas)
0.09
214
67
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
77 Rat 18 mo Takenaka et al. 1983

7 d/wk 0.0134 M (CEL: lung epidermoid
(Wistar) carcinomas,
23 hr/d CdCl2
mucoepidermoid
carcinomas)
0.0134
215
a The number corresponds to entries in Figure 3-1.
b Used to derive an acute-duration inhalation minimal risk level (MRL) of 0.00003 mg Cd/m3 (0.03 ug Cd/m3); concentration was adjusted for intermittent exposure (6.2 hours/day, 5
days/week) and divided by an uncertainty factor of 300 (10 for use of a LOAEL, 3 for extrapolation from animals to humans with dosimetric adjustment, and 10 for human variability).
3. HEALTH EFFECTS
c The chronic-duration inhalation MRL of 0.00001 mg Cd/m3 (0.01 ug Cd/m3) was calculated from the 95% lower confidence limit of the urinary cadmium level associated with a 10%
increased risk of low molecular weight proteinuria (0.5 ug/g creatinine) estimated from a meta-analysis of select environmental exposure studies. An air concentration (together with
an assumed dietary intake of 0.3 ug Cd/kg/day) which would result in this urinary cadmium concentration was estimated using the ICRP human respiratory tract model and a
modification of the Nordberg-Kjellström pharmacokinetic model (see Appendix A for details on the meta-analysis and extrapolation to air concentration). This air concentration of 0.1
ug Cd/m3 was divided by an uncertainty factor of 3 for human variability and a modifying factor of 3.
Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; F = Female; Gastro = gastrointestinal; Gd = gestational day; Hemato =
hematological; hr = hour(s); Immuno/Lymphoret = immunological/lymphoreticular; LC50 = lethal concentration, 50% kill; LDH = lactate dehydrogenase; LOAEL =
lowest-observed-adverse-effect level; M = male; min = minute(s); Metab = metabolic; mo = month(s); NOAEL = no-observed-adverse-effect level; NS = not specified; occup =
occupational; PMN = polymorphonuclear leukocyte; Resp = respiratory; WBC = white blood cells; wk = week(s); yr = year(s)
68
Figure 3-1 Levels of Significant Exposure to Cadmium - Inhalation
Acute (≤14 days)
CADMIUM
Systemic
r
na
l
pho
ti t
ym
to ry tes ne e igh /L
th p ira troin atic a l ocri y W uno
D ea Res G as H ep Ren End B od Imm
mg/m3
1000
4r 18r
100
5r 20r
2r 7h
10 1 6m 3r 22s 16r
10r 17r 19r 17r 10r 15r 17r
8r 9r 11r 12r 23h 24h 9r 11r
3. HEALTH EFFECTS
21m 16r 21m 16r
13r
1 22s
21m 16r 26m
9r 11r 12r 24h 9r 12r 24h
14r 25m
0.1 25m
21m 16r
0.01
0.001
0.0001
1E-5
c-Cat -Humans f-Ferret n-Mink Cancer Effect Level-Animals Cancer Effect Level-Humans LD50/LC50
d-Dog k-Monkey j-Pigeon o-Other LOAEL, More Serious-Animals LOAEL, More Serious-Humans Minimal Risk Level
69
r-Rat m-Mouse e-Gerbil LOAEL, Less Serious-Animals LOAEL, Less Serious-Humans for effects
p-Pig h-Rabbit s-Hamster NOAEL - Animals NOAEL - Humans other than
q-Cow a-Sheep g-Guinea Pig Cancer
Figure 3-1 Levels of Significant Exposure to Cadmium - Inhalation (Continued)
Intermediate (15-364 days)
CADMIUM
Systemic
lar al al
y u tin gic
r as
c es
ato iov int lo
ath spir rd stro mato p ati
c
na
l
De Re Ca Ga He He Re
mg/m 3
10
45h 45h
44h 44h 44h
28r
3. HEALTH EFFECTS
1 27r 35r 36r 35r
37r 42m 37r 42m 37r 37r 42m 37r 42m 37r
41r 40r 41r 40r 41r
46h
30r
37r 40r 41r 40r
0.1 31r 43m 33r 34r 38r 33r 34r 39r 39r
29r 42m
39r
39r
42m 37r
0.01
70
CADMIUM
Systemic
l
ht
tive enta
eig lic uc pm r*
yW tabo ro
d
elo ce
d p v n
mg/m3 Bo Me Re De Ca
10
36r
53r
3. HEALTH EFFECTS
1 32r 35r 36r 48r 49r
42m 37r 50r 50r
54r
40r 41r 55m 53r

36r
50r 50r
32r 47r 52r
0.1 39r 39r

56r
55m
51r 52r
*Doses represent the lowest dose tested per study that produced a tumorigenic
0.01 response and do not imply the existence of a threshold for the cancer endpoint.
71
Chronic (≥365 days)
CADMIUM
Systemic
ry ht
to eig r*
th p ira al yW ce
a s n d n
De Re Re Bo Ca
mg/m3
10
57
0.1 58r 60r 61r 62r 62r 71 75r 76r

65
70r
59r 65 66 68 72r 73r 74r
64 67 69
67
3. HEALTH EFFECTS
70r 66 77r
0.01
0.001
0.0001 63
10-4
Estimated
Upper-Bound
1E-5
10-5 Human Cancer
Risk Levels
1E-6
10-6
1E-7
10-7
1E-8 response and do not imply the existence of a threshold for the cancer endpoint.
72
CADMIUM 73
3. HEALTH EFFECTS
had no improvement in respiratory function. Precise estimates of cadmium concentrations leading to

acute respiratory effects in humans are not currently available.
The initial symptoms of respiratory distress observed in the higher acute exposures do not occur
following lower-level, longer-term inhalation exposures (Friberg 1950). Longer-term occupational
exposure to levels of cadmium below those causing lung inflammation, however, have been reported to
cause emphysema and dyspnea in humans (Bonnell 1955; Friberg 1950; Lane and Campbell 1954; Smith
et al. 1960). Kjellström et al. (1979) reported a significant increase in deaths due to respiratory diseases
in cadmium-exposed battery factory workers exposed for >5 years.
A significant, dose-dependent excess in the ratio of observed to expected deaths from bronchitis (i.e.,
standardized mortality ratio [SMR]=434) but not emphysema was found among 6,995 men occupationally
exposed to cadmium for an average of 11 years (Armstrong and Kazantzis 1983). The dose level was not
determined.
The earlier occupational studies did not control for the health effects of cigarette smoking. There is some
evidence that cadmium may accelerate the development of emphysema in smokers. Leduc et al. (1993)
report a case history of a 59-year-old male worker who smoked a pack of cigarettes per day since age 16,
but had no prior history of respiratory disease in 1975 until developing emphysema in 1979 after inhaling
various concentrations of cadmium (range of 0.0164–1.192 mg/m3, mean of 0.446 mg/m3, about nine
times the threshold value of 0.050 mg/m3) for 4 years as a furnace operator. Very high levels of cadmium
in air samples at the workplace and in the patient’s blood, urine, and lung tissue confirmed massive
exposures. Lung-function tests declined rapidly, with a faster than usual onset of emphysema compared
to other smokers. The mean concentration of cadmium in a removed section of lung was 580 μg/g dry
tissue, compared to 14 μg/g in three unexposed controls matched for age, sex, and smoking habit who had
also undergone resection of a bronchial carcinoma. The authors state that this case supports the
hypothesis for an etiological role of cadmium fume inhalation in the development of emphysema.
More recent studies that controlled for smoking report lung impairment in cadmium-exposed workers
(Chan et al. 1988; Cortona et al. 1992; Davison et al. 1988; Smith et al. 1976). Cortona et al. (1992)
measured respiratory function parameters in 69 smoking and nonsmoking male subjects (average age 45)
who were exposed to concentrations of 0.008–1.53 mg/m3 of cadmium fumes over a period of
several years in a factory that produced cadmium alloys (silver-cadmium-copper). Forced Expiratory
Volume (FEV), Forced Vital Capacity (FVC), Residual Volume (RV), Transfer Factor by the carbon
CADMIUM 74
3. HEALTH EFFECTS
monoxide method (TLCO), and Transfer Coefficient (KCO) were measured in these exposed individuals.
The study found that there were no significant differences in the FVC, FEV, TLCO, and KCO between
the workers exposed to cadmium fumes and control (non-exposed) individuals. There was a significant
increase in RV of >8% in exposed workers; this effect was notably greater in those with higher
cumulative exposures to cadmium (>10%). It is uncertain how much of a factor on the increased RV was
due to the tendency of smokers to develop an initial emphysematous alteration in lung tissue due to
smoking.
Davison et al. (1988) evaluated lung function in 101 men who had manufactured copper-cadmium alloy
in a plant in England for ≥1 years since 1926. The exposed men were compared to controls from the
factory’s other seven divisions matched for age and employment status. Smoking in exposed and control
men was similar. Between 1951 and 1983, 933 measurements of airborne cadmium had been made,
697 with static samplers and 236 with personal samplers. The various sampling methods used before
1964 are no longer considered to be reliable, so estimates of air concentrations were made based on
changes in production techniques, ventilation, levels of production, and discussions with occupational
health physicians, industrial hygienist, the management, and the workers. Cadmium concentrations in air
from 1926 to 1972 were determined to have declined from 0.6 to 0.156 mg/m3. In 1973, concentrations
were 0.085 mg/m3; from 1974 to 1983, concentrations ranged from 0.034 to 0.058 mg/m3. The lung
function of 77 of the men occupationally exposed to cadmium was significantly impaired compared to the
unexposed controls, with the greatest abnormalities in the highest-dose group. Forced expiratory volume
in one second, ratio of forced expiratory volume to forced vital capacity, transfer factor, or transfer
coefficient were significantly lower than expected and radiographic total lung capacity, residual volume,
and the ratio of these two were significantly higher than expected. The greatest abnormalities were
observed in workers with the highest cumulative exposure and the highest liver cadmium levels.
Regression of the lung transfer coefficient versus cadmium exposure indicated a linear relationship with
no apparent threshold.
Smith et al. (1976) studied the pulmonary function of 17 high-exposure workers, 12 low-exposure
workers, and 17 controls. Cadmium air concentrations where high-exposure subjects worked were
>0.2 mg/m3. High-exposure subjects had worked at the plant a median of 26.4 years, with a maximum of
40.2 years, and low-exposure subjects had worked a median of 27.1 years, with a maximum of 34.8 years.
Workers with high exposure to cadmium had significantly decreased the FVC compared to low-exposure
workers and controls. Chest X-rays indicated mild or moderate interstitial fibrosis in 29% of high
exposure workers. A dose-response relationship was found between FVC and urinary cadmium, and
CADMIUM 75
3. HEALTH EFFECTS
with months of exposure to cadmium fume, but not cadmium sulfate aerosol. In an analysis of the
smoking habits, there was no significant difference between the two cadmium-exposed groups with
respect to the proportion of present or past cigarette smokers, the intensity or duration of cigarette
smoking, or cigar or pipe smoking habits. The control subjects, however, had a significantly (p<0.05)
“higher” exposure to cigarette smoke than the cadmium exposed workers with substantially greater
numbers of pack-years, cigarettes smoked per day, and years smoked. A step-down and multiple
regression analyses with a dependent variable of FVC (as percent of predicted), and the independent
variables, age-height, cigarette pack-years, and urinary cadmium, resulted in no indication that an
interaction between the independent variables led to the observed relationship between FVC and
cadmium excretion.
Other studies, however, have not shown a cadmium-related increase in impaired respiratory function.
Edling et al. (1986) studied Swedish workers occupationally exposed to cadmium oxide fume from
cadmium-containing solders. Cadmium-containing solder had been used at the plant from 1955 to 1978.
The results from the lung-function analysis showed no significant difference in symptoms or lung
function between the cadmium-exposed and the reference group. The exposed and the reference groups
were similar with respect to sex, age, and height. There was a higher percentage of smokers in the
reference group (52%) than in the exposed group (42%), but the difference was not statistically
significant. The authors could not explain why significant differences in effects were not seen in these
workers since other studies have shown significant effects at comparable cadmium exposure levels. The
authors suggest that a possible bias could have been introduced if people who had worked for >5 years in
the plant had changed their occupation because of lung disease, so that only “healthy” workers remained.
Significant effects may also have been found if the reference group included workers other than those
who worked with solder, but the purpose of the study was to resolve the effects of cadmium exposure
among workers with similar occupations. Evaluating the data from smokers and nonsmokers separately
also showed no significant impairment in lung function between smoking exposed and smoking
unexposed or nonsmoking exposed and nonsmoking unexposed. The lung impairment due to smoking
was observed in that smokers in both the exposed and unexposed groups had a somewhat deteriorated
closing volume and other lung function indicators in accordance with previous studies on the effects of
smoking. These results support the hypothesis that the response to occupational dust exposure differs
from the response to tobacco smoking.
Another possible reason for differing results is that lung injury caused by high-level cadmium exposure
may be partially reversible (Bonnell 1955; Chan et al. 1988), with a return towards normal several years
CADMIUM 76
3. HEALTH EFFECTS
after exposures have been significantly reduced. Chan et al. (1988) studied a cohort of 36 female and
8 male workers at a Singapore cadmium battery factory exposed to cadmium oxide dust. Cadmium
concentrations in air were 0.03–0.09 mg/m3 (geometric means). Lung function was measured using
spirometry, helium dilution, tidal sampling, X-ray, and respiratory symptoms. The recovery of lung
function after reduction or cessation of occupational exposure to cadmium dusts was assessed. Total lung
capacity increased following reduction of exposure and, following cessation of exposure, vital capacity,
FEV, and prevalence of respiratory symptoms all improved. Blood and urine cadmium concentrations
were considerably lower with the reduction or cessation of exposure and were consistent with a decrease
in the cadmium air levels.
Additional respiratory symptoms less frequently reported in workers occupationally exposed to cadmium
are chronic rhinitis and impairment or loss of the sense of smell (Adams et al. 1969; Bonnell 1955;
Friberg 1950; Liu et al. 1985; Rose et al. 1992). The cause of these effects may be chronic irritation or
necrosis of the nasal membranes, as they are generally found only in individuals with high-level exposure.
An increased prevalence of abnormal parasinus radiographic findings in cadmium-exposed workers
compared to other published reports on non-exposed populations was reported by Shaham et al. (1993).
Studies in animals confirm that inhalation exposure to cadmium can lead to respiratory injury. Single
acute exposures in rats to 5–10 mg Cd/m3 as cadmium oxide dust, cadmium oxide fume, or cadmium
chloride for 1–5 hours resulted in moderate to severe, multifocal interstitial pneumonitis, diffuse alveolitis
with hemorrhage, increased lung weight, inhibition of macrophages, focal interstitial thickening, edema,
and necrosis of alveolar type 1 cells leading to type 2 cell hyperplasia and fibroblasts (Boudreau et al.
1989; Buckley and Bassett 1987b; Bus et al. 1978; Grose et al. 1987; Hart et al. 1989a; NTP 1995;
Palmer et al. 1986). Similar results (i.e., severe pneumonitis) were seen in hamsters exposed to cadmium
chloride at 10 mg/m3 for 30 minutes (Henderson et al. 1979) and in rabbits exposed to cadmium oxide
dusts at 4.5 mg/m3 for 2 hours (Grose et al. 1987). Exposures in rats to cadmium chloride at 6.1 mg
Cd/m3 1 hour/day for 5, 10, or 15 days resulted in emphysema; a 3-day exposure to 61 mg Cd/m3 for
1 hour/day resulted in pulmonary hemorrhage (Snider et al. 1973). Repeated exposure to 0.088 mg Cd/m3
as cadmium oxide for 2 weeks resulted in minimal to mild alveolar histiocytic (macrophage) infiltration
in rats and mice, focal inflammation surrounding alveolar ducts and extending into the adjacent alveolar
septa in rats, and hyperplasia in tracheobronchial lymph nodes in mice (NTP 1995). At higher
concentrations, the severity of these lesions increased (the severity of the lung lesions was scored as
moderate at ≥0.88 mg Cd/m3) and necrosis of the epithelial lining of the alveolar ducts was observed at
≥0.26 mg Cd/m3 in rats and 0.88 mg Cd/m3 in mice. The NTP (1995) study also found significant
CADMIUM 77
3. HEALTH EFFECTS
increases in the incidence of lesions in the nasal cavity; minimal-to-mild degeneration of the olfactory
epithelium was observed in rats and mice exposed to 0.88 mg Cd/m3 and hyperplasia and inflammation of
respiratory epithelium were observed in rats at 2.6 mg Cd/m3.
Persistent damage has been reported in an animal model following a single intratracheal exposure to 25,
100, or 400 μg cadmium chloride/kg body weight (Driscoll et al. 1992). Although most BALF
biochemical (lactate dehydrogenase, total protein, and N-acetylglucosaminidase) and cellular (neutrophils
and lymphocyte numbers) parameters returned to control levels 28 days after exposure, histopathological
alterations including inflammation and fibrosis were still present 90 days post-exposure and the incidence
and severity of the lesions were greater at 90 days compared to 28 days.
Intermediate-duration exposure to cadmium results in similar respiratory effects as seen in the acute
exposures. Concentration-related increases in the severity and types of respiratory lesions have been
observed. Because the intermediate-duration studies used different exposure protocols, intermittent
exposure studies were duration-adjusted to continuous exposure (Table 3-2) to facilitate comparisons
across these studies. The lowest adverse effect level for lung effects was 0.004 mg Cd/m3 for alveolar
epithelial hyperplasia in mice (NTP 1995). At 0.008–0.07 mg Cd/m3, inflammation and minimal fibrosis
were observed in rats, mice, and rabbits (Johansson et al. 1984; NTP 1995; Oberdörster et al. 1994) and
marked inflammation and moderate fibrosis were observed in rats at 0.17 mg Cd/m3 (NTP 1995). At
≥0.34 mg Cd/m3, emphysema and chronic pneumonia were observed in rats and rabbits (Friberg 1950;
Prigge 1978b). In addition to the widely reported effects in the lungs, NTP (1995) reported minimal
lesions in the larynx of rats (epithelial degeneration) and mice (squamous metaplasia) exposed to
0.022 mg Cd/m3 and minimal lesions in the nasal cavity in rats (inflammation of respiratory epithelium)
and mice (degeneration of olfactory epithelium) exposed to 0.088 mg Cd/m3. The toxicity of cadmium to
the respiratory tract following intermediate-duration exposure is highlighted by the NTP (1995) rat and
mouse studies. As summarized in Table 3-3, rats and mice were exposed to five concentrations (0.022,
0.044, 0.088, 0.22, and 0.88 mg Cd/m3 as cadmium oxide) 6.33 hours/day, 5 days/week for 13 weeks.
The earliest effects observed were alveolar histiocytic infiltrates, alveolar epithelial hyperplasia, and
tracheal epithelial hyperplasia or squamous metaplasia; these lesions were all graded as minimal. With
increasing concentrations, the severity of most lesions increased as did the type of lesion.
There are fewer chronic-inhalation exposure studies that specifically reported systemic respiratory effects.
Oldiges and Glaser (1986) report increased lung weights (amount unspecified) in rats from exposure to
either cadmium sulfate at 0.092 mg Cd/m3 or cadmium sulfide at 0.254 mg Cd/m3 for 22 hours/day,
CADMIUM 78
3. HEALTH EFFECTS
Table 3-2. Comparison of Lung Effects Across Intermediate-Duration Inhalation

Studies
Duration-
adjusted
Adverse adverse
Exposure effect level effect level
Species frequency/duration (mg Cd/m3) (mg Cd/m3) Effect Reference
Mouse 6.33 hours/day, 0.022 0.004 Alveolar NTP 1995
5 days/week, 13 weeks hyperplasia
Rat 6.33 hours/day, 0.044 0.008 Alveolar NTP 1995
5 days/week, 13 weeks histiocytic
infiltrates and
hyperplasia
Mouse 6.33 hours/day, 0.044 0.008 Minimal NTP 1995
5 days/week, 13 weeks fibrosis
Mouse 6.33 hours/day, 0.088 0.017 Moderate NTP 1995
5 days/week, 13 weeks inflammation
Rat 6.33 hours/day, 0.22 0.017 Minimal NTP 1995
Mouse 6 hours/day, 0.1 0.02 Inflammation Oberdörster
5 days/week, 4 weeks et al. 1994
Rat 24 hours/day, 0.025 0.025 Proliferations Prigge 1978a
7 days/week, 90 days
Rat 6.33 hours/day, 0.22 0.04 Inflammation NTP 1995
5 days/week, 13 weeks
Rat 6.33 hours/day, 0.88 0.17 Marked NTP 1995
5 days/week, 13 weeks inflammation
and
moderate
fibrosis
Mouse 6.33 hours/day, 0.88 0.17 Moderate NTP 1995
Rat 6 hours/day, 0.33 0.06 Fibrosis Kutzman et
5 days/week, 62 days al. 1986
Rabbit 6 hours/day, 0.4 0.07 Inflammation Johansson et
5 days/week 4–6 weeks al. 1984
Rabbit 3 hours/day, 4 0.34 Pneumonia/ Friberg 1950
21 days/month, 9 months emphysema
Rabbit 3 hours/day, 5.6 0.53 Emphysema Friberg 1950
23 days/month, 7 months
Rat 24 hours/day, Prigge 1978b
7 days/week
CADMIUM 79
3. HEALTH EFFECTS
Table 3-3. Severity of Respiratory Effects in Rats and Mice Exposed to

Cadmium Oxide for 13 Weeksa
Concentration (mg Cd/m3)

0 0.022 0.044 0.088 0.22 0.88
Male rats
Lung
b c
Alveolar histiocytic infiltrate — — 1.0 2.0 3.0 3.0
Alveolar epithelial hyperplasia — — 1.0 1.0 2.0 2.1
Inflammation — — — — 2.6 4.0
Fibrosis — — — 1.0 2.0 2.7
Mediastinal lymph node
inflammation — — — 1.3 3.2 3.3
Larynx
Epithelial degeneration 1.0 1.0 1.0 1.0 1.0
Nose
Olfactory epithelium — — — 1.0 3.0
degeneration
Olfactory epithelium — — — — — 1.3
respiratory metaplasia
squamous metaplasia
Respiratory epithelium — — — — 1.0 2.6
inflammation
Respiratory epithelium — — — — — 1.5
degeneration
Female rats
Lung
Alveolar histiocytic infiltrate — — 1.0 2.1 3.0 3.0
Alveolar epithelial hyperplasia — — 1.0 1.0 2.0 2.1
Inflammation — — — 1.6 3.5
Fibrosis — — — 1.0 2.0 2.1
Mediastinal lymph node
inflammation — — 1.0 1.5 3.6 4.0
Larynx
Epithelial degeneration — 1.0 1.0 1.0 1.0 1.0
Nose
Olfactory epithelium — — — — 1.0 2.8
degeneration
squamous metaplasia
Respiratory epithelium — — — 1.0 1.8 1.8
inflammation
CADMIUM 80
3. HEALTH EFFECTS
Table 3-3. Severity of Respiratory Effects in Rats and Mice Exposed to

Cadmium Oxide for 13 Weeksa
Concentration (mg Cd/m3)

0 0.022 0.044 0.088 0.22 0.88
Male mice
Lung
Alveolar epithelial hyperplasia — 1.0 1.0 1.8 1.7 2.0
Inflammation — — — 3.0 2.2 2.7
Fibrosis — — 1.0 1.0 1.0 1.0
Tracheobronchial lymph node
hyperplasia — — 1.0 2.3 2.4 2.7
Larynx
Squamous metaplasia — 1.0 1.0 1.0 1.0 1.1
Nose
Olfactory epithelium — — — 1.0 1.7 2.0
degeneration
Olfactory epithelium — — — — 1.0
squamous metaplasia
hyaline droplets
Female mice
Lung
Alveolar histiocytic infiltrate — 1.0 1.0 2.0 2.0 3.0
Alveolar epithelial hyperplasia — — — 1.4 2.0 2.0
Inflammation — — — 2.3 2.1 2.9
Fibrosis — — 1.0 1.0 1.0 1.0
Tracheobronchial lymph node
hyperplasia — — 1.0 1.5 2.0 2.4
Larynx
Squamous metaplasia — 1.0 1.0 1.0 1.0 1.0
Nose
Olfactory epithelium — — — 1.0 1.0 2.0
degeneration
hyaline droplets
a
Animals were exposed for 6.33 hours/day, 5 days/week.
b
No lesions present or not significantly different from control group.
c
Severity score: 1 = minimal, 2 = mild, 3 = moderate, 4 = marked
Source: NTP 1995

CADMIUM 81
3. HEALTH EFFECTS
7 days/week for 413–455 days. Takenaka et al. (1983) observed adenomatous hyperplasia in the
bronchoalveolar region in rats from exposure to cadmium chloride at 0.0134 mg Cd/m3 for 23 hours/day,
7 days/week for 18 months.
The available data suggest that there may be species differences in the respiratory toxicity of cadmium.
In a comparison of the pulmonary response to exposure to 0.1 mg Cd/m3 as cadmium chloride
6 hours/day, 5 days/week for 4 weeks, Oberdörster et al. (1994) found that the inflammatory response in
the lungs of mice was greater than that of rats exposed to the same cadmium concentration. However, the
cadmium lung burden in mice was twice as high as the rat’s lung burden. In the NTP (1995) study,
adverse lung effects were observed at lower concentrations in mice compared to rats, but at the higher
concentrations, the severity of the lung effects were greater in the rats. Although these data suggest
species differences in the pulmonary toxicity of cadmium, more information is needed to evaluate if there
are differences at given lung burdens.
Based on differences in the pharmacokinetic properties of various cadmium compounds, it is expected

that differences in toxicity would be observed. As discussed in Oberdörster (1992), cadmium chloride
and cadmium oxide elicited similar responses following a single intratracheal dose, whereas no response
was observed for cadmium sulfide. However, Glaser et al. (1990) found similar responses following
repeated exposures to various cadmium compounds.
Hart and colleagues (Hart 1986; Hart et al. 1989a, 2001) demonstrated that repeated low-concentration
exposure to cadmium results in the development of adaptive survival response. In rats exposed to 1.6 mg
Cd/m3 as cadmium acetate 3 hours/day, 5 days/week, thickening of the alveolar septa and mononuclear
cell and polymorphonuclear leukocyte aggregates were observed after 2 weeks of exposure (Hart 1986).
However, the inflammatory response was decreased after 3 weeks of exposure and no significant
histopathological alteration were observed in rats exposed for 4, 5, or 6 weeks. After 5 weeks of
cadmium exposure, a single high concentration (8.4 mg Cd/m3) resulted in less pulmonary damage
compared to non-pretreated animals (Hart et al. 1989a). Multiple pulmonary resistance factors appear to
contribute to this resistance/tolerance. These factors include increased levels of metallothionein,
glutathione, and γ-glutamylcysteinesynthetase (Hart et al. 2001). However, as suggested by Hart et al.
(2001), cadmium-adapted alveolar epithelial cells have a reduced ability to repair DNA damage and
apoptotic cell death is attenuated in these cells; thus, cadmium adapted animals may be more susceptible
to tumor formation.
CADMIUM 82
3. HEALTH EFFECTS
Cardiovascular Effects. Inhalation exposure to cadmium does not appear to have significant effects
on the cardiovascular system. Most studies of workers occupationally exposed to cadmium have not
found cadmium-related cardiovascular toxicity. In some studies, the mortality from cardiovascular
disease was lower in the cadmium-exposed population. Armstrong and Kazantzis (1983) reported that a
cohort of 6,995 British men occupationally exposed to cadmium for an average duration of 11 years had a
significantly lower mortality from vascular disease.
Fifty-three male workers exposed to cadmium and lead and 52 male controls were examined for
correlations in urine levels and blood pressure. The average duration of exposure was 12.5 years.
Correlations between blood pressure and urinary cadmium in exposed workers were not significant after
controlling for age or age and heart rate. Exposure to lead was a significant confounding factor (de Kort
et al. 1987).
Friberg (1950) investigated the health of workers in a manufacturing plant that made cadmium-containing
electrodes used in the production of batteries. Fifty-eight workers (30–50 years of age) were divided into
two groups based on number of years at the plant. Workers were clinically examined for subjective
symptoms and corresponding morphological or functional changes of the respiratory, cardiovascular, and
excretory systems. The cardiovascular exam was largely unremarkable. Only a slight rise in blood
pressure in a few cases was observed in Group 1. Electrocardiograms (EKG) were not significantly
different from a matched control group in Group 1. Group 2 had neither increased blood pressure nor
altered EKGs.
Kazantzis et al. (1988) studied mortality in a cohort of 6,958 cadmium-exposed male workers with
average occupational exposures of 12 years. This was a follow-up study to the work of Armstrong and
Kazantzis (1983). There was a significant deficit in deaths from cerebrovascular disease among men
occupationally exposed to cadmium. There was no significant excess risk from hypertensive or renal
disease.
Smith et al. (1980) studied 16 male high-exposure production workers and 11 male low-exposure office
and supervisory workers for renal function. Average duration of exposure was 25 years. High-exposure
workers were exposed to cadmium oxide concentrations of 0.23–45.2 mg/m3 and cadmium sulfide
concentrations of 0.04–1.27 mg/m3. No difference was found in hypertension between high- and low-
exposure workers, adjusted for age and weight or cigarette smoking.
CADMIUM 83
3. HEALTH EFFECTS
Sorahan and Waterhouse (1983) examined mortality rates in a cohort of 3,025 nickel-cadmium battery
workers (2,559 males and 466 females). Cadmium levels in air ranged from 0.05 to 2.8 mg/m3, primarily
as cadmium oxide. Duration of exposure ranged from 1 to >6 years. No increase in mortality from
diseases of the circulatory system (e.g., hypertension) was seen in cadmium-exposed workers.
Staessen and Lauwerys (1993), in a study known as the Cadmibel Study (a cross-sectional population
study), evaluated 2,327 people from a random sample of the population of four Belgian districts chosen to
provide a wide range of environmental exposure to cadmium. Participants completed a questionnaire
regarding their medical history, current and past occupations, smoking habits, alcohol consumption, and
intake of medications. Urine and blood samples were taken, and pulse rate, blood pressure, height, and
weight were recorded. Exposure to cadmium was considered to be by both the oral and inhalation routes.
Cadmium levels in blood and urine were significantly increased in the high-exposure areas compared to
the low-exposure areas (p<0.001). Blood pressure was not correlated with the urine or blood cadmium
levels. The prevalence of hypertension or other cardiovascular diseases was similar in all four districts,
and was not correlated with urine or blood cadmium levels. A follow-up investigation of 692 participants
of this study also showed no correlation with urine or blood calcium levels and the prevalence of
hypertension after 5 years (Staessen et al. 2000). These results do not support a hypothesis that cadmium
increases blood pressure, prevalence of hypertension, or other cardiovascular diseases.
One study found a statistically significant increase in blood pressure in exposed workers compared to
controls (Thun et al. 1989), but mortality in this cohort was lower than expected (Thun et al. 1985).
There are limited data on the cardiotoxicity of cadmium in animals. No significant alterations in systolic
blood pressure or histological alterations in the heart were observed in rats exposed to cadmium oxide
concentrations as high as 0.88 mg Cd/m3 for 13 weeks (NTP 1995).
Gastrointestinal Effects. In the cohort he studied, Friberg (1950) found no association between
inhalation cadmium exposure in workers and symptoms of gastrointestinal toxicity. Symptoms that had
been reported in case histories from the 1920s included pain or tenderness at the epigastrium associated
with nausea and some constipation. No other human studies report any cadmium associated gastro-
intestinal toxicity from inhalation exposure.
In the only animal study located, Rusch et al. (1986) observed erosion of the stomach in rats from
exposure to cadmium carbonate at 132 mg Cd/m3 for 2 hours. Postmortem evaluation was performed at
CADMIUM 84
3. HEALTH EFFECTS
1, 3, 7, and 30 days postexposure. After the inhalation exposure in a whole-body chamber, rats were
vacuumed to remove any cadmium carbonate dust adhering to the ventral and dorsal fur. The 132 mg
Cd/m3 dose is relatively high. Three of the 10 test animals died during the 2-hour exposure so the
significance of the gastrointestinal effect in this study is unclear.
Hematological Effects. The evidence concerning hematological effects following inhalation

exposure to cadmium is conflicting. Lowered hemoglobin concentrations and decreased packed cell
volumes have been observed in some studies of workers occupationally exposed to cadmium (Bernard et
al. 1979; Friberg 1950; Kagamimori et al. 1986), but not in others (Bonnell 1955; Chan et al. 1988;
Davison et al. 1988). The changes that were found often were not statistically significant (Bernard et al.
1979; Friberg 1950), and examination of bone marrow of some workers with lowered hemoglobin
revealed no detectable abnormalities (Friberg 1950).
Conflicting results on the hematologic effect of cadmium after inhalation exposure have also been
obtained with animal studies. Rabbits exposed to cadmium oxide dust at 4 mg/m3 for 3 hours/day,
21 days/month for 9 months developed eosinophilia and a slightly lower hemoglobin (Friberg 1950). In
contrast, rats exposed to cadmium oxide dust at 0.052 mg Cd/m3 for 24 hours/day for 90 days had
increased hemoglobin and hematocrit that were attributed to decreased lung function (Prigge 1978a).
Prigge (1978b) also reported increased hemoglobin and hematocrit in rats continuously exposed to
cadmium chloride at 0.204 mg Cd/m3 and higher for 21 days. Other studies report no Cd-related
hematological effects. A nearly continuous 30-day exposure in rats to cadmium sulfide at 1.034 mg
Cd/m3 had no effect on red blood cell counts (Glaser et al. 1986). A nearly continuous 218-day exposure
in rats to cadmium oxide dust or fume at 0.090 mg Cd/m3 had no effect on a routine hematological
evaluation (specific tests not reported) (Oldiges and Glaser 1986). A partial explanation for these
conflicting results may be that Cd-induced anemia primarily results from impaired absorption of iron
from the diet following gastrointestinal exposure to cadmium (see Section 3.2.2.2), and the amount of
gastrointestinal exposure following cadmium inhalation is variable depending on the form and dose.
Musculoskeletal Effects. Case studies indicate that calcium deficiency, osteoporosis, or

osteomalacia can develop in some workers after long-term occupational exposure to high levels of
cadmium (Adams et al. 1969; Blainey et al. 1980; Bonnell 1955; Kazantzis 1979; Scott et al. 1980).
Effects on bone generally arise only after kidney damage has occurred and are likely to be secondary to
resulting changes in calcium, phosphorus, and vitamin D metabolism (Blainey et al. 1980).
CADMIUM 85
3. HEALTH EFFECTS
No studies were located regarding musculoskeletal effects in animals after inhalation exposure to
cadmium.
Hepatic Effects. Liver effects are not usually associated with inhalation exposure to cadmium.
Friberg (1950) reported some nonspecific signs of liver disease in some workers from a group exposed to
cadmium in the air for 20 years. Test results included increased serum gamma-globulin, and other
indicators of abnormal serum globulins, including the flocculation test results of a positive Takata
reaction and/or an elevated thymol values. These tests (the latter of which are not used today) were
nonspecific indicators of cirrhosis or hepatitis. The significance of these test results with respect to
cadmium exposure is questionable. Subsequent studies on workers exposed to cadmium in the air have
not reported adverse liver effects (Adams et al. 1969; Bonnell 1955).
Liver effects have occasionally been found in animal studies. Cats examined within one day of inhalation
exposure to an unspecified concentration of cadmium oxide fume had a variety of hepatic lesions, and
liver changes from cell granulation at low doses to fatty infiltration at high doses (Prodan 1932).
Increased serum alanine aminotransferase activity, indicative of liver damage, was seen in rats exposed
for 30 days to 0.1 mg/m3 cadmium, but activity had returned to normal 2 months after exposure (Glaser et
al. 1986). Kutzman et al. (1986) reported an increased liver relative weight in rats from a cadmium
chloride exposure at 1.06 mg Cd/m3 for 6 hours/day, 5 days/week, for 62 days. Increased liver weight
was not observed from a continuous cadmium chloride exposure at 0.029 mg Cd/m3 for 255 days, from a
continuous cadmium oxide exposure at 0.090 mg Cd/m3 for 218 days, or from a continuous cadmium
sulfate exposure at 0.095 mg Cd/m3 for 413 days (Oldiges and Glaser 1986). Similar negative results
were reported by Prigge (1978a, 1978b) for a 21-day exposure to cadmium chloride at 0.581 mg Cd/m3,
and for a 63-day exposure to cadmium oxide at 0.105 mg Cd/m3 (a dose that was very toxic to the lungs).
A continuous high-dose exposure to cadmium sulfide at 2.247 mg Cd/m3 for 105 days did result in an
unspecified increase in liver weight in surviving rats (Oldiges and Glaser 1986). Cadmium accumulates
in the liver as well as the kidney, the main target organ for cadmium toxicity. The resistance of the liver
to toxic effects from cadmium may be related to a higher capacity of the liver to produce metallothionein
that would bind to cadmium and would lower the concentrations of free cadmium ions (see Section 3.4.3).
Renal Effects. There is very strong evidence that the kidney is one of the main target organ of
cadmium toxicity following extended inhalation exposure. The sensitivity of the kidney to cadmium was
recognized in an early investigation of workers exposed to cadmium oxide dust and cadmium fumes in a
factory producing nickel-cadmium batteries (Friberg 1950). These workers suffered from a high
CADMIUM 86
3. HEALTH EFFECTS
incidence of abnormal renal function, indicated by proteinuria and a decrease in glomerular filtration rate.
Many studies examining cadmium workers have reported various effects on the kidneys. Similar signs of
renal damage have been observed in many other studies of workers occupationally exposed to cadmium
(Adams et al. 1969; Bernard et al. 1979; Beton et al. 1966; Bonnell 1955; Bustueva et al. 1994; Chia et al.
1989; Elinder et al. 1985a, 1985b; Falck et al. 1983; Gompertz et al. 1983; Iwata et al. 1993; Jakubowski
et al. 1987; Järup and Elinder 1993; Järup et al. 1988; Kjellström et al. 1977a; Liu et al. 1985; Mason et
al. 1988; Piscator 1966; Roels et al. 1981b; Rose et al. 1992; Smith et al. 1980; Thun et al. 1989). Most
of these studies did not report cadmium exposure levels; rather, urinary cadmium, blood cadmium, or
cumulative exposures were used as biomarkers of exposure. Thus, these studies are not presented in the
LSE table (Table 3-1). Selected occupational exposure studies are summarized in Table 3-4.
One of the first signs of kidney effects is tubular dysfunction characterized by an increased urinary
excretion of low-molecular-weight proteins such as β2-microglobulin, human complex-forming
glycoprotein (pHC) (also referred to as α1-microglobulin), and retinol binding protein or increased
urinary levels of intracellular enzymes such as N-acetyl-β-glucosaminidase (NAG) (European Chemicals
Bureau 2007; Järup et al. 1998b). Numerous occupational exposure studies have reported increases in
urinary levels of these biomarkers (Bernard et al. 1990; Chen et al. 2006a, 2006b; Chia et al. 1992;
Elinder et al. 1985b; Falck et al. 1983; Jakubowski et al. 1987, 1992; Järup and Elinder 1994; Järup et al.
1988; Kawada et al. 1989; Roels et al. 1993; Shaikh et al. 1987; Thun et al. 1989; Toffoletto et al. 1992;
Verschoor et al. 1987). At higher exposure levels, increased urinary levels of high-molecular-weight
proteins such as albumin have been reported (Bernard et al. 1979, 1990; Chen et al. 2006a, 2006b; Elinder
et al. 1985b; Mason et al. 1988; Roels et al. 1989, 1993; Thun et al. 1989), but there is some debate as to
whether this represents glomerular damage (Bernard et al. 1979; Roels et al. 1989) or severe tubular
damage (Elinder et al. 1985a; Mason et al. 1988; Piscator 1984).
Chronic exposure to very high cadmium levels can result in glomerular damage resulting in decreases in
glomerular filtration rate (GFR) (Friberg 1950; Järup et al. 1995b; Roels et al. 1991). Järup et al. (1995b)
found a dose-response relationship between blood cadmium levels and GFR in cadmium workers. At
blood cadmium levels of 5.6 to <8.4 μg/L, 33.3% of the workers had decreased GFR (defined as <80% of
referents); whereas all subjects with blood cadmium levels of ≥8.4 μg/L exhibited a decreased GFR.
Another study did not find alterations in GFR in workers with urinary cadmium levels of approximately
11 μg/g creatinine; however, an exacerbation of the age-related decline in maximal GFR was observed
CADMIUM 87
3. HEALTH EFFECTS
Table 3-4. Summary of Occupational Exposure Studies Examining Renal Effects
Population Effect Adverse effect level Reference

Zinc-cadmium smelter Age-related decline in maximal U-Cd: 11.1 μg/g Roels et al. 1991
workers (n=87) GFR was exacerbated in workers creatinine
with cadmium-induced
microproteinuria.
Workers using Significant increase in urinary β2M U-Cd: 5 μg/g Verschoor et al.
cadmium pigments in and NAG levels. creatinine 1987
plastic production or
using cadmium in
welding (n=27)
Cadmium alloy workers Higher incidence of increased U-Cd: 10 μg/g Toffoletto et al. 1992
(n=164) urinary β2M levels (>250 μg/L cut- creatinine
off) when urinary cadmium levels
exceeded 10 μg/g creatinine on
one or more occasions, as
compared to workers who never
exceeded the 10 μg/g creatinine
level.
Cadmium smelter Significant increase in urinary U-Cd: 13.3 μg/g Shaikh et al. 1987
workers (n=53) protein and β2M levels. creatinine
Non-ferrous smelter Significant increase in urinary U-Cd: >10 μg/g Bernard et al. 1990
workers (n=58) β2M, RBP protein, pHC, albumin, creatinine
and transferrin levels.
Workers exposed to Significant correlation between U-Cd: 1.1–1.4 μg/g Kawada et al. 1989
cadmium pigment dust urinary cadmium and NAG levels; creatinine
(n=58) significant correlation with β2M at
one of the two time points.
Zinc-cadmium smelter Significant association between U-Cd: 4 μg/g Roels et al. 1993
workers (n=50) urinary cadmium levels and creatinine
urinary levels of NAG, albumin,
and transferrin. At higher urinary
cadmium levels (10 μg/g
creatinine), there were significant
associations with RBP and β2M.
Battery workers 10% prevalence of abnormal β2M U-Cd: 1.5 μg/g Järup and Elinder
(n=561) levels (220 μg/g creatinine cut-off). creatinine for 1994
≥60 years of age
U-Cd: 5 μg/g
creatinine for
<60 years of age
Alkaline battery factory 10% prevalence of renal U-Cd: 10–15 μg/g Jakubowski et al.
workers (n=102) dysfunction (β2M >380 μg/g creatinine 1987
creatinine; RBP >130 μg/g
creatinine).
Workers at a factory 25% prevalence of abnormal β2M U-Cd: 2–5 μg/g Elinder et al. 1985a
using cadmium- levels (300 μg/g creatinine cut-off). creatinine
containing solders
(n=60)
CADMIUM 88
3. HEALTH EFFECTS
Table 3-4. Summary of Occupational Exposure Studies Examining Renal Effects
Population Effect Adverse effect level Reference

Workers at nickel- Significant increase in pHC and U-Cd: 5–10 μg/g Chia et al. 1992
cadmium battery factory NAG levels (after adjustment for creatinine
(n=92) age, gender, and race).
Cadmium smelter Significant increases in levels β2M U-Cd: 5–10 μg/g Chen et al. 2006a,
workers (n=85) and NAG levels and increased creatinine 2006b
prevalence of abnormal levels of
these biomarkers.
Alkaline battery factory 10% prevalence of renal B-Cd: 300 μg-years/L Jakubowski et al.
workers (n=141) dysfunction (β2M >300 μg/L; RBP (30 years of 10 μg/L) 1992
>300 μg/L).
Battery workers Approximately 10% prevalence of B-Cd: 5.6 μg/L Järup et al. 1988
(n=440) abnormal β2M levels (35 μg/mmol Cumulative exposure:
3
creatinine cut-off). 691 μg-years/m
Cadmium recovery Significant association between Cumulative exposure: Thun et al. 1989
plant workers (n=45) cumulative exposure and urinary 300 mg/m3
β2M, RBP, phosphate, and
calcium and serum creatinine
levels.
Workers exposed to Increased urinary β2M and protein Cumulative exposure: Falck et al. 1983
3
cadmium fumes (n=33) levels (mean 6,375 μg/g creatinine 1,137 μg/m /years
and 246 mg/g creatinine,
respectively) in 7 workers (mean
in remaining 23 workers 53 μg/g
creatinine and 34 mg/g creatinine).
U-Cd = urinary cadmium, B-Cd = blood cadmium; GFR = glomerular filtration rate; pHC = human complex-forming
glycoprotein (also referred to as α1-microglobulin); NAG = N-acetyl-β-glucosaminidase; β2M = β2-microglobulin;
prt = protein; RBP = retinol binding protein
CADMIUM 89
3. HEALTH EFFECTS
(Roels et al. 1991). Other studies reported increases in serum creatinine levels, which are suggestive of
impaired GFR (Roels et al. 1989; Thun et al. 1989).
Depressed tubular resorption of other solutes such as enzymes, amino acids, glucose, calcium, copper,
and inorganic phosphate have been reported in workers with signs of tubular proteinuria (Elinder et al.
1985a, 1985b; Falck et al. 1983; Gompertz et al. 1983; Mason et al. 1988). An increased frequency of
kidney stone formation has also been reported in cadmium workers (Elinder et al. 1985a; Falck et al.
1983; Järup and Elinder 1993; Kazantzis 1979; Scott et al. 1978; Thun et al. 1989; Trevisan and Gardin
2005). This effect is likely to be secondary to disruption of calcium metabolism due to kidney damage.
Järup and Elinder (1993) calculated an incidence rate ratio (IRR) (after adjustment for age and calendar
time) of 3.0 (95% CI 1.3–6.8) for the occurrence of kidney stones among workers with a cumulative
exposure of ≥5000 μg/m3 years; the IRR was not significantly elevated at lower cumulative exposure
levels. Significant increases in kidney stone formation were observed in workers with increased urinary
cadmium (median of 3.7 μg/g creatinine), blood cadmium (median of 7 μg/L), and urinary
β2-microglobulin (median of 155 μg/g creatinine). The increased kidney stone formation may be
secondary to the cadmium-induced kidney damage disruption of calcium metabolism.
Hellström et al. (2001) evaluated the association between occupational cadmium exposure and end stage
renal disease among cadmium workers and residents living near a cadmium facility; renal replacement
therapy was used as a surrogate for renal disease. The standardized rate ratios (SRRs) (95% CI) were
2.1 (0.6–5.3) and 2.5 (0.7–6.5) in male workers aged 20–79 or 40–79 years, respectively. Although the
SRRs were not statistically significant, the ratios were significantly elevated in residents presumably
exposed to lower cadmium levels (see Section 3.2.2.2 for more information on these results). Studies
examining the cause of death among cadmium workers have not found significant increases in the
standardized mortality ratios (SMRs) for nephritis or nephrosis (Armstrong and Kazantzis 1983; Järup et
al. 1998a) or nonmalignant renal disease (Thun et al. 1985).
The data from studies of cadmium workers provide strong, clear evidence that the kidney is a sensitive
target following chronic exposure, but the data do not clearly identify a threshold of toxicity. The earliest
indication of an effect on the kidney is an increase in urinary levels of low molecular weight proteins
particularly β2-microglobulin, retinol binding protein, and pHC. However, there is some question as to
the adversity of these early indicators because increased excretion of low molecular weight proteins
precede the clinical manifestations (Bernard et al. 1997; Järup et al. 1998b). As noted by Bernard et al.
(1997), the assessment of the health significance of changes affecting a biomarker involves localizing the
CADMIUM 90
3. HEALTH EFFECTS
changes in the sequence of events that ultimately results in compromised renal function and appreciating
the probability that these changes may lead to a deterioration of renal function. Their guidelines for
interpreting β2-microglobulin levels in cadmium workers are presented in Table 3-5.
Another aspect of interpreting alterations in renal biomarkers and assessing risk is the issue of the
reversibility of cadmium-induced tubular dysfunction and impaired glomerular filtration rate. In workers
exposed to high levels of cadmium, cessation of exposure does not generally result in a reversibility of
kidney damage. Increases in urinary levels of β2-microglobulin, retinol binding protein, or total protein
(Elinder et al. 1985b; Järup et al. 1993; Mason et al. 1999; Piscator 1984; Roels et al. 1989; Thun et al.
1989) or a decrease in glomerular filtration rate (Järup et al. 1993; Piscator 1984; Roels et al. 1989) have
been observed in workers years after cadmium exposure cessation. However, in workers exposed to low
levels of cadmium, cessation of exposure resulted in decreased or no change in urinary β2-microglobulin
levels (McDiarmid et al. 1997; van Sittert et al. 1993). In studies by Roels et al. (1997) and Trzcinka-
Ochocka et al. (2002), former cadmium workers were divided into groups based on historical cadmium
levels and urinary β2-microglobulin or retinol binding protein levels. Both studies found that the
reversibility of tubular dysfunction was dependent on the cadmium body burden and the severity of
microproteinuria at the time cadmium exposure was reduced or ceased. In the Roels study, significant
decreases in retinol binding protein levels and no change in β2-microglobulin levels were observed in
workers whose urinary cadmium levels never exceeded 10 μg/g creatinine. Decreases in
β2-microglobulin and retinol binding protein levels were also observed in workers whose
β2-microglobulin levels were <300 μg/g creatinine or between 300 and 1,500 μg/g creatinine and urinary
cadmium levels were >10 μg/g creatinine, but were never >20 μg/g creatinine. However, a progression of
microproteinuria (increased urinary levels of β2-microglobulin and retinol binding protein levels) was
observed in workers who had initial β2-microglobulin levels >1,500 μg/g creatinine and urinary cadmium
levels >20 μg/g creatinine. In contrast, Trzcinka-Ochocka et al. (2002) found decreases in
β2-microglobulin and retinol binding protein levels in groups of workers with initial β2-microglobulin
and retinol binding protein levels of ≤300, >300, ≤1,500, or ≥1,500 μg/g creatinine; in all groups, the
initial mean urinary cadmium levels were >20 μg/g creatinine. However, the risk of increased excretion
of retinol binding protein was higher in the groups of workers with initial retinol binding protein levels of
>300 μg/g creatinine. Logistic regression analysis demonstrated that the initial level of retinol binding
protein was the most important determinant in reversibility of tubular proteinuria and that the influence of
urinary cadmium level or length of time since exposure cessation was not statistically significant.
CADMIUM 91
3. HEALTH EFFECTS
Table 3-5. Guidelines for Interpreting β2-microglobulin Levels
β2-Microglobulin level Significance

<300 μg/g creatinine Normal value.
300–1,000 μg/g creatinine Incipient cadmium tubulopathy (possibility of
reversibility after removal from exposure). No
change in GFR.
1,000–10,000 μg/g creatinine Irreversible tubular proteinuria which may lead to
accelerated decline in the GFR with age. GFR
normal or slightly altered.
>10,000 μg/g creatinine Overt cadmium nephropathy usually associated
with decreased GFR.
GFR = glomerular filtration rate
Source: Bernard et al. 1997

CADMIUM 92
3. HEALTH EFFECTS
The available occupational exposure data suggest that tubular dysfunction generally develops only after
cadmium reaches a threshold concentration in the renal cortex. However, a number of factors can
influence urinary levels of β2-microglobulin or retinol binding protein and direct relationship between
urinary levels of these proteins and a kidney cadmium concentration has not been established. Based on
the findings of early occupational exposure studies, a number of investigators estimated that the “critical
concentration” of cadmium in the renal cortex associated with increased incidence of renal dysfunction in
an occupational setting was about 200 μg/g wet weight (Friberg et al. 1974; Kjellström et al. 1977a; Roels
et al. 1983); this corresponds to a urinary cadmium levels of 5–10 μg/g creatinine (European Chemicals
Bureau 2007). Although 10 μg/g creatinine was initially established as a threshold urinary cadmium
concentration, there is sufficient evidence to suggest that adverse effects occur at lower urinary cadmium
levels (Chen et al. 2006a, 2006b; Chia et al. 1992; Elinder et al. 1985b; Järup and Elinder 1994; Kawada
et al. 1989; Roels et al. 1993; Verschoor et al. 1987).
Indications of renal dysfunction associated with airborne cadmium exposure has also been observed in
residents living near a lead/zinc smelter in the United Kingdom with high cadmium stack emissions
(Thomas et al. 2009) and a zinc smelter in Norway (Bråtveit et al. 2011). In both studies, the subjects
were exposed to airborne cadmium and elevated cadmium levels in the soil. The Thomas et al. (2009)
study found a significant association between urinary cadmium levels and modeled atmospheric cadmium
concentrations. The mean urinary cadmium concentrations were 0.22 and 0.34 nmol/mmol creatinine
(approximately 0.22 and 0.34 µg/g creatinine) in males and females, respectively, in the Thomas et al.
(2009) study and 0.44 and 0.42 µg/g creatinine in males and females, respectively, in the Bråtveit et al.
(2011) study; Bråtveit et al. (2011) also measured urinary cadmium levels in the residents living in a
nonpolluted area and found no significant differences in urinary cadmium levels between the two groups.
Thomas et al. (2009) found significant correlations between urinary cadmium levels and urinary NAG
levels in males and females and pHC in females. Additionally, the study found a significant dose-
response relationship between urinary cadmium levels and NAG levels above the reference level of
1.25 IU/mmol creatinine. Bråtveit et al. (2011) also found a significant association between urinary pHC
levels and urinary cadmium levels; however, there were no significant differences in pHC levels between
residents living in the polluted areas and the control area.
Early animal studies confirmed that renal damage occurs following inhalation exposure to cadmium.
Rabbits developed proteinuria after a 4-month inhalation exposure to cadmium metal dust at 4 mg/m3 for
3 hours/day, 21 days/month; histologic lesions were found after an additional 3–4 months of exposure
(Friberg 1950). Friberg (1950) noted that the degree of proteinuria was not especially pronounced. Most
CADMIUM 93
3. HEALTH EFFECTS
subsequent studies using inhalation exposure have not found proteinuria (Glaser et al. 1986; Kutzman et
al. 1986; Prigge 1978a, 1978b), primarily because the levels of exposure and durations of follow up (e.g.,
1–5 mg/m3 for intermediate exposures; 0.2–2 mg/m3 for chronic exposures) that produce serious
respiratory effects have not been sufficient to produce a critical concentration of cadmium in the kidney.
Dermal Effects. Dermal toxicity does not appear to be a significant effect of inhalation exposure to
cadmium. Studies of workers occupationally exposed to cadmium have not reported dermal effects
following acute or chronic exposure (Barnhart and Rosenstock 1984; Bonnell 1955; Friberg 1950). No
study was located that specifically examined dermal toxicity in humans or animals following inhalation
exposure to cadmium.
Ocular Effects. Ocular toxicity does not appear to be a significant effect of inhalation exposure to
cadmium. Studies of workers occupationally exposed to cadmium have not reported ocular effects
following acute or chronic exposure (Barnhart and Rosenstock 1984; Bonnell 1955; Friberg 1950). No
study was located that specifically examined ocular toxicity in humans following inhalation exposure to
cadmium.
Rats exposed to a single 2-hour inhalation exposure to about 100 mg Cd/m3 as cadmium pigments had
excessive lacrimation 4 hours after exposure (Rusch et al. 1986), but this was likely due to a direct
irritation of the eyes rather than a systemic effect.
Body Weight Effects. No data were found regarding the effects of inhaled cadmium on human body
weights.
In animals, cadmium has been shown to significantly reduce body weights. An acute exposure to
cadmium oxide fumes at 112 mg Cd/m3 for 2 hours (Rusch et al. 1986) and cadmium oxide dust at 4.6 mg
Cd/m3 for 3 hours (Buckley and Bassett 1987b) resulted in a significant reduction of body weight in male
rats. Cadmium chloride at 6.5 mg Cd/m3 for 1 hour or 4.5 mg Cd/m3 for 2 hours produced significant
reductions in male rat body weights (Bus et al. 1978; Grose et al. 1987). Cadmium carbonate at 132 mg
Cd/m3 for 2 hours slowed rat body weight gains (Rusch et al. 1986). NOAELs for acute cadmium
chloride exposure have been reported at 0.45 mg Cd/m3 for 2 hours (Grose et al. 1987); 0.17 mg Cd/m3
for 6 hours/day for 10 days (Klimisch 1993); and 6 mg Cd/m3 for 2 hours (Palmer et al. 1986). NOAELs
for cadmium sulfide and cadmium selenium sulfide were much higher at 99 mg Cd/m3 for 2 hours and
97 mg Cd/m3 for 2 hours, respectively (Rusch et al. 1986). The effect of cadmium on body weight gain
CADMIUM 94
3. HEALTH EFFECTS
appears to compound-related, with cadmium chloride the most toxic and cadmium sulfide the least toxic.
These compound-related differences are probably related to difference in absorption.
The body weight response also appears to be duration-related; lower NOAELs and LOAELs have been
identified for intermediate-duration exposure. Levels of cadmium that significantly reduce rat body
weights when administered for an intermediate exposure duration have been reported for cadmium
chloride at around 1 mg Cd/m3 for female and male rats (Baranski and Sitarek 1987; Kutzman et al.
1986), for cadmium chloride at around 0.394 mg Cd/m3 for pregnant female rats (Prigge 1978a), and for
cadmium dusts at 0.1 mg Cd/m3 for female rats (Prigge 1978a). NOAELs have been reported for
intermediate exposures to cadmium chloride at 0.394 mg Cd/m3 for female nonpregnant rats (Prigge
1978a), 0.33 mg Cd/m3 for rats (Kutzman et al. 1986), and 0.0508 mg Cd/m3 for male rats (Takenaka et
al. 1983). NOAELs have been reported for intermediate exposures to cadmium oxide dust at 0.16 mg
Cd/m3 for female rats (Baranski and Sitarek 1987) and 0.45 mg Cd/m3 for male rabbits (Grose et al.
1987); and for cadmium sulfide at 1.034 mg Cd/m3 for male rats (Glaser et al. 1986). A NOAEL for
chronic exposure in rats to cadmium sulfate has been reported as 0.95 mg Cd/m3 (Oldiges and Glaser
1986).
Other Systemic Effects. Yellow discoloration of the teeth has occasionally been reported in
workers occupationally exposed to high levels of cadmium (Friberg 1950; Liu et al. 1985). No data were
located to indicate that this was related to any functional impairment.
3.2.1.3 Immunological and Lymphoreticular Effects
There is limited evidence for immunological effects following inhalation exposure to cadmium. The
blood of workers exposed to cadmium for 1–14 years had a slight but statistically significant decrease in
the generation of reactive oxygen species by leukocytes compared to unexposed controls (Guillard and
Lauwerys 1989). The toxicological significance of this effect is unclear.
Karakaya et al. (1994) measured blood and urine concentrations of cadmium, and serum IgG, IgM, and
IgA in a group of 37 males employed in zinc/cadmium smelters and a small Cd-electroplating plant.
Blood cadmium concentrations were significantly higher in exposed workers compared to controls in both
the urine (2.39 versus 0.69 μg/100 mL, p<0.001) and the blood (5.55 versus 2.01 μg/g creatinine, p<0.05).
No differences between the exposed and control serum concentrations of IgG, IgM, and IgA populations
were observed. No changes in blood counts of white blood cells (lymphocyte, neutrophil, and eosinophil)
CADMIUM 95
3. HEALTH EFFECTS
were found between exposed and control populations, except for significantly increased monocyte counts.
No other studies were located regarding immunological effects in humans following inhalation exposure
to cadmium.
Acute inhalation exposure to cadmium chloride in mice at 0.190 mg Cd/m3 for 2 hours can affect immune
function, causing suppression of the primary humoral immune response (Graham et al. 1978). The
NOAEL for immunological effects from the study by Graham et al. (1978) was 0.11 mg Cd/m3.
Krzystyniak et al. (1987) reported spleen lymphocyte cytotoxicity at 0.88 mg Cd/m3 for 1 hour.
At intermediate-duration exposures, Kutzman et al. (1986) observed increased spleen relative weights and
lymphoid hyperplasia from inhalation of cadmium chloride aerosols at 1.06 mg Cd/m3 6 hours/day,
5 days/week for 62 days. Prigge (1978b) also observed increased relative spleen weights in pregnant
females at 0.394 mg Cd/m3 for an exposure of 24 hours/day for 21 days during gestation. Oldiges and
Glaser (1986) observed enlarged thoracic lymph nodes in dead animals in a chronic-exposure study with
cadmium sulfate at 0.092 mg Cd/m3 for 22 hours/day, 7 days/week for 413–455 days; and in an
intermediate study with cadmium oxide dust at 0.090 mg Cd/m3 for 22 hours/day, 7 days/week for
218 days. However, other studies have found no effect on natural killer cell activity or viral induction of
interferon in mice (Daniels et al. 1987). Evidence concerning the effect of inhalation exposure to
cadmium on resistance to infection is conflicting, because the same exposure decreases resistance to
bacterial infection while increasing resistance to viral infection (Bouley et al. 1982). The highest NOAEL
values and all LOAEL values from each reliable study for immunological effects in each species and
duration category are recorded in Table 3-1 and plotted in Figure 3-1.
3.2.1.4 Neurological Effects
Neurotoxicity is not generally associated with inhalation exposure to cadmium, although a few studies
have specifically looked for neurological effects. Hart et al. (1989b) reported that in a group of 31 men
occupationally exposed to cadmium in a refrigerator coil manufacturing plant (average
exposure=14.5 years) there was a modest correlation between cadmium exposure and decreased
performance on neuropsychologic tests for attention, psychomotor speed, and memory. The limited
number of men studied makes it difficult to evaluate the significance of this effect.
Rose et al. (1992) studied the presence and severity of olfactory impairment in workers chronically
exposed to cadmium fumes generated during a brazing operation. Detailed occupational history, medical
CADMIUM 96
3. HEALTH EFFECTS
history, and smoking history, and symptoms were collected for 55 workers. Body burden was estimated
using urinary cadmium levels, and renal damage was assessed by urinary β2-microglobulin levels.
Olfactory test scores from these workers were compared to a reference group of 16 male subjects that
were selected according to the following criteria: (1) no history of taste or smell complaints, (2) no
history of surgery to the upper respiratory tract, (3) no upper respiratory tract infection within 2 days of
testing, and (4) no history of having been tested. The dose of the cadmium oxide fume received by the
workers being evaluated in this study was not reported or estimated. For both the exposed workers and
the reference group, 38% were smokers. A significant olfactory impairment was observed in the workers
compared to the reference group (p<0.003). Thirteen percent of the workers were either moderately or
severely hyposmic compared to none in the reference group, 44% of the workers were mildly hyposmic
compared to 31% of the reference group, and only 44% of workers were normosmic. Although the
odor-identification test findings for workers were similar to those of the reference group, butanol
detection threshold scores were significantly lower in the worker population (p<0.005). The workers with
both higher urinary cadmium levels and tubular proteinuria had the most significant olfactory
dysfunction, with a selective defect in odor threshold. The results suggest that chronic occupational
cadmium exposure sufficient to cause renal damage is also associated with impairment in olfactory
function. Some limitations of the study are that historical exposure to other confounders cannot be ruled
out, the classification for nephrotoxicity is based on a single 24-hour urine β2-microglobulin level, and
the smoking history of the reference group was unknown. No other human neurological studies from
inhaled cadmium were found.
In rats, cadmium carbonate produced tremors from exposure to 132 mg Cd/m3 for 2 hours, and cadmium
fumes produced reduced activity at 112 mg Cd/m3 for 2 hours (Rusch et al. 1986). Studies on continuous
exposure to cadmium for 30 days have shown no neurological effects at 0.105 mg Cd/m3 for cadmium
chloride, 0.098 mg Cd/m3 for cadmium dusts, or 1.034 mg Cd/m3 for cadmium sulfide (Glaser et al.
1986). Cadmium chloride had no neurological effects at 0.33 mg Cd/m3 for 5 days/week, 6 hours/day for
a total of 62 daily exposures, but did significantly increase relative brain weight at 1.034 mg Cd/m3
(Kutzman et al. 1986). No other studies were located regarding neurological effects in adult animals after
inhalation exposure to cadmium. Neurological effects in offspring of rats exposed to cadmium by
inhalation during gestation are discussed in Section 3.2.1.5. The highest NOAEL values and all LOAEL
values from each reliable study for neurological effects in each species and duration category are recorded
in Table 3-1 and plotted in Figure 3-1.
CADMIUM 97
3. HEALTH EFFECTS
3.2.1.5 Reproductive Effects
Evidence is insufficient to determine an association between inhalation exposure to cadmium and

reproductive effects.
Gennart et al. (1992) studied male reproductive effects of cadmium in 83 occupationally exposed blue-
collar Belgian workers in two smelting operations. The workers were exposed to cadmium in dust and
fumes. Information was recorded on age, residence, education, occupational and health history, actual
and previous occupations, smoking habits, and coffee and alcohol consumption. Fertility parameters
included dates of birth of wife and husband, date of marriage, and number of children born alive and their
dates of birth. Blood and urine samples were also collected from each worker. Some cadmium workers
had been excessively exposed; 25% of them already had signs of kidney dysfunction as evidenced by
microproteinuria and/or a serum creatinine level >13 mg/L. No effects were observed on male fertility as
evidenced by no significant influence of cadmium on the probability of a live birth. The limitation of this
study, as described by the authors, included the fact that the wives were not interviewed and, therefore,
factors that could have influenced their reproductive ability were not considered.
Men occupationally exposed to cadmium at levels causing renal damage had no change in testicular
endocrine function, as measured by serum levels of testosterone, luteinizing hormone, and follicle-
stimulating hormone (Mason 1990).
Noack-Fuller et al. (1993) measured concentrations of cadmium, lead, selenium, and zinc in whole semen
and seminal fluid of 22 unexposed men (13 were smokers) to evaluate intra-individual variability and to
examine the statistical association between element concentrations and semen characteristics and sperm
motion parameters. None of the men had any known occupational exposure to cadmium.
Concentrations of cadmium were similar in semen and seminal plasma (0.40±0.23 and 0.34±0.19 μg/L,
respectively). Sperm motility (p<0.02), linear velocity (p<0.001), and curvilinear velocity (CV)
(p<0.002) were significantly correlated with semen cadmium levels. Intra-individual coefficients of
variation for sperm count (CV=46±4%) and sperm concentration (CV=37±6%) showed the highest
variability. No positive correlation was found between cadmium concentration in semen and sperm
density. The smokers had slightly elevated levels of cadmium. The concentrations of cadmium in semen
of these volunteers were very low. Additional studies are needed (preferably with larger sample sizes) to
evaluate the robustness of this association between cadmium (at the low levels detected) and sperm
motion parameters. Saaranen et al. (1989) measured cadmium, selenium, and zinc in seminal fluid and
CADMIUM 98
3. HEALTH EFFECTS
serum in 64 men, half of whom were smokers. Smokers had significantly higher serum cadmium
concentration than nonsmokers. Seminal fluid cadmium was also elevated in smokers, and was higher
than serum cadmium in smokers consuming >20 cigarettes daily. Semen quality was measured for
volume, sperm density, morphology, motility, and number of immature germ cells. No differences were
found in semen quality or fertility between smokers and nonsmokers. There was no significant
correlation between seminal fluid cadmium levels and semen quality or fertility.
Xu et al. (1993a) measured trace elements in blood and seminal plasma and their relationship to sperm
quality in 221 Singapore men (age range 24–54; mean 34.8) who were undergoing initial screening for
infertility. Men with significant past medical history and those who had been occupationally exposed
were excluded. Parameters monitored included semen volume and sperm density, motility, morphology,
and viability. Graphite furnace atomic absorption was used to determine cadmium concentration in blood
and semen. No differences were observed in sperm quality (density, motility, morphology, volume, and
viability) of the 221 men compared to a cohort of 38 fertility proven men (wives had recently conceived).
Cadmium levels in blood did have a significant inverse relationship with sperm density (r=-0.15, p<0.05)
in oligospermic men (sperm density <20 million/mL), but not in normospermic men. There was a
significant reduction in sperm count in men with blood cadmium of >1.5 μg/L. Also, there was a weak
negative correlation between defective sperm and concentration of cadmium in semen (r=-0.21, p<0.05).
The volume of semen was inversely proportional to the cadmium concentration in semen (r=-0.29,
p<0.05). These findings suggest that cadmium may have an effect on the male reproductive system.
Limitations of the study include lack of control for potential confounding factors such as the lower levels
of zinc in seminal plasma, and the validity of using infertile men as the study group (i.e., again because of
confounding factors that may be affecting both cadmium levels and sperm levels).
A postmortem study of men occupationally exposed to cadmium who died from emphysema found high
levels of cadmium in their testes, but no histologic lesions other than those attributable to terminal illness
(Smith et al. 1960)
Russian women occupationally exposed to cadmium concentrations up to 35 mg/m3 had no irregularities

in their menstrual cycles (Tsvetkova 1970). Fertility and other indices of reproductive function were not
measured. No studies were located that showed reproductive effects in women following inhalation
CADMIUM 99
3. HEALTH EFFECTS
In rats, exposure to cadmium oxide dusts at 1 mg Cd/m3 for 5 hours/day, 5 days/week for 20 weeks,
increased the duration of the estrous cycle (Baranski and Sitarek 1987). Male and female rats exposed to
cadmium concentrations of 1.06 mg/m3 as cadmium chloride for 6 hours/day, 5 days/week for 62 days
and subsequently mated with unexposed controls showed no loss in reproductive success measured by
viable embryos and preimplantation losses, but males did have an increased relative testes weight
(Kutzman et al. 1986). Similarly, no alterations in fertility in female rats exposed to 0.16 mg Cd/m3 as
cadmium oxide for 5 months prior to mating with unexposed males and during the mating and gestation
periods (Baranski 1984). Tsvetkova (1970) studied rats exposed to cadmium sulfate aerosols at 2.8 mg
Cd/m3 before and during pregnancy. A lengthening of the estrous cycle was observed 2 months after the
start of exposure in one-half of the exposed animals. By the fourth month, diestrus was 6.2 days in the
exposed group compared to 1.2 days in controls. An increased in estrous cycle length was also observed
in rats exposed to 0.88 mg Cd/m3 as cadmium oxide for 13 weeks (NTP 1995); this study also reported a
significant decrease in spermatid counts in males exposed to the same cadmium concentration. No other
studies were found on reproductive effects in animals. The highest NOAEL values and all LOAEL
values from each reliable study for reproductive effects in each species and duration category are
recorded in Table 3-1 and plotted in Figure 3-1.
3.2.1.6 Developmental Effects
Russian women occupationally exposed to cadmium at concentrations ranging from 0.02 to 35 mg/m3 had
offspring with decreased birth weights compared to unexposed controls, but without congenital
malformations (Tsvetkova 1970). No association was found between birth weights of offspring and
length of maternal cadmium exposure. Moreover, no control was made for parity, maternal weight,
gestational age, or other factors known to influence birth weight (Tsvetkova 1970). A nonsignificant
decrease in birth weight was found in offspring of women with some occupational exposure to cadmium
in France; however, no adverse effects were documented in these newborns (Huel et al. 1984). Huel et al.
(1984) used hair samples to estimate exposure, and this method is limited without controls to distinguish
between exogenous and endogenous sources. No other studies were located regarding developmental
effects in humans after inhalation exposure to cadmium.
In utero exposure to cadmium results in significant decreases in pup viability, fetal body weight, pup
body weight gain, delays in ossification, and impaired performance on neurobehavioral tests. Decreases
in pup viability (percentage of pups born alive that survived until postnatal day 4) were observed in the
offspring of rats exposed to 0.16 mg Cd/m3 as cadmium oxide for 5 months prior to mating and during
CADMIUM 100
3. HEALTH EFFECTS
mating and gestation day 1–20 (Baranski 1984). Decreases in fetal body weight were observed in the
offspring of rats exposed to ≥0.581 mg Cd/m3 as cadmium chloride (Prigge 1978b) or cadmium oxide
(NTP 1995) and mice exposed ≥0.4 mg Cd/m3 as cadmium oxide (NTP 1995); maternal toxicity
(decreased body weight gain and/or hypoactivity and dyspnea) were also observed at these exposure
levels. Although Baranski (1984) did not find significant alterations in birth weight, a decrease in pup
body weight gain was observed in the offspring of rats exposed to 0.16 mg Cd/m3 as cadmium oxide.
Delays in skeletal ossification have also been observed in the offspring of rats and mice exposed to
1.7 mg Cd/m3 as cadmium oxide (NTP 1995); although Baranski (1985) also reported a delay in
ossification in the offspring of rats, it is unclear whether the effect was observed at 0.02 mg Cd/m3,
0.16 mg Cd/m3, or both.
Baranski (1984, 1985) evaluated the potential of cadmium to induce neurobehavioral effects in the
offspring of rats exposed to 0.02 or 0.16 mg Cd/m3 as cadmium oxide for 5 months prior to mating,
during mating and gestation day 1–20; the studies reported similar effects and it is unclear whether the
papers are reporting the results from separate experiments. The neurobehavioral alterations included
decreased exploratory motor activity and avoidance acquisition in 3 month old male and female offspring,
respectively, exposed to 0.02 mg Cd/m3. At 0.16 mg Cd/m3, decreased avoidance acquisition in 3 month
old female offspring, exploratory motor activity in 3 month old male and female offspring, ambulations in
open field test in 5 month old male offspring, and spontaneous mobility in male offspring and
prolongation of latency in negative geotaxis test.
3.2.1.7 Cancer
The relationship between occupational exposure to cadmium and increased risk of cancer (particularly
lung and prostate cancer) has been explored in a number of occupational exposure studies. The results of
these studies are conflicting and the carcinogenicity of cadmium has not been unequivocally established.
Overall, the results provide suggestive evidence of an increased risk of lung cancer in humans following
prolonged inhalation exposure to cadmium. Initial studies indicated an elevation in prostate cancer
among men occupationally exposed to cadmium (Kipling and Waterhouse 1967; Kjellström et al. 1979;
Lemen et al. 1976), but subsequent investigations found either no increases in prostate cancer or increases
that were not statistically significant (Elinder et al. 1985c; Kazantzis et al. 1988; Sorahan 1987; Sorahan
and Esmen 2004; Thun et al. 1985). Based on an analysis of the mortality data from a 5-year update of
the cohort from 17 plants in England and a review of the other epidemiological evidence, Kazantzis et al.
(1992) concluded that cadmium does not appear to act as a prostatic carcinogen.
CADMIUM 101
3. HEALTH EFFECTS
Significant increases in mortality from lung cancer have been reported in workers employed at a U.S.
cadmium recovery facility (Stayner et al. 1992a; Thun et al. 1985), nickel-cadmium battery facilities in
England (Sorahan 1987) and Sweden (Järup et al. 1998a), and in a cohort of workers at cadmium
processing facilities and/or smelters (Ades and Kazantzis 1988; Kazantzis et al. 1988). However, no clear
relationships between level and duration of cadmium exposure and lung cancer risk have been established
and many of these studies did not account for confounding exposure to other carcinogenic metals
(particularly arsenic and nickel) and cigarette smoking.
The possible association between occupational exposure to cadmium and lung cancer was investigated in
several studies of a cohort of workers employed at a U.S. cadmium recovery facility. The cohort was
initially examined by Lemen et al. (1976) who found a significant increase in deaths from malignant
neoplasms of the respiratory tract among hourly workers employed for at least 2 years between 1940 and
1969. A re-examination of the cohort (deaths through 1978) also found statistically significant
standardized mortality rates (SMRs) for malignant neoplasms in the respiratory tract (Thun et al. 1985).
To adjust for possible arsenic exposure (between 1918 and 1925, the facility functioned as an arsenic
smelter), workers were divided based on year of hire. Mortality from lung cancer was significantly
elevated in workers hired prior to 1926 and among workers hired after 1926 with 2 or more years of
employment. Dividing the workers into three exposure groups based on estimated cumulative exposure
resulted in a significant dose-related trend for lung cancer deaths; in the highest exposure group
(cumulative exposures >8 years-mg/m3), a 2- to 8-fold increase in the risk of lung cancer deaths was
observed (Thun et al. 1985). A subsequent analysis of these data (workers followed through 1985) used
comparisons of rates with the cohort rather than the U.S. population (Stayner et al. 1992a). Lung cancer
mortality was significantly increased among non-Hispanic whites, among workers with the highest
cumulative exposure (>2,291 days-mg/m3), and among workers with the longest time since first exposure
(>20 years). Lamm et al. (1992, 1994) used nearly the same data set for the U.S. cohort as Stayner et al.
(1992a) in a nested case-control analysis that used the period of hire as a surrogate for arsenic exposure.
Based on this analysis as a means to control for the confounding factor of arsenic exposure, Lamm et al.
(1992, 1994) reported no residual association of lung cancer with cadmium. They also reported that cases
were eight times more likely to have been cigarette smokers than were controls. Lamm et al. (1992,
1994) conclude that arsenic exposure and cigarette smoking were the major determinants of lung cancer
risk, not cadmium exposure.
CADMIUM 102
3. HEALTH EFFECTS
The reasons for these conflicting conclusions based on the same cohort data are unclear. Doll (1992)
suggested some possible reasons including: (1) that the total number of cases was small (n=25) and that
only 21 of these cases were included in both studies (i.e., each study included some cases that were not
included in the other study); (2) that Stayner et al. (1992a) used national rather than regional mortality
rates; (3) that the Lamm et al. (1992, 1994) control series was overmatched, although the matching by
date of hire was necessary to control for arsenic exposure; and (4) that there are some concerns about the
validity (i.e., biological relevance) of the dose-response-models used by Stayner et al. (1992a). In a
response to Doll (1992), Stayner et al. (1993) reported that use of regional mortality rates would increase
rather than decrease support for their conclusion, and that the nested case-control analysis of Lamm et al.
(1992) used overmatched controls. Stayner et al. (1993) provided additional analyses including the use of
the Armitage-Doll multistage model to support the conclusion of an increased risk of cancer from
cadmium exposure. Sorahan and Lancashire (1994) subsequently raised concerns about inconsistencies
and inaccuracies in the NIOSH job history data used in these studies on the U.S. cohort. Sorahan and
Lancashire (1997) then conducted further analyses, based on detailed job histories extracted from time
sheet records, to better resolve the potential confounding affects of arsenic. Poisson regression was used
to investigate risks of mortality from lung cancer in relation to four concentrations of accumulative
exposure to cadmium (<400, 400–999, 1,000–1,999, and >2,000 mg-days/m3). After adjustment for age
attained, year of hire, and Hispanic ethnicity; Sorahan and Lancashire (1997) report a significant positive
trend (p<0.05) between cumulative exposure to cadmium and risks of mortality from lung cancer.
However, when the exposure to cadmium was evaluated with or without concurrent exposure to arsenic, a
significant trend for lung cancer was only found for exposure to cadmium received in the presence of
arsenic trioxide. Since there were only 21 deaths from lung cancer, Sorahan and Lancashire (1997) state
that it is impossible to determine which of the following three hypotheses is the correct one: (1) cadmium
oxide in the presence of arsenic trioxide is a human lung carcinogen, (2) cadmium oxide and arsenic
trioxide are human lung carcinogens and cadmium sulphate and cadmium sulphide are not (i.e., cadmium
sulphate and cadmium sulphide were the main cadmium compounds of exposure when arsenic was not
present), or (3) arsenic trioxide is a human carcinogen and the three cadmium compounds are not
carcinogenic.
The carcinogenicity of cadmium has also been examined in European alloy, battery, smelter, and process
workers. A study of workers at two copper-cadmium alloy facilities in the United Kingdom found no
significant increase in lung cancer mortality (Sorahan et al. 1995). Dividing the workers into groups
based on cumulative cadmium exposure or time since first exposure did not result in significant increases
in lung cancer deaths in the alloy workers. An initial study of workers at nickel-cadmium battery
CADMIUM 103
3. HEALTH EFFECTS
manufacturing facilities in the United Kingdom found a significant increase in cancer of the respiratory
tract (Sorahan and Waterhouse 1983). A subsequent study (Sorahan 1987) found an increase in lung
cancer deaths among workers with the highest exposure first employed between 1926 and 1946; no
association was found in workers employed after 1946. Another study of nickel-cadmium battery
workers in the United Kingdom did not find significant increases in lung cancer deaths (Sorahan and
Esmen 2004), although a significant increase in pharyngeal cancer deaths was observed. A study of
nickel cadmium battery workers in Sweden found an increase in lung cancer mortality, but the increase
was not statistically significant (Elinder et al. 1985c). An update of this study, which includes additional
workers, found a significant increase in lung cancer deaths (Järup et al. 1998a). However, there was no
exposure-response relationship between cumulative exposure to cadmium (or nickel) and the risk of lung
cancer. A significant increase in lung cancer mortality was observed in workers employed at a zinc-lead-
cadmium smelter (Ades and Kazantzis 1988). However, no relationship between cumulative cadmium
exposure and lung cancer deaths was found, suggesting that cadmium was not the causative agent.
Another study of workers in 19 facilities in the United Kingdom that process cadmium did not find a
statistically significant increase in lung cancer deaths (Armstrong and Kazantzis 1983). An update of this
study found a significant increase in lung cancer deaths (Kazantzis et al. 1988). However, >60% of the
lung cancer deaths were workers at the zinc-lead-cadmium smelter examined by Ades and Kazantzis
(1988).
Studies in rats provide strong evidence of the lung carcinogenic potential of chronically inhaled cadmium.
Oldiges et al. (1989) reported a clear dose response increase in lung tumors in male and female rats from
an 18-month continuous exposure to either cadmium chloride, cadmium oxide dusts, cadmium oxide
fume, cadmium sulfate, or cadmium sulfide. In the cadmium chloride study at 30 μg/m3, the observation
period in the males had to be shortened to 30 months (rather than 31) because of mortality in excess of
75%. No lung tumors were observed in control rats after 31 months of observation. A high incidence of
nodules and tumors was seen in 30 μg/m3 exposures to cadmium chloride in both males and females.
Results showed lung nodules in 18 of 20 males and 15 of 18 females and primary lung tumors in 15 of
20 males and 13 of 18 females. Tumor incidence as bronchioalveolar adenomas, adenocarcinomas,
squamous cell carcinomas, or combined epidermoid carcinoma and adenocarcinoma were 2, 12, 0, and
1 for males; and 4, 7, 0, and 2 for females, respectively. Increased lung tumors in males and females were
also observed with chronic exposures to cadmium oxide dust or fume at 30 μg/m3, to cadmium sulfate at
90 μg/m3, and to cadmium sulfide at 90 μg/m3 (Oldiges et al. 1989). Cadmium sulfate produced by
photolysis of cadmium sulfide under the experimental conditions may have contributed to some of the
response observed with cadmium sulfide (Konig et al. 1992).
CADMIUM 104
3. HEALTH EFFECTS
Takenaka et al. (1983) also demonstrated cadmium carcinogenicity in male rats exposed to cadmium
chloride aerosols at 0.0134, 0.0257, and 0.0508 mg Cd/m3 for 18 months. The exposure produced a dose-
related increase in lung epidermoid carcinomas, adenocarcinomas, and mucoepidermoid carcinomas
starting at 20 months. No other type of tumor was observed to increase with increasing dose.
In a protocol similar to the studies by Oldiges et al. (1989), Heinrich et al. (1989) did not observe an
increase in lung tumors in male or female Syrian golden hamsters from chronic inhalation exposure to
either cadmium oxide dust or fumes, cadmium chloride, cadmium sulfate, or cadmium sulfide. In female
mice, lung tumor incidence increased at all dose levels, but incidence in the controls was also high, and
the cadmium-induced increases were not statistically significant. Lung tumors in the cadmium-treated
mice also did not increase in a dose-responsive manner except for a weak increase from exposure to the
cadmium oxide fumes (Heinrich et al. 1989).
The available data provide inconclusive evidence on the potential of cadmium to induce lung cancer in
humans. The strongest evidence comes from early studies of workers at a U.S. cadmium recovery facility
(Stayner et al. 1992a; Thun et al. 1985), but later examinations of this cohort did not find conclusive
evidence (Lamm et al. 1992, 1994; Sorahan and Lancashire 1997). The inconsistent results may be due to
the small number of lung cancer cases and adjustments for possible early exposure to arsenic. Some
studies of European cadmium workers have found significant increases in lung cancer (Ades and
Kazantzis 1988; Järup et al. 1998a; Kazantzis et al. 1988; Sorahan 1987; Sorahan and Waterhouse 1983),
but lung cancer deaths were not significantly associated with cumulative cadmium levels or duration of
exposure and the investigators concluded that the effects may not have been related to cadmium exposure.
Based on an early 1990s analysis of the available human and animal data, IARC (1993) classified
cadmium as carcinogenic to humans (Group 1), based on sufficient evidence for carcinogenicity in both
human and animal studies. Similarly, the DHHS (NTP 2011) classified cadmium and certain cadmium
compounds as substances known to be human carcinogens. EPA classified cadmium as a probable human
carcinogen by inhalation (Group B1), based on limited evidence of an increase in lung cancer in humans
and sufficient evidence of lung cancer in rats (IRIS 2012). EPA estimated an inhalation unit risk (the risk
corresponding to lifetime exposure to 1 μg/m3) of 1.8x10-3 based on the Thun et al. (1985) study (IRIS
2012). A range of concentrations that correspond to upper bound lifetime excess risks of 10-4–10-7 is
shown in Figure 3-1.
CADMIUM 105
3. HEALTH EFFECTS
3.2.2 Oral Exposure
Information on health effects of oral exposure to cadmium in humans is derived mainly from studies of
residents living in cadmium-polluted areas. Cadmium exposure in these populations is often estimated by
blood or urinary cadmium levels (see Section 3.8.1). Exposure in these cases occurs primarily through
the diet, but smokers in these cohorts are also exposed to cadmium by inhalation. When evaluating oral
exposure studies, smoking was treated as a confounding variable rather than an exposure route because of
the large number of toxic compounds (in addition to cadmium) present in cigarette smoke, and because
the primary concern is effects attributable to cadmium. Cadmium is more readily found in the free ionic
form in water, while in food, the cadmium ion generally exists in a complex with a variety of ligands,
including proteins such as metallothionein (Crews et al. 1989; Groten et al. 1990; Nordberg et al. 1986).
Experimental studies in animals have generally used soluble salts of cadmium (such as cadmium chloride)
for food, drinking water, and gavage exposures. The toxicological properties of the cadmium ion do not
appear to depend on the counter ion, although absorption may be significantly affected by protein
complexes (see Section 3.3.1.2).
3.2.2.1 Death
Intentional ingestion of cadmium has been used as a means of suicide, causing death due to massive fluid
loss, edema, and widespread organ destruction (Buckler et al. 1986; Wisniewska-Knypl et al. 1971). The
doses ingested in two known fatal cases were estimated to be 25 mg Cd/kg from cadmium iodide
(Wisniewska-Knypl et al. 1971) and 1,840 mg Cd/kg from cadmium chloride (Buckler et al. 1986). Time
to death after cadmium iodide ingestion was 7 days (Wisniewska-Knypl et al. 1971) and 33 hours after
ingestion of the cadmium chloride (Buckler et al. 1986).
In rats and mice, acute oral LD50 (lethal dose, 50% kill) values for cadmium range from about 100 to
300 mg/kg (Baer and Benson 1987; Basinger et al. 1988; Kostial et al. 1978; Kotsonis and Klaassen 1978;
Shimizu and Morita 1990). The lowest dose causing death (2 of 20 animals) was 15.3 mg/kg in Sprague-
Dawley rats (Borzelleca et al. 1989). Very young animals have lower LD50 values than adult animals
(Kostial et al. 1978, 1989); this effect may be related to the greater fractional absorption of ingested
cadmium in the immature organism (see Section 3.4.1.2). For example, the LD50 values in rats aged 2, 3,
6, 18, and 54 week are 47, 240, 216, 170, and 109 mg/kg, respectively (Kostial et al. 1978).
Deaths related to cadmium exposure have been reported in only two of the intermediate exposure studies
found. In a study in Wistar rats exposed to cadmium chloride by gavage at 40 mg Cd/kg/day,
CADMIUM 106
3. HEALTH EFFECTS
5 days/week for up to 14 weeks; 4 of 13 female Wistar rats died by 8 weeks (Baranski and Sitarek 1987).
In mice, Blakley (1986) studied the effect of cadmium on chemical- and viral-induced tumor production.
Female albino Swiss mice (8 weeks old, n=41) were administered cadmium chloride in the drinking water
for 280 days at doses of 0, 5, 10, or 50 ppm. These mice have a high incidence of spontaneous
lymphocytic leukemia of thymic origin. A significant 33% increase (p=0.0228, chi-square analysis) in
deaths from virally induced leukemia was observed from exposure to 1.9 or 9.5 mg Cd/kg/day. The
deaths were attributed to cadmium-impaired immunosurveillance mechanisms that control expression of
the murine lymphocytic leukemia virus.
The LOAEL values from each reliable study for lethality in each species and duration category are
recorded in Table 3-6 and plotted in Figure 3-2.
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each
species and duration category are recorded in Table 3-6 and plotted in Figure 3-2.
Respiratory Effects. No studies were located regarding respiratory effects in humans after oral
No respiratory effects were observed in Rhesus monkeys from 4 mg/kg/day of cadmium chloride in the
food for 9 years (Masaoka et al. 1994). Intermediate-duration oral exposure caused fibrosis in lungs of
rats exposed to 2.4 mg Cd/kg/day of cadmium chloride after 6 and 16 weeks (Miller et al. 1974b).
Petering et al. (1979) observed a reduced static compliance and lung lesions (not specified) in male
Sprague-Dawley rats exposed to 1.2 mg Cd/kg/day in water for 200 days. Zinc-deficient rats were more
susceptible to lung lesions from exposure to cadmium chloride (Petering et al. 1979). Rats exposed to
cadmium chloride at 3.62 mg Cd/kg/day in the drinking water for 120 days developed emphysema
(Petering et al. 1979). No histopathologic lesions of the lung were found in male Sprague-Dawley rats
after 24 weeks of exposure to cadmium in drinking water at a maximum dose of 8 mg/kg/day (Kotsonis
and Klaassen 1978). Lung weight was unchanged in Wistar rats after 90 days of exposure in drinking
water at 16 mg/kg/day (Prigge 1978a). Effects on the lung following oral exposure to cadmium may be
secondary to systemic changes (Petering et al. 1979); however, the studies that found lung effects did not
examine other systemic effects in the exposed rats (Miller et al. 1974b; Petering et al. 1979).
Table 3-6 Levels of Significant Exposure to Cadmium - Oral
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments
ACUTE EXPOSURE
Death
1 Rat once
29 (LD50 at 8 days; 2 weeks Kostial et al. 1978
(NS) (G) old) CdCl2
29
129 F (LD50 at 8 days; 6 weeks

old)
129
104 F (LD50 at 8 days; 18

weeks old)
104
230
3. HEALTH EFFECTS
2 Rat once Kotsonis and Klaassen 1977
225 M (LD50 at 14 days)
(Sprague- (GW)
CdCl2
225
Dawley)
232
3 Rat 2 wk
42 M (7/9 died within 2 weeks) Kotsonis and Klaassen 1978
(Sprague- (W)
CdCl2
42
Dawley)
233
4 Rat once Shimizu and Morita 1990

327 M (LD50 at 24 hours; fed
(Sprague- (GW) rats)
Dawley) CdCl2
327
107 M (LD50 at 24 hours; fasted

rats)
107
236
5 Mouse once Baer and Benson 1987

95.5 M (LD50 at 96 hours)
(Swiss- (GW)
CdCl2
95.5
Webster)
238
6 Mouse once Basinger et al. 1988

112 M (5/10 died within 8 days)
(ICR) (GW)
CdCl2
112
107
239
Table 3-6 Levels of Significant Exposure to Cadmium - Oral (continued)
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
Systemic
7 Rat 10 d Baranski 1985
Gd 7-16 Bd Wt 2F 12 F (14% decreased
(Wistar) maternal body weight) CdCl2
2
once
(GW) 12
245
8 Rat 10 d Borzelleca et al. 1989

1 x/d Hemato 31.3 M 65.6 M (increased hemoglobin,
(Sprague- hematocrit, erythrocytes) CdCl2
31.3
Dawley) (GW) 138 F

138
65.6
246
Hepatic 65.6 M 138 M (focal necrosis of

hepatocytes)
65.6
3. HEALTH EFFECTS
138
Renal 15.3 (focal necrosis of tubular

epithelium)
15.3
Bd Wt 15.3 M (18% decreased body 31.3 M (23% decreased body

weight) weight)
15.3 31.3
31.3 F 65.6 F (18% decreased body

weight)
31.3
65.6

Hepatic 13.9
(Sprague- (W)
CdCl2
13.9
Dawley)
247
Renal 13.9
13.9
Bd Wt 13.9
13.9
1.1 M 7.8 M (14% decreased body 11.2 M (25% decreased body

weight) weight)
1.1
7.8 11.2
108
CADMIUM
Exposure/ LOAEL
Duration/
(Route)

Cardio 150 M
(Sprague- (GW)
CdCl2
150
Dawley)
248
Hemato 150 M
150
Hepatic 150 M
150
Renal 25 M (50% decrease in urine

flow for first 2 days)
25
Bd Wt 100 150 M (initial 12% decreased
3. HEALTH EFFECTS
body weight)
100
150
11 Rat Gd 6-15 Machemer and Lorke 1981

Gastro 6.13 F 61.32 F (intestinal necrosis,
(Long- Evans) (GW) hemorrhage, ulcers) CdCl2
6.13
61.32
249
Bd Wt 1.84 F 6.13 F (27% decrease in body 18.39 F (persistent 50% decrease

weight gain during in maternal body weight
1.84
treatment) gain)
6.13 18.39
12 Rat Gd 6-15 Machemer and Lorke 1981

Gastro 12.5 F
(Long- Evans) (F)
CdCl2
12.5
250
Bd Wt 3.5 F 12.5 F (transient 19% decrease

in maternal body weight
3.5
gain during treatment)

12.5
13 Rat 12 d Sakata et al. 1988

Hemato 12 M (anemia)
(Wistar) (W)
CdCl2
12
251
109
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
14 Rat once Shimizu and Morita 1990

Hepatic 75 M (focal degeneration and
(Sprague- (GW) necrosis of parenchymal
Dawley) CdCl2
cells)
75
252
15 Mouse once Andersen et al. 1988

Gastro 15.7 M 30.4 M (gastritis and enteritis) 88.8 M (severe gastric necrosis)
(CBA/Bom) (GW)
CdCl2
15.7 30.4 88.8
253
Hepatic 15.7 M 30.4 M (fatty infiltration of liver

cells, occasional
15.7
hepatocellular necrosis)
3. HEALTH EFFECTS
30.4
Renal 59.6 88.8 M (tubular necrosis and

casts)
59.6
88.8
16 Mouse once Basinger et al. 1988

Gastro 112 M (glandular stomach
(ICR) (GW) epithelial necrosis) CdCl2
112
254
Hepatic 112 M (extensive hepatocellular

coagulative necrosis)
112
Renal 112 M
112
Immuno/ Lymphoret
1 x/d 65.6 M 65.6 F (increased leukocyte
(Sprague- counts) CdCl2
65.6
Dawley) (GW) 31.3 F

31.3
65.6
255
Neurological
25 M 50 M (decreased motor
(Sprague- (GW) activity) CdCl2
25
Dawley)
110
50
256
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
Reproductive
19 Rat once Bomhard et al. 1987
50 M 100 M (testicular necrosis)
(Wistar) (GW)
CdCl2
50 100
257

1 x/d 138 F 65.6 M (testicular atrophy and
(Sprague- loss of spermatogenic CdCl2
138
Dawley) (GW) elements)

65.6
258
21 Rat once Dixon et al. 1976

25 M
(Sprague- (GW)
CdCl2
25
3. HEALTH EFFECTS
Dawley)
259

50 M 100 M (testicular necrosis;
(Sprague- (GW) decreased CdCl2
50
Dawley) spermatogenesis;
decreased number
females producing pups)
100
260
23 Mouse once Andersen et al. 1988

30.3 M 59.6 M (testicular necrosis)
(CBM/ Bom) (GW)
CdCl2
30.3 59.6
263
Developmental
24 Rat 10 d Baranski 1985
Gd 7-16 2 F (delayed ossification of 40 (fused lower limbs,
(Wistar) the sternum and ribs) absent limbs, decreased
once CdCl2
number of live fetuses,
(GW) 2
increased number of
resorptions)
40
264
111
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
25 Rat 1 x/d Machemer and Lorke 1981

6.13 18.39 (increased number of
(Long- Evans) Gd 6-15 fetuses with CdCl2
6.13
(GW) malformations)
18.39
265
26 Rat 10 d Machemer and Lorke 1981

12.5
(Long- Evans) Gd 6-15
CdCl2
12.5
(F)
266
INTERMEDIATE EXPOSURE
Death
3. HEALTH EFFECTS
5 d/wk 40 F (4/13 died by week 8;
(Wistar) 7/13 by week 14)
(GW) CdCl2
40
269
28 Mouse 280 d
1.9 F (24/41 died by 280 days) Blakley 1986
(Swiss) (W)
CdCl2
1.9
273
Systemic
29 Monkey 10 wk Chopra et al. 1984
Bd Wt 5M
(Rhesus) (F)
CdCl2
5
276

5 d/wk Bd Wt 4F 40 F (29% decreased
(Wistar) maternal body weight) CdCl2
4
(GW)
40
280
31 Rat 2-10 mo Bernard et al. 1988a

Renal 30 F (B2-microglobulinuria)
(Sprague- (W)
CdCl2
30
Dawley)
282
112
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
32 Rat daily Brzoska and

12 mo Musc/skel 0.2 M 0.5 M (increased lumbar spine
(Wistar) 0.2
deformities, decreased in Moniuszko-Jakoniuk 2005a,

(W) lumbar spine and femur 2005b; Brzoska et al. 2010
mineralization, altered CdCl2
bone turnover
parameters)
0.5
1031
33 Rat daily b
Musc/skel 0.2 F (decreased bone Brzoska and
(Wistar) 12 mo Moniuszko-Jakoniuk 2005d;
mineralization,
(W) mechanical properties of Brzoska et al. 2005a, 2005c
3. HEALTH EFFECTS
tibia and femur, and CdCl2
altered bone turnover
parameters)
0.2
1030
34 Rat daily Brzoska et al. 2004b, 2005b

12 mo Musc/skel 0.3 F (alterations in bone
(Wistar) mineral content and
(W) CdCl2
density and mechanical
properties of lumbar
vertebral and femoral
bones)
0.3
1029
35 Rat 4 or 7 mo Cardenas et al. 1992a

Renal 15.2 F (albuminuria,
(Sprague- (W) transferrinuria,
Dawley) CdCl2
B2-microglobulinuria)
15.2
283
36 Rat 190 d Carmignanti and Boscolo 1984

Cardio 1.4 M (20% increase in diastolic
(Sprague- (W) blood pressure)
Dawley) Cd acetate
1.4
284
Bd Wt 2.8 M
113
2.8
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
37 Rat 12 wk Cha 1987

Hepatic 8.58 M (necrosis of central
(Sprague- (W) lobules)
Dawley) CdCl2
8.58
285
Renal 8.58 M (necrosis of proximal

tubular epithelial cells
and cloudy swelling)
8.58
Bd Wt 8.58 M (23% decreased in body

weight gain; 9% total
body weight decrease)
3. HEALTH EFFECTS
8.58
38 Rat 170 d Cifone et al. 1989a

Bd Wt 56 F
(Wistar) (W)
CdCl2
56
286
39 Rat 3 mo Decker et al. 1958

Hemato 2 (anemia)
(Sprague- (W)
CdCl2
2
Dawley)
287
Bd Wt 2 F (15% decreased body 2 M (25% decreased body

weight) weight)
2 2
40 Rat 4-60 wk Gatta et al. 1989

Renal 1.18 (vesiculation of proximal
(Wistar) (W) tubules) CdCl2
1.18
288
41 Rat 4 wk Groten et al. 1990

Hemato 2.5 M (anemia)
(F)
CdCl2
2.5
290
Renal 2.5 M
2.5
114
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
42 Rat 120 d Itokawa et al. 1974

(Wistar) (W)
CdCl2
3.6
292
Renal 3.6 M (tubular necrosis and

casts, glomerular
adhesions)
3.6
43 Rat 7 wk
Cardio 2.5 M (congested myocardium, Jamall et al. 1989
(Sprague- (F) separation of muscle
Dawley) CdCl2
fibers)
3. HEALTH EFFECTS
2.5
293
Renal 2.5 M
2.5
Bd Wt 2.5 M
2.5
44 Rat 90 d Kawamura et al. 1978

Hemato 8 F (anemia)
(Wistar) (W)
CdCl2
8
294
Musc/skel 8 F (osteomalacia changes)

8
Renal 8 F (decreased renal

clearance)
8
Endocr 8F
8
Bd Wt 8 F (12% decreased body

weight)
8
45 Rat 22 d Kelman et al. 1978

Gd 0-21 Hemato 1.5 F (slight anemia)
(Sprague-
form not specified
1.5
Dawley) (W)
295
Musc/skel 3.8 F
115
3.8
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
46 Rat 24 wk Kotsonis and Klaassen 1978

Resp 8M
(Sprague- (W)
CdCl2
8
Dawley)
297
Cardio 8M
8
Gastro 8M
8
Hemato 8M
8
Musc/skel 8M
8
Hepatic 8M
3. HEALTH EFFECTS
8
Renal 1.2 M 3.1 M (proteinuria, slight focal

tubular necrosis)
1.2
3.1
Endocr 8M
8
Bd Wt 8M
8
47 Rat 8 weeks Larregle et al. 2008

daily Hepatic 18 M (increased serum and
(Wistar) liver triglyceride levels;
(W) CdCl2
increased serum
cholesterol levels)
18
1039
48 Rat 3 mo Loeser and Lorke 1977a

Cardio 3
(Wistar) (F)
CdCl2
3
302
Hemato 3
3
Hepatic 3
3
Renal 3
3
Endocr 3
3
116
Bd Wt 3
3
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
49 Rat 6-16 wk Miller et al. 1974b

Resp 2.4 (lung fibrosis)
(Sprague- (W)
CdCl2
2.4
Dawley)
304
50 Rat 6 wk Muller et al. 1988

5 d/wk Hepatic 0.25 M
(Sprague-
Cd acetate
0.25
Dawley) 1 x/d
(GW)
306
Bd Wt 0.25 M
0.25
3. HEALTH EFFECTS
51 Rat 4 wk Ogoshi et al. 1989
Hemato 0.8 F (decreased hematocrit
(NS) (W) and hemoglobin) CdCl2
0.8
307
Musc/skel 0.8 F (decreased bone

strength in young
animals)
0.8
Bd Wt 0.8 1.6 F (10% decreased body

weight gain)
0.8
1.6
52 Rat 200 d Petering et al. 1979

Resp 0.6 M 1.2 M (reduced static
(NS) (W) compliance, lung lesions) CdCl2
0.6
1.2
309

Resp 3.62 M (emphysema)
(Sprague- (W)
CdCl2
3.62
Dawley)
310
117
CADMIUM
Exposure/ LOAEL
Duration/
(Route)

(90 d prior to Hemato 5.23 F
(Sprague-
CdCl2
5.23
Dawley) Gd 1-21)
(W)
311
55 Rat Gd 1- Ld 1 Pond and Walker 1975

Bd Wt 19.7 F (77-80% decreased
(Sprague- (F) maternal weight gain)
Dawley) CdCl2
19.7
315
56 Rat 90 d Prigge 1978a

Resp 16 F
3. HEALTH EFFECTS
(Wistar) (W)
CdCl2
16
316
Hemato 4 F (23% decreased serum

iron)
4
Renal 4F 8 F (35% increase in urine

protein)
4
Bd Wt 8F
8
57 Rat 12, 26, 50, or Sakata et al. 1988

100 d Hemato 12 M (iron deficient anemia)
(Wistar)
CdCl2
12
(W)
317
58 Rat 7-12 mo Viau et al. 1984

Renal 13 F
(Sprague- (W)
CdCl2
13
Dawley)
324
Bd Wt 13 F
13
118
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
59 Mouse 252 d Bhattacharyya et al. 1988a,

Musc/skel 0.65 F (decrease in femur
(CF1) (F) calcium content in mice 1988b
undergoing repeated
pregnancy/lactation
periods)
0.65
327
60 Mouse 3-11 wk Malave and de Ruffino 1984

Bd Wt 12.5 M (63% decreased body
(C57BL/6) (W) weight gain) CdCl2
12.5
356
3. HEALTH EFFECTS
61 Mouse 16-46 wk Waalkes et al. 1993
Bd Wt 232 M (45% decreased body
(B6C3F1) (W) weight) CdCl2
232
331
62 Mouse Gd 1-19 Webster 1978

Hemato 4.8 F 9.6 F (anemia)
(QS/CH) (W)
CdCl2
4.8 9.6
332
Bd Wt 4.8 F 9.6 F (14% decrease in

maternal weight gain)
4.8
9.6
63 Dog 3 mo Loeser and Lorke 1977b

Cardio 0.75
(Beagle) (F)
CdCl2
0.75
335
Hemato 0.75
0.75
Hepatic 0.75
0.75
Renal 0.75
0.75
Bd Wt 0.75
0.75
119
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
64 Rabbit 9 mo Boscolo and Carmignani 1986

Cardio 1.6 M (increased aortic
(New (W) resistance, reduced
Zealand) CdCl2
contractility)
1.6
336
Renal 1.6 M
1.6
Bd Wt 1.6 M
1.6
65 Rabbit 200 d Stowe et al. 1972

(New Zealand (W)
CdCl2
14.9
and Belgian
3. HEALTH EFFECTS
Giant)
338
Hepatic 14.9 M (focal hepatic fibrosis and

biliary hyperplasia)
14.9
Renal 14.9 M (tubular necrosis,

glomerular and interstitial
fibrosis)
14.9
Endocr 14.9
14.9
Bd Wt 14.9 M (11% decrease in body

weight)
14.9
Immuno/ Lymphoret
66 Monkey 10 wk Chopra et al. 1984
5 M (increased cell-mediated
(Rhesus) (F) immune response) CdCl2
5
341
67 Rat 170 d Cifone et al. 1989a

28 F (biphasic decrease then
(Wistar) (W) increase in natural killer CdCl2
cell activity)
120
28
343
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
68 Rat 3 mo Loeser and Lorke 1977a

3
(Wistar) (F)
CdCl2
3
344
69 Mouse 3 wk Blakley 1985

1.4 F 2.8 F (decreased humoral
(BDF1) (W) immune response) CdCl2
1.4
2.8
349
70 Mouse 280 d Blakley 1986

1.9 F (greater susceptibility to
(Swiss) (W) murine lymphocytic CdCl2
leukemia virus)
3. HEALTH EFFECTS
1.9
350
71 Mouse 26 d Blakley 1988

12.5 F
(BDF1) (W)
CdCl2
12.5
351
72 Mouse 30 d Bouley et al. 1984

22 M
(Swiss- (W)
Cd acetate
22
Webster)
353
73 Mouse 10 wk Exon et al. 1986

57 M
(Swiss- (W)
CdCl2, Cd acetate, or Cd
57
Webster)
354 sulfate
74 Mouse 12-16 wk Krzystyniak et al. 1987

19 F 57 F (reduced number of
(C57BL/6N) (W) SRBC-activated, CdCl2
19
plaque-forming cells)
57
355
121
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
75 Mouse 3-11 wk Malave and de Ruffino 1984

12.5 M (decreased suppressor
(C57BL/6) (W) cell activity) CdCl2
12.5
356
76 Mouse 10 wk Ohsawa et al. 1988

0.75 M (induction of anti-nuclear
(ICR) (W) autoantibodies) CdCl2
0.75
357
Neurological
5 d/wk 4F 40 F (aggressive behavior)
(Wistar)
3. HEALTH EFFECTS
CdCl2
4 40
(GW)
358
78 Rat 3-24 wk Kotsonis and Klaassen 1978

1.2 M 3.1 M (decreased motor
(Sprague- (W) activity) CdCl2
1.2
Dawley)
3.1
359
79 Rat 55 d Nation et al. 1984

1M 5 M (increased passive
(Sprague- (F) avoidance) CdCl2
1
Dawley)
5
361
80 Rat 60 d Nation et al. 1990

9 M (decreased motor
(Sprague- (F) activity)
Dawley) CdCl2
9
363
Reproductive
5 d/wk 4F 40 F (increased duration of
(Wistar) estrus cycle) CdCl2
4
(GW)
40
367
122
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
82 Rat 11 wk Baranski et al. 1983

5 d/wk 4F
(Wistar)
CdCl2
4
(GW)
368
83 Rat 10 wk Bomhard et al. 1987 Histopathology only.

1 x/wk 5M
(Wistar)
CdCl2
5
(GW)
370
84 Rat 12 wk Cha 1987

8.58 M (necrosis and atrophy of
(Sprague- (W) seminiferous tubule
Dawley) CdCl2
3. HEALTH EFFECTS
epithelium)
8.58
372
85 Rat 4 wk Groten et al. 1990 Histopathology only.

2.5 M
(F)
CdCl2
2.5
374
86 Rat 4 wk Kostial et al. 1993

4.8 F
(albino) (W)
CdCl2
4.8
376
87 Rat 24 wk Kotsonis and Klaassen 1978

8M
(Sprague- (W)
CdCl2
8
Dawley)
377
88 Rat 3 mo Loeser and Lorke 1977a Histopathology only.

3
(Wistar) (F)
CdCl2
3
379
89 Rat 120 d Saxena et al. 1989

12.6 M (decreased sperm count
(NS) (W) and motility, seminiferous Cd acetate
tubular damage)
12.6
384
123
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
90 Rat 70-80 d Zenick et al. 1982

4.64 M
(Long- Evans) (W)
CdCl2
4.64
387
91 Dog 3 mo Loeser and Lorke 1977b

0.75
(Beagle) (F)
CdCl2
0.75
390
Developmental
92 Rat 21 d Ali et al. 1986
Gd 1-21 0.706 (delayed development of
(Wistar) sensory motor
(W) Cd acetate
coordination reflexes;
increased motor activity)
3. HEALTH EFFECTS
0.706
391
93 Rat 20 d Baranski 1987 Decreased maternal

Gd 1-20 9.6 (decreased fetal body
(Wistar) weight [12%], body water and food
(W) CdCl2 consumption.
length [7%], and
hematocrit [13%])
9.6
392
94 Rat 11 wk Baranski et al. 1983

5 d/wk 0.04 (pup behavioral
(Wistar) alterations)
1 x/d CdCl2
(GW) 0.04
393
124
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
Figure (Strain) System (mg/kg) (mg/kg) (mg/kg) Chemical Form Comments
95 Rat 11-94 d Desi et al. 1998

Gd 5-15 14 M (decreased horizontal
(Wistar) ambulation and rearing
Ld 2-28 CdCl2
1 x/d activity; increased
ppd 1-56 frequency of
5 d/wk somatosensory, visual,
1 x/d and auditory
electrocorticogram;
(GW) prolonged latency and
duration of evoked
potentials)
14
1002
3. HEALTH EFFECTS
96 Rat Gd 0- Ld 21 Gupta et al 1993
5 (decreased pup brain
(Druckery) (W) and body weight at 7, 14, Cd acetate
and 21 days)
5
394
97 Rat Gd 0-20 Kelman et al. 1978

1.5 (12% decreased
(Sprague- (W) hematocrit)
Dawley) form not specified
1.5
395
98 Rat 10 wk Kostial et al. 1993

4.8 (12% decrease in pup
(albino) (W) body weight at weaning) CdCl2
4.8
396
99 Rat approx. 49 d Nagymajtenyi et al. 1997

4 wk old through 7 M (alterations in ambulation
(Wistar) behavior; prolonged
mating CdCl2
7 d/wk latency and duration of
1 x/d somatosensory evoked
potentials)
(GO)
7
1016
125
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
100 Rat 60 d prior to Gd Petering et al. 1979

1 2.61 (decreased live birth
(Sprague- weight)
Dawley) or CdCl2
Gd 1-21 2.61
(W)
397
101 Rat Gd 1- Ld 1 Pond and Walker 1975

19.7 (13-19% decreased pup
(Sprague- (F) birth weight)
Dawley) CdCl2
19.7
399
3. HEALTH EFFECTS
102 Rat 21 d Saxena et al. 1986
Gd 0-20 21
(ITRC)
Cd acetate
21
(W)
400
103 Rat 15 d Sorell and Graziano 1990

Gd 6-20 0.63 4.7 (8% decreased fetal body
(Sprague- weight) CdCl2
0.63
Dawley) (W)
4.7
401
104 Rat 9 wk Sutou et al. 1980

1 x/d 1 10 (delayed ossification,
(Sprague- decreased body weight) form not specified
1
Dawley) (GW)
10
402
105 Mouse 19 d Webster 1978

Gd 1-19 2.4 (decreased fetal body
(QS/CH) weight; severe anemia)
(W) CdCl2
2.4
404
CHRONIC EXPOSURE
Systemic
106 Human c
Renal 0.0003 F Buchet et al. 1990; Jarup et al.
0.0003
2000; Suwazono et al. 2006

1036 form not specified
126
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
107 Human NS Nogawa et al. 1989

lifetime Renal 0.0021
form not specified
0.0021
(F)
437
108 Human >25 yr Shiwen et al. 1990

lifetime Hemato 0.0078
Cd metal
0.0078
(environ)
441
Musc/skel 0.0078
0.0078
Renal 0.0078 (increased excretion of

low molecular weight
3. HEALTH EFFECTS
proteins)
0.0078
109 Monkey 9 yr Akahori et al. 1994

Cardio 0.53 M 1.71 M (increased blood
(Rhesus) (F) pressure during the first CdCl2
0.53
1.5 years)
1.71
448
110 Rat 18 mo Bernard et al. 1992

Renal 13 F (loss of glomerular
(Sprague- (W) polyanion charge barrier, CdCl2
Dawley) proteinuria)
13
451
111 Rat 72 wk Bomhard et al. 1984

Renal 3.5 17.5 (8 to 9-fold increase in
(Wistar) (F) LDH and GST starting at CdCl2
3.5
13 weeks)
17.5
452
127
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
112 Rat daily Brzoska and

24 mo Musc/skel 0.08 F (decreases in bone
(Wistar) mineral content and Moniuszko-Jakoniuk 2004a,
(W) density of lumbar spine, 2004b; Brzoska 2011
altered bone turnover CdCl2
paramters, increases in
deformed and fractured
vertebral bodies)
0.08
1032
113 Rat 12 mo Decker et al. 1958

Hemato 0.79
(Sprague- (W)
CdCl2
0.79
Dawley)
3. HEALTH EFFECTS
453
Bd Wt 0.79
0.79
114 Rat M: 92 wk Fingerle et al. 1982

F: 84 wk Cardio 4.01
(Sprague-
CdCl2
4.01
Dawley) (W)
454
Renal 0.8 1.51 (proximal tubule lesions)

0.8 1.51
Bd Wt 4.01
4.01
115 Rat 6, 12, or 18 mo Mangler et al 1988

Cardio 2.281 F
(Sprague- (W)
CdCl2
2.281
Dawley)
456
Hepatic 2.281 F
2.281
Renal 2.337 F (cloudy swelling of

tubular cells)
2.337
Bd Wt 2.281 F
2.281
128
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
116 Rat 31 mo Sato et al. 1978

Musc/skel 3.6 (muscle atrophy)
(Wistar) (W)
CdCl2
3.6
458
Bd Wt 3.6
3.6
117 Rat 2 yr Shaikh et al. 1989

Renal 2.6 M
(Wistar) (W)
CdCl2
2.6
460
118 Rat 77 wk Waalkes and Rehm 1992

Bd Wt 3.5 M 7 M (10% decreased body
(Wistar) (F) weight) CdCl2
3.5
3. HEALTH EFFECTS
7
461
119 Mouse 18 months Bhattacharyya et al. 1988c

Musc/skel 0.65 F 6.5 F (loss of bone calcium in
(CF1) (F) 0.65
ovariectomized mice)
6.5
1038
120 Mouse 12 mo Hays and Margaretten 1985

Hemato 57 (anemia and bone
(CBA/H) (W) marrow hypoplasia) form not specified
57
464
Renal 57
57
Bd Wt 57 (21% decreased terminal

body weight)
57
Neurological
121 Rat 31 mo Sato et al. 1978
3.6 (peripheral neuropathy)
(Wistar) (W)
CdCl2
3.6
469
129
CADMIUM
Exposure/ LOAEL
Duration/
(Route)
Cancer
122 Rat 77 wk Waalkes and Rehm 1992
3.5 M (CEL: increased rates of
(Wistar) (F) prostatic adenomas) CdCl2
3.5
488
a The number corresponds to entries in Figure 3-2.
b The intermediate-duration oral MRL of 0.0005 mg Cd/kg/day (0.5 ug Cd/kg/day) was calculated using a benchmark dose analysis. The BMDL1std of 0.05 mg Cd/kg/day was
divided by an uncertainty factor of 100 (10 to account for extrapolation from animals to humans and 10 for human variability).
c The chronic-duration oral MRL of 0.0001 mg Cd/kg/day (0.1 ug Cd/kg/day) was calculated from the 95% lower confidence limit of the urinary cadmium level associated with a 10%
increased risk of low molecular weight proteinuria (0.5 ug/g creatinine) estimated from a meta-analysis of select environmental exposure studies. An intake which would result in this
3. HEALTH EFFECTS
urinary cadmium concentration was estimated using a modification of the Nordberg-Kjellström pharmacokinetic model (see Appendix A for details on the meta-analysis and
extrapolation to dietary intake). This dose of 0.3 ug/kg/day was divided by an uncertainty factor of 3 for human variability.
Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; (F) = feed; F = Female; (G) = gavage; Gastro = gastrointestinal; Gd =
gestational day; (GO) = gavage in oil; GST = glutathione-S-transferase; (GW) = gavage in water; Hemato = hematological; Immuno/Lymphoret = immunological/lymphoreticular; LD50
= lethal dose, 50% kill; LDH = Lactate dehydrogenase; LOAEL = lowest-observed-adverse-effect level; M = male; mo = month(s); Musc/skel = musculoskeletal; NOAEL =
no-observed-adverse-effect level; NS = not specified; ppd = post-parturition day; Resp = respiratory; SRBC = sheep red blood cells; (W) = drinking water; wk = week(s); x = time(s); yr
= year(s)
130
Figure 3-2 Levels of Significant Exposure to Cadmium - Oral
Acute (≤14 days)
CADMIUM
Systemic
r
lar al l ho l
u tin
gic
a t
ym
p l ve nta
sc tes igh gic
a ti e
ic va in olo c e o/L lo uc pm
th tem dio tro at ati al yW un ro od lo
a s r s m p n d m u pr ve
De Sy Ca Ga He He Re Bo Im Ne Re De
mg/kg/day
1000
4r
2r
10r 10r 10r 10r

1r 8r 8r 20r
3. HEALTH EFFECTS
6m 1r 4r 16m 16m 16m
100 5m 10r 19r 22r
15m 15m
14r
8r 11r 8r 8r 17r 17r 20r
15m 23m
18r 19r 22r
3r 24r
1r 8r 15m 8r 15m 8r 17r 23m

10r 18r 21r
11r 25r
15m 15m 8r 8r
9r 9r 9r
12r 13r 7r 12r 26r
9r
10
9r
11r 11r 25r
12r
7r 24r
11r
9r
1
131
Figure 3-2 Levels of Significant Exposure to Cadmium - Oral (Continued)
CADMIUM
Systemic
r al l tal
y ula tin ica ele
r as
c es g k
ato v int olo los c
ath s pir rdio stro mat s cu pati na
l
De Re Ca Ga He Mu He Re
mg/kg/day
1000
100
27r
31r
56r 47r 35r
65h 65h 58r 65h
10 57r
46r 46r 46r 62m 44r 46r 44r 46r 37r 46r 37r 44r 56r
3. HEALTH EFFECTS
62m 54r
53r 42r 56r 45r 42r 56r
48r 48r 48r 46r 48r
49r 43r 41r 41r 43r
28m 39r
36r 64h 45r 64h
1 52r 40r 46r
63d 63d 51r 51r 63d 63d
52r 59m
32r
34r
50r
32r 33r
0.1
0.01
0.001
0.0001
132
CADMIUM
Systemic r
pho
t al e
igh ym tiv
ri ne e o/L logic duc
d oc d yW mu
n
u ro pro
En Bo Im Ne Re
mg/kg/day
1000
61m
100
38r 73m 74m
30r 77r 81r
67r
55r 72m 74m
65h 60m 58r 65h 71m 75m 89r
10 62m 37r 80r 84r
44r 46r 44r 46r 56r 87r
3. HEALTH EFFECTS
29k 62m 66k 79r 83r 86r 90r
30r 77r 81r 82r
48r 36r 48r 69m 68r 78r 88r
43r 85r
39r 39r 70m
51r 64h 69m
1 78r 79r
63d 51r 76m 91d
50r
0.1
0.01
0.001
0.0001
133
CADMIUM
l
e nta
lo pm
ve
De
mg/kg/day
1000
100
101r 102r
95r
10 93r 104r
99r
3. HEALTH EFFECTS
96r 98r 103r
105m 100r
97r
1 104r
92r 103r
0.1
94r
0.01
0.001
0.0001
134
Chronic (≥365 days)
CADMIUM
Systemic
r l tal
cula gica ele ht al
as olo los
k eig gic r*
iov t u tic al yW ro
lo
ce
rd ma sc p a n d u n
Ca He Mu He Re Bo Ne Ca
mg/kg/day
100
120m 120m 120m
111r
110r
10
119m 118r
114r 116r 111r 114r 116r 118r 121r 122r
115r 115r 115r 117r 115r
109k 114r
3. HEALTH EFFECTS
1
113r 114r 113r
119m
109k
0.1
112r
0.01
108 108 108
107
0.001
106
0.0001 response and do not imply the existence of a threshold for the cancer endpoint.
135
CADMIUM 136
3. HEALTH EFFECTS
Cardiovascular Effects. Studies regarding cardiovascular effects in humans after oral exposure to
cadmium have primarily investigated relationships between blood pressure and biomarkers of cadmium
exposure such as cadmium levels in blood, urine, or other tissues. Smoking is an important confounding
factor, because of the higher blood, urine, and tissue cadmium levels of smokers (see Section 3.4) and the
known cardiovascular toxicity of cigarette smoking. Case-control and cohort epidemiologic studies that
adequately control for smoking have typically found no association between body cadmium levels
(primarily reflecting dietary exposure) and hypertension (Beevers et al. 1980; Cummins et al. 1980;
Ewers et al. 1985; Lazebnik et al. 1989; Satarug et al. 2005; Shiwen et al. 1990); however, some studies
have found positive correlations (Geiger et al. 1989; Swaddiwuhipong et al. 2010; Tulley and Lehmann
1982) or negative correlations (Kagamimori et al. 1986; Staessen et al. 1984). Similar conflicting
findings have been reported in studies analyzing death rates from cardiovascular disease among
populations with dietary cadmium exposure (Inskip et al. 1982; Shigematsu 1984). Disorders of the
cardiac conduction system, lower blood pressure, and decreased frequency of cardiac ischemic changes
were found among elderly women with past high dietary exposure to cadmium (Kagamimori et al. 1986).
Rhythmic disturbances, including ventricular fibrillation, were seen in an individual who had ingested
25 mg/kg cadmium as cadmium iodide (Wisniewska-Knypl et al. 1971).
Several studies conducting cross-sectional analysis on data from the National Health and Nutrition
Examination Surveys (NHANES), investigated associations between blood and urine cadmium levels and
cardiovascular effects (Agarwal et al. 2011; Eguogu et al. 2009; Everett and Frithsen 2008; Menke et al.
2009; Navas-Acien et al. 2005; Peters et al. 2010; Tellez-Plaza et al. 2008, 2010). Among adult
participants in the NHANES 1988–1994 survey followed for mortality through 2000, the multivariable
(including smoking)-adjusted hazard ratios of cardiovascular mortality associated with a 2-fold increase
in creatinine-corrected urinary cadmium were 1.21 (95% CI of 1.07–1.36) in men and 0.93 (95% CI of
0.84–1.04) in women (Menke et al. 2009). The hazard ratios for coronary heart disease mortality were
1.36 (95% CI of 1.11–1.66) and 0.82 (95% CI of 0.76–0.89). Thus, the study suggests an association
between elevated cadmium exposure and increased risk of cardiovascular mortality in men, but not in
women. Urinary cadmium levels were found to be strongly associated with peripheral arterial disease
(PAD, defined as blood pressure ankle brachial index <0.0 in at least one leg) in analysis conducted on
728 participants (at least 40 years of age) in the NHANES 1999–2000 study (Navas-Acien et al. 2005)
and approximately 6,500 participants (≥40 years of age) in the NHANES 1999–2004 survey (Tellez-Plaza
et al. 2010). Navas-Acien et al. (2005) reported that individuals with PAD had a 36% higher mean urine
cadmium level than individuals without PAD; this study also found that individuals with PAD had 49%
CADMIUM 137
3. HEALTH EFFECTS
higher urinary tungsten levels and urinary antimony levels exceeding 0.1 μg/L. In the Tellez-Plaza et al.
(2010) analysis, the odds ratio for PAD comparing men with urinary cadmium levels in the highest
quartile (≥0.69 µg/g creatinine) with the lowest quartile (<0.20 µg/g creatinine) was 4.90 (95% CI of
1.55–15.54), after adjustment for age, race/ethnicity, education, smoking habits, and a variety of
cardiovascular risk factors. In contrast, the odds ratio in women was 0.56 (95% CI of 0.18–1.71). When
the women were divided by smoking habit, there was a positive progressive dose-response relationship
and the odds ratio for PAD comparing the 80th with the 20th percentile for urinary cadmium was 1.46
(95% CI of 0.75–2.85) and for blood cadmium was 2.88 (95% CI of 1.10–7.50). Another study found a
modest increase in systolic or diastolic blood pressure associated with increasing blood cadmium levels
(geometric mean blood cadmium levels among all participants was 0.4 μg/L); no associations with blood
pressure and urinary cadmium levels were found (Tellez-Plaza et al. 2008). The association between
blood cadmium levels and blood pressure was stronger in participants who never smoked than in former
smokers or current smokers. There were no associations between hypertension and cadmium levels in
blood or urine. In the third study, analysis on 4,912 participants (45–79 years old) in the NHANES 1988–
1994 survey found a significant association between urinary cadmium levels and myocardial infarction in
women, but not men (Everett and Frithsen 2008). After adjusting for numerous risk factors including
smoking, race, and family history, a significant increase in the risk of myocardial infarction was observed
in women with urinary cadmium levels of ≥0.88 μg/g creatinine. Agarwal et al. (2011) found
significantly higher blood cadmium levels among participants with cardiovascular and cerebrovascular
disease in the NHANES 1999–2006 survey, as compared to participants without disease. The odds ratio
of cardiovascular and cerebrovascular disease comparing the lowest blood cadmium quartile to the
highest quartile was 1.44 (95% CI of 1.07–1.95) after adjusting for age, gender, race, education,
hypertension, diabetes, hypercholesterolemia, BMI, c-reactive protein, and smoking. Peters et al. (2010)
found that a 50% increase in blood or urinary cadmium levels resulted in a significant increase in the risk
of stroke and congestive heart failure among participants in the NHANES survey. After adjusting for age,
gender, race/ethnicity, education, BMI, poverty income ratio, alcohol consumption, smoking status, and
disease (diabetes, hypertension, hypercholesterolemia, and chronic kidney disease), the odds ratios (95%
CI) for stroke were 1.38 (1.14–1.67) and 1.10 (1.00–1.20) for 50% increases in blood and urinary
cadmium levels, respectively; 50% increases in blood and urinary cadmium levels resulted in odds ratios
(95% CI) for congestive heart failure of 1.48 (1.17–1.87) and 1.12 (1.04–1.21), respectively. A
significant negative correlation between urinary cadmium levels and volume of oxygen consumed at sub-
maximum activity (VO2 max) among white males or Mexican American females (Egwuogu et al. 2009);
however, no significant associations were found in black or Mexican American males and white and
black females. Using a similar approach, Eum et al. (2008) and Lee et al. (2011) used data from the
CADMIUM 138
3. HEALTH EFFECTS
Korean National Health and Nutrition Examination Survey (KNHANES) to assess the possible
associations between cadmium exposure and cardiovascular effects. Eum et al. (2008) found a positive
association (adjusted for age, gender, education, smoking status, alcohol intake, BMI, self-reported
hypertension, family history of hypertension, and blood lead level) between blood cadmium levels and
systolic, diastolic, and mean arterial blood pressure among adults. When comparing participants with the
highest tertile of blood cadmium (1.87–5.52 µg/L) to those in the lowest tertile (0.18–1.28 µg/L), the
multivariable adjusted odds ratio was 1.521 (95% CI of 1.129–2.049). In a similar analysis, Lee et al.
(2011) divided the subjects by gender and found that an interquartile range increase (0.91 µg/L) in blood
cadmium was associated with an elevated risk of hypertension (odds ratio of 1.4; 95% CI of 1.1–1.8) only
in men. Lee et al. (2011) also found significant associations between an interquartile range increase in
blood cadmium and the risk of ischemic heart disease in women (odds ratio of 2.28; 95% CI of 1.26–
4.15). No significant associations between blood cadmium and risk of stroke were found.
In a study of children enrolled in the Treatment of Lead-Exposed Children trial, no significant

associations between blood cadmium levels and blood pressure in 5 and 7 years olds following treatment
for elevated blood lead levels (Cao et al. 2009).
A single gavage dose of 150 mg/kg cadmium in male Sprague-Dawley rats had no effect on blood
pressure (Kotsonis and Klaassen 1977). Oral exposure of rats, rabbits, and monkeys to cadmium over
intermediate and chronic durations has been found to increase blood pressure in some studies (Akahori et
al. 1994; Boscolo and Carmignani 1986; Carmignani and Boscolo 1984; Kopp et al. 1982; Perry et al.
1989; Tomera and Harakal 1988), but not in others (Fingerle et al. 1982; Kotsonis and Klaassen 1978;
Loeser and Lorke 1977a, 1977b; Mangler et al. 1988; Wills et al. 1981). In general, studies showing an
effect on blood pressure have had control groups with lower blood pressure than studies showing no
effect, and observed increases in blood pressure are generally small. At least in rats, the effect on blood
pressure appears to be biphasic, reaching a maximum effect (an increase of 12–14 mm Hg in average
systolic pressure) at intakes of 0.07 mg/kg/day, but decreasing to normal or even below normal at intakes
10–100 times higher (Kopp et al. 1982). Enlarged and arteriosclerotic hearts have been found in rats
orally exposed to 0.35 mg Cd/kg/day for 3 years (Schroeder et al. 1965) or to 2.79 mg Cd/kg/day for
100 days (Wilson et al. 1941), but this effect is likely to be secondary to cadmium-induced anemia
(Wilson et al. 1941). Histopathologic lesions of heart tissues (congestion, separation of muscle fibers)
and decreased activity of antioxidant enzymes, but no increase in peroxidation, were found among rats
given 2.5 mg/kg/day of cadmium in the diet for 7 weeks (Jamall et al. 1989).
CADMIUM 139
3. HEALTH EFFECTS
Gastrointestinal Effects. Numerous human and animal studies indicate that oral exposure to
cadmium in high concentrations causes severe irritation to the gastrointestinal epithelium (Andersen et al.
1988; Frant and Kleeman 1941). Common symptoms in humans following ingestion of food or
beverages containing high concentrations of cadmium include nausea, vomiting, salivation, abdominal
pain, cramps, and diarrhea (Baker and Hafner 1961; Buckler et al. 1986; Frant and Kleeman 1941;
Nordberg et al. 1973; Shipman 1986; Wisniewska-Knypl et al. 1971). Although exact doses have not
been measured, gastrointestinal symptoms have been caused in children by 16 mg/L cadmium in soft
drinks (Nordberg et al. 1973) and 13 mg/L cadmium in popsicles (Frant and Kleeman 1941). Assuming
an intake of 0.15 L (Nordberg et al. 1973) and a body weight of 35 kg, the emetic dose is 0.07 mg/kg.
Although few studies have specifically examined gastrointestinal effects of longer-term cadmium
exposure, no surveys of environmentally exposed populations have reported gastrointestinal symptoms
(Morgan and Simms 1988; Roels et al. 1981a; Shigematsu 1984).
In rats and mice, histopathologic lesions (e.g., severe necrosis, hemorrhage, ulcers) in the gastrointestinal
epithelium have been observed after high (>30 mg/kg/day) acute-duration oral cadmium exposure by
gavage (Andersen et al. 1988; Basinger et al. 1988; Machemer and Lorke 1981), but not after lower levels
(8 mg/kg/day in drinking water) for 24 weeks (Kotsonis and Klaassen 1978).
Hematological Effects. Oral cadmium exposure reduces gastrointestinal uptake of iron, which can
result in anemia if dietary intake of iron is low. Anemia has been found in some instances among humans
with chronic dietary exposure to cadmium (Kagamimori et al. 1986), but other studies have found no
significant relationship between dietary cadmium exposure and anemia in humans (Roels et al. 1981a;
Shiwen et al. 1990). Hypoproteinemia and hypoalbuminemia were reported in a male who ingested
25 mg/kg cadmium as cadmium iodide (Wisniewska-Knypl et al. 1971).
A number of studies have demonstrated that oral exposure to cadmium frequently produces anemia in
laboratory animals, and that additional iron prevents anemia (Decker et al. 1958; Groten et al. 1990; Hays
and Margaretten 1985; Itokawa et al. 1974; Kawamura et al. 1978; Kelman et al. 1978; Kozlowska et al.
1993; Ogoshi et al. 1989; Pleasants et al. 1992, 1993; Pond and Walker 1972; Sakata et al. 1988; Sorell
and Graziano 1990; Stowe et al. 1972; Watanabe et al. 1986; Webster 1978; Wilson et al. 1941).
Decreases in serum iron have also been reported (Prigge 1978a). Borzelleca et al. (1989) reported slight
but statistically significant increases in hemoglobin, hematocrit, and erythrocytes in male rats at
65.6 mg/kg/day once a day for 10 days, but no change in females. Male Sprague-Dawley rats receiving a
single gavage dose of 150 mg/kg cadmium showed no signs of anemia 14 days later (Kotsonis and
CADMIUM 140
3. HEALTH EFFECTS
Klaassen 1977), but anemia was produced in male Wistar rats after 12 days of drinking-water exposure to
12 mg/kg/day (Sakata et al. 1988). Most intermediate-duration exposure studies in rats have shown
evidence of anemia at doses of 2–14 mg/kg day (Decker et al. 1958; Groten et al. 1990; Itokawa et al.
1974; Kawamura et al. 1978; Pleasants et al. 1993; Pond and Walker 1972; Sakata et al. 1988; Wilson et
al. 1941). However, some intermediate-duration studies have found no change in hemoglobin (Kotsonis
and Klaassen 1978; Loeser and Lorke 1977a; Petering et al. 1979; Prigge 1978a) in rats treated at similar
doses. Anemia has also been seen in intermediate-duration studies in mice (Webster 1978) and rabbits
(Stowe et al. 1972), but not in dogs (Loeser and Lorke 1977b). The result in dogs may be due to the
relatively low dose of cadmium (0.75 mg/kg/day) used in this study. Hematological effects following
chronic-duration oral exposure to cadmium are less well characterized. In monkeys maintained on
4 mg/kg/day cadmium in food, pale feces, and clinical signs of anemia occurred after 90 weeks, but the
anemia was associated with a decreased food intake rather than an increase in reticulocytes (Masaoka et
al. 1994). Anemia was not present in rats exposed via drinking water for 12 months to the relatively low
dose of 0.79 mg/kg/day (Decker et al. 1958). The number of erythroid progenitor cells in bone marrow is
decreased in mice exposed to 57 mg/kg/day of cadmium in drinking water for 12 months (Hays and
Margaretten 1985), but is increased in rats exposed to 12 mg/kg/day of cadmium in drinking water for up
to 100 days (Sakata et al. 1988). Thus, the question remains open whether factors, in addition to reduced
gastrointestinal absorption of iron, such as direct cytotoxicity to marrow or inhibition of heme synthesis
may contribute to anemia.
Musculoskeletal Effects. Osteomalacia, osteoporosis, bone fractures, and decreased bone mineral
density have been observed in several populations exposed to elevated levels of cadmium in the diet.
Bone effects were first reported in residents in the Jinzu River Basin, a cadmium-contaminated area in
Japan. The disease termed Itai-Itai or "ouch-ouch" disease most often affected women with several risk
factors such as poor nutrition, multiparity, and postmenopausal status (Shigematsu 1984). The disease
was characterized by multiple fractures of the long bones, osteomalacia, and osteoporosis in combination
with proteinuria (Järup et al. 1998b; Nordberg et al. 1997). Other Japanese populations with dietary
cadmium exposure have also been found to have elevated osteoporosis and osteomalacia in both men and
women (Kido et al. 1989b). Kagamimori et al. (1986) evaluated elderly Japanese women with heavy
cadmium exposure from ingesting polluted drinking water, rice, and fish during World Wars I and II; and
continued low-grade cadmium exposure from agricultural produce. Of 56 cases of Itai-Itai disease,
26 were accompanied by osteomalacia and 26 were without osteomalacia. Another study found that the
degree of loss of bone density is correlated with urinary excretion of β2-microglobulin, an index of renal
injury (see Section 3.5.2) (Kido et al. 1990a). The bone effects observed in Itai-Itai disease and in other
CADMIUM 141
3. HEALTH EFFECTS
studies of Japanese populations exposed to high levels of cadmium in rice are primarily due to kidney
damage, which results from a progressive disturbance in renal metabolism of vitamin D to its biologically
active form (Nogawa et al. 1987, 1990) and an increased urinary excretion of calcium (Buchet et al.
1990). These results suggest that bone changes may be secondary to disruption in kidney of vitamin D
metabolism and resulting imbalances in calcium absorption and excretion. A recent study of women
living in the Jinzu River basin found that bone turnover, particularly bone formation, was influenced by
renal tubular function (Aoshima et al. 2003). However, it is possible that some bone effects are not
mediated via the kidney.
Bone effects have also been observed in communities outside of Japan and in populations exposed to low
levels of cadmium. In a study of Swedish women environmentally exposed to cadmium, a significant
negative relationship between urinary cadmium levels and bone mineral density was observed (Åkesson
et al. 2005); the mean urinary cadmium level of the population was 0.52 μg/L. In Swedish residents
living in an area with known cadmium pollution from battery manufacturing facilities, significant
associations were noted between blood cadmium levels and bone mineral density and between urinary
cadmium levels and risk of fractures and osteoporosis. There were significant decreases in bone mineral
density in environmentally exposed subjects older than 60 years of age with blood cadmium levels of
≥0.56 μg/L (Alfvén et al. 2002a). Increases in the risk of bone fractures were observed in subjects
(approximately 10% of all subjects examined had environmental and occupational exposure to cadmium)
older than 50 years of age with urinary cadmium levels >2 μg/g creatinine; no significant associations
were found in subjects under 50 years of age (Alfvén et al. 2004). Another study of this population found
significant increases in the risk of osteoporosis among men >60 years of age with urinary cadmium levels
≥5 μg/g creatinine; however, an increased risk of osteoporosis was not observed in women (Alfvén et al.
2000). A Belgian study in which residents living near zinc smelters found a 2-fold increase in cadmium
exposure (as assessed via urinary cadmium levels) was associated with a decrease in proximal and distal
forearm bone density of approximately 0.1 g/cm2 among postmenopausal women (Staessen et al. 1999).
For women with urinary cadmium levels >1 μg/day, the incidence of bone fracture was 13.5 per
1,000 person-years. Another study of a subset of the women living near a zinc smelters (Schutte et al.
2008) provides suggestive evidence that cadmium has a direct osteotoxic effect. Significant associations
between urinary cadmium levels and the levels of two pyridinium crosslinks of collagen (urinary levels of
hydroxylysylpyridinoline and lysylpyridinoline), proximal forearm bone mineral density, and serum
parathyroid hormone levels were found. In almost all of the examined women, urinary levels of retinol
binding protein were below the cut-off level of 338 μg/day, suggesting no cadmium-induced effect on
renal tubular function. Several biomarkers of bone damage were examined in a subsequent follow-up
CADMIUM 142
3. HEALTH EFFECTS
study of some of the women (Schutte et al. 2008) only 1 of the 294 women examined had evidence of
renal dysfunction (increased retinol binding protein). Significant associations between urinary cadmium
excretion and two biomarkers of bone resorption (urinary hydroxylysylpyridinoline and lysylpyridinoline)
were found. Although significant associations between urinary cadmium levels and biomarkers of renal
dysfunction were observed in Polish adults living in a cadmium-polluted area, the only association
between urinary cadmium and bone biomarkers was a significant decrease in bone mineral density among
males with urinary cadmium levels of ≥2 µg/g creatinine (Trzcinka-Ochocka et al. 2010). Similar results
have been observed in several studies of residents living in areas of China with moderate or high
cadmium pollution levels (Jin et al. 2004b; Nordberg et al. 2002; Wang et al. 2003; Zhu et al. 2004).
There were significant increases in the prevalence of low forearm bone mineral density in
postmenopausal women with urinary cadmium levels >20 μg/g creatinine and in men, premenopausal
women, and postmenopausal women with blood cadmium levels >20 μg/L (Nordberg et al. 2002). An
increase in bone fractures was observed in males and females over the age of 40 years living in the area of
high cadmium exposure (mean urinary cadmium levels in the area were 9.20 and 12.86 μg/g creatinine in
the males and females, respectively) (Wang et al. 2003). A significant dose-response relationship
between urinary cadmium levels and the prevalence of osteoporosis was observed (Jin et al. 2004b; Wang
et al. 2003; Zhu et al. 2004); the Jin et al. (2004b) study found that 23 of the 31 subjects with osteoporosis
also exhibited signs of renal dysfunction. A subsequent study by this group examined 316 male and
female residents living in areas with moderate or heavy cadmium pollution 10 years after the source of
rice was switched to commercially available rice from nonpolluted areas (Chen et al. 2009). As in the
earlier studies, significant decreases in forearm bone mineral density were observed in the women living
in the moderately polluted area and in the men and women living in the heavily polluted areas. When the
subjects were divided by age, decreases in bone mineral density were observed in women 60–69 or
≥70 years old in both cadmium polluted areas and in men ≥70 years living in the heavily polluted area. A
significantly higher prevalence of osteoporosis was also observed in women living in the polluted areas
and the prevalence increased with increasing urinary cadmium levels. In another study of this population,
Chen et al. (2011) found a higher prevalence of osteoporosis (assessed in 2006) among women with renal
dysfunction (urinary albumin >15 mg/g creatinine and urinary NAG ≥12 IU/g creatinine; renal
biomarkers assessed in 1998) or tubular damage (urinary NAG ≥12 IU/g creatinine); no significant
association was found for glomerular damage (urinary albumin ≥15 mg/g creatinine). Significantly lower
bone mineral density levels were also found in women with tubular damage, as compared to those without
tubular damage. In men, no significant associations between the prevalence of osteoporosis or bone
mineral density and alterations in renal biomarkers were found. Chen et al. (2011) also compared the
change in bone mineral damage from 1998 to 2006 in subjects with and without evidence of kidney
CADMIUM 143
3. HEALTH EFFECTS
damage and found a significantly greater decrease in bone mineral damage among women with tubular
damage. In a study of adults living near an industrial complex in Korea, significant associations between
high urinary cadmium levels (≥1.0 µg/g creatinine) and osteopenia were observed in males and females
(Shin et al. 2011). Bone mineral density was also negatively associated with urinary cadmium levels.
In a substudy of a population-based health survey in Sweden (Engström et al. 2009), a significantly lower
bone mineral density was observed in postmenopausal women with elevated urinary cadmium levels
(median of 1.1 µg/g creatinine, 5–95th percentile of 0.69–1.7 µg/g creatinine) as compared to women with
low urinary cadmium levels (median of 0.36 µg/g creatinine; 5–95th percentile of 0.18–0.73 µg/g
creatinine). Significant decreases in serum parathyroid hormone levels and increases in urinary
deoxypyridinoline levels (indicative of increased bone resorption) were also found in the high urinary
cadmium group; however, there were no significant alterations in serum 1,25-dihydroxyvitamin D levels
Significant elevations in biomarkers of renal dysfunction (urinary NAG and pHC and estimated
glomerular filtration rate) were also in the high urinary cadmium group. In the U.S. general population
(using data collected during NHANES III, 1988–1994), a significant association was found between
urinary cadmium levels and osteopenia and osteoporosis among adults with urinary cadmium levels of
>1 µg/g creatinine (Wu et al. 2010). Using the same NHANES data set, Gallagher et al. (2008) found a
43% increased risk of osteoporosis (hip bone mineral density defined) (odds ratio of 1.43; 95% CI of
1.02–2.00) among women ≥50 years of age with urinary cadmium levels of 0.50–1.00 µg/g creatinine, as
compared to women with urinary cadmium levels of <0.50 µg/g creatinine.
Using data collected during NHANES III (1988–1994), Arora et al. (2008, 2008) examined the possible
association between urinary cadmium levels and dental health in children and adults. In children aged 6–
12 years, a significant association (adjusted for age, gender, ethnicity, education level, poverty status, log-
transformed blood lead, log-transformed serum cotinine, and dietary sucrose intake) between urinary
cadmium levels and dental caries in deciduous teeth among children with low external tobacco smoke
exposure; no significant associations were found in permanent teeth (Arora et al. 2008). A significant
association (after adjustment for gender, age, education level of household head, race/ethnicity, household
poverty status, time since last visit to dentist, missing teeth, serum cotinine, smoking habits, exposure to
external tobacco smoke, blood lead, diabetes, renal dysfunction, and bone mineral density) between
urinary cadmium and periodontal disease (presence of attachment loss of at least 4 mm in >10% of sites
examined) in adults (≥18 years of age) (Arora et al. 2009). A logistic regression model predicted a 56%
increase in the prevalence of periodontal disease associated with a 3-fold increase in urinary cadmium
levels (0.18–0.63 µg/g creatinine).
CADMIUM 144
3. HEALTH EFFECTS
A number of animal studies confirm the findings of the epidemiology data suggesting that the bone is a
sensitive target of cadmium toxicity. Decreases in bone mineralization and bone mineral density have
been observed in female rats exposed to ≥0.2 mg Cd/kg/day in the lumbar spine, femur, and tibia
(Brzóska et al. 2004b, 2005a, 2005b, 2005c) and in male rats exposed to ≥0.5 mg Cd/kg/day (Brzóska and
Moniuszko-Jakoniuk 2005a, 2005b; Brzóska et al. 2010; Yokota and Tonami 2008) for an intermediate
duration and in female rats chronically exposed to 0.08 mg Cd/kg/day (Brzóska 2012; Brzóska and
Moniuszko-Jakoniuk 2004a, 2004b). In the series of studies conducted by Brzóska and associates, the
occurrence of osteopenia and osteoporosis was evaluated using data for bone mineral density of the
cadmium-exposed rats, control rats, and healthy adult rats. Osteopenia was observed in male rats exposed
to 0.5 mg Cd/kg/day for 12 months (Brzóska and Moniuszko-Jakoniuk 2005a, 2005b) and in female rats
exposed to 0.08 mg Cd/kg/day for 12 or 18 months (Brzóska and Moniuszko-Jakoniuk 2004a, 2004b);
osteoporosis was observed in male rats exposed to 4 mg Cd/kg/day for 12 months (Brzóska and
Moniuszko-Jakoniuk 2005a, 2005b) and in female rats exposed to 0.08 mg Cd/kg/day for 24 months
(Brzóska and Moniuszko-Jakoniuk 2004a, 2004b).
The decreases in bone mineralization resulted in altered mechanical properties (e.g., stiffness, load,
displacement at load) of the vertebral body, femur, and tibia and increases in the number of animals with
deformed or fractured lumbar spinal bone in female rats exposed to ≥0.2 mg Cd/kg/day for an
intermediate duration (Brzóska and Moniuszko-Jakoniuk 2005d; Brzóska et al. 2004b, 2005b, 2005a,
2005c, 2010; Ogoshi et al. 1989); increases in lumbar spine deformities were also observed in male rats
exposed to 0.5 mg Cd/kg/day for 12 months (Brzóska and Moniuszko-Jakoniuk 2005a, 2005b) and in
female rats exposed to 0.08 mg Cd/kg/day for 24 months (Brzóska 2012; Brzóska and Moniuszko-
Jakoniuk 2004a, 2004b).
The studies by Brzóska and associates reported significant alterations in biochemical markers of bone
turnover. During the first 6 months of a 1-year study, significant decreases in osteocalcin concentrations
were observed in female rats exposed to ≥0.2 mg Cd/kg/day; no alterations were observed during the last
6 months of the study (Brzóska and Moniuszko-Jakoniuk 2005d). Observed changes in alkaline
phosphatase levels included decreases in total serum levels in the 4 mg Cd/kg/day group after 6, 9, or
12 months of exposure, decreases in trabecular bone levels at ≥0.2 mg Cd/kg/day after 3, 6, or 9 months
of exposure and at 0.5 mg Cd/kg/day at 12 months, decreases in cortical bone levels at 4 mg Cd/kg/day
after 3 months of exposure, and increases in trabecular bone and cortical bone alkaline phosphatase at
4 mg Cd/kg/day after 12 months (Brzóska and Moniuszko-Jakoniuk 2005d). Serum C-terminal
CADMIUM 145
3. HEALTH EFFECTS
telopeptides of type I collagen concentration (CTX) was significantly decreased after 3 or 6 months of
exposure or increased after 9 or 12 months in rats exposed to ≥0.2 mg Cd/kg/day (Brzóska and
Moniuszko-Jakoniuk 2005d). As noted by Brzóska and Moniuszko-Jakoniuk (2005d), these alterations in
bone turnover markers indicate that cadmium exposure at the stage of intensive skeletal development
leads to low bone turnover and induces high bone turnover due to enhanced resorption at the stage of
consolidation of bone mass and at skeletal maturity.
Decreased calcium content of bone and increased urinary calcium excretion are common findings in
intermediate- and chronic-duration studies in the 0.2–8 mg Cd/kg/day range (Brzóska and Moniuszko-
Jakoniuk 2005d; Kawamura et al. 1978; Nogawa et al. 1981b; Pleasants et al. 1992; Watanabe et al.
1986). In contrast, Kotsonis and Klaassen (1978) reported no change in bone calcification after a
24-week exposure via drinking water at 8 mg/kg/day, and Kelman et al. (1978) reported no significant
change in stable or radiolabeled calcium in any maternal rat tissues from a 3.8 mg/kg/day in drinking
water for 22 days during gestation.
Gender, age, and nutritional state appear to influence cadmium toxicity on bone. In the series of
experiments conducted by Brzóska and associates, alterations in bone mineral density and the mechanical
strength of the lumbar spine and femur were observed in female rats exposed to ≥0.2 mg Cd/kg/day and
in male rats at 0.5 mg Cd/kg/day (Brzóska and Moniuszko-Jakoniuk 2005a, 2005b, 2005d; Brzoska et al.
2005a, 2005c); no adverse bone effects were observed in males exposed to 0.2 mg Cd/kg/day. In the
Ogoshi et al. (1989) study, decreases in the mechanical strength of the femur bone were observed in
young rats (21 days of age) exposed to 0.8 mg Cd/kg/day for 4 weeks; however, no alterations in bone
strength were observed in adult (24 weeks of age) or elderly (1.5 years of age) rats exposed to cadmium
doses as high as 25.6 mg Cd/kg/day for 4 weeks. Adverse effects on bone are exacerbated by a calcium-
deficient diet (Itokawa et al. 1974; Kimura et al. 1974; Larsson and Piscator 1971; Wang and
Bhattacharyya 1993; Wang et al. 1994), by ovariectomy (Bhattacharyya et al. 1988c), or by multiple
rounds of gestation and lactation (Bhattacharyya et al. 1988b).
Hepatic Effects. Liver damage is not usually associated with oral cadmium exposure, except at very
high levels of exposure. In humans, a fatal dose of cadmium can cause pronounced liver damage
(Buckler et al. 1986; Wisniewska-Knypl et al. 1971). Nishino et al. (1988) reported increased serum
concentrations of the urea-cycle amino acids among individuals exposed to cadmium in the diet, and that
these levels reflected liver as well as kidney damage. No cadmium-related alterations in liver biomarkers
including serum levels of alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase,
CADMIUM 146
3. HEALTH EFFECTS
lactate dehydrogenase, and γ-glutamyl transpeptidase were observed in women living in cadmium
nonpolluted areas in Japan (Ikeda et al. 1997, 2000). No other studies were located regarding hepatic
effects in humans after oral exposure to cadmium.
Hepatic effects have been found in rats, mice, and rabbits after oral cadmium exposure. Acute exposure
via gavage at doses of 30–138 mg/kg/day causes liver necrosis in most studies (Andersen et al. 1988;
Basinger et al. 1988; Borzelleca et al. 1989; Shimizu and Morita 1990), although histopathologic
evidence of liver damage was not seen in one study at a gavage dose of 150 mg/kg (Kotsonis and
Klaassen 1977). Exposure of rats for 10 days to drinking water containing 13.9 mg Cd/kg/day was
without effect on the liver (Borzelleca et al. 1989). Depletion of liver glutathione by fasting increases the
liver necrosis following acute oral exposure to cadmium in rats (Shimizu and Morita 1990).
In a 10-week study, male Rhesus monkeys exposed to 4 mg/kg/day cadmium chloride via gavage, had a
significant decrease in glutathione peroxidase in liver, kidney, heart, and lung in the following order:
liver>kidney>heart>lung; a significant decrease in glutathione S-transferase (GST) activity towards
1-chloro-2,4-dinitrobenzene in all four organs in the following order: liver>lung>kidney>heart; and a
significant increase in GST activity towards ethacrynic acid in all four organs in the following order:
heart>lung>kidney>liver (Sidhu et al. 1993). Intermediate-duration exposure causes histopathologic
changes in the liver (e.g., necrosis of central lobules, focal hepatic fibrosis, biliary hyperplasia) at doses of
1.6–15 mg/kg/day (Cha 1987; Gill et al. 1989b; Miller et al. 1974a; Renugadevi and Prabu 2010;
Schroeder et al. 1965; Stowe et al. 1972; Wilson et al. 1941), and metabolic alterations (e.g., decreased
cytochrome c oxidase activity in mitochondria, increased ALT and AST activities) at doses of 0.05–
10 mg/kg/day (Groten et al. 1990; Muller and Stacey 1988; Muller et al. 1988; Renugadevi and Prabu
2010; Sporn et al. 1970; Steibert et al. 1984; Tewari et al. 1986b). Decreased relative liver weight to
body weight has also been reported in male rats fed 5.95 mg/kg/day for 6 weeks (Kozlowska et al. 1993).
Hypertriglyceridemia was observed in male rats exposed to 18 mg Cd/kg/day as cadmium chloride in the
drinking water for 8 weeks (Larregle et al. 2008); the increase in plasma triglycerides was likely due to a
decrease in lipoprotein lipase activity (key enzyme in triglyceride hydrolysis). A significant increase in
liver triglyceride level was also observed; this increase was attributed to increased triglyceride synthesis.
Other intermediate and chronic duration studies have not found liver effects in animals following oral
exposure. These studies include a daily gavage exposure of 14 mg/kg/day for 6 weeks in rats (Hopf et al.
1990), a 3-month exposure to cadmium in food at 3 mg/kg/day in rats (Loeser and Lorke 1977a), a
CADMIUM 147
3. HEALTH EFFECTS
24-week exposure to cadmium in water at 8 mg/kg/day in rats (Kotsonis and Klaassen 1978), and a
3-month exposure in food at 0.75 mg/kg/day in dogs (Loeser and Lorke 1977b). Kopp et al. (1982) report
no hepatic effects from a chronic exposure of 18 months to cadmium in water at 0.65 mg/kg/day in rats.
Renal Effects. Numerous studies indicate that the kidney is the primary target organ of cadmium
toxicity following extended oral exposure, with effects similar to those seen following inhalation
exposure (see Section 3.2.1.2). Most of the data involves chronic exposure to cadmium; two case reports
involving acute exposure to large doses of cadmium also found kidney effects. In two fatal cases of oral
cadmium poisoning, anuria was present in one individual who ingested 25 mg/kg cadmium as cadmium
iodide. Damage to the kidneys was reported at autopsy, but was not further specified (Wisniewska-Knypl
et al. 1971). The kidneys were reported as normal at autopsy in an individual who died 2 days after
ingesting 1,840 mg/kg cadmium (Buckler et al. 1986).
Several studies have found associations between increased mortality and renal dysfunction in residents
living in cadmium polluted areas. Significant increases in SMRs were found in residents living in
cadmium polluted areas of Japan with elevated levels of biomarkers of renal dysfunction (Arisawa et al.
2001, 2007b; Iwata et al. 1991a, 1991b; Matsuda et al. 2002; Nakagawa et al. 1993; Nishijo et al. 1995,
2004a, 2006). Among the studies that examined cause of death, significant increases in deaths from renal
diseases were found in the residents that were categorized as biomarker-positive (urinary levels of the
renal biomarker was higher than the cut-off value); the cut-off values used were β2-microglobulin
≥1,000 μg/g creatinine (Arisawa et al. 2001, 2007b; Iwata et al. 1991a, 1991b; Nakagawa et al. 1993;
Nishijo et al. 2004a, 2006) or retinol binding protein ≥4 mg/L (Nishijo et al. 1995). Other studies have
found that mortality increased in proportion to the renal biomarker level (β2-microglobulin, protein, or
glucose) (Iwata et al. 1991a, 1991b; Matsuda et al. 2002; Nakagawa et al. 1993; Nishijo et al. 2004a,
2006). Increases in mortality from renal diseases have also been observed among populations living in
cadmium polluted areas of Belgium (Lauwerys and De Wals 1981) and England (Inskip et al. 1982);
however, statistical analysis was not reported in the Belgium study and the increase in renal disease was
not statistically significant in the other study. In a nationwide study in Japan, no significant associations
between the levels of cadmium in brown rice and deaths from all causes or age-adjusted renal
insufficiency mortality rate were found (Koizumi et al. 2010).
Elevated levels of several biomarkers of renal dysfunction and/or associations between cadmium burden
and these biomarkers have been found in studies of populations living in cadmium nonpolluted areas of
Japan (Ezaki et al. 2003; Ikeda et al. 1999; Suwazono et al. 2000; Oo et al. 2000; Uno et al. 2005;
CADMIUM 148
3. HEALTH EFFECTS
Yamanaka et al. 1998), South Korea (Hwangbo et al. 2011), Belgium (Buchet et al. 1990; Roels et al.
1981a), and the United States (Ferraro et al. 2010; Noonan et al. 2002) and in populations living in
cadmium polluted areas of China (Cai et al. 1990, 1992, 1998; Jin et al. 2002, 2004a, 2004c; Nordberg et
al. 1997; Wu et al. 2001), Japan (Cai et al. 2001; Hayano et al. 1996; Horiguchi et al. 2010; Ishizaki et al.
1989; Izuno et al. 2000; Kawada et al. 1992; Kido and Nogawa 1993; Kobayashi et al. 2002b, 2009b;
Monzawa et al. 1998; Nakadaira and Nishi 2003; Nakashima et al. 1997; Nogawa et al. 1989; Osawa et
al. 2001; Watanabe et al. 2002), Thailand (Honda et al. 2010; Teeyakasem et al. 2007), Sri Lanka
(Bandara et al. 2010), Sweden (Järup et al. 2000; Olsson et al. 2002), and Poland (Trzcinka-Ochocka et
al. 2004). Most of these studies did not estimate cadmium intake; rather, exposure was characterized
based on the levels of cadmium in rice, blood, or urine. The oral route is assumed to be the primary route
of exposure, although the inhalation route, particularly in smokers, may have contributed to the overall
cadmium body burden. The epidemiology data are summarized in Table 3-7 and brief discussions of the
better designed studies providing valuable dose-response data follows.
Buchet et al. (1990) examined 1,699 non-occupationally exposed males and females (aged 20–80 years)
living in Belgium. Urinary cadmium levels significantly correlated with urinary β2-microglobulin, retinol
binding protein, NAG, amino acid, and calcium levels; the partial r2 values were 0.0036, 0.0210, 0.0684,
0.0160, and 0.0168, respectively. The probability that individuals would have abnormal values for the
renal biomarkers (defined as >95th percentile for subjects without diabetes or urinary tract diseases and
who did not regularly take analgesics) was estimated using logistic regression models with adjustments
for age, gender, smoking, disease, and use of analgesics. It was estimated that >10% of
β2-microglobulin, retinol binding protein, amino acid, and calcium values would be abnormal when
24-hour urinary cadmium levels were >3.05, 2.87, 2.74, 4.29, or 1.92 μg/24 hour, respectively.
Järup et al. (2000) examined 1,021 individuals living near a nickel-cadmium battery plant in Sweden for
at least 5 years (n=799) or employed as battery workers (n=222). The mean urinary cadmium levels were
0.81 and 0.65 μg/g creatinine in males and females, respectively. Urinary cadmium levels were
significantly associated with urinary human complex-forming glycoprotein (pHC; also referred to as
α1-microglobulin) levels, after adjustment for age. The relationship remained statistically significant
after removal of the cadmium workers from the analysis. The prevalence of abnormal pHC values
(defined as exceeding the 95th percentile in a Swedish reference population; >7.1 and 5.3 mg/g creatinine
for males and females, respectively) was estimated to increase by 10% at urinary cadmium levels of
1 μg/g creatinine. The European Chemicals Bureau (2007) recalculated the probability of HC proteinuria
(using the raw data from Järup and associates) to account for the differences in age of the reference
CADMIUM 149
3. HEALTH EFFECTS
Table 3-7. Summary of Human Studies Examining Renal Effects
Mean urinary Effect

Population studied cadmium level biomarker Results Reference
General population 1.26 μg/g creat. β2M Significant correlation between Ezaki et al.
(Japan) pHC urinary cadmium and effect 2003
10,753 females; 35– biomarkers; however, no
60 years old significant relationship was
established when age was
factored into analysis.
General population 2.1 μg/g creat. β2M Significant correlation between Ikeda et al.
(Japan) pHC urinary cadmium (not corrected 1999
470 nonsmoking for creat.) and pHC and β2M.
females
General population 1.8 μg/g creat. (M) β2M Significant correlation between Suwazono et
(Japan) 2.4 μg/g creat. (F) Total protein urinary cadmium and protein al. 2000
1,105 males, NAG and β2M. Dose-response
1,648 females; relationship between urinary
>50 years old cadmium and prevalence of
abnormal effect biomarker
levels.
General population 2.2–3.4 μg/L (M) total protein Significant correlation (with age Oo et al.
(Japan) 2.8–3.9 μg/L (F) NAG adjustment) between urinary 2000
568 males, β2M cadmium and effect
742 females; biomarkers.
≥50 years old
General population 1.3 μg/g creat. (M) β2M Significant correlation between Yamanaka et
(Japan) 1.3 μg/g creat. (F) total protein urinary cadmium and effect al. 1998
558 males, NAG biomarkers (NAG was only
743 females; significant in females).
≥50 years old Dose-response relationship
between urinary cadmium and
prevalence of abnormal effect
biomarker levels.
General population 0.8 μg/g creat. (M) β2M Significant associations Uno et al.
(Japan) 1.8 μg/g creat. (F) protein between urinary cadmium and 2005
410 males, (median levels) NAG effect biomarkers (protein only
418 females; 40– significant in males).
59 years old Dose-response relationship
between urinary cadmium and
biomarker levels.
General population Glomerular Significant association between Hwangbo et
(South Korea) filtration rate elevated blood cadmium levels al. 2011
955 males, and decreased glomerular
954 females; filtration rate in females only.
≥20 years of age
CADMIUM 150
3. HEALTH EFFECTS
Mean urinary Effect

General population 0.040–0.093 μg/hour β2M Dose-response relationship Roels et al.
(Belgium) protein between urinary cadmium and 1981a
175 females; mean amino acids urinary protein and amino
age 81.1–82.3 years albumin acids; significant relationship
old with β2M and albumin only in
the two areas with highest
urinary cadmium levels.
General population β2M Significant correlation between Buchet et al.
(Belgium) protein urinary cadmium and effect 1990
1,699 males, NAG biomarkers.
females; 20–80 years amino acids Dose-response relationship
old calcium between urinary cadmium and
biomarker levels.
General population 0.07 μg/g creat. β2M No significant associations Noonan et al.
(United States) (M, child) NAG (after correction for age, sex) 2002
88 males, 0.08 μg/g creat. AAP between urinary cadmium and
71 females; 6– (F, child) albumin effect biomarkers in children.
17 years old; 0.24 μg/g creat. Significant association (after
71 males, (M, adult) age and gender adjustment)
80 females; 0.23 μg/g creat. between urinary cadmium and
≥18 years old (F, adult) NAG and AAP in adults. Dose-
response relationship between
urinary cadmium and NAG and
AAP.
General population 0.29 µg/g creat. albumin Significant association (after Ferraro et al.
(United States) age, gender, race/ethnicity, and 2010
2,644 males, BMI adjustment) between
2,782 females urinary cadmium >1 µg/g
≥20 years old (data creatinine and urinary albumin
from NHANES 1999– to creatinine ratio of >20 mg/g
2006) (males) or 30 mg/g (females).
Residents in 11.27 μg/g creat. β2M Significantly higher effect Cai et al.
cadmium-polluted NAG biomarkers levels. 1990, 1992
area (China)
433 males and
females
Residents in β2M Significant dose-response Cai et al.
cadmium-polluted relationship between urinary 1998
area (China) cadmium, blood cadmium, and
219 males and cumulative Cd intake and β2M;
females prevalence of abnormal values.
CADMIUM 151
3. HEALTH EFFECTS
Mean urinary Effect

Residents in High: 11.18 μg/g β2M Significant correlation between Jin et al.
cadmium-polluted creat. RBP urinary cadmium and effect 2002
area (China) Mod.: 3.55 μg/g albumin biomarkers.
118 males, creat.
170 females in high Dose-response relationship
exposure group between urinary cadmium and
80 males, prevalence of abnormal effect
158 females in biomarker levels.
moderate exposure
group
Residents in β2M Dose-response relationship Jin et al.
cadmium-polluted NAG between urinary cadmium and 2004c
area (China) NAG-B prevalence of abnormal effect
118 males, RBP biomarker levels.
170 females in high albumin
exposure group
80 males,
158 females in
moderate exposure
group
Residents in 9.12 μg/g creat. β2M Dose-response relationship Jin et al.
cadmium-polluted NAG between urinary cadmium and 2004a
area (China) albumin prevalence of abnormal effect
66 males, 22 females biomarker levels.
Residents in High: 9.40 μg/L (M) β2M Dose-response relationship Nordberg et
cadmium-polluted 12.13 μg/L (F) albumin between urinary cadmium and al. 1997
area (China) Mod.: 1.28 μg/L (M) prevalence of abnormal effect
120 males, 2.05 μg/L (F) biomarker levels.
127 females in high
exposure group
125 males,
122 females in
moderate exposure
group
Residents in 6.1 μg/g creat. (M) β2M Effect biomarkers significantly Wu et al.
cadmium-polluted 7.5 μg/g creat. (F) NAG higher than controls. 2001
area (China) calcium Dose-response relationship
122 males, between urinary cadmium and
125 females effect biomarkers.
Residents in 6.8–6.9 μg/g creat. β2M Higher prevalence of abnormal Cai et al.
cadmium-polluted effect biomarkers compared to 2001
area (Japan) controls.
127 males; mean
age 72.1–73.6 years
old
CADMIUM 152
3. HEALTH EFFECTS
Mean urinary Effect

Residents in 3.16–4.08 μg/g creat. β2M No significant association Horiguchi et
cadmium-polluted between urinary cadmium and al. 2004
area (Japan) effect biomarkers.
1,178 females
Residents in β2M Significant association between Izuno et al.
cadmium-polluted cadmium intake and effect 2000
area (Japan) biomarkers in males only.
82 males, 56 females
Residents in Protein Significant association between Kobayashi et
cadmium-polluted cadmium intake and increased al. 2002a;
area (Japan) prevalence of abnormal levels Watanabe et
634 males, of urinary protein in males. al. 2002
411 females
Residents in 4.6 μg/g creat. (M) Potassium Significantly higher urinary Monzawa et
cadmium-polluted 7.2 μg/g creat. (F) sodium potassium levels, compared to al. 1998
area (Japan) controls. Significant correlation
1,419 males, between urinary potassium and
1,745 females urinary cadmium and β2M.
Urinary sodium not significantly
different than controls and not
correlated with urinary
cadmium.
Residents in 2.69 μg/g creat. (M) β2M Significant correlation between Nakadaira
cadmium-polluted 4.68 μg/g creat. (F) pHC urinary cadmium and effect and Nishi
area (Japan) NAG biomarkers (except β2M in 2003
44 males, 54 females protein males).
inorganic
phosphorus
Residents in β2M Significant correlation between Nakashima
cadmium-polluted protein cadmium concentration in rice et al. 1997
area (Japan) amino and effect biomarkers.
832 males, nitrogen Dose-response relationship
871 females between cadmium levels in rice
and prevalence of abnormal
β2M (males) and protein
(females) levels.
Residents in Protein Dose response relationship Osawa et al.
cadmium-polluted between cadmium levels in rice 2001
area (Japan) and prevalence of abnormal
826 males, effect biomarker levels.
641 females
Residents in β2M Dose response relationship Nogawa et
cadmium-polluted between cadmium in rice and al. 1989
area (Japan) effect biomarkers.
878 males,
972 females
CADMIUM 153
3. HEALTH EFFECTS
Mean urinary Effect

Residents in 4.56 μg/g creat. (M) β2M β2M significantly higher than Ishizaki et al.
cadmium-polluted 7.15 μg/g creat. (F) controls. 1989
area (Japan) Dose-response relationship
1,424 males, between urinary cadmium and
1,754 females prevalence of abnormal β2M
levels.
Residents in β2M Dose response relationship Kido and
cadmium-polluted between cadmium in rice and Nogawa
area (Japan) prevalence of abnormal β2M 1993
878 males, levels.
972 females
Residents in 4.56 μg/g creat. (M) β2M Dose response relationship Hayano et al.
cadmium-polluted 7.15 μg/g creat. (F) between urinary cadmium and 1996
area (Japan) prevalence of abnormal β2M
1,403 males, levels.
1,716 females;
≥50 years old
Residents in 1.78 μg/g creat. (M) NAG Significant correlation between Kawada et
cadmium-polluted 2.27 μg/g creat. (F) urinary cadmium and NAG. al. 1992
area (Japan)
120 males,
280 females
Residents in 6.30 µg/g creat. β2M Significant correlation between Horiguchi et
cadmium-polluted urinary cadmium and β2M. al. 2010
area (Japan)
129 females; 34–
74 years of age
Residents in 12 μg/g creat. β2M Significant correlation between Teeyakasem
cadmium-polluted pHC urinary cadmium and effect et al. 2007
area (Thailand) NAG biomarkers.
58 males, 70 females protein Dose-response relationship
albumin between urinary cadmium and
prevalence of abnormal β2M
levels.
Residents in 5.3 μg/g creat. (M) β2M Dose-response relationship Honda et al.
cadmium-polluted 5.8 µg/g creat. (F) NAG between urinary cadmium and 2010
area (Thailand) prevalence of abnormal β2M
307 males, levels (≥1,000 µg/g creatinine)
488 females; in females and NAG (≥9 IU/g
>30 years of age creatinine) in males and
females.
Residents in 0.81 μg/g creat. (M) pHC Linear relationship between Järup et al.
cadmium-polluted 0.66 μg/g creat. (F) urinary cadmium and pHC 2000
area (includes (relationship remained
occupationally significant after removal of
exposed subjects occupationally exposed
(Sweden) subjects.
CADMIUM 154
3. HEALTH EFFECTS
Mean urinary Effect

Residents in 0.26 μg/g creat. β2M Significant correlation between Olsson et al.
cadmium-polluted protein HC urinary and blood cadmium and 2002
area (Sweden) NAG effect biomarkers.
57 males, 48 females albumin β2M clearance was significantly
explained by urinary cadmium
levels.
Residents in 0.97 μg/g creat. β2M In childhood exposure group, Trzcinka-
cadmium-polluted (childhood exposure) RBP significant correlations between Ochocka et
area (Poland) 2.23 μg/g creat. NAG urinary cadmium and β2M, al. 2004
44 males, (adult exposure) NAG-A RBP, and albumin. In adult
128 females only NAG-B exposure group, significant
exposed as adults albumin correlations between urinary
72 males, 64 females cadmium and all effect
exposed as children biomarkers.
AAP = alanine aminopeptidase; β2M = β2-microglobulin; creat. = creatinine; BMI = body mass index; F = female;
M = male; Mod. = moderate; NAG = N-acetyl-β-glucosaminidase; NHANES = National Health and Nutrition
Examination Survey; pHC = human complex-forming glycoprotein, also referred to as α1M; RBP = retinol binding
protein
CADMIUM 155
3. HEALTH EFFECTS
population (mean of 40 years) and study population (mean of 53 years). Based on these recalculations,
the urinary cadmium level associated with a 10% increased probability of abnormal pHC values (20%
total probability) was 2.62 μg/g creatinine for the total population. In the environmental exposed
subgroup, a urinary cadmium level of 0.5 μg/g creatinine was associated with a 13% probability
(doubling of the probability in reference population) of abnormal pHC values.
Noonan et al. (2002) examined residents in Pennsylvania living near a defunct zinc smelting facility
(geometric mean urinary cadmium level of 0.14 μg/g creatinine) and a reference community located
10 miles from the facility (geometric mean urinary cadmium levels of 0.12 μg/g creatinine). The data
from the two communities were pooled because there were no differences in urinary cadmium levels
between them. β2-microglobulin, NAG, alanine aminopeptidase (AAP), and albumin levels were
measured as biomarkers of renal dysfunction. The geometric mean urinary cadmium levels were 0.07 and
0.08 μg/g creatinine in 88 males and 71 females aged 6–17 years and 0.24 and 0.23 μg/g creatinine in
71 males and 80 females aged ≥18 years. No significant correlations between urinary cadmium levels
and renal biomarkers were observed in the children, after adjustment for creatinine, age, and gender. In
adults, significant correlations (after adjustment for creatinine, age, gender, smoking, and self-reported
diabetes or thyroid disease) between urinary cadmium and NAG (partial correlation coefficient of 0.20,
95% CI of 0.05–0.36) and AAP (partial correlation coefficient of 0.21 and 95% CI of 0.05–0.36) were
observed. Significant dose-effect relationships were also found for these two biomarkers. Urinary
cadmium levels were not significantly associated with elevated levels of β2-microglobulin or albumin.
Nogawa et al. (1980) examined 878 males and 972 females aged ≥50 years living in the Kakehashi River
basin in Japan; the Kakehashi River, cadmium polluted from an upstream mine, was used to irrigate rice
fields. β2-Microglobulin measured in morning urine samples was used as a biomarker of renal
dysfunction and cadmium intake was estimated from rice samples collected in 1974. Cadmium levels in
rice were considered to be representative of cadmium intake because over 70% of the total cadmium
intake has been shown to come from rice. Cadmium in the rice ranged from 0.10 to 0.69 μg/g.
β2-Microglobulin levels were significantly higher in the study population compared to a reference
population of 113 males and 161 females living in a nearby area. A significant dose-related association
between total cadmium intake and prevalence of abnormal β2-microglobulin values (defined as
β2-microglobulin levels of ≥1,000 μg/g creatinine) was found. The total cadmium intake, which resulted
in a prevalence of abnormal β2-microglobulin levels equal to the control group, was 1,678 mg in males
(prevalence in controls was 6.0%) and 1,763 mg in females (prevalence in controls was 5.0%). A further
analysis of the exposed subjects (Hochi et al. 1995) found that the prevalence of abnormal
CADMIUM 156
3. HEALTH EFFECTS
β2-microglobulin levels (using a cut-off level of 1,000 μg/g creatinine) exceeded the prevalence in the
reference population when cadmium intake was ≥2 g and the subjects were divided into subgroups by
age. The prevalence of abnormal β2-microglobulin levels at a given cadmium intake increased with age.
Yamanaka et al. (1998) examined 558 males and 743 females aged ≥50 years living in a cadmium
nonpolluted area in Japan. Urinary cadmium level was used as a biomarker of exposure and urinary
β2-microglobulin, total protein, and NAG as biomarkers of renal dysfunction. The geometric mean
urinary cadmium levels were 1.3 and 1.3 μg/g creatinine in males and females, respectively. Significant
correlations (after adjustment for age) between urinary cadmium levels and total protein,
β2-microglobulin, and NAG were found. Abnormal levels of renal biomarkers were defined as exceeding
the 84% upper limit value calculated from a referent group of 2,778 non-exposed individuals; the cut-off
values were 124.8 and 120.8 mg/g creatinine for total protein in males and females, 492 and 403 μg/g
creatinine for β2-microglobulin, and 8.0 and 8.5 U/g creatinine for NAG. Dose-response relationships
between urinary cadmium levels and prevalence of abnormal levels of β2-microglobulin, total protein,
and NAG were found. The odds ratios (95% CI) were 6.589 (3.383–12.833), 3.065 (1.700–5.526), and
1.887 (1.090–3.268) for protein, β2-microglobulin, and NAG in males and 17.486 (7.520–40.660),
5.625 (3.032–10.435), and 2.313 (1.399–3.824) for protein, β2-microglobulin, and NAG in females.
Another study of residents living in a cadmium nonpolluted area of Japan examined 346 males and
529 females from one area (area A) and 222 males and 413 females in another area (area B); all subjects
were ≥50 years of age and were not occupationally exposed to heavy metals (Oo et al. 2000). The
geometric mean urinary cadmium levels were 2.2 and 2.8 μg/L in males and females in area A and
3.4 and 3.9 μg/L in area B. Significant correlations (with adjustment for age) were found between urinary
cadmium and urinary levels of protein, β2-microglobulin (not significant in males in area B) and NAG
levels. A significant association between urinary cadmium levels and the prevalence (cut-off levels from
same referent population as Yamanaka et al. 1998) of abnormal levels of urinary protein (cut-off level of
113.8 and 96.8 μg/L in males and females), β2-microglobulin (378 and 275 μg/L) (only significant in
females in area A), and NAG (8.0 and 7.2 μg/L). The odds ratios (95% CI) for an increase in prevalence
of abnormal renal biomarkers were 8.810 (3.401–22.819) and 11.282 (3.301–38.362) for protein in males
in areas A and B, respectively, 8.234 (3.696–18.343) and 23.901 (8.897–64.210) for protein in females in
areas A and B; 2.558 (1.246–5.248) for β2-microglobulin in females in area A; 47.944 (14.193–161.954)
and 9.940 (3.153–31.340) for NAG in males in areas A and B; and 72.945 (21.873–243.263) and
25.374 (9.452–68.117) for NAG in females in areas A and B.
CADMIUM 157
3. HEALTH EFFECTS
In a re-examination of the populations studied by Yamanaka et al. (1998) and Oo et al. (2000), Suwazono
et al. (2000) measured cadmium levels in blood and urine and urinary levels of total protein,
β2-microglobulin, and NAG in 1,105 males and 1,648 females over the age of 50 years. The geometric
mean concentrations of cadmium in urine were 1.8 and 2.4 μg/g creatinine in males and females,
respectively, and blood cadmium levels were 2.0 and 1.8 ng/g in males and females. After adjustment for
age, significant associations between urinary cadmium levels and urinary protein and β2-microglobulin in
males and females were found. Additionally, blood cadmium levels were significantly associated with
urinary protein and NAG levels in males and urinary protein, β2-microglobulin, and NAG levels in
females. Cut-off levels (defined as the 84% upper limit values from 424 male and 1,611 female
nonsmoking subjects) of 157.4 and 158.5 mg/g creatinine for protein in males and females, respectively,
507 and 400 μg/g creatinine for β2-microglobulin in males and females, respectively, and 8.2 and
8.5 μg/g creatinine for NAG in males and females, respectively, were used to evaluate the prevalence of
abnormal levels of renal biomarkers. Logistic regression analysis demonstrated significant associations
between urinary cadmium levels and increased prevalence of abnormal levels of total protein (odds ratio
of 3.923, 95% CI of 2.2028–7.590) and β2-microglobulin (odds ratio of 2.259, 95% CI of 1.372–3.717) in
males; in females, significant associations were found for total protein (odds ratio of 7.763; 95% CI of
4.231–14.243), β2-microglobulin (odds ratio of 2.259, 95% CI of 1.879–4.281), and NAG (odds ratio of
1.882, 95% CI of 1.311–2.702). For blood cadmium levels, the only significant association found was for
an increased prevalence of abnormal total protein levels in females (odds ratio of 3.490, 95% CI of 1.661–
7.331).
Jin et al. (2002) examined three populations living various distances from a nonferrous metal smelter.
The geometric mean levels of urinary cadmium were 11.18 and 12.86 μg/g creatinine in males (n=294)
and females (n=171) in the highly polluted area, 3.55 and 4.45 μg/g creatinine in males (n=243) and
females (n=162) in the moderately polluted area, and 1.83 and 1.79 μg/g creatinine in males (n=253) and
females (n=155) in the control area. Significant correlations were found between urinary (and blood)
cadmium levels and renal biomarkers (β2-microglobulin, retinol binding protein, and albumin). Cut-off
values for β2-microglobulin, retinol binding protein, and albumin of 300 μg/g creatinine, 300 μg/g
creatinine, and 15 mg/g creatinine, respectively, were used to assess possible dose-response relationships
(no additional information was provided); although 300 μg/g creatinine was reported as the cut-off values
for β2-microglobulin, subsequent analysis of this data set (Jin et al. 2004c) reported a cut-off value of
800 μg/g creatinine. Significant dose-response relationships between urinary (and blood) cadmium and
the prevalence of abnormal levels of renal markers of kidney dysfunction were found.
CADMIUM 158
3. HEALTH EFFECTS
Unlike the studies discussed above, Hellström et al. (2001) used the incidence of renal replacement
therapy (dialysis or kidney transplantation) as an indicator of renal dysfunction, in particular, end-stage
renal disease. Residents of Kalmar County, Sweden were divided into four exposure groups: high
exposure (workers at cadmium battery production facility), moderate (residents living within 2 km of the
cadmium battery facility), low (residents living between 2 and 10 km of the facility), and no exposure
(residents living at least 10 km from the facility); all subjects were 20–79 years of age. The Mantel-
Haenszel rate ratio (MH-RR) for renal replacement therapy in the cadmium exposed group was
1.8 (95% CI 1.3–2.3); among the environmentally exposed group, the MH-RR was 1.7 (95% CI 1.3–2.3).
The age SRRs were 1.9 (95% CI 1.3–2.5) and 1.9 (95% CI 1.2–2.6) for subjects in the moderate exposure
group aged 20–79 years or 40–79 years, respectively. The trend for increasing MH-RR with increasing
exposure was statistically significant. The age SRRs were not significantly elevated in the low exposure
group. The investigators noted that the causes of end stage renal disease were similar in the cadmium
exposed and unexposed groups. When only primary renal diseases (excludes renal failure secondary to
diabetes or vascular or systemic diseases) were considered, the MH-RR was 1.7 (95% CI 1.1–2.6) for all
cadmium exposed individuals and 2.1 (95% CI 1.4–3.2) for cadmium exposed individuals aged 40–
79 years. Although urinary cadmium levels were not assessed in this study, other studies in this area
found mean urinary cadmium levels of 1.0 and 0.46 μg/g creatinine in residents living within 0.5 and 0.5–
1 km, respectively, of the battery facility (Järup et al. 1995a) and 0.38 and 0.55 μg/g creatinine in men
and women, respectively, living in the contaminated area (Alfvén et al. 2000). Ferraro et al. (2011) and
Swaddiwudhipong et al. (2011) used another approach for evaluating kidney damage by examining the
association between elevated urinary cadmium levels and kidney stone formation. Using the NHANES
survey data from 1988 to 1994, Ferraro et al. (2011) found significantly higher urinary cadmium levels in
individuals with a history of kidney stone formation, as compared to individuals without a history of
kidney stone formation. However, after adjusting for age, race/ethnicity, BMI, smoking habits, region of
residence, and daily intake of calcium and sodium, a significant association was only found in females;
the odds ratio of kidney stones was 1,40 (95% CI of 1.06–1.86) among individuals with a urinary
cadmium level of >1 µg/g. Swaddiwudhipong et al. (2011) found a significant association between
urinary cadmium levels and prevalence of urinary stone formation among adults living in cadmium-
contaminated areas of Thailand.
Although there is strong evidence to suggest a relationship between urinary cadmium excretion and
excretion of renal biomarkers (particularly low molecular weight proteins such as β2-microglobulin, pHC,
and retinol binding protein), there is less agreement about the significance of the early renal changes and
the threshold urinary cadmium levels associated with renal damage. Several studies monitoring
CADMIUM 159
3. HEALTH EFFECTS
populations following a decrease in cadmium exposure have attempted to address the question of the
reversibility of early renal changes. In Japan, cadmium-contaminated soil used in rice paddies was
replaced resulting in decreasing urinary cadmium levels in residents consuming rice grown in these fields
(Cai et al. 2001; Iwata et al. 1993; Kobayashi et al. 2008b; Sato et al. 2010). Although, cadmium
exposure decreased over the same time period, the levels of renal biomarkers increased (Cai et al. 2001;
Iwata et al. 1993; Kido et al. 1988; Kobayashi et al. 2008b; Sato et al. 2010) and the prevalence of
abnormal values remained higher compared to the reference population (Cai et al. 2001). Although
significant decreases in urinary cadmium levels were observed over time, cadmium burdens still remained
high; urinary cadmium levels at the later time periods were 6.03–9.6 μg/g creatinine (Cai et al. 2001;
Iwata et al. 1993; Kido et al. 1988). Kobayashi et al. (2008b) found significant correlations (after
adjustment for age) between the amount of time since soil replacement and increases in urinary levels of
retinol binding protein, total protein, and glucose (males only). In contrast, a follow-up study of a portion
of the population examined by Buchet et al. (1990) found small, but statistically significant, decreases in
urinary cadmium levels and urinary levels of β2-microglobulin, NAG, and retinol binding protein (Hotz
et al. 1999). Urinary cadmium levels in this study (0.6–0.9 μg/g creatinine at baseline and 0.5–0.8 μg/g
creatinine at follow up) were much lower than levels in the Japanese studies. Wu et al. (2008) examined
biomarkers of renal dysfunction before (measured in 1995) and after (measured in 1998) remediation in
148 adults living in an area of China with cadmium pollution. The subjects were divided into two groups
based on whether or not they had elevated β2-microglobulin levels in 1995. Among the subjects with no
alteration in β2-microglobulin levels in 1995, there were no significant changes in β2-microglobulin
levels in subjects with urinary cadmium levels of <10 µg/g creatinine in 1995 and significant increases in
β2-microglobulin levels in the subjects with initial urinary cadmium levels of ≥10 µg/g creatinine. In the
subjects with elevated β2-microglobulin levels in 1995, there were significant decreases in
β2-microglobulin in subjects with urinary cadmium levels of <5 µg/g creatinine, no changes in subjects
with urinary cadmium levels of 5 µg/g creatinine, and significant increases in β2-microglobulin levels in
subjects with urinary cadmium levels of ≥10 µg/g creatinine. A similar pattern was found for urinary
albumin levels, with significant decreases in urinary albumin levels in subjects previously diagnosed with
albuminuria and urinary cadmium levels of <5 µg/g creatinine and no changes in urinary albumin levels
in subjects with urinary cadmium levels of ≥5 µg/g creatinine. In subjects without albuminuria in 1995,
there were increases at the higher urinary cadmium levels (5 and 20 µg/g creatinine). Although the data
are inconclusive, the results of these studies provide some indication of reversibility of renal damage
resulting from substantial decreases in cadmium exposure among subjects exposed to low levels of
cadmium. However, renal damage may continue to progress in subjects initially exposed to higher levels
of cadmium.
CADMIUM 160
3. HEALTH EFFECTS
A number of investigators have examined different approaches to establishing a safe cadmium body
burden (as assessed by urinary cadmium levels). Several BMD analyses of data from populations living
in cadmium nonpolluted areas in Sweden (Suwazono et al. 2006) or Japan (Kobayashi et al. 2006, 2008a;
Suwazono et al. 2011a, 2011b, 2011c; Uno et al. 2005) or cadmium polluted areas in Japan (Shimizu et
al. 2006) or China (Jin et al. 2004c) have been conducted. The analyses used urinary cadmium levels as a
biomarker of cadmium exposure and the prevalence of abnormal levels of β2-microglobulin, pHC,
protein, NAG, retinol binding protein, albumin, or glomerular filtration rate as biomarkers of renal
effects. Two approaches were used for BMD modeling: dichotomous variable (Jin et al. 2004c;
Kobayashi et al. 2006; Shimizu et al. 2006; Uno et al. 2005) or hybrid (Kobayashi et al. 2008a; Suwazono
et al. 2006, 2011a, 2011b, 2011c) approaches. In the dichotomous variable approach, urinary cadmium
excretion was divided into categories and the distribution of abnormal values (exceeding the cut-off
value) was fit to dichotomous BMD models. As noted by Suwazono et al. (2010), one limitation of this
approach is that it does not allow for adjustment for potential covariates, particularly age; additionally, the
results may fluctuate depending on the categorization of exposure, number of categories, or dose
intervals. The hybrid approach eliminates the categorization of subjects by exposure (e.g., urinary
cadmium levels) and is based on a continuous measure of outcome and allows for the adjustment of
potential covariates such as age and BMI. As summarized in Table 3-8, the BMDs for urinary cadmium
levels vary widely between the studies depending on the renal biomarker and the cut-off level used. For
example, when NAG is used as the effect biomarker, the BMD0.05 (dose associated with a 5% extra risk)
values of 0.64, 12.0–10.8, and 6.36–7.74 μg/g creatinine were calculated by Suwazono et al. (2006),
Kobayashi et al. (2006), and Jin et al. (2004c) when the 95% upper limit cut-off value of 3.6, 16.0–16.6,
and 15.0 U/g creatinine, respectively, was used. The results of the two BMD approaches were similar
when similar cut-off levels were used. The BMDL (95% confidence bound of the BMD) is typically
considered a no adverse effect level; the results of these BMD analyses suggest that chronic exposure to
cadmium resulting in urinary cadmium levels of 0.3–11.31 or 0.6–11.4 μg/g creatinine would be
associated with a 5 or 10% additional risk of renal dysfunction.
Ikeda and associates used regression analysis to predict a threshold urinary cadmium level. Plotting
urinary cadmium levels against β2-microglobulin levels taken from published data from populations
living in cadmium polluted and non polluted areas of Japan resulted in a distribution shaped like the letter
“J”. The threshold level was defined as the point of flexion in the “J” shaped curve. In the first
investigation (Ikeda et al. 2003b), the point of flexion was estimated as the point of intersection between
two regression lines: one with no elevation in β2-microgloublin from non-exposed populations and the
CADMIUM 161
3. HEALTH EFFECTS
Table 3-8. Benchmark Dose Estimations of Urinary Cadmium Levels (µg/g

Creatinine)

General NAG 3.6 U/g creat. Profile 0.64 0.50 1.08 0.83 Suwazono et
population (95% cut-off)a likelihood al. 2006
(Sweden) pHC 6.8 mg/g creat. method 0.63 0.49 1.05 0.81
790 females; (95% cut-off)a
53–64 years old
Estimated 78.5 1.08 0.70 1.80 1.18
GFR mL/minute
(95% cut-off)a
Residents in β2M 507 μg/g creat. Quantal 1.5 (M) 1.2 (M) 3.1 (M) 2.5 (M) Shimizu et
cadmium- (M) linear 1.4 (F) 1.1 (F) 2.9 (F) 2.3 (F) al. 2006
polluted 400 μg/g creat. model
(1,397 males, (F)
1,706 females) (84% cut-off)b
and cadmium 507 μg/g creat. Log- 3.7 (M) 2.9 (M) 5.1 (M) 4.2 (M)
nonpolluted (M) logistic 2.6 (F) 1.5 (F) 6.3 (F) 2.7 (F)
areas (Japan) 400 μg/g creat. model
(130 males, (F)
159 females); (84% cut-off)b
≥50 years old
994 μg/g creat. Quantal 2.3 (M) 1.8 (M) 4.7 (M) 3.7 (M)
(M) linear 1.7 (F) 1.4 (F) 3.5 (F) 2.9 (F)
784 μg/g creat. model
(F)
(95% cut-off)c
994 μg/g creat. Log- 4.8 (M) 3.9 (M) 6.3 (M) 5.5 (M)
(M) logistic 4.4 (F) 3.2 (F) 6.4 (F) 5.1 (F)
784 μg/g creat. model
(F)
(95% cut-off)c
Residents in β2M 915.5 µg/g Profile 4.0 (M) 3.5 (M) Suwazono et
cadmium- creat. (M) likelihood 4.0 (F) (3.7 )F) al. 2011b
polluted 897.1 µg/g method
(1,397 males, creat.
1,706 females)d (95% cut-off)e
and cadmium
nonpolluted
areas (Japan)
(520 males,
700 females);
≥50 years old
CADMIUM 162
3. HEALTH EFFECTS

Creatinine)

General Protein 157 mg/g Log- 3.6 (M) 3.1 (M) 5.6 (M) 4.9 (M) Kobayashi et
population creat. (M) logistic 4.8 (F) 4.2 (F) 7.5 (F) 6.6 (F) al. 2006
(Japan) 159 mg/g model
1,114 males, creat. (F)
1,664 females (84% cut-off)f
309 mg/g 10.6 (M) 6.8 (M) 15.3 (M) 9.6 (M)
creat. (M) 8.7 (F) 7.3 (F) 12.0 (F) 9.9 (F)
311 mg/g
creat. (F)
(95% cut-off)g
β2M 507 μg/g creat. 2.9 (M) 2.4 (M) 5.0 (M) 4.0 (M)
(M) 3.8 (F) 3.3 (F) 6.6 (F) 5.5 (F)
400 μg/g creat.
(F)
(84% cut-off)f
994 μg/g creat. 6.4 (M) 4.5 (M) 10.2 (M) 7.1 (M)
(M) 8.7 (F) 7.3 (F) 12.0 (F) 9.9 (F)
784 μg/g creat.
(F)
(95% cut-off)g
NAG 8.2 U/g creat. 4.8 (M) 3.3 (M) 8.3 (M) 5.7 (M)
(M) 4.7 (F) 3.7 (F) 8.3 (F) 6.4 (F)
8.5 U/g creat.
(F)
(84% cut-off)f
16.0 U/g creat. 12.0 (M) 7.7 (M) 16.4 (M) 10.3 (M)
(M) 10.8 (F) 8.5 (F) 14.8 (F) 11.4 (F)
16.6 U/g creat.
(F)
(95% cut-off)g
General β2M 492 µg/g creat. Multiple 3.0 (M) 2.7 (M) 5.0 (M) 4.6 (M) Kobayashi et
population (M) logistic 3.4 (F) 3.2 (F) 5.7 (F) 5.4 (F) al. 2008a
(Japan) 407 µg/g creat. model
1,181 males, (F)
1,748 females (84% cut-off)h
965 µg/g creat. 4.9 (M) 4.5 (M) 7.4 (M) 6.8 (M)
(M) 5.9 (F) 5.6 (F) 8.6 (F) 8.1 (F)
798 µg/g creat.
(F)
(97.5% cut-off)i
1,000 µg/g 5.0 (M) 4.6 (M) 7.5 (M) 6.9 (M)
creat. 6.7 (F) 6.3 (F) 9.4 (F) 8.9 (F)
CADMIUM 163
3. HEALTH EFFECTS

Creatinine)

General Protein 159 mg/g Profile 2.6 (M) 2.1 (M) Suwazono et
population creat. (M) likelihood 1.7 (F) 1.5 (M) al. 2011c
(Japan) 93 mg/g creat. method
547 males, (F)
aged ≥50 years β2M 708 µg/g creat. 3.4 (M) 2.6 (M)
(M) 1.7 (F) 1.4 (F)
415 µg/g creat.
(F)
(95% cut-off)e
NAG 10.7 IU/g 6.3 (M) 4.1 (M)
creat. (M) 4.3 (F) 3.1 (F)
11.1 IU/g
creat. (F)
(95% cut-off)j
General Protein 70 mg/g creat. Quantal 0.9 (M) 0.6 (M) 1.9 (M) 1.2 (M) Uno et al.
population (M) linear 3.2 (F) 1.8 (F) 6.6 (F) 3.6 (F) 2005
(Japan) 70 mg/g creat. model
410 males, (F)
418 females; (84% cut-off)k
40–59 years old β2M 233 μg/g creat. 0.5 (M) 0.4 (M) 1.0 (M) 0.7 (M)
(M) 0.9 (F) 0.8 (F) 1.8 (F) 1.3 (F)
274 μg/g creat.
(F)
(84% cut-off)k
NAG 2.4 U/g creat. 0.3 (M) 0.3 (M) 0.7 (M) 0.6 (M)
(M) 0.8 (F) 0.6 (F) 1.6 (F) 1.2 (F)
2.5 U/g creat.
(F)
(84% cut-off)k
General Protein 67.7 mg/g Profile 1.3 (M) 0.9 (M) Suwazono et
population creat. (M) likelihood 3.2 (F) 1.9 (F) al. 2011a
(Japan)l 94.6 mg/g method
209 males, creat. (F)
40–49 years old β2M 224.5 µg/g 0.9 (M) 0.7 (M)
creat. (M) 2.2 (F) 1.5 (F)
298.9 µg/g
creat. (F)
(95% cut-off)a
NAG 2.2 IU/g creat. 0.7 (M) 0.6 (M)
(M) 1.3 (F) 0.6 (F)
2.1 IU/g creat.
(F)
(95% cut-off)a
CADMIUM 164
3. HEALTH EFFECTS

Creatinine)

General Protein 94.5 mg/g Profile 1.6 (M) 1.1 (M) Suwazono et
population creat. (M) likelihood 5.7 (F) 3.4 (F) al. 2011a
(Japan)j 92.7 mg/g method
201 males, creat. (F)
50–59 years β2M 322.1 µg/g 1.8 (M) 1.2 (M)
creat. (M) 2.4 (F) 1.8 (F)
296.7 µg/g
creat. (F)
(95% cut-off)a
NAG 2.5 IU/g creat. 1.0 (M) 0.8 (M)
(M) 3.2 (F) 2.3 (F)
3.3 IU/g creat.
(F)
(95% cut-off)a
Residents in NAG 15.0 U/g creat. Quantal 6.36 (M) 5.83 (M) Jin et al.
cadmium highly (95% cut-off)m linear 7.74 (F) 5.46 (F) 2004c
polluted area NAG-B 4.0 U/g creat. logistic 4.88 (M) 3.98 (M)
(China) (95% cut-off)k regression 4.24 (F) 3.70 (F)
123 males, model
171 females β2M 800 μg/g creat. 5.86 (M) 4.74 (M)
Residents in (95% cut-off)m 9.98 (F) 8.47 (F)
cadmium RBP 0.300 mg/g 5.99 (M) 4.87 (M)
moderately creat. 9.03 (F) 7.63 (F)
polluted area (95% cut-off)m
(China) Albumin 25.0 mg/g 16.72 11.18
81 males, creat. (M) (M)
162 females (95% cut-off)m 14.42 (F) 11.31 (F)
a th
95 percentile of effect biomarkers on the “hypothetical” control distribution at a urinary cadmium level of zero.
b
c
d
Same population of residents living in polluted area as Shimizu et al. (2006).
e th
to mean age.
f
g
h th
84 percentile level in subjects from nonpolluted areas.
i th
97.5 percentile level in subjects from nonpoulluted areas.
j th
to mean age in females only.
k
84% upper limit value of the target population.
l
Same population as Uno et al. (2005), divided into two age groups.
m
95% upper limit value from a control group 98 males and 155 females living in a cadmium nonpolluted area.
BMD = benchmark dose; BMDL = lower 95% confidence limit on the benchmark dose; BMR = benchmark response;
β2M = β2-microglobulin; creat. = creatinine; F = female; M = male; NAG = N-acetyl-β-D-glucosaminidase;
NAG-B = N-acetyl-β-D-glucosaminidase’s isoform B; RBP = retinol binding protein
CADMIUM 165
3. HEALTH EFFECTS
other when β2-microglobulin was >400 or >1,000 μg/g creatinine using data from exposed populations.
Although no specific data were given for the two populations, the investigators noted that the highest
urinary cadmium levels in the non-exposed populations were 5.6 and 3.6 μg/g creatinine in females and
males, respectively. The points of intersection of the regression lines were 11.0 and 11.7 μg/g creatinine
in females using the >400 and 1,000 μg/g creatinine criteria, respectively, and 10.0 and 11.0 μg/g
creatinine in males. The second investigation also used published data on Japanese populations living in
polluted and nonpolluted areas (Ikeda et al. 2005b). The urinary cadmium levels ranged from 0.2 to
7.8 μg/g creatinine and from 0.8 to 31.6 μg/g creatinine in the nonpolluted and polluted areas,
respectively, and the data for the two populations were combined. Plotting urinary cadmium levels
against β2-microglobulin levels showed that there was a marked increase in β2-microglobulin levels
(levels exceeded 1,000 μg/g creatinine) when urinary cadmium levels exceeded 4 μg/g creatinine. The
urinary cadmium levels at the point of intersection of the regression line for urinary cadmium levels of
≤2 or ≤5 μg/g creatinine was 6.7 and 6.7 μg/g creatinine using ordinary scales and 3.7 and 3.7 μg/g
creatinine using double logarithmic scales. These urinary cadmium levels corresponded to β2-micro-
globluin levels of 139 and 267 μg/g creatinine with the ordinary scales and 118 and 118 μg/g creatinine
using the double logarithmic scales. Using these regression equations and a critical β2-microglobulin
level of 1,000 μg/g creatinine resulted in urinary cadmium levels of 7.6 (ordinary scales) or 8.1 (double
logarithmic scales) μg/g creatinine. Based on this analysis, the investigators concluded that at urinary
cadmium levels of >4 μg/g creatinine, there is a substantial increase in β2-microglobulin levels (Ikeda et
al. 2005b). Similarly, Kobayshi et al. (2009a) estimated the threshold level for lifetime cadmium intake
using BMD modeling in 2607 adults, aged ≥50 years, residing for at least 30 years in an area of Japan
with known cadmium contamination. A lifetime cadmium intake of 1.16–2.43 g in males and 0.86–
1.79 g in women would be associated with a 5% additional risk of proteinuria and/or glucosuria.
A third approach used to identify a threshold level was a meta-analysis conducted by Gamo et al. (2006)
using published data on environmentally exposed populations. Urinary cadmium was used as a
biomarker of exposure and the prevalence of abnormal levels of β2-microglobulin as an indicator of renal
dysfunction. The investigators estimated maximum permissible geometric mean urinary cadmium levels
in age- and gender-specific populations that would not result in a significant increase in the prevalence of
abnormal β2-microglobulin levels. They concluded that the geometric mean urinary cadmium level for a
population in a small geographical area should not exceed 3 μg/g creatinine; in a nationwide population,
the geometric mean should not exceed 2 μg/g creatinine.
CADMIUM 166
3. HEALTH EFFECTS
Numerous studies in rats, mice, and rabbits confirm that oral exposure to cadmium causes kidney damage
including proteinuria and tubular damage (Andersen et al. 1988; Bernard et al. 1980, 1988a, 1992;
Bomhard et al. 1984; Borzelleca et al. 1989; Cardenas et al. 1992a, 1992b; Cha 1987; Fingerle et al. 1982;
Gatta et al. 1989; Gill et al. 1989b; Itokawa et al. 1974; Kawamura et al. 1978; Kotsonis and Klaassen
1978; Kozlowska et al. 1993; Mangler et al. 1988; Masaoka et al. 1994; Pleasants et al. 1992, 1993;
Prigge 1978a; Steibert et al. 1984; Stowe et al. 1972; Wilson et al. 1941). Histopathological findings
include focal necrosis of proximal tubular epithelial cells and cloudy swelling in renal tubules (Cha 1987).
Some studies have also shown no effect on renal function (Basinger et al. 1988; Borzelleca et al. 1989;
Boscolo and Carmignani 1986; Groten et al. 1990; Jamall et al. 1989; Loeser and Lorke 1977a, 1977b).
In acute-duration gavage studies in rats, decreased urine flow (Kotsonis and Klaassen 1977) and
histopathologic evidence of kidney damage have been reported (Borzelleca et al. 1989) at the very high
doses of 150 and 138 mg/kg/day, respectively. No effect on renal function was reported in rats receiving
13.9 mg/kg/day for 10 days in drinking water (Borzelleca et al. 1989). Mice treated with a single gavage
dose showed tubular necrosis at 88.8 mg/kg in one study (Andersen et al. 1988), but no effects on the
kidney in another study at a dose of 112 mg/kg (Basinger et al. 1988). Proteinuria is a common finding in
intermediate-duration oral exposure studies in rats (Bernard et al. 1988a; Cardenas et al. 1992a, 1992b;
Kotsonis and Klaassen 1978; Prigge 1978a), as are histopathologic changes in the kidney (Gatta et al.
1989; Itokawa et al. 1974; Kotsonis and Klaassen 1978; Wilson et al. 1941). Renal clearance was
decreased in one study (Kawamura et al. 1978). Both increases (Pleasants et al. 1992, 1993) and
decreases (Kozlowska et al. 1993) in relative kidney weight have been reported. These effects occurred
in rats at doses ranging from 2 to 30 mg/kg/day. No renal effects were seen in dogs receiving
0.75 mg/kg/day cadmium for 3 months (Loeser and Lorke 1977b), but interstitial renal fibrosis was
observed in rabbits exposed to 14.9 mg/kg/day for 200 days (Stowe et al. 1972). Renal dysfunction has
been reported in Rhesus monkeys exposed to 1.2 mg/kg/day for 9 years, but not at 0.4 mg/kg/day
(Masaoka et al. 1994). Adverse renal effects are common in rats following chronic-duration oral
exposure to cadmium. Proteinuria (Bernard et al. 1992; Bomhard et al. 1984) and histopathologic damage
(Fingerle et al. 1982; Mangler et al. 1988) have been reported at doses ranging from 1.8 to
12.5 mg/kg/day cadmium.
The hypothesis that a critical concentration of approximately 200 μg/g in the renal cortex must be reached
before proteinuria develops is generally supported by the animal data (Bhattacharyya et al. 1988c;
Kotsonis and Klaassen 1978; Mangler et al. 1988; Shaikh et al. 1989; Viau et al. 1984).
CADMIUM 167
3. HEALTH EFFECTS
Endocrine Effects. Using data from the NHANES 1988–1994, Schwartz et al. (2003) investigated
possible associations between cadmium exposure (as measured by urinary cadmium levels) and the
prevalence of impaired fasting glucose and diabetes. Analysis on 8,722 participants of the survey
(≥40 years old) showed a dose-related increase in both impaired fasting glucose and diabetes after
adjusting for age, ethnicity, sex, and BMI. No other studies were located regarding endocrine effects in
humans after oral exposure to cadmium.
Studies on the potential toxicity of cadmium to the endocrine system consist of studies conducting
histopathologic examination of endocrine tissues and studies examining 24-hour variations in hormone
release. No adverse effects were seen in parathyroid glands from female Wistar rats exposed to 8 mg
Cd/kg/day via drinking water for 90 days (Kawamura et al. 1978) or in adrenal gland from male Sprague-
Dawley rats exposed to 8 mg/kg/day via drinking water for 24 weeks (Kotsonis and Klaassen 1978).
Pituitary, adrenals, thyroid, and thymus were unaffected in Wistar rats exposed to 3 mg/kg/day cadmium
via feed for 3 months (Loeser and Lorke 1977a). Wilson et al. (1941) reported pancreatic atrophy and
pancreatitis in rats from cadmium at 2.79 mg/kg/day via feed for 100 days. In rabbits exposed to 14.9 mg
Cd/kg body weight/day via drinking water for 200 days, the pancreas had moderate concentrations of
cadmium, but no interstitial fibrosis or other pathologic alterations (Stowe et al. 1972). Alterations in the
24-hour pattern of plasma adrenocorticotropin hormone and growth hormone levels were observed in rats
exposed to 0.92 or 1.8 mg Cd/kg/day as cadmium chloride in drinking water for 30 days (Caride et al.
2010b); significant increases in adenocorticotropin hormone and thyroid stimulating hormone levels were
also observed. Cadmium also disrupted the daily pattern of aspartate, glutamate, and glutamine content in
the anterior and posterior pituitary gland in rats exposed to 0.92 or 1.8 mg Cd/kg/day as cadmium
chloride in drinking water for 30 days (Caride et al. 2010a).
Dermal Effects. No studies were located regarding dermal effects in humans after oral exposure to
cadmium.
Coarse fur was reported in Long-Evans rats receiving 6.13 mg/kg/day cadmium during Gd 6–15
(Machemer and Lorke 1981). A ruffled hair coat was reported in Wistar rats receiving 40 mg/kg/day
cadmium by gavage 5 days/week for 14 weeks (Baranski and Sitarek 1987). No other reports of dermal
effects after oral exposure to cadmium were located.
Ocular Effects. No studies were located regarding ocular effects in humans or animals after oral
CADMIUM 168
3. HEALTH EFFECTS
Body Weight Effects. No studies were located regarding body weight effects in humans after oral
Decreased body weight and decreased rates of growth are common findings in studies where experimental
animals are orally exposed to cadmium. Sprague-Dawley rats receiving a single gavage dose of
150 mg/kg cadmium exhibited a 12% decrease in body weight, but 100 mg/kg had no effect (Kotsonis
and Klaassen 1977). Daily gavage doses of 15.3 mg/kg over a 10-day period caused a 79% decrease in
body weight gain in male Sprague-Dawley rats (Borzelleca et al. 1989). Significant reductions in
maternal weight gain have also been reported (Baranski 1985; Machemer and Lorke 1981).
Body weight reductions are also seen in intermediate-duration studies. For example, in a 14-week
exposure via drinking water in male Long-Evans rats, 2.9 mg/kg/day had no effect on body weight gain;
however, 5.8 mg/kg/day caused a 6–23% decrease and 11.6 mg/kg/day caused a 47–58% decrease
(Pleasants et al. 1992, 1993). In general, intermediate-duration doses in feed or drinking water of
≤3 mg/kg/day have either no effect or only a small effect (10–20% decrease) on body weight in rats
(Carmignani and Boscolo 1984; Jamall et al. 1989; Loeser and Lorke 1977a; Muller et al. 1988; Ogoshi et
al. 1989; Perry et al. 1989; Wilson et al. 1941). Higher doses (4–14 mg/kg/day) had no effect in some
studies (Kostial et al. 1993; Kotsonis and Klaassen 1978; Prigge 1978a; Viau et al. 1984) and small
effects in others (Cha 1987; Kawamura et al. 1978; Kozlowska et al. 1993). A 29% decrease in maternal
weight gain was observed in rats exposed to a high dose of 40 mg/kg/day (Baranski and Sitarek 1987). In
mice, a dose of 4.8 mg/kg/day had no effect on maternal weight gain, but a dose of 9.6 mg/kg/day caused
a 14% decrease (Webster 1978). A high dose of 232 mg/kg/day in mice caused a 29% decrease in body
weight (Waalkes et al. 1993). Beagle dogs were unaffected at 0.75 mg/kg/day (Loeser and Lorke 1977b),
as were rabbits at up to 2.2 mg/kg/day (Boscolo and Carmignani 1986; Tomera and Harakal 1988). A
small decrease (11%) was seen in rabbits exposed to 14.9 mg/kg/day for 200 days (Stowe et al. 1972).
A chronic-duration study in Rhesus monkeys reported decreased growth rates at 0.4 mg/kg/day, but no
effect at 0.12 mg/kg/day (Masaoka et al. 1994). No effect on body weight was seen in rats at up to
4.4 mg/kg/day (Decker et al. 1958; Fingerle et al. 1982; Mangler et al. 1988), but a small effect was seen
at 7 mg/kg/day (Waalkes and Rehm 1992). Decreased terminal body weight was observed in mice after
12 months of drinking-water exposure to a high dose of 57 mg/kg/day (Hays and Margaretten 1985).
CADMIUM 169
3. HEALTH EFFECTS
Metabolic Effects. Hyperthermia and metabolic acidosis were reported in a human male who had
ingested 25 mg/kg cadmium as cadmium iodide (Wisniewska-Knypl et al. 1971).
No studies were located regarding metabolic effects in animals after oral exposure to cadmium.
No studies were located regarding immunological effects in humans after oral exposure to cadmium.
Numerous studies in rats, mice, and monkeys have established the capability of cadmium to affect the
immune system, but the clinical significance of the effects is not clear. In mice, intermediate-duration
oral exposure to cadmium has been shown to increase resistance to viral infection (Exon et al. 1986), to
be without effect on natural or acquired resistance to infection (Bouley et al. 1984), and to increase
mortality from virally-induced leukemia (Blakley 1986; Malave and de Ruffino 1984). Oral cadmium
exposure has also been found to suppress the humoral immune response of mouse splenic cells to sheep
red blood cell antigen in 6-week-old mice (Blakley 1985), but not in 12-month-old mice (Blakley 1988).
The author suggests that “natural” age-related immune system dysfunction masked any cadmium
suppressive effect in the 12-month-old mice, and that immunotoxicological investigations in aged models
appear to be a poor indicator of immune response in the general population. Oral cadmium exposure has
also been found to increase the cell-mediated immune response of monkeys (Chopra et al. 1984), to
induce anti-nuclear antibodies in mice (Ohsawa et al. 1988), to increase circulating leukocytes in female
rats (Borzelleca et al. 1989), and to exhibit time-dependent inhibitory and stimulative effects (Cifone et al.
1989b) or no effect (Stacey et al. 1988a) on natural killer cell activity in rats. The highest NOAEL values
and all LOAEL values from each reliable study for immunological effects in each species and duration
category are recorded in Table 3-6 and plotted in Figure 3-2.
A few studies have reported an association between environmental cadmium exposure and neuropsycho-
logical functioning. These studies used hair cadmium as an index of exposure (see Section 3.8.1 for a
discussion of the limitations of using hair as an indicator of exposure). End points that were affected
included verbal IQ in rural Maryland children (Thatcher et al. 1982), acting-out and distractibility in rural
Wyoming children (Marlowe et al. 1985), and disruptive behavior in Navy recruits (Struempler et al.
1985). The usefulness of the data from these studies is limited because of the potential confounding
CADMIUM 170
3. HEALTH EFFECTS
effects of lead exposure; lack of control for other possible confounders including home environment,
caregiving, and parental IQ levels; and an inadequate quantification of cadmium exposure.
Although cadmium-induced neurotoxicity has not been clearly demonstrated in human studies, it has been
observed in animal studies. Both a single oral exposure (Kotsonis and Klaassen 1977) and intermediate-
duration exposure of adult rats to cadmium resulted in significantly decreased motor activity (Kotsonis
and Klaassen 1978; Nation et al. 1990). Intermediate-duration oral exposure to cadmium has also been
reported to cause weakness and muscle atrophy (Sato et al. 1978), induce aggressive behavior (Baranski
and Sitarek 1987), induce anxiety as manifested by increased passive avoidance behavior (Nation et al.
1984) and by increased ethanol consumption (Nation et al. 1989), and alter brain biogenic amine content
and enzyme activities (Murthy et al. 1989). Doses associated with these effects range from 5 to
40 mg/kg/day cadmium. Degenerative changes in the choroid plexus have been reported in mice exposed
to 1.4 mg/kg/day cadmium in drinking water for 22 weeks (Valois and Webster 1989). Peripheral
neuropathy has been reported in rats after a 31-month exposure to cadmium in drinking water (Sato et al.
1978). Neurological effects in offspring of animals orally exposed to cadmium during gestation are
discussed in Section 3.2.2.5. The highest NOAEL values and all LOAEL values from each reliable study
for neurological effects in each species and duration category are recorded in Table 3-6 and plotted in
Figure 3-2.
Several studies have examined the possible association between increased cadmium exposure and male
reproductive toxicity; however, most studies focused on sex steroid hormone levels and the results appear
to be inconsistent. Akinloye et al. (2006) found significant associations between increasing blood
cadmium levels and increasing levels of serum luteinizing hormone, follicle stimulating hormone,
prolactin, and testosterone among infertile men (sperm counts <20 million/cm3 or no spermatozoa in
semen). A significant association between increased blood cadmium levels and increased serum
testosterone was also found in a group of workers with slight to moderate lead exposure (Telišman et al.
2000); however, neither study controlled for smoking. A study by Jurasović et al. (2004) found
significant associations between blood cadmium levels and increased serum estradiol, follicle stimulating
hormone, and testosterone levels in infertile men after adjusting for age, smoking, alcohol consumption,
and biomarkers of lead, copper, zinc, and selenium. In contrast, a study of Chinese men living in areas
with high levels of cadmium in rice did not find significant correlations between urinary or blood
cadmium levels and serum testosterone, follicle stimulating hormone, or luteinizing hormone levels after
CADMIUM 171
3. HEALTH EFFECTS
adjusting for BMI, age, smoking, and alcohol consumption (Zeng et al. 2004a). However, they did find
that the prevalence of abnormally elevated serum testosterone levels (>95th percentile for controls)
increased with exposure to cadmium. Using NHANES III data, Menke et al. (2008) found significant
associations between urinary cadmium levels and serum testosterone and estradiol levels, but the
associations were no longer significant after adjusting from smoking status and serum cotinine levels.
Differences in study populations (e.g., infertile men, background cadmium exposure, high cadmium
dietary exposure) and confounding factors (e.g., smoking, lead exposure) limit the interpretation of these
results.
Four studies examined the possible association between cadmium exposure and sperm quality. In
infertile men, increasing serum cadmium levels were significantly associated with abnormal sperm
morphology and decreased sperm counts, sperm motility, and sperm viability (Akinloye et al. 2006).
Another study found significant associations between blood cadmium levels and abnormal sperm
morphology and decreased sperm motility in workers with slight to moderate lead exposure (Telišman et
al. 2000). As noted previously, neither study adjusted for smoking. No significant correlations between
blood cadmium levels and sperm quality were observed in infertile men with or without adjustment for
smoking (Jurasović et al. 2004). Similarly, no significant association between blood cadmium levels and
abnormal semen parameters were observed in infertile men (Benoff et al. 2009), although seminal plasma
cadmium levels were significantly negatively correlated with sperm concentration and sperm motility in
whole semen. Among men exposed to high levels of environmental cadmium, blood cadmium levels
were significantly higher in men with abnormal digital rectal examinations of the prostate and trend
analysis showed a dose-response relationship between cadmium exposure and the prevalence of abnormal
prostate specific antigen (Zeng et al. 2004b).
Data on possible reproductive toxicity of cadmium in women are limited to two studies examining the
possible association between cadmium body burden and endometriosis and one study examining
fecundability. Among infertile Japanese, no association between urinary cadmium levels and the risk of
endometriosis was observed (Itoh et al. 2008). Jackson et al. (2008) found a significant association
between blood cadmium levels and risk of endometriosis using NHANES 1999–2002 data. Blood
cadmium levels were significantly higher among women with endometriosis as compared to women
without endometriosis. When comparing participants with the highest tertile of blood cadmium (0.5–
8.5 µg/L) with the lowest tertile (<0.3 µg/L), the multivariate (including lead and mercury blood levels,
race/ethnicity, smoking status, age) adjusted odds ratio was 3.39 (95% CI of 1.37–8.40). No association
between blood cadmium levels and risk of uterine myomas was found. The possible association between
CADMIUM 172
3. HEALTH EFFECTS
elevated cadmium body burden and time to pregnancy was examined among 400 couples participating in
the Longitudinal Investigation of Fertility and the Environment (LIFE) Study (Buck Louis et al. 2012).
After adjusting for several variables (age, BMI, cotinine, parity, and serum lipids), female urine cadmium
levels were associated with a reduction in the fecundability odds ratio (0.78; 95% CI of 0.63–0.97) (a
fecundability odds ratio of <1 denotes a longer time to pregnancy).
A number of animal studies have shown adverse reproductive effects to male and female reproductive
capacity from cadmium exposure. In male rats and mice, acute oral exposure to near-lethal (60–
100 mg/kg) doses can cause testicular atrophy and necrosis (Andersen et al. 1988; Bomhard et al. 1987;
Borzelleca et al. 1989), and concomitant decreased fertility (Kotsonis and Klaassen 1978). Lower-dose
acute exposures of 25–50 mg/kg did not result in reproductive toxicity in male animals (Andersen et al.
1988; Bomhard et al. 1987; Dixon et al. 1976).
The following intermediate-duration dosing regimens resulted in neither testicular histopathologic lesions
nor a decrease in male reproductive success: 0.25 mg Cd/kg/day via gavage for 10 weeks (Bomhard et al.
1987); 5 mg/kg/day via water for 30–90 days (Dixon et al. 1976); 2.5 mg/kg/day via food for 4 weeks
(Groten et al. 1990); 8 mg/kg/day via water for 24 weeks (Kotsonis and Klaassen 1978); 3 mg/kg/day via
food for 12 weeks (Loeser and Lorke 1977a, 1977b); 2.9 mg/kg/day via water for 14 weeks (Pleasants et
al. 1992); and 4.64 mg/kg/day via water for 70–80 days (Zenick et al. 1982). Some dosing regimens have
resulted in adverse reproductive effects. Male rats exposed to 8.58 mg Cd/kg/day in water for 10 weeks
developed necrosis and atrophy of seminiferous tubule epithelium (Cha 1987). Rats exposed to
5.8 mg/kg/day via water for 14 weeks (Pleasants et al. 1992) or 11.6 mg/kg/day via water for 14 weeks
(Pleasants et al. 1993) developed increased testes weight. Rats exposed to 12.9 mg/kg/day in water for
120 days developed significantly increased relative testis weight, decreased sperm count and motility,
decreased seminiferous tubular diameter, and seminiferous tubular damage (pyknotic nuclei,
multinucleated giant cells, interstitial edema, and dilated blood vessels) (Saxena et al. 1989). In a
protocol designed to assess the effects of vitamins on cadmium toxicity, Pleasants et al. (1992, 1993)
reported that vitamins A and D3 reduced the amount of cadmium-related increase in testis weight.
Bomhard et al. (1987) reported no histopathologic lesions (other than those found in control animals as
part of aging) in testes of rats receiving 10 weekly doses of 5 mg Cd/kg and followed for up to 30 months.
Higher doses of cadmium were generally needed to elicit a reproductive toxic response in females
compared to the males. Although a dose of 65.6 mg Cd/kg/day via gavage for 10 days was sufficient to
produce testicular atrophy and loss of spermatogenic element in male rats, no effects were seen in female
CADMIUM 173
3. HEALTH EFFECTS
rats up to 138 mg/kg/day (Borzelleca et al. 1989). Decreased percentage of fertilized females and
percentage of pregnancies were reported at 61.32 mg Cd/kg/day via gavage for 10 days during gestation
(Gd 6–15) (Machemer and Lorke 1981). No effect was seen at doses up to 18.39 mg/kg/day (Machemer
and Lorke 1981). Baranski (1987) also reported no treatment related effects on number or percentage of
females pregnant with 28.8 mg Cd/kg/day via gavage for gestation days (Gds) 1–20. Baranski and
Sitarek (1987), however, administered 40 mg/kg by gavage 5 days/week for 14 weeks to female rats and
observed a significant increased duration (twice as long) of the estrus cycle starting at 7–8 weeks and
persisting to 14 weeks of exposure and the termination of the experiment. This adverse effect was not
seen at 4 mg/kg (Baranski et al. 1983; Baranski and Sitarek 1987).
Petering et al. (1979) exposed female rats to either 2.61 mg/kg/day via drinking water for 60 days prior to
gestation or during gestation, or 5.23 mg/kg/day via drinking water for 111 days including 90 days prior
gestation plus 21 days during gestation. These doses had no significant effects compared with controls
for the number of pups stillborn. Pond and Walker (1975) also observed no effects in females from a
cadmium exposure of 19.7 mg/kg/day via food for 21–25 days, including Gd 1 through lactation day (Ld)
1, on number of pups born. No effects from a cadmium exposure on number of pups born to females
were observed for an exposure of 8.2 mg/kg/day via food for 15 days, including Gd 6–20 (Sorell and
Graziano 1990).
A dose of 10 mg Cd/kg/day once a day via gavage for 9 weeks (6 weeks prior to gestation and 3 weeks of
gestation) significantly decreased the number of copulating and pregnant females, and the number of
implants and live fetuses (Sutou et al. 1980). No effect was seen at 1 mg/kg/day (Sutou et al. 1980).
Reproductive effects on both male and female rats orally exposed to 2.5 mg/kg/day via drinking water for
180 days may have resulted in the observed decrease in litter size and increased interval between litters.
Both males and females were treated over two generations. Three of five pairs failed to breed in the
second generations (Schroeder and Mitchener 1971). No histopathologic lesions were found in testes or
uteri of dogs given cadmium chloride at 0.75 mg/kg/day via food for 3 months (Loeser and Lorke 1977b).
Male rats were exposed to 0–14 mg Cd/kg/day via food for 77 weeks. The incidence of prostatic
hyperplasias was increased above controls (1.8%) from the 3.5 mg Cd/kg/day dose. The overall incidence
for prostatic lesions for all cadmium-treated groups was much lower in zinc-deficient rats, possibly
because of a marked increase in prostatic atrophy that was associated with reduced zinc intake.
Moreover, there was not a clear dose-response increase in prostatic proliferative lesions. Testicular
CADMIUM 174
3. HEALTH EFFECTS
tumors (exclusively benign interstitial tumors) increased significantly only at the highest-dose cadmium
with diets adequate in zinc. Male Wistar rats exposed to cadmium in the drinking water at 0, 25, 50, 100,
or 200 ppm developed tumors of the prostate (50 ppm), testes (200 ppm), and hematopoietic system
(50 ppm), while dietary zinc deficiency has complex, apparently inhibitory effects on cadmium
carcinogenesis by this route (Waalkes and Rehm 1992).
The highest NOAEL values and all LOAEL values from each reliable study for reproductive effects in
each species and duration category are recorded in Table 3-6 and plotted in Figure 3-2.
There are very limited data on the developmental effects of cadmium in humans. Several studies have
examined the possible relationship between maternal cadmium levels and newborn size. No significant
association between maternal blood cadmium levels and newborn body weight were observed in women
with mean blood cadmium levels of 0.7 μg/L (Mokhtar et al. 2002), 1.04 μg/L (Nishijo et al. 2004b),
1.4 μg/L (Galicia-García et al. 1997), or 1.72 μg/L (Zhang et al. 2004) or urinary cadmium levels of
>2 nmol/mmol creatinine (Nishijo et al. 2002); the Nishijo et al. (2002, 2004b), and Zhang et al. (2004)
studies used statistical adjustments for maternal age, maternal size, and/or gestation age. Two studies
found an association between cord blood cadmium levels and decreasing birthweight (Galicia-García et
al. 1997; Salpietro et al. 2002); however, the association was only statistically significant in the Salpietro
et al. (2002) study. A significant association between newborn height and maternal blood cadmium levels
was observed in women with a mean blood cadmium level of 9.29 nmol/L (Nishijo et al. 2004b); other
studies have not found this association (Mokhtar et al. 2002; Nishijo et al. 2002; Zhang et al. 2004).
Nishijo et al. (2002) found a significant negative correlation between maternal urinary cadmium levels
and gestation length; Mokhtar et al. (2002) did not find a significant association between maternal blood
cadmium levels and gestation length.
Urinary cadmium content was measured in women 3 days after giving birth and compared to smoking
habits and birth weight of offspring. Among nonsmoking women, when cadmium content was expressed
as μg/L, cadmium levels were higher in women with infants of below-normal birth weight. However,
when cadmium content was expressed as μg/g creatinine, cadmium levels were lower in women with
infants with below-normal birth weight. Cadmium levels in smoking women were lower in both μg/L
and μg/g in women with infants with below-normal birth weight (Cresta et al. 1989).
CADMIUM 175
3. HEALTH EFFECTS
Cao et al. (2009) examined the possible association between postnatal exposure to cadmium (as measured
by blood cadmium) and neurodevelopment in children participating in the Treatment of Lead-Exposed
Children trial. Blood cadmium levels in the children were comparable to levels in the NHANES 2005–
2006 survey, and blood lead levels were between 20 and 44 µg/dL at referral. No significant associations
(after adjustment for multiple variables including parent’s education, gender, and concurrent blood lead
levels) between blood cadmium levels and scores on neuropsychological and behavioral tests were found
in children evaluated at age 5 and 7 years or IQ evaluated at 2, 5, and 7 years of age.
A number of studies in rats and mice indicate that cadmium can be fetotoxic from oral exposures prior to
and during gestation. This fetotoxicity is most often manifested as reduced fetal or pup weights (Ali et al.
1986; Baranski 1987; Gupta et al. 1993; Kelman et al. 1978; Kostial et al. 1993; Petering et al. 1979;
Pond and Walker 1975; Sorell and Graziano 1990; Sutou et al. 1980; Webster 1978; Whelton et al. 1988),
but malformations, primarily of the skeleton, have been found in some studies (Baranski 1985; Machemer
and Lorke 1981; Schroeder and Mitchener 1971). Malformations or skeletal effects reported include
sirenomelia (fused lower limbs), amelia (absence of one or more limbs), and delayed ossification of the
sternum and ribs (Baranski 1985); dysplasia of facial bones and rear limbs, edema, exenteration,
cryptorchism, and palatoschisis (Machemer and Lorke 1981); and sharp angulation of the distal third of
the tail (Schroeder and Mitchener 1971). Dosing levels were in the 1–20 mg/kg/day range.
The most sensitive indicator of developmental toxicity of cadmium in animals appears to be neuro-
behavioral development. Offspring of female rats orally exposed to cadmium at a dose of 0.04 mg/kg/day
prior to and during gestation had reduced exploratory locomotor activity and rotorod performance at age
2 months (Baranski et al. 1983). Pups from dams exposed to 0.7 mg/kg/day during gestation had
significant delays in cliff aversion and swimming behavior. Locomotor activity was significantly
increased. In post-weaning measurements, locomotor activity was significantly decreased in treated
groups at 60 days of age; conditioned avoidance behavior was also significantly decreased when tested at
60 and 90 days of age (Ali et al. 1986).
Nagymajtenyi et al. (1997) also reported behavioral and functional neurotoxicological changes caused by
cadmium in a three-generational study in rats. Three consecutive generations of Wistar rats were orally
treated by gavage with 3.5, 7.0, or 14.0 mg Cd/kg bw (as cadmium chloride diluted in distilled water)
over the period of pregnancy, lactation, and 8 weeks after weaning. Behavioral (open field behavior) and
electrophysiological (spontaneous and evoked cortical activity, etc.) parameters of male rats from each
generation were investigated at the age of 12 weeks. The main behavioral outcomes were increased
CADMIUM 176
3. HEALTH EFFECTS
vertical exploration activity (rearing) and increased exploration of an open-field center. The spontaneous
and evoked electrophysiological variables showed dose- and generation-dependent changes (increased
frequencies in the electrocorticogram, lengthened latency and duration of evoked potentials, etc.)
signaling a change in neural functions. The results indicate that low-level, multigeneration exposure of
rats to inorganic cadmium can affect nervous system function.
Desi et al. (1998) continued the above studies to further evaluate cadmium associated changes in behavior
and neurological function in rats following different dosage regimens during pregnancy. Female Wistar
rats were given 3.5, 7.0, or 14.0 mg Cd/kg body weight (cadmium chloride dissolved in distilled water) in
three different treatment regimes: days 5–15 of pregnancy; days 5–15 of pregnancy + 4 weeks of
lactation; and days 5–15 of pregnancy + 4 weeks of lactation followed by the same oral treatment of male
rats of the F1 generation for 8 weeks. The behavioral (open-field exploration) and electrophysiological
(electrocorticogram, cortical-evoked potentials, conduction velocity and refractory periods of a peripheral
nerve) parameters of F1 male rats exposed by various treatments were investigated at the age of 12 weeks.
The results indicate that cadmium altered the spontaneous and evoked electrophysiological functions
(e.g., increased the frequency of the electrocorticogram, lengthened the latency and duration of evoked
potentials, etc.) in a dose- and duration-dependent manner. Only combining treatment during the prenatal
development and the 4-week suckling period resulted in a significant dose-dependent decrease of
horizontal and vertical exploratory activity and a significantly lower exploration frequency of the open-
field center. The results suggest that low-level pre- and postnatal inorganic cadmium exposure affects the
electrophysiological and higher order functions of the nervous system.
Neurochemical alterations have also been observed in the offspring of rats administered cadmium acetate
in drinking water during gestation (1.12 mg Cd/kg/day) and lactation (2.41 mg Cd/kg/day) (Antonio et al.
2010). The alterations included decreased serotonin in dorsal hippocampus and dihydroxyphenylacetic
acid in brain cortex and rostral neostriatum and increased 5-hydroxyindolacetic acid in dorsal
hippocampus and brain cortex and glutamate in the dorsal hippocampus.
A study by Gupta et al. (1993) examined the developmental profiles of DNA, RNA, proteins, DNA
synthesis, thymidine kinase activity, and concentrations of zinc and cadmium in the brain of neonates
from dams exposed to cadmium acetate at 5–6.3 mg/kg/day in drinking water during gestation, and 7–
8 mg/kg/day during a 21-day lactation period. Pup brain and body weights were significantly decreased
in the cadmium exposed pups on Ld 7–21. Cadmium brain accumulation was significantly increased in
exposed pups on Ld 7 and remained at similar levels on Ld 14 and 21. DNA and thymidine kinase brain
CADMIUM 177
3. HEALTH EFFECTS
levels were significantly decreased in treated pups compared with controls on Ld 7, 14, and 21. The
toxicological significance of changes in DNA incorporation and thymidine kinase activity are uncertain.
Xu et al. (1993b) determined lipid peroxide (LPO) concentrations in rat pups in various organs as an
index of cadmium toxicity. Male and female Wistar mice were exposed to cadmium in drinking water at
0, 5.7, or 14.25 mg/kg/day for 2 months prior to mating. The pregnant females continued to be exposed
during gestation and lactation. Litter size and pup survival rates were unaffected by cadmium. Body
weights were not statistically different between the exposed and control groups. In pups, brain weights
(at 5.7 and 14.25 mg/kg/day) and liver, kidney, and heart weights (at 14.25 mg/kg/day) were significantly
decreased. Although the relative organ weights were lower in the high-dose group, the difference from
controls was not statistically significant. LPO concentrations in all organs were significantly increased in
pups on Ld 7 at 14.25 mg/kg/day except in the kidney; concentrations in the liver, heart, and brain were
131.5, 156, and 237.4%, respectively, of the concentrations in controls.
In contrast to most of the study results, Saxena et al. (1986) reported no developmental effects from an
exposure to 21 mg Cd/kg/day via drinking water during gestation (Gd 0–20). This study evaluated
simultaneous exposure to lindane (20 mg lindane/kg via gavage on Gd 6–14) and cadmium acetate in
drinking water at doses that individually did not cause maternal or developmental effects. Maternal
toxicity (significantly decreased weight gain) and developmental toxicity were only observed in the
cadmium plus lindane group. Fetal body weight was significantly decreased; intrauterine death and the
rate of skeletal anomalies were significantly increased. Anomalies consisted of decreased ossification,
wavy ribs, and scrambled sternebrae.
The highest NOAEL values and all LOAEL values from each reliable study for developmental effects in
each species and duration category are recorded in Table 3-6 and plotted in Figure 3-2.
3.2.2.7 Cancer
Epidemiology studies have examined the possible association between exposure to elevated levels of
cadmium and overall cancer rates or specific cancer rates. Older studies have examined cancer rates
among residents of cadmium polluted areas but did not estimate cadmium exposure levels. No significant
increase in cancer rates was found among residents of a cadmium-polluted village in England (Inskip et
al. 1982) or in prostate, kidney, or urinary tract cancer among residents of a cadmium-polluted area of
Belgium (Lauwerys and De Wals 1981). Another study found that the geographic distribution of elevated
CADMIUM 178
3. HEALTH EFFECTS
rates of prostate cancer incidence paralleled the distribution of elevated cadmium concentrations in water,
soil, or grain crops in Alberta, Canada (Bako et al. 1982). In a retrospective mortality study of residents
of three areas of Japan classified on the basis of rice cadmium content as highly polluted, slightly
polluted, or nonpolluted, no significant differences were found in mortality from cancer of all sites
including prostate cancer (Shigematsu 1984). Inhabitants of cadmium-polluted areas of Japan with
elevated urinary retinol binding protein excretion had a mortality rate from malignant neoplasms no
different from expected (Nakagawa et al. 1987).
Three more recent studies of populations living in cadmium-polluted areas have used blood or urine to
examine dose-response relationships for carcinogenic risk. Among residents living in a cadmium-
polluted area of China, significantly higher blood cadmium levels were observed in subjects with
suspected prostate cancer (based on digital rectal examination) as compared to subjects with normal
digital rectal examination results (Zeng et al. 2004); there were no significant differences in urinary
cadmium levels. However, a significant trend was found for the number of cases with positive prostate-
specific antigen levels and urinary cadmium levels. In a study of residents living in an area of Japan that
previously had high levels of cadmium contamination, a significant increase in cancer mortality was
observed among subjects with urinary β2-microglobulin levels of ≥1,000 µg/g creatinine (Arisawa et al.
2001); however, no increases in cancer incidence were observed in exposed subjects or in subjects with
elevated urinary β2-microglobulin, urinary cadmium, or blood cadmium levels. In a follow-up study that
extended the observation period from 15 to 23 years, no alterations in cancer mortality or cancer
incidence were observed in the exposed population as compared to referent populations (Arisawa et al.
2007b). However, when the subjects were divided into two groups based on urinary β2-microglobulin
levels, the relative risk of cancer deaths in males and females with β2-microglobulin levels of
≥1,000 µg/g creatinine was 2.58 (95% CI of 1.25–5.36) compared to residents with urinary
β2-microglobulin levels of <1,000 µg/g creatinine.
Several case-control studies have examined the possible association between cadmium body burden and
increased risk of cancer among the general populations. In a study conducted in Belgium, a significant
relationship between bladder cancer and blood cadmium levels was reported (Kellen et al. 2007). After
adjustment for age, gender, occupational exposure to polyaromatic hydrocarbons or aromatic amines, and
smoking, the odds ratio was 5.7 (95% CI of 3.3–9.9) when comparing the risk of bladder cancer for
subjects in the highest blood cadmium tertile to those in the lowest tertile. Another case-control study
examined the possible relationship between urinary cadmium levels and breast cancer risk in the United
States (McElroy et al. 2006). The breast cancer risk (after adjustment for a number of variables including
CADMIUM 179
3. HEALTH EFFECTS
age, parity, family history of breast cancer and BMI) in women with urinary cadmium levels in the
highest quartile was 2.29 (95% CI of 1.3–4.2) as compared to women in the lowest quartile; the
investigators noted that adjusting for smoking status did not change the risk estimate. Similarly, a
significant increase in the risk of breast cancer was observed among women living in Long Island, New
York with urinary cadmium levels >0.60 µg cadmium/g creatinine, as compared to women with urinary
cadmium levels of <0.22 µg cadmium/g creatinine after controlling for age, menopausal status, smoking
and alcohol use, and family history (Gallagher et al. 2010). Another study of residents of the East Nile
Delta region in Egypt with pancreatic cancer found a significant association between pancreatic cancer
risk and serum cadmium levels; the odds ratio was 1.12 (95% CI of 1.04–1.23) (Kriegel et al. 2005). The
study also found a significant association between farming and risk of pancreatic cancer. The results of
this study should be interpreted cautiously since the study did not adjust for smoking status or farming
occupation.
In a Swedish population-based study of postmenopausal women, an increased risk of endometrial cancer

was found in women with elevated cadmium intake (Åkesson et al. 2008). Among women who never
smoked, did not use postmenopausal hormones, had a BMI of <27 kg/m2, and consistently had a cadmium
intake above the median intake for the study, the relative risk of endometrial cancer was 2.86 (95% CI of
1.05–7.79).
One study examined cadmium, zinc, and copper in human kidney tumors and normal kidneys. Kidneys
with renal cell carcinoma in cortex from 31 cases (20 men and 11 women) were compared to kidneys of
patients who had died from causes other than a malignant disease from 17 controls (9 men and 8 women).
No patients in this study had been occupationally exposed. Smoking habits for patients were recorded.
The level of cadmium in tumor tissue did not correlate with cadmium in cortex or medulla in the same
kidney. No significant difference was found between cases and controls, although smoking cases had
higher levels of cadmium. It was concluded that cadmium was not a risk factor for renal cell carcinoma
(Hardell et al. 1994).
In rats and mice, earlier studies on chronic oral exposure to cadmium did not report an increased overall
cancer incidence or the incidence of specific tumor types (Kanisawa and Schroeder 1969; Levy and Clack
1975; Levy et al. 1975; Löser 1980; Mangler et al. 1988; Schroeder et al. 1964, 1965). However,
maximum daily doses tested were only 1 mg/kg/day in mice (Schroeder et al. 1964) and 3.5 mg/kg/day in
rats (Löser 1980) and, in most of these studies, histopathologic examination was limited compared to
contemporary standards. Löser (1980) did perform a relatively thorough histological examination. A few
CADMIUM 180
3. HEALTH EFFECTS
additional animal studies of noncancer effects of chronic-duration oral cadmium exposure have indicated
that no dose-related increases in tumors were found at maximum doses of 4.01 mg/kg/day in rats
(Fingerle et al. 1982) or 8 mg/kg/day in mice (Watanabe et al. 1986).
Waalkes and Rehm (1992) evaluated the effects of chronic dietary zinc deficiency on oral cadmium
carcinogenesis in male Wistar rats. Rats were exposed for 77 weeks to cadmium at 0, 1.75, 3.5, 7.0, or
14.0 mg cadmium/kg/day as cadmium chloride in a diet containing an adequate or a deficient amount of
zinc. A significant increase in the incidence of proliferative lesions (hyperplasia and adenomas) was
observed in the prostate of rats exposed to 1.75 mg cadmium/kg/day in the zinc-adequate (22.7%) or zinc-
deficient (15.4%) groups, as compared to controls (1.9%). However, the incidences of prostatic lesions
were not significantly increased in rats exposed to higher cadmium doses. The incidence of large
granular lymphocyte leukemia was significantly increased in rats fed the zinc-adequate diet with 3.5 or
7.0 mg cadmium/kg/day, but not at 14.0 mg cadmium/kg/day; however, an increased incidence was
observed at 14.0 mg cadmium/kg/day in the zinc-deficient rats. Exposure to 14.0 mg cadmium/kg/day
also resulted in a significant increase in interstitial cell tumors of the testes in the group fed a zinc-
adequate diet. The results of the study suggest that dietary zinc deficiency may inhibit the carcinogenic
potential of cadmium, but additional research is needed.
A subsequent study by Waalkes et al. (1993) using male B6C3F1 mice evaluated the effects of cadmium
exposure on tumor incidence at various times after the initiation of the carcinogenic process. The
possible role of metallothionein in the susceptibility of transformed cells to cadmium cytotoxicity was
also evaluated. At 5 weeks of age, mice received an intraperitoneal injection of N-nitrosodiethylamine
(NDEA) at 90 mg/kg. At 2, 4, 8, 16, or 32 weeks post-NDEA injection, mice received water containing
1,000 ppm cadmium ad libitum for up to 48 weeks of post-NDEA exposure. Cadmium exposure caused a
marked "reduction" in liver tumor incidence in NDEA-treated mice even when given as late as 32 weeks
after the initial NDEA treatment. Cadmium alone eliminated the spontaneously occurring incidence of
liver tumors (i.e., 0 of 25 compared with 5 of 25 in the controls). Liver tumors produced by NDEA were
typically basophilic adenomas. Cadmium resulted in a modest reduction in lung tumor incidence,
statistically significant (28% reduction) only for the 16–48-week cadmium-treated group pretreated with
NDEA. Lung tumors were typically adenomas of alveolar cell origin. Cadmium alone eliminated
spontaneously occurring lung tumors compared with the controls. Cadmium significantly reduced the
multiplicity of tumors induced by NDEA. NDEA alone typically induced seven tumors per lung, while
NDEA plus cadmium treatment reduced the number of tumors to 2.5–3.5 (data taken from a graph) with
some cases showing an 80% reduction in tumor numbers. Lung tumors found in the cadmium plus
CADMIUM 181
3. HEALTH EFFECTS
NDEA-treatment groups were also smaller in overall size than those found in the NDEA-only treatment
groups. Relatively little metallothionein was present in liver carcinomas, liver adenomas, and lung
adenomas as indicated by immunohistochemistry. This finding was confirmed biochemically for the liver
tumors. The authors concluded that cadmium can effectively “impair” tumor formation in the lungs and
liver of male B6C3F1 mice and that cadmium appears to be able to selectively destroy existing
preneoplastic and/or tumor cells (adenomas). The mechanism may involve a reduced activity and
responsiveness of the metallothionein system in transformed liver cells.
A two-stage initiation/promotion experiment evaluated the promoting effects of cadmium chloride in the
drinking water in rats. Cadmium exposure resulted in the following alterations in tumorigenic outcome:
in the liver, hepatocellular carcinomas (initiated with diethyl nitrosamine) were decreased; in the stomach,
tumors (initiated with N-methyl-N’-nitro-nitrosoguanidine plus NaCl at 10% in the diet) were not
affected; in the kidney, tumors (initiated with N-ethyl-N-hydroxyethyl nitrosamine) showed increased
dysplastic foci but no increase in renal cell tumors; in the pancreas, tumors (initiated with N-nitrosobis
[2-oxopropyl] amine) had a nonsignificant increase in adenocarcinomas (female hamster study); and in
the skin (initiated with 7,12-dimethyl benz(a)anthracene), there was no effect (female SENCAR mouse
study) (Kurokawa et al. 1989).
3.2.3 Dermal Exposure
3.2.3.1 Death
No studies were located regarding death in humans after dermal exposure to cadmium.
Some guinea pigs died 2 or 6 weeks after being exposed in a skin depot (3.1 cm2) to 2 mL of 0.239 molar
aqueous of cadmium chloride (0.14 mg/kg body weight) (Wahlberg 1965). However, it is difficult to
attribute these deaths to cadmium exposure, due to the low dose compared to oral LD50 values and to the
fact that no necropsy was done to determine whether the exposed guinea pigs might have died from
pneumonia (which killed some control guinea pigs) (Wahlberg 1965).
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological,

musculoskeletal, hepatic, or renal effects in humans or animals after dermal exposure to cadmium.
CADMIUM 182
3. HEALTH EFFECTS
Dermal Effects. Among eczema patients routinely patch-tested with 2% cadmium chloride, 25 out of
1,502 showed some reaction (Wahlberg 1977). Since no reaction was found at lower dilutions in reactive
patients (Wahlberg 1977), the effect was likely direct irritation of the skin and is indicated as a LOAEL
value in Table 3-9.
No studies were located regarding dermal effects in animals after dermal exposure to cadmium.
Ocular Effects. No studies were located regarding ocular effects in humans after dermal exposure to
cadmium.
Rats exposed to high concentrations of cadmium pigments or cadmium oxide in air had excessive
lacrimation four hours after exposure (Rusch et al. 1986), possibly due to a direct irritation effect on the
eyes.
Dermal exposure to cadmium does not appear to affect the immune system significantly. One report of
workers with extensive exposure to cadmium dust reported an increase in complaints of eczema (Friberg
1950); however, no subsequent studies have confirmed any association. Routine patch tests among
dermatitis and eczema patients using up to 2% cadmium chloride solutions have found skin irritation at
2%, but no evidence of allergic reactions at a dose of 1% among people without known prior cadmium
exposure (Rudzki et al. 1988; Wahlberg 1977) or among workers occupationally exposed to cadmium
(Rudzki et al. 1988). Individuals with yellow tattoos containing cadmium sulfide often experience
swelling of the surrounding skin on exposure to ultra violet (UV) irradiation (Bjornberg 1963); however,
this may be the result of dermal damage from the photoconductivity of cadmium sulfide rather than a
direct immunological reaction.
Guinea pigs showed no contact sensitization following intradermal or topical exposure to cadmium
chloride at concentrations up to 0.5% (Wahlberg and Boman 1979). The NOAEL values from each
reliable study for immunological effects in each species and duration category are recorded in Table 3-9.
Table 3-9 Levels of Significant Exposure to Cadmium - Dermal
CADMIUM
Exposure/ LOAEL
Duration/
Species Frequency Reference
(Strain) (Route)
System NOAEL Less Serious Serious Chemical Form Comments
ACUTE EXPOSURE
Systemic
Human once Dermal Wahlberg 1977 492
1 2 (skin irritation)
Percent (%) Percent (%) CdCl2
492
Percent (%) Percent (%)
Rat 2 hr Ocular Rusch et al. 1986 1002
(Sprague- 99 (excessive lacrimation) 112 (eyes closed from

mg/m³ mg/m³ exposure) CdSeS
Dawley)
1002 mg/m³ mg/m³
97 (excessive lacrimation)
mg/m³
mg/m³
3. HEALTH EFFECTS
Immuno/ Lymphoret
Human once Rudzki et al. 1988 493
493 1
Percent (%) CdCl2
Percent (%)
hr = hour(s); Immuno/Lymphoret = immunological/lymphoreticular; LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level
183
CADMIUM 184
3. HEALTH EFFECTS
No studies were located regarding the following health effects in humans or animals after dermal
exposure to cadmium:

3.2.3.7 Cancer
3.3 GENOTOXICITY
The genotoxic potential of cadmium has been studied in in vivo studies of cadmium workers, members of
the general population, and rodents as summarized in Table 3-10. Although not always consistent, these
results suggest that cadmium is a clastogenic agent, as judged by the induction of DNA damage,
micronuclei, sister chromatid exchange (SCE), and chromosomal aberrations.
Palus et al. (2003) examined peripheral lymphocytes from workers occupationally exposed to cadmium
and found statistically significant increases compared to the control population in micronuclei rates and
sister chromatid exchanges as well as evidence of an increased incidence of leukocytes with DNA
fragmentation. Examination of lymphocytes and leukocytes from workers occupationally exposed to
cadmium and lead or to cadmium, lead, and zinc showed increased frequency of chromosomal aberrations
compared to control groups (Abrahim et al. 2011; Bauchinger et al. 1976; Deknudt and Leonard 1975;
Deknudt et al. 1973), but this effect was not observed in men exposed primarily to cadmium (Bui et al.
1975; O'Riordan et al. 1978). Human lymphocytes from individuals inhabiting cadmium-polluted areas
of China have been found to have increased micronuclei rates and a higher frequency of chromosomal
aberrations and severe aberration types, in comparison to control populations with either no known
exposure to cadmium or low-level exposure (Fu et al. 1999; Tang et al. 1990). Bui et al. (1975) examined
blood samples from four female Japanese patients with Itai-Itai disease and found no evidence to indicate
that cadmium is capable of inducing chromosomal damage.
For the most part, cadmium exposure via inhalation (Valverde et al. 2000), oral (Devi et al. 2001; Kasuba
et al. 2002), and parenteral (Fahmy and Aly 2000; Kasuba et al. 2002; Mukherjee et al. 1988a; Saplakoglu
et al. 1997; Wronska-Nofer et al. 1999; Zhou et al. 2004b) routes has been shown to be associated with
DNA damage and induction of micronuclei in rodent cells.
CADMIUM 185
3. HEALTH EFFECTS
Table 3-10. Genotoxicity of Cadmium In Vivo
Species (test system) End point Results Reference

Mammalian cells:
Inhalation exposure:
Human lymphocytes Chromosomal aberrations + Deknudt et al. 1973
Human lymphocytes Chromosomal aberrations – Bui et al. 1975
Human lymphocytes Chromosomal aberrations + Deknudt and Leonard 1975
Human lymphocytes Chromosomal aberrations + Bauchinger et al. 1976
Human lymphocytes Chromosomal aberrations – O’Riordan et al. 1978
Human lymphocytes Chromosomal aberrations + Alessio et al. 1993
Human lymphocytes Chromosomal aberrations + Abrahim et al. 2011
Human lymphocytes Sister chromatid exchanges + Abrahim et al. 2011
Human lymphocytes Sister chromatid exchanges + Palus et al. 2003
Human lymphocytes Micronuclei + Palus et al. 2003
Human lymphocytes DNA damage + Palus et al. 2003
Mouse bone marrow DNA damage + Valverde et al. 2000
Mouse brain cells DNA damage + Valverde et al. 2000
Mouse testicular cells DNA damage + Valverde et al. 2000
Mouse liver cells DNA damage + Valverde et al. 2000
Mouse kidney cells DNA damage + Valverde et al. 2000
Mouse lung cells DNA damage + Valverde et al. 2000
Mouse nasal epithelial cells DNA damage + Valverde et al. 2000
Oral exposure:
Rat bone cells Altered gene expression + Ohba et al. 2007
Mouse bone marrow Chromosomal aberrations – Deknudt and Gerber 1979
Mouse bone marrow Chromosomal aberrations + Mukherjee et al. 1988b
Rat bone marrow Chromosomal aberrations – Desi et al. 2000
Human leukocytes Chromosomal aberrations + Shiraishi and Yoshida 1972
Human lymphocytes Chromosomal aberrations – Bui et al. 1975
Human lymphocytes Chromosomal aberrations + Tang et al. 1990
Human lymphocytes Chromosomal aberrations + Fu et al. 1999
Mouse leukocytes DNA damage + Devi et al. 2001
Rat lymphocytes DNA damage + Kasuba et al. 2002
Rat spermatogenesis Dominant lethal mutations – Sutou et al. 1980
Rat spermatogenesis Dominant lethal mutations – Zenick et al. 1982
Rat lymphocytes Micronuclei + Kasuba et al. 2002
Human lymphocytes Micronuclei + Fu et al. 1999
Intraperitoneal exposure:
Mouse oocytes Aneuploidy – Mailhes et al. 1988
Mouse spermatocytes Chromosomal aberrations + Selypes et al. 1992
CADMIUM 186
3. HEALTH EFFECTS
Table 3-10. Genotoxicity of Cadmium In Vivo
Species (test system) End point Results Reference

Mouse bone marrow Chromosomal aberrations + Fahmy and Aly 2000
Mouse spermatocytes Chromosomal aberrations + Fahmy and Aly 2000
Mouse bone marrow Chromosomal aberrations – Bruce and Heddle 1979
Mouse bone marrow Chromosomal aberrations + Mukherjee et al. 1988a
Mouse spermatocytes Chromosomal translocations – Gilliavod and Leonard 1975
Rat lung cells DNA strand breaks + Saplakoglu et al. 1997
Rat kidney cells DNA strand breaks + Saplakoglu et al. 1997
Rat liver cells DNA strand breaks – Saplakoglu et al. 1997
Mouse spermatogenesis Dominant lethal mutations – Epstein et al. 1972
Mouse spermatogenesis Dominant lethal mutations – Gilliavod and Leonard 1975
Mouse oocytes Dominant lethal mutations – Suter 1975
Rat lymphocytes hprt locus Gene mutation ± Jianhua et al. 2006
Mouse bone marrow Micronuclei ± Mukherjee et al. 1988a
Mouse bone marrow Micronuclei + Wronska-Nofer et al. 1999
Mouse bone marrow Micronuclei + Fahmy and Aly 2000
Mouse bone marrow Sister chromatid exchanges + Mukherjee et al. 1988a
Mouse bone marrow Sister chromatid exchanges + Fahmy and Aly 2000
Mouse spermatozoa Sperm morphology – Bruce and Heddle 1979
Mouse spermatozoa Sperm morphology + Mukherjee et al. 1988a
Syrian hamster embryo cells Transformation + DiPaulo and Castro 1979
Subcutaneous exposure:
Mouse testicular cells Altered gene expression + Zhou et al. 2004b
Mouse blastocysts Aneuploidy + Watanabe and Endo 1982
Syrian hamster oocytes Aneuploidy + Watanabe et al. 1979
Mouse bone marrow Chromosomal aberrations + Karmakar et al. 1998
Mouse testicular cells DNA damage – Zhou et al. 2004b
Rat lymphocytes DNA damage + Kasuba et al. 2002
Rat lymphocytes Micronuclei + Kasuba et al. 2002
Mouse bone marrow Sister chromatid exchanges – Nayak et al. 1989
Mouse fetal liver and lung Sister chromatid exchanges – Nayak et al. 1989
cells
– = negative result; + = positive result; ± = weakly positive result; DNA = deoxyribonucleic acid
CADMIUM 187
3. HEALTH EFFECTS
Evidence of the potential for cadmium to induce SCE (Fahmy and Aly 2000; Mukherjee et al. 1988a;
Nayak et al. 1989) and chromosomal aberrations (Bruce and Heddle 1979; Desi et al. 2000; DiPaulo and
Castro 1979; Fahmy and Aly 2000; Karmakar et al. 1998; Mukherjee et al. 1988a; Tang et al. 1990;
Watanabe et al. 1979) is mixed. Data regarding the aneugenic potential of cadmium are limited and also
conflicting. Watanabe and Endo (1982) observed an increased incidence of mouse blastocysts with
trisomies and triploidies from female mice treated subcutaneously with cadmium compared to control
mice. Watanabe et al. (1979) reported that subcutaneous exposure to cadmium induced mutagenicity in
hamster oocytes, and in particular, induced the production of diploid oocytes. However, Mailhes et al.
(1988) did not observe an increased incidence of hyperploid oocytes in female mice treated with cadmium
via intraperitoneal injection.
No evidence for germ cell mutations (the dominant lethal test) has been observed in male rats orally
exposed to cadmium (Sutou et al. 1980; Zenick et al. 1982) or in mice exposed to cadmium via inhalation
(Gilliavod and Leonard 1975; Suter 1975) or intraperitoneal exposure (Epstein et al. 1972). However,
chromosomal aberrations in mouse spermatocytes and Syrian hamster oocytes (Fahmy and Aly 2000;
Selypes et al. 1992; Watanabe et al. 1979) and altered gene expression in mouse testicular cells (Zhou et
al. 2004b) have been observed following cadmium exposure.
Data based on in vitro examination of the genotoxic effects of cadmium in microorganisms, yeast, insects,
and mammalian cells are summarized in Table 3-11. For the most part, in vitro data support the in vivo
data suggesting that cadmium has the potential to induce DNA damage, micronuclei, chromosomal
aberrations, and genetic mutations.
In vitro studies have shown that cadmium induces genetic mutations in hamster and mouse cells
(Amacher and Paillet 1980; Filipic and Hei 2004; Honma et al. 1999; Jianhua et al. 2006; Oberly et al.
1982), transformation in rodent cells (Casto et al. 1979; Terracio and Nachtigal 1988), unscheduled DNA
synthesis in rat cells (Denizeau and Marion 1989), DNA breaks in human cells (Depault et al. 2006;
Lopez-Ortal et al. 1999; Mikhailova et al. 1997), DNA lesions in hamster cells (Jianhua et al. 2006), and
inhibits DNA repair in human and hamster cells (Lutzen et al. 2004; Lynn et al. 1997). Misra et al.
(1998) did not observe DNA damage in rat cells following treatment with cadmium, but DNA damage
has been noted in human cells (Fatur et al. 2002; Rozgaj et al. 2002).
Chromosomal aberrations following cadmium exposure have been observed in Chinese hamster ovary
cells (Cai and Arenaz 1998; Deaven and Campbell 1980; Rohr and Bauchinger 1976), but studies on
CADMIUM 188
3. HEALTH EFFECTS
Table 3-11. Genotoxicity of Cadmium In Vitro
Results
With Without
Species (test system) End point activation activation Reference
Prokaryotic organisms:
Bacillus subtilis DNA repair No data ± Nishioka 1975
B. subtilis DNA repair No data ± Kanematsu et al. 1980
Salmonella typhimurium Gene mutation – – Bruce and Heddle 1979
(plate incorporation)
S. typhimurium Gene mutation – – Milvy and Kay 1978
(liquid suspension)
S. typhimurium Gene mutation No data ± Mandel and Ryser 1984
(liquid suspension)
S. typhimurium Gene mutation – + Wong 1988
(plate incorporation)
Eukaryotic organisms:
Yeast:
Saccharomyces cerevisiae Gene mutation No data + Putrament et al. 1977
S. cerevisiae lntrachromosomal No data + Schiestl et al. 1989
recombination
Insects:
Drosophila melanogaster Dominant lethal No data + Vasudev and Krishnamurthy
mutations 1979
D. melanogaster Nondisjunction No data – Ramel and Magnusson
1979
D. melanogaster Sex-linked No data – Inoue and Watanabe 1978
recessive lethal
mutations
Mammalian cells:
Mouse spleen cells Chromosomal No data + Fahmy and Aly 2000
aberration
Chinese hamster ovary Hy Chromosomal No data + Rohr and Bauchinger 1976
cells aberration
Chinese hamster ovary CHO Chromosomal No data + Deaven and Campbell 1980
cells aberration
Chinese hamster ovary CHO Chromosomal No data + Cai and Arenaz 1998
cells aberration
Human leukocytes Chromosomal No data + Shiraishi et al. 1972
aberrations
Human blood lymphocytes Chromosomal No data – Paton and Allison 1972
aberration
Human blood lymphocytes Chromosomal No data + Shiraishi et al. 1972
aberration
CADMIUM 189
3. HEALTH EFFECTS
Results
With Without
Human blood lymphocytes Chromosomal No data – Deknudt and Deminatti 1978
aberration
Human blood lymphocytes Chromosomal No data ± Gasiorek and Bauchinger
aberration 1981
Human blood lymphocytes DNA breaks No data + Depault et al. 2006
Human lymphoblastoid cells DNA breaks No data + Mikhailova et al. 1997
Human fetal hepatic WRL-68 DNA breaks No data + Lopez-Ortal et al. 1999
cells
Chinese hamster ovary DNA damage No data – Misra et al. 1998
CHO-K1 cells
Rat L6 myoblast cells DNA damage No data – Misra et al. 1998
Rat Clone 9 liver cells DNA damage No data – Misra et al. 1998
Rat TRI 1215 liver cells DNA damage No data – Misra et al. 1998
Human blood lymphocytes DNA damage No data + Rozgaj et al. 2002
Human hepatoma cells DNA damage No data + Fatur et al. 2002
(HepG2)
V79 Chinese hamster lung DNA lesions No data + Jianhua et al. 2006
cells
Chinese hamster ovary DNA repair No data + Lynn et al. 1997
CHO-K1 cells
Human 293T-Tet-Off-hMLH1 DNA repair No data + Lutzen et al. 2004
cells
V79 Chinese hamster lung Gene mutation No data + Jianhua et al. 2006
cells hprt locus
AL human-hamster hybrid Gene mutation No data + Filipic and Hei 2004
CD59 gene
Mouse lymphoma L5178Y Gene mutation No data ± Amacher and Paillet 1980
thymidine kinase locus
Mouse lymphoma L5178Y Gene mutation No data + Oberly et al. 1982
Mouse lymphoma L5178Y Gene mutation + + Honma et al. 1999
Human blood lymphocytes Micronuclei No data + Migliore et al. 1999
Human blood lymphocytes Micronuclei No data – Kasuba and Rozgaj 2002
(G0 phase)
Human blood lymphocytes Micronuclei No data + Kasuba and Rozgaj 2002
(S phase)
Human diploid fibroblasts Micronuclei No data + Seoane and Dulout 2001
(MRC-5)
Mouse spleen cells Sister chromatid No data + Fahmy and Aly 2000
exchanges
CADMIUM 190
3. HEALTH EFFECTS
Results
With Without
Human blood lymphocytes Sister chromatid No data – Bassendowska-Karska and
exchanges Zawadzka-Kos 1987
Human blood lymphocytes Sister chromatid No data – Saplakoglu and Iscan 1998
(G0 phase) exchanges
Human blood lymphocytes Sister chromatid No data + Saplakoglu and Iscan 1998
(S phase) exchanges
Syrian hamster embryo cells Transformation No data + Casto et al. 1979
Rat ventral prostate cells Transformation No data + Terracio and Nachtigal 1988
Rat hepatocytes Unscheduled DNA No data + Denizeau and Marion 1989
synthesis
C = negative result; + = positive result; ± = weakly positive; CHO = Chinese hamster ovary; DNA = deoxyribonucleic
acid; NA = not applicable; RNA = ribonucleic acid
CADMIUM 191
3. HEALTH EFFECTS
human cells have shown mixed results (Deknudt and Deminatti 1978; Gasiorek and Bauchinger 1981;
Paton and Allison 1972; Shiraishi et al. 1972). For the most part, in vitro studies have not shown
cadmium to induce SCE in human cells (Bassendowska-Karska and Zawadzka-Kos 1987; Saplakoglu and
Iscan 1998). However, a study by Fahmy and Aly (2000) did observe SCE in mouse spleen cells
following cadmium treatment. Kasuba and Rozgaj (2002) and Saplakoglu and Iscan (1998) evaluated the
ability of cadmium to induce micronuclei and SCE in human lymphocytes in vitro respectively, at two
different stages of the cell cycle, G0 and S phase. These studies observed that the genotoxicity of
cadmium may vary depending on the stage of the cell cycle as both micronuclei and SCE were induced in
cells in S phase, but not in cells in G0 phase. These observations may in part explain some of the
contradictory findings regarding cadmium genotoxicity in the literature.
Positive mutagenicity results have been found in some studies using bacterial cells (Kanematsu et al.
1980; Mandel and Ryser 1984; Nishioka 1975; Wong 1988), in studies using yeast (Putrament et al. 1977;
Schiestl et al. 1989), and in a single study using Drosophila melanogaster (Vasudev and Krishnamurthy
1979). Other studies report negative mutagenicity results in bacterial cells (Bruce and Heddle 1979;
Milvy and Kay 1978) and in D. melanogaster (Inoue and Watanabe 1978; Ramel and Mangusson 1979).
3.4 TOXICOKINETICS
Cadmium metal and cadmium salts are not well absorbed; approximately 25, 1–10, or <1% of the dose is
absorbed following inhalation, oral, or dermal exposure. Several factors can influence inhalation and oral
absorption efficiency; for example, cadmium in cigarette smoke has a higher absorption efficiency due to
its small particle size and cadmium absorption from the gastrointestinal tract is increased in individuals
with poor iron status. Following absorption from any route of exposure, cadmium widely distributes
throughout the body, with the highest concentrations found in the liver and kidney. Cadmium is not
known to undergo any direct metabolic conversion such as oxidation, reduction, or alkylation. Absorbed
cadmium is excreted very slowly, with urinary and fecal excretion being approximately equal.
Approximately 0.007 and 0.009% of the body burden is excreted in the urine and feces, respectively, per
day.
CADMIUM 192
3. HEALTH EFFECTS
3.4.1 Absorption
3.4.1.1 Inhalation Exposure
Cadmium metal and cadmium salts have low volatility and exist in air primarily as fine suspended
particulate matter. When inhaled, some fraction of this particulate matter is deposited in the airways or
the lungs, and the rest is exhaled. Large particles (greater than about 10 μm in diameter) tend to be
deposited in the upper airway, while small particles (approximately 0.1 μm) tend to penetrate into the
alveoli. While some soluble cadmium compounds (cadmium chloride and cadmium sulfate) may undergo
limited absorption from particles deposited in the respiratory tree, the major site of absorption is the
alveoli. Thus, particle size, which controls alveolar deposition, is a key determinant of cadmium
absorption in the lung (Nordberg et al. 1985).
No direct data are available on cadmium deposition, retention, or absorption in the human lung. Data
from animal studies indicate that lung retention is greatest after short-term exposure (5–20% after
15 minutes to 2 hours) (Barrett et al. 1947; Henderson et al. 1979; Moore et al. 1973; Rusch et al. 1986).
The initial lung burden declines slowly after exposure ceases (Henderson et al. 1979; Moore et al. 1973;
Rusch et al. 1986) due to absorption of cadmium and lung clearance of deposited particles. After longer
periods of inhalation exposure to cadmium, somewhat lower lung retentions are found (Glaser et al.
1986). The absorption of cadmium in lung differs somewhat among chemical forms, but the pattern does
not correlate with solubility (Glaser et al. 1986; Rusch et al. 1986).
Based on comparison of cadmium body burdens in human smokers and nonsmokers, cadmium absorption
from cigarettes appears to be higher than absorption of cadmium aerosols measured in animals (Nordberg
et al. 1985). The chemical form of cadmium in cigarette smoke is likely to be similar to that produced by
other combustion processes, primarily cadmium oxide aerosols. The greater absorption of cadmium from
cigarette smoke is likely due to the very small size of particles in cigarette smoke and the consequent very
high alveolar deposition (Nordberg et al. 1985; Takenaka et al. 2004).
Based on the physiology of the human respiratory tree, a comprehensive model has been developed to
predict the kinetics of inhaled cadmium in humans (Nordberg et al. 1985). Results of this model suggest
that only about 5% of particles >10 μm in diameter will be deposited, up to 50% of particles <0.1 μm will
be deposited, and between 50 and 100% of cadmium deposited in the alveoli will ultimately be absorbed
(Nordberg et al. 1985).
CADMIUM 193
3. HEALTH EFFECTS
3.4.1.2 Oral Exposure
Most ingested cadmium passes through the gastrointestinal tract without being absorbed (Kjellström et al.
1978). Measurement of gastrointestinal absorption is complicated by the fact that not all of a dose
initially retained in the gastrointestinal system can be considered to be absorbed, because some portion
may be trapped in the intestinal mucosa without crossing into the blood or lymph (Foulkes 1984). Thus,
measures of whole-body cadmium retention may overestimate cadmium absorption (at least in the short-
term). On the other hand, some absorbed cadmium may be excreted in urine or feces, so that retention
may underestimate exposure. However, this underestimate is probably minor because excretion of
absorbed cadmium is very slow (see Section 3.4.4.2).
Cadmium absorption has been estimated based on the retention of cadmium in the bodies of humans
following ingestion of radioactive cadmium. Estimated cadmium absorption ranged from 1.1 to 10.6%
(Flanagan et al. 1978; McLellan et al. 1978; Newton et al. 1984; Rahola et al. 1973; Shaikh and Smith
1980; Vanderpool and Reeves 2001). Although some studies have reported higher absorption levels (25–
42%), this was based on cadmium retention measurements for 3–5 days after exposure that was probably
too short to accurately measure cadmium transfer from the intestinal mucosa to circulation (Crews et al.
2000; Rahola et al. 1973). Using estimated cadmium intakes from national data and measured renal and
urinary cadmium levels in healthy nonsmokers, cadmium absorption rates of 3–5% have been estimated
(Ellis et al. 1979; Morgan and Sherlock 1984). In a balance study of women with high background
cadmium intakes (mean urinary cadmium levels of 2.7–5.16 μg/g creatinine); the mean absorption rate in
subjects examined for 7 days was 6.5% (Horiguchi et al. 2004).
The body store of iron influences cadmium absorption; subjects with low iron stores (assessed by serum
ferritin levels) had an average absorption of 6 and 8.9%, while those with adequate iron stores had an
average absorption of 2.3 and 2.4% (Flanagan et al. 1978; Shaikh and Smith 1980). Several
epidemiology studies have found significant negative correlations between body iron (assessed via serum
ferritin and/or transferring levels) and cadmium body burden (blood cadmium and/or urinary cadmium
levels) among men and women (Apinan et al. 2010) and among never-smoking, nonpregnant, non-
menopausal women (Gallagher et al. 2011; Meltzer et al. 2010). Studies in rats have shown that iron
deficiency results in the upregulation of divalent metal transporter 1 (DMT1) and metal transporter
protein 1 (MTP1) in the duodenum, which may facilitate the absorption of cadmium (Kim et al. 2007;
Ryu et al. 2004). Other epidemiology studies have found significantly higher cadmium body burdens in
women with lower iron stores (Kippler et al. 2009). In contrast, a study of anemic females with high
CADMIUM 194
3. HEALTH EFFECTS
background cadmium levels did not find a significant alteration in cadmium absorption, as compared to
healthy females; however, cadmium absorption was lower in the anemic group (13.6%) than in healthy
group (27.4%) (Horiguchi et al. 2004). It is not known if the differences in the methods used to estimate
cadmium absorption (kinetic study using radiolabelled cadmium versus a balance study) or the high
background cadmium intake in the Horiguchi study resulted in the discrepancy between the two studies.
There is some indication that not all forms of cadmium are equally absorbed. Some populations with
high dietary-cadmium exposure from Bluff oysters (McKenzie-Parnell et al. 1988) or seal meat (Hansen
et al. 1985) have been found not to have elevated blood-cadmium levels, perhaps due to the particular
form of cadmium in these foods.
Crews et al. (2000) estimated that 42% of a cadmium dose incorporated into porridge was retained in the
body 5 days after exposure (as measured by fecal excretion of radiolabelled cadmium); however, the fecal
collection period was probably too short to accurately measure cadmium absorption. The investigators
also attempted to measure cadmium absorption in 12-month-old infants; 18% of the labeled cadmium in
the porridge was retained in the body after 4 days. As with the adult data, the collection period may have
been too short to accurately measure cadmium absorption in the infants.
Most estimates of cadmium absorption in animals are somewhat lower than the values found from human
studies, particularly after prolonged exposure. In mice, 0.27–3.2% of an oral dose of cadmium chloride
was retained after 3–5 days (Bhattacharyya et al. 1981; Engstrom and Nordberg 1979), and in rats, 2–3%
of a single oral dose of cadmium chloride was retained (Moore et al. 1973; Schafer et al. 1990).
Following 30 days of oral exposure, 0.2–0.3% of an administered dose was retained in rats (Muller et al.
1986). After 4 weeks of dietary exposure to cadmium, absorption of cadmium was reduced to one-third
the absorption of rats without pre-exposure to cadmium (Schafer et al. 1990). Cadmium pigments
(cadmium sulfide and cadmium sulfoselenide) appear to be absorbed much less than cadmium chloride in
rats (ILZRO 1977). Increases in absorption have been observed during gestation and lactation, 0.37 and
0.35% of cadmium administered via gavage was absorbed in mice on gestation days 8 and 15 and 0.56,
0.60, and 0.30% on lactation days 10, 17, and 24, as compared to 0.27% in nonpregnant controls;
absorption was only significantly different from nonpregnant controls on lactation days 10 and 17
(Bhattacharyya et al. 1981). Similar findings were observed in mice continuously exposed to cadmium
during pregnancy and/or lactation (Bhattacharyya et al. 1982, 1986).
The absorption of cadmium from the gastrointestinal tract has been extensively studied in rats and mice,
and a number of factors are recognized that influence absorption. Absorption appears to take place in two
CADMIUM 195
3. HEALTH EFFECTS
phases: uptake from lumen into mucosa, and transfer into the circulation (Foulkes 1985). Phase 1 may
involve sequestering of cadmium by metallothionein (Foulkes 1980), but any protective effect is
overloaded at moderate doses (Kotsonis and Klaassen 1978). Uptake behaves like a saturable process
with fractional absorption decreasing at high concentrations (Foulkes 1980). There is evidence, however,
to suggest that this saturation results from charge neutralization at the membrane (Foulkes 1985), so that
it need not be assumed that there is a specific system for carrying cadmium into the body. At doses high
enough to damage gastrointestinal mucosa, fractional absorption is increased (Andersen et al. 1988; Goon
and Klaassen 1989; Lehman and Klaassen 1986). Cadmium bound to metallothionein was absorbed by
rats to a lesser extent than cadmium added to the diet as cadmium chloride, but kidney cadmium content
was only slightly less (Groten et al. 1990).
Maitani et al. (1984) compared the distribution of cadmium after oral administration of either cadmium
ions or Cd-thionein in male CF-1 mice given 0.5 mg Cd/kg, per os (po), as cadmium chloride in saline,
cadmium chloride in control rat liver homogenate, cadmium thionein in saline, Cd-TH in liver
homogenate, or liver homogenate from Cd-treated rats. In all cases, 85–90% of the cadmium dose was
present in feces within 24 hours. However, in groups receiving cadmium chloride, more cadmium was
found in feces on days 2 and 3, compared to those receiving cadmium-thionein. In a companion study,
tissue levels indicated that less cadmium was absorbed when rats received cadmium-thionein in saline
than cadmium chloride in saline. Cadmium-thionein added to liver homogenate or liver homogenate
containing cadmium-thionein increased the absorption of cadmium, resulting in renal cadmium levels
similar to those in mice receiving cadmium chloride in saline. The kidney/liver cadmium concentration
ratio (9) was the same for cadmium-thionein in all three media. Although Cd-TH gave much higher
kidney/liver cadmium ratios than cadmium chloride (9 versus 2), renal cadmium concentrations were the
same or lower than after cadmium chloride treatments. The authors concluded that the high kidney/liver
cadmium ratio after cadmium-thionein treatment versus cadmium chloride was due to lower
concentrations of cadmium in liver rather than marked increases in renal cadmium levels. While the
chemical form of cadmium administered affects the absorption and distribution, the amount of cadmium
reaching the kidney after cadmium-thionein administration is similar to that after cadmium chloride
administration.
At moderate doses of cadmium, the presence of divalent and trivalent cations, such as calcium,
chromium, magnesium, and zinc, may decrease cadmium uptake, probably by a nonspecific effect on the
charge distribution of the intestinal brush border membrane (Foulkes 1985). However, the influence of
cations on cadmium absorption is complex, because zinc can increase the amount of cadmium absorbed
CADMIUM 196
3. HEALTH EFFECTS
from the intestine (Jaeger 1990). A refined diet high in fat and protein increases cadmium absorption in
mice, partially due to increased gastrointestinal passage time (Schafer et al. 1986). Studies in newborn
rats and pigs also provide evidence that diet constituents influence cadmium absorption; absorption of
cadmium chloride was higher when administered in water compared to cereal-based infant formula
(Eklund et al. 2001, 2004). Diets low in iron increase cadmium absorption (Flanagan et al. 1978; Reeves
and Chaney 2001, 2002; Schafer et al. 1990); a diet low in calcium will also increase cadmium absorption
(Reeves and Chaney 2001, 2002). In contrast, low levels of dietary iron did not increase cadmium
absorption in suckling piglets; however, iron supplementation did increase cadmium absorption (Öhrvik
et al. 2007); this difference may be due to the high cadmium dose used in the study. Zinc deficiency may
result in an increased accumulation of cadmium in the intestinal wall, but does not affect transport into the
blood (Foulkes and Voner 1981; Hoadley and Cousins 1985). The absorption of cadmium in rats depends
on age, with measured absorption decreasing from 12 to 5 to 0.5% at 2 hours, 24 hours, and 6 weeks after
birth, respectively (Sasser and Jarboe 1977). Sasser and Jarboe (1980) also reported that absorption of
cadmium in the gastrointestinal tract of young guinea pigs was 20-fold higher than in adult guinea pigs.
Thus, for a given individual, the absorption following oral exposure to cadmium is likely to depend on
physiologic status (age; body stores of iron, calcium, and zinc; pregnancy history; etc.) and, also, on the
presence and levels of ions and other dietary components ingested with the cadmium.
3.4.1.3 Dermal Exposure
A few measurements of dermal absorption of cadmium in animals have been made, with only one in vitro
study using human skin to determine the percutaneous absorption of cadmium.
A study by Wester et al. (1992) evaluated the percutaneous absorption of cadmium from water and soil
into and through human skin using in vitro skin cells. Radioactive cadmium (109cadmium chloride) was
made to a concentration of 116 ppb in water or 13 ppb in filtered soil (26% sand, 26% clay, 48% silt,
0.9% organic content). Cadmium chloride was administered either at 5 μL/cm2 or 2 volumes of
2.5 μL/cm2 (the same amount of cadmium apparently applied). Human cadaver skin dermatomed at
500 μm was placed in flow-through skin cells and perfused with human plasma. Approximately 0.1–
0.6% of the cadmium chloride in water entered the plasma perfusate over the 16-hour perfusion period,
while 2.4–12.7% of applied dose remained in the skin. Most of the cadmium (74–93%) remained
unabsorbed and was recovered from the skin surface. Total recoveries ranged from 88±20 to 103±3.
When cadmium-contaminated soil (13 ppb cadmium chloride) was applied to the skin surface, plasma
levels ranged from 0.02 to 0.07% of the applied dose, while the skin contained 0.06–0.13% of applied
CADMIUM 197
3. HEALTH EFFECTS
dose. Surface wash ranged from 82 to 102% of applied dose. Total recoveries were from 83±33 to
106±2. The large differences between water and soil absorption into the plasma and retention in the skin
were attributed to differences in cadmium partition coefficients, measured to be 3.61x101 for stratum
corneum (powdered):water and 1.03x105 for soil:water. These measurements indicate that soil has a
relatively higher affinity for cadmium than does the stratum corneum. The transfer of cadmium from soil
to skin depends on the soil’s binding capacity and water retention and variables describing the physical
contact with the skin. When cadmium levels in the soil were increased from 6.5 to 65 ppb, skin levels
correspondingly increased, but plasma receptor fluid levels remained constant. This suggests that, with in
vitro perfusion, the surface concentration of cadmium will influence skin cadmium concentration, but that
absorption into plasma receptor fluid is relatively independent of the skin surface concentration. The
authors offer the caveat that in vitro methods can influence results and therefore, the receptor fluid
accumulation must be interpreted with caution. The authors calculate that a whole-body exposure to
cadmium at 116 ppb in water with 0.5% absorption will result in a daily systemic intake of about 10 μg
cadmium.
A few animal studies are available that describe the percutaneous absorption of cadmium as estimated
from the accumulation of cadmium in the liver and kidneys of mice and rabbits. Male rabbits (strain not
specified) dosed with cadmium chloride percutaneously via a 1% aqueous solution (6.1 mg cadmium) or
2% ointment (12.2 mg cadmium) over a 10-cm2 shaved area (Kimura and Otaki 1972). Animals were
treated 5 times over 3 weeks (duration of exposure not reported) and were killed 2 weeks after the last
application. Only cadmium contents of liver and kidney were measured, so total absorption through the
skin may have been greater. Accumulated amounts of cadmium in the liver and kidneys were found to be
0.4–0.61% 2 weeks after the end of cadmium exposure. This percentage was similar for aqueous solution
or hydrocarbon ointment. Similarly, male hairless mice (strain not specified) were dosed with cadmium
chloride percutaneously with a 2% ointment (containing 0.61 mg cadmium) 1 or 5 times in a week
(duration of exposure not reported) and killed 1 week later (Kimura and Otaki 1972). Accumulated
amounts of cadmium in the liver and kidneys were found to be 0.2–0.87%.
Cadmium was detected in liver, kidneys, and urine following dermal exposure in guinea pigs (Skog and
Wahlberg 1964). The disappearance of cadmium from cadmium chloride in water applied to guinea pig
skin was dependent on concentration, with a peak mean absorption of 1.8% over 5 hours at 0.239 molar
cadmium (about a 2.7% solution). Less absorption occurred both at higher and lower concentrations of a
cadmium chloride solution applied to the skin (Skog and Wahlberg 1964).
CADMIUM 198
3. HEALTH EFFECTS
The results from all of these studies suggest that dermal absorption is slow, and would be of concern only
in situations where concentrated solutions would be in contact with the skin for several hours or longer.
3.4.2 Distribution
Cadmium is widely distributed in the body, with the major portion of the body burden located in the liver
and kidney. Animals and humans appear to have a similar pattern of distribution that is relatively
independent of route of exposure, but somewhat dependent on duration of exposure.
Cadmium was found in autopsy samples from nearly all organs of a worker extensively exposed to
cadmium dust, with greatest concentrations in the liver, kidney, pancreas, and vertebrae (Friberg 1950).
In workers dying from inhalation of cadmium, lung-cadmium concentration was somewhat lower than
liver or kidney cadmium concentration (Beton et al. 1966; Lucas et al. 1980; Patwardhan and Finckh
1976). The concentration of cadmium in the liver of occupationally exposed workers generally increases
in proportion to intensity and duration of exposure to values up to 100 μg/g (Gompertz et al. 1983; Roels
et al. 1981b). The concentration of cadmium in the kidney rises more slowly than in the liver after
exposure (Gompertz et al. 1983) and begins to decline after the onset of renal damage at a critical
concentration of 160–285 μg/g (Roels et al. 1981b).
In animals acutely exposed to cadmium carbonate aerosols, about 60% of the inhaled dose is found in the
gastrointestinal tract, transported by mucociliary clearance (Moore et al. 1973). Following a 2-hour
inhalation of approximately 100 mg/m3 of cadmium, cadmium concentration in rat liver increased from
an initial concentration of 0.8 μg/g in males and 1.9 μg/g in females immediately after exposure up to a
peak of about 2 μg/g in males and 3.8 μg/g in females 1 week postexposure, then declined to 1.7 and
2.5 μg/g, respectively, by 30 days postexposure. The kidney concentrations were initially <0.5 μg/g in
males and females, rising to approximately 8 μg/g in both sexes by 1 week postexposure and to 18 μg/g in
males and 15 μg/g in females by 30 days postexposure (Rusch et al. 1986).
As discussed in Chapter 6, most nonoccupationally exposed people are exposed to cadmium primarily
through the diet. Cadmium can be detected in virtually all tissues in adults from industrialized countries,
with greatest concentrations in the liver and kidney (Chung et al. 1986; Sumino et al. 1975). Average
CADMIUM 199
3. HEALTH EFFECTS
cadmium concentrations in the kidney are near zero at birth, and rise roughly linearly with age to a peak
(typically around 40–50 μg/g wet weight) between ages 50 and 60, after which kidney concentrations
plateau or decline (Chung et al. 1986; Hammer et al. 1973; Lauwerys et al. 1984). Liver cadmium
concentrations also begin near zero at birth, increase to typical values of 1–2 μg/g wet weight by age 20–
25, then increase only slightly thereafter (Chung et al. 1986; Hammer et al. 1973; Lauwerys et al. 1984;
Sumino et al. 1975).
Distribution of cadmium in animals after oral exposure is similar to that found in humans, with highest
accumulation in the liver and kidneys, and lower levels spread throughout the rest of the body (Kotsonis
and Klaassen 1978; Weigel et al. 1984). Liver and kidney cadmium concentrations are comparable after
short-term exposure (Andersen et al. 1988; Jonah and Bhattacharyya 1989), but the kidney concentration
exceeds the liver concentration following prolonged exposure (Kotsonis and Klaassen 1978), except at
very high exposures (Ando et al. 1998; Bernard et al. 1980; Hiratsuka et al. 1999). In mice orally
exposed to cadmium during lactation, 53% of the whole-body cadmium was found in the kidneys as
compared to 27% in nonpregnant controls (Bhattacharyya et al. 1982).
Maitani et al. (1984) compared the distribution of cadmium in rats after an acute oral administration of
either cadmium ions or cadmium bound to metallothionein. In all cases, 85–90% of the dose was present
in the feces within 24 hours postexposure. More of the cadmium-thionein was retained after 2–3 days,
and less of the cadmium-thionein was distributed to the liver than was the case for the ionic cadmium.
Kidney levels were comparable.
The placenta may act as a partial barrier to fetal exposure to cadmium. Cadmium concentration has been
found to be approximately half as high in cord blood as in maternal blood in several studies including
both smoking and nonsmoking women (Kuhnert et al. 1982; Lauwerys et al. 1978; Truska et al. 1989).
Accumulation of cadmium in the placenta at levels about 10 times higher than maternal blood cadmium
concentration has been found in studies of women in Belgium (Roels et al. 1978) and the United States
(Kuhnert et al. 1982); however, in a study in Czechoslovakia, the concentration of cadmium in the
placenta was found to be less than in either maternal or cord blood (Truska et al. 1989). In mice orally
exposed to cadmium during pregnancy, maternal blood, placental, and fetal cadmium concentrations were
essentially equal among control animals (with environmental cadmium exposure), but placental
concentration increased with cadmium dose much more rapidly than either maternal blood or fetal
cadmium concentration (Sorell and Graziano 1990). Thus, timing and level of cadmium exposure may
influence the uptake of cadmium by the placenta, perhaps explaining the conflicting human studies.
CADMIUM 200
3. HEALTH EFFECTS
Goyer and Cherian (1992) localized metallothionein in full-term human placenta and in fetal cells in
human placenta. Metallothionein was present in trophoblasts (which facilitate transport of substances
entering the placenta from the maternal blood), Hofbauer cells (motile macrophages capable of
phagocytosis and protein ingestion), amniotic epithelial cells (fetal derivatives), and decidual cells
(endometrial stromal cells that have been transformed under hormonal influence into large pale cells, rich
in glycogen). The mechanism by which the placenta transports the essential metals, copper and zinc,
while limiting the transport of cadmium is unknown, but may involve the approximately 1,000-fold
higher concentration of zinc in the placenta and the higher affinity of cadmium than zinc for
metallothionein.
Cadmium levels in human milk are 5–10% of levels in blood, possibly due to inhibited transfer from
blood because of metallothionein binding of cadmium in blood cells (Radisch et al. 1987). Bhattacharyya
et al. (1982) examined the maternal transfer of cadmium to pups during gestation and lactation in mice.
Approximately 3, 11, and 25% of maternal cadmium was transferred to the pups following gestation-only
exposure, lactation-only exposure, and gestation and lactation exposure, respectively.
No studies were located regarding distribution in humans after dermal exposure to cadmium. Elevated
levels of cadmium were found in the liver and kidneys of rabbits and mice dermally exposed to cadmium
(Kimura and Otaki 1972).
3.4.3 Metabolism
Cadmium is not known to undergo any direct metabolic conversion such as oxidation, reduction, or
alkylation. The cadmium (+2) ion does bind to anionic groups (especially sulfhydryl groups) in proteins
(especially albumin and metallothionein) and other molecules (Nordberg et al. 1985). Plasma cadmium
circulates primarily bound to metallothionein, and albumin (Foulkes and Blanck 1990; Roberts and Clark
1988).
3.4.4 Elimination and Excretion
Most cadmium that is ingested or inhaled and transported to the gut via mucociliary clearance is not
absorbed and is excreted in the feces. Absorbed cadmium is excreted very slowly, with urinary and fecal
CADMIUM 201
3. HEALTH EFFECTS
excretion being approximately equal (Kjellström and Nordberg 1978). The half-time for cadmium in the
whole body in humans was >26 years (Shaikh and Smith 1980) and half-times of several months up to
several years have been calculated in mice, rats, rabbits, and monkeys (Kjellström and Nordberg 1985).
Half-times in the slowest phase were from 20 to 50% of the maximum life span of the animal (Kjellström
and Nordberg 1985). In the human body, the main portion of the cadmium body burden is found in the
liver and kidney and in other tissues (particularly muscle, skin, and bone). After reviewing the literature,
Kjellström and Nordberg (1985) developed a range of half-times from their kinetic model of 6–38 years
for the human kidney and 4–19 years for the human liver.
Cadmium excretion in urine of occupationally exposed workers increases proportionally with body
burden of cadmium, but the amount of cadmium excreted represents only a small fraction of the total
body burden unless renal damage is present; in this case, urinary cadmium excretion markedly increases
(Roels et al. 1981b). Fecal excretion in workers occupationally exposed to cadmium reflects mainly
cadmium dust swallowed from industrial air and/or incidentally ingested from contaminated hands
(Adamsson et al. 1979).
In rats, following a 2-hour inhalation exposure to cadmium carbonate, cadmium was primarily eliminated
in the feces, with a minor component (approximately 1% of fecal excretion) in the urine (Rusch et al.
1986). Cadmium excretion by both routes declined with time after exposure, with significantly elevated
excretion found at 7 days, but not 30 days, after exposure (Rusch et al. 1986). Most of the cadmium
initially excreted in the feces was probably not absorbed, but rather represented particles transported from
the lung to the gastrointestinal tract (Moore et al. 1973).
Following oral exposure, the major proportion of administered cadmium is found in the feces, because
absorption is so low (see Section 3.4.1.2) (Kjellström et al. 1978). Among five healthy adult volunteers,
fecal excretion of a single dose of radiolabeled cadmium declined with time up to 45 days after ingestion,
while urinary excretion remained at a low, near-constant level (Rahola et al. 1973). After about 20 days,
fecal and urinary excretion appeared to be comparable (Rahola et al. 1973). In contrast, among
four healthy adults ingesting cadmium in intrinsically labeled crabmeat, fecal excretion was 30 times
higher than urinary excretion up to 10 weeks after ingestion of the test meal (Newton et al. 1984). In rats
orally exposed to up to 0.35 mg/kg/day of cadmium in the diet for 60 days, no significant increase in
CADMIUM 202
3. HEALTH EFFECTS
urinary cadmium content was found (Weigel et al. 1984). The overall excretion of absorbed cadmium is
slow, with biological half-times of 70–270 days in rats or mice orally exposed to cadmium (Engstrom and
Nordberg 1979; Moore et al. 1973).
In a comprehensive model developed for human cadmium toxicokinetics, parameters for urinary and fecal
excretion were derived by adjustments to empirical data derived from human and animal studies
(Kjellström and Nordberg 1978, 1985). Fecal excretion constitutes unabsorbed cadmium plus "true"
excretion originating from blood via the intestinal wall (a function of cadmium body burden) and from
bile via the liver (a function of cadmium liver burden) (Kjellström and Nordberg 1985). Urinary
excretion depends on blood concentration and kidney concentration, and total excretion is assumed to
equal daily intake at steady state. Using these methods and assumptions, daily fecal and urinary excretion
is estimated to be 0.007 and 0.009% of body burden, respectively (Kjellström and Nordberg 1978, 1985).
A whole-body retention half-time estimate of >26 years was obtained by Shaikh and Smith (1980) in a
study using orally ingested radiolabelled cadmium and monitoring a subject for over 2 years.
Groups of 10 female outbred albino rats were exposed to cadmium in drinking water (as cadmium
chloride) at 0 or 4.8 mg/kg/day for 10 weeks (at 4 weeks prior to mating, at 3 weeks of gestation, or
3 weeks into lactation). After weaning, exposure to cadmium was terminated. In dams, kidney
concentrations exceeded liver concentrations, while in pups, the renal and liver concentrations were
similar at all times during exposure. In pups, both hepatic and renal cadmium concentrations
considerably increased only during the second half of the lactation period (Ld 11–21). The concentrations
in the dams were several orders higher than in the offspring. After discontinuation of exposure, organ
concentration slightly decreased in dams (2% in liver and 12% in kidneys), while in pups, the decrease
was 84% in the liver and 62% in the kidneys. These values do not indicate cadmium elimination but
rather dilution caused by growth (Kostial et al. 1993).
No studies were located regarding excretion in humans after dermal exposure to cadmium. Cadmium was
reportedly detected in urine in guinea pigs dermally exposed to aqueous cadmium chloride, but no details
are available (Skog and Wahlberg 1964).
CADMIUM 203
3. HEALTH EFFECTS
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and
disposition of chemical substances to quantitatively describe the relationships among critical biological
processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry
models. PBPK models are increasingly used in risk assessments, primarily to predict the concentration of
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various
combinations of route, dose level, and test species (Clewell and Andersen 1985). Physiologically based
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to
quantitatively describe the relationship between target tissue dose and toxic end points.
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to
delineate and characterize the relationships between: (1) the external/exposure concentration and target
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and
Krishnan 1994; Andersen et al. 1987a). These models are biologically and mechanistically based and can
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species. The biological basis of
PBPK models results in more meaningful extrapolations than those generated with the more conventional
use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and
Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen
1994; Leung 1993). PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters. The
numerical estimates of these model parameters are incorporated within a set of differential and algebraic
equations that describe the pharmacokinetic processes. Solving these differential and algebraic equations
provides the predictions of tissue dose. Computers then provide process simulations based on these
solutions.
The structure and mathematical expressions used in PBPK models significantly simplify the true
complexities of biological systems. If the uptake and disposition of the chemical substance(s) are
adequately described, however, this simplification is desirable because data are often unavailable for
CADMIUM 204
3. HEALTH EFFECTS
many biological processes. A simplified scheme reduces the magnitude of cumulative uncertainty. The
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste
sites) based on the results of studies where doses were higher or were administered in different species.
Figure 3-3 shows a conceptualized representation of a PBPK model.
If PBPK models for cadmium exist, the overall results and individual models are discussed in this section
in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations.
3.4.5.1 Summary of Cadmium PBPK Models
Several models have been reported to describe the kinetics of cadmium in mammalian systems. Of these
models, the Nordberg-Kjellström model (Kjellström and Nordberg 1978; Nordberg and Kjellström 1979)
has been the most widely used for cadmium risk assessment. Three of the most relevant cadmium models
will be discussed here.
3.4.5.2 Cadmium PBPK Model Comparison
Although the Nordberg-Kjellström model (Kjellström and Nordberg 1978; Nordberg and Kjellström
1979) has its limitations, it provides the best overall description of cadmium toxicokinetics and is largely
based on human data. The Shank (Shank et al. 1977) and Matsubara-Khan (Matsubara-Khan 1974)
models are not as useful for human risk assessment applications, but they do provide useful insights into
the absorption, distribution, and compartmentalization of cadmium in laboratory animals. These insights
may have some future use in human risk assessment as PBPK models for cadmium continue to be refined.
CADMIUM 205
3. HEALTH EFFECTS
Figure 3-3. Conceptual Representation of a Physiologically Based

Pharmacokinetic (PBPK) Model for a
Hypothetical Chemical Substance
Inhaled chemical Exhaled chemical
Ingestion
Lungs
Liver
Vmax
Km GI
Tract A
V R
E Fat T
N E
O R
U Slowly I
S perfused A
tissues L
Richly
B perfused
L tissues B
O L
Feces
O O
D O
Kidney
D
Urine
Skin
Chemicals
contacting skin
Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a
hypothetical chemical substance. The chemical substance is shown to be absorbed via the skin, by inhalation, or by
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source: adapted from Krishnan and Andersen 1994

CADMIUM 206
3. HEALTH EFFECTS
3.4.5.3 Discussion of Cadmium Models
The Nordberg-Kjellström Model
The Nordberg-Kjellström model (Kjellström and Nordberg 1978; Nordberg and Kjellström 1979) is a
linear multicompartment model that is the most commonly used model for cadmium risk assessment work
today. The Nordberg-Kjellström schematic model diagram is shown in Figure 3-4.
Risk assessment. The Nordberg-Kjellström model has been demonstrated to be a useful model in
human risk assessment work. Frazier (1994), however, noted that the model has two major limitations:
(1) the linear nature of the model may not adequately allow a good description of known nonlinearities in
biological responses to cadmium dosing, and (2) the phenomenological approach taken with this model
does not provide a foundation for incorporating biological variability into the model parameters.
Description of the Model. The Nordberg-Kjellström model (see Figure 3-4) is a linear multi-
compartment model that describes the disposition of cadmium via the oral and inhalation routes of
exposure only. Dermal exposure and subsequent absorption through the skin were assumed to be
negligible in this model. For inhalation exposures, the model accounts for different deposition patterns
for different size particles in nasopharyngeal, tracheobronchial, and alveolar regions of the respiratory
tract. Particles with mass median aerodynamic diameter (MMAD) of 5 μm (i.e., cadmium-laden dust)
were assumed to distribute mainly to the nasopharyngeal region (75%), with lesser amounts depositing in
the alveolar (20%) and tracheobronchial (5%) regions. Particles of 0.05 μm MMAD (i.e., cigarette
smoke) were assumed to deposit 50% in the alveolar compartment, 10% in the tracheobronchial
compartment, and none in the nasopharyngeal compartment. The remaining amounts are exhaled. For all
particle sizes initially deposited in the nasopharyngeal and tracheobronchial compartments, mucociliary
clearance clears some particles from the respiratory tract to enter the oral compartment for absorption or
out of the body and back to the environment. Assumed model coefficient values and the available
physiological parameters are shown in Table 3-12.
For the oral route of exposure, cadmium may enter the gastrointestinal tract via food or water
contaminated with cadmium, or as cadmium particles embedded in mucus from the respiratory tract via
the mucociliary/tracheobronchial escalator. By either route of exposure, the model assumes that cadmium
enters into any of three blood compartments (B) (see Figure 3-4). B1 is the plasma compartment where
CADMIUM 207
3. HEALTH EFFECTS
Figure 3-4. A Schematic Representation of the Nordberg-Kjellström Model
A G
C1
= A
C2 = A Gastrointestinal
tract intake
Lung E1
Intestines E2
C3
=
E1 E2
=
C6
Daily uptake 1
I2
=C
I2 7=
I– I (m
= o=
I1 C8
)
CX = B1 C16 = B2
Blood 1. B1 Blood 2. B2 Blood 3. B3
C18 =
K
C17 = B3
C9 = E1
C10 = T
C1
C13 = L L
4=
2
=
C1
B1
Other tissues Liver Kidney

T L K
K
=
C11 = B1 C15 = L (1 – C17) = B3 19
C
Feces Urine
F U
Source: Kjellström and Nordberg 1978

CADMIUM 208
3. HEALTH EFFECTS
Table 3-12. Assumed Model Parameters and Some Physiologic Parameters for
the Nordberg-Kjellström Model
Values fitting to
Coefficient or parameter Assumed range Unita empirical data
Model parameters
C1 0.1–0.2 (cigarette smoke) 0.1
0.4–0.9 (factory smoke) 0.7
C2 0.4–0.6 (cigarette smoke) 0.4
0.1–0.3 (factory smoke) 0.13
-1
C3 0.01–1.0 day 0.05
-1
C4 0.1xC3 = 0.001–0.1 day 0.005
C5 0.03–0.1 0.048
-1
C6 0.05 day 0.05
C7 0.2–0.4 0.25
C8 0.5–5.0 μg 1
C9 0.4–0.8 0.44
-1
C10 0.00004–0.0002 day 0.00014
C11 0.05–0.5 0.27
C12 0.1–0.4 0.25
-1
C13 0–0.0001 day 0.00003
-1
C14 0.0001–0.0003 day 0.00016
-1
C15 0–0.0001 day 0.00005
-1
C16 0.004–0.015 day 0.012
C17 0.8–0.98 0.95
-1
C18 0–0.0001 day 0.00001
-1
C19 0.00002–0.0002 day 0.00014
CX 0 01–0.05 0.04
C20 0.05–0.5 0.1
-1
C21 0–0.000002 day 0.0000011
Physiologic parameters
Average liver weight 1,500 gram
Average blood volume 70 mL/kg
Average blood specific gravity 1.06
Average daily urine excretion (adult) 1.0 L
Average daily urine excretion (aged) 0.9 L
Average daily urine excretion (child) 0.5 L
a
Blanks indicate a unitless value.
Source: Kjellström and Nordberg 1978; Nordberg and Kjellström 1979

CADMIUM 209
3. HEALTH EFFECTS
cadmium may bind to plasma components (i.e., albumin and other organic constituents). B2 is the red-
blood cell compartment, which represents the accumulation of cadmium in erythrocytes, while
B3 represents the binding of cadmium to metallothionein. The model does not take into account
induction of metallothionein after cadmium exposure. From the blood, cadmium is calculated to
distribute to either the liver, kidney, or "other tissues," the major accumulation sites. Elimination is either
via the feces or in the urine. The transport of cadmium between the compartments is assumed to follow
first-order exponential functions and is driven on concentration-dependent gradients.
Validation of the model. The Nordberg-Kjellström model was validated using several independent
sets of human data from both Sweden and Japan. The data set by Friberg et al. (1974) estimated that
smoking 20 cigarettes a day would result in an inhalation of 2–4 μg/day of cadmium, assuming smoking
started at 20 years of age and daily cadmium intake from food was 16 μg/day. Based on the Friberg et al.
(1974) data, the model predictions of cadmium concentrations in the kidney agreed well with the
observed data from a study by Elinder et al. (1978); however, the model predicted higher than expected
values for liver cadmium compared to the observed data from the Elinder study. The model's urinary
excretion of cadmium (0.84 μg/24 hours for a 50-year-old person) agreed well with the observed data
(0.56–0.8 μg/24 hours). The model predicted blood cadmium levels for Swedish smokers to be about
2 ng/g which compared well to the actual concentration of 1.6 ng/g.
The model was also validated against a data set for an average 45-year-old Japanese person living in
Tokyo whose daily intake of cadmium is 40 μg via food and 2.7 μg via the inhalation route. Subjects
were assumed to be smokers averaging 24 cigarettes a day starting at age 20. Based on these exposure
conditions, the measured values for cadmium in the kidney, liver, and "other tissues" (in this case, muscle
only) were reported to be 65, 3.4, and 0.2 μg/g, respectively, with the model predicting 48, 3.2, and
0.18 μg/g. For blood and urine, the measured values were 4.5 μg/g for blood and 1.1 μg/L for urine; the
model predicted 3.4 μg/g and 1.3 μg/24 hours (assuming 1 L of urine output/day, the value would be
1.3 μg/L).
Another study of Japanese people reported cadmium concentrations in urine in relation to high cadmium
concentrations in rice in their daily diet. For people who consumed rice containing 0.04 μg/g of rice
(240 μg/day), the observed urinary level of cadmium was 7 μg/L; consumption of rice containing 1.1 μg
cadmium/g of rice (660 μg/day), resulted in an observed value of 14 μg/L of urine. After making certain
assumptions about the average daily consumption of rice containing an assumed amount of cadmium, and
CADMIUM 210
3. HEALTH EFFECTS
assuming an average urine production of 1 L/day, the model calculated urinary levels of 4.8 and
15.5 μg/L of urine, agreeing well with the observed values.
The model was also validated against a data set with high concentrations of cadmium in air (50 μg/m3)
(Piscator 1972) and blood cadmium concentrations ranging from 10 to 50 ng/g whole blood. Calculated
blood, urine, liver, and kidney levels of cadmium agreed only roughly with the observed values; however,
the authors concluded that the model predictions may not be accurate based on the observations that
workers with long exposure histories had most likely experienced higher exposure levels in the past,
skewing the data set, resulting in poor model predictions. Another data set by Piscator (1984) involved a
group of Swedish workers involved in polishing cadmium-plated objects, who were exposed to high
concentrations of cadmium for ≤2 years. Cadmium levels were measured in the urine and blood. When
this exposure data set was input into the model, the model could not adequately predict blood and urine
levels for these workers.
Target tissues. The Nordberg-Kjellström model assumes that the kidney and liver are the two
specific target tissues in which cadmium accumulates. The model also accounts for all other tissue
accumulation in the "other tissues" compartment (i.e., muscle). The model assumes a human liver tissue
half-life (t1/2) of 4–19 years and a kidney t1/2 of 6–38 years. For the "other tissue" compartments, t1/2 was
assumed to be 9–47 years. The Nordberg-Kjellström model does account for the loss of renal tubular
epithelial cells leading to a loss of tubular reabsorptive capacity. This loss of cells could conceivably
result in an increase in the excretion of cadmium from the tubules and an increase in the transport of
cadmium from the tubules to the blood. This loss of cells is theorized to account for the large t1/2 range
for cadmium in the kidney. The model assumed that no changes in the movement of cadmium from the
kidney to blood occurred with age and that the loss of cadmium from the kidney to the urine increased
linearly after the age of 30.
The Nordberg-Kjellström model also accounted for differences in kidney and liver weights among
different age groups and between peoples of different ethnic origins. The model corrected for differences
in liver, kidney, blood, and "other tissue" weights with relation to age (1 and 79 years of age) and
ethnicity (Japan and Sweden).
Species extrapolation. The Nordberg-Kjellström model was based solely on data collected from
humans and was intended for human risk assessment applications. The model did not address any
potential application for this model of cadmium in laboratory animals.
CADMIUM 211
3. HEALTH EFFECTS
High-low dose extrapolation. The Nordberg-Kjellström model has been shown to adequately
predict fluid and tissue concentrations via the oral and inhalation routes of exposure for humans exposed
to low doses of cadmium. However, the model has difficulty in adequately predicting fluid and tissue
concentrations in humans exposed to high concentrations of cadmium, especially for those individuals
exposed to high concentrations via the inhalation route.
Interroute extrapolation. The Nordberg-Kjellström model adequately predicted the fate of cadmium
in target tissues after exposure via the inhalation and oral routes. The dermal route of exposure was not
incorporated into the model parameters and was considered an insignificant route of exposure in humans.
The Shank Model
Risk assessment. The Shank model (Shank et al. 1977) may have the potential to serve as an
alternative mathematical model for predicting the retention of cadmium in biological systems.
Unfortunately, no human data were used to validate the Shank model for use as a risk assessment tool in
cases of human exposure. In addition, the Shank model was validated only for the intravenous and
subcutaneous routes of exposure; no data were presented for the oral, inhalation, or dermal routes of
exposure.
Description of the model. A schematic representation of the Shank model is illustrated in

Figure 3-5. The model mathematically represents the dynamic transport of cadmium between
compartments in a mammalian biological system based on the male adult SW/NIH mouse as the test
animal species. The intent was to predict the retention of cadmium in other species of animals (including
humans) without requiring an adjustment of species-specific rate constants from within the model.
Male adult mice of the SW/NIH strain were dosed intravenously with 109Cd as 109Cd acetate. Mice
received 1–3 intravenous injections spaced 48 hours apart. Animals in each group were sacrificed at
2 and 10 minutes and 1, 10, and 48 hours after the last dose. Tissues (liver, kidney, pancreas, spleen,
gastrointestinal tract, testes, carcass, and feces) were harvested and the radioactivity recorded. A nine-
compartment model was derived. Cadmium kinetics between compartments are described by first-order
kinetics. The individual compartment retention values, obtained from the distribution study, were
incorporated into the model equations and the rate constants derived.
CADMIUM 212
3. HEALTH EFFECTS
Figure 3-5. A Schematic Representation of the Shank Model
Kidney
RKB*K RBK*B
Spleen
Liver
RSB*S
RLB*L
RBS*B
RBL*B
Blood
RBC*B
RGB*G
RGB*B
RTB*T
RPB*P
Residual G.I.
carcass
RBP*B
RGF*G
RBT*B
Pancreas
RTB*T
Testes Feces
Source: Forrester 1968

CADMIUM 213
3. HEALTH EFFECTS
Validation of the model. The Shank model was validated using three independent data sets. Mann
(1973) dosed dogs, goats, and sheep with one intravenous injection of 109Cd acetate (30 μCi), and the liver
and kidneys were examined for cadmium content 8 weeks after administration. The Shank model's
predicted values of cadmium retention in liver and kidneys at 8 weeks after a single administration were
in good agreement with the observed values of the Mann (1973) study in all three species. Only data
from the liver and kidneys were available for evaluation. A data set from a study by Gunn et al. (1968b)
was used to evaluate the ability of the Shank model to predict the retention of cadmium in liver and
kidney after a single subcutaneous administration of cadmium chloride. Animals in that study were
sacrificed 2 weeks after administration, and the liver and kidneys were examined for cadmium content.
The model values for the same time period were in very close agreement with observed values. Again,
only data from the liver and kidneys were available for evaluation. Finally, a data set by Shanbaky (1973)
was used to test the model's validity with multiple injections of cadmium acetate in rats. Five injections
of cadmium acetate were administered over a 48-hour period; liver, kidneys, pancreas, spleen, and
gastrointestinal tract were examined for cadmium content. The Shank model was found to be in close
agreement with the arithmetic means of observed values found in the Shanbaky (1973) study.
No human data were presented to validate the model's effectiveness in predicting the cadmium retention
in human target tissues after either a single or multiple dosing regime.
Target tissues. The target tissues for this model included the liver, kidney, pancreas, spleen,
gastrointestinal tract, testes, and carcass of laboratory animals. No human tissue was used to derive
cadmium retention in any of these tissues.
Species extrapolation. The model used goats, dogs, rats, mice, and sheep with various doses and
dosing schemes of cadmium acetate and cadmium chloride and was found to serve as a good predictor of
cadmium retention in the target tissues listed above. No human data were presented to determine if the
model could satisfactorily predict the cadmium retention in human target tissues.
High-low dose extrapolation. High- and low-dose extrapolation was not specifically addressed by
the Shank model.
Interroute extrapolation. Interroute extrapolations were addressed in a limited fashion by the Shank
model. The model appeared to adequately predict the amount of cadmium retention in the target organs
CADMIUM 214
3. HEALTH EFFECTS
of laboratory animals, in particular the liver and kidney, when dosed by either the intravenous or
subcutaneous routes. The inhalation and dermal routes of exposure, and other parenteral routes of
exposure (intramuscular, intraperitoneal, intradermal, etc.) were not addressed by the Shank model. No
human data were presented to determine if interroute extrapolations were valid.
The Matsubara-Khan Model
Risk assessment. The Matsubara-Khan model (Matsubara-Khan 1974) has not been used as a tool
in risk assessment for humans. This model does demonstrate that cadmium kinetics and biological half-
lives vary by tissue.
Description of the model. The Matsubara-Khan model is a simple model that attempted to fit
cadmium elimination kinetic parameters into either a one- or two-compartment model. To obtain the data
for the model, male and female ICR mice (8 weeks of age) were administered a single subcutaneous
injection of a known amount of 109cadmium chloride. Specific groups of mice were sacrificed at 1, 2, 4,
8, 16, 32, 64, or 128 days after injection. At the time of sacrifice, blood, liver, kidney, salivary gland,
stomach wall and stomach contents, small intestine and small intestine contents, and colon wall and colon
contents were removed and the amount of 109Cd remaining in these tissues was determined.
An oral study was conducted in conjunction with the subcutaneous study described above. In the oral
study, 8-week-old male mice (ddd x BALB/c; F1) were orally administered 115mcadmium chloride by
gavage. Groups of mice were sacrificed at 1, 2, 4, 8, 16, 32, 64, or 128 days after injection. At the time
of sacrifice, liver, kidney, salivary gland, stomach wall, gonad, and spleen were removed and the amount
of 115mCd remaining in these tissues was determined.
The rate of uptake, rate constants, and biological half-lives determined for the subcutaneous and orally
dosed mice are summarized in Table 3-13. Matsubara-Khan found that tissue kinetics in mice dosed
subcutaneously with 109cadmium chloride fit into either a one- or two-compartment model, depending on
the tissue. The data from the digestive tract organs (stomach wall, small intestine, and colon) were best
fitted into a 1-compartment model, with a strained fit of the data from the digestive tract contents
(stomach, small intestine, and colon contents) to the one-compartment model. Data from the blood, liver,
kidneys, and salivary glands were best fitted to the two-compartment model. Extremely small second-rate
constants in the kidneys and salivary glands indicate that the elimination of cadmium from these tissues is
CADMIUM 215
3. HEALTH EFFECTS
Table 3-13. Estimated Parameters, Rate of Uptake, Rate Constants, and

Biological Half-Lives in Selected Mouse Organs After Subcutaneous
and Oral Administrations of 109CdCI2
Rate of uptake Rate constants b and c Biological half-life

(95% CL) (95% CL) (days)
Organ SC PO SC PO SC PO
Liver 21 8.7 0.011 0.016 631.2 430.76
0.57 0.91
Kidney 22 1.4 0.0007 0.016 9902.3 4332.3
0.30 0.30
Salivary gland 21 0.33 0.0016 0.0047 4330.95 1500.89
0.73 0.78
Blood 0.15 NM 0.024 NM 291.1 NM
0.65
Stomach wall 1.7 0.36 0.0073 0.017 95 41
Stomach contents 0.68 NM 0.062 NM 11 NM
Small intestine 0.95 NM 0.01 NM 69 NM
Small intestine contents 2.5 NM 0.067 NM 10 NM
Colon 1.4 NM 0.013 NM 53 NM
Colon contents 4.1 NM 0.15 NM 4.6 NM
Gonad NM 0.37 NM 0.012 NM 58
Spleen NM 0.44 NM 0.0011 NM 630
CL = confidence limits; PO = oral; SC = subcutaneous; NM = not measured
Source: Matsubara-Khan 1974

CADMIUM 216
3. HEALTH EFFECTS
very slow. For the oral study, similar findings were observed, with data from the gonads and spleen
fitting the one-compartment model best. Biological half-lives were invariably longer for the
subcutaneously dosed animals, while the rate constants were slightly smaller for the subcutaneously dosed
animals. Sex-related differences in rate of uptake, rate constants, and biological half-lives were not
found, except in the kidney data in which females had slightly smaller rate constants.
Validation of the model. No independent data sets were used to validate the Matsubara-Khan
model.
Target tissues. For the subcutaneous injection study, the Matsubara-Khan model used blood, liver,
kidney, salivary gland, stomach wall and stomach contents, small intestine and small intestine contents,
and colon wall and colon contents. For the oral study, the model used liver, kidney, salivary glands,
stomach wall, gonads, and spleen.
Species extrapolation. No species extrapolations were performed in the Matsubara-Khan model.
High-low dose extrapolation. No high-low dose extrapolations were performed in the Matsubara-
Khan model.
Interroute extrapolation. The Matsubara-Khan model compared the oral and subcutaneous routes
and reported similar rate constants for many of the tissues examined. Biological half-lives varied
considerably for the kidney and salivary gland, but were not much different for liver between the two
routes of exposure.
3.5 MECHANISMS OF ACTION
3.5.1 Pharmacokinetic Mechanisms
Absorption. Cadmium can be absorbed by the inhalation, oral, and dermal routes of exposure
regardless of its chemical form (chloride, carbonate, oxide, sulfide, sulfate, or other forms). Absorption
by the dermal route of exposure, however, is relatively insignificant for cadmium, although small
amounts are absorbed percutaneously over a long period of time (Wester et al. 1992). Absorption is
mainly of concern from inhalation and oral exposures.
CADMIUM 217
3. HEALTH EFFECTS
Gastrointestinal tract absorption of cadmium (in any chemical form) is relatively low when compared to
the total amount of cadmium absorbed via the inhalation route. In humans, cadmium absorption has been
reported to be approximately 1–10% ((Flanagan et al. 1978; McLellan et al. 1978; Newton et al. 1984;
Rahola et al. 1973; Shaikh and Smith 1980; Vanderpool and Reeves 2001). In other species,
gastrointestinal tract absorption of cadmium has been determined to be 1–2% in mice and rats (Decker et
al. 1958; Ragan 1977), 0.5–3.0% in monkeys (Friberg et al. 1974), 2% in goats (Miller et al. 1969), 5% in
pigs and lambs (Cousins et al. 1973; Doyle et al. 1974), and nearly 16% in cattle (Miller et al. 1967).
Lehman and Klaassen (1986) investigated the dose-dependence of cadmium absorption and disposition in
male Sprague-Dawley rats. Cadmium absorption was estimated to be 0.35 and 1% following oral
exposure to 1 or 10,000 μg/kg, respectively. Goon and Klaassen (1989) measured absorption of cadmium
in rat intestine in situ and reported that the intestinal absorption of cadmium is dosage independent at low
dosages of cadmium (<10 μg/kg) and dosage dependent at high dosages (>10 μg/kg). They also
evaluated the role of metallothionein and concluded that saturation of intestinal metallothionein is not a
major determinant of the observed dosage-dependent absorption of cadmium.
Although the mechanism involved in the intestinal absorption of cadmium has not been fully elucidated,
there is evidence that one or more transporter proteins are involved. Several studies have found evidence
that divalent metal transporter I protein plays an important role in the gastrointestinal absorption of
cadmium (Kim et al. 2007; Park et al. 2002; Ryu et al. 2004). However, studies in knockout mice suggest
that other transporter proteins are involved with cadmium absorption (Min et al. 2008; Ryu et al. 2004;
Suzuki et al. 2007).
In some cases, cadmium bound to metallothionein (as in food) is not absorbed or distributed from the
gastrointestinal tract as readily as ionic cadmium. Mice had lower blood and liver cadmium levels from
oral exposure to cadmium-metallothionein, compared to levels from cadmium chloride exposure for
comparable doses, but the cadmium-metallothionein resulted in higher kidney cadmium levels. Sharma et
al. (1983) reported that human exposure to very high intakes of cadmium during the consumption of
oysters resulted in increases in whole blood and urine cadmium levels; however, the increase was not
proportional to the level of intake.
A higher fraction of inhaled cadmium than ingested cadmium is absorbed. The total amount of cadmium
absorbed by the body via the lungs depends on the particle size. Larger particles are deposited in the
nasopharyngeal and tracheobronchial airways via impaction, and are largely cleared by mucociliary
processes, leading to absorption by the gastrointestinal tract. Smaller particles reach the smaller airways
CADMIUM 218
3. HEALTH EFFECTS
and alveoli, and depending on the particle's solubility, are absorbed and distributed to the rest of the body.
Solubility in lung fluids plays a role in absorption from the lung into the body of cadmium salts.
Theoretically, the highly soluble salts, chloride, nitrate, acetate, and sulfate would be expected to give the
highest blood levels following inhalation exposure to a given air concentration. The insoluble cadmium
salts, the various sulfides, should yield the lowest blood level. The lung, however, is rich in carbon
dioxide that is continuously transferred from the blood. Particles of the various cadmium sulfides within
the lung can react with this carbon dioxide. Lung tissue may then absorb and transfer solubilized or
released cadmium ions to the blood.
No direct data, however, are available on cadmium deposition, retention, or absorption in the human lung.
Data from animal studies indicate that lung retention is greatest after short-term exposure, 5–20% after
15 minutes to 2 hours (Barrett et al. 1947; Henderson et al. 1979; Moore et al. 1973; Rusch et al. 1986).
The initial lung burden declines slowly after exposure ceases (Henderson et al. 1979; Moore et al. 1973;
Rusch et al. 1986), due to the absorption of cadmium and the lung clearance of deposited particles. After
longer periods of inhalation exposure to cadmium, somewhat lower lung retentions are found (Glaser et
al. 1986). The absorption of cadmium in the lung differs somewhat among chemical forms, but the
pattern apparently does not correlate well with solubility in water (Glaser et al. 1986; Rusch et al. 1986).
Retention of cadmium has been reported to be >40% in rats (Moore et al. 1973), 40% in canines (Friberg
et al. 1974), and 10–20% in mice (Potts et al. 1950).
The cadmium levels in cigarettes range from 0.28 to 3.38 μg (Elinder et al. 1985b; Watanabe et al. 1987);
the mean in 38 U.S. brands was 1.07 μg (Watanabe et al. 1987). Approximately 10% of the cadmium in
cigarettes is inhaled (Elinder et al. 1985b). Based on comparison of cadmium body burdens in human
smokers and nonsmokers, cadmium absorption from cigarettes appears to be higher than absorptions of
cadmium aerosols measured in animals (Nordberg et al. 1985). The chemical form of cadmium in
cigarette smoke is likely to be similar to that produced by other combustion processes, primarily cadmium
oxide aerosols. The greater absorption of cadmium from cigarette smoke is likely due to the very small
size of particles in cigarette smoke and the consequent very high alveolar deposition (Nordberg et al.
1985).
Distribution and Metabolism. Absorbed cadmium is distributed throughout the body, with the
highest concentrations found in the liver and kidneys. Cadmium is not known to undergo direct
metabolic conversions. It has a high affinity for the sulfyhydryl groups of albumin and metallothionein
(Nordberg et al. 1985). The interaction between cadmium and metallothionein plays a critical role in the
CADMIUM 219
3. HEALTH EFFECTS
toxicokinetics and toxicity, as discussed in Section 3.5.2, of cadmium. Metallothionein sequesters a large
fraction of tissue cadmium (Shaikh 1982) and studies in metallothionein transgenic and metallothionein-
null mice suggest that metallothionein influences tissue retention, but may not affect cadmium
distribution to the liver, kidney, pancreas, or spleen (Liu and Klaassen 1996; Liu et al. 1996; Wong and
Klaassen 1980a). Metallothionein turns over with half-lives of 2.8 days in the rat liver and 5 days in the
kidney (Shaikh and Smith 1976); however, cadmium is retained in both organs bound mainly to
metallothionein. It has a retention half-time of 73 days in the liver and a life-time in the kidneys (Shaikh
1982).
Shaikh et al. (1993) report that disposition of cadmium in mouse liver, kidney, and testes is different for
different strains, sex, or age. Different dose levels (i.e., subcutaneous doses in the 5–30 μmol/kg body
weight range) also altered the disposition. Liver cadmium levels and metallothionein levels did not
always correlate with hepatotoxicity. The difference in the tissue accumulation of cadmium may relate to
variations in the hormonal or other intrinsic factors that affect cellular uptake of cadmium, subcellular
distribution of cadmium, or metallothionein metabolism.
Excretion. Since a small fraction of the cadmium presented to the gastrointestinal tract is absorbed,
most of the oral dose is excreted via the feces. After inhalation exposure to cadmium, the initial lung
burden of cadmium-laden particles depositing in the nasopharyngeal or central airways will be cleared via
the mucociliary mechanisms, possibly undergoing a small amount of absorption by the oral route. The
remaining cadmium particles will be absorbed in the lung. Once absorbed cadmium has distributed
throughout the body (primarily to the liver and kidney), the amounts of fecal and urinary excretion of
cadmium are approximately equal. The amount of cadmium in the urine of occupationally exposed
workers increases proportionally with body burden of cadmium, but the amount of cadmium excreted
represents only a small fraction of the total body burden unless renal damage is present; in this case,
urinary cadmium excretion increases markedly (Roels et al. 1981b).
Klaassen and Kotsonis (1977) evaluated biliary excretion of an intravenous bolus of cadmium chloride in
the rat, rabbit, and dog. Marked species variation in biliary excretion was observed with rabbits at about
1/6th the rate of the rats, and dogs about 1/300th the rate of the rats. In the rat, the bile/plasma
concentration ratio of cadmium was highly dose dependent, increasing with higher dose; at 0.1 mg/kg, the
bile/plasma ratio was 2.6 and at 3.0 mg/kg, the bile/plasma ratio was 133. The bile/liver concentration
ratio of cadmium was equal to or much lower than 1 decreasing to <1% for the low dose regimen.
CADMIUM 220
3. HEALTH EFFECTS
3.5.2 Mechanisms of Toxicity
Cadmium is toxic to a wide range of organs and tissues; however, the primary target organs of cadmium
toxicity are the kidneys; bone and lung (following inhalation exposure) are also sensitive targets of
toxicity. Changes in the kidney due to cadmium toxicity have been well established. Chronic exposure to
cadmium by the oral or inhalation routes has produced proximal tubule cell damage, proteinuria (mainly
low-molecular weight proteins, such as β2-microglobulin), glycosuria, amino aciduria, polyuria,
decreased absorption of phosphate, and enzymuria in humans and in a number of laboratory animal
species. The clinical symptoms result from the degeneration and atrophy of the proximal tubules, or (in
worse cases) interstitial fibrosis of the kidney (Stowe et al. 1972). Cadmium has been shown to perturb
lipid composition and enhance lipid peroxidation (Gill et al. 1989b). Depletion of antioxidant enzymes,
specifically glutathione peroxidase and superoxide dismutase, has been proposed as the mechanism of
cadmium’s cardiotoxic effects (Jamall and Smith 1985a), but subsequent studies showed that cardiotoxic
mechanisms other than peroxidation are also present (Jamall et al. 1989). Cadmium has been shown to
alter zinc, iron and copper metabolism (Petering et al. 1979) as well as selenium (Jamall and Smith
1985b). Xu et al. (1995) propose that an initiating step in cadmium-induced toxicity to the testes is
cadmium interference with zinc-protein complexes that control DNA transcription which subsequently
leads to apoptosis. Cadmium sequestration by metallothionein (or a chelator in the case of the Xu et al.
[1995] study) prevents cadmium from disrupting zinc-dependent transcriptional controls.
Cardenas et al. (1992a) investigated a cadmium-induced depletion of glomerular membrane polyanions

and the resulting increased excretion of high-molecular-weight proteins. Interference with glomerular
membrane polyanionic charge may precede the tubular damage as a more sensitive and early response to
cadmium (Roels et al. 1993). Acute or chronic doses of cadmium have also been reported to reduce
hepatic glycogen stores and to increase blood glucose levels. Intralobular fibrosis, cirrhosis, focal
mononuclear infiltrates, and proliferation of the smooth endoplasmic reticulum are among the nonspecific
histopathological indicators of cadmium toxicity.
Cadmium complexed with metallothionein from the liver can redistribute to the kidney (Dudley et al.
1985). When metallothionein-bound cadmium is transported to the kidney, it readily diffuses and is
filtered at the glomerulus, and may be effectively reabsorbed from the glomerular filtrate by the proximal
tubule cells (Foulkes 1978). In the kidneys, exogenous metallothionein is degraded in lysosomes and
released cadmium is sequestered by the endogenous metallothionein as well as other proteins (Cherian
CADMIUM 221
3. HEALTH EFFECTS
and Shaikh 1975; Squibb et al. 1984; Vestergaard and Shaikh 1994). This non-metallothionein-bound
cadmium can then induce new metallothionein synthesis in the proximal tubule (Squibb et al. 1984).
Early work indicated that metallothionein binding decreased the toxicity of cadmium, and the ability of
the liver to synthesize metallothionein appeared to be adequate to bind all the accumulated cadmium
(Goyer et al. 1989; Kotsonis and Klaassen 1978). The rate of metallothionein synthesis in the kidney is
lower than in the liver (Sendelbach and Klaassen 1988), and is thought to be insufficient, at some point, to
bind the intrarenal cadmium (Kotsonis and Klaassen 1978). Renal damage is believed to occur when the
localization of cadmium, or an excessive concentration of cadmium, is unbound to metallothionein.
Acute exposure to low levels of cadmium bound to metallothionein produced an intracellular renal
damage as described above (Squibb et al. 1984), but damage to brush-border membranes of the renal
tubule has also been reported from metallothionein-bound cadmium (Suzuki and Cherian 1987)
suggesting other toxic mechanisms may be present.
Dorian et al. (1992a) evaluated the intra-renal distribution of 109cadmium-metallothionein injected

(intravenously) into male Swiss mice at a nonnephrotoxic dose (0.1 mg Cd/kg) and concluded that
cadmium-metallothionein-induced nephrotoxicity might be due, at least in part, to its preferential uptake
of cadmium-metallothionein into the S1 and S2 segments of the proximal tubules, the site of cadmium-
induced nephrotoxicity. In a companion study, Dorian et al. (1992b) reported that this preferential renal
uptake was also observed after administration of various doses of [35S]cadmium-metallothionein. In
contrast to the earlier observed persistency of 109cadmium in the kidney after 109cadmium-metallothionein
administration, however, 35S disappeared rapidly (with a half-life of approximately 2 hours); 24 hours
after injection of [35S]cadmium-metallothionein, there was very little 35S left in the kidneys. These
observations indicate that the protein portion of cadmium-metallothionein is rapidly degraded after renal
uptake of cadmium metallothionein and that the released cadmium is retained in the kidney.
The toxic effects and distribution of cadmium were compared after intravenous injection of 109cadmium-
metallothionein at 0.05–1 mg Cd/kg body w eight and 109cadmium chloride at 0.1–3 mg/kg in male Swiss
mice (Dorian et al. 1995). Cadmium-metallothionein increased urinary excretion of glucose, and protein
indicated renal injury, with dosages as low as 0.2 mg Cd/kg. In contrast, renal function was unaltered by
cadmium chloride administration, even at dosages as high as 3 mg Cd/kg. Cadmium-metallothionein
distributed almost exclusively to the kidney, whereas cadmium chloride preferentially distributed to the
liver. However, a high concentration of cadmium was also found in the kidneys after cadmium chloride
administration (i.e., the renal cadmium concentration after administration of a high but nonnephrotoxic
CADMIUM 222
3. HEALTH EFFECTS
dose of cadmium chloride was equal to or higher than that obtained after injection of nephrotoxic doses of
cadmium-metallothionein). Light microscopic autoradiography studies indicated that cadmium from
cadmium-metallothionein preferentially distributed to the convoluted segments (S1 and S2) of the
proximal tubules, whereas cadmium from cadmium chloride distributed equally to the various segments
(convoluted and straight) of the proximal tubules. However, the concentration of cadmium at the site of
nephrotoxicity, the proximal convoluted tubules, was higher after cadmium chloride than after cadmium-
metallothionein administration. A higher cadmium concentration in both apical and basal parts of the
proximal cells was found after cadmium chloride than after cadmium-metallothionein administration.
The authors suggest that cadmium-metallothionein is nephrotoxic, and cadmium chloride is not
nephrotoxic because of a higher concentration of cadmium in the target cells after cadmium-
metallothionein. Dorian and Klaassen (1995) evaluated the effects of zinc-metallothionein on
109
cadmium-metallothionein renal uptake and nephrotoxicity and concluded that zinc-metallothionein is
not only nontoxic to the kidney at a dose as high as 5 μmole metallothionein/kg, but it can also protect
against the nephrotoxic effect of cadmium-metallothionein without decreasing renal cadmium
concentration.
To further test the hypothesis that nephrotoxicity produced from chronic cadmium exposure results from a
cadmium-metallothionein complex, Liu et al. (1998) exposed metallothionein-null mice to a wide range
of cadmium chloride doses, 6 times/week for up to 10 weeks. Renal cadmium burden increased with dose
and duration up to 140 μg Cd/g kidney in control mice (i.e., metallothionein normal) with a 150-fold
increase in renal metallothionein levels (800 μg metallothionein/g kidney). Renal cadmium was much
lower in metallothionein-null mice (10 μg Cd/g), and metallothionein levels were not detectable. The
maximum tolerated dose of cadmium (as indicated by routine urinalysis and histopathology measures)
was approximately 8 times higher in control mice than in metallothionein-null mice. Lesions were more
severe in metallothionein-null mice than in controls.
The critical concentration of cadmium in the renal cortex that is likely to produce renal dysfunction also
remains a topic of intense investigation. Whether the critical concentration of urinary cadmium is closer
to 5 or 10 μg Cd/g creatinine, corresponding to about 100 and 200 μg cadmium/g kidney, respectively, is
the current focus of the debate. In one analysis, the critical concentration producing dysfunction in 10%
of a susceptible population has been estimated to be approximately 200 μg cadmium/g kidney; 50% of the
susceptible population would experience dysfunction with a kidney concentration of 300 μg/g (Ellis et al.
1984, 1985; Roels et al. 1983).
CADMIUM 223
3. HEALTH EFFECTS
Studies in humans and animals have demonstrated that the bone is a sensitive target of cadmium toxicity.
It is likely that cadmium acts by direct and indirect mechanisms, which can lead to decreased bone
mineral density and increased fractures (Brzóska and Moniuszko-Jakoniuk 2005c, 2005d). Studies in
young animals suggest that cadmium inhibits osteoblastic activity, resulting in a decrease in the synthesis
of bone organic matrix and mineralization (Brzóska and Moniuszko-Jakoniuk 2005d). The decreased
osteoblastic activity may also influence osteoclastic activity leading to increased bone resorption. During
intense bone growth, effects on osteoblasts result in decreased bone formation; after skeletal maturity,
cadmium exposure results in increased bone resorption. Cadmium-induced renal damage can also result
in secondary effects on bone (Brzóska and Moniuszko-Jakoniuk 2005c). Cadmium-induced renal damage
interferes with the hydroxylation of 25-hydroxy-vitamin D to form 1,25-dihydroxy-vitamin D. Decreased
serum concentration of 1,25-dihydroxy-vitamin D, along with impaired kidney resorptive function, result
in calcium and phosphate deficiency (via decreased gastrointestinal absorption and increased calcium and
phosphate urinary loss). To maintain calcium and phosphate homeostasis, parathyroid hormone is
released, which enhances bone resorption.
3.5.3 Animal-to-Human Extrapolations
The effects of cadmium exposure have been studied in humans and in many laboratory animal species.
The target organs are similar among species, with the kidneys, bone, and lungs (inhalation only) being the
primary organs for cadmium induced toxicity. Absorption, distribution, and excretion of cadmium after
oral and inhalation exposures are roughly similar among species; however, there are some notable
differences and caveats. Most estimates of cadmium absorption in animals are somewhat lower than the
values found from human studies, particularly after prolonged exposure. Differences in the breathing
patterns between rats (obligatory nose breathers) and humans (mouth and nose breathers) may also result
in radically different lung burden patterns (and hence, different absorption profiles) of cadmium particles
in the lungs. Many of the common laboratory animals (in particular the mouse and rat) provide useful
information on the toxic effects of cadmium; due to their relatively short lifespan, however, they may not
be as useful from a risk assessment point of view in determining the human lifetime effects from inhaling
cadmium in air, or ingesting it in food and water. Rates of synthesis and inducibility of metallothionein
also differ among species, sex, and target organ.
Even within species there can be significant differences in metallothionein synthesis, and these
differences correlate to the degree of cadmium toxicity observed (e.g., the mouse) (Shaikh et al. 1993).
The Shaikh et al. (1993) study employed acute exposures. Strain differences in carcinogenic effects have
CADMIUM 224
3. HEALTH EFFECTS
also been reported for chronic exposures of subcutaneously administered cadmium chloride in male DBA
and NFS mice. DBA mice developed lymphomas, while NFS mice developed hepatocellular adenomas
and carcinomas, and sarcomas at the injection site. Both strains developed nonneoplastic testicular
lesions (fibrosis and mineralization) (Waalkes and Rhem 1992).
Metal-metal interactions are also an important factor in cadmium kinetics and toxicity, and organ specific
metal concentrations and metabolism can differ among species. It is thought that further development of
PBPK/PD models will assist in addressing these differences and in extrapolating the animal data to
support risk assessments in humans.
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine
system because of the ability of these chemicals to mimic or block endogenous hormones. Chemicals
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate
terminology to describe such effects remains controversial. The terminology endocrine disruptors,
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to
develop a screening program for “...certain substances [which] may have an effect produced by a
naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to
convey the fact that effects caused by such chemicals may not necessarily be adverse. Many scientists
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to
the health of humans, aquatic animals, and wildlife. However, others think that endocrine-active
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist
in the natural environment. Examples of natural hormone mimics are the isoflavinoid phytoestrogens
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992). These chemicals are derived from plants and are
similar in structure and action to endogenous estrogen. Although the public health significance and
descriptive terminology of substances capable of affecting the endocrine system remains controversial,
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction,
development, and/or behavior (EPA 1997a). Stated differently, such compounds may cause toxicities that
CADMIUM 225
3. HEALTH EFFECTS
are mediated through the neuroendocrine axis. As a result, these chemicals may play a role in altering,
for example, metabolic, sexual, immune, and neurobehavioral function. Such chemicals are also thought
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994;
Giwercman et al. 1993; Hoel et al. 1992).
No studies were located regarding endocrine disruption in humans and/or animals after exposure to
cadmium.
No in vitro studies were located regarding endocrine disruption of cadmium.
3.7 CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to
maturity at 18 years of age in humans, when all biological systems will have fully developed. Potential
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.
Relevant animal and in vitro models are also discussed.
Children are not small adults. They differ from adults in their exposures and may differ in their
susceptibility to hazardous chemicals. Children’s unique physiology and behavior can influence the
extent of their exposure. Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993). Children may be more or less
susceptible than adults to health effects, and the relationship may change with developmental age
(Guzelian et al. 1992; NRC 1993). Vulnerability often depends on developmental stage. There are
critical periods of structural and functional development during both prenatal and postnatal life, and a
particular structure or function will be most sensitive to disruption during its critical period(s). Damage
may not be evident until a later stage of development. There are often differences in pharmacokinetics
and metabolism between children and adults. For example, absorption may be different in neonates
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants
and young children (Ziegler et al. 1978). Distribution of xenobiotics may be different; for example,
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are
CADMIUM 226
3. HEALTH EFFECTS
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek
1966; Widdowson and Dickerson 1964). The infant also has an immature blood-brain barrier (Adinolfi
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975). Many
xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages of growth
and development, levels of particular enzymes may be higher or lower than those of adults, and
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and
Kearns 1997; NRC 1993; Vieira et al. 1996). Whether differences in xenobiotic metabolism make the
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of
the parent compound to its toxic form or in detoxification. There may also be differences in excretion,
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).
Children and adults may differ in their capacity to repair damage from chemical insults. Children also
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others
may decrease susceptibility to the same chemical. For example, although infants breathe more air per
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar
absorption (NRC 1993).
Occupational and environmental exposure studies in adults provide strong evidence that the lung
(inhalation exposure only) and kidneys are sensitive targets of toxicity; it is likely that these effects would
also be seen in children. Because cadmium is a cumulative toxin and has a very long half-time in the
body, exposures to children in even low amounts may have long-term adverse consequences. Average
cadmium concentrations in the kidney are near zero at birth, and rise roughly linearly with age to a peak
(typically around 40–50 μg/g wet weight) between the ages of 50 and 60 years, after which kidney
concentrations plateau or decline (Chung et al. 1986; Hammer et al. 1973; Lauwerys et al. 1984). There
are limited data on the renal toxicity of cadmium in children. One study found significant associations
between urinary and blood cadmium levels with urinary levels of NAG and retinol binding protein (de
Burbure et al. 2006); however, the investigators cautioned that the early response observed in this group
of children exposed to elevated levels of cadmium (and other metals) may reflect an early renal response
that may be adaptive and/or reversible. Another study (Trzcinka-Ochocka et al. 2004) found higher
urinary concentrations of β2-microglobulin and retinol binding protein in a population exposed to high
CADMIUM 227
3. HEALTH EFFECTS
levels of cadmium starting in childhood as compared to a group only exposed as adults even though
urinary cadmium levels were lower (statistical comparisons of urinary cadmium levels were not made
between the groups). These data suggest that adults exposed to cadmium as children may be more
susceptible to the renal toxicity of cadmium than persons only exposed as adults. This is supported by the
findings of Jacquillet et al. (2007) of renal damage in mature rats exposed to cadmium via gestation and
lactation.
There are epidemiological data suggesting that the bone is also a sensitive target of cadmium toxicity
(Åkesson et al. 2005; Alfvén et al. 2000, 2002a, 2004; Aoshima et al. 2003; Jin et al. 2004b; Nordberg et
al. 2002; Staessen et al. 1999; Wang et al. 2003; Zhu et al. 2004). Epidemiology studies suggest that the
elderly may be more susceptible than younger adults; however, no studies examined childhood exposure.
Animal studies suggest that young animals are more susceptible than adult or elderly animals (Ogoshi et
al. 1989).
A potential for cadmium to have adverse neurological effects is an important consideration. However,
only a few studies have reported an association between environmental cadmium exposure and
neuropsychological functioning. End points that were affected included verbal IQ in rural Maryland
children (Thatcher et al. 1982), and acting-out and distractibility in rural Wyoming children (Marlowe et
al. 1985). The usefulness of the data from these studies is limited, however, because of the potential
confounding effects of lead exposure; lack of control for other possible confounders including home
environment, caregiving, and parental IQ levels; and inadequate quantification of cadmium exposure (i.e.,
the studies used hair cadmium as an index of exposure, which has some limitations because of potential
confounding from exogenous sources). Several animal studies have reported alterations in performance
on neurobehavioral tests in rats exposed to cadmium via gestation and lactation (Ali et al. 1986; Baranski
et al. 1983; Desi et al. 1998; Nagymajtenyi et al. 1997). Several studies have examined the possible
association between cadmium exposure and newborn birth weight, and most reliable studies have not
found a significant association (Galicia-García et al. 1997; Mokhtar et al. 2002; Nishijo et al. 2002,
2004b; Zhang et al. 2004). Animal studies have found significant decreases in body weight or skeletal
anomalies or malformations in the offspring of rats exposed to high doses of cadmium (Ali et al. 1986;
Baranski 1985, 1987; Gupta et al. 1993; Kelman et al. 1978; Kostial et al. 1993; Machemer and Lorke
1981; Petering et al. 1979; Pond and Walker 1975; Schroeder and Mitchener 1971; Sorell and Graziano
1990; Sutou et al. 1980; Webster 1978; Whelton et al. 1988).
CADMIUM 228
3. HEALTH EFFECTS
Oral cadmium exposure has also been reported to suppress the T-lymphocyte and macrophage-dependent
humoral immune response of 6-week-old mice against sheep red blood cells (Blakley 1985), but not of
12-month-old mice (Blakley 1988). The investigators cautioned that “natural” age-related immune
system dysfunction may have masked any cadmium suppressive effect.
Children are most likely to be exposed to cadmium in food or water. Most ingested cadmium passes
through the gastrointestinal tract without being absorbed. In adults, only about 1/20 of the total ingested
cadmium (in food or water) is absorbed (McLellan et al. 1978, Rahola et al. 1973; Shaikh and Smith
1980). The retention of cadmium in the gut slowly decreases over a period of 1–3 weeks after ingestion
in adults (Rahola et al. 1973). The absorption of cadmium in rats depends on age, with measured
absorption decreasing from 12 to 5 to 0.5% at 2 hours, 24 hours, and 6 weeks after birth, respectively
(Sasser and Jarboe 1977). Sasser and Jarboe (1980) also reported that absorption of cadmium in the
gastrointestinal tract of young guinea pigs was 20-fold higher than in adult guinea pigs.
Tissue distribution and retention of cadmium differed between 4- and 70-day-old rats. Cadmium was 3–
6 times more concentrated in the newborn spleen, bone, brain, testes, and muscle than in the adult rat
2 hours after an intravenous administration of 1 mg Cd/kg body weight. Liver concentration of
metallothionein was 20 times greater in the newborn than in the adult; kidney metallothionein concen-
trations were comparable, but liver cadmium was only 30% higher and kidney cadmium was 50% higher
in the newborn. Nineteen days post-cadmium exposure, the retention of cadmium in the liver, kidney,
and lung was similar in both the newborn and the adult rat (Wong and Klaassen 1980a). Goering and
Klaassen (1984b) report that high levels of metallothionein in 10-day-old rats play an important role in
their resistance to liver damage, presumably by binding and retaining cadmium. However, the tissue
distribution data led Wong and Klaassen (1980a) to propose that metallothionein does not play a major
role in the tissue distribution and retention of cadmium in the young.
Cadmium can be transferred to offspring in breast milk. Cadmium levels in human milk are 5–10% of
levels in blood, possibly due to inhibited transfer from blood because of metallothionein binding of
cadmium in blood cells (Radisch et al. 1987). A significant association between urinary cadmium levels
and cadmium levels in breast milk was found in women environmentally exposed to cadmium (Nishijo et
al. 2002). In female outbred albino rats exposed to cadmium in drinking water (as cadmium chloride) at
0 or 4.8 mg/kg/day for 10 weeks (at 4 weeks prior to mating, 3 weeks of gestation, or 3 weeks into
lactation), kidney concentrations exceeded liver concentrations, while in their pups, the renal and liver
concentrations were similar at all times during exposure. In pups, both hepatic and renal cadmium
CADMIUM 229
3. HEALTH EFFECTS
concentrations considerably increased only during the second half of the lactation period (Ld 11–21). The
cadmium tissue concentrations in dams were several orders higher than in offspring. Another study found
a positive correlation between cadmium levels in breast milk and cadmium levels in the pups’ kidneys in
rats receiving an intravenous injection of cadmium on lactation days 3–16 (Petersson Grawé and
Oskarsson 2000).
Although studies on elimination of cadmium from the tissues of children are not available, the results of
studies in animals provide some insight. Most cadmium that is ingested or inhaled and transported to the
gut via mucociliary clearance is excreted in the feces. Of the cadmium that is absorbed into the body,
most is excreted very slowly, with urinary and fecal excretion being approximately equal (Kjellström and
Nordberg 1978). Half-times for cadmium in the whole body of mice, rats, rabbits, and monkeys have
been calculated to be from several months up to several years (Kjellström and Nordberg 1985). Half-
times in the slowest phase were 20–50% of the maximum life span of the animal (Kjellström and
Nordberg 1985). In the human body, the main portion of the cadmium body burden is found in the liver
and kidney and in other tissues (particularly muscle, skin, and bone). After reviewing the literature,
Kjellström and Nordberg (1985) developed a range of half-times from their kinetic model of between
6 and 38 years for the human kidney and between 4 and 19 years for the human liver. These high values
indicate the persistence of cadmium in the body and the importance of minimizing exposures in children
to prevent long-term accumulation and toxicity.
(Kuhnert et al. 1982); however, in another study in Czechoslovakia, the concentration of cadmium in the
placenta was found to be less than in either maternal or cord blood (Truska et al. 1989). In mice orally
exposed to cadmium during pregnancy, maternal blood, placental, and fetal cadmium concentrations were
essentially equal among control animals (with environmental cadmium exposure), but placental
concentration increased with cadmium dose much more rapidly than either maternal blood or fetal
cadmium concentration (Sorell and Graziano 1990). Thus, timing and level of cadmium exposure may
influence the uptake of cadmium by the placenta, perhaps explaining the conflicting human studies.
CADMIUM 230
3. HEALTH EFFECTS
Of particular importance to the toxicokinetics and toxicity of cadmium is its interaction with the protein
metallothionein. Metallothionein is a low-molecular-weight protein, very rich in cysteine, which is
capable of binding as many as seven cadmium atoms per molecule and is inducible in most tissues by
exposure to cadmium, zinc, and other metals (Waalkes and Goering 1990). Metallothionein binding
decreases the toxicity of cadmium (Goyer et al. 1989; Kotsonis and Klaassen 1978). Goyer and Cherian
(1992) localized metallothionein in full-term human placenta and in fetal cells in human placenta.
Metallothionein was present in trophoblasts (which facilitate transport of substances entering the placenta
from the maternal blood), Hofbauer cells (motile macrophages capable of phagocytosis and protein
ingestion), amniotic epithelial cells (fetal derivatives), and decidual cells (endometrial stromal cells that
have been transformed under hormonal influence into large pale cells, rich in glycogen). The mechanism
by which the placenta transports the essential metals, copper and zinc, while limiting the transport of
cadmium is unknown, but may involve the approximately 1,000-fold higher concentration of zinc in the
placenta and the higher affinity of cadmium than zinc for metallothionein.
Chan and Cherian (1993) report that pregnancy in Sprague-Dawley rats previously administered cadmium
chloride (1.0 mg Cd/kg body weight subcutaneously, daily for 8 days) leads to a mobilization of cadmium
from the liver (40% decrease compared to nonpregnant cadmium treated controls) and an increase in the
kidneys (60% increase). A similar pattern is seen for metallothionein. Plasma cadmium and
metallothionein also increased in the pregnant group. Placental cadmium increased in the cadmium-
treated rats compared to the untreated controls. In this rat model, then, pregnancy resulted in a transfer of
hepatic cadmium and metallothionein via the blood to the kidney and placenta.
3.8 BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC
1989).
The National Report on Human Exposure to Environmental Chemicals provides an ongoing assessment
of the exposure of the U.S. population to environmental chemicals using biomonitoring. This report is
available at http://www.cdc.gov/exposurereport/. The biomonitoring data for cadmium from this report is
discussed in Section 6.5. A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the
product of an interaction between a xenobiotic agent and some target molecule(s) or cell(s) that is
measured within a compartment of an organism (NAS/NRC 1989). The preferred biomarkers of exposure
CADMIUM 231
3. HEALTH EFFECTS
are generally the substance itself, substance-specific metabolites in readily obtainable body fluid(s), or
excreta. However, several factors can confound the use and interpretation of biomarkers of exposure.
The body burden of a substance may be the result of exposures from more than one source. The
substance being measured may be a metabolite of another xenobiotic substance (e.g., high urinary levels
of phenol can result from exposure to several different aromatic compounds). Depending on the
properties of the substance (e.g., biologic half-life) and environmental conditions (e.g., duration and route
of exposure), the substance and all of its metabolites may have left the body by the time samples can be
taken. It may be difficult to identify individuals exposed to hazardous substances that are commonly
found in body tissues and fluids (e.g., essential mineral nutrients such as copper, zinc, and selenium).
Biomarkers of exposure to cadmium are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an
organism that, depending on magnitude, can be recognized as an established or potential health
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung
capacity. Note that these markers are not often substance specific. They also may not be directly
adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers of effects caused
by cadmium are discussed in Section 3.8.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability

to respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic or
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the
biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Cadmium
Cadmium levels in blood, urine, feces, liver, kidney, hair, and other tissues have been used as biological
indicators of exposure to cadmium. A discussion of the utility and limitations of each for human
biomonitoring is provided below.
Blood cadmium levels are principally indicative of recent exposure(s) to cadmium rather than whole-body
burdens (Ghezzi et al. 1985; Järup et al. 1988; Lauwerys et al. 1994; Roels et al. 1989). The 50th
CADMIUM 232
3. HEALTH EFFECTS
percentile of blood cadmium concentrations in adults living in the United States was 0.330 μg/L (CDC
2011). Environmental exposure can elevate blood cadmium concentration to above 10 μg/L (Kido et al.
1990a, 1990b; Shiwen et al. 1990). Workers occupationally exposed to cadmium by inhalation may have
blood cadmium levels ranging up to 50 μg/L (Roels et al. 1981b).
Urine cadmium levels primarily reflect total body burden of cadmium, although urine levels do respond
somewhat to recent exposure (Bernard and Lauwerys 1986). Use of a biokinetic model, such as the
Nordberg-Kjellström model, allows estimation of cadmium dietary consumption or airborne cadmium
levels from urinary cadmium levels; these models are described in greater detail in Section 3.4.5.3. When
the critical level for renal damage has been reached, urinary cadmium levels rise sharply because of the
release of intrarenal cadmium along with decreased renal reabsorption of cadmium (Lauwerys et al. 1994;
Roels et al. 1981b). In the U.S. general population, the geometric mean urinary cadmium level in adults
is 0.232 μg/L (or 0.247 μg/g creatinine) (CDC 2011). In populations with substantial environmental or
occupational exposure, values can range up to 50 μg/g creatinine, (Falck et al. 1983; Roels et al. 1981b;
Tohyama et al. 1988). In environmentally exposed individuals, Buchet et al. (1990) report that abnormal
values of various biomarkers are found in 5% of the population with urinary excretion of cadmium above
the 2–4 μg Cd/24 hour level (approximately 1–3 μg/g creatinine). Significant correlations between total
cadmium exposure and urinary cadmium levels have been found in environmentally exposed populations
(Kido et al. 2004; Kobayashi et al. 2005; Shimbo et al. 2000). Among environmentally exposed subjects,
there was good agreement between urinary cadmium levels measured at different times, suggesting that a
single determination would be an accruement measure (Ikeda et al. 2005a).
Fecal cadmium may be used as a direct indicator of daily dietary intake of cadmium because dietary
cadmium is poorly absorbed in the gastrointestinal tract (Kjellström et al. 1978). In workers exposed by
inhalation, fecal cadmium has been used to estimate the amount of inhaled cadmium transported to the
gastrointestinal tract and the amount of dust ingested incidentally at work (Adamsson et al. 1979). Fecal
cadmium primarily reflects recently ingested cadmium and, therefore, is not a good indicator of past
cadmium exposure (Shaikh and Smith 1984).
Liver and kidney tissues preferentially accumulate cadmium, and concentrations of cadmium in liver and
kidney may be measured using non-invasive techniques such as in vivo neutron activation analysis or in
the kidney by X-ray fluorescence analysis (Christoffersson et al. 1987; Scott and Chettle 1986); however,
the limit of detection is near background levels (Nordberg 2010). Levels in both tissues increase with age
and level of cadmium exposure, but kidney cadmium concentration tends to peak around age 50–60,
CADMIUM 233
3. HEALTH EFFECTS
while liver cadmium concentration continues to rise. Typical values for a 60-year-old North American
with average environmental cadmium exposure are 25–40 μg/g wet weight in kidney cortex and 1–3 μg/g
wet weight in liver (Elinder 1985b). In workers exposed to cadmium by inhalation, values up to 300 μg/g
wet weight in kidney and 100 μg/g wet weight in liver can be found (Christoffersson et al. 1987; Roels et
al. 1981b). Because kidney cadmium content begins to decline after the onset of cadmium-induced renal
dysfunction, liver cadmium may be a better indicator of cadmium exposure than kidney cadmium, and it
has been suggested that kidney dysfunction is likely to appear at liver cadmium concentrations between
30 and 60 μg/g wet weight (Roels et al. 1981b). In vivo liver and kidney cadmium measurements
involving neutron activation analysis or X-ray fluorescence require complex and costly equipment and
may pose a radiation hazard (Shaikh and Smith 1984), and those involving biopsy specimens (Lindqvist
et al. 1989) require a painful and invasive procedure. Therefore, these methods for in vivo analysis are
better suited for monitoring of occupationally exposed workers than environmentally exposed populations
(Scott and Chettle 1986). Among cadmium workers, significant correlations of kidney cadmium levels
with urinary and blood cadmium levels and liver cadmium with urinary cadmium levels were found
(Börjesson et al. 1997, 2001). Similar correlations (urinary cadmium with renal cadmium) in an autopsy
study of subjects without occupational exposure to cadmium; a urinary cadmium level of 1.7 μg/g
creatinine was equivalent to a renal cadmium level of 50 μg/g (Orlowski et al. 1998).
Hair levels of cadmium have been used as a measure of cadmium exposure, although the possibility of
exogenous contamination has led to substantial controversy concerning the reliability of hair levels as a
measure of absorbed dose (Frery et al. 1993; Huel et al. 1984; Lauwerys et al. 1994, Shaikh and Smith
1984; Wilhelm et al. 1990). Recent evidence has shown a correlation between cadmium levels in the hair
of newborn infants and their mothers (Huel et al. 1984) and between cadmium levels in scalp and pubic
hair (Wilhelm et al. 1990), indicating that among environmentally exposed populations, external
contamination may not be significant for hair samples taken close to the scalp. Under occupational
conditions, external contamination may be a more substantial problem (Shaikh and Smith 1984).
On the other hand, Frery et al. (1993) evaluated hair levels in a male population with a high expected
exposure to tobacco smoke and in a population of pregnant woman and their newborns; they concluded
that cadmium hair analysis was a reliable indicator for the subjects with the highest exposure, but was not
sensitive enough to resolve differences for low level exposures. Newborn cadmium hair levels were a
more sensitive indicator than mother’s hair, but the research was not able to determine if this was
attributable to physiological changes or the lower reliability of the mother’s head hair. Exogenous
contamination is not considered a problem for newborn hair. The authors state that the variability
CADMIUM 234
3. HEALTH EFFECTS
introduced by exogenous contamination can be minimized by using the first 8 cm of hair from the scalp
and by using careful washing techniques. There was also no significant difference between hair levels for
passive or nonsmokers indicating that either the above mentioned precautions worked or that the passive
smoke source of exposure was not significant.
Cadmium measurements have been made on a variety of other biological materials, including milk
(Schulte-Lobbert and Bohn 1977; Sikorski et al. 1989), placenta (Kuhnert et al. 1982; Roels et al. 1978;
Saaranen et al. 1989), nails (Takagi et al. 1988), teeth (Sharon 1988), and cataractous lenses (Racz and
Erdohelyi 1988). Although in some cases it could be established that levels in these tissues were higher
among smokers than nonsmokers, the significance of cadmium levels as a marker of recent or total
cadmium exposure has not been established for any of these tissues.
Studies in cadmium workers suggest that metallothionein levels may also be a biomarker of cadmium
exposure. Elevated levels of metallothionein gene expression were observed in peripheral blood
lymphocytes in highly exposed workers. The level of metallothionein gene expression was significantly
correlated with blood and urinary cadmium levels (Lu et al. 2001). Urinary metallothionein correlates
with cadmium concentrations in liver, kidney, and urine (Shaikh and Smith 1984; Tohyama et al. 1981).
Relatively strong correlations have been found between urinary metallothionein and urinary cadmium
levels in exposed humans (Kawada et al. 1990), and a dose-related increase in urinary metallothionein
was found in rats exposed to cadmium in drinking water for up to 2 years (Shaikh et al. 1989). Hochi et
al. (1995) also found a significant relationship between cadmium intake and urinary metallothionein
levels among residents consuming cadmium-contaminated rice.
3.8.2 Biomarkers Used to Characterize Effects Caused by Cadmium
Acute inhalation exposure to high levels of cadmium causes respiratory damage and may lead to death.
No information was located on biomarkers of respiratory effects in humans, but based on animal
experiments, activity of alkaline phosphatase in the surfactant fraction of BALF has been suggested as a
sensitive marker of pulmonary damage following acute cadmium inhalation (Boudreau et al. 1989). Such
a biomarker of effect is not specific to cadmium exposure and would be most relevant to occupational
exposures.
Renal dysfunction, usually first manifested as impaired tubular reabsorption of filtered solutes, is
generally considered the primary toxic effect of chronic cadmium exposure (see Section 3.2). Impaired
CADMIUM 235
3. HEALTH EFFECTS
kidney function has been measured by increased levels of solutes (proteins, amino acids, uric acid,
calcium, copper, phosphorous, etc.) in urine and/or serum. Excess urinary excretion of low-molecular-
weight proteins and solutes is associated with decreased tubular reabsorption. Increased excretion of
high-molecular-weight proteins or decreased serum clearance of creatinine reflect glomerular
dysfunction, which is generally associated with progressive renal damage (Roels et al. 1989). A brief
discussion of the utility and limitations of several measures of tubular damage as biomarkers of effects of
cadmium exposure is provided below. These biomarkers are normally found in the urine and elevated
levels are not specific for cadmium.
Urinary β2-microglobulin, a low molecular weight protein, has been widely used as an indicator of
tubular renal dysfunction (Arisawa et al. 1997; Piscator 1984; Roels et al. 1981a; Smith et al. 1980).
However, tubular renal dysfunction can be caused by exposures and diseases other than cadmium, so
β2-microglobulin is not a specific marker of cadmium-induced effects (Shaikh and Smith 1984).
Practical considerations in using urinary β2-microglobulin as a marker of tubular renal dysfunction
include the need to control the pH of samples to prevent the rapid degradation that occurs at pH values
below 5.5 (Shaikh and Smith 1984), and the fact that urinary β2-microglobulin excretion normally rises
with age (Roels et al. 1989).
Urinary retinol-binding protein is also considered to be a sensitive indicator of decreased tubular

reabsorption, but it also is not specific for cadmium-induced damage in the kidney (Shaikh and Smith
1984; Topping et al. 1986). Retinol-binding protein is more stable in urine than β2-microglobulin
(Bernard and Lauwerys 1981) and appears to be of approximately equal sensitivity and specificity for
detecting tubular proteinuria in cadmium-exposed populations (Topping et al. 1986). Levels of both
proteins fluctuate over time, so regular, repeated sampling may be necessary to establish abnormal levels
(Ormos et al. 1985).
Human complex-forming glycoprotein (pHC, also referred to as α1-microglobulin) is another sensitive

marker of tubular renal dysfunction (Moriguchi et al. 2004, 2005a; Pless-Mulloli et al. 1998; Tohyama et
al. 1986). As with retinol binding protein, pHC is more stable in urine than β2-microglobulin at room
temperature and low urinary pH levels.
Urinary N-acetyl-β-D-glucosaminidase (NAG), a lysosomal enzyme present in high concentrations in the

proximal tubule, has been shown to correlate with urinary cadmium levels in occupationally and
environmentally exposed subjects (Jin et al. 1999; Kalahasthi et al. 2007) and has a better correlation with
CADMIUM 236
3. HEALTH EFFECTS
urinary cadmium levels than does β2-microglobulin at low cadmium exposure levels (urinary cadmium
<10 μg/g creatinine) (Chia et al. 1989; Kawada et al. 1990; Mueller et al. 1989). However, increased
urinary NAG activity can result from effects other than nephrotoxicity (Bernard and Lauwerys 1989). Jin
et al. (1999) suggest that measurement of the B isozyme (NAG-B), which is released into the urine
following tubular cell breakdown, may be a sensitive measure of renal damage.
Other enzymes, proteins, and amino acids in urine have been suggested as biological markers of incipient
renal or liver damage resulting from cadmium exposure. Markers found to be sensitive indicators in
exposed humans include trehalase (Iwata et al. 1988), alanine aminopeptidase (Mueller et al. 1989), and
calcium (Buchet et al. 1990). Changes in urinary alkaline phosphatase, γ-glutamyl transferase, urate, and
phosphate tend to be significant only after other markers of renal damage are clearly elevated (Mason et
al. 1988). Several other enzymatic markers of cadmium-induced renal damage have been suggested
based on animal studies (Bomhard et al. 1984; Gatta et al. 1989; Girolami et al. 1989). Aminoaciduria
has been found to be more sensitive than proteinuria for renal damage in animal studies (Nomiyama et al.
1975), but less sensitive in humans (Axelsson and Piscator 1966). Recent work by Prozialeck et al.
(2007) suggest that kidney injury molecule 1 may be a sensitive marker for renal dysfunction. At present,
not enough information is available to determine which, if any, of these parameters provide sensitive and
specific indicators of cadmium-induced renal damage.
At the present time, there is no single biological indicator for cadmium toxicity that is entirely adequate
when considered alone. Measurement of cadmium levels in various biological materials can provide an
indication of recent or total cadmium exposure, but the probability of adverse effects cannot be reliably
predicted except at high exposure levels. Measurement of a variety of markers of renal dysfunction can
provide a sensitive measure of early kidney toxicity, but cannot establish whether cadmium exposure was
the cause.
There is also considerable controversy as to whether the critical concentration of urinary cadmium is
closer to 5 or 10 μg Cd/g creatinine, corresponding to about 100 and 200 ppm in the kidney, respectively.
Roels et al. (1993) correlated a number of markers with cadmium in blood and urine in a study population
of workers occupationally exposed to cadmium from cadmium smelting operations. Three main
groupings of thresholds were identified corresponding with different markers of effects: one around 2 μg
Cd/g creatinine mainly associated with biochemical alterations (increased urinary 6-keto-prostaglandin
F1x and urinary sialic acid), a second around 4 μg Cd/g creatinine associated with increased excretion of
high molecular weight proteins (possibly due to disruption of the glomerular membrane polyanionic
CADMIUM 237
3. HEALTH EFFECTS
charge) and tubular antigens or enzymes (BBA, NAG), and a third around 10 μg Cd/g creatinine
associated with increased excretion of low molecular weight proteins and other indicators. The 10 μg
Cd/g creatinine level had previously been proposed as the biological threshold for cadmium-induced
nephropathy. Whether the earlier changes are indicative of irreversible adverse renal effects remains an
area of continued investigation.
To further evaluate the reversibility of proteinuria, Roels et al. (1997) studied the progression of
cadmium-induced renal tubular dysfunction in cadmium workers according to the severity of the
microproteinuria at the time the exposure was substantially decreased. A total of 32 cadmium male
workers were divided into two groups on the basis of historical records of urinary cadmium concentration
(CdU) covering the period until 1984. The workers with CdU values of >10 μg Cd/g creatinine were
subdivided further on the basis of the urinary concentration of β2-microglobulin (β2-MG-U) measured
during the first observation period (1980–1984). In each group, the tubular microproteinuria as reflected
by β2-MG-U and the concentration of retinol-binding protein in urine as well as the internal cadmium
dose as reflected by the concentration of cadmium in blood and urine were compared between the first
and second (1990–1992) observation periods. Increased microproteinuria was often diagnosed in cases
with CdU values of >10 μg Cd/g creatinine. The progression of tubular renal function was found to
depend on the extent of the body burden of cadmium (as reflected by CdU) and the severity of the initial
microproteinuria at the time high cadmium exposure was reduced or ceased. When cadmium exposure
was reduced and β2-MG-U did not exceed the upper reference limit of 300 μg/g creatinine, the risk of
developing tubular dysfunction at a later stage was likely to be low, even in cases with historical CdU
values occasionally >10 but always <20 μg Cd/g creatinine. When the microproteinuria was mild
(β2-MG-U >300 and ≤1,500 μg/g creatinine) at the time exposure was reduced, and the historical CdU
values had never exceeded 20 μg Cd/g creatinine, there was indication of a reversible tubulotoxic effect
of cadmium. When severe microproteinuria (β2-MG-U >1,500 μg/g creatinine) was diagnosed in
combination with historical CdU values exceeding 20 μg Cd/g creatinine, Cd-induced tubular dysfunction
was progressive in spite of reduction or cessation of cadmium exposure.
For more information on biomarkers for renal and hepatic effects of chemicals see Agency for Toxic
Substances and Disease Registry Subcommittee Report on Biological Indicators of Organ Damage
(Agency for Toxic Substances and Disease Registry 1990a). For information on biomarkers for
neurological effects see OTA (1990).
CADMIUM 238
3. HEALTH EFFECTS
3.9 INTERACTIONS WITH OTHER CHEMICALS
Cadmium toxicity can be influenced by a wide variety of other chemicals. In humans, dietary
deficiencies of calcium, protein, and vitamin D are likely to account for increased susceptibility to bone
effects following cadmium exposure (Kjellström 1986c). Iron deficiency has been shown to increase
gastrointestinal absorption of cadmium in humans (Flanagan et al. 1978), while oral zinc supplementation
has been demonstrated to decrease the oral absorption of cadmium. No other information was located
concerning interaction of cadmium with other chemicals in humans.
In animals, a few interactions following inhalation exposure have been evaluated. In rats exposed to
cadmium chloride by inhalation, simultaneous exposure to zinc oxide prevents fatalities (Oldiges and
Glaser 1986) and lung cancer (Oldiges et al. 1989). Exposure to an atmosphere containing 80% oxygen
aggravated pulmonary damage from cadmium chloride inhalation in mice (Martin and Witschi 1985).
The toxicity of oral exposure to cadmium in animals has been shown to be influenced by several factors.
In Japanese quail, cadmium toxicity was intensified by single or combined deficiencies of zinc, copper,
iron, calcium, and protein (Fox et al. 1979). A calcium-deficient diet in animals has been shown to
aggravate cadmium immunotoxicity (Chopra et al. 1984) and fetotoxicity (Pond and Walker 1975).
Simultaneous exposure to lindane increased the developmental toxicity of cadmium in rats (Saxena et al.
1986). Female rats have an increased susceptibility to cadmium-induced bone loss due to multiple rounds
of gestation and lactation (Bhattacharyya et al. 1988b) or ovariectomy (Bhattacharyya et al. 1988c),
possibly related to associated effects on trace element status. Hopf et al. (1990) report that exposure to
ethanol and cadmium in a liquid diet produced liver damage in rats at doses that were not separately
hepatotoxic. In contrast, Kershaw et al. (1990) reported that ethanol pretreatment in male Sprague-
Dawley rats substantially reduced the lethal and hepatotoxic properties of cadmium, possibly due to a
reduced interaction between cadmium and target sites in liver organelles and cytosolic high-molecular-
weight (HMW) proteins. Ethanol pretreatment in this study decreased (approximately 60%) the content
of cadmium in nuclei, mitochondria, and endoplasmic reticulum, and nearly eliminated the association of
cadmium with cytosolic HMW proteins. Reduction in the concentration of cadmium in potential target
sites of intoxication was caused by a metallothionein-promoted sequestration of cadmium to the cytosol.
When cadmium is co-administered with ethanol in rats, there is a pronounced increase in cadmium
accumulation in various regions of the brain (e.g., the corpus striatum and cerebral cortex). The cadmium
is not bound to metallothionein, and there is a marked increase in lipid peroxidation and inhibition of
CADMIUM 239
3. HEALTH EFFECTS
membrane bound enzymes (Pal et al. 1993a, 1993b). Rats pretreated with acetaminophen are more
sensitive to the renal toxicity of cadmium in water (Bernard et al. 1988a). Co-administration of lead and
cadmium in the diet of rats had additive effects in reducing body weights, but neurologic toxicity was
antagonized (Nation et al. 1990).
Numerous interactions have been demonstrated in animals using parenteral exposure, generally indicating
that induction of metallothionein by pretreatment with zinc, selenium, or other metals, reduces toxicity of
parenteral cadmium exposure (Gunn et al. 1968a, 1968b; Naruse and Hayashi 1989; Yamane et al. 1990).
Zinc, calcium, or magnesium can prevent injection site, testicular, and prostatic cancers induced by
subcutaneous or intramuscular injection of cadmium, but these interactions have been shown to be a
complex phenomenon, dependent on dose, route, and target organ (Poirier et al. 1983; Waalkes et al.
1989). Mn(II) pretreatment reduces Cd(II)-induced lethality (Goering and Klaassen 1985). Cadmium has
been noted to have an inhibitory effect on manganese uptake (Gruden and Matausic 1989). In addition,
manganese appears to be capable of increasing the synthesis of the metal-binding protein metallothionein
(Waalkes and Klaassen 1985). Data from a study by Goering and Klaasen (1985) suggest that manganese
pretreatment increases the amount of Cd+2 bound to metallothionein, thereby decreasing hepatotoxicity
due to unbound Cd+2. The significance of these observations to humans exposed to cadmium and
manganese by the oral or inhalation routes is not clear.
Induction of hepatic metallothionein by cold stress reduced the acute toxicity of cadmium given by
gavage to mice (Baer and Benson 1987). In addition to effects on metallothionein induction, substances
may interact with cadmium by altering the competition among metal ions for enzyme or regulatory
protein binding sites. For example, simultaneous administration of garlic (which is high in reduced
sulfhydryl groups) decreases oral cadmium renal toxicity in rats (Cha 1987).
Coexposure to selenium reduced the clastogenic effect of cadmium on mouse bone marrow (Mukherjee et
al. 1988b). Selenium deficiency enhances cadmium-induced cardiotoxicity possibly mediated via lipid
peroxidation indicated by a significant reduction in the activities of the selenoenzyme, glutathione
peroxidase. Selenium supplements in the diet prevented cadmium’s cardiotoxic effect (Jamall and Smith
1985a). Selenium has also been shown to prevent testicular damage in rats (Kar et al. 1960; Omaye and
Tappel 1975). In testes, selenium as selenite given before or during cadmium administration was shown
to divert the binding of cadmium from low molecular proteins to higher molecular weight proteins (Chen
et al. 1975; Whanger 1992). In contrast, Jamall and Smith (1985c) report a shift in cadmium binding
from metallothionein to lower weight proteins in kidney and liver from a diet supplemented with
CADMIUM 240
3. HEALTH EFFECTS
selenium compared to a selenium deficient diet. The selenium-cadmium interaction thus appears to be
dependent on the duration and sequence of coexposure and possibly the organ-specific levels of
selenoenzymes or other essential metals.
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
A susceptible population will exhibit a different or enhanced response to cadmium than will most persons
exposed to the same level of cadmium in the environment. Reasons may include genetic makeup, age,
health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke). These
parameters result in increased absorption, reduced detoxification or excretion of cadmium, or
compromised function of organs affected by cadmium. Populations who are at greater risk due to their
unusually high exposure to cadmium are discussed in Section 6.7, Populations with Potentially High
Exposures.
Differences in individual sensitivity to cadmium have not been systematically studied, but based on what
is known about cadmium toxicity, some inferences can be made. Populations with depleted stores of
calcium, iron, or other dietary components due to multiple pregnancies and/or dietary deficiencies could
be expected to have increased cadmium absorption from the gastrointestinal tract. Urinary cadmium
levels have been shown to be correlated with iron status among pregnant women (Åkesson et al. 2002).
However, a general population study of women living in Japan (Tsukahara et al. 2003) did not find
significantly elevated levels of urinary cadmium, β2-microglobulin, or pHC among women with anemia
or iron deficiency, as compared to healthy women. Populations with kidney damage from causes
unrelated to cadmium exposure, including diabetes, some drugs and chemicals, and the natural age-related
decline in kidney function, could be expected to exhibit nephrotoxicity at lower cadmium exposures than
those of normal healthy adults (Buchet et al. 1990). There is also some evidence to suggest that diabetics
may be more susceptible to the toxicity of cadmium (Åkesson et al. 2005; Buchet et al. 1990; Haswell-
Elkins et al. 2008). Elevated levels of metallothionein-antibody have been significantly associated with
excretion of biomarkers of tubular dysfunction among cadmium workers (Chen et al. 2006a), but not with
urinary or blood cadmium levels. In a study of diabetics, metallothionein-antibodies were significantly
associated with urinary levels of β2-microglobulin levels, which were indicative of cadmium toxicity but
not with urinary albumin levels, which would be indicative of glomerular damage (Chen et al. 2006c).
However, a significant association between elevated albumin creatinine ratio and urinary cadmium levels
was found in another study of diabetics (Haswell-Elkins et al. 2008) and the frequency of albuminuria
CADMIUM 241
3. HEALTH EFFECTS
was 64% among diabetics with high urinary cadmium levels of 1–2 µg/g creatinine and 80% among those
with urinary cadmium levels of >2 µg/g creatinine.
A discussion of the susceptibility of children is found in Section 3.7, Children’s Susceptibility.
3.11 METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of
exposure to cadmium. However, because some of the treatments discussed may be experimental and
unproven, this section should not be used as a guide for treatment of exposures to cadmium. When
specific exposures have occurred, poison control centers and medical toxicologists should be consulted
for medical advice. The following texts provide specific information about treatment following exposures
to cadmium:
Caravati EM, McGuigan MA, MacGregor Whyte I, et al. Cadmium fume pneumonitis. In: Medical
toxicology, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1411-1414.
Leikin JB, Paloucek FP. 2002. Cadmium. In: Poisoning and toxicology handbook. Hudson, OH: Lexi-
Comp, Inc., 309-310.
Viccellio P. 1998. Cadmium, mercury, and arsenic. In: Emergency toxicology. 2nd ed. Philadelphia,
PA: Lippincott-Raven Publishers, 379-380.
3.11.1 Reducing Peak Absorption Following Exposure
Inhalation exposure to high concentrations of cadmium can be particularly dangerous because initial
symptoms are often as mild as those associated with low-level exposure, and exposed individuals who are
unaware either of the presence of cadmium or of the dangers of inhaling cadmium may allow exposure to
continue until a harmful or even fatal dose is received (Beton et al. 1966; Lucas et al. 1980). Severe
respiratory symptoms that may develop within a few hours of high-dose inhalation exposure include
tracheobronchitis, pneumonitis, and pulmonary edema, accompanied by additional nonspecific flu-like
symptoms (sweating, shivering, malaise) (Beton et al. 1966). Aside from removing a victim to fresh air
and providing supportive medical care, no effective means have been reported for reducing absorption
following inhalation exposure to cadmium (Bronstein and Currance 1988; EPA 1989d). Supportive
medical care of individuals with inhalation exposure to high levels of cadmium includes monitoring for
respiratory distress, assisting ventilation as needed, and administering humidified oxygen (Bronstein and
Currance 1988; EPA 1989d). If pulmonary edema develops, individuals may be treated with
CADMIUM 242
3. HEALTH EFFECTS
supplemental oxygen, positive-pressure mechanical ventilation, and administration of diuretics,

intravenous fluids, and steroid medications. Antibiotic therapy and monitoring fluid balance (due to
kidney function impairment) may also be required (Beton et al. 1966; Bronstein and Currance 1988; EPA
1989d; Haddad and Winchester 1990).
Oral exposure to cadmium is not an immediate threat because high doses are irritating enough to induce
vomiting. In fact, the only known acute fatalities from oral exposure to cadmium followed intentional
ingestion of high doses (Baker and Hafner 1961; Buckler et al. 1986; Frant and Kleeman 1941; Nordberg
et al. 1973; Shipman 1986; Wisniewska-Knypl et al. 1971). Although inducing vomiting is sometimes
recommended following ingestion of cadmium (Ellenhorn and Barceloux 1988; Stutz and Janusz 1988),
concentrated cadmium solutions may be caustic, and esophageal damage could result from spontaneous or
induced vomiting. Administration of water or milk may be indicated for patients able to swallow
(Bronstein and Currance 1988; EPA 1989d). Administration of cathartics such as sorbitol or magnesium
sulfate to enhance elimination from the gastrointestinal tract has been recommended (EPA 1989d; Stutz
and Janusz 1988); however, the administration of activated charcoal to bind unabsorbed cadmium does
not appear to be effective (Agency for Toxic Substances and Disease Registry 1990b; Ellenhorn and
Barceloux 1988).
The intestinal absorption of cadmium at levels below those leading to gastrointestinal damage is relatively
low (5–10% of the administered dose) (Flanagan et al. 1978; McLellan et al. 1978; Newton et al. 1984;
Rahola et al. 1973). Other polyvalent cations including calcium, magnesium, and zinc can interfere with
cadmium uptake (Foulkes 1985), but administration of competing cations can in some cases increase
rather than decrease cadmium absorption (Jaeger 1990), and is therefore not recommended for the
treatment of cadmium ingestion. Oral administration of some compounds that chelate cadmium such as
meso-2,3-dimercaptosuccinic acid has been found in rodent studies to reduce absorption following acute
oral exposure to cadmium, but other chelators such as dithiocarbamates can increase toxicity (see
Section 3.4.1.2). At present, no recommendations for chelation treatment to reduce absorption can be
made (Jones and Cherian 1990). Administration of garlic (which is high in reduced sulfhydryl groups)
has been shown to decrease oral cadmium toxicity in rats (Cha 1987). Thus, use of garlic could be an
area of future research.
Dermal or ocular exposure to high levels of cadmium may cause irritation (Wahlberg 1977) and should be
treated by removing contaminated clothing, washing the skin, and thoroughly flushing the eyes (EPA
CADMIUM 243
3. HEALTH EFFECTS
1989d; Stutz and Janusz 1988). These measures will also reduce the relatively small potential for dermal
absorption of cadmium (see Section 3.4.1.3).
3.11.2 Reducing Body Burden
A variety of chelating agents have been evaluated (Cantilena and Klaassen 1981; Jones et al. 1992, 1994;
Kostial et al. 1996; Singh et al. 1996). Some of the more familiar chelators that are beneficial for other
toxic metals actually increase cadmium toxicity by mobilizing the cadmium and substantially increasing
the renal concentrations and toxicity (Agency for Toxic Substances and Disease Registry 1990b;
Goldfrank et al. 1990; Jones and Cherian 1990). One such agent is the chelating agent dimercaprol (also
known as BAL, British Anti-Lewisite), commonly used for treating cases of lewisite toxicosis. BAL is
widely recognized as harmful in treating cadmium exposures. Some sources recommend using ethylene-
diamine tetraacetic acid (EDTA) salts (Cantilena and Klaassen 1980, 1981; Ellenhorn and Barceloux
1988; Stutz and Janusz 1988) or use of EDTA with caution about potential nephrotoxicity (EPA 1989d;
Haddad and Winchester 1990). Other chelators that have reduced the cadmium burden in animal studies
include diethylenetriaminepentaacetic acid (DTPA), 2,3-dimercaptosuccinic acid (DMSA), and various
dithiocarbamates (Cantilena and Klaassen 1981, 1982b; Kamenosono et al. 2002a; Wang et al. 1999).
Cantilena and Klaassen (1982a) demonstrated the importance of rapid administration of DTPA, EDTA, or
DMSA following acute cadmium exposure if they are to be effective. Waalkes et al. (1983) evaluated the
role of metallothionein in the acute drop in chelator efficacy following cadmium poisoning in male
Sprague-Dawley rats. Although the chelator, DTPA, reduced cadmium content in the various organs
when given immediately after cadmium, it was ineffective at all later times. Increases in hepatic and
renal metallothionein did not occur until 2 hours after cadmium, and did not coincide with the earlier drop
in chelator efficacy. Blockade of metallothionein synthesis by actinomycin D treatment (1.25 mg/kg,
1 hour before Cd) failed to prolong the chelators effectiveness. Furthermore, newborn rats have high
levels of hepatic metallothionein, which had no effect on the time course of chelator effectiveness since
DTPA still decreased cadmium organ contents, if given immediately following cadmium, but had no
effect if given 2 hours after cadmium. The authors concluded that metallothionein does not have an
important role in the acute decrease in efficacy of chelation therapy for cadmium poisoning. The quick
onset of chelator ineffectiveness may be due to the rapid uptake of cadmium into tissues, which makes it
relatively unavailable of chelation.
CADMIUM 244
3. HEALTH EFFECTS
Jones et al. (1992, 1994) investigated a series of monoalkyl and monoalkyl esters of meso-2,3-di-
mercaptosuccinic acid. Monoisoamyl meso-2,3-dimercaptosuccinate (Mi-ADMS) was an effective
chelating agent for reduction of kidney and liver cadmium when administered either parenterally or orally
(Jones et al. 1992). This finding was supported by a study by Eybl et al. (1994), which showed that
Mi-ADMS, administered orally every 48 hours for 12 days after acute cadmium exposure, was effective
at reducing cadmium in the kidney and liver, but not in the testes and brain. Monophenethyl meso-
2,3-dimercaptosuccinic acid, mono(3-phenylpropyl) meso-2,3-dimercaptosuccinic acid, and
mono(2-phenoxyethyl) meso-2,3-dimercaptosuccinic acid compounds successfully remove “aged”
cadmium deposits and can be administered via a variety of routes (Jones et al. 1994).
Another area of chelation therapy research is in the use of multiple chelators. Blaha et al. (1995)
evaluated the ability of two carbodithioate chelators, sodium N-(4-methylbenzyl)-4-O-(β-D-galacto-
pyranosyl)-D-glucamine-N-carbodithioate (MeBLDTC) and sodium 4-carboxyamidopiperidine-
N-carbothioate (INADTC), singly or in combination to reduce cadmium burden from chronically exposed
rats. The combination therapy resulted in a synergistic effect on increased biliary excretion and reduced
renal cadmium that, in the case of biliary excretion, was more than doubled that expected for a simple
additive interaction.
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
The toxic effects of cadmium are generally thought to be caused by "free" cadmium ions; that is,
cadmium not bound to metallothionein or other proteins (Goyer et al. 1989). However, cadmium bound
to metallothionein may have the capacity to directly damage renal tubular membranes during uptake
(Suzuki and Cherian 1987). Free cadmium ions may have a number of adverse effects, including
inactivation of metal-dependent enzymes, activation of calmodulin, and initiation of the production of
active oxygen species (Palmer et al. 1986; Waalkes and Goering 1990).
Respiratory damage caused by acute, high-level inhalation exposure to cadmium can cause impaired lung
function that can last many years after exposure (Barnhart and Rosenstock 1984; Townshend 1982). No
treatments other than supportive care and avoidance of additional risk factors for lung injury are presently
known.
The kidneys appear to be highly vulnerable to chronic cadmium exposure by either the oral or inhalation
routes. The basis for the preferential sensitivity of the kidney is related to the filtering and reabsorption of
CADMIUM 245
3. HEALTH EFFECTS
circulating cadmium-metallothionein complex, which is then thought to be degraded in the tubular cell
lysosomes and released as free intracellular cadmium. The toxic effect results from the limited ability of
the kidney to synthesize new cytosolic metallothionein in response to an increasing cadmium load (Goyer
et al. 1989). Cadmium bound to metallothionein, however, may also have nephrotoxic activity (Suzuki
and Cherian 1987).
No treatments are currently available that specifically target free cadmium ions in the renal cortex, but
zinc and calcium can stimulate metallothionein synthesis and may also compete with cadmium for
enzyme binding sites. Thus, zinc, and/or calcium supplementation might help reduce renal cadmium
toxicity, at least in zinc- or calcium-deficient individuals. It is not known whether administration of these
compounds would be beneficial in individuals with adequate zinc and calcium intakes, and their clinical
use is not currently recommended. Since one of the postulated mechanisms of cadmium toxicity is the
stimulation and production of active oxygen species, it is possible that increasing the cellular levels of
antioxidants such as superoxide dismutase, reduced sulfur compounds (particularly glutathione),
vitamin C, vitamin E, or β-carotene could reduce renal cadmium toxicity by scavenging active oxygen
species prior to reaction with cellular components. Several animal studies have examined co-
administration of several antioxidants on cadmium-induced kidney damage. Beneficial effects were
found for vitamin E (Shaikh and Tang 1999; Shaikh et al. 1999a), N-acetyl cysteine (Kaplan et al. 2008;
Shaikh et al. 1999a, 1999b), glycine (Shaikh and Tang 1999), glycyrrhizin (Nomiyama and Nomiyama
1998), and a drug containing glycyrrhizin, glycine, and cysteine (Shaikh and Tang 1999; Shaikh et al.
1999a). However, antioxidants are not currently recommended for the treatment of cadmium-exposed
humans.
Treatments for the cadmium-related effects on bone have not been evaluated. Although the mechanism of
bone damage has not been fully elucidated, it is likely that calcium loss and altered vitamin D
metabolism, which result from cadmium-induced kidney damage, play an important role. Thus,
treatments that interfere with the renal damage will likely have a beneficial effect on bone.
Research in chelation therapy is promising for agents that can interfere or possibly reverse the toxic
effects of cadmium. Xu et al. (1995, 1996) demonstrated that monoisoamyl meso-2,3-dimercapto-
succinate, when administered within 1 hour after acute exposure, prevents the formation of cadmium-
induced apoptotic DNA fragmentation and associated histopathological injury in the testes of rats. Perry
et al. (1989) report a reversal of the cadmium induced hypertension in rats with the chelator d-myo-
inositol-1,2,6-triphosphate.
CADMIUM 246
3. HEALTH EFFECTS
3.12 ADEQUACY OF THE DATABASE
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of cadmium is available. Where adequate information is not
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the
initiation of a program of research designed to determine the health effects (and techniques for developing
methods to determine such health effects) of cadmium.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean
that all data needs discussed in this section must be filled. In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of Cadmium
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to
cadmium are summarized in Figure 3-6. The purpose of this figure is to illustrate the existing information
concerning the health effects of cadmium. Each dot in the figure indicates that one or more studies
provide information associated with that particular effect. The dot does not necessarily imply anything
about the quality of the study or studies, nor should missing information in this figure be interpreted as a
“data need”. A data need, as defined in ATSDR’s Decision Guide for Identifying Substance-Specific
Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and Disease Registry 1989),
is substance-specific information necessary to conduct comprehensive public health assessments.
Generally, ATSDR defines a data gap more broadly as any substance-specific information missing from
the scientific literature.
There is a massive database regarding the health effects of cadmium. In humans, the majority of studies
have involved workers exposed by inhalation or residents of cadmium-polluted areas exposed primarily in
the diet. Quantitative estimates of exposure levels are not available for many of these studies; however,
many studies provided information on urinary cadmium levels that would be reflective of the cadmium
body burden. Lethality, systemic toxicity, genotoxicity, and cancer have been studied in humans more
CADMIUM 247
3. HEALTH EFFECTS
Figure 3-6. Existing Information on Health Effects of Cadmium
Systemic
tic
o re
ph
m
/ Ly ta
l
iat
e gic ti ve en
ed olo gic uc pm ic
t h e m n ic un o lo o d lo t ox er
ea ut t er ro m ur pr ve no nc
D Ac In Ch Im Ne Re De Ge Ca
Inhalation
Oral
Dermal
Human
Systemic ic
r et
pho
m
e /Ly e ta
l
iat gic gic cti
v en
ed olo u m xic
t h t e rm nic un r olo rod e lop o to ce
r
ea cu te hr
o m eu ep ev en n
D A In C Im N R D G Ca
Inhalation
Oral
Dermal
Animal
Existing Studies
CADMIUM 248
3. HEALTH EFFECTS
extensively than immunotoxicity or neurotoxicity, with less being known about reproductive or
developmental toxicity of cadmium in humans following inhalation or oral exposure. In animals, effects
following oral exposures have generally been more thoroughly investigated than those following
inhalation exposure, and few studies of cadmium toxicity following dermal exposure in humans were
located.
3.12.2 Identification of Data Needs
Acute-Duration Exposure. There are limited data on the acute toxicity of cadmium in humans.
Although there are numerous reports of respiratory effects in workers exposed to high concentrations of
cadmium, there are no reliable estimates of levels associated with these effects. Animal studies provide
support for identification of the respiratory tract as the most sensitive target of toxicity following
inhalation exposure. Acute exposures to high levels of airborne cadmium has resulted in pneumonia,
emphysema, and edema in laboratory animals (Boudreau et al. 1989; Buckley and Bassett 1987b; Bus et
al. 1978; Grose et al. 1987; Hart 1986; Henderson et al. 1979; NTP 1995; Palmer et al. 1986) and lower
concentrations were associated with focal inflammation and minimal fibrosis (NTP 1995). A decreased
immune response in mice was observed at similar cadmium concentrations (Graham et al. 1978;
Krzystyniak et al. 1987). Other adverse effects observed at higher concentrations include erosions of the
stomach, decreases in body weight, and reduced activity (Rusch et al. 1986). The available acute-
duration animal data were considered adequate for derivation of an acute-duration inhalation MRL for
cadmium.
There are no reliable human studies on the toxicity of cadmium following acute-duration oral exposure.
In laboratory animals, acute exposure to high doses of cadmium resulted in a variety of effects, including
altered hematological parameters, focal necrosis and degeneration of the liver, focal necrosis in renal
tubular epithelium, necrosis and ulceration in the stomach and intestines, decreased motor activity, and
testicular atrophy and necrosis (Andersen et al. 1988; Basinger et al. 1988; Bomhard et al. 1987;
Borzelleca et al. 1989; Dixon et al. 1976; Kotsonis and Klaassen 1977; Machemer and Lorke 1981;
Sakata et al. 1988; Shimizu and Morita 1990). There is some indication that developmental effects
(delays in ossification and increased malformations) may occur at lower cadmium doses (Baranski 1985;
Machemer and Lorke 1981). The acute-duration oral database was not considered adequate for derivation
of an MRL because the results of the study that identified the lowest LOAEL (Baranski 1985) were
inadequately reported and were inconsistent with a longer-duration study conducted by the same
investigator. Although the data suggest that the developing organism is the most sensitive target,
CADMIUM 249
3. HEALTH EFFECTS
additional studies are needed to support this assumption. Studies characterizing the dose-response
relationships for the most sensitive effects are needed for derivation of an acute-duration oral MRL.
No reliable information was located regarding toxicity following dermal exposure to cadmium, but based
on the lack of reported effects in the workers handling cadmium compounds, it seems unlikely that
dermal exposure could deliver a significant dose of cadmium.
Intermediate-Duration Exposure. There are limited data on the toxicity of cadmium in humans
following intermediate-duration exposure.
Intermediate-duration inhalation studies in laboratory animals have identified several targets of toxicity
including the respiratory tract (Glaser et al. 1986; Kutzman et al. 1986; NTP 1995; Prigge 1978a),
reproductive effects (Baranski and Sitarek 1987; NTP 1995), and developing nervous system (Baranski
1984, 1985). At the lowest cadmium concentration tested, alveolar histiocytic infiltration and
degeneration or metaplasia in the larynx were observed in mice (NTP 1995) and neurodevelopmental
effects were observed in rats (Baranski 1984, 1985). These LOAELs were considered for derivation of an
intermediate-duration inhalation MRL; however, an MRL based on the human equivalent concentration
of the LOAELs would be lower than the chronic-duration inhalation MRL based on human data.
Additional studies are needed to identify no-adverse-effect levels in animals for these sensitive targets of
toxicity.
A number of studies have been conducted involving intermediate-duration oral exposure to laboratory
animals. The results of these studies suggest that the growing bone is the most sensitive target. The
skeletal effects observed in young rats include decreases in bone mineral density, impaired mechanical
strength, increased fractures, and increased bone turnover (Brzóska and Moniuszko-Jakoniuk 2005a,
2005b, 2005d; Brzóska et al. 2004b, 2005a, 2005b, 2005c; Ogoshi et al. 1989). Developmental effects,
including impaired renal function and neurodevelopmental alterations, have been observed at similar dose
levels (Ali et al. 1986; Baranski et al. 1983; Jacquillet et al. 2007). At higher doses, observed effects
included renal damage (proteinuria, tubular necrosis, and decreased renal clearance), liver necrosis, and
anemia (Cha 1987; Gatta et al. 1989; Groten et al. 1990; Itokawa et al. 1974; Kawamura et al. 1978;
Kawamura et al. 1978; Kotsonis and Klaassen 1978; Prigge 1978a), altered immune response (Blakley
1985, 1986; Chopra et al. 1984), decreased motor activity (Kotsonis and Klaassen 1978; Nation et al.
1990), and necrosis and atrophy of seminiferous tubules and decreased sperm count and motility (Cha
CADMIUM 250
3. HEALTH EFFECTS
1987; Saxena et al. 1989). The database of intermediate-duration animal studies was considered adequate
for derivation an intermediate-duration oral MRL based on skeletal effects in growing rats.
No intermediate-duration dermal data were identified in humans or animals. Studies of possible toxicity
in animals following intermediate-duration dermal exposure to cadmium are needed to evaluate potential
health effects in humans exposed to cadmium primarily by the dermal route.
Chronic-Duration Exposure and Cancer. Data on the chronic toxicity of inhaled cadmium in
humans come from numerous occupational exposure studies; no reliable animal studies examining
noncancerous end points were identified. These studies have identified the respiratory tract (emphysema,
impaired lung function) (Chan et al. 1988; Cortona et al. 1992; Davison et al. 1988; Smith et al. 1976) and
the kidney (tubular proteinuria, decreased glomerular filtration rate, increased excretion of low molecular
weight proteins) (Bernard et al. 1990; Chen et al. 2006a, 2006b; Chia et al. 1992; Elinder et al. 1985a;
Falck et al. 1983; Jakubowski et al. 1987, 1992; Järup and Elinder 1994; Järup et al. 1988; Shaikh et al.
1987; Toffoletto et al. 1992; Verschoor et al. 1987) as the most sensitive targets of toxicity. Comparisons
of the adverse effect levels for these two end points are difficult because the studies on respiratory effects
typically reported air concentrations (current levels or estimated cumulative exposure) as the exposure
biomarker and those examining renal effects typically used urinary cadmium levels as the exposure
biomarker; based on limited data, the kidney appears to be the more sensitive target. Studies examining
both end points in occupationally exposed populations would provide valuable information on sensitivity.
None of the available human studies were considered adequate for derivation of an inhalation MRL
because cadmium air concentrations were poorly characterized or no data were provided on the
contribution of dietary cadmium to the cadmium body burden. However, the similarities on the toxicity
and toxicokinetics of cadmium following inhalation and oral exposure allow for the use of the oral
database to derive an inhalation MRL.
There is an extensive database of studies examining the chronic oral toxicity of cadmium in humans.
These environmental exposure studies have identified two sensitive targets of cadmium toxicity—the
skeletal system and the kidney. The skeletal effects included increased risk of osteoporosis and bone
fractures and decreases in bone mineral density (Alfvén et al. 2000, 2004; Nordberg et al. 2002; Schutte et
al. 2008; Staessen et al. 1999; Wang et al. 2003). Renal effects range from death due to renal failure
(Arisawa et al. 2001, 2007b; Iwata et al. 1991a, 1991b; Matsuda et al. 2002; Nakagawa et al. 1993;
Nishijo et al. 1995, 2004a, 2006) to increases in the prevalence of low molecular weight proteinuria
(Buchet et al. 1990; Cai et al. 1990, 1992, 1998, 2001; Hayano et al. 1996; Ishizaki et al. 1989; Izuno et
CADMIUM 251
3. HEALTH EFFECTS
al. 2000; Järup et al. 2000; Jin et al. 2002, 2004a, 2004c; Kawada et al. 1992; Kido and Nogawa 1993;
Kobayashi et al. 2002a; Monzawa et al. 1998; Nakashima et al. 1997; Nogawa et al. 1989; Noonan et al.
2002; Nordberg et al. 1997; Olsson et al. 2002; Oo et al. 2000; Osawa et al. 2001; Roels et al. 1981b;
Suwazono et al. 2006; Teeyakasem et al. 2007; Trzcinka-Ochocka et al. 2004; Uno et al. 2005; Yamanaka
et al. 1998; Wu et al. 2001). Animal studies confirm the identification of the kidney and bone as the most
sensitive targets of cadmium toxicity (Akahori et al. 1994; Bernard et al. 1992; Bomhard et al. 1984;
Brzóska and Moniuszko-Jakoniuk 2004a, 2004b; Fingerle et al. 1982; Mangler et al. 1988). Sufficient
information from human studies is available to derive a chronic oral MRL. No information was located
regarding dermal toxicity of chronic cadmium exposure in humans or animals, and studies of dermal
toxicity are needed to evaluate risks to populations exposed to cadmium primarily by dermal contact.
The evidence of carcinogenicity from human studies is limited, due to uncertainties in cadmium exposure
estimates and confounding factors including exposure to arsenic, a known human lung carcinogen, and
smoking. Occupational exposure studies have found significant increases in lung cancer mortalities
(Ades and Kazantzis 1988; Järup et al. 1998a; Kazantzis et al. 1988; Stayner et al. 1992a; Sorahan 1987;
Sorahan and Waterhouse 1983; Thun et al. 1985). However, lung cancer deaths were often not
significantly associated with cadmium exposure or duration. Other studies have not found increases in
lung cancer deaths (Armstrong and Kazantzis 1983; Elinder et al. 1985c; Lamm et al. 1992, 1994;
Sorahan and Esmen 2004; Sorahan and Lancashire 1997). Additional occupational exposure studies
controlling for these exposures and providing more precise cadmium dose estimates are needed to provide
more definitive evidence of the carcinogenic potential in humans of inhaled cadmium. Evidence for the
carcinogenicity of cadmium by the inhalation route is available from studies in rats (Takenaka et al.
1983). Additional studies in animals are needed to evaluate the lack of an observed increase in lung
cancer in mice and hamsters exposed to cadmium by inhalation (Heinrich et al. 1989). Cadmium has not
been shown to be carcinogenic following oral exposure in humans (Bako et al. 1982; Hardell et al. 1994;
Inskip et al. 1982; Lauwerys and De Wals 1981; Nakagawa et al. 1987; Shigematsu 1984). In rats,
however, cadmium increased tumors of the prostate, testes, and hematopoietic system (Waalkes et al.
1992). Additional lifetime-exposure studies in rats, mice, and hamsters orally exposed to cadmium at
sufficiently high doses are needed to further define the carcinogenic potential of cadmium.
Genotoxicity. The evidence for the genotoxicity of cadmium is mixed (see Tables 3-10 and 3-11). In
vitro studies have provided both positive and negative results (Amacher and Paillet 1980; Bruce and
Heddle 1979; Casto et al. 1979; Denizeau and Marion 1989; Depault et al. 2006; Fatur et al. 2002; Filipic
and Hei 2004; Honma et al. 1999; Jianhua et al. 2006; Lopez-Ortal et al. 1999; Lutzen et al. 2004; Lynn et
CADMIUM 252
3. HEALTH EFFECTS
al. 1997; Mikhailova et al. 1997; Oberly et al. 1982; Rozgaj et al. 2002; Shiraishi et al. 1972; Terracio and
Nachtigal 1988). Studies of chromosomal aberrations in humans (Bui et al. 1975; Deknudt and Leonard
1975; Fu et al. 1999; O'Riordan et al. 1978; Tang et al. 1990) and animals (Bruce and Heddle 1979; Desi
et al. 2000; DiPaulo and Castro 1979; Fahmy and Aly 2000; Karmakar et al. 1998; Mukherjee et al.
1988a; Tan et al. 1990; Watanabe et al. 1979) exposed to cadmium have also found both positive and
negative results. DNA damage has been consistently observed in in vitro studies (Devi et al. 2001;
Fahmy and Aly 2000; Kasuba et al. 2002; Mukherjee et al. 1988a; Saplakoglu et al. 1997; Valverde et al.
2000; Wronska-Nofer et al. 1999; Zhou et al. 2004b). In animals, parenteral, but not inhalation or oral,
cadmium exposure has been found to cause germ cell mutations (Gilliavod and Leonard 1975; Suter
1975; Sutou et al. 1980; Watanabe and Endo 1982; Zenick et al. 1982). Additional studies investigating
effects in exposed humans using larger populations with quantitative estimates of exposure would be
useful to evaluate the human genotoxicity of cadmium.
Reproductive Toxicity. Only limited or conflicting evidence is available to evaluate the potential for
cadmium exposure to cause reproductive toxicity in humans. Some studies report no effect on male
fertility (Gennart et al. 1992), sex hormone levels (Mason 1990; Menke et al. 2008; Zeng et al. 2004a),
sperm density (Noack-Fuller et al. 1993), or semen quality (Jurasović et al. 2004; Saaranen et al. 1989),
while others report a reduction in sperm number or viability (Akinloye et al. 2006; Telišman et al. 2000;
Xu et al. 1993a) or alterations in sex steroid hormone levels (Akinloye et al. 2006; Jurasović et al. 2004;
Telišman et al. 2000). In one study, men occupationally exposed to cadmium at levels resulting in renal
damage had no change in testicular function (Mason 1990). Adverse effects in animals from inhalation
exposure have been reported including increased duration of the estrous cycle (Baranski and Sitarek 1987;
NTP 1995; Tsvetkova 1970), and increased relative testes weight but no loss in reproductive success
(Kutzman et al. 1986). Adverse reproductive effects in animals from high-dose, acute, oral cadmium
exposure have been reported including testicular atrophy and necrosis (Andersen et al. 1988; Bomhard et
al. 1987; Borzelleca et al. 1989), and decreased fertility (Kotsonis and Klaassen 1978; Machemer and
Lorke 1981). At lower doses and intermediate exposures, adverse effects have included necrosis and
atrophy of seminiferous tubule epithelium (Cha 1987), increased testes weight (Pleasants et al. 1992,
1993), increased prostatic hyperplasias (Waalkes and Rehm 1992), significantly increased relative testes
weight, decreased sperm count and motility, decreased seminiferous tubular diameter, seminiferous
tubular damage (Saxena et al. 1989), and decreased fertility (Sutou et al. 1980). Other animal studies for
lower dose intermediate exposures, however, report no adverse effects (Baranski et al. 1983; Bomhard et
al. 1987; Groten et al. 1990; Kostial et al. 1993; Kotsonis and Klaassen 1978; Loeser and Lorke 1977a;
Pleasants et al. 1992; Pond and Walker 1975; Zenick et al. 1982). Additional studies in animals, as well
CADMIUM 253
3. HEALTH EFFECTS
as retrospective, case-matched studies of reproductive success of populations for which occupational or

environmental exposure to cadmium has been estimated, are needed to further evaluate the potential
reproductive toxicity of cadmium in humans. Additional studies would be useful (preferably with larger
sample sizes) to evaluate the robustness of the association between cadmium and adverse effects on
sperm.
Developmental Toxicity. The potential for cadmium exposure to cause developmental toxicity from
pre- or postnatal exposures in humans is not known. One study in occupationally exposed women
reported children with lowered birth weights, but with no increase in malformations (Tsvetkova 1970).
However, no control was made for parity, maternal weight, gestational age, or other factors known to
influence birth weight. Many animal studies demonstrate that developmental toxicity may occur
following cadmium exposure by oral routes with a relatively few studies reporting developmental effects
following inhalation or oral exposure (Ali et al. 1986; Baranski 1985, 1987; Baranski et al. 1983; Gupta et
al. 1993; Kelman et al. 1978; Kostial et al. 1993; Machemer and Lorke 1981; Petering et al. 1979; Pond
and Walker 1975; Schroeder and Mitchener 1971; Sorell and Graziano 1990; Sutou et al. 1980; Webster
1978; Whelton et al. 1988). At lower inhalation and oral doses, impaired performance on
neurobehavioral tests have been observed (Ali et al. 1986; Baranski et al. 1983; Desi et al. 1998;
Nagymajtenyi et al. 1997). Retrospective, case-matched studies of developmental toxicity among
children of women with known occupational or environmental exposure to cadmium are needed to
evaluate the potential for cadmium exposure to cause human developmental toxicity such as skeletal
malformations and neurobehavioral effects (as suggested in animal studies). Studies are also needed to
follow up on the results of increased susceptibility of young to bone damage (Ogoshi et al. 1989) or
suppression of the immune response (Blakley 1985) reported in animals. The difference in the immune
response (using the same protocol) between young mice (Blakley 1985) and older mice (Blakley 1988)
should also be further evaluated. Studies of postnatal cadmium exposure to children, especially for
children with diets deficient in calcium, protein, or iron, would be useful to evaluate whether increased
cadmium absorption from the diet leads to developmental effects.
Immunotoxicity. A variety of immunologic effects have been found in animals exposed to cadmium
by the oral or inhalation routes (Blakley 1988; Bouley et al. 1984; Cifone et al. 1989a). However, the
biological significance of these effects is not clear, and there is little information available on
immunotoxicity in humans. Investigations of immunologic function of populations occupationally or
environmentally exposed to cadmium, and follow-up mechanistic studies in animals are needed to
evaluate the potential immunotoxicity of cadmium exposure in humans.
CADMIUM 254
3. HEALTH EFFECTS
Neurotoxicity. A few studies have suggested an association between cadmium exposure in humans
and impaired neuropsychologic functioning at levels below those causing nephrotoxicity (Hart et al.
1989b; Marlowe et al. 1985; Thatcher et al. 1982). Neurotoxicity has also been found in animal studies
(Nation et al. 1984; Wong and Klaassen 1982). Additional studies to investigate neurologic effects in
populations with known cadmium exposure and studies of possible mechanisms of neurotoxicity in
animals are needed to evaluate the potential neurotoxicity of cadmium exposure to humans. In addition,
studies examining neurobehavioral end points in children would be useful.
Epidemiological and Human Dosimetry Studies. Cause/effect relationships for renal toxicity of
cadmium have been derived from studies of workers occupationally exposed to cadmium by inhalation
(Bernard et al. 1990; Chen et al. 2006a, 2006b; Chia et al. 1992; Elinder et al. 1985b; Falck et al. 1983;
Jakubowski et al. 1987, 1992; Järup and Elinder 1994; Järup et al. 1988; Kawada et al. 1989; Roels et al.
1993; Shaikh et al. 1987; Thun et al. 1989; Toffoletto et al. 1992; Verschoor et al. 1987) and of
populations environmentally exposed to cadmium in the diet (Buchet et al. 1990; Cai et al. 1990, 1992,
1998, 2001; Hayano et al. 1996; Ishizaki et al. 1989; Izuno et al. 2000; Järup et al. 2000; Jin et al. 2002,
2004a, 2004c; Kawada et al. 1992; Kido and Nogawa 1993; Kobayashi et al. 2002b; Monzawa et al.
1998; Nakadaira and Nishi 2003; Nakashima et al. 1997; Nogawa et al. 1989; Noonan et al. 2002;
Nordberg et al. 1997; Roels et al. 1981a; Olsson et al. 2002; Oo et al. 2000; Osawa et al. 2001; Suwazono
et al. 2000; Teeyakasem et al. 2007; Trzcinka-Ochocka et al. 2004; Uno et al. 2005; Watanabe et al.
2002Wu et al. 2001; Yamanaka et al. 1998). There is also epidemiological evidence that chronic
environmental exposure to cadmium can result in decreases in bone mineral density and increases in the
risk of bone fractures and osteoporosis (Åkesson et al. 2005; Alfvén et al. 2000, 2004; Schutte et al. 2008;
Staessen et al. 1999). Additional studies are needed to elucidate the mechanisms of these bone effects in
humans and to determine if the skeletal system is a more sensitive target of cadmium toxicity than the
kidney effects. Measurement of additional toxicity end points (reproductive, developmental,
immunological, and neurological) in these well characterized populations are needed to evaluate whether
any of these effects may occur at exposure levels below those leading to kidney damage. Additional
development of PBPK/PD models is needed to evaluate human exposure scenarios. In its assessment of
the U.S. population’s exposure to environmental chemicals, the CDC measured urinary cadmium levels.
If urinary cadmium levels are monitored in future assessments, it would be useful to also measure
biomarkers of tubular dysfunction; these data would be useful in examining possible relationships
between cadmium exposure and renal function in the general population.
CADMIUM 255
3. HEALTH EFFECTS
Biomarkers of Exposure and Effect.
Exposure. Cadmium levels can be measured in a variety of tissues and fluids, including blood, urine,
milk, liver, kidney, hair, and nails (Elinder and Lind 1985; Roels et al. 1981b; Sharma et al. 1982). Blood
cadmium is a useful indicator of recent cadmium exposure, and urinary cadmium is a useful indicator of
total body burden (Shaikh and Smith 1984). The most important indicator of the potential for
toxicological injury is generally considered to be the cadmium concentration in the renal cortex, but
individuals vary in the concentration causing renal effects (the "critical concentration") (Roels et al.
1981b). Methods for in vivo measurement of cadmium content in the kidney exist, but they are complex
and expensive, and involve some exposure to ionizing radiation (Scott and Chettle 1986). Efforts to
develop easier, safer, and less costly methods for in vivo analysis are needed, as well as studies to
determine factors influencing individual variation in critical concentrations. Although many studies
correct urinary cadmium levels for creatinine concentration, several investigators (Alessio et al. 1985;
Ikeda et al. 2003a; Moriguichi et al. 2005b) have questioned the validity of this approach due to wide
intra- and interindividual variability and age-related decline in levels. Additional studies are needed to
further investigate methods to account for dilution in urine spot samples.
Effect. A number of sensitive tests are available to detect early stages of renal dysfunction that are
known to be caused by cadmium exposure. These include analysis of urinary excretion of
β2-microglobulin, retinol-binding protein, metallothionein, or enzymes (Shaikh and Smith 1984).
However, renal damage detected by these tests is not necessarily associated with cadmium exposure.
Additional studies are needed to evaluate current or potentially new urinary or serum biomarkers in
cadmium-exposed populations and their association with incipient injury to the kidney caused by
cadmium. The bone is a sensitive target of cadmium toxicity, particularly during growth and in the
elderly; studies are needed to develop sensitive biomarkers to detect early signs of bone damage.
Absorption, Distribution, Metabolism, and Excretion. Good information exists on cadmium

toxicokinetics in humans and animals. PBPK/PD models have been developed to predict the critical
organ dose as a function of route, duration, and level of exposure by the inhalation and oral routes
(Kjellström and Nordberg 1978, 1985). Although general factors influencing absorption, distribution,
metabolism, and excretion are known, additional studies are needed to provide information on metal
metabolism and interactions that support quantitative evaluation of individual variations and resulting
differences in renal cadmium accumulation. Very limited information exists on the dermal absorption of
CADMIUM 256
3. HEALTH EFFECTS
cadmium (Skog and Wahlberg 1964; Wester et al. 1992). Additional studies on the dermal absorption of
cadmium are needed.
Comparative Toxicokinetics. Animal and human studies have generally reported comparable
toxicokinetics of cadmium (Kjellström and Nordberg 1985; Nordberg et al. 1985), suggesting that rats,
mice, and rabbits are suitable models for cadmium toxicity in humans. However, some concerns have
been raised about the appropriateness of the rat model for cadmium-induced lung tumors in humans
because of differences in the morphology of the rat respiratory tract and resulting differences in cadmium
particle deposition patterns and target cell populations. This is especially of concern because cadmium
appears to be a contact carcinogen for lung cancer. Additional studies on the differences between the rat
and human clearance rates, speciation at the level of the target cell, and protein transporters (as they relate
to solubility and susceptibility) are needed to evaluate the appropriateness of the rat model for predicting
cadmium-induced human lung cancers. Additional studies on differences in species, strain, sex, age, and
other factors on cadmium kinetics and carcinogenic or other systemic effects are also needed to
extrapolate the animal data to potential human toxicity. Additional studies establishing the toxicokinetics
of cadmium in pregnant animals are needed to assess the relevance of the developmental effects observed
in animals.
Methods for Reducing Toxic Effects. The mechanisms of cadmium absorption across epithelial
layers are likely to be via nonspecific mechanisms (Foulkes 1989). No methods are known for
influencing absorption across the lung, but absorption across the gastrointestinal tract may be influenced
by dietary status (Flanagan et al. 1978). Studies to determine whether dietary adjustments might help
decrease cadmium uptake from food or water are needed. Studies to determine the effects of dietary
deficiencies in calcium are needed to further evaluate the risk of cadmium exposure to susceptible
populations. Uptake across the skin is probably sufficiently slow that simple washing of exposed areas is
adequate to prevent excessive absorption (Skog and Wahlberg 1964).
Once cadmium is absorbed, it tends to accumulate in the kidney, which is the main target tissue for
chronic low-dose exposure. The cellular and molecular basis for the preferential accumulation in the
kidney is only partially understood (Waalkes and Goering 1990), and additional studies to define the rate-
limiting steps in renal uptake and renal clearance of cadmium are needed to design strategies for reducing
the rate of cadmium accumulation in this tissue. Additional studies on existing and new chelating agents
and different treatment regimens are needed to improve the clinical therapies for acute and chronic
exposures to cadmium.
CADMIUM 257
3. HEALTH EFFECTS
The mechanism of cadmium toxicity in renal cells and other tissues probably involves binding of free
cadmium ions to key cellular enzymes and proteins (Waalkes and Goering 1990). Thus, any agent that
prevents cadmium from binding might help prevent toxicity. The endogenous cadmium-binding protein
can serve this function; however, metallothionein-cadmium complexes may have renal toxicity (Suzuki
and Cherian 1987). Additional studies on the role of metallothionein in cadmium toxicity would be
useful. Additional studies are needed on alternative substrate molecules or drugs that could interact with
free cadmium and prevent binding to key cellular enzymes, as well as the ability of antioxidants to reduce
damage from active-oxygen species produced by cadmium in tissues.
The impaired renal function that is the typical adverse effect of excessive cadmium exposure is neither
clinically treatable nor reversible (Agency for Toxic Substances and Disease Registry 1990b; Roels et al.
1989). Studies on potential supportive treatment or remedies for cadmium-induced mild renal impairment
would be valuable.
The bone is also a sensitive target of cadmium toxicity; however, methods for the treatment of the
observed effects, decreased bone mineral density and increased fractures, have not been developed and
are needed.
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and
developmental effects expressed either prenatally or during childhood, are discussed in detail in the
Developmental Toxicity subsection above.
There is limited information on the toxicity of cadmium in children. Although it is likely that children
will have similar effects as adults, there is some suggestive evidence that childhood exposure may result
in increased renal toxicity, as compared to persons only exposed as adults (Trzcinka-Ochocka et al. 2004).
Additionally, studies in animals suggest that young animals are more susceptible to cadmium-induced
bone damage than adults (Ogoshi et al. 1989); this has not been investigated in humans. Studies are
needed to evaluate whether there are age-specific differences in the toxicity of cadmium in humans. As
discussed in the Developmental Toxicity section above, there are limited data on the developmental
toxicity of cadmium in humans, particularly potential neurodevelopmental effects and additional studies
are needed.
CADMIUM 258
3. HEALTH EFFECTS
Additional research is needed on the toxicokinetics of cadmium during long-term, low-level exposures to
determine the potential long-term tissue burdens that are likely to result especially for the susceptible
tissues of liver, kidney, and bone. Data in animals suggest that children may absorb more cadmium than
adults, but there are no human data examining these potential differences in the toxicokinetic properties of
cadmium. Additional information is needed on cadmium transport across the blood-brain barrier in the
developing fetus, and the role of metallothionein in the placenta.
Neurological and behavioral studies are needed that use the more sophisticated measures available today
to evaluate children for in utero, acute, and longer term exposures. These studies should have the
appropriate controls for confounding factors such as lead, parental use of ethanol, and living conditions.
Additional studies are needed to evaluate whether or not biomarkers of cadmium exposure and effects
that have been developed for adults are also applicable to children. If not, new biomarkers of exposure
and effect need to be developed.
The effects of nutritional status (iron, zinc, and calcium levels) on cadmium absorption and accumulation
in children need further evaluation. Improved regimens and choices for chelation therapy are also
needed.
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:
Exposures of Children.
3.12.3 Ongoing Studies
A number of research projects are in progress investigating the health effects of cadmium. These projects
are summarized in Table 3-14.
CADMIUM 259
3. HEALTH EFFECTS
Table 3-14. Ongoing Studies on Cadmium
Investigator Study topic Institution Sponsor

Fadrowski, J Determination if environmental John Hopkins University National Institute of
cadmium exposure is Environmental Health
associated with chronic kidney Sciences
disease in children
Nebert, DW Identify and characterize University of Cincinnati National Institute of
genes responsible for Environmental Health
interindividual differences in Sciences
the response to cadmium
Thomas, DG Examination of the possible Oklahoma State National Research Initiative
and Kennedy, association between cadmium University
TS levels in maternal blood and
breast milk and cognitive
development in infants
Newcomb, PA Examination of the possible Fred Hutchinson Cancer National Institute of
association between cadmium Research Center Environmental Health
exposure and risk of breast Sciences
cancer
Louie, MC Examination of the Dominican University of National Cancer Institute
contribution of cadmium to the California
progression of breast cancer
Meliker, JR Examination of possible State University of New National Institute of
association between cadmium York, Stony Brook Environmental Health
exposure and breast cancer Sciences
risk
Rull, RP Examination of possible Northern California National Institute of
association between cadmium Cancer Environmental Health
exposure and endometrial Sciences
cancer risk
El Mauayed, M Examination of the possible Northwestern University National Institute of
association between cadmium Environmental Health
exposure and diabetes risk in Sciences
carriers of a genetic variation
of the zinc transporter ZnT8
Guallar, EO Possible association between Johns Hopkins University National Institute of
cadmium exposure and Environmental Health
cardiovascular risk in children Sciences
Heggland, SJ Mechanisms of cadmium- Albertson College of National Institute of
induced osteotoxicity Idaho Environmental Health
Sciences
Source: FEDRIP 2012

CADMIUM 260
3. HEALTH EFFECTS

CADMIUM 261
4. CHEMICAL AND PHYSICAL INFORMATION
4.1 CHEMICAL IDENTITY
Table 4-1 lists the common synonyms, trade names, and other pertinent identification information for
cadmium and its most important compounds.
4.2 PHYSICAL AND CHEMICAL PROPERTIES
Table 4-2 lists important physical and chemical properties of cadmium and its most important
compounds.
CADMIUM 262
Table 4-1. Chemical Identity of Cadmium and Compoundsa
Characteristic Information
Chemical name Cadmium Cadmium carbonate Cadmium chloride
b
Synonym(s) Colloidal cadmium Otavite ; cadmium Caddyb; Vi-Cadb; cadmium
monocarbonate; dichloride; dichlorocadmium
carbonic acid; cadmium
salt
Registered trade name(s) No data No data No data
b b b
Chemical formula Cd CdCO3 CdCl2
b b b
Chemical structure Cd CdCO3 CdCl2
Identification numbers:
CAS registry 7440-43-9b 513-78-0b 10108-64-2
NIOSH RTECS No data No data No data
EPA hazardous waste D006 D006 D006
OHM/TADS No data No data No data
DOT/UN/NA/IMDG shipping No data No data NA2570/IMCO 6.1
HSDB 282 1612 278
NCI No data No data No data
CADMIUM 263
Table 4-1. Chemical Identity of Cadmium and Compoundsa
Characteristic Information
Chemical name Cadmium oxide Cadmium sulfate Cadmium sulfide
Synonym(s) Aska-Ridb; cadmium Cadmium sulphate; Cadmium monosulfide;
fume; cadmium sulfuric acid; cadmium cadmium yellow; cadmium
monoxide (2+) salt orange; cadmopur yellow;
greenockiteb; capsebonb
Registered trade name(s) No data No data No data
b b
Chemical formula CdO CdSO4 CdSb
Chemical structure CdOb CdSO4b CdSb
Identification numbers:
CAS registry 1306-19-0b 10124-36-4b 1306-23-6b
NIOSH RTECS No data No data No data
EPA hazardous waste D006 D006 D006
OHM/TADS No data No data No data
DOT/UN/NA/IMDG shipping UN2570/IMCO 6.1 No data No data
HSDB 1613 274 1614
NCI No data No data No data
a
All information obtained from HSDB 2008 except where noted.
b
O’Neil et al. 2006.
CAS = Chemical Abstracts Service; DOT/UN/NA/IMDG = Department of Transportation/United Nations/North

America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System;
RTECS = Registry of Toxic Effects of Chemical Substances
CADMIUM 264
Table 4-2. Physical and Chemical Properties of Cadmium and Compoundsa
Property Cadmium Cadmium carbonate

b b
Molecular weight 112.41 172.42
b c
Color Silver-white White
b b
Physical state Lustrous metal Powder or rhombohedral leaflets
b
Melting point 321 °C Decomposes at 357 °C
b
Boiling point 765 °C No data
3 b 3f
Density at 20 °C 8.65 g/cm at 25 °C 4.58 g/cm
Odor Odorless No data
Odor threshold:
Water No data No data
Air No data No data
Solubility:
b f
Water at 20 °C Insoluble Insoluble
f
Organic solvents Acids, NH4NO3 Acids, especially HNO3,
c
concentrated NH4 solution
Partition coefficients:
Log Kow No data No data
Log Koc No data No data
-3
Vapor pressure 7.5x10 mmHg at 257 °C No data
Henry's law constant at 25 °C No data No data
Autoignition temperature 250 °C No data
Flashpoint No data No data
Flammability limits No data No data
Conversion factors No data No data
Explosive limits No data No data
CADMIUM 265
Property Cadmium chloride Cadmium oxide

b
c b
Color White Dark brown
b b
Physical state Rhombohedral crystals Infusible powder or cubic crystals
b
Melting point 568 °C Decomposes at 950 ºC
b
Boiling point 960 °C Decomposes at 950 ºC
3 e 3
Density at 20 °C 4.047g/cm at 25 °C Crystals 8.15 g/cm ; amorphous
3c
powder 6.95 g/cm
c
Odor Odorless Odorless
Odor threshold:
Air No data No data
Solubility:
b b
Water at 20 °C Soluble Insoluble
Organic solvents Acetone, slightly soluble in MEOH Dilute acid, slowly soluble in NH4
b b
and ETOH salts
e e
Vapor pressure 10 mmHg at 656 °C , 40 mmHg at 1 mmHg at 1,000 °C ; 10 mm Hg at
d d
736 °C , 760 mmHg at 967 °C 1149 ºC; 40 mm Hg at 1257 ºC
Autoignition temperature No data No data
CADMIUM 266
Property Cadmium sulfate Cadmium sulfide

b b
c b c
Color Colorless Light yellow or orange ; brown
b b
Physical state Monoclinic crystals (hydrate) Cubic or hexagonal structure
c c
Melting point 1,000 °C 1,750 °C
c
Boiling point No data Sublimes in N2 at 980 °C
3b 3 b
Density at 20 °C 4.69 g/cm 4.82 g/cm , hexagonal structure ,
3 b
4.5 g/cm , cubic structure
Odor Odorless No data
Odor threshold:
Air No data No data
Solubility:
c b
Water at 20 °C Soluble Soluble at 1.3 mg/L at 18 °C
c
Organic solvents Insoluble in alcohol , acetone, Concentrated or warm dilute
f b
ammonia mineral acids
Vapor pressure at 20 °C No data No data
Autoignition temperature No data No data
a
All information from HSDB 2008, except where noted.
b
O’Neil et al. 2006.
c
Sax and Lewis 2001.
d
Farnsworth 1980.
e
Sax and Lewis 2000.
f
Lide 2005.
CADMIUM 267
5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1 PRODUCTION
Cadmium is a widely but sparsely distributed element found in the earth's crust at concentrations ranging
from 0.1 to 5 ppm, primarily as sulfide minerals in association with zinc ores, zinc-bearing lead ores, and
or complex copper-lead-zinc ores (Morrow 2001). Approximately 3 kg of cadmium for each ton of zinc
are produced (OECD 1995). About 80% of cadmium production is associated with zinc production,
while the other 20% is associated with lead and copper byproduct production and the recapture of
cadmium from finished products (Morrow 2001). Between 2003 and 2006, the annual cadmium refinery
production in the United States declined from 1,450 to 700 metric tons, dropping 52% between 2005 and
2006 (USGS 2007, 2008). Demand for cadmium in the nickel-cadmium (Ni-Cd) battery industry is
strengthening as demand in other areas, like coatings and pigments, has been decreasing due to
environmental concerns and regulations. Despite this demand, primary production of cadmium may
decrease as zinc prices increase, since producers may choose to discard the cadmium byproduct instead of
refining it (USGS 2008).
One company produced primary cadmium in the United States during 2007: Clarksville (Zinifex Ltd.),
Clarksville, Tennessee. The Big River Zinc Corporation (Korea Zinc Co, Ltd), Sauget, Illinois operation
was closed in 2006, citing mine closures and the increasing price of zinc concentrate (USGS 2008). In
June 2006, it was purchased by ZincOx Resources plc, Surrey, United Kingdom (USGS 2007). A third
company in Ellwood, Pennsylvania, International Metals Reclamation Co. Inc. (INMETCO), recovers
cadmium from spent nickel-cadmium batteries, which began reclaiming cadmium in 1995 (USGS 2007).
In 2005, it was estimated that the total cadmium recovery rate was only 12%, with an estimated
40,000 tons of cadmium being disposed of in municipal waste or held in household storage or industry
stockpiles between 1996 and 2005 (USGS 2007).
The following companies are currently cited as major producers of cadmium compounds: GFS
Chemicals Inc., Columbus, Ohio (cadmium chloride, cadmium sulfate); CERAC Inc., Milwaukee,
Wisconsin (cadmium sulfide); and EP Scientific Products, LLC (cadmium sulfide) (SRI 2007). BASF
Catalysts LLC, Louisville, Kentucky was specifically cited as a major producer of cadmium sulfide/
sulfoselenide pigments (SRI 2007).
Tables 5-1 and 5-2 list the facilities in each state that manufacture or process cadmium and cadmium
compounds, respectively, the intended use, and the range of maximum amounts stored on site. The data
CADMIUM 268
Table 5-1. Facilities that Produce, Process, or Use Cadmium
Minimum Maximum
Number of amount on site amount on site
Statea facilities in poundsb in poundsb Activities and usesc
AL 19 0 999,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
AR 14 0 999,999 1, 2, 3, 5, 6, 7, 8, 10, 12, 13, 14
AZ 12 0 999,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 13
CA 41 0 99,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
CO 8 1,000 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 12
CT 5 0 99,999 7, 8, 10, 11
FL 6 0 99,999 1, 2, 3, 4, 6, 7, 8, 10, 12
GA 8 0 999,999 1, 3, 6, 8, 13, 14
IA 9 0 99,999 1, 5, 7, 8, 12, 13
ID 6 10,000 999,999 1, 3, 5, 12, 13
IL 25 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14
IN 10 0 999,999 1, 2, 5, 7, 8, 9, 10, 12
KS 6 100 99,999 1, 3, 7, 8, 12
KY 11 0 999,999 1, 2, 3, 5, 6, 7, 8, 11
LA 7 0 999,999 1, 3, 5, 6, 8, 10, 12, 13
MA 13 0 99,999 1, 2, 3, 4, 7, 8, 10
MD 5 100 49,999,999 1, 2, 4, 5, 6, 13
MI 19 0 99,999 1, 2, 3, 5, 6, 7, 8, 10, 12, 13, 14
MN 10 0 999,999 1, 3, 4, 7, 8, 9, 10, 11, 12, 13
MO 7 0 999,999 1, 2, 3, 4, 5, 6, 8, 14
MS 7 0 9,999 5, 7, 8, 12
NC 13 0 9,999,999 1, 5, 7, 8, 9, 10, 12, 14
NE 9 100 99,999 1, 2, 5, 7, 8, 12
NH 4 0 999 1, 3, 8, 12
NJ 18 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
NV 2 10,000 99,999 1, 2, 3, 5, 12, 13
NY 21 0 9,999,999 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14
OH 32 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OK 16 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13
OR 7 0 9,999,999 1, 5, 8, 12
PA 35 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
PR 1 0 99 8
RI 4 0 9,999 2, 3, 7, 8
SC 20 0 9,999,999 1, 3, 5, 6, 7, 8, 9, 10, 11, 12
TN 17 0 9,999,999 1, 2, 3, 4, 5, 7, 8, 9, 11, 12, 13
TX 28 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 14
UT 8 0 99,999 1, 5, 6, 7, 8, 12, 13
CADMIUM 269
Table 5-1. Facilities that Produce, Process, or Use Cadmium
Minimum Maximum
VA 12 0 99,999 1, 5, 7, 8, 9, 10, 11, 13
WA 5 0 9,999 1, 2, 3, 5, 10, 13
WI 14 0 49,999,999 3, 7, 8, 10, 11, 12
WV 3 100 99,999 7, 8, 12
WY 1 0 99 1, 13
a
Post office state abbreviations used.
b
Amounts on site reported by facilities in each state.
c
Activities/Uses:
1. Produce 6. Impurity 11. Chemical Processing Aid
2. Import 7. Reactant 12. Manufacturing Aid
3. Onsite use/processing 8. Formulation Component 13. Ancillary/Other Uses
4. Sale/Distribution 9. Article Component 14. Process Impurity
5. Byproduct 10. Repackaging
Source: TRI09 2011 (Data are from 2009)

CADMIUM 270
Table 5-2. Facilities that Produce, Process, or Use Cadmium Compounds
Minimum Maximum
AK 14 0 499,999,999 1, 5, 7, 9, 11, 12, 14
AL 31 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 14
AR 19 100 999,999 1, 2, 3, 5, 7, 8, 12, 13, 14
AZ 30 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 12, 13, 14
CA 28 0 49,999,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13
CO 10 100 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14
CT 28 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
DE 2 100 9,999 1, 5
FL 11 0 999,999 1, 2, 3, 5, 6, 8, 12, 13, 14
GA 15 0 999,999 1, 2, 3, 5, 6, 7, 8, 13
IA 5 0 99,999 1, 5, 7, 8, 9, 12
ID 14 100 9,999,999 1, 5, 6, 7, 11, 12, 13, 14
IL 46 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 14
IN 19 0 999,999 1, 5, 7, 8, 13, 14
KS 7 0 99,999 1, 7, 8, 11, 13
KY 19 100 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 12, 13
LA 12 0 999,999 1, 2, 3, 5, 7, 8, 12, 13
MA 14 0 999,999 1, 3, 4, 5, 6, 7, 8, 12, 13
MD 9 1,000 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 13
MI 24 0 99,999,999 1, 3, 5, 6, 7, 8, 10, 11, 12, 13
MN 10 100 999,999 1, 5, 7, 8, 9, 13
MO 14 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 13
MS 9 0 999,999 1, 5, 7, 8, 12
MT 3 1,000 9,999,999 1, 2, 3, 4, 5, 6, 13
NC 14 0 49,999,999 1, 7, 8, 13
NE 8 1,000 999,999 1, 2, 5, 8, 12, 13, 14
NH 1 1,000 9,999 7, 10
NJ 35 0 9,999,999 1, 2, 3, 4, 6, 7, 8, 9, 10, 12
NM 6 1,000 9,999,999 1, 5, 13
NV 22 100 49,999,999 1, 2, 3, 5, 6, 7, 9, 10, 12, 13, 14
NY 26 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14
OH 82 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OK 19 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13
OR 4 100 99,999 1, 5, 8
PA 67 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13
PR 1 100 999 8
CADMIUM 271
Table 5-2. Facilities that Produce, Process, or Use Cadmium Compounds
Minimum Maximum
RI 8 100 99,999 2, 3, 7, 8, 11
SC 18 0 999,999 1, 4, 5, 6, 7, 8, 11, 12, 13, 14
TN 35 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 14
TX 36 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14
UT 15 1,000 49,999,999 1, 5, 6, 7, 8, 12, 13
VA 11 0 99,999 1, 5, 7, 8, 12, 14
WA 17 0 999,999 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14
WI 14 100 49,999,999 1, 3, 5, 7, 8, 10, 11, 12
WV 8 0 999,999 1, 2, 3, 7, 8, 11, 12, 13
a
Post office state abbreviations used.
b
Amounts on site reported by facilities in each state.
c
Activities/Uses:
1. Produce 6. Impurity 11. Chemical Processing Aid
2. Import 7. Reactant 12. Manufacturing Aid
3. Onsite use/processing 8. Formulation Component 13. Ancillary/Other Uses
4. Sale/Distribution 9. Article Component 14. Process Impurity
5. Byproduct 10. Repackaging

CADMIUM 272
listed in Tables 5-1 and 5-2 are derived from the Toxics Release Inventory (TRI) (TRI09 2011). Because
only certain types of facilities were required to report, this is not an exhaustive list.
Cadmium metal is available in purities ranging from 99.5 to 99.999% in the following grades: technical,
powder, pure sticks, ingots, slabs, and high-purity crystals (<10 ppm impurities) (HSDB 2008).
Cadmium (as cadmium oxide) is obtained mainly as a byproduct during the processing of zinc-bearing
ores (e.g., sphalerites), and also from the refining of lead and copper from sulfide ores (e.g., galena)
(Morrow 2001). Cadmium oxide produced during roasting of ores is reduced with coke, and cadmium
metal is separated by distillation or electrodeposition (Elinder 1985a). Commercial-grade cadmium oxide
is available in purities ranging from 99 to 99.9999%; common impurities are lead and thallium (NTP
2005). Cadmium chloride is produced by reacting molten cadmium with chlorine gas at 600 °C or by
dissolving cadmium metal or the oxide, carbonate, sulfide, or hydroxide in hydrochloric acid and
subsequently vaporizing the solution to produce a hydrated crystal (HSDB 2008; IARC 1993). In
preparing the anhydrous cadmium chloride salt, the hydrate is refluxed with thionyl chloride or calcined
in a hydrogen chloride atmosphere (HSDB 2008). Commercial cadmium chloride is available as a
hydrate mixture with a purity range of 95.0–99.999% (NTP 2005).
The commercial preparation of cadmium sulfate usually involves dissolution of the metal oxide,
carbonate, or sulfide in sulfuric acid with subsequent cooling or evaporation (HSDB 2008). Anhydrous
cadmium sulfate is prepared by oxidation of the sulfide or sulfite at elevated temperatures (Herron 2003);
or by melting cadmium with ammonium or sodium peroxodisulfate (Schulte-Schrepping and Piscator
2002). Cadmium sulfate monohydrate, which is the cadmium compound most often marketed, is
produced by evaporating a cadmium sulfate solution above 41.5 °C (Schulte-Schrepping and Piscator
2002). Cadmium sulfate is available in technical and C.P. (chemically pure) grades (Lewis 2001).
Cadmium sulfide can be prepared by a direct reaction with hydrogen sulfide and cadmium vapor or
between sulfur and cadmium metal or cadmium oxide (Herron 2003). Cadmium sulfide is available in
technical, N.F. (national formulary grade), and high-purity (single crystals) (Lewis 2001). Cadmium
carbonate is produced by heating an acidified solution of cadmium chloride and urea in a sealed tube at
200 °C, the slow absorption of carbon dioxide to cadmium oxide, or the precipitation of the hemihydrate
from reaction of ammonium carbonate in cadmium ion solution (Herron 2003).
CADMIUM 273
5.2 IMPORT/EXPORT
Imports of cadmium into the United States declined steadily from 1994 through 1998, dropping from
1,110 metric tons per year to an estimated 650 metric tons in 1998 (USGS 1999). In 1986, imports of
cadmium metal for consumption increased significantly to 3,000 metric tons, but continually decreased
into the 1990s. From 2003 to 2005, cadmium imports of metal, alloys, and scrap increased from 112 to
288 tons, 74–207 tons of which were metal-only imports (USGS 2008). Cadmium imports peaked in
2005 and then declined through 2007, with 172 tons of cadmium metal only and 174 tons of metal, alloys,
and scrap imported (USGS 2008). The principal supplying countries were Australia (41%), Canada
(20%), China (10%), and Peru (9%) (USGS 2008).
In the mid-1990s, exports varied widely from 38 metric tons in 1993, to 1,450 metric tons in 1994, to
550 metric tons in 1997. In 2003, cadmium exports (reported as metal, alloys, and scraps) were 615 tons,
with exports decreasing to only 154 tons the following year (USGS 2008). Exports surged again in 2005
to 686 tons, but have since been steadily decreasing from 483 tons in 2006 to 304 tons in 2007 (USGS
2008).
5.3 USE
Cadmium, its alloys, and its compounds are used in a variety of consumer and industrial materials. The
dominant use of cadmium is in active electrode materials in Ni-Cd batteries (83% of total cadmium use)
(USGS 2008). Cadmium demand for other uses such as pigments for plastics, ceramics, and glasses;
stabilizers for polyvinyl chloride (PVC) against heat and light; engineering coatings on steel and some
nonferrous metals; and components of various specialized alloys have been decreasing. (Elinder 1992;
IARC 1993; Thornton 1992; USGS 2008). Cadmium salts have been used in a limited capacity as a
fungicide for golf courses and home lawns (EPA 2006b). Cadmium chloride is used in photography,
photocopying, dyeing, calico printing, vacuum tube manufacture, pigment manufacture, galvanoplasty,
lubricants, ice-nucleation agents, and in the manufacture of special mirrors (Herron 2003). However, the
significance of cadmium chloride as a commercial product is declining (IARC 1993).
Cadmium-based colorants are used mainly in engineering plastics, ceramics, glasses, and enamels (IARC
1993; OECD 1995). Cadmium sulfide is especially important in this industry, especially in glasses and
plastics; however, environmental and health concerns have contributed to a decrease in its production
(Herron 2003). Cadmium sulfide (yellow) and cadmium selenide (red) are combined to create solid
C.P. toners ranging in color from yellows and oranges to reds and maroons (Herron 2003). Cadmium
CADMIUM 274
sulfide and cadmium telluride are used in solar cells and a variety of electronic devices which depend on
cadmium’s semiconducting properties (Herron 2003; IARC 1993; OECD 1995). The photoconductive
and electroluminescent properties of cadmium sulfide have been applied in manufacturing a variety of
consumer goods (IARC 1993). Cadmium sulfate solution is used in standard Weston cells (Herron 2003).
Though cadmium metal consumption for batteries has grown steadily since the 1980s and currently
consumes 83% of the cadmium produced, other uses of cadmium began declining in the mid 1990s.
Pigment, stabilizer, coating, and alloy markets for cadmium are decreasing due to environmental concerns
(USGS 1997, 2008). Proposed legislation, particularly in the European Union, restricting cadmium in
consumer products may have a negative effect on cadmium demand (USGS 2008). Excessive exports
from Bulgaria and Russia in 1997 caused a drop in the average price of cadmium from $1.84 per pound in
1995 to $0.51 per pound in 1997. Also, Ni-Cd batteries have been replaced in some markets by lithium-
ion and nickel metal hydride batteries (USGS 2008). As of 2006, Ni-Cd batteries made up 18% of the
rechargeable battery market, down from 56% in 1996 with global sales decreasing 16% between 2005 and
2006 (USGS 2008). Despite this trend, demand for cadmium may increase due to new market
opportunities for Ni-Cd batteries (USGS 2008). Regulations by local authorities have forced the
recycling of cadmium in Ni-Cd batteries, further depressing the demand for primary cadmium metal
(USGS 1999).
5.4 DISPOSAL
Cadmium-containing wastes are subject to regulations concerning their treatment, storage, and disposal
(see Chapter 8) (EPA 1982a; HSDB 2008; U.S. Bureau of Mines 1990). In many states, the disposal of
Ni-Cd batteries as municipal waste is prohibited (USGS 2007). Incineration of municipal wastes,
particularly from older, poorly controlled facilities, is a potential environmental source of cadmium. In
modern incineration plants, about 99.9% of cadmium was captured in boilers and control equipment
(OECD 1995).
A range of physicochemical processes is available for treatment of cadmium in liquid waste process
streams, including ion exchange, electrolysis, cementation, and adsorption. Both ion exchange and
sulfide precipitation are used as alternate processes aimed at achieving low cadmium residuals in liquid
wastes (UN 1985). Combining processes, for example, conducting the primary precipitation of cadmium
as hydroxide followed by secondary precipitation of residual cadmium as sulfide, has also been adopted.
The more general application of the sulfide precipitation technique, however, is constrained due to a
CADMIUM 275
tendency for formation of colloidal precipitate, the toxicity and odor of hydrogen sulfide, and the
necessity to oxidize residual sulfide occurring in emissions prior to discharge (UN 1985).
The most widely used treatment process involves the alkaline precipitation of cadmium as hydroxide or
basic salts (UN 1985). Removal of specific metal species during hydroxide precipitation is pH-
dependent, and some components of the waste stream can influence the solubility of cadmium hydroxide.
After filtration, the sludge formed from the conversion of soluble cadmium compounds to insoluble
compounds can be deposited in a suitable landfill (UN 1985).
Various cadmium-bearing wastes are subject to aggressive leaching in refuse media, particularly under
aerobic conditions (UN 1985). While liquid wastes are banned from land disposal, the leaching tendency
is accentuated in the presence of brine solutions. Also, the mobility of cadmium in landfill conditions
could be enhanced in the presence of mineral acids, which tend to solubilize cadmium compounds, or
amine-containing materials, which tend to complex cadmium ions. Waste containing mineral acids,
cyanides, organic solvents, and amine-type substances should not be landfilled near cadmium-bearing
wastes (UN 1985).
In the laboratory, a recommended method for recovering cadmium from small quantities of cadmium
oxide wastes uses a minimum amount of concentrated nitric acid to form nitrates. The solution is
evaporated in a hood to form a thin paste, and then diluted with water and saturated with hydrogen
sulfide. After the filtration, the precipitate is washed, dried, and returned to the supplier (UN 1985).
Cadmium recovery from scrap metals and batteries is becoming increasingly popular, with the main
emphasis being on recycling Ni-Cd batteries (Morrow 2001). Battery recycling is relatively easy and can
be achieved using pyrometallurgical (high temperature) or hydrometallurgical (wet chemical) processes
(Morrow 2001). In these processes, the metallic waste that contains iron, nickel, cadmium, and their
oxides and hydroxides are separated from the other battery components and then converted back to a
metal that has a technical purity required for the production of new batteries (Morrow 2001). Cadmium-
based coatings can be recycled using electric-arc furnace (EAF) dust, which is obtained through the re-
melting of scrap steel that contains cadmium coatings and cadmium impurities (Morrow 2001).
INMETCO in Ellwood, Pennsylvania recovers cadmium from spent Ni-Cd batteries, and has developed
several collection programs to help facilitate battery recycling (USGS 2007). Although participation in
battery recycling has increased in businesses, communities, and retailers, the total recovery of cadmium in
2005 was only 12% (USGS 2007).
CADMIUM 276

CADMIUM 277
6. POTENTIAL FOR HUMAN EXPOSURE
6.1 OVERVIEW
Cadmium has been identified in at least 1,014 of the 1,669 hazardous waste sites that have been proposed
for inclusion on the EPA National Priorities List (NPL) (HazDat 2007). Cadmium compounds have been
identified in at least 3 of the 1,669 hazardous waste sites. However, the number of sites evaluated for
cadmium is not known. The frequency of these sites can be seen in Figures 6-1 and 6-2. Of the
1,014 sites where cadmium has been identified, 1,005 are located within the United States, 6 are located
in the Commonwealth of Puerto Rico (not shown), 2 are located in Guam, and 1 is located in the Virgin
Islands. All sites where cadmium compounds were detected are located in the United States.
Cadmium occurs in the earth’s crust at an abundance of 0.1–0.5 ppm and is commonly associated with
zinc, lead, and copper ores. It is also a natural constituent of ocean water, with average levels between
<5 and 110 ng/L; with higher levels reported near coastal areas and in marine phosphates and
phosphorites (Morrow 2001). Natural emissions of cadmium to the environment can result from volcanic
eruptions, forest fires, generation of sea salt aerosols, or other natural phenomena (EPA 1985a; Morrow
2001; Shevchenko et al. 2003). Cadmium is refined and consumed for use in batteries (83%), pigments
(8%), coatings and platings (7%), stabilizers for plastics (1.2%), and nonferrous alloys, photovoltaic
devices, and other (0.8%) (USGS 2008). Nonferrous metal mining and refining, manufacture and
application of phosphate fertilizers, fossil fuel combustion, and waste incineration and disposal are the
main anthropogenic sources of cadmium in the environment.
Cadmium can be released to the atmosphere through metal production activities, fossil fuel combustion,
and waste incineration. The main cadmium compounds found in air are cadmium oxide, chloride, and
sulfate, and these compounds are expected to undergo minimal transformation in the atmosphere (EPA
1980d). The major fate of cadmium in air is through transport and deposition. Cadmium can travel long
distances in the atmosphere and then deposit (wet or dry) onto surface soils and water, which can result in
elevated cadmium levels even in remote locations (Shevchenko et al. 2003). Results from the 2006 final
report of EPA’s Urban Air Toxic Monitoring program reported average daily cadmium levels of
<0.01 μg/m3 at several monitoring sites throughout the United States (EPA 2007). These sites include:
Bountiful, Utah; Northbrook, Illinois; Austin, Texas; St. Louis, Missouri; Indianapolis, Indiana; and
Birmingham, Alabama (EPA 2007). Atmospheric concentrations of cadmium are generally highest in the
vicinity of cadmium-emitting industries (Elinder 1985a; Pirrone et al. 1996). Due to advances in
pollution control technology, cadmium emissions to air are not expected to increase, even though
CADMIUM 278
Figure 6-1. Frequency of NPL Sites with Cadmium Contamination

CADMIUM 279
Figure 6-2. Frequency of NPL Sites with Cadmium Compounds Contamination

CADMIUM 280
cadmium-emitting industries are expected to grow (Herron 2003; Morrow 2010; Schulte-Schrepping and
Piscator 2002). Except for those who live near cadmium-emitting industries, inhalation of cadmium in
the ambient air is not a major source of exposure.
The main sources of cadmium to soil include atmospheric deposition and direct application methods such
as phosphate fertilizer use and sewage sludge disposal. Some phosphate fertilizers can contain up to
300 mg Cd/kg (Alloway and Steinnes 1999). Wet and dry deposition of cadmium from the atmosphere
may also contribute sizable amounts of cadmium to soil in the areas surrounding sources of atmospheric
emissions (EPA 1985a; Mielke et al. 1991). Cadmium’s mobility in soil depends on several factors
including the pH of the soil and the availability of organic matter. Generally, cadmium will bind strongly
to organic matter and this will, for the most part, immobilize cadmium (Autier and White 2004).
However, immobilized cadmium is available to plant life and can easily enter the food supply. Cadmium
in soil tends to be more available when the soil pH is low (acidic) (Elinder 1992).
Water sources near cadmium-emitting industries, both with historic and current operations, have shown a
marked elevation of cadmium in water sediments and aquatic organisms (Angelo et al. 2007; Arnason and
Fletcher 2003; Brumbaugh et al. 2005; Mason et al. 2000; Paulson 1997). In surface water and
groundwater, cadmium can exist as the hydrated ion or as ionic complexes with other inorganic or organic
substances. While soluble forms may migrate in water, cadmium is relatively nonmobile in insoluble
complexes or adsorbed to sediments. Cadmium is taken up and retained by aquatic and terrestrial plants
and is concentrated in the liver and kidney of animals that eat the plants (Elinder 1985a).
For the U.S. population, cadmium exposure through the drinking water supply is of minor concern. EPA
requires water suppliers to limit the cadmium concentration in water to <5 μg/L (EPA 2006a).
In the United States, the largest source of cadmium exposure for nonsmoking adults and children is
through dietary intake (NTP 2005). Based on the mean cadmium daily intakes of males and females aged
6–60 years reported by Choudhury et al. (2001), age-weighted mean cadmium intakes of 0.35 µg/kg/day
for males and 0.30 µg/kg/day for females were calculated for U.S. nonsmokers. In general, vegetables,
particularly leafy vegetables such as lettuce (0.051 mg/kg) and spinach (0.124 mg/kg), have the highest
concentrations of cadmium; the concentrations of cadmium in all vegetables ranged from 0.001 to
0.124 mg/kg (FDA 2010; Morrow 2001). Peanuts, soybeans, and sunflower seeds have naturally high
levels of cadmium (Morrow 2001); the mean concentration of cadmium in legumes and nuts ranged from
0.001 to 0.054 mg/kg (FDA 2010). People who regularly consume shellfish and organ meats (liver and
CADMIUM 281
kidney) have an increased risk of cadmium exposure, as these organisms tend to accumulate cadmium
(Elinder 1985a).
Tobacco leaves naturally accumulate cadmium (Morrow 2001). Cadmium levels in cigarettes vary
greatly depending on the source of production. Cigarettes produced in Mexico were found to have the
highest level of cadmium per cigarette (arithmetic mean [AM] ± arithmetic standard deviation [ASD] =
2.03 µg/cigarette ±0.33), while cigarettes from India were found to have the lowest (arithmetic mean ±
arithmetic standard deviation = 0.35 µg/cigarette ±0.09). The arithmetic mean for the United States was
1.07 µg/cigarette ±0.11 (Watanabe et al. 1987). Tobacco contains approximately 0.5–2.0 μg cadmium per
cigarette, and about 10% is inhaled when smoked (Morrow 2010). The geometric mean blood cadmium
level for the heavy smoker subgroup in New York City was reported as 1.58 μg/L, compared to the
geometric mean of 0.77 μg/L for all New York City adults (McKelvey et al. 2007).
6.2 RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of
facilities are required to report (EPA 2005). This is not an exhaustive list. Manufacturing and processing
facilities are required to report information to the TRI only if they employ 10 or more full-time
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011,
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.),
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces,
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI
chemical in a calendar year (EPA 2005).
Additional releases of cadmium to the environment occur from natural sources and from processes such
as combustion of fossil fuel, incineration of municipal or industrial wastes, or land application of sewage
sludge or fertilizer (EPA 1985a). Quantitative information on releases of cadmium to specific
environmental media is discussed below.
CADMIUM 282
6.2.1 Air
Estimated releases of 731 pounds (~0.3 metric tons) of cadmium to the atmosphere from 41 domestic
manufacturing and processing facilities in 2009, accounted for about 0.18% of the estimated total
environmental releases of cadmium from facilities required to report to the TRI (TRI09 2011). These
releases are summarized in Table 6-1. Estimated releases of 11,567 pounds (~5.2 metric tons) of
cadmium compounds to the atmosphere from 85 domestic manufacturing and processing facilities in
2009, accounted for about 0.55% of the estimated total environmental releases of cadmium from facilities
required to report to the TRI (TRI09 2011). These releases are summarized in Table 6-2.
Cadmium is released to the atmosphere from both natural and anthropogenic sources. Cadmium is widely
distributed in the earth's crust (EPA 1985a) with concentrations reported between 0.1 and 0.5 ppm and
higher levels in sedimentary rocks (Morrow 2001). Consequently, cadmium may be released to the air
from entrainment of dust particles, volcanic eruptions, forest fires, or other natural phenomena (EPA
1985a; Morrow 2001). Cadmium exists in ocean waters at average levels ranging from <5 to 110 ng/L
and may transport to the atmosphere through natural processes like generation of sea-salt aerosols
(Morrow 2001; Shevchenko et al. 2003). Increased cadmium levels in the air over the Russian Arctic
have been detected during the summer and autumn seasons and are believed to be attributed to natural
processes, while the levels detected during the winter and spring seasons were due to anthropogenic
sources (Shevchenko et al. 2003).
However, industrial activities are the main sources of cadmium release to air (EPA 1985a), and emissions
from anthropogenic sources have been found to exceed those of natural origin by an order of magnitude
(IARC 1993). Major industrial sources of cadmium emissions include zinc, lead, copper, and cadmium
smelting operations; coal and oil-fired boiler; other urban and industrial emissions; phosphate fertilizer
manufacture; road dust; and municipal and sewage sludge incinerators (Alloway and Steinnes 1999;
Morrow 2001). Emission of cadmium through nonferrous metal production in 1995 was highest in Asia
with 1,176 tonnes and North America emitting 191 tonnes. Estimated emissions of cadmium from
municipal waste and sewage sludge incineration in North America were 8 and 7 tonnes/year, respectively,
in the mid-1990s (Pacyna and Pacyna 2001). Additional sources that contribute negligible amounts of
cadmium are rubber tire wear, motor oil combustion, cement manufacturing, and fertilizer and fungicide
application (Wilber et al. 1992). Average cadmium emission factors for combustion of coal and oil are
about 0.1 and 0.05 g/ton, respectively. Cement production releases an estimated 0.01 g/ton cement and
CADMIUM 283
Table 6-1. Releases to the Environment from Facilities that Produce, Process, or
Use Cadmiuma
Reported amounts released in pounds per yearb

Total release
c d e f g h i j
State RF Air Water UI Land Other On-site Off-sitek On- and off-site
AL 2 13 122 0 36,955 11 37,087 13 37,100
AR 3 4 7 0 0 100 6 105 111
AZ 1 0 0 0 16,005 0 16,005 0 16,005
CA 2 426 169 0 13,992 20 14,263 344 14,607
FL 1 0 0 0 0 0 0 0 0
GA 1 26 0 0 5 0 26 5 31
IA 1 0 0 0 0 0 0 0 0
IN 1 3 0 0 0 0 3 0 3
KS 2 0 0 0 0 0 0 0 0
KY 1 19 0 0 0 0 19 0 19
LA 2 75 0 0 61 0 136 0 136
MI 1 0 0 0 5 0 0 5 5
NC 2 30 0 0 0 0 30 0 30
NE 1 1 0 0 10,282 0 10,249 34 10,283
NV 1 2 0 0 40,681 524 40,683 524 41,207
NY 2 0 11 0 0 8 11 8 19
OH 4 7 0 104,579 22,337 1 126,586 338 126,924
OK 1 13 0 0 38,780 0 38,793 0 38,793
OR 1 1 0 0 13,575 1 13,577 1 13,577
PA 1 59 3 0 0 0 62 0 62
TN 2 5 0 0 38,186 2,519 5 40,705 40,710
TX 3 1 22 37,988 0 26 37,990 47 38,037
UT 3 11 4 0 22,020 2,849 22,031 2,853 24,884
VA 1 0 0 0 0 0 0 0 0
CADMIUM 284
Use Cadmiuma

Total release
c d e f g h i j
WI 1 35 0 0 181 0 35 181 216
Total 41 731 338 142,567 253,065 6,059 357,597 45,164 402,760
a
The TRI data should be used with caution since only certain types of facilities are required to report. This is not an
exhaustive list. Data are rounded to nearest whole number.
b
Data in TRI are maximum amounts released by each facility.
c
Post office state abbreviations are used.
d
Number of reporting facilities.
e
The sum of fugitive and point source releases are included in releases to air by a given facility.
f
Surface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal
and metal compounds).
g
Class I wells, Class II-V wells, and underground injection.
h
Resource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface
impoundments, other land disposal, other landfills.
i
Storage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for
disposal, unknown
j
The sum of all releases of the chemical to air, land, water, and underground injection wells.
k
Total amount of chemical transferred off-site, including to POTWs.
RF = reporting facilities; UI = underground injection

CADMIUM 285
Use Cadmium Compoundsa

Total release
c d e f g h i j
AK 3 129 3 0 61,176 0 61,308 0 61,308
AL 4 221 122 0 698,581 0 698,681 243 698,924
AR 1 0 0 0 0 131 0 131 131
AZ 3 611 5 0 63,392 0 63,753 255 64,008
CA 1 0 0 0 115 0 0 115 115
CO 1 1 0 0 0 0 1 0 1
CT 1 0 0 0 0 0 0 0 0
FL 1 0 0 0 0 0 0 0 0
GA 3 8 3 0 0 0 9 3 11
ID 2 6,409 6 0 386,455 0 392,870 0 392,870
IL 5 59 117 215 33,651 1,553 1,289 34,306 35,595
IN 3 76 6 0 13,361 41 82 13,402 13,484
LA 1 0 0 0 0 0 0 0 0
MA 3 25 251 0 0 1,021 25 1,272 1,297
MD 1 0 0 0 0 12,400 0 12,400 12,400
MI 1 0 5 0 250 0 0 255 255
MO 1 593 265 0 6,178 9 6,987 58 7,045
NC 1 0 0 0 0 0 0 0 0
NE 1 250 0 0 250 21,000 250 21,250 21,500
NJ 2 5 1 0 1,488 140 5 1,629 1,634
NV 4 40 0 0 165,471 0 165,506 5 165,511
NY 1 0 21 0 0 0 21 0 21
OH 10 37 102 0 4,264 15,604 1,471 18,536 20,007
OK 1 31 0 0 0 0 31 0 31
PA 8 646 326 0 2,596 9,442 721 12,289 13,010
SC 1 255 10 0 6,165 0 265 6,165 6,430
TN 5 1,997 597 0 192,927 428 195,516 433 195,949
TX 7 30 335 2,118 334,113 2,583 334,650 4,529 339,179
UT 4 130 133 0 54,954 107 55,217 107 55,324
WA 1 2 2 0 0 5 4 5 9
WI 3 10 27 0 1 6,623 10 6,651 6,661
CADMIUM 286
Use Cadmium Compoundsa

Total release
c d e f g h i j
WV 1 2 7 0 1,018 0 518 509 1,027
Total 85 11,567 2,346 2,333 2,026,406 71,087 1,979,190 134,549 2,113,739
a
The TRI data should be used with caution since only certain types of facilities are required to report. This is not an
exhaustive list. Data are rounded to nearest whole number.
b
Data in TRI are maximum amounts released by each facility.
c
Post office state abbreviations are used.
d
Number of reporting facilities.
e
The sum of fugitive and point source releases are included in releases to air by a given facility.
f
Surface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal
and metal compounds).
g
Class I wells, Class II-V wells, and underground injection.
h
Resource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface
impoundments, other land disposal, other landfills.
i
Storage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for
disposal, unknown
j
The sum of all releases of the chemical to air, land, water, and underground injection wells.
k
Total amount of chemical transferred off-site, including to POTWs.
RF = reporting facilities; UI = underground injection

CADMIUM 287
pig iron and steel production releases an estimated 0.1 g/ton (Pacyna and Pacyna 2001). Atmospheric
cadmium exists mainly in the forms of cadmium oxide and cadmium chloride (Morrow 2001).
Cadmium emissions have decreased dramatically since the 1960s as primary cadmium producers now use
the electrolytic process and pollution control technologies such as agglomeration, electrostatic
purification of gas exhaust, and exhaust filtration have been implemented (Herron 2003; Morrow 2001;
Schulte-Schrepping and Piscator 2002). Anthropogenic cadmium emissions have decreased by over 90%
in the last 50 years (Morrow 2010).
There is a potential for release of cadmium to air from hazardous waste sites. Cadmium has been
detected in air samples collected at 50 of the 1,014 NPL hazardous waste sites where cadmium was
detected in some environmental medium (HazDat 2007). Cadmium compounds were detected in air
samples collected at one of three NPL hazardous waste sites where cadmium compounds were detected.
The HazDat information used includes data from NPL sites only.
6.2.2 Water
Estimated releases of 338 pounds (~0.15 metric tons) of cadmium to surface water from 41 domestic
manufacturing and processing facilities in 2009, accounted for about 0.084% of the estimated total
environmental releases from facilities required to report to the TRI. This estimate includes releases to
wastewater treatment and publicly owned treatment works (TRI09 2011). These releases are summarized
in Table 6-1. Estimated releases of 2,346 pounds (~1.1 metric tons) of cadmium compounds to surface
water from 85 domestic manufacturing and processing facilities in 2009, accounted for about 0.11% of
the estimated total environmental releases from facilities required to report to the TRI. This is estimate
includes releases to wastewater treatment and publicly owned treatment works (TRI09 2011). These
releases are summarized in Table 6-2.
Cadmium may be released to water by natural weathering processes, by discharge from industrial
facilities or sewage treatment plants, atmospheric deposition, by leaching from landfills or soil, or
phosphate fertilizers (EPA 1981a, 1985a; IJC 1989; Morrow 2001). Cadmium may also leach into
drinking water supplies from pipes in the distribution system (Elinder 1985a). The average level of
cadmium in ocean water has been reported between <5 and 110 ng/L, with higher levels reported near
coastal areas and in marine phosphates and phosphorites (Morrow 2001).
CADMIUM 288
Smelting of nonferrous metal ores has been estimated to be the largest anthropogenic source of cadmium
released into the aquatic environment. Cadmium contamination can result from entry into aquifers of
mine drainage water, waste water, tailing pond overflow, and rainwater runoff from mine areas (IARC
1993). The upper Clark Fork River in Montana is contaminated with large amounts of cadmium from
past mining activities between 1880 and 1972. While mining wastes are no longer released into the river,
an estimated 14.5 million cubic meters of tailings have been incorporated into the river bed, floodplain,
and reservoir sediments (Canfield et al. 1994). Other human sources include spent solutions from plating
operations and phosphate fertilizers. Cadmium constitutes up to 35 mg/kg of phosphorous pentoxide, a
component of phosphate-based fertilizers, in the United States (IARC 1993). Atmospheric fallout of
cadmium to aquatic systems is another major source of cadmium to the environment (IARC 1993;
Muntau and Baudo 1992).
A large proportion of the cadmium load in the aquatic environment is due to diffuse pollution originating
from many different sources rather than from point sources. In the estuarine portion of the Hudson River,
it has been found that more cadmium was released from agricultural and urban run-off than from
industrial and municipal sewage treatment plants (Muntau and Baudo 1992). In an urban environment,
there are also multiple sources of cadmium to waste water. In an urban waste water study conducted in
the United Kingdom, cadmium was detected in the waste water originating from industrial, commercial,
and private sectors, with the highest average cadmium concentration detected in the waste water of new
(<5 years old) private housing (0.375 μg/L) (Rule et al. 2006).
There is also a potential for release of cadmium to water from hazardous waste sites. Cadmium has been
detected in surface water samples collected at 354 of the 1,014 NPL hazardous waste sites, and in
groundwater samples collected at 675 of the 1,014 NPL hazardous waste sites where cadmium has been
detected in some environmental medium (HazDat 2007). The HazDat information used includes data
from NPL sites only.
6.2.3 Soil
Estimated releases of 253,065 pounds (~115 metric tons) of cadmium to soils from 41 domestic
manufacturing and processing facilities in 2009, accounted for about 63% of the estimated total
environmental releases of cadmium from facilities required to report to the TRI (TRI09 2011). An
additional 142,567 pounds (~65 metric tons), constituting about 35% of the total environmental
emissions, were released via underground injection and to Class I wells, Class II-V wells (TRI09 2011).
CADMIUM 289
These releases are summarized in Table 6-1. Estimated releases of 2,026,406 pounds (~919 metric tons)
of cadmium compounds to soils from 85 domestic manufacturing and processing facilities in 2009,
accounted for about 96% of the estimated total environmental releases from facilities required to report to
the TRI. An additional 2,333 pounds (~1 metric tons), constituting about 0.1% of the total environmental
emissions, were released via underground injection and to Class I wells, Class II-V wells (TRI09 2011).
These releases are summarized in Table 6-2.
Major sources of cadmium to soil include atmospheric emissions, direct application, and accidental or
fugitive contamination. Direct application emissions refer to phosphate fertilizers, phosphogypsum and
other byproduct gypsums (from the manufacture of phosphoric acid and phosphorite), sewage sludges,
composted municipal solid waste, and residual ashes from wood, coal, or other types of combustion.
Contamination sources include industrial site contamination, mine waste dumps, and corrosion of metal
structures (Alloway and Steinnes 1999).
Approximately 61% of the 5.6 million dry tons of sewage sludge produced annually in the United States
is landspread (NRC 2002). The EPA ceiling limit for the cadmium content of sludge applied to land is
85 mg/kg in sewage sludge, the cumulative pollution loading rate is 39 kg/ha, and the maximum annual
cadmium loading of 1.9 kg-ha-1·year-1 (EPA 2011a). Estimated cadmium concentrations in sewage
sludge range from 0.21 to >11.8 mg/kg (EPA 2009a). Sludges from treatment plants that serve cadmium
industries (i.e., battery manufacturing) tend to have higher levels of cadmium (Alloway and Steinnes
1999).
Phosphate fertilizers are a major source of cadmium input to agricultural soils (EPA 1985a). The natural
cadmium concentration in phosphates ranges from 3 to 100 μg/g (EPA 1985a; Singh 1994). Some may
contain up to 300 mg Cd/kg (Alloway and Steinnes 1999). It is estimated that over 8 million tons of
phosphate fertilizer were used in the United States in 2010 (USDA 2012). Any soil treated with these
fertilizers will have a cadmium input, but exactly how much will vary (Alloway and Steinnes 1999). For
example, continuous fertilization with a high rate of triple super-phosphate (1,175 kg P-ha-1·year-1) for a
period of 36 years resulted in a 14-fold increase in cadmium content of surface soils (Singh 1994).
Wet and dry deposition of cadmium from the atmosphere may also contribute sizable amounts of
cadmium to soil in the areas surrounding sources of atmospheric emissions, such as incinerators and
vehicular traffic, which may release cadmium from burned fuel and tire wear (EPA 1985a; Mielke et al.
1991). High-temperature sources, such as smelters and incinerators, release small particles that are ideal
CADMIUM 290
for long-range atmospheric transport. Also, vapors emitted from high temperature processes will
preferentially condense onto smaller particles, thus making vapor emissions available for transport
(Steinnes and Friedland 2006). Aerosols containing cadmium can be carried very long distances in the
atmosphere before being deposited to soils. In the soils in southern Norway, most of the cadmium and
other heavy metals that are deposited from the atmosphere originate from other parts of Europe (Alloway
and Steinnes 1999). Long-range atmospheric deposition is more evident in organic-rich soils as they have
a tendency to concentrate heavy metals (Steinnes and Friedland 2006).
There is also a potential for release of cadmium to soil from hazardous waste sites. Cadmium has been
detected in soil samples collected at 606 of the 1,014 NPL hazardous waste sites and in sediment samples
collected at 392 of the 1,014 NPL hazardous waste sites where cadmium has been detected in some
environmental medium (HazDat 2007). The HazDat information used includes data from NPL sites only.
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning
Cadmium is expected to partition primarily to soil (80–90%) when released to the environment.
Although particulate and vapor cadmium may be released to the air, the net flux to soil will be positive as
cadmium will eventually deposit onto soils (Morrow 2001; Wilber et al. 1992).
Cadmium and cadmium compounds have negligible vapor pressures (see Table 4-2) but can be released
to the environment by emissions from municipal waste incinerators, nonferrous metal production, and
other high-temperature processes (Morrow 2001). Cadmium emitted to the atmosphere from combustion
processes condense onto very small particulates that are in the respirable range (<10 μm) and are subject
to long-range transport (Steinnes and Friedland 2006; Wilber et al. 1992). These cadmium pollutants may
be transported from a hundred to a few thousand kilometers and have a typical atmospheric residence
time of about 1–10 days before deposition occurs (EPA 1980d). Larger cadmium-containing particles
from smelters and other pollutant sources are also removed from the atmosphere by gravitational settling,
with substantial deposition in areas downwind of the pollutant source. Cadmium-containing particulates
may dissolve in atmospheric water droplets and be removed from air by wet deposition.
Cadmium is more mobile in aquatic environments than most other heavy metals (e.g., lead). In most
natural surface waters, the affinities of complexing ligands for cadmium generally follow the order of
humic acids > CO32– > OH– ≥ Cl– ≥ SO42– (EPA 1979). In unpolluted natural waters, most cadmium
CADMIUM 291
transported in the water column will exist in the dissolved state as the hydrated ion Cd(H2O)62+. Minor
amounts of cadmium are transported with the coarse particulates, and only a small fraction is transported
with the colloids. In unpolluted waters, cadmium can be removed from solution by exchange of cadmium
for calcium in the lattice structure of carbonate minerals (EPA 1979). In polluted or organic-rich waters,
adsorption of cadmium by humic substances and other organic complexing agents plays a dominant role
in transport, partitioning, and remobilization of cadmium (EPA 1979). Cadmium concentration in water
is inversely related to the pH and the concentration of organic material in the water (EPA 1979). Because
cadmium exists only in the +2 oxidation state in water, aqueous cadmium is not strongly influenced by
the oxidizing or reducing potential of the water. However, under reducing conditions, cadmium may
form cadmium sulfide, which is poorly soluble and tends to precipitate (EPA 1983c; McComish and Ong
1988). Free (ionic) cadmium seems to be the toxic form and becomes much more prevalent at low
salinity (Sprague 1986). Cadmium has a relatively long residence time in aquatic systems. In Lake
Michigan, a mean residence time of 4–10 years was calculated for cadmium compared to 22 years
calculated for mercury (Wester et al. 1992).
Precipitation and sorption to mineral surfaces, hydrous metal oxides, and organic materials are the most
important processes for removal of cadmium to bed sediments. Humic acid is the major component of
sediment responsible for adsorption. Sorption increases as the pH increases (EPA 1979). Sediment
bacteria may also assist in the partitioning of cadmium from water to sediments (Burke and Pfister 1988).
Both cadmium-sensitive and cadmium-resistant bacteria reduced the cadmium concentration in the water
column from 1 ppm to between 0.2 and 0.6 ppm, with a corresponding increase in cadmium concentration
in the sediments in the simulated environment (Burke and Pfister 1988). Studies indicate that
concentrations of cadmium in sediments are at least one order of magnitude higher than in the overlying
water (EPA 1979). The mode of sorption of cadmium to sediments is important in determining its
disposition to remobilize. Cadmium associated with carbonate minerals, precipitated as stable solid
compounds or co-precipitated with hydrous iron oxides, is less likely to be mobilized by resuspension of
sediments or biological activity. Cadmium that is adsorbed to mineral surfaces such as clay, or to organic
materials, is more easily bioaccumulated or released in the dissolved state when the sediment is disturbed
(EPA 1979). Cadmium may redissolve from sediments under varying ambient conditions of pH, salinity,
and redox potential (DOI 1985; EPA 1979; Feijtel et al. 1988; Muntau and Baudo 1992). Cadmium is not
known to form volatile compounds in the aquatic environment, so partitioning from water to the
atmosphere does not occur (EPA 1979).
CADMIUM 292
Debusk et al. (1996) studied the retention and compartmentalization of lead and cadmium in wetland
microcosms. Differences between measured concentrations in inflow and outflow samples indicated that
approximately half of the added cadmium was retained in the wetland microcosms. Experiments showed
that nearly all trace metals were present in the sediments as sulfides, limiting their bioavailability and
toxicity. The results of their analyses and a lack of noticeable biological effects suggested that in
wetlands containing organic sediments, the sediment chemistry dominates cycling of the trace metals.
In soils, pH, oxidation-reduction reactions, and formation of complexes are important factors affecting the
mobility of cadmium (Bermond and Bourgeois 1992; Herrero and Martin 1993). Cadmium can
participate in exchange reactions on the negatively charged surface of clay minerals. In acid soils, the
reaction is reversible. However, adsorption increases with pH and may become irreversible (Herrero and
Martin 1993). Cadmium also may precipitate as insoluble cadmium compounds, or form complexes or
chelates by interaction with organic matter. Available data suggest that organic matter is more effective
than inorganic constituents in keeping cadmium unavailable (McBride 1995). Examples of cadmium
compounds found in soil are Cd3(PO4)2, CdCO3, and Cd(OH)2 (Herrero and Martin 1993). These
compounds are formed as the pH rises. It has been found that about 90% of cadmium in soils remains in
the top 15 cm (Anonymous 1994).
The mobility and plant availability of cadmium in wetland soils are substantially different from upland
soils. Cadmium tends to be retained more strongly in wetland soils and is more available to plants under
upland conditions (Gambrell 1994). Debusk et al. (1996) compared heavy metal uptake by cattails and
duckweed wetland microcosms and found that duckweed, on a whole-plant basis, accumulates cadmium
more effectively than cattail does. The potential cadmium removal rate for duckweed is 2–4 mg
Cd/m2/day.
Cadmium in soils may leach into water, especially under acidic conditions (Elinder 1985a; EPA 1979).
Roy et al. (1993) demonstrated that chlorine complexation in the leachate of ash from a municipal solid
waste incinerator can result in a decrease in cadmium sorption by two common clays, kaolinite and illite.
They also found that cationic competitive sorption enhances mobility in soils. Cadmium-containing soil
particles may also be entrained into the air or eroded into water, resulting in dispersion of cadmium into
these media (EPA 1985a). Contamination of soil by cadmium is of concern because the cadmium is taken
up efficiently by plants and, therefore, enters the food chain for humans and other animals. A low soil
pH, which is becoming prevalent in many areas of the world due to acid rain, increases the uptake of
cadmium by plants (Elinder 1992).
CADMIUM 293
Aquatic and terrestrial organisms bioaccumulate cadmium (Handy 1992a, 1992b; Kuroshima 1992; Naqvi
and Howell 1993; Roseman et al. 1994; Suresh et al. 1993). Cadmium concentrates in freshwater and
marine animals to concentrations hundreds to thousands of times higher than in the water (EPA 1979).
Reported bioconcentration factors (BCFs) range from <200 to 18,000 for invertebrates (van Hattum et al.
1989), from 3 to 4,190 for fresh water aquatic organisms (ASTER 1995), and from 5 to 3,160 for
saltwater aquatic organisms (ASTER 1994). Bioconcentration in fish depends on the pH and the humus
content of the water (John et al. 1987). Because of their high ability to accumulate metals, some aquatic
plants have been suggested for use in pollution control. For example, it has been suggested that the
rapidly-growing water hyacinth (Eichhornia crassipes) could be used to remove cadmium from domestic
and industrial effluents (Ding et al. 1994; Muntau and Baudo 1992).
The data indicate that cadmium bioaccumulates in all levels of the food chain. Cadmium accumulation
has been reported in grasses and food crops, and in earthworms, poultry, cattle, horses, and wildlife
(Alloway et al. 1990; Beyer et al. 1987; Gochfeld and Burger 1982; Kalac et al. 1996; Munshower 1977;
Ornes and Sajwan 1993; Rutzke et al. 1993; Sileo and Beyer 1985; Vos et al. 1990). The metal burden of
a crop depends on uptake by the root system, direct foliar uptake and translocation within the plant, and
surface deposition of particulate matter (Nwosu et al. 1995). In general, cadmium accumulates in the
leaves of plants and, therefore, is more of a risk in leafy vegetables grown in contaminated soil than in
seed or root crops (Alloway et al. 1990). He and Singh (1994) report that, for plants grown in the same
soil, accumulation of cadmium decreased in this order: leafy vegetables, root vegetables, and grain crops.
Alloway et al. (1990) also demonstrated that uptake of cadmium decreased in this order: lettuces,
cabbages, radishes, and carrots. Nwosu et al. (1995) investigated the uptake of cadmium and lead in
lettuce and radish grown in loam soil spiked with known mixtures of CdCl2 and Pb(NO3)2. They found
that the mean uptake of cadmium by lettuce and radish increased as the concentrations of cadmium and
lead in the soil increased. Their results supported previous findings that cadmium is absorbed by passive
diffusion and translocated freely in the soil. The observed decline in cadmium uptake by lettuce at
400 mg/kg could be attributed to saturation of the active binding sites on the plant root system or by early
toxicological responses of the plant root. The study also supported earlier findings that radish did not
accumulate as much cadmium as lettuce.
Some studies have concluded that soil pH is the major factor influencing plant uptake of cadmium from
soils (Smith 1994). Amending soil with lime raises the pH, increasing cadmium adsorption to the soil and
reducing bioavailability (He and Singh 1994; Thornton 1992). One study found that in peeled potato
CADMIUM 294
tubers, potato peelings, oat straw, and ryegrass, cadmium concentrations generally decreased as simple
linear functions of increasing soil pH over the range of pH values measured (pH 3.9–7.6) (Smith 1994).
Soil type also affects uptake of cadmium by plants. For soils with the same total cadmium content,
cadmium has been found to be more soluble and more plant-available in sandy soil than in clay soil (He
and Singh 1994). Similarly, cadmium mobility and bioavailability are higher in noncalcareous than in
calcareous soils (Thornton 1992). Oxidation-reduction potential may also have a large effect on soil-to-
plant cadmium transport. The absorption of cadmium paddy rice is significantly affected by the
oxidation-reduction potential of the soil. The oxidation-reduction potential of rice paddy soils shifts
drastically compared to upland soils due to submerging and draining techniques. Cadmium to rice ratios
(cadmium concentration in brown rice/cadmium concentration in soil) were the smallest when the rice
was grown under submerged conditions during the whole growth period. The ratios were the largest
when the soil (coarse Toyama soil) was drained after the tillering stage. This is due to changes in
cadmium solubility. Under flooded conditions, cadmium sulfide formation increases, and thus, cadmium
solubility decreases (Iimura 1981).
Since cadmium accumulates largely in the liver and kidneys of vertebrates and not in the muscle tissue
(Harrison and Klaverkamp 1990; Sileo and Beyer 1985; Vos et al. 1990), and intestinal absorption of
cadmium is low, biomagnification through the food chain may not be significant (Sprague 1986). In a
study of marine organisms from the Tyrrhenian Sea, no evidence of cadmium biomagnification was found
along pelagic or benthic food webs (Bargagli 1993). Although some data indicate increased cadmium
concentrations in animals at the top of the food chain, comparisons among animals at different trophic
levels are difficult, and the data available on biomagnification are not conclusive (Beyer 1986; Gochfeld
and Burger 1982). Nevertheless, uptake of cadmium from soil by feed crops may result in high levels of
cadmium in beef and poultry (especially in the liver and kidneys). This accumulation of cadmium in the
food chain has important implications for human exposure to cadmium, whether or not significant
biomagnification occurs.
Boularbah et al. (1992) isolated sic cadmium-resistant bacterial strains from a soil receiving dredged
sediments and containing 50 mg Cd/kg. The isolates tolerated higher cadmium concentrations than the
control strain and accumulated cadmium at concentrations ranging from 0 to 100 mg/L. One of the
isolates, Bacillus brevis, was found to be the most resistant to cadmium, with the ability to accumulate up
to 70 mg Cd/g of cells dry weight, and may have some use in reclamation of metal-contaminated soils.
CADMIUM 295
6.3.2 Transformation and Degradation
6.3.2.1 Air
Little information is available on the atmospheric reaction of cadmium (EPA 1980d). The common
cadmium compounds found in air (oxide, sulfate, chloride) are stable and not subject to photochemical
reactions (EPA 1980d). Cadmium sulfide may photolyze to cadmium sulfate in aqueous aerosols (Konig
et al. 1992). Transformation of cadmium among types of compounds in the atmosphere is mainly by
dissolution in water or dilute acids (EPA 1980d).
6.3.2.2 Water
In fresh water, cadmium is present primarily as the cadmium(+2) ion and Cd(OH)2 and CdCO3
complexes, although at high concentrations of organic material, more than half may occur in organic
complexes (McComish and Ong 1988). Some cadmium compounds, such as cadmium sulfide, cadmium
carbonate, and cadmium oxide, are practically insoluble in water. However, water-insoluble compounds
can be changed to water-soluble salts by interaction with acids or light and oxygen. For example,
aqueous suspensions of cadmium sulfide can gradually photoxidize to soluble cadmium (IARC 1993).
Cadmium complexation with chloride ion increases with salinity until, in normal seawater, cadmium
exists almost entirely as chloride species (CdCl+, CdCl2, CdCl3–) with a minor portion as Cd2+. In
reducing environments, cadmium precipitates as cadmium sulfide in the presence of sulfide ions
(McComish and Ong 1988). Photolysis is not an important mechanism in the aquatic fate of cadmium
compounds (EPA 1983c), nor is biological methylation likely to occur (EPA 1979).
6.3.2.3 Sediment and Soil
Transformation processes for cadmium in soil are mediated by sorption from and desorption to water, and
include precipitation, dissolution, complexation, and ion exchange (McComish and Ong 1988).
Important factors affecting transformation in soil include the cation exchange capacity, pH, and content of
clay minerals, carbonate minerals, oxides, organic matter, and oxygen (McComish and Ong 1988).
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to cadmium depends in part on the reliability of
supporting analytical data from environmental samples and biological specimens. Concentrations of
cadmium in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits
CADMIUM 296
of current analytical methods. In reviewing data on cadmium levels monitored or estimated in the
environment, it should also be noted that the amount of chemical identified analytically is not necessarily
equivalent to the amount that is bioavailable. The analytical methods available for monitoring cadmium
in a variety of environmental media are detailed in Chapter 7.
6.4.1 Air
Cadmium levels in ambient air generally range from 0.1 to 5 ng/m3 in rural areas, 2–15 ng/m3 in urban
areas, and 15–150 ng/m3 in industrialized areas. Remote areas can contain lower levels of cadmium
(Morrow 2001). Cadmium can undergo long-range atmospheric transport and deposition causing
cadmium contamination in areas with no local cadmium inputs. Smoking can greatly affect indoor air
concentrations of cadmium. In nonsmoking environments, there is little difference between indoor and
outdoor air quality (Morrow 2001). Monitoring studies conducted for EPA’s 2006 Final Report for the
Urban Air Toxics Monitoring Program detected cadmium in ambient air at several monitoring sites
throughout the United States. At all detection sites in Bountiful, Utah; Northbrook, Illinois; Austin,
Texas; St. Louis, Missouri; Indianapolis, Indiana; and Birmingham, Alabama average daily cadmium
levels in ambient air were <0.01 μg/m3. In Bountiful, Utah average daily cadmium levels were reported
as 0.0008 μg/m3 (EPA 2007).
Emission rates of cadmium from solid waste incinerators have been found to range from 20 to
2,000 μg/m3 from the stacks of traditional incinerators and from 10 to 40 μg/m3 from advanced
incinerators. Advances in pollution control and increased government regulations have resulted in
decreased cadmium emissions to the environment (EPA 1990a; Herron 2003; Morrow 2001; Schulte-
Schrepping and Piscator 2002). Although there may be an increase in fossil fuel combustion and waste
incineration, it does not appear likely that overall cadmium emissions to air will increase substantially in
the United States.
Cadmium levels in aerosols over Russian Arctic seas were measured in order to understand the magnitude
of long-range atmospheric deposition. Ten-year average monthly mean concentrations ranged from
0.002 to 0.080 ng/m3 in Franz Josef Land and from 0.0026 to 0.048 ng/m3 in Sevemaya Zemlya. The
highest concentrations were reported in the spring season and the lowest concentrations reported in the
autumn for both sampling sites. During the winter and spring months, it was estimated that >50% of the
average air pollutant concentrations in the Russian Arctic are due to atmospheric pollution. The
CADMIUM 297
anthropogenic sources of cadmium to the Russian Arctic are the industrial areas of Northern Europe, Kola
Peninsula, and the Urals and Norilsk regions (Shevchenko et al. 2003).
Atmospheric concentrations of cadmium are generally highest in the vicinity of cadmium-emitting

industries such as smelters, municipal incinerators, or fossil fuel combustion facilities (Elinder 1985a;
Pirrone et al. 1996). The mean annual concentration of airborne cadmium in an area about 1 km from a
zinc smelter in Colorado was 0.023 μg/m3 (2.3x10-5 mg/m3) (IARC 1993). Sweet et al. (1993) conducted
a study of airborne inhalable particulate matter (PM-10) over a 2-year period in two urban/industrial areas
(southeast Chicago and East St. Louis) and one rural area in Illinois. There was a significant difference
between the cadmium levels in the urban areas and the cadmium levels in the rural area. Cadmium
concentrations in the East St. Louis area were 5–10 times higher, with a range of <4 to 115 ng/m3
(average 15[24] ng/m3) for fine particles and a range of <4–97 ng/m3 (average 10[18] ng/m3) for course
particles. In the Kikinda region of Serbia and Montenegro, where metal processing and construction
industries are located, a mean annual atmospheric deposit of 36.0 μg/m2 per day was reported in 1995. A
period of decreased industrial production, which decreased atmospheric cadmium deposits by 93%,
resulted in 17% cadmium reduction in cattle feed and 13% in milk (Vidovic et al. 2005). Moss studies
conducted by Hasselbach et al. (2005) in the area of the Red Dog Mine in Alaska reported cadmium
levels >24 mg/kg dry weight in moss adjacent to the ore haul road. Ore dust containing heavy metals
escapes from the ore trucks on the haul road and can be deposited in the nearby area (Hasselbach et al.
2005).
Annual average concentrations of atmospheric cadmium over three Great Lakes reflect the influence of
industrialization and urbanization; Lake Erie’s levels of 0.6 ng/m3 were higher than fine particle
concentrations of 0.2 ng/m3 over Lake Michigan and <0.2 ng/m3 over Lake Superior (Sweet et al. 1998).
In the Lake Michigan Urban Air Toxics Study of dry deposition of metals, the flux of cadmium on the
south side of Chicago was reported at about 0.01 mg/m2/day and levels in rural Michigan and over Lake
Michigan were far lower (Holsen et al. 1993).
6.4.2 Water
The average level of cadmium in ocean water has been reported between <5 and 110 ng/L, with higher
levels reported near coastal areas and in marine phosphates and phosphorites (Morrow 2001).
CADMIUM 298
Thornton (1992) reports that waters from the vicinity of cadmium-bearing mineral deposits may have
cadmium concentrations of ≥1,000 μg/L. The cadmium concentration of natural surface water and
groundwater is usually <1 μg/L (Elinder 1985a, 1992). EPA requires water suppliers to limit the
cadmium concentration in drinking water to <5 μg/L (EPA 2006a).
Groundwater in New Jersey has an estimated median level of 1 μg Cd/L with a high level of 405 μg/L. In
a survey of groundwater surrounding waste sites, a concentration of 6,000 μg Cd/L was found (NTP
1994). The National Urban Runoff Program measured cadmium concentrations in urban storm water
runoff; concentrations ranged from 0.1 to 14 μg/L in 55% of samples that were positive for cadmium
(Cole et al. 1984). Cadmium in highway run-off has been detected at levels of 0.0–0.06 mg/L (0.0–
60 μg/L).
In the estuarine portion of the Hudson River, more cadmium was released from agricultural and urban
run-off than from industrial and municipal sewage treatment plants (Muntau and Baudo 1992). In an
urban environment, there are also multiple sources of cadmium to waste water, based on an urban waste
water study conducted in the United Kingdom. Cadmium was detected in the waste water originating
from industrial, commercial, and private sectors, with the highest average cadmium concentration
detected in the foul water of new (<5 years old) private housing (0.375 μg/L) (Rule et al. 2006).
Cadmium was detected in the contaminated groundwater plume near in the Moon Creek watershed in the
Couer D’Alene Mining District of Idaho at concentrations of ≤0.077 mg/L. The cadmium was
transported to the creek with the plume where it was subsequently diluted (Paulson 1997). In the Spring
River Basin of Kansas, Missouri, and Oklahoma, part of the Tri-State Mining District, cadmium was
detected in surfaces waters at concentrations ranging from <1.0 to 24 μg/L (peak flow) and from <1.0 to
75.0 μg/L (base flow). It was detected in the sediment of the sampling sites at concentrations ranging
from 0.62 to 300 μg/g dry weight in the <250 μm sediment fraction and from 0.89 to 180 μg/g dry weight
in the <63 μm fraction (Angelo et al. 2007).
6.4.3 Sediment and Soil
Cadmium concentrations in soils not contaminated by anthropogenic sources range from 0.06 to
1.1 mg/kg, with a minimum of 0.01 mg/kg and a maximum of 2.7 mg/kg (Alloway and Steinnes 1999).
Cadmium content in marine sediments ranges from 0.1 to 1.0 μg/g (ppm) in the Atlantic and Pacific
oceans (Thornton 1992). Average cadmium concentration in agricultural soils of remote locations was
reported as 0.27 mg/kg (Holmgren et al. 1993). Soils with parent materials such as black shale (cadmium
CADMIUM 299
content up to 24 mg/kg) may have higher concentrations of natural cadmium. Since the U.S. mandatory
limit of cadmium in sewage sludge is <20 mg/kg, soils receiving sewage sludge should not have
heightened cadmium levels (Alloway and Steinnes 1999). Topsoil concentrations are often more than
twice as high as subsoil levels as the result of atmospheric fallout and contamination (Pierce et al. 1982).
Cadmium will partition mostly to soil and sediment when released to the environment. Atmospheric
deposition is a major source of surface soil contamination, which allows cadmium to be introduced into
the food supply (Alloway and Steinnes 1999; Morrow 2001).
Markedly elevated levels may occur in topsoils near sources of contamination. Moss studies conducted
by Hasselbach et al. (2005) in the area of the Red Dog Mine in Alaska reported cadmium levels
>24 mg/kg dry weight in moss (n=151), as a measure atmospheric deposition onto soil surfaces, within
10 m of the ore haul road. Ore dust containing heavy metals escapes from the ore trucks during loading
and unloading at the mine and port site settles on the surfaces of the trucks, which blow off the trucks
during transport on the haul road and deposited in the nearby area. The mean cadmium concentrations in
moss and subsurface soil throughout the entire study were 1.86 and 0.27 mg/kg dry weight, respectively.
Cadmium concentrations in moss and subsurface soil were 0.08–24.30 and 0.07–0.75 mg/kg dry weight.
There did not appear to be a connection between the elevated subsurface cadmium levels and the local
geochemistry. Geospatial analysis showed that areas as far as 12 km north of the haul road may be
affected by mining emission depositions (Hasselbach et al. 2005). In the vicinity of a smelter in Helena,
Montana, average soil values were 72 ppm within 1 km and 1.4 ppm between 18 and 60 km (EPA 1981a).
Total cadmium concentrations in soil samples taken from a Superfund site in southeast Kansas ranged
from 15 to 86 mg/kg (ppm). In the same study, soil samples were extracted with diethylenetriamine-
pentaacetic acid (DPTA) to approximate the plant-available metal concentrations. Extractable cadmium
concentrations ranged from 0.6 to 10 mg/kg (ppm) (Abdel-Saheb et al. 1994). Soil cadmium levels in
five Minnesota cities were highest in areas with the most vehicular traffic (>2 ppm in about 10% of inner-
city samples) and also showed a pattern consistent with past deposition from a sewage-sludge incinerator
(Mielke et al. 1991). Cadmium levels >750 mg/kg have been found in sites polluted by nonferrous metal
mining and smelting have been reported (Alloway and Steinnes 1999).
In the Spring River Basin of Kansas, Missouri, and Oklahoma, part of the Tri-State Mining District,
cadmium was detected in surfaces waters at concentrations of <1.0–24 μg/L (peak flow) and <1.0–
75.0 μg/L (base flow). Cadmium was detected in the sediment of the sampling sites at concentrations
ranging from 0.62 to 300 μg/g dry weight in the <250 μm sediment fraction and from 0.89 to 180 μg/g
dry weight in the <63 μm fraction (Angelo et al. 2007). A study conducted in 1999 at the Patroon Creek
CADMIUM 300
Reservoir in Albany County, New York sampled sediment cores for heavy metals, including cadmium.
The watershed includes two industrial sites: one in operation from 1955 to present and the other
operating from 1958 to 1984. Sediment samples in the interval of 0–1.68 m showed an average cadmium
concentration of 1.69 mg/kg. This concentration is comparable to other stream and reservoir sediments
impacted by industrial pollution (Arnason and Fletcher 2003). Sediments of the Sawmill River in
Yonkers, New York contained the highest cadmium levels (6.9 mg/kg) in the Hudson River Basin during
a sampling study conducted between 1992 and 1995 (USGS 1998b).
Surficial sediments collected from 18 locations in three major tributaries to Newark Bay, New Jersey, had
a mean cadmium concentration of 10±6 mg/kg (ppm) dry weight (Bonnevie et al. 1994). The highest
cadmium concentrations were found in the Ironbound section of the Passaic River, a heavily
industrialized area (29 mg/kg and 14 mg/kg), and in the Arthur Kill on the northwest side of Prall’s Island
(15 mg/kg). An investigation of metals distribution in sediments along the Hudson River estuary revealed
that cadmium concentrations in suspension were higher than in the bottom sediments by a factor of 30
(Gibbs 1994).
Soils derived from dredged material in confined disposal facilities in the Great Lakes Region had
cadmium concentrations (dry weight) of <1.9–32 ppm (Beyer and Stafford 1993). In an analytical survey
of sewage sludges from 16 large cities in the United States, cadmium concentrations ranged from 2.72 to
242 ppm (dry weight). Besides the sample with a cadmium concentration of 242 ppm, all other sludges
had cadmium contents ≤14.7 ppm (Gutenmann et al. 1994).
6.4.4 Other Environmental Media
Cadmium levels in food can vary greatly depending on the type of food, agricultural and cultivating
practices, and amount atmospheric deposition and other anthropogenic contamination. In general, leafy
vegetables, such as lettuce and spinach, and staples, such as potatoes and grains, contain relatively high
values of cadmium. Peanuts, soybeans, and sunflower seeds have naturally high levels of cadmium.
Meat and fish container lower amounts of cadmium, with the exception of animal organ meats, such as
kidney and liver, as these organs concentrate cadmium (Morrow 2001).
As part of the U.S. Food and Drug Administration (FDA) Total Diet Study, average concentrations of
cadmium in 14 food groups were analyzed from samples collected in 56 American cities. Cadmium was
found in nearly all samples at varying concentrations. In general, the eggs, milk and cheese, condiments
CADMIUM 301
and sweeteners, beverages, and fats and dressings groups contained low concentrations of cadmium
(≤0.004 mg/kg) (FDA 2010). Food items that contained high levels of cadmium were dry roasted peanuts
(0.054 mg/kg), shredded wheat cereal (0.050 mg/kg), boiled spinach (0.124 mg/kg), iceberg lettuce
(0.051 mg/kg), leaf lettuce (0.064 mg/kg), and potato chips (0.057 mg/kg) (FDA 2010). Table 6-3
summarizes the data from this study.
Watanabe et al. (1996) measured the cadmium content in rice samples from various areas in the world
during the period from 1990 to 1995. Twenty-nine samples collected in the United States had a geometric
mean of 7.43 ng Cd/g, with a standard deviation of 2.11. Shellfish, liver, and kidney meats have higher
concentrations than other fish or meat (up to 1 ppm) (Elinder 1985a; IARC 1993; Schmitt and
Brumbaugh 1990). Particularly high concentrations of cadmium of 2–30 mg/kg (ppm) fresh weight have
been found in the edible brown meat of marine shellfish (Elinder 1992). Cadmium concentrations up to
8 μg/g in oysters and 3 μg/g in salmon flesh have been reported (IARC 1993). Sprague (1986) reviewed
tissue concentrations of cadmium for marine mollusks and crustaceans. They found that drills, a type of
sea snail, were higher in cadmium (average, 26 μg/g dry weight) than almost all other mollusks, although
scallops and whelks also tended to be high. Oysters from polluted areas averaged 18 μg/g dry weight,
which was significantly higher than oysters from clean areas (average concentration 1.4 µg/g dry weight).
Clams were relatively low in cadmium (average, 0.5–1.0 μg/g dry weight). The average concentration of
cadmium in clams from polluted areas was only 2.7 μg/g dry weight, but this was significantly higher
than levels in clams from clean areas. In Fiscal Year (FY) 1985/1986, the FDA conducted a survey of
cadmium, lead, and other elements in fresh clams and oysters collected from U.S. coastal areas used for
shellfish production (Capar and Yess 1996). Average cadmium levels (wet weight) were
0.09±0.06 mg/kg (ppm) (n=75) in hardshell clams, 0.05±0.04 mg/kg (n=59) in softshell clams,
0.51±0.31 mg/kg (n=104) in Eastern oysters, and 1.1±0.6 mg/kg (n=40) in Pacific oysters. In FY91, FDA
analyzed 5 samples of domestic clams and 24 samples of domestic oysters (collected from both coasts)
for cadmium and found average concentrations of 0.06 and 0.62 mg/kg, respectively (Capar and Yess
1996). Although no conclusions can be drawn in light of the small numbers of FY91 samples, these
results do not appear to be appreciably different from those of the FY85/86 survey..
Cadmium is accumulated mainly in the hepatopancreas (digestive gland) of the crab, and cadmium levels
as high as 30–50 ppm have been detected in this edible part of the animal. Cadmium levels as high as
10 ppm also have been measured in some species of wild-growing edible mushrooms (Lind et al. 1995).
Lind et al. (1995) conducted a feeding study in mice to determine the bioavailability of cadmium from
crab hepatopancreas and mushroom in relation to organic cadmium. The cadmium accumulation in the
CADMIUM 302
Table 6-3. Mean Concentrations of Cadmium for FDA’s Total Diet Study Market
Baskets 2006-1 through 2008-4
Food product Mean concentration range (mg/kg)

Milk and cheese Not detected–0.002
Eggs Not detected–0.0003
Meat, poultry, and fish Not detected–0.069
Legumes and nuts 0.001–0.054
Grain products 0.0001–0.028
Fruit Not detected–0.015
Vegetables 0.001–0.124
Mixed dishes and meals 0.003–0.021
Desserts Not detected–0.028
Condiments and sweeteners 0.001–0.0002
Fats and dressings Not detected–0.004
Beverages Not detected–0.001
Infant and junior foods 0.0002–0.026
Source: FDA 2010

CADMIUM 303
liver and kidney of the mice was used as an estimate of the intestinal absorption. The group that was fed
crab accumulated less cadmium in the liver and kidney than the groups fed mushrooms or inorganic
cadmium salt. They concluded from the results of the study that cadmium from boiled crab has a lower
bioavailability for absorption in the gastrointestinal tract of mice than inorganic cadmium and cadmium
from dried mushrooms. Almost all (99%) of the cadmium in the boiled crab hepatopancreas was
associated with insoluble ligands, probably denatured protein. In fresh crab hepatopancreas, most of the
cadmium is in a soluble form bound to metallothionein (Lind et al. 1995).
Significant concentrations of cadmium have been observed in fish living in stormwater ponds in Florida,
especially in the redear sunfish, a bottom feeder (Campbell 1994). The mean cadmium concentration in
redear sunfish living in stormwater ponds was 1.64 mg/kg wet weight compared to 0.198 mg/kg for
redear sunfish living in control ponds. Similarly, the mean cadmium concentration in largemouth bass
living in stormwater ponds was 3.16 mg/kg wet weight compared to 0.241 mg/kg for largemouth bass
living in control ponds. Red drum, flounder, and seatrout collected from South Carolina estuaries during
the period 1990–1993 had consistently low cadmium levels throughout the sampling area and with
respect to species (Mathews 1994). The mean concentration for all fillets and whole fish was 86.2 ppb
wet weight, with 70.7% (n=164) of the samples having <25 ppb.
Cadmium and other heavy metals were detected in several of the freshwater invertebrates and fish of two
Maryland streams. Due to their remote location and lack of source inputs, it is believed that the cadmium
contamination was a result of long-range atmospheric deposition. Samples were taken from the
Herrington Creek tributary (HCRT) and Blacklick Run (BLK) during October 1997, April 1998, and July
1998. Cadmium concentrations in the trout of BLK ranged from about 37 to 90 ng/g wet, with the older
specimens having the higher cadmium concentrations. Cadmium concentrations in crayfish ranged from
about 40 to 160 ng/g wet in BLK, with the younger specimens containing the highest levels of cadmium.
Crayfish in HRCT ranged from 45 to 155 ng/g, with the highest levels in the middle age group. In
crayfish, cadmium strongly accumulates in the gills, while the kidney accumulates cadmium in trout
(Mason et al. 2000).
Cadmium concentrations in the fish of the mining-contaminated waters of Oklahoma were reported by
Brumbaugh et al. (2005). This area was part of the Tri-State Mining District that was extensively mined
for lead and zinc from the mid-1800s to the 1950s, and contains nonremediated sites. Blood and carcass
cadmium concentrations differed between species and sites, but were generally greatest in carp. Carcass
cadmium in catfish were relatively low, with <0.1 μg/g dry weight in 34 of 36 samples.
CADMIUM 304
Cadmium concentrations of ≥0.5 ppm have been found in rice grown in cadmium-polluted areas of Japan
(Nogawa et al. 1989) and China (Shiwen et al. 1990). Tobacco also concentrates cadmium from the soil,
and cadmium content of cigarettes typically ranges from 1 to 2 μg/cigarette (Elinder 1985a, 1992).
Some food crops, including confectionery sunflowers, have a propensity to take up cadmium from the soil
in which they are grown and deposit it in the kernels. In a study to determine the cadmium burden of
persons who report regular consumption of sunflower kernels, Reeves and Vanderpool (1997) analyzed
19 different lots of sunflower kernels from the 1995 crop grown in the northern Great Plains region of
North Dakota and Minnesota. They found a range of 0.33–0.67 μg Cd/g, with a mean±standard deviation
of 0.48±0.11 μg/g fresh weight. The study showed that high intakes of sunflower kernels increased the
intake of cadmium. However, the amount of cadmium in whole blood or in red blood cells was not
affected by cadmium intake. The authors pointed out that an increased intake of sunflowers will increase
not only the cadmium intake, but also the intake of copper and phytate. In turn, this could reduce the
availability of cadmium from this food source.
DOI (1985) examined the concentrations of cadmium in a variety of aquatic and terrestrial flora and fauna
and identified six trends: (1) in general, marine biota contained significantly higher cadmium residues
than their freshwater or terrestrial counterparts; (2) cadmium tends to concentrate in the viscera of
vertebrates, especially in the liver and kidneys; (3) cadmium concentrations are higher in older organisms
than in younger ones, especially in carnivores and marine vertebrates; (4) higher concentrations for
individuals of a single species collected at various locations are almost always associated with proximity
to industrial/urban areas or point-source discharges of cadmium-containing wastes; (5) background levels
of cadmium in crops and other plants are generally <1.0 mg/kg (ppm); and (6) cadmium concentrations in
biota are dependent upon the species analyzed, the season of collection, ambient cadmium levels, and the
sex of the organism.
During a study monitoring cadmium levels in 331 cigarette packs from over 20 areas around the world it
was found that the mean cadmium level per cigarette was 1.15 µg/cigarette ±0.43 (AM±ASD) or
1.06 µg/cigarette ±1.539 (geometric mean [GM]±geometric standard deviation[GSD]). Cigarettes from
Mexico had the highest mean level of cadmium with an AM±ASD of 2.03 µg/cigarette ±0.33 or a
GM±GSD of 2.00 µg/cigarette ±1.190. Cigarettes from India had the lowest mean levels of cadmium
with an AM±ASD of 0.35 µg/cigarette ±0.09 or a GM±GSD of 0.34 µg/cigarette ±1.284. The arithmetic
CADMIUM 305
mean for the United States was 1.07 µg/cigarette ±0.11 and the GM±GSD was 1.06 µg/cigarette ±1.115
(Watanabe et al. 1987).
The cadmium content of coals varies widely; concentrations of 0.01–180 μg/g (ppm) have been reported
for the United States (Thornton 1992; Wilber et al. 1992).
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
The general population may be exposed to cadmium through ingestion of food and drinking water,
inhalation of particulates from ambient air or tobacco smoke, or ingestion of contaminated soil or dust.
For nonsmokers, food is the major source of cadmium exposure (NTP 2005). Inhalation of cigarette
smoke is the major source of cadmium exposure for smokers (CDC 2005). Cadmium is introduced to the
food chain through agricultural soils, which may naturally contain cadmium, or from anthropogenic
sources such as atmospheric deposition or direct application methods such as phosphate fertilizer
application and municipal waste composting (Alloway and Steinnes 1999; Morrow 2001). Cadmium-
plated utensils and galvanized equipment used in food processing and preparation; enamel and pottery
glazes with cadmium-based pigments; and stabilizers used in food-contact plastics are also sources of
food contamination (Galal-Gorchev 1993). Cadmium levels in soils are not a direct indicator of the level
of cadmium in the food supply, with the exception of extreme contamination, as other factors such as the
type of crop and farming methods are important (Morrow 2001).
Based on food intake rates and food-cadmium concentrations, the estimated geometric mean daily intake
of cadmium for the U.S. population is 18.9 μg/day, down from an estimated 30 μg/day in the 1980s
(Choudhury et al. 2001; Gartrell et al. 1986). Based on the mean cadmium daily intakes for males and
females aged 6–60 years reported by Choudhury et al. (2001), age-weighted mean cadmium intakes of
0.35 µg/kg/day for males and 0.30 µg/kg/day for females were calculated for U.S. nonsmokers.
In the Fourth National Report on Human Exposures to Environmental Chemicals reported by the CDC
(2011) results from the National Health and Nutrition Examination Survey (NHANES) 1999–2008 were
reported. Cadmium levels in blood (see Table 6-4), urine (creatine corrected) (see Table 6-5), and urine
(see Table 6-6) was evaluated for a variety age groups and ethnicities. Blood cadmium reflects both
recent and cumulative exposures and urinary cadmium reflects cadmium exposure and the concentration
of cadmium in the kidneys.
CADMIUM 306
Table 6-4. Geometric Mean and Selected Percentile Blood Concentrations (μg/L)
of Cadmium in the U.S. Population from 1999 to 2008
Geometric Selected percentiles (95% CI)

a
Survey mean (95% Sample
th th th th
Group years CI) 50 75 90 95 size
Total, age 1 and 1999–2000 0.412 (0.378– 0.300 (0.300– 0.600 (0.500– 1.00 (0.900– 1.30 (1.20– 7,970
older 0.449) 0.400) 0.600) 1.00) 1.40)
2001–2002 Not calculated 0.300 (<LOD– 0.400 (0.400– 0.900 (0.900– 1.30 (1.20– 8,945,
0.300) 0.500) 1.10) 1.60)
2003–2004 0.304 (0.289– 0.300 (0.300– 0.500 (0.500– 1.10 (1.00– 1.60 (1.50– 8,372
0.320) 0.300) 0.600) 1.20) 1.60)
2005–2006 0.310 (0.294– 0.270 (0.250– 0.501 (0.460– 1.02 (0.910– 1.53 (1.34– 8,407
0.327) 0.280) 0.560) 1.13) 1.75)
2007–2008 0.315 (0.300– 0.270 (0.260– 0.500 (0.460– 1.00 (0.900– 1.51 (1.30– 8,266
0.331) 0.280) 0.560) 1.13) 1.77)
Age group
1–5 Years 1999–2000 Not calculated <LOD 0.300 (<LOD– 0.400 (0.300– 0.400 (0.300– 723
0.300) 0.400) 0.400)
2001–2002 Not calculated <LOD <LOD <LOD 0.300 (<LOD– 898
0.300)
2003–2004 Not calculated <LOD <LOD 0.200 (0.200– 0.200 (0.200– 910
0.300) 0.400)
2005–2006 Not calculated <LOD <LOD <LOD 0.230 (0.210– 968
0.250)
2007–2008 Not calculated <LOD <LOD 0.210 (<LOD– 0.240 (0.220– 817
0.230) 0.260)
6–11 Years 1999–2000 Not calculated <LOD 0.300 (<LOD– 0.400 (0.300– 0.400 (0.400– 905
0.300) 0.400) 0.500)
2001–2002 Not calculated <LOD <LOD <LOD 0.400 (0.300– 1,044
0.400)
2003–2004 Not calculated <LOD 0.200 (<LOD– 0.300 (0.200– 0.300 (0.300– 856
0.200) 0.300) 0.300)
2005–2006 Not calculated <LOD <LOD 0.220 (0.200– 0.260 (0.230– 934
0.300) 0.280)
2007–2008 Not calculated <LOD <LOD 0.230 (0.210– 0.260 (0.240– 1,011
0.240) 0.280)
12–19 Years 1999–2000 0.333 (0.304– 0.300 (<LOD– 0.300 (0.300– 0.800 (0.600– 1.10 (0.900– 2,135
0.366 0.300) 0.400) 0.900) 1.10)
2001–2002 Not calculated <LOD 0.300 (<LOD– 0.400 (0.400– 0.800 (0.600– 2,231
0.300) 0.500) 1.10)
2003–2004 Not calculated 0.200 (<LOD– 0.300 (0.300– 0.600 (0.500– 0.900 (0.800– 2,081
0.200) 0.300) 0.700) 1.10)
2005–2006 Not calculated <LOD 0.250 (0.240– 0.520 (0.500– 0.960 (0.820– 1,996
0.270) 0.700) 1.08)
0.270) 0.670) 1.19)
CADMIUM 307

a
th th th th
≥20 Years 1999–2000 0.468 (0.426– 0.400 (0.300– 0.600 (0.600– 1.00 (1.00– 1.50 (1.40– 4,207
0.513) 0.400) 0.700) 1.10) 1.60)
2001–2002 Not calculated 0.300 (0.300– 0.600 (0.500– 1.10 (0.900– 1.60 (1.30– 4,772
0.400) 0.600) 1.20) 1.80)
2003–2004 0.378 (0.359– 0.400 (0.300– 0.600 (0.600– 1.20 (1.20– 1.80 (1.60– 4,525
0.398) 0.400) 0.700) 1.30) 1.90)
2005–2006 0.373 (0.352– 0.330 (0.310– 0.610 (0.570– 1.17 (1.06– 1.72 (1.53– 4,509
0.395) 0.350) 0.660) 1.26) 1.95)
2007–2008 0.376(0.354– 0.330 (0.310– 0.600 (0.550– 1.16 (1.02– 1.70 (1.50– 5,364
0.399) 0.350) 0.670) 1.30) 1.96)
Gender
Males 1999–2000 0.403 (0.368– 0.400 (0.300– 0.600 (0.500– 1.00 (0.900– 1.30 (1.20– 3,913
0.441) 0.400) 0.600) 1.10) 1.50)
2001–2002 Not calculated 0.300 (<LOD– 0.400 (0.400– 0.900 (0.900– 1.40 (1.20– 4,339
0.300) 0.500) 1.10) 1.80)
2003–2004 0.283 (0.266– 0.300 (0.200– 0.500 (0.500– 1.10 (1.00– 1.60 (1.50– 4,131
0.300) 0.300) 0.500) 1.20) 1.60)
2005–2006 Not calculated 0.240 (0.220– 0.470 (0.420– 1.02 (0.910– 1.53 (1.27– 4,092
0.260) 0.530) 1.12) 1.86)
2007–2008 0.299 (0.283– 0.240 (0.230– 0.470 (0.420– 1.05 (0.930– 1.60 (1.30– 4,147
0.317) 0.260) 0.540) 1.19) 1.90)
Females 1999–2000 0.421 (0.386– 0.300 (0.300– 0.600 (0.500– 1.00 (0.800– 1.30 (1.10– 4,057
0.460) 0.400) 0.600) 1.00) 1.40)
2001–2002 Not calculated 0.300 (0.300– 0.500 (0.500– 1.00 (0.900– 1.40 (1.20– 4,606
0.400) 0.600) 1.10) 1.60)
2003–2004 0.326 (0.300– 0.300 (0.300– 0.600 (0.500– 1.10 (1.00– 1.60 (1.50– 4,241
0.300) 0.300) 0.600) 1.20 ) 1.70)
2005–2006 0.329 (0.311– 0.290 (0.280– 0.530 (0.480– 1.02 (0.870– 1.54 (1.33– 4,315
0.349) 0.310) 0.580) 1.18)_ 1.79)
2007–2008 0.331 (0.316– 0.290 (0.280– 0.530 (0.480– 0.980 (0.860– 1.43 (1.29– 4,119
0.348) 0.310) 0.570) 1.10)_ 1.63)
Race/ethnicity
Mexican 1999–2000 0.395 (0.367– 0.400 (0.300– 0.400 (0.400– 0.700 (0.700– 1.10 (0.900– 2,742
Americans 0.424) 0.400) 0.500) 0.900) 1.30)
0.400) 0.700) 1.30)
2003–2004 0.235 (0.26– 0.200 (0.200– 0.400 (0.300– 0.600 (0.500– 1.00 (0.800– 2,085
0.255) 0.300) 0.400) 0.800) 1.50)
2005–2006 Not calculated 0.220 (0.200– 0.350 (0.300– 0.580 (0.510– 0.820 (0.710– 2,236
0.240) 0.400) 0.680) 1.00)
2007–2008 Not calculated 0.220 (0.210– 0.350 (0.320– 0.570 (0.510– 0.870 (0.690– 1,712
0.230) 0.370) 0.660) 1.02)
CADMIUM 308

a
th th th th
Non-Hispanic 1999–2000 0.393 (0.361– 0.300 (0.300– 0.600 (0.500– 1.00 (0.800– 1.40 (1.10– 1,842
blacks 0.427) 0.400) 0.600) 1.10) 1.50)
0.500) 1.00) 1.50)
2003–2004 0.304 (0.275– 0.300 (0.300– 0.500 (0.400– 1.00 (0.900– 1.50 (1.30– 2,292
0.337) 0.300) 0.600) 1.20) 1.70)
2005–2006 0.307 (0.290– 0.260 (0.250– 0.490 (0.440– 1.03 (0.880– 1.50 (1.23– 2,193
0.326) 0.280) 0.570) 1.21) 1.79)
2007–2008 0.333 (0.316– 0.280 (0.270– 0.550 (0.480– 1.20 (1.02– 1.81 (1.45– 1,746
0.352) 0.300) 0.620) 1.36) 2.13)
Non-Hispanic 1999–2000 0.376 (0.470– 0.400 (0.300– 0.500 (0.500– 1.00 (0.900– 1.30 (1.20– 2,716
whites 0.209) 0.400) 0.600) 1.10) 1.40)
0.600) 1.10) 1.80)
2003–2004 0.313 (0.296– 0.300 (0.300– 0.600 (0.500– 1.10 (1.00– 1.60 (1.50– 3,478
0.331) 0.300) 0.600) 1.20) 1.70)
2005–2006 0.321 (0.300– 0.270 (0.250– 0.540 (0.470– 1.08 (0.930– 1.64 (1.40– 3,310
0.343) 0.300) 0.610) 1.23) 1.94)
2007–2008 0.210 (0.303– 0.270 (0.260– 0.520 (0.470– 1.05 (0.920– 1.55 (1.30– 3,461
0.341) 0.290) 0.580) 1.20) 1.80)
a
The proportion of results below the LOD was too high to provide a valid result.
CI = confidence interval; LOD = limit of detection
Source: CDC 2011

CADMIUM 309
Table 6-5. Geometric Mean and Selected Percentile Urine Concentrations

(Creatinine Corrected) (μg/g Creatinine) of Cadmium in the
U.S. Population from 1999 to 2008

a
th th th th
Total, age 6 and 1999–2000 0.181 (0.157– 0.219 (0.199– 0.423 (0.391– 0.712 (0.645– 0.933 (0.826– 2,257
older 0.209) 0.238) 0.446) 0.757) 1.07)
2001–2002 0.199 (0.181– 0.212 (0.194– 0.404 (0.377– 0.690 (0.630– 0.917 (0.813– 2,689
0.218) 0.232) 0.440) 0.754) 0.998)
2003–2004 0.210 (0.201– 0.208 (0.189– 0.412 (0.381– 0.678 (0.650– 0.940 (0.833– 2,543
0.219) 0.226) 0.438) 0.716) 1.04)
2005–2006 0.189 (0.169– 0.180 (0.160– 0.370 (0.310– 0.650 (0.590– 0.910 (0.770– 2,576
0.210) 0.200) 0.430) 0.720) 1.08)
2007–2008 0.193 (0.177– 0.190 (0.180– 0.370 (0.330– 0.660 (0.580– 0.960 (0.850– 2,627
0.210) 0.210) 0.410) 0.740) 1.06)
Age group
6–11 Years 1999–2000 Not calculated 0.085 (0.063– 0.147 (0.123– 0.210 (0.171– 0.300 (0.184– 310
0.107) 0.182) 0.316) 0.607)
2001–2002 0.075 (0.059– 0.100 (0.083– 0.166 (0.136– 0.233 (0.206– 0.291 (0.221– 368
0.094) 0.112) 0.192) 0.281) 0.440)
2003–2004 0.090 (0.078– 0.091 (0.075– 0.126 (0.111– 0.200 (0.147– 0.308 (0.178– 287
0.104) 0.104) 0.156) 0.350) 0.415)
2005–2006 0.081 (0.072– 0.080 (0.070– 0.130 (0.110– 0.170 (0.150– 0.200 (0.180– 355
0.092) 0.090) 0.140) 0.190) 0.240)
2007–2008 0.084 (0.076– 0.080 (0.080– 0.120 (0.110– 0.180 (0.150– 0.260 (0.180– 394
0.092) 0.090) 0.140) 0.240) 0.430)
12–19 Years 1999–2000 0.071 (0.051– 0.093 (0.084– 0.147 (0.130– 0.215 (0.204– 0.283 (0.222– 648
0.098) 0.106) 0.163) 0.240) 0.404)
2001–2002 0.078 (0.067– 0.091 (0.085– 0.136 (0.123– 0.191 (0.175– 0.280 (0.234– 762
0.091) 0.101) 0.143) 0.234) 0.321)
2003–2004 0.086 (0.077– 0.084 (0.074– 0.122 (0.113– 0.176 (0.154– 0.234 (0.187– 724
0.096) 0.097) 0.135) 0.198) 0.274)
2005–2006 0.076 (0.071– 0.080 (0.070– 0.120 (0.110– 0.50 (0.140– 0.210 (0.160– 701
0.081) 0.0990) 0.130) 0.180) 0.240)
2007–2008 0.070 (0.062– 0.070 (0.070– 0.110 (0.100– 0.150 (0.130– 0.180 (0.160– 376
0.079) 0.080) 0.110) 0.160) 0.200)
≥20 Years 1999–2000 0.267 (0.247– 0.288 (0.261– 0.484 (0.433– 0.769 (0.727– 1.07 (0.927– 1,299
0.289) 0.304) 0.545) 0.818) 1.17)
2001–2002 0.261 (0.236– 0.273 (0.247– 0.481 (0.426– 0.776 (0.691– 0.979 (0.874– 1,559
0.289) 0.303) 0.518) 0.850) 1.12)
2003–2004 0.268 (0.255– 0.270 (0.247– 0.490 (0.444– 0.767 (0.688– 1.02 (0.909– 1,532
0.281) 0.292) 0.538) 0.830) 1.14)
2005–2006 0.240 (0.216– 0.250 (0.200– 0.440 (0.400– 0.730 (0.660– 1.02 (0.850– 1,520
0.267) 0.260) .0500) 0.820) 1.18)
2007–2008 0.247 (0.227– 0.250 (0.220– 0.430 (0.390– 0.740 (0.670– 1.05 (0.930– 1,857
0.270) 0.270) 0.70) 0.840) 1.16)
CADMIUM 310


a
th th th th
Gender
Males 1999–2000 0.154 (0.131– 0.174 (0.158– 0.329 (0.293– 0.617 (0.537– 0.788 (0.696– 1,121
0.182) 0.191) 0.382) 0.700) 0.929)
2001–2002 0.159 (0.143– 0.168 (0.157– 0.334 (0.304– 0.532 (0.491– 0.757 (0.690– 1,334
0.177) 0.182) 0.364) 0.653) 0.856)
2003–2004 0.173 (0.161– 0.162 (0.143– 0.325 (0.300– 0.591 (0.560– 0.740 (0.678– 1,277
0.187) 0.185) 0.352) 0.631) 0.795)
2005–2006 0.160 (0.145– 0.150 (0.130– 0.300 (0.260– 0.362 (0.560– 0.820 (0.710– 1,271
0.177) 0.160) 0.340) 0.340) 0.990)
2007–2008 0.160 (0.146– 0.160 (0.140– 0.290 (0.260– 0.520 (0.430– 0.740 (0.600– 1,327
0.175) 0.180) 0.330) 0.650) 0.960)
Females 1999–2000 0.211 (0.170– 0.267 (0.239– 0.473 (0.423– 0.783 (0.690– 1.09 (0.813– 1,136
0.261) 0.308) 0.551) 0.917) 1.38)
2001–2002 0.245 (0.216– 0.263 (0.228– 0.479 (0.414– 0.792 (0.687– 0.985 (0.876– 1,355
0.278) 0.297) 0.541) 0.884) 1.16)
2003–2004 0.252 (0.238– 0.253 (0.227– 0.487 (0.438– 0.802 (0.716– 1.06 (0.940– 1,266
0.266) 0.288) 0.533) 0.906) 1.21)
2005–2006 0.220 (0.193– 0.220 (0.180– 0.420 (0.370– 0.690 (0.590– 0.990 (0.780– 1,305
0.252) 0.250) 0.470) 0.850) 1.31)
2007–2008 0.231 (0.211– 0.230 (0.200– 0.440 (0.390– 0.770 (0.700– 1.09 (0.970– 1,300
0.254) 0.270) 0.480) 0.860) 1.17)
Race/ethnicity
Mexican 1999–2000 0.175 (0.137– 0.181 (0.144– 0.331 (0.266– 0.612 (0.441– 0.843 (0.674– 780
Americans 0.223) 0.225) 0.418) 0.828) 1.13)
2001–2002 0.156 (0.136– 0.170 (0.150– 0.282 (0.263– 0.501 (0.388– 0.693 (0.507– 682
0.177) 0.184) 0.340) 0.614) 0.839)
2003–2004 0.160 (0.147– 0.159 (0.140– 0.296 (0.256– 0.531 (0.418– 0.718 (0.562– 614
0.181) 0.183) 0.311) 0.667) 0.950)
2005–2006 0162 (0.146– 0.150 (0.140– 0.280 (0.220– 0.480 (0.430– 0.570 (0.520– 652
0.181) 0.170) 0.340) 0.510) 0.640)
2007–2008 0.162 (0.144– 0.160 (0.130– 0.280 (0.220– 0.530 (0.390– 0.720 (0.520– 515
0.183) 0.180) 0.340) 0.640) 1.07)
Non-Hispanic 1999–2000 0.183 (0.140– 0.201 (0.168– 0.414 (0.343– 0.658 (0.516– 0.873 (0.722– 546
blacks 0.240) 0.241) 0.472) 0.827) 0.962)
2001–2002 0.190 (0.156– 0.195 (0.174– 0.385 (0.336– 0.676 (0.559– 0.917 (0.725– 667
0.232) 0.225) 0.449) 0.850) 1.08)
2003–2004 0.190 (0.173– 0.185 (0.168– 0.338 (0.288– 0.700 (0.500– 0.865 (0.708– 717
0.210 ) 0.207) 0.431) 0.818) 1.10)
2005–2006 0.171 (0.159– 0.160 (0.140– 0.320 (0.290– 0.550 (0.500– 0.700 (0.610– 692
0.183) 0.180) 0.370) 0.580) 0.730)
2007–2008 0.180 (0.164– 0.170 (0.160– 0.330 (0.290– 0.600 (0.470– 0.770 (0.690– 589
0.197) 0.190) 0.390) 0.700) 0.900)
CADMIUM 311


a
th th th th
Non-Hispanic 1999–2000 0.175 (0.146– 0.219 (0.191– 0.432 (0.387– 0.729 (0.666– 1.00 (0.826– 760
whites 0.209) 0.250) 0.470) 0.783) 1.16)
2001–2002 0.205 (0.184– 0.224 (0.208– 0.421 (0.382– 0.719 (0.668– 0.931 (0.806– 1,132
0.229) 0.242) 0.470) 0.784) 1.05)
2003–2004 0.220 (0.209– 0.221 (0.197– 0.434 (0.398– 0.687 (0.647– 1.00 (0.830– 1,070
0.235) 0.253) 0.476) 0.767) 1.08)
2005–2006 0.193 (0.169– 0.180 (0.160– 0.390 (0.310– 0.680 (0.630– 0.930 (0.800– 1,041
0.221) 0.220) 0.480) 0.750) 1.07)
2007–2008 0.199 (0.178– 0.200 (0.180– 0.380 (0.340– 0.700 (0.630– 1.03 (0.880– 1,095
0.221) 0.220) 0.440) 0.810) 1.13)
a
Source: CDC 2011

CADMIUM 312
Table 6-6. Geometric Mean and Selected Percentile Urine Concentrations (μg/L)

a
th th th th
Total, age 6 and 1999–2000 0.193 (0.169– 0.232 (0.214– 0.475 (0.436– 0.858 (0.763– 1.20 (1.06– 2,257
older 0.220) 0.249) 0.519) 0.980) 1.33)
2001–2002 0.210 (0.189– 0.229 (0.207– 0.458 (0.423– 0.839 (0.753– 1.20 (1.07– 2,690
0.235) 0.255) 0.482) 0.919) 1.28)
2003–2004 0.211 (0.196– 0.210 (0.200– 0.450 (0.400– 0.800 (0.730– 1.15 (0.980– 2,543
0.226) 0.230) 0.500) 0.880) 1.26)
2005–2006 0.191 (0.170– 0.200 (0.170– 0.400 (0.360– 0.780 (0.700– 1.05 (0.960– 2,576
0.216) 0.220) 0.460) 0.860) 1.17)
2007–2008 0.185 (0.173– 01.80 (0.170– 0.380 (0.360– 0.700 (0.50– 1.00 (0.920– 2,627
0.198) 0.200) 0.400) 0.770) 1.12)
Age group
6–11 Years 1999–2000 Not calculated 0.078 (0.061– 0.141 (0.115– 0.219 (0.178– 0.279 (0.211– 310
0.101) 0.173) 0.233) 0.507)
2001–2002 0.061 (<LOD– 0.077 (0.067– 0.140 (0.112– 0.219 (0.184– 0.282 (0.260– 368
0.081) 0.092) 0.160) 0.262) 0.326)
2003–2004 0.077 (0.065– 0.080 (0.060– 0.120 (0.100– 0.190 (0.160– 0.310 ( 287
0.090) 0.090) 0.160) 0.310) 0.170–0.610)
2005–2006 0.066 (0.056– 0.060 (0.050– 0.110 (0.090– 0.180 ( 0.240 (0.160– 355
0.078) 0.080) 0.130) 0.130–0.240) 0.290)
2007–2008 0.064 (0.058– 0.060 (0.050– 0.110 (0.090– 0.180 (0.140– 0.230 (0.180– 394
0.071) 0.070) 0.130) 0.210) 0.310)
12–19 Years 1999–2000 0.092 (0.067– 0.128 (0.107– 0.202 (0.183– 0.329 (0.272– 0.424 (0.366– 648
0.126) 0.148) 0.232) 0.372) 0.596)
2001–2002 0.109 (0.087– 0.135 (0.114– 0.210 (0.189– 0.327 (0.289– 0.442 (0.366– 762
0.136) 0.157) 0.247) 0.366) 0.480)
2003–2004 0.121 (0.190– 0.130 (0.110– 0.200 (0.160– 0.300 (0.260– 0.390 (0.330– 724
0.134) 0.150) 0.190) 0.360) 0.490)
2005–2006 0.099 (0.090– 0.110 (0.100– 0.170 (0.150– 0.240 (0.210– 0.310 (0.250– 701
0.109) 0.120) 0.190) 0.280) 0.430)
2007–2008 0.089 (0.079– 0.080 (0.070– 0.150 (0.140– 0.260 (0.200– 0.330 (0.280– 376
0.100) 0.110) 0.170) 0.300) 0.410)
≥20 Years 1999–2000 0.281 (0.253– 0.306 (0.261– 0.551 (0.510– 0.979 (0.836– 1.31 (1.13– 1,299
0.313) 0.339) 0.621) 1.13) 1.57)
2001–2002 0.273 (0.249– 0.280 (0.261– 0.545 (0.493– 0.955 (0.855– 1.28 (1.20– 1,560
0.299) 0.308) 0.607) 1.06) 1.43)
2003–2004 0.260 (0.238– 0.210 (0.210– 0.260 (0.470– 0.890 (0.800– 1.25 (1.09– 1,532
0.284) 0.300) 0.580) 0.990) 1.46)
2005–2006 0.241 (0.213– 0.250 (0.220– 0.490 (0.440– 0.860 (0.790– 1.12 (1.06– 1,520
0.272) 0.290) 0.560) 0.930) 1.32)
2007–2008 0.232 (0.215– 0.240 (0.210– 0.450 (0.410– 0.790 (0.730– 1.13 (0.990– 1,857
0.251) 0.260) 0.490) 0.870) 1.44)
CADMIUM 313

a
th th th th
Gender
Males 1999–2000 0.199 (0.165– 0.227 (0.193– 0.462 (0.381– 0.892 (0.748– 1.41 (0.980– 1,121
0.241) 0.263) 0.539) 1.15) 1.83)
2001–2002 0.201 (0.177– 0.223 (0.191– 0.445 (0.393– 0.870 (0.741– 1.22 (1.12– 1,335
0.229) 0.257) 0.481) 1.03) 1.38)
2003–2004 0.206 (0.190– 0.210 (0.190– 0.440 (0.390– 0.790 (0.700– 1.01 (0.890– 1,277
0.222) 0.230) 0.490) 0.870) 1.25)
2005–2006 0.195 (0.176– 0.210 (0.190– 0.400 (0.360– 0.800 (0.730– 1.17 (1.01– 1,271
0.217) 0.230) 0.440) 0.890) 1.30)
2007–2008 0.179 (0.162– 0.180 (0.160– 0.360 (0.320– 0.670 (0.540– 0.950 (0.800– 1,327
0.197) 0.200) 0.400) 0.780) 1.14)
Females 1999–2000 0.187 (0.153– 0.239 (0.220– 0.492 (0.456– 0.806 (0.705– 1.10 (1.01– 1,136
0.229) 0.255) 0.540) 0.980) 1.19)
2001–2002 0.219 (0.192– 0.234 (0.202– 0.466 (0.433– 0.817 (0.733– 1.17 (0.918– 1,355
0.251) 0.265) 0.519) 0.886) 1.36)
2003–2004 0.216 (0.195– 0.210 (0.200– 0.450 (0.400– 0.820 (0.700– 120 (1.02– 1,266
0.238) 0.240) 0.530) 0.960) 1.37)
2005–2006 0.188 ( 0.190 (0.170– 0.400 (0.350– 0.750 (0.640– 0.980 (0.830– 1,305
0.160–0.221) 0.200) 0.480) 0.860) 1.20)
2007–2008 0.191 (0.177– 0.190 (0.170– 0.400 (0.370– 0.740 (0.670– 1.09 (0.940– 1,300
0.207) 0.200) 0.430) 0.840) 1.38)
Race/ethnicity
Mexican 1999–2000 0.191 (0.157– 0.202 (0.167– 0.438 (0.351– 0.813 (0.686– 1.12 (0.886– 780
Americans 0.233) 0.221) 0.551) 0.977) 1.38)
2001–2002 0.160 (0.135– 0.181 (0.171– 0.321 (0.285– 0.559 (0.430– 0.766 (0.633– 683
0.189) 0.198) 0.362) 0.733) 1.15)
2003–2004 0.175 (0.151– 0.170 0.150– 0.350 0.290– 0.680 (0.520– 1.04 (0.820– 614
0.203 0.210) 0.430) 0.820) 1.20)
2005–2006 0.173 (0.152– 0.180 (0.160– 0.340 (0.300– 0.560 (0.500– 0.780 (0.660– 652
0.193) 0.200) 0.380) 0.630) 0.900)
2007–2008 0.160 (0.141– 0.170 (0.140– 0.320 (0.290– 0.570 (0.520– 0.730 (0.640– 515
0.182) 0.210) 0.380) 0.640) 0.840)
Non-Hispanic 1999–2000 0.283 (0.208– 0.312 (0.243– 0.633 (0.498– 1.22 (0.892– 1.48 (1.30– 546
blacks 0.387) 0.412) 0.806) 1.38) 1.72)
2001–2002 0.277 (0.229– 0.302 (0.257– 0.580 (0.476– 1.04 (0.843– 1.51 (1.28– 667
0.336) 0.354) 0.713) 1.38) 1.74)
2003–2004 0.265 (0.237– 0.270 (0.220– 0.550 (0.440– 0.960 0.810– 1.52 (1.06– 717
0295) 0.320) 0.640) 1.17) 1.82)
2005–2006 0.236 (0.240– 0.240 (0.210– 0.480 (0.420– 0.830 (0.670– 1.04 (0.870– 692
0.210) 0.260) 0.530) 0.930) 1.26)
2007–2008 0.246 (0.218– 0.260 (0.220– 0.460 (0.420– 0.840 (0.690– 1.40 (0.900– 589
0.277) 0.300) 0.530) 0.980) 1.85)
CADMIUM 314

a
th th th th
Non-Hispanic 1999–2000 0.175 (0.148– 0.220 (0.194– 0.455 (0.388– 0.797 (0.714– 1.17 (0.963– 760
whites 0.206) 0.246) 0.510) 1.01) 1.47)
2001–2002 0.204 (0.179– 0.221 (0.191– 0.445 (0.394– 0.813 (0.717– 1.17 (0.989– 1,132
0.231) 0.255) 0.479) 0.875) 1.24)
2003–2004 0.209 (0.192– 0.200 (0.190– 0.440 (0.390– 0.790 (0.700– 1.13 (0.940– 1,070
0.226) 0.220) 0.500) 0.860) 1.26)
2005–2006 0.185 (0.159– 0.200 (0.160– 0.400 (0.330– 0.780 (0.670– 1.05 (0.940– 1,041
0.216) 0.230) 0.480) 0.920) 1.25)
2007–2008 0.177 (0.161– 0.170 (0.150– 0.370 (0.330– 0.690 (0.620– 1.00 (0.880– 1,095
0.195) 0.190) 0.400) 0.780) 1.12)
a
Source: CDC 2011

CADMIUM 315
As a part of the New York City Health and Nutrition Examination Survey (NYC HANES), 2004 blood
cadmium levels were evaluated in 1,811 New York City adults (age 20 years and older). The variables
used in this study were sex, age, race/ethnicity, place of birth, family income, education, and smoking
status (see Table 6-7 for detailed results of this study). The geometric mean blood cadmium
concentration in New York City adults was 0.77 μg/L, slightly higher than the 1999–2000 estimated
national mean of 0.47 μg/L with heavy smokers having the highest geometric mean blood cadmium level
of 1.58 μg/L, higher than any other subgroup. The reason for the elevated blood cadmium levels in
nonsmoking, New York City adults is not known, although it was speculated that higher shellfish
consumption may be the cause of elevated blood cadmium levels in Asian subgroup (McKelvey et al.
2007).
Vahter et al. (1996) studied the dietary intake and uptake of cadmium in nonsmoking women consuming
a mixed diet low in shellfish (n=34) or with shellfish once a week or more (n=17). The shellfish diets,
with a median of 22 μg Cd/day, contained twice as much cadmium as the mixed diets, which had a
median of 10.5 μg Cd/day. In spite of the differences in the daily intake of cadmium, there were no
statistically significant differences in the blood cadmium concentrations of the shellfish group (0.25 μg/L)
and the mixed diet group (0.23 μg/L) or in the urinary cadmium concentrations of the shellfish and mixed
diet groups (0.10 μg/L in both groups). These results indicate a lower absorption of cadmium in the
shellfish group than in the mixed diet group or a difference in kinetics. The authors suggested that a
higher gastrointestinal absorption of cadmium in the mixed diet group could be explained in part by their
lower body iron stores as measured by the concentrations of serum ferritin (S-fer). A median S-fer
concentration of 18 μg/L was measured for the mixed diet group compared to a median of 31 μg/L for the
shellfish group.
Except in the vicinity of cadmium-emitting industries or incinerators, the intake of cadmium from
drinking water or ambient air is of minor significance (Elinder 1985a). Cadmium is removed from waste
water and sewage through precipitation to hydroxide or carbonate compounds and ultimate separation
(Schulte-Schrepping and Piscator 2002). EPA requires water suppliers to limit the cadmium
concentration in water to <5 μg/L (EPA 2006a).
IARC (1993) reports that the total body burden of non-occupationally exposed adult subjects has been
estimated to range from 9.5 to 50 mg in the United States and Europe. People living near sources of
cadmium pollution may be exposed to higher levels of cadmium. Ambient air cadmium concentrations in
industrialized areas was estimated between 15 and 150 ng/m3 (Morrow 2001). During a study conducted
CADMIUM 316
Table 6-7. Blood Cadmium Concentrations, Geometric Means, Adjusted

Proportional Change in Means, and 95th Percentiles in
New York City Adults in Population Subgroups
Results
Crude weighted Adjusted proportional Crude weighted
geometric mean change in mean 95th percentile
blood cadmium blood cadmium blood cadmium
Variable Numbera (μg/L) (μg/L)b (μg/L)
Total: 1,811 0.77 — 1.88
Male 762 0.76 1.00 1.95
Female 1,049 0.79 1.07 1.83
20–39 years old 903 0.76 1.00 1.82
40–59 years old 673 0.84 1.16 2.19
≥60 years old 235 0.77 1.15 1.52
c
White, non-Hispanic 529 0.73 1.04 1.71
c
Black, non-Hispanic 390 0.80 1.11 1.97
c
Asian, non-Hispanic 231 0.99 1.41 2.36
c
Hispanic 630 0.73 1.00 1.73
Place of birth:
United States 882 0.76 1.00 1.95
Outside the United
States 923 0.79 1.02 1.73
Family income ($ U.S.):
<20,000 610 0.86 1.00 2.33
20,000–49,999 566 0.77 0.94 1.76
50,000–74,999 256 0.74 0.92 1.76
≥75,000 304 0.69 0.91 1.43
Education:
<Bachelors 1,252 0.82 1.09 2.02
Bachelors or greater 551 0.69 1.00 1.43
Smoking status:
Never smoked 1,036 0.66 1.00 1.28
Former smoker 310 0.71 1.07 1.32
Current smoker 449 1.22 1.88 3.00
a
Totals do not all equal 1,811 because of missing data.
b
The exponential β coefficient from a log-linear multiple regression that includes all covariates in the table. Sample
size for adjust analysis is 1,707, after excluding study participants for whom covariate data are missing.
c
Excludes 27 participants who self-classified as “other”.
Source: McKelvey et al. 2007

CADMIUM 317
in Germany between March and May 2000, cadmium levels in child-mother pairs, as a function of
ambient air quality, were compared between populations in the urban, industrialized area of Duisburg and
the rural area of North Rhine Westphalia. Cadmium levels in the ambient air of Duisburg-South ranged
from 1.5 to 31 ng/m3, compared to 0.5 ng/m3 in the rural are of Westphalia. Cadmium levels in the blood
and urine of mothers in the industrialized area were higher than in the rural areas. Cadmium levels in the
blood and urine of the children did not differ between the two areas. In the industrialized area, regression
analysis indicated a significant influence of cadmium in ambient air on cadmium in blood (Wilhelm et al.
2005).
It has been estimated that tobacco contains 1.7 μg cadmium per cigarette, and about 10% is inhaled when
smoked (Morrow 2001; NTP 2005). Tobacco leaves naturally accumulate large amounts of cadmium
(Morrow 2001). During a study monitoring cadmium levels in 331 cigarette packs from over 20 areas
around the world, it was found that the mean cadmium level per cigarette was 1.15 µg/cigarette
±0.43 (AM±ASD) or 1.06 µg/cigarette ±1.539 GM±GSD. Cigarettes from Mexico had the highest mean
level of cadmium with an AM±ASD of 2.03 µg/cigarette ±0.33 or a GM±GSD of 2.00 µg/cigarette
±1.190. Cigarettes from India had the lowest mean levels of cadmium with an AM±ASD of 0.35
µg/cigarette ±0.09 or a GM±GSD of 0.34 µg/cigarette ±1.284 (Watanabe et al. 1987). The amount of
cadmium absorbed from smoking one pack of cigarettes per day is about 1–3 μg/day (Lewis et al. 1972a;
Nordberg et al. 1985), roughly the same as from the diet. This large contribution is due to the greater
absorption of cadmium from the lungs than from the gastrointestinal tract (Elinder 1985a). Direct
measurement of cadmium levels in body tissues confirms that smoking roughly doubles cadmium body
burden in comparison to not smoking, with kidney concentrations averaging 15–20 μg/g wet weight for
nonsmokers and 30–40 μg/g wet weight for heavy smokers at the age of 50–60 (Ellis et al. 1979; Hammer
et al. 1973; Lewis et al. 1972a, 1972b). Ellis et al. (1979) found an increase in kidney cadmium of
0.11±0.05 mg per pack-year (AM±ASD) of smoking and an increase in liver cadmium concentration of
0.077±0.065 μg/g per pack-year (AM±ASD). Because excretion of cadmium is very slow, half-lives of
cadmium in the body are correspondingly long (17–38 years) (Wester et al. 1992).
Workers in a variety of occupations may be exposed to cadmium and cadmium compounds. Occupations
with potential exposure to cadmium are listed in Table 6-8 (IARC 1993).
Highest levels of occupational exposure would be expected to occur in operations involving heating
cadmium-containing products by smelting, welding, soldering, or electroplating, and also in operations
associated with producing cadmium powders (OSHA 1990). The primary route of occupational exposure
CADMIUM 318
Table 6-8. Occupations with Potential Exposure to Cadmium and Cadmium

Compounds
Occupation
a
Alloy production Phosphorous production
a a
Battery production Pigment production and use
a
Brazing Plastics production
Coating Plating
Diamond cutting Printing
Dry color formulation Semiconductor and superconductor production
Electroplating Sensors production
a
Electrical contacts production Smelting and refining
Enameling Solar cells production
Engraving Soldering
Glasswork Stabilizer production
Laser cutting Textile printing
Metallizing Thin film production
Paint production and use Transistors production
Pesticide production and use Welding
a
Activity with high risk because atmospheric concentrations of cadmium are high and the number of workers
employed is significant.
Source: IARC 1993

CADMIUM 319
is through inhalation of dust and fumes, and also incidental ingestion of dust from contaminated hands,
cigarettes, or food (Adamsson et al. 1979).
Concentrations of airborne cadmium found in the workplace vary considerably with the type of industry
and the specific working conditions. Processes that involve high temperatures can generate cadmium
oxide fumes that are absorbed very efficiently through the lungs (IARC 1993). Deposition and absorption
of dust containing different compounds depend upon particle size (IARC 1993). These exposures can be
controlled through use of personal protective equipment and good industrial hygiene practices, and
through operating procedures designed to reduce workplace emissions of cadmium (OSHA 1990).
Data from the National Occupational Exposure Survey (NOES), conducted by NIOSH from 1981 to
1983, estimated the number of workers potentially exposed to various chemicals in the workplace during
the same period (NIOSH 1990); these data are summarized in Table 6-9. The NOES database does not
contain information on the frequency, level, or duration of exposure of workers to any of the chemicals
listed. It provides only estimates of workers potentially exposed to the chemicals.
6.6 EXPOSURES OF CHILDREN
This section focuses on exposures from conception to maturity at 18 years in humans. Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults. A child’s exposure may differ from an adult’s exposure in many ways.
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a
larger skin surface in proportion to their body volume. A child’s diet often differs from that of adults.
The developing human’s source of nutrition changes with age: from placental nourishment to breast milk
or formula to the diet of older children who eat more of certain types of foods than adults. A child’s
behavior and lifestyle also influence exposure. Children crawl on the floor, put things in their mouths,
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors. Children
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).
Children are most likely to be exposed to cadmium in from ingestion of food (NTP 2005). There are no
data on gastrointestinal absorption of cadmium in children, although very limited evidence exists that
cadmium absorption from the gut may be greater in young animals. Oral absorption is discussed in more
detail in Section 3.4.1.2. A study performed in Cincinnati, Ohio, investigated cadmium in human milk
CADMIUM 320
Table 6-9. Estimated Number of Workers Potentially Exposed to Various

Chemicals in the Workplace in 1981–1983
Chemical Number of workers potentially exposed

Cadmium sulfide 45,562
Cadmium oxide 15,727
Cadmium (pure) 335
Cadmium dust (form unknown) 3,893
Cadmium powder (form unknown) 486
Cadmium sulfate 1,313
1:1 Cadmium salt of carbonic acid 164
Cadmium (form unknown) 88,968
Total 153,486
Source: NIOSH 1990

CADMIUM 321
and found a mean concentration of 19 ppb (0.019 ppm) (Jensen 1983). The NHANES 1999–2008
reported cadmium levels in blood (see Table 6-4) and urine (see Tables 6-5 and 6-6) for children in
different age groups (CDC 2011). The NYC HANES did not test for blood cadmium levels in children,
although the blood cadmium levels in adults were slightly higher than the national average (McKelvey et
al. 2007). Results of the U.S. FDA Total Diet Study (Capar and Cunningham 2000) reported cadmium
levels in infant and junior foods ranged from no detection to 0.090 mg/kg. According to the National
Human Exposure Assessment Survey (NHEXAS), children in EPA Region V (Great Lakes Region) have
a mean dietary cadmium exposure of 17 (±1.8) μg/kg for minority children and 21 (±2.2) μg/kg for non-
minority children (Pellizzari et al. 1999).
Except in the vicinity of cadmium-emitting industries or incinerators, the intake of cadmium from
drinking water or ambient air is of minor significance (Elinder 1985a). Ambient air cadmium
concentrations in industrialized areas has been estimated between 15 and 150 ng/m3 (Morrow 2001).
Cadmium levels in the ambient air of Duisburg-South, Germany ranged from 1.5 to 31 ng/m3, compared
to 0.5 ng/m3 in the rural are of Westphalia. Cadmium levels in the blood and urine of mothers in the
industrialized area were higher than in the rural areas. Cadmium levels in the blood and urine of the
children did not differ between the two areas. In the industrialized area, regression analysis indicated a
significant influence of cadmium in ambient air on cadmium in blood (Wilhelm et al. 2005). Children in
the homes of parents who smoke also can be exposed to cadmium through the inhalation of environmental
tobacco smoke. There is potential for cadmium originating from second-hand smoke to settle onto
surfaces; thus, there is a possibility that children may ingest cadmium from contaminated surfaces by the
hand-to-mouth pathway. Although no data were found, children playing near hazardous waste sites could
be exposed to cadmium in soil by hand-to-mouth activity and/or soil pica. No case studies were found on
accidental poisoning of children by swallowing cadmium-containing batteries or by ingesting cadmium-
containing household pesticides, which also are potential routes of exposure. No information was found
concerning differences in the weight-adjusted intakes of cadmium by children.
In the Workers’ Home Contamination Study conducted under the Workers’ Family Protection Act
(DHHS 1995), several studies were identified that reported home contamination with cadmium
originating from parental occupation in a lead smelter. In a study of 396 children of ages 1–9 years living
<900 m from a primary lead smelter, 380 children (96%) had blood cadmium (CdB) levels >0.0089 μg/L
(Carvalho et al. 1986). The geometric mean and standard deviation were 0.087 µmol/L and 2.5,
respectively. No significant relationship was found between parental occupation in the smelter and CdB
in children, but a significant relationship was found between presence of smelter dross in the house and
CADMIUM 322
elevated CdB in children. Higher CdB was significantly associated with shorter distance from the home
to the smelter. In a similar study of 263 children (ages 1–9 years), living <900 m from a primary lead
smelter, the mean cadmium in hair was significantly higher at 6.0 ppm for children whose fathers worked
in lead smelters than the concentration of 3.7 ppm for children whose fathers had other jobs (Carvalho et
al. 1989). In a study of 9 children from families of lead workers and 195 children (ages 4–17 years) from
other families, the children from the families of lead workers had significantly higher geometric mean
urinary cadmium (CdU) (0.34 μg/L ±2.6) than children from other families (0.13 μg/L ±2.2). The CdB
levels of children from families of lead workers were higher than those of the children from other
families, but the difference was not statistically significant (Brockhaus et al. 1988). Maravelias et al.
(1989) measured the CdBs of 514 children (ages 5–12) from four schools located within various distances
(500–1500 m) from a lead smelter. The geometric mean and geometric standard deviation CdB was
0.36 μg/L ±1.4, respectively, with a range of 0.1–3.1 μg/L. Children from the school closest to the
smelter had higher CdB levels than children from other schools, but no relationship was found between
childrens’ CdB and parental employment in the smelter.
(Kuhnert et al. 1982); however, in a study in Czechoslovakia, the concentration of cadmium in the
placenta was found to be less than in either maternal or cord blood (Truska et al. 1989). Baranowska
(1995) also measured the concentrations of cadmium and lead in human placenta and in maternal and
neonatal (cord) blood to assess the influence of a strongly polluted environment on the content of metals
in tissues and on the permeability of the placenta to cadmium and lead. Samples for the study were
collected from women living in the industrial district of Upper Silesia, one of the most polluted regions in
Poland. The mean (range) concentration of cadmium in the air was 11.3 (2.1–25.4) ng/m3
(0.0113 [0.0021–0.0254] μg/m3). The mean concentrations of cadmium were 4.90 ng/mL
(0.00490 μg/mL) in venous blood, 0.11 μg/g in placenta, and 1.13 ng/mL (0.00113 μg/mL) in cord blood.
The researcher concluded that the placenta is a better barrier for cadmium than for lead, based upon the
relative decrease in metal concentrations from placenta to cord blood. The mechanism by which the
placenta transports the essential metals, copper and zinc, while limiting the transport of cadmium is
unknown, but may involve the approximately 1,000-fold higher concentration of zinc in the placenta and
the higher affinity of cadmium than zinc for metallothionein (Goyer and Cherian 1992). Timing and level
CADMIUM 323
of cadmium exposure may influence the uptake of cadmium by the placenta, perhaps explaining the
conflicting human studies. Galicia-García et al. (1995) performed analyses of cadmium in maternal, cord,
and newborn blood for 50 births in a Mexico City hospital. Multiple regression analyses applied to the
data indicated a significant association between cord and newborn blood and between cord and maternal
blood, but not among maternal and newborn blood. Birth weight of the newborns was found to be
inversely associated with cord blood cadmium levels and smoking habits.
The analysis of Weidenberg et al. (2011) on the bioavailability of cadmium present in inexpensive
jewelry suggests that substantial quantities of cadmium may be released from jewelry that is mouthed or
swallowed and that the amount released was greatly varied from item to item.
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES
The greatest potential for above-average exposure of the general population to cadmium is from smoking,
which may double the exposure of a typical individual. Smokers who are exposed to cadmium in the
workplace are at highest risk (CDC 2005). Individuals living near zinc or lead smelting operations,
municipal incinerators, or other industrial processes emitting cadmium to the air will also have above-
average exposure (Elinder 1985a). Exposures through inhalation are diminishing due to pollution
controls at such facilities, but exposure resulting from soil contamination may continue to be significant.
Persons who have corrosive drinking water and cadmium-containing plumbing, who habitually consume
cadmium-concentrating foods (kidney, liver, and shellfish), or who ingest grains or vegetables grown in
soils treated with municipal sludge or phosphate fertilizer all may have increased exposure (Elinder
1985a). The 2004 NYC HANES indicated that the New York City Asian population, especially those
born in China, had higher concentrations of cadmium in blood. The authors speculate that this might be
due to higher consumption of fish and shellfish (McKelvey et al. 2007).
Multiple pathways of exposure may exist for populations at hazardous waste sites contaminated with
cadmium (ingestion of contaminated drinking water or garden vegetables, inhalation of airborne dust,
incidental ingestion of contaminated soil).
Persons who consume large quantities of sunflower kernels can be exposed to higher levels of cadmium.
Reeves and Vanderpool (1997) identified specific groups of men who were likely to consume sunflower
kernels. The groups included baseball and softball players, delivery and long-distance drivers, and line
workers in sunflower kernel processing plants.
CADMIUM 324
Recreational and subsistence fishers that consume appreciably higher amounts of locally caught fish from
contaminated waterbodies may be exposed to higher levels of cadmium associated with dietary intake
(EPA 1993a). Cadmium contamination has triggered the issuance of several human health advisories. As
of December 1997, cadmium was identified as the causative pollutant in five fish and shellfish
consumption advisories in New York and another in New Jersey. EPA is considering including cadmium
as a target analyte and has recommended that this metal be monitored in fish and shellfish tissue samples
collected as part of state toxics monitoring programs. EPA recommends that residue data obtained from
these monitoring programs be used by states to conduct risk assessments to determine the need for issuing
fish and shellfish consumption advisories for the protection of the general public as well as recreational
and subsistence fishers. Under the same program, EPA has issued a statewide advisory in Maine for
cadmium in moose (EPA 1998).
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research
designed to determine the health effects (and techniques for developing methods to determine such health
effects) of cadmium.
Physical and Chemical Properties. The chemical and physical properties of cadmium and its salts
are known well enough to permit estimation of the environmental fate of the compounds (Elinder 1985a,
1992). Additional information on properties does not appear to be crucial for evaluating potential fate.
CADMIUM 325
Production, Import/Export, Use, Release, and Disposal. According to the Emergency

Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required
to submit substance release and off-site transfer information to the EPA. The TRI, which contains this
information for 2009, became available in February of 2011. This database is updated yearly and should
provide a list of industrial production facilities and emissions.
The production volume, producers, import/export quantities, and uses of cadmium in the United States are
well documented (SRI 2007; USGS 2007, 2008). Recycling of cadmium from spent batteries is
increasing, and there are some data to suggest that there is still a large portion of cadmium being disposed
of as municipal waste (USGS 2007). More data concerning the amount of municipal disposal would be
helpful. Disposal of cadmium-containing wastes is regulated by the federal government, and data are
available for industrial disposal practices (EPA 1982a; HSDB 2008; U.S. Bureau of Mines 1990). Most
releases of cadmium are not from production of the metal or its compounds, but from combustion or
smelter emissions, land application of sewage sludge and fertilizers, and other sources; estimates of these
releases have been made (TRI09 2011).
Environmental Fate. Cadmium partitioning among media occurs, and this partitioning depends on
local environmental conditions (Elinder 1985a, 1992). Cadmium may be subject to long-range transport
in air and water (EPA 1980d). Cadmium is persistent in all media, although it may form organic
complexes in soil and water under certain environmental conditions (EPA 1979). These processes, which
are important for determining the environmental fate of cadmium, seem to be relatively well understood.
Therefore, additional information on environmental fate does not appear to be essential to evaluate
potential human exposure to cadmium.
Bioavailability from Environmental Media. Factors that control the bioavailability of cadmium
from air, water, soil, and food have been investigated. Intestinal absorption of cadmium from food is low,
about 5–10% (McLellan et al. 1978; Newton et al. 1984; Rahola et al. 1973), but the absorption of
cadmium from soil is not known. Absorption from the lungs is somewhat greater, averaging about 25%
(Nordberg et al. 1985). Estimates of dermal absorption of cadmium from soil and water on human skin
have been made (Wester et al. 1992). There is some evidence that bioavailability of cadmium to plants
and worms from contaminated soil is greater following remediation (Van Gestel et al. 1988). Additional
information on the factors influencing bioavailability, particularly from remediated soil, are needed to
assess residual risk to populations in the vicinity of reclaimed hazardous waste sites.
CADMIUM 326
Food Chain Bioaccumulation. Sufficient data are available to indicate that cadmium is
concentrated in plants, aquatic organisms, and animals (Alloway et al. 1990; Beyer 1986; Handy 1992a,
1992b; Kuroshima 1992; Naqvi and Howell 1993; Roseman et al. 1994; Suresh et al. 1993; Vos et al.
1990). In vertebrates, cadmium accumulates in the liver and kidneys (Harrison and Klaverkamp 1990;
Sileo and Beyer 1985; Vos et al. 1990). There is strong evidence for food chain bioaccumulation, but the
potential for biomagnification is uncertain. Additional studies on biomagnification are needed to provide
data for more accurate evaluation of the environmental impact of cadmium contamination.
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of cadmium in
contaminated media at hazardous waste sites are needed so that the information obtained on levels of
cadmium in the environment can be used in combination with the known body burden of cadmium to
assess the potential risk of adverse health effects in populations living in the vicinity of hazardous waste
sites.
Current ambient air quality surveys testing for cadmium concentrations in rural and urban locations in the
United States is lacking. Since the major source of exposure to cadmium is through dietary intake and
since cadmium emissions to air are not expected to increase, there may be less interest in these data.
There are several long-range atmospheric transport studies, but since these were conducted Europe and
Russia, they only illustrate the potential for cadmium contamination via atmospheric deposition in the
United States (Reimann et al. 1997; Shevchenko et al. 2003; Vidovic et al. 2005). There is also minimal
data on current levels of cadmium in agricultural soils of the United States and the identification of the
sources of cadmium levels, whether they are native geochemistry, phosphate fertilizers, atmospheric
deposition, etc. (Xue et al. 2000). Continuing monitoring efforts in all media would allow more precise
estimation of current sources and levels of human exposure and would assist in identifying major sources
contributing to current exposure.
Exposure Levels in Humans. Cadmium has been detected in human blood, urine, breast milk,
liver, kidney, and other tissues, both in occupationally exposed individuals and in the general population
(CDC 2011; McKelvey et al. 2007; OSHA 1990). The NHANES and NYC HANES provide current data
on the levels of cadmium in humans (CDC 2011; McKelvey et al. 2007). Other large-scale surveys
concentrating on urban, agricultural, and suburban communities would be beneficial in understanding
cadmium exposure to the U.S. population. Also, more information is needed on the specific exposure
levels for different cadmium salts to determine if cadmium sulfides, for example, are associated with less
harmful effects than cadmium oxides (Chettle and Ellis 1992).
CADMIUM 327
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. Cadmium has been measured in maternal and neonatal (cord) blood and in
placenta (Baranowska 1995; Galicia-García et al. 1995; Kuhnert et al. 1982; Lauwerys et al. 1978; Roels
et al. 1978; Truska et al. 1989), but the resulting data are sometimes conflicting with respect to the uptake
of cadmium by the placenta. Research on the effects of timing and level of exposure on cadmium uptake
by the placenta might help to explain these conflicting human studies. More recent data would be useful,
both from women and children living in unpolluted areas (for background levels) and in polluted areas
such as those near existing or former lead smelters.
There are some current data concerning cadmium exposure in children (Capar and Cunningham 2000;
CDC 2011; Pellizzari et al. 1999). The NHANES 1999–2008 reported cadmium levels in blood (see
Table 6-4) and urine (see Table 6-5) for children in different age groups (CDC 2011). The NYC HANES
did not test for blood cadmium levels in children, although the blood cadmium levels in adults were
slightly higher than the national average (McKelvey et al. 2007). Results of the U.S. FDA Total Diet
Study (Capar and Cunningham 2000) reported cadmium levels in infant and junior foods ranged from no
detection to 0.090 mg/kg. According to the NHEXAS, children in EPA Region V (Great Lakes Region)
have a mean dietary cadmium exposure of 17 (±1.8) μg/kg for minority children and 21 (±2.2) μg/kg for
non-minority children (Pellizzari et al. 1999).
Some body burden data are available for children living near lead smelters (Lagerkvist and Lundstrom
2004; Leroyer et al. 2001; Jin et al. 2002). However, none of the studies took place in the United States.
Body burden data from children living in polluted and unpolluted regions (for background levels) of the
United States are needed.
Current information on whether children are different in their weight-adjusted intake of cadmium via oral,
inhalation, and dermal exposures was not located. A study to determine this information would be useful.
Also, no information was found on childhood specific means to reduce cadmium exposure.
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data
Needs: Children’s Susceptibility.
CADMIUM 328
Exposure Registries. The State of New York has established the Heavy Metals Registry for
surveillance of occupational heavy metals absorption. Cadmium levels >10 μg/L in blood and 5 μg/L in
urine are reported to the registry. The number of adults with reportable levels has varies per year, but
there have always been <50 adults reported per year. Between 1995 and 2003, the number of reportable
adults was <5, and these exposures are due mostly to exposure for people working as jewelers and casting
machine operators (NYS Dept of Health 2006).
No other exposure registries for cadmium were located. This substance is not currently one of the
compounds for which a subregistry has been established in the National Exposure Registry. The
substance will be considered in the future when chemical selection is made for subregistries to be
established. The information that is amassed in the National Exposure Registry facilitates the
epidemiological research needed to assess adverse health outcomes that may be related to exposure to this
substance.
The Federal Research in Progress (FEDRIP 2008) database provides additional information obtainable
from a few ongoing studies that may fill in some of the data needs identified in Section 6.8.1. These
studies are summarized in Table 6-10.
CADMIUM 329
Investigator Affiliation Research description Sponsor

Birnbaum ER Caldera Biomarkers of response to environmental National Institute of
Pharmaceuticals, stressors Environmental
Inc., Los Alamos, Health Sciences
New Mexico
Chen Z X-Ray Optical Direct measurement of trace elements in National Center for
Systems, Inc. body fluids Research
East Greenbush, Resources
New York
Dweik BM Giner, Inc., Field-deployable monitor to assess personal National Institute of
Newton, exposure to multiple heavy metals Environmental
Massachusetts Health Sciences
Fallin MD Johns Hopkins AGE-related epigenetic changes - National Institute of

University, environmental causes and disease Environmental
Baltimore, consequences Health Sciences
Maryland
Fox MA Johns Hopkins Environmental exposure to metal mixtures National Institute of
University, and kidney disease Environmental
Baltimore, Health Sciences
Maryland
Larkin PM Ecoarray, Inc. Developing and using sheepshead minnow National Institute of
Alachua, Florida microarrays for ecotoxicology Environmental
Health Sciences
Mo J Kumetrix, Inc, Automatic multi-analyte in-situ bioassay for National Institute of
Union City, monitoring exposure to toxic metals Environmental
California Health Sciences
Polette-Niewold Mayan Pigments, SBIR phase II: One-step environmentally- National Science
LA Inc. friendly synthesis of novel organic/inorganic Foundation
hybrid pigments
Santra S University of Selective detection of toxic heavy metal ions National Science
Central Florida using highly sensitive quantum dot probes Foundation
Basta N; Raun Oklahoma State Chemistry and bioavailability of waste U.S. Department of
WR University constituents in soils Agriculture
Basta NT Oklahoma State Heavy metal and trace element chemistry in U.S. Department of
University soils: Chemical speciation and bioavailability Agriculture
Basta NT; Lower Ohio State Heavy metal and trace element U.S. Department of
SK; Lanno R University biogeochemistry in soils: Chemical Agriculture
speciation, bioavailability, and toxicity
Bleam WF; University of Verifying and quantifying the specific U.S. Department of
Helmke PA Wisconsin complexation of metals to humic substances Agriculture
Chaney RL Beltsville Characterization and remediation of potential U.S. Department of
Agricultural trace element and phosphate risks from Agriculture
Research Center contaminated soils
Chaney RL Beltsville Risk assessment and remediation of soil and U.S. Department of
Agricultural amendment trace elements Agriculture
Research Center
CADMIUM 330

Chaney RL; Virginia Effects of long-term biosolids applications on U.S. Department of
Daniels WL Polytechnic phytoavailability of soil cadmium and zinc Agriculture
Institute
Chang AC; Page University of Chemistry and bioavailability of waste U.S. Department of
AL California, constituents in soils Agriculture
Riverside
Eick MJ Virginia Trace element and ligand adsorption/ U.S. Department of
Polytechnic desorption from soil constituent surfaces Agriculture
Institute
Hopkins DG North Dakota Influence of geologic materials and pedogenic U.S. Department of
State University processes on trace elements in soil Agriculture
landscapes
Hunt JR; Lykken University of Whole body counting and radiotracer U.S. Department of
GI North Dakota methods in research on mineral requirements Agriculture
in human nutrition
Kpomblekou- Tuskegee Trace elements in broiler littered soils: Fate U.S. Department of
Ademawou K; University and effects on nitrogen transformation Agriculture
Ankumah RO
Martinez CE Pennsylvania Chemical and biogeochemical processes U.S. Department of
State University involved in trace and toxic element cycling in Agriculture
soils
Morrissey MT Oregon State Characterization of the cadmium health risk, U.S. Department of
University concentrations and ways to minimize Agriculture
cadmium residues in shellfish
Schwab AP; Purdue University Chemistry and bioavailability of waste U.S. Department of
Joern B; Johnston constituents in soils Agriculture
C
Sparks DL University of Rates and mechanisms of metal and U.S. Department of
Delaware metalloid sorption/surfaces Agriculture
Thomas, DG; Oklahoma State Maternal dietary nutrients and neurotoxins in U.S. Department of
Kennedy TS University infant cognitive development Agriculture
Williams PL University of Environmental health impacts of soil U.S. Department of
Georgia contamination Agriculture
National Risk Biomonitoring of source water quality U.S. Environmental
Management Protection Agency
Research
Laboratory
Petterson L National Efficient monitoring of heterogeneous media U.S. Environmental
Exposure and electronic wastes Protection Agency
Research Lab
Environmental
Sciences Division
Characterization
and Monitoring
Branch
CADMIUM 331

Petterson L National Geochemical and interfacial applications for U.S. Environmental
Exposure assessing ecological toxicant exposures Protection Agency
Research Lab
Ecosystems
Research Division
Ecosystems
Assessment
Branch
Nolan P Office of Regional Lower Merrimack River fish tissue study U.S. Environmental
Administrator Protection Agency
Office of
Environmental
Measurement and
Evaluation
Janes D Office of Risks of heavy metals to aquatic organisms U.S. Environmental
Research and from multiple exposure routes Protection Agency
Development
National Health
and
Environmental
Effects Research
Lab Mid-
Continent
Ecology Division
Sources: FEDRIP 2008; SI/EPA 2007

CADMIUM 332

CADMIUM 333
7. ANALYTICAL METHODS
The purpose of this chapter is to describe the analytical methods that are available for detecting,
measuring, and/or monitoring cadmium, its metabolites, and other biomarkers of exposure and effect to
cadmium. The intent is not to provide an exhaustive list of analytical methods. Rather, the intention is to
identify well-established methods that are used as the standard methods of analysis. Many of the
analytical methods used for environmental samples are the methods approved by federal agencies and
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH). Other
methods presented in this chapter are those that are approved by groups such as the Association of
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).
Additionally, analytical methods are included that modify previously used methods to obtain lower
detection limits and/or to improve accuracy and precision.
7.1 BIOLOGICAL MATERIALS
The most common analytical procedures for measuring cadmium concentrations in biological samples use
the methods of atomic absorption spectroscopy (AAS) and inductively coupled plasma atomic emission
spectroscopy (ICP/AES). These basic methods of analysis are well defined and generally accepted for the
analysis of cadmium.
Samples are prepared for AAS and ICP/AES methods in a variety of ways. Digestion with nitric acid is
most common (Roberts and Clark 1986; Sharma et al. 1982). Cadmium in blood and plasma measured by
graphite furnace atomic absorption spectroscopy (GFAAS) facilitated by a wet ashing pretreatment of
samples resulted in good accuracy and reproducibility. The sample detection limit using this method was
0.4 μg/L (Roberts and Clark 1986). This method was also precise and highly reproducible in determining
cadmium in whole blood, urine, and hair with 99–99.4% recoveries reported (Sharma et al. 1982). The
matrix may also be modified with diammonium hydrogen phosphate or other agents such as palladium
(Pd)-based modifiers (Moreira et al. 1995). Detection limits as low as 0.1 μg/L with recoveries ranging
from 93 to 111% are reported using this technique (Subramanian and Meranger 1981; Subramanian et al.
1983). If the concentration of cadmium in the dissolved sample is below the detection limit,
preconcentration techniques, such as chelation and extraction, may be employed (Gross et al. 1976;
Sharma et al. 1982). Various ICP methods have been developed for measuring cadmium levels in
biological materials. ICP dynamic reaction cell mass spectrometry (ICP-DRC-MS) has been shown to
eliminate molybdenum-based polyatomic interferences, resulting in a reduction of observed urine
cadmium concentrations, as compared to ICP-MS measurements (Jarrett et al. 2008). Since cadmium is a
CADMIUM 334
ubiquitous element, the risk of contamination during sampling, processing, and analysis must be
minimized by strict laboratory procedures (Elinder and Lind 1985). In procedures for micro-
determination, all glass and plastic-ware should be acid-washed and subsequently rinsed with double-
distilled water.
Current analytical improvements deal primarily with the methods of sample preparation and sample
introduction to the analytical systems in order to lower the detection limits or decrease sample analysis
time. Various improvements in the methods of extraction, preconcentration, chelation, complexation, and
sample introduction have been developed for use with biological media. Detection limits as low as
0.003 μg/L were reported (Espinosa Almendro et al. 1992; Cordero et al. 1994; Jeng et al. 1994; Katskov
et al. 1994; Komárek et al. 1991; Ma et al. 1994b; Welz et al. 1991).
The cadmium concentration in biological samples may also be measured by a number of other methods
such as radiochemical neutron activation analysis (RNAA). One RNAA procedure involving a rapid
two-step solvent extraction was used for determining cadmium in tissue samples (Tandon et al. 1994).
Another method to determine cadmium in biological materials is based on the ion-exchange scheme
developed by SAMSAHL where cadmium is trapped on an anion exchange resin. With this method,
recovery of 98% and a detection limit of 4 μg/kg were reported. The accuracy of the method was
estimated by three different approaches: analysis using radiotracers in inactive sample solutions; by
analyzing standards, pipetted on filter paper, and processed as samples; and determination by RNAA
(Woittiez and Tangonan 1992).
Cadmium concentration in tissue may be measured both in vivo (Ellis 1985; Scott and Chettle 1986) and
in vitro (Lieberman and Kramer 1970) by neutron activation analysis (NAA). Direct in vivo assessment
of body burden in humans focused on the measurements of cadmium in the kidney and liver by NAA.
The detection limits reported are approximately 2 mg cadmium for the total kidney and 1.5 μg/g for the
liver (Ellis 1985); 1.9 mg cadmium for the kidney; and 1.3 μg/g for the liver (Scott and Chettle 1986).
X-ray fluorescence is also used for in vivo measurement of cadmium in the kidney (Christoffersson et al.
1987; Nilsson and Skerfving 1993; Scott and Chettle 1986; Skerfving and Nilsson 1992). The in vivo
techniques are used for clinical measurements of individuals occupationally exposed to cadmium.
Additional methods applicable to the analysis of cadmium in biological media include ICP/MS (Stroh
1993; Vanhoe et al. 1994), ICP/AES (Cordero et al. 1994; Espinosa Almendro et al. 1992), and high
performance liquid chromatography (HPLC) (Chang and Robinson 1993; Steenkamp and Coetzee 1994).
CADMIUM 335
Electrothemal vaporization ICP/MS has been utilized for the analysis of dentin and enamel from teeth
(Grünke et al. 1996). Electrochemical methods such as adsorptive cathodic stripping voltametry (ACSV)
and potentiometric stripping analysis (PSA) have been applied to hair analysis (Zhang et al. 1993), animal
tissues (LaBar and Lamberts 1994), and body fluids (Ostapczuk 1993).
Table 7-1 summarizes some of the methods used for sample preparation and analysis of cadmium in
biological samples.
7.2 ENVIRONMENTAL SAMPLES
Analysis for cadmium in environmental samples is usually accomplished by AAS or AES techniques,
with samples prepared by digestion with acid, preconcentrated with a chelating resin, or direct aspiration
with no preparation (APHA 1977a, 1977b; EPA 1983a, 1983b, 1997b; OSHA 2002a, 2004; USGS 1985).
Since cadmium in air is usually associated with particulate matter, standard methods involve collection of
air samples on glass fiber or membrane filters, acid extraction of the filters, and subsequent analysis
(APHA 1977a, 1977b; OSHA 2002a, 2002b). Inductively-coupled plasma spectrometry (ICP) analysis in
standard methods is also popular. ICP analysis for water and air samples can be run in tandem with mass
spectrometry (MS) or AES (EPA 1996b, 1997b, 2003; NIOSH 2003; OSHA 2002b). ACSV (Nimmo and
Fones 1994), differential pulse anodic stripping voltametry (DP-ASV) (Nam et al. 1994), and epithermal
NAA (Landsberger and Wu 1993) have also been used for air analysis. The accuracy of the analysis of
cadmium in acid digested atmospheric samples, measured by ACSV, was evaluated and compared with
GFAAS and ICP/MS.
Several methods standardized by EPA (1983a, 1983b, 1994b, 1996a, 1996b, 1997b, 2000, 2003) are used
for measuring concentrations of cadmium in water. Techniques to compensate for chemical and matrix
interferences in all three methods are described by EPA (1983a, 1983b, 1994b, 1996a, 1996b, 1997b,
2000, 2003). After soils and solid wastes are extracted or solubilized by acid digestion, they may be
analyzed for cadmium by the same AAS methods that are used for water (EPA 1986d, 1986e). Water can
also be analyzed for cadmium by NAA methods (Saleh et al. 1993), PSA methods (Ostapczuk 1993), and
anodic stripping voltametry (ASV) (Daih and Huang 1992).
Sediment and soil samples have been analyzed for cadmium using the methods of GFAAS (Klemm and
Bombach 1995). Preparation of the samples is generally accomplished by treatment with HCl and HNO3.
CADMIUM 336
Table 7-1. Analytical Methods for Determining Cadmium in Biological Materials
Sample
Analytical detection Percent
Sample matrix Preparation method method limit recovery Reference
a
Blood Digestion with nitric acid; AAS <1 ng/mL 99 Sharma et al.
chelation with APDC and 1982
extraction with MIBK
Blood Modification of matrix with GFAAS 0.1 μg/L 100.8±4.3 Subramanian
diammonium hydrogen and Meranger
phosphate/Triton X-100 1981
Blood/plasma Digestion with nitric acid; wet GFAAS 0.4 μg/L No data Roberts and
ashed Clark 1986
Serum Dilution with ammonia/Triton ICP/MS 0.01 ng/mL No data Stroh 1993
X-100
Tissue and blood Microwave digestion FAAS/flow 0.15 μg/L No data Welz et al.
injection 1991
system
a
Human milk Dilution with deionized and AAS <0.01 ppb No data Schulte-
double distilled water Lobbert and
Bohn 1977
a
Hair Digestion with nitric acid AAS 0.07 μg/g 99 Sharma et al.
1982
Kidney None (in vivo) XRF 170.1 μg/g No data Christoffersson
et al. 1987
a
Kidney/liver Chelation and extraction with AAS/direct 0.01 ppm No data Gross et al.
solvent aspiration (liver) 1976
1.9 mg
(kidney)
Kidney/liver None (in vivo) NAA 1.3 μg/g No data Scott and
(liver) Chettle 1986
1.9 mg
(kidney)
Muscle Wet ashed with concentrated NAA 50 ppb 50–65 Lieberman and
sulfuric acid Kramer 1970
Urine Dilution with nitric acid ETAAS 0.045 μg/L 97–101 Komárek et al.
1991
Urine Modification of matrix with GFAAS 0.09 ng/mL 92.7–111.1 Subramanian
diammonium hydrogen et al. 1983
phosphate/nitric acid
a
Urine Digestion with nitric acid AAS 5.67 ng/mL 99.4 Sharma et al.
1982
Biological Microwave digestion followed ICP/AES 0.15 ng/mL No data Cordero et al.
materials by extraction with APTH in 1994
MlBK
Biological Extraction with 1,5-bis(di- ICP/AES 0.1 ng/mL No data Espinosa
materials 2-pyridylmethylene) Almendro et al.
thiocarbonohydrazide in MlBK 1992
CADMIUM 337
Table 7-1. Analytical Methods for Determining Cadmium in Biological Materials
Sample
Analytical detection Percent
Sample matrix Preparation method method limit recovery Reference
Biological Digestion with acid GFAAS/flow 0.003 μg/L No data Ma et al. 1994a
materials injection
system
Biological fluids Acidification PSA 0.001 μg/kg No data Ostapczuk
(blood, urine) 1993
Biological Dry tissues; irradiation RNAA 4 μg/kg 98 Woittiez et al.
materials followed by acid digestion 1992
Teeth, dentin, Digested in nitric acid, diluted ETV-ICP-MS No data No data Grünke et al.
and enalmel with water PN-ICP-MS 1996
Whole blood, Modified with palladium ETAAS 0.22 μg/L No data Moreira et al.
urine based modifier 1995
Biological Digested with nitric acid and B-9001-95; No data 93 USGS 1996
materials hydrogen peroxide ICP-AES
a
Lowest concentration found
AAS = atomic absorption spectroscopy; APDC = ammonium pyrrolidenedithiocarbamate; APTH = 1,3-bis-

[1-(2-pyridyl)ethylidene] thiocarbon-hydride; ETAAS = electrothermal atomic absorption spectroscopy; FAAS = flame
atomic absorption; GFAAS = graphite furnace atomic absorption; ICP/AES = inductively coupled plasma atomic
emission spectroscopy; ICPIMS = inductively coupled plasma mass spectrometry; MlBK = methyl isobutyl ketone;
NAA = neutron activation analysis; PSA = potentiometric stripping analysis; RNAA = radio chemical neutron
activation analysis; XRF = x-ray fluorescence
CADMIUM 338
The most common method for analysis of cadmium in foods is AAS (Bruhn and Franke 1976; Dabeka
1979; Muys 1984), with GFAAS being one of the most common AAS methods used (Cabrera et al.
1995). The FDA’s Total Diet Study 1991–1996 analyzed cadmium and other element concentrations in
food by dry ash mineralization and GFAAS (Capar and Cunningham 2000). RNAA (Greenberg et al.
1979), differential pulse ASV (Satzger et al. 1982, 1984), and the calorimetric dithizone method (AOAC
1984) may also be employed. The AAS techniques appear to be most sensitive, with recoveries ranging
from 94 to 109% (Bruhn and Franke 1976; Muys 1984). A method used to isolate cadmium by first
extracting with bismuth diethyldithiocarbamate (Bi[DDC]3) and then with zinc diethyldithiocarbamate
(Zn[DDC]2) in chloroform and then measuring by RNAA showed 94–106% recovery (Greenberg et al.
1979).
Table 7-2 summarizes some of the methods used for sample preparation and analysis of cadmium in
environmental samples.
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research
designed to determine the health effects (and techniques for developing methods to determine such health
effects) of cadmium.
Methods for Determining Biomarkers of Exposure and Effect.
Exposure. Measurements of cadmium in liver and kidney are all useful biological indices for human
exposure to cadmium (Roels et al. 1981b). Human milk, human placentas, and maternal and neonatal
CADMIUM 339
Table 7-2. Analytical Methods for Determining Cadmium in Environmental

Samples
Sample Analytical Sample Percent

matrix Preparation method method detection limit recovery Reference
3
Air Collection on glass fiber Method 0.005 μg/m 90 APHA 1977b
filter; ashed with 311; AAS
hydrochloric and nitric
acids
Air Collection on membrane Method 0.05 μg per No data NlOSH 1994
filter; ashed with 7048; AAS sample
acids
Air Collection on membrane Method 0.3 ng/mL 99.8– NIOSH 2003
filter; digestion with nitric 7300; ICP 105.2
acid and perchloric acid
Air Collection using filters, Method 0.004 μg/mL 99.5 OSHA 2002a
wipes, or bulk materials; 121;
desorbed with water AAS/AES
extractions and mineral
acid digestions
a
Air Collection on membrane Method 0.14 μg No data OSHA 2002b
b
filter; digested in nitric 125G; 0.47 μg
acid, sulfuric acid, and ICP-AES
hydrogen peroxide
3 a
Air Collection on membrane Method 0.2 μg/m (AAS) No data OSHA 2004
3 b
filter; digested with nitric 189; AAS/ 0.70 μg/m (AAS)
3
acid and small amounts of AAS-HGA 0.007μg/m (AAS-
a
hydrochloric acid HGA)
3
0.025 μg/m
b
(AAS-HGA)
a
Air Collection on membrane Method 0.0062 μg/mL No data OSHA 1991
b
filter, wipe, or bulk 206; ICP- 0.0205 μg/mL
material; digest with nitric AES
and hydrochloric acids
Air Irradiation UF filters Epithermal 8 ng No data Landsberger et al.
NAA 1993
Air Acid digestion with filters ACSV 0.6 ng/mL 100 Nimmo and Fones
(aerosols) 1994
3
Atmospheric Direct analysis ETV-ICP- pg/m range No data Lüdke et al. 1997
particles MS
Water Digestion with nitric acid Method 5 μg/L 94±24 EPA 1983a
213.1;
AAS/direct
aspiration
Water Digestion with nitric acid Method 0.1 μg/L 96–99 EPA 1983b
213.2;
AAS/
GFAAS
CADMIUM 340

Samples

Water On-line preconcentration GFAAS/ 0.8 ng/L No data Welz et al. 1992
with ion exchange or flow
sorbent extraction injection
columns system
Water Digestion with nitric acid Method 0.0075 μg/L No data EPA 1996a
1637;
chelation
and
GFAAS
Water Digestion with nitric acid Method 0.025 μg/L No data EPA 1996b
1638; ICP-
MS
Water Preconcentrated with Method 0.0024 μg/L No data EPA 1997b
chelating resin 1640;
Online
Chelation/
ICP-MS
Water Digested with hydrochloric Method 0.1 μg/L 98±1.1 EPA 2003
and nitric acids 200.5;
AVICP-
AES
Water and Digestion with acids Method 1 μg/L (aqueous); 82–98 EPA 1994a
Wastes 200.7; 0.2 mg/kg (solids)
ICP-AES
Various Digestion with nitric and Method No data 97 EPA 2000
hydrochloric acids 6010C;
ICP-AES
Water and No preconcentration or I-1135; 10 μg/L No data USGS 1985
sediments pretreatment AAS
Water Digested with whole water I-4471-97; 5 μg/L No data USGS 1998a
ICP-OES
Various Direct aspiration with no I-5135; 10 μg/L No data USGS 1985
preconcentration or AAS
pretreatment
Soil Digestion with nitric acid Method 0.005 mg/L No data EPA 1986e
7130;
AAS/direct
aspiration
Soil Digestion with nitric acid Method 0.1 μg/L No data EPA 1986d
7131;
GFAAS
Soil and Ultrasonic slurry in dilute GFAAS No data 100±10 Klemm and Bombach
sediment nitric acid 1995
CADMIUM 341

Samples

Sediment Digestion with LEAFS 500 fg No data Zhou et al. 1998
acid
Soil and Digestion with hydrofluoric GFAAS/ 0.8 μg/L No data Ma et al. 1994b
sediment acid and nitric acid; flow
complexation with DDPA injection
using on-line sorbent system
extraction system
Food Dry ashed; oxidization ASV/ 1 ng/g 99–108 Satzger et al. 1984
with nitric acid differential
pulse
Food Dry ashed; complexation AAS 0.1 ng/g 97.5±2.5 Bruhn and Franke
with APCD; extraction 1976
with isoamyl acetate
c
Food Extraction with Bi(DDC)3 RNAA 0.029 μg/g 94–106 Greenberg et al. 1979
then with Zn(DDC)2 in
chloroform
Food Microwave digestion with GFAAS 0.004 μg/g 94–101 Yang et al. 1995
(24 hour nitric acid and hydrogen
diet) peroxide
c
Food Dry ashed; complexation GFAAS 0.1 ppb 94–109 Muys 1984
with NaDDTC; extraction
with IBMK
Food Homogenization followed GFAAS 0.01 ppb 94–108 Zhang et al. 1997
by wet ashing
Fruit Homogenized fruit slurried ETAAS 0.3 ng/g 97.7±0.3 Cabrera et al. 1995
with zirconia
a
Qualitative detection limit
b
Quantitative detection limit
c
Lowest concentration found
AAS = atomic absorption spectroscopy; ACSV = adsorptive cathodic stripping voltametry; APCD = ammonium
pyrrolidino carbodithioate; ASV = anodic stripping voltametry; AVICP-AES = axially viewed inductively coupled
plasma-atomic emission spectrometry; Bi(DDC)3 = bismuth diethyldithiocarbamate; DDPA = ammonium
diethyldithiophosphate; ETV-ICP-MS = electrothermal vaporization inductively coupled plasma mass spectrometry;
GFAAS = graphite furnace atomic absorption; HGA = heated graphite atomizer; IBMK = isobutyl methyl ketone;
ICP = inductively coupled plasma; LEAFS = laser-excited atomic fluorescence spectrometry; MS = mass
spectrometry; NAA = neutron activation analysis; NaDDTC = sodiumdiethyl-dithiocarbomate; OES = optical emission
spectroscopy; RNAA = radiochemical neutron activation analysis; Zn(DDC)2 = zinc diethyldithiocarbamate
CADMIUM 342
blood have been investigated as means to determine exposures of women and infants to cadmium
(Baranowska 1995; Abadin et al. 1997). Sensitive and selective methods are available for the detection
and quantitation of cadmium in these biological materials (Elinder and Lind 1985; Sharma et al. 1982).
Improved methods for sample preparation and in vivo analysis of liver and kidney content are needed to
assist in monitoring environmentally exposed populations.
Effect. Sensitive methods are also available for measuring biological markers of cadmium effect,
particularly urine or serum concentration of β2-microglobulin, retinol-binding protein, metallothionein,
and creatinine (Kawada et al. 1990; Roels et al. 1989; Topping et al. 1986).
Methods for Determining Parent Compounds and Degradation Products in Environmental

Media. Cadmium is ubiquitous in the environment and does not degrade. It is found in air, water, soil,
sediments, and food. Analytical methods exist for the analysis of cadmium in all of these environmental
media, and these methods have the sensitivity to measure background levels and detect elevated
concentrations due to anthropogenic sources such as hazardous waste sites (EPA 1983a, 1983b, 1994b,
1996a, 1996b, 1997b, 2000, 2003). Additional research to reduce chemical and matrix interferences are
needed to improve the speed and accuracy of the analyses.
The National Report on Human Health Exposure to Environmental Chemicals is an ongoing

biomonitoring assessment conducted by CDC. This survey measures over 200 chemicals in blood and
urine from random samples collected from participants in the National Health and Nutrition Examination
Survey (NHANES). The National Exposure Report was last published in 2009 and an update of
biomonitoring levels for some of the chemicals, including cadmium, was published in 2012 (CDC 2012).
The information in Table 7-3 was found as a result of a search of the Federal Research in Progress
database (FEDRIP 2008).
CADMIUM 343
Table 7-3. Ongoing Analytical Methods Studies on Cadmium

Parker D University of Isotopic dilution methods for probing the U.S. Department of
California bioavailability of trace elements in soils and Agriculture
sediments
Pierzynski G Kansas State Chemistry, bioavailability, and toxicity of U.S. Department of
University constituents in residuals and residual treated Agriculture
soils
Schwab AP; Joern B; Purdue Chemistry and bioavailability of waste U.S. Department of
Johnston C University constituents in soils Agriculture
Santra S University of Selective detection of toxic heavy metal ions National Science
Central Florida using highly sensitive quantum dot probes Foundation
Swain G Michigan Diamond microelectrode arrays: New U.S. Department of
State materials for the electrochemical detection of Agriculture
University aqueous analytes
Source: FEDRIP 2008

CADMIUM 344

CADMIUM 345
8. REGULATIONS, ADVISORIES, AND GUIDELINES
MRLs are substance-specific estimates, which are intended to serve as screening levels, are used by
ATSDR health assessors and other responders to identify contaminants and potential health effects that
may be of concern at hazardous waste sites.
ATSDR has derived an acute-duration inhalation MRL of 0.03 μg Cd/m3 for cadmium. This MRL is
based on a LOAEL of 0.088 mg Cd/m3 (LOAELHEC of 0.01 mg Cd/m3) for respiratory effects in rats
exposed to cadmium oxide 6.2 hours/day, 5 days/week for 2 weeks (NTP 1995) and an uncertainty factor
of 300 (10 for the use of a LOAEL, 3 for extrapolation from animals to humans with dosimetric
adjustments, and 10 for human variability).
ATSDR has derived a chronic-duration inhalation MRL of 0.01 μg Cd/m3 for cadmium. This MRL is
based on the 95% lower confidence limit of the urinary cadmium level associated with a 10% extra risk of
low molecular weight proteinuria (UCDL10) estimated from a meta-analysis of environmental exposure
data. An air concentration that would result in this urinary cadmium level (0.5 μg/g creatinine), assuming
a dietary cadmium intake of 0.3 μg/kg/day, was estimated using biokinetic models. The estimated air
concentration of 0.1 μg Cd/m3 was divided by an uncertainty factor of 3 for human variability and a
modifying factor of 3.
The EPA has not established a reference concentration (RfC) for cadmium.
ATSDR has derived an intermediate-duration oral MRL of 0.5 μg Cd/kg/day for cadmium. This MRL is
based on a BMDLstd1 of 0.05 mg Cd/kg/day for skeletal effects in young female rats exposed to cadmium
chloride in drinking water for 6, 9, or 12 months (Brzóska and Moniuszko-Jakoniuk 2005d) and an
uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human variability).
ATSDR has derived a chronic-duration oral MRL of 0.1 μg Cd/kg/day for cadmium. This MRL is based
on the UCDL10 for low molecular weight proteinuria estimated from a meta-analysis of environmental
exposure data. A cadmium intake that would result in the UCDL10 (0.5 μg/g creatinine) at age 55 was
estimated using pharmacokinetic models. The cadmium intake of 0.33 μg/kg/day was divided by an
uncertainty factor of 3 for human variability.
CADMIUM 346
The EPA has established a reference dose (RfD) of 5x10-4 mg/kg/day in water and 1x10-3 mg/kg/day in
food (IRIS 2012). The RfD is based on a chronic intake that would result in a kidney concentration of
200 μg/g ww.
The international and national regulations, advisories, and guidelines regarding cadmium in air, water,
and other media are summarized in Table 8-1.
Cadmium compounds are included on the list of 189 chemicals listed as hazardous air pollutants under
Section 112 of the Clean Air Act as amended (EPA 2007). Cadmium also is on the list of chemicals
appearing in the Emergency Planning and Community Right-To-Know Act of 1986 (EPA 2008g). Under
Title III of this statute, owners and operators of facilities that manufacture, import, process, or otherwise
use the chemicals on this list of report annually their release of those chemicals to any environmental
media.
Cadmium and cadmium chloride are designed as hazardous substances under Section 311 of the Clean
Water Act; any discharge of these chemicals over a specified threshold level into navigable waters is
subject to reporting requirements (EPA 2008c).
Cadmium is a hazardous waste under the Resource Conservation and Recovery Act (RCRA) under
several circumstances. Groundwater monitoring is required at municipal solid waste landfills (EPA
2008d) and cadmium is considered a priority persistent, bioaccumulative, and toxic (PBT) chemical under
RCRA waste minimization chemical listing (EPA 1998).
CADMIUM 347
Table 8-1. Regulations, Advisories, and Guidelines Applicable to Cadmium
Agency Description Information Reference

INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification IARC 2008
a
Cadmium and cadmium Group 1
compounds
WHO Air quality guidelines WHO 2000
b,c 3
Cadmium 5 ng/m
Drinking water quality guidelines WHO 2004
Cadmium 0.003 mg/L
NATIONAL
Regulations and
Guidelines:
a. Air
ACGIH Biological exposure indices ACGIH 2007
Cadmium and inorganic
compounds
Cadmium in urine 5 μg/g creatinine
Cadmium in blood 5 μg/L
TLV (8-hour TWA)
3
Cadmium 0.01 mg/m
Hazardous air pollutant EPA 2007
Cadmium compounds Yes 42 USC 7412
NIOSH REL (10-hour TWA) NIOSH 2005
f
Cadmium Potential occupational
carcinogens
Cadmium oxide Potential occupational
carcinogens
IDLH
3
Cadmium (as Cd) 9 mg/m
3
Cadmium oxide (as Cd) 9 mg/m
Category of pesticides NIOSH 1992b
g
Cadmium carbonate Group II pesticide
h
Cadmium chloride Group I pesticide
g
Cadmium sulfate Group II pesticide
CADMIUM 348

NATIONAL (cont.)
OSHA PEL (8-hour TWA) for general industry OSHA 2007a
Cadmium (as Cd) 5 μg/m
3 29 CFR
1910.1027
PEL (8-hour TWA) for shipyard OSHA 2007b
industry 29 CFR
3 1915.1027
PEL (8-hour TWA) for construction OSHA 2007c
industry 29 CFR
3 1926.1127
b. Water
EPA Designated as hazardous substances EPA 2008b
in accordance with 40 CFR 116.4
Section 311(b)(2)(A) of the Clean
Water Act
Cadmium chloride Yes
Drinking water standards and health EPA 2011b
advisories
Cadmium
1-day health advisory for a 0.04 mg/L
10-kg child
10-day health advisory for a 0.04 mg/L
10-kg child
DWEL 0.02 mg/L
Lifetime 0.005 mg/L
National primary drinking water EPA 2009b
standards
Cadmium
MCL 0.005 mg/L
Public health goal 0.005 mg/L
Reportable quantities of hazardous EPA 2008c
substances designated pursuant to 40 CFR 117.3
Section 311 of the Clean Water Act
Cadmium chloride 10 pounds
Toxic pollutants designated pursuant EPA 2008h
to Section 307(a)(1) of the Clean 40 CFR 401.15
Water Act
Cadmium and compounds Yes
c. Food
FDA Bottled drinking water FDA 2007
Cadmium 0.005 mg/L 21 CFR 165.110
EAFUS No data FDA 2008
CADMIUM 349

NATIONAL (cont.)
d. Other
ACGIH Carcinogenicity classification ACGIH 2007
j
Cadmium A2
j
Cadmium compounds (as Cd) A2
EPA Carcinogenicity classification IRIS 2012
k
Cadmium Group B1
Inhalation unit risk
-3 3
Cadmium 1.8x10 per μg/m
RfC
Cadmium No data
RfD
Cadmium
-3
Food 1x10 mg/kg-day
-4
Water 5x10 mg/kg-day
RCRA waste minimization PBT priority EPA 1998
chemical list 63 FR 60332
Cadmium Yes
Standards for owners and operators of EPA 2008d
hazardous waste TSD facilities; 40 CFR 264,
groundwater monitoring list Appendix IX
Cadmium Yes
Superfund, emergency planning, and
community right-to-know
Designated CERCLA hazardous EPA 2008e
substance 40 CFR 302.4
l,m
Cadmium Yes
n
Cadmium and compounds Yes
o
Cadmium chloride Yes
Reportable quantity
Cadmium 10 pounds
p
Cadmium and compounds None
Cadmium chloride 10 pounds
CADMIUM 350

NATIONAL (cont.)
EPA Superfund, emergency planning, and
community right-to-know
Effective date of toxic chemical EPA 2008g
release reporting 40 CFR 372.65
Cadmium 01/01/1987
q
Cadmium compounds 01/01/1987
Extremely Hazardous Substances EPA 2008f
Cadmium oxide 40 CFR 355,
Appendix A
Reportable quantity 100 pounds
Threshold planning quantity 100/10,000 pounds
NTP Carcinogenicity classification NTP 2011
Cadmium and cadmium Known to be human
compounds carcinogens
a
Group 1: The agent is carcinogenic to humans.
b
The guideline value is based on the prevention of a further increase of cadmium in agricultural soils, which is
likely to increase the dietary intake.
c
TWA based on effects other than cancer or odor/annoyance using an averaging time of 1 year.
d
Respriable fraction.
e
Higher current priority chemical for guideline development.
f
REL applies to all cadmium compounds (as Cd).
g
Group II pesticide: Contains the pesticides that pose as significant risk of carcinogenic, teratogenic, neurotoxic, or reproductive
effects
h
Group I pesticide: Contains the pesticides that pose as significant risk of adverse acute health effects at low concentrations
i
The CMC is an estimate of the highest concentration of a material in surface water to which an aquatic community can be
exposed briefly without resulting in an unacceptable effect. The CCC is an estimate of the highest concentration of a material in
surface water to which an aquatic community can be exposed indefinitely without resulting in an unacceptable effect.
j
A2: Suspected human carcinogen.
k
Group B1: Probable human carcinogen based on limited evidence of carcinogenicity in humans.
l
Designated CERCLA hazardous substance pursuant to Section 307(a) of the Clean Water Act.
m
No reporting of releases of this hazardous substance is required if the diameter of the pieces of the solid metal released is
larger than 100 micrometers (0.004 inches).
n
Designated CERCLA hazardous substance pursuant to Section 307(a) of the Clean Water Act and Section 112 of the Clean Air
Act.
o
Designated CERCLA hazardous substance pursuant to Section 311(b)(2) of the Clean Water Act.
p
Indicates that no reportable quantity is being assigned to the generic or broad class.
q
Cadmium compounds: Includes any unique chemical substance that contains cadmium as part of that chemical's
infrastructure.
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels;
CCC = Criterion Continuous Concentration; CERCLA = Comprehensive Environmental Response, Compensation, and Liability
Act; CFR = Code of Federal Regulations; CMC = Criteria Maximum Concentration; DWEL = drinking water equivalent level;
EAFUS = Everything Added to Food in the United States; EPA = Environmental Protection Agency; FDA = Food and Drug
Administration; IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life or health;
IRIS = Integrated Risk Information System; MCL = maximum contaminant level; NIOSH = National Institute for Occupational
Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health Administration;
PBT = persistant, bioaccumulative, and toxic; PEL = permissible exposure limit; RCRA = Resource Conservation and Recovery
Act; REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; TLV = threshold
limit values; TSD = treatment, storage, and disposal; TWA = time-weighted average; USC = United States Code; WHO = World
Health Organization
CADMIUM 351
9. REFERENCES
Abadin HG, Hibbs BF, Pohl HR. 1997. Breast-feeding exposures of infants to cadmium, lead, and
mercury: A public health viewpoint. Toxicol Ind Health 13(4):495-517.
Abdel-Saheb I, Schwab AP, Banks MK, et al. 1994. Chemical characterization of heavy metal
contaminated soil in southeast Kansas. Water Air Soil Pollut 78:73-82.
Abrahim KS, Abdel-Gawad NB, Mahmoud AM, et al. 2011. Genotoxic effect of occupational exposure
to cadmium. Toxicol Ind Health 27(2):173-179.
ACGIH. 2007. Cadmium. Threshold limit values for chemical substances and physical agents and
biological exposure indices. Cincinnati, OH: American Conference of Governmental Industrial
Hygienists, 17.
Adams RG, Harrison JF, Scott P. 1969. The development of cadmium-induced proteinuria, impaired
renal function, and osteomalacia in alkaline battery workers. Q J Med 152:425-443.
Adamsson E, Piscator M, Nogawa K. 1979. Pulmonary and gastrointestinal exposure to cadmium oxide
dust in a battery factory. Environ Health Perspect 28:219-222.
Ades AE, Kazantzis G. 1988. Lung cancer in a non-ferrous smelter: The role of cadmium. Br J Ind
Med 45:435-442.
Adinolfi M. 1985. The development of the human blood-CSF-brain barrier. Dev Med Child Neurol
27:532-537.
Adlercreutz H. 1995. Phytoestrogens: Epidemiology and a possible role in cancer protection. Environ
Health Perspect Suppl 103(7):103-112.
Agarwal, S; Zaman, T; Tuzcu, EM; et al. 2011. Heavy metals and cardiovascular disease: Results from
the National Health and Nutrition Examination Survey (NHANES) 1999-2006. Angiology 62(5):422-
429.
Agency for Toxic Substances and Disease Registry. 1989. Decision guide for identifying substance-
specific data needs related to toxicological profiles. Atlanta, GA: Agency for Toxic Substances and
Disease Registry, Division of Toxicology.
Agency for Toxic Substances and Disease Registry. 1990a. Biomarkers of organ damage or dysfunction
for the renal, hepatobiliary, and immune systems. Subcommittee on Biomarkers of Organ Damage and
Dysfunction. Atlanta, GA: Agency for Toxic Substances and Disease Registry.
Agency for Toxic Substances and Disease Registry. 1990b. Case studies in environmental medicine:
Cadmium toxicity. Atlanta, GA: Agency for Toxic Substances and Disease Registry.
_______________________
* Not cited in text

CADMIUM 352
9. REFERENCES
Akahori F, Masaoka T, Arai S. 1994. A nine-year chronic toxicity study of cadmium in monkeys. II.
Effects of dietary cadmium on circulatory function plasma cholesterol and triglyceride. Vet Hum Toxicol
36(4):290-294.
Åkesson A, Berglund M, Schutz A, et al. 2002. Cadmium exposure in pregnancy and lactation in
relation to iron status. Am J Public Health 92(2):284-287.
Åkesson A, Julin B, Wolk A. 2008. Long-term dietary cadmium intake and postmenopausal endometrial
cancer incidence: A population-based prospective cohort study. Cancer Res 68(15):6435-6441.
Åkesson A, Lundh T, Vahter M, et al. 2005. Tubular and glomerular kidney effects in Swedish women
with low environmental cadmium exposure. Environ Health Perspect 113(11):1627-1631.
Akinloye O, Arowojolu AO, Shittu OB, et al. 2006. Cadmium toxicity: A possible cause of male
infertility in Nigeria. Reprod Biol 6(1):17-30.
Alessio L, Apostoli P, Forni A, et al. 1993. Biological monitoring of cadmium exposure: An Italian
experience. Scand J Work Environ Health 19:27-33.
Alessio L, Berlin A, Dell’Orto A, et al. 1985. Reliability of urinary creatinine as a parameter used to
adjust values of urinary biological indicators. Int Arch Occup Environ Health 55:99-106.
Alfvén T, Elinder CG, Carlsson MD, et al. 2000. Low-level cadmium exposure and osteoporosis. J
Bone Miner Res 15(8):1579-1586.
Alfvén T, Elinder CG, Hellstrom L, et al. 2004. Cadmium exposure and distal forearm fractures. J Bone
Miner Res 19(6):900-905.
Alfvén T, Jarup L, Elinder C. 2002a. Cadmium and lead in blood in relation to low bone mineral density
and tubular proteinuria. (Erratum in: Environ Health Perspect 110(9):A505). Environ Health Perspect
110(7):699-702.
Ali MM, Murthy RC, Chandra SV. 1986. Developmental and long term neurobehavioral toxicity of low
level in utero cadmium exposure in rats. Neurobehav Toxicol Teratol 8:463-468.
Alloway BJ, Steinnes E. 1999. Anthropogenic additions of cadmium to soils. In: Cadmium in soils and
plants. Kluwer Academic Publishers, 97-123.
Alloway BJ, Jackson AP, Morgan H. 1990. The accumulation of cadmium by vegetables grown on soils
contaminated from a variety of sources. Sci Total Environ 91:223-236.
Altman PK, Dittmer DS. 1974. Biological handbooks: Biology data book. Vol. III. 2nd ed. Bethesda,
MD: Federation of American Societies for Experimental Biology, 1987-2008, 2041.
Amacher DE, Paillet SC. 1980. Induction of trifluorothymidine-resistant mutants by metal ions in
L5178Y/TK+/-cells. Mutat Res 78:279-288.
Andersen ME, Krishnan K. 1994. Relating in vitro to in vivo exposures with physiologically based tissue
dosimetry and tissue response models. In: Salem H, ed. Animal test alternatives: Refinement,
reduction, replacement. New York, NY: Marcel Dekker, Inc., 9-25.
CADMIUM 353
9. REFERENCES
Andersen ME, Clewell HJ, Gargas ML, et al. 1987a. Physiologically based pharmacokinetics and the
risk assessment process for methylene chloride. Toxicol Appl Pharmacol 87:185-205.
*Andersen ME, MacNaughton MG, Clewell HJ, et al. 1987b. Adjusting exposure limits for long and
short exposure periods using a physiological pharmacokinetic model. Am Ind Hyg Assoc J
48(4):335-343.
*Andersen O, Nielsen JB, Jones MM. 1989. Effects of dithiocarbamates on intestinal absorption and
organ distribution of cadmium chloride in mice. Pharmacol Toxicol 64:239-243.
Andersen O, Nielsen JB, Svendsen P. 1988. Oral cadmium chloride intoxication in mice: Effects of
dose on tissue damage, intestinal absorption and relative organ distribution. Toxicology 48:225-236.
Ando M, Hiratsuka N, Nakagawa J, et al. 1998. Cadmium accumulation in rats treated orally with
cadmium chloride for 8 months. J Toxicol Sci 23(3):243-248.
*Ando M, Matsui S, Jinno H, et al. 1988. Generation of hypophosphatemia in rats by continuous oral
administration of cadmium. Toxicology 53:1-10.
Angelo RT, Cringan MS, Chamberlain DL, et al. 2007. Residual effects of lead and zinc mining on
freshwater mussels in the Spring River Basin (Kansas, Missouri, and Oklahoma, USA). Sci Total
Environ 384:467-496.
Anonymous. 1994. Heavy metals in sewage sludge. Food Chem Toxicol 32(6):583-588.
Antonio MT, Peinado V, Gonzalez JC, et al. 2010. Effects of maternal cadmium administration on
development of monoaminergic, GABAergic and glutamatergic systems. Environ Toxicol Pharmacol
29(1):87-90.
AOAC. 1984. In: Williams S, ed. Official methods of analysis of the Association of Official Analytical
Chemists. 14th ed. Arlington, VA: Association of Official Analytical Chemists, Inc., 444-453.
Aoshima K, Fan J, Cai Y, et al. 2003. Assessment of bone metabolism in cadmium-induced renal tubular
dysfunction by measurements of biochemical markers. Toxicol Lett 136(3):183-192.
APHA. 1977a. Tentative method of analysis for cadmium content of atmospheric particulate matter.
Method 304. In: Katz M, ed. Methods of air sampling and analysis. 2nd ed. Washington, DC:
American Public Health Association, 444-446.
APHA. 1977b. Tentative method of analysis for cadmium content of atmospheric particulate matter by
atomic absorption spectroscopy. Method 311. In: Katz M, ed. Methods of air sampling and analysis.
2nd ed. Washington, DC: American Public Health Association, 466-471.
Apinan R, Satarug S, Ruengweerayut R, et al. 2010. The influence of iron stores on cadmium body
burden in a Thai population. Environ Geochem Health 32(3):237-242.
Arisawa K, Nakano A, Honda S, et al. 1997. Reproducibility of urinary β-microglobulin and cadmium
excretion among residents in a cadmium-polluted area during a 3-year period. Toxicol Lett 91:147-152.
Arisawa K, Nakano A, Saito H, et al. 2001. Mortality and cancer incidence among a population
previously exposed to environmental cadmium. Int Arch Occup Environ Health 74:255-262.
CADMIUM 354
9. REFERENCES
*Arisawa K, Uemura H, Hiyoshi M, et al. 2007a. Cadmium-induced renal dysfunction and mortality in
two cohorts: Disappearance of the association in a generation born later. Toxicol Lett 169(3):214-221.
Arisawa K, Uemura H, Hiyoshi M, et al. 2007b. Cause-specific mortality and cancer incidence rates in
relation to urinary β2-microglobulin: 23-Year follow-up study in a cadmium-polluted area. Toxicol Lett
173(3):168-174.
Armstrong BG, Kazantzis G. 1983. The mortality of cadmium workers. Lancet 1(8339):1425-1427.
Arnason JG, Fletcher BA. 2003. A 40+ year record of Cd, Hg, Pb, and U deposition in sediments of
Patroon Reservoir, Albany County, NY, USA. Environ Pollut 123:383-391.
Arora M, Weuve J, Schwartz J, et al. 2008. Association of environmental cadmium exposure with
pediatric dental caries. Environ Health Perspect 116(6):821-825.
Arora M, Weuve J, Schwartz J, et al. 2009. Association of environmental cadmium exposure with
periodontal disease in U.S. adults. Environ Health Perspect 117(5):739-744.
*Arvidson B. 1980. Regional differences in severity of cadmium-induced lesions in the peripheral

nervous system in mice. Acta Neuropathol (Berl) 49:213-223.
ASTER. 1994. ASTER (Assessment Tools for the Evaluation of Risk) ecotoxicity profile. Duluth, MN:
Environmental Research Laboratory, U.S. Environmental Protection Agency.
ASTER. 1995. ASTER (Assessment Tools for the Evaluation of Risk) ecotoxicity profile. Duluth, MN:
U.S. Environmental Protection Agency, Environmental Research Laboratory.
Aurelio L-M, Pilar DL, Fulgencio GG, et al. 1993. Levels of cadmium, lead and zinc protoporphyrin
absorption in different risk groups. Ann Occup Hyg 37(6):655-663.
Autier V, White D. 2004. Examination of cadmium sorption characteristics for a boreal soil near
Fairbanks, Alaska. J Hazard Mater 106B:149-155.
Axelsson B, Piscator M. 1966. Renal damage after prolonged exposure to cadmium. An experimental
study. Arch Environ Health 12:360-373.
Baer KN, Benson WH. 1987. Influence of chemical and environmental stressors on acute cadmium
toxicity. J Toxicol Environ Health 22:35-44.
Baker TD, Hafner WG. 1961. Cadmium poisoning from a refrigerator shelf used as an improvised
barbecue grill. Public Health Rep 76:543-544.
Bako G, Smith ES, Hanson J, et al. 1982. The geographical distribution of high cadmium concentrations
in the environment and prostate cancer in Alberta. Can J Public Health 73:92-94.
*Balaraman R, Gulati OD, Bhatt JD, et al. 1989. Cadmium-induced hypertension in rats. Pharmacology
38:226-234.
Bandara JM, Wijewardena HV, Liyanege J, et al. 2010. Chronic renal failure in Sri Lanka caused by
elevated dietary cadmium: Trojan horse of the green revolution. Toxicol Lett 198(1):33-39.
CADMIUM 355
9. REFERENCES
Baranowska I. 1995. Lead and cadmium in human placentas and maternal and neonatal blood (in a
heavily polluted area) measured by graphite furnace atomic absorption spectrometry. Occup Environ
Med 52(4):229-32.
Baranski B. 1984. Behavioral alterations in offspring of female rats repeatedly exposed to cadmium
oxide by inhalation. Toxicol Lett 22:53-61.
Baranski B. 1985. Effect of exposure of pregnant rats to cadmium on prenatal and postnatal
development of the young. J Hyg Epidemiol Microbiol Immunol 29:253-262.
Baranski B. 1987. Effect of cadmium on prenatal development and on tissue cadmium, copper and zinc
concentrations in rats. Environ Res 42:54-62.
Baranski B, Sitarek K. 1987. Effect of oral and inhalation exposure to cadmium on the oestrous cycle in
rats. Toxicol Lett 36:267-273.
Baranski B, Stetkiewicz I, Sitarek K, et al. 1983. Effects of oral, subchronic cadmium administration on
fertility, prenatal and postnatal progeny development in rats. Arch Toxicol 54:297-302.
Bargagli R. 1993. Cadmium in marine organisms from the Tyrrhenian Sea: No evidence of pollution or
biomagnification. Oebalia 19:13-25.
Barnes DG, Dourson M. 1988. Reference dose (RfD): Description and use in health risk assessments.
Regul Toxicol Pharmacol 8:471-486.
Barnhart S, Rosenstock L. 1984. Cadmium chemical pneumonitis. Chest 86:789-791.
Barrett HM, Irwin DA, Semmons E. 1947. Studies on the toxicity of inhaled cadmium. I. The acute
toxicity of cadmium oxide by inhalation. J Ind Hyg Toxicol 29:279-285.
Basinger MA, Jones MM, Holscher MA, et al. 1988. Antagonists for acute oral cadmium chloride
intoxication. J Toxicol Environ Health 23:77-89.
Bassendowska-Karska E, Zawadzka-Kos M. 1987. Cadmium sulfate does not induce sister chromatid
exchanges in human lymphocytes in vitro. Toxicol Lett 37:173-175.
Bauchinger M, Schmid E, Einbrodt HJ, et al. 1976. Chromosome aberrations in lymphocytes after
occupational exposure to lead and cadmium. Mutat Res 49:57-62.
Beevers DG, Cruickshank JK, Yeoman WB, et al. 1980. Blood-lead and cadmium in human
hypertension. J Environ Pathol Toxicol 4:251-260.
Benoff S, Hauser R, Marmar JL, et al. 2009. Cadmium concentrations in blood and seminal plasma:
Correlations with sperm number and motility in three male populations (infertility patients, artificial
insemination donors, and unselected volunteers). Mol Med 15(7-8):248-262.
Berger GS, ed. 1994. Epidemiology of endometriosis. In: Endometriosis: Advanced management and
surgical techniques. New York, NY: Springer-Verlag, 3-7.
CADMIUM 356
9. REFERENCES
*Berlin M, Fredricsson B, Linge G. 1961. Bone marrow changes in cadmium poisoning in rabbits. Arch
Environ Health 3:58-66.
Bermond A, Bourgeois S. 1992. Influence of soluble organic matter on cadmium mobility in model
compounds and in soils. Analyst 117(3):685-687.
Bernard AM, Lauwerys R. 1981. Retinol binding protein in urine: A more practical index than urinary
β2-microglobulin for the routine screening of renal tubular function. Clin Chem 27:1781-1782.
Bernard AM, Lauwerys R. 1986. Effects of cadmium exposure in humans. In: Foulkes EC, ed.
Handbook of experimental pharmacology. Vol. 80. Berlin: Springer Verlag, 135-177.
Bernard AM, Lauwerys R. 1989. Cadmium, NAG activity, and β2-microglobulin in the urine of
cadmium pigment workers. Br J Ind Med 46:679-680.
Bernard A, Buchet JP, Roels H, et al. 1979. Renal excretion of proteins and enzymes in workers exposed
to cadmium. Eur J Clin Invest 9:11-22.
Bernard A, Goret A, Buchet JP, et al. 1980. Significance of cadmium levels in blood and urine during
long-term exposure of rats to cadmium. J Toxicol Environ Health 6:175-184.
Bernard A, Lauwerys R, Amor AO. 1992. Loss of glomerular polyanion correlated with albuminura in
experimental cadmium nephropathy. Arch Toxicol 66:272-278.
Bernard A, Stolte H, DeBroe ME, et al. 1997. Urinary biomarkers to detect significant effects of
environmental and occupational exposure to nephrotoxins. IV. Current information on interpreting the
health implications of tests. Renal Fail 19(4):553-566.
Bernard AM, de Russis R, Amor AO, et al. 1988a. Potentiation of cadmium nephrotoxicity by
acetaminophen. Arch Toxicol 62:291-294.
*Bernard AM, Lauwerys R, Gengoux P, et al. 1984. Anti-laminin antibodies in Sprague-Dawley and
brown Norway rats chronically exposed to cadmium. Toxicology 31:307-313.
*Bernard AM, Ouled A, Roels H, et al. 1988b. Lack of relationship between urinary
plycosaminoglycans and indices of tubular or glomerular renal damage: Urinary GAG are an unreliable
nephrotoxicity index. Nephron 48:82-83.
*Bernard AM, Ouled Amor A, Lauwerys RR. 1988c. Decrease of erythrocytes and glomerular
membrane negative charges in chronic cadmium poisoning. Br J Ind Med 45:112-115.
Bernard AM, Roels H, Cardenas A, et al. 1990. Assessment of urinary protein 1 and transferrin as early
markers of cadmium nephrotoxicity. Br J Ind Med 47:559-565.
Beton DC, Andrews GS, Davies HJ, et al. 1966. Acute cadmium fume poisoning; five cases with one
death from renal necrosis. Br J Ind Med 23:292-301.
*Bevan C, Foulkes EC. 1989. Interaction of cadmium with brush border membrane vesicles from the rat
small intestine. Toxicology 54:297-309.
CADMIUM 357
9. REFERENCES
Beyer WN. 1986. A reexamination of biomagnification of metals in terrestrial food chains [Letter].
Environ Toxicol Chem 5:863-864.
Beyer WN, Stafford C. 1993. Survey and evaluation of contaminants in earth worms and in soils derived
from dredged material at confined disposal facilities in the Great Lakes region. Environ Monit Assess
24:151-165.
Beyer WN, Hensler G, Moore J. 1987. Relation of pH and other soil variables to concentrations of Pb,
Cu, Zn, Cd, and Se in earthworms. Pedobiolgia 30:167-172.
Bhattacharyya MH, Sellers DA, Peterson DP. 1986. Postlactational changes in cadmium retention and
mice orally exposed to cadmium during pregnancy and lactation. Environ Res 40:145-154.
Bhattacharyya MH, Whelton BD, Peterson DP. 1981. Gastrointestinal absorption of cadmium in mice
during gestation and lactation. I. Short-term exposure studies. Toxicol Appl Pharmacol 61:335-342.
Bhattacharrya MH, Whelton DB, Peterson DP. 1982. Gastrointestinal absorption of cadmium in mice
during gestation and lactation. II. Continuous exposure studies. Toxicol Appl Pharmacol 66:368-375.
Bhattacharyya MH, Whelton BD, Peterson DP, et al. 1988a. Kidney changes in multiparous mice fed a
nutrient-sufficient diet containing cadmium. Toxicology 50:205-215.
Bhattacharyya MH, Whelton BD, Peterson DP, et al. 1988b. Skeletal changes in multiparous mice fed a
nutrient-sufficient diet containing cadmium. Toxicology 50:193-204.
Bhattacharyya MH, Whelton BD, Stern PH, et al. 1988c. Cadmium accelerates bone loss in
ovariectomized mice and fetal rat limb bones in culture. Proc Natl Acad Sci 85:8761-8765.
Bjornberg A. 1963. Reactions to light in yellow tattoos from cadmium sulfide. Arch Dermatol
88:267-271.
Blaha K, Nerudova J, Jehlicova H, et al. 1995. In vivo and in vitro efficacy of a new carbodithioate for
the mobilization of cadmium. J Toxicol Environ Health 44:87-100.
Blainey JD, Adams RG, Brewer DB, et al. 1980. Cadmium-induced osteomalacia. Br J Ind Med
37:278-284.
Blakley BR. 1985. The effect of cadmium chloride on the immune response in mice. Can J Comp Med
49:104-108.
Blakley BR. 1986. The effect of cadmium on chemical- and viral-induced tumor production in mice. J
Appl Toxicol 6:425-429.
Blakley BR. 1988. Humoral immunity in aged mice exposed to cadmium. Can J Vet Res 52:291-292.
*Boisset M, Girard F, Godin J, et al. 1978. Cadmium content of lung, liver and kidney in rats exposed to
cadmium oxide fumes. Int Arch Occup Environ Health 41:41-53.
Bomhard E, Maruhn D, Paar D, et al. 1984. Urinary enzyme measurements as sensitive indicators of
chronic cadmium nephrotoxicity. Contrib Nephrol 42:142-147.
CADMIUM 358
9. REFERENCES
Bomhard E, Vogel O, Loser E. 1987. Chronic effects on single and multiple oral and subcutaneous
cadmium administration on the testes of Wistar rats. Cancer Lett 36:307-315.
Bonnell JA. 1955. Emphysema and proteinuria in men casting copper-cadmium alloys. Br J Ind Med
12:181-197.
Bonnevie NL, Huntley SL, Found BW, et al. 1994. Trace metal contamination in surficial sediments for
Newark Bay, New Jersey. Sci Total Environ 144:1-16.
*Borgman RF, Au B, Chandra RK. 1986. Immunopathology of chronic cadmium administration in mice.
Int J Immunopharmacol 8:813-817.
Börjesson J, Bellander T, Järup L, et al. 1997. In vivo analysis of cadmium in battery workers versus
measurements of blood, urine, and workplace air. Occup Environ Med 54(6):424-431.
Börjesson J, Gerhardsson L, Schutz A, et al. 2001. Kidney cadmium as compared to other markers of
cadmium exposure in workers at a secondary metal smelter. Am J Ind Med 39(1):19-28.
Borzelleca JF, Clarke EC, Condcie LW. 1989. Short-term toxicity (1 and 10 days) of cadmium chloride
in male and female rats: Gavage and drinking water. J Am Coll Toxicol 8:377-404.
Boscolo P, Carmignani M. 1986. Mechanisms of cardiovascular regulation in male rabbits chronically

exposed to cadmium. Br J Ind Med 43:605-610.
Boudreau J, Vincent R, Nadeau D, et al. 1989. The response of the pulmonary surfactant-associated
alkaline phosphatase following acute cadmium chloride inhalation. Am Ind Hyg Assoc J 50:331-335.
Boularbah A, Morel JL, Bitton, et al. 1992. Cadmium biosorption and toxicity to six cadmium-resistant
gram-positive bacteria isolated from contaminated soil. Environ Toxicol Water Qual 7:237-246.
Bouley G, Arsac F, Dubreuil A, et al. 1984. Natural and acquired resistance of mice to infection by
airborne Klebsiella pneumoniae after subchronic intoxication by cadmium administered orally. Sci Total
Environ 38:55-62.
Bouley G, Chaumard C, Quero AM, et al. 1982. Opposite effects of inhaled cadmium microparticles on
mouse susceptibility to an airborne bacterial and an airborne viral infection. Sci Total Environ
23:185-188.
Bråtveit, M; Mageroy, N; Gundersen, H; et al. 2011. Biomarker of chronic cadmium exposure in a

population residing in the vicinity of a zinc producing plant. Sci Total Environ 409:4222-4228.
Brockhaus A, Collet W, Dolgner R, et al. 1988. Exposure to lead and cadmium of children living in
different areas of North-West Germany: Results of biological monitoring studies 1982-1986. Int Arch
Occup Environ Health 60:211-222.
Bronstein AC, Currance PL. 1988. Emergency care for hazardous materials exposure. St. Louis, MO:
The C.V. Mosby Company, 133-134.
Bruce WR, Heddle JA. 1979. The mutagenic activity of 61 agents as determined by the micronucleus,
salmonella, and sperm abnormality assays. Can J Genet Cytol 21:319-334.
CADMIUM 359
9. REFERENCES
Bruhn JC, Franke AA. 1976. Lead and cadmium in California raw milk. J Dairy Sci 59:1711-1717.
Brumbaugh WG, Schmitt CJ, May TW. 2005. Concentrations of cadmium, lead, and zinc in fish from
mining-influenced waters of Northeastern Oklahoma: Sampling of blood, carcass, and liver for aquatic
biomonitoring. Arch Environ Contam Toxicol 49:76-88.
Brzóska MM. 2012. Low-level chronic exposure to cadmium enhances the risk of long bone fractures:
A study on a female rat model of human lifetime exposure. J Appl Toxicol 32(1):34-44.
Brzóska MM, Moniuszko-Jakoniuk J. 2004a. Low-level exposure to cadmium during the lifetime
increases the risk of osteoporosis and fractures of the lumbar spine in the elderly: Studies on a rat model
of human environmental exposure. Toxicol Sci 82:468-477.
Brzóska MM, Moniuszko-Jakoniuk J. 2004b. Low-level lifetime exposure to cadmium decreases

skeletal mineralization and enhances bone loss in aged rats. Bone 35(5):1180-1191.
Brzóska MM, Moniuszko-Jakoniuk J. 2005a. Bone metabolism of male rats chronically exposed to
cadmium. Toxicol Appl Pharmacol 207(3):195-211.
Brzóska MM, Moniuszko-Jakoniuk J. 2005b. Effect of chronic exposure to cadmium on the mineral
status and mechanical properties of lumbar spine of male rats. Toxicol Lett 157(2):161-172.
Brzóska MM, Moniuszko-Jakoniuk J. 2005c. Effect of low-level lifetime exposure to cadmium on

calciotropic hormones in aged female rats. Arch Toxicol 79(11):636-646.
Brzóska MM, Moniuszko-Jakoniuk J. 2005d. Disorders in bone metabolism of female rats chronically
exposed to cadmium. Toxicol Appl Pharmacol 202(1):68-83.
*Brzóska MM, Kaminski M, Dziki M, et al. 2004a. Changes in the structure and function of the kidney
of rats chronically exposed to cadmium. II. Histoenzymatic studies. Arch Toxicol 78(4):226-231.
Brzóska MM, Majewska K, Kupraszewicz E. 2010. Effects of low, moderate and relatively high chronic
exposure to cadmium on long bones susceptibility to fractures in male rats. Environ Toxicol Pharmacol
29(3):235-245.
Brzóska MM, Majewska K, Moniuszko-Jakoniuk J. 2004b. Mineral status and mechanical properties of
lumbar spine of female rats chronically exposed to various levels of cadmium. Bone 34(3):517-526.
Brzóska MM, Majewska K, Moniuszko-Jakoniuk J. 2005a. Bone mineral density, chemical composition
and biomechanical properties of the tibia of female rats exposed to cadmium since weaning up to skeletal
maturity. Food Chem Toxicol 43(10):1507-1519.
Brzóska MM, Majewska K, Moniuszko-Jakoniuk J. 2005b. Mechanical properties of femoral diaphysis

and femoral neck of female rats chronically exposed to various levels of cadmium. Calcif Tissue Int
76(4):287-298.
Brzóska MM, Majewska K, Moniuszko-Jakoniuk J. 2005c. Weakness in the mechanical properties of

the femur of growing female rats exposed to cadmium. Arch Toxicol 79(5):277-288.
Buchet JP, Lauwerys R, Roels H, et al. 1990. Renal effects of cadmium body burden of the general
population. Lancet 336:699-702.
CADMIUM 360
9. REFERENCES
Buckler HM, Smith WD, Rees WD. 1986. Self poisoning with oral cadmium chloride. Br Med J
292:1559-1560.
*Buckley BJ, Bassett DJ. 1987a. Glutathione redox status of control and cadmium oxide-exposed rat
lungs during oxidant stress. J Toxicol Environ Health 22:287-299.
Buckley BJ, Bassett DJ. 1987b. Pulmonary cadmium oxide toxicity in the rat. J Toxicol Environ Health
22:233-250.
Buck Louis GM, Sundaram R, Schisterman EF, et al. 2012. Heavy metals and couple fecundity, the
LIFE Study. Chemosphere [Epub ahead of print].
Bui TH, Lindsten J, Nordberg GJ. 1975. Chromosome analysis of lymphocytes from cadmium workers
and Itai-itai patients. Environ Res 9:187-195.
*Bunker VW, Lawson MS, Delues HT, et al. 1984. The intake and excretion of lead and cadmium by
the elderly. Am J Clin Nutr 39:803-808.
Burke BE, Pfister RM. 1988. The removal of cadmium from lake water by lake sediment bacteria. In:
Proceedings of the Annual Meeting of the American Society for Microbiology, Miami Beach, Florida,
USA, May 8-13, 1988.
Bus JS, Vinegar A, Brooks SM. 1978. Biochemical and physiologic changes in lungs of rats exposed to
a cadmium chloride aerosol. Am Rev Respir Dis 118:573-580.
Bustueva KA, Revich BA, Bezpalko LE. 1994. Cadmium in the environment of three Russian cities and
in human hair and urine. Arch Environ Health 49(4):284-288.
Cabrera C, Lorenzo ML, Lopez MC. 1995. Lead and cadmium contamination in dairy products and its
repercussion on total dietary intake. J Agric Food Chem 43:1605-1609.
*Caflisch CR. 1994. Effect of orally administered cadmium on in situ pH, PCO2, and bicarbonate
concentration in rat testis and epididymis. J Toxicol Environ Health 42(3):323-30.
Cai MY, Arenaz P. 1998. Antimutagenic effect of crown ethers on heavy metal-induced sister chromatid
exchanges. Mutagenesis 13:27-32.
Cai S, Wang J, Xue J, et al. 1992. A judgment of attribution of increase in urine β2-microglobulin after
environmental cadmium exposure. Biomed Environ Sci 5(2):130-135.
Cai S, Yui L, Hu Z, et al. 1990. Cadmium exposure and health effects among residents in an irrigation
area with ore dressing wastewater. Sci Total Environ 90:67-73.
Cai S, Yue L, Jin T, et al. 1998. Renal dysfunction from cadmium contamination of irrigation water:
Dose-response analysis in a Chinese population. Bull World Health Org 76(22):153-159.
Cai Y, Aoshima K, Katoh T, et al. 2001. Renal tubular dysfunction in male inhabitants of a cadmium-
polluted area in Toyama, Japan-an eleven year follow-up study. J Epidemiol 11(4):180-189.
CADMIUM 361
9. REFERENCES
Campbell KR. 1994. Concentrations of heavy metals associated with urban runoff in fish living in
stormwater treatment ponds. Arch Environ Contam Toxicol 27:352-356.
Canfield TJ, Kemble NE, Brumbaugh WG, et al. 1994. Use of benthic invertebrate community structure
and the sediment quality triad to evaluate metal-contaminated sediment in the upper Clark Fork River,
Montana. Environ Toxicol Chem 13(12):1999-2012.
Cantilena LR, Klaassen CD. 1980. The effect of ethylenediaminetetraacetic acid (EDTA) and EDTA
plus salicylate on acute cadmium toxicity and distribution. Toxicol Appl Pharmacol 53(3):510-514.
Cantilena LR, Klaassen CD. 1981. Comparison of the effectiveness of several chelators after single
administration on the toxicity, excretion, and distribution of cadmium. Toxicol Appl Pharmacol
58:452-460.
Cantilena LR, Klaassen CD. 1982a. Decreased effectiveness of chelation therapy with time after acute
cadmium poisoning. Toxicol Appl Pharmacol 63:173-180.
Cantilena LR, Klaassen CD. 1982b. The effect of repeated administration of several chelators on the
distribution and excretion of cadmium. Toxicol Appl Pharmacol 66:361-367.
Cao, Y; Chen, A; Radcliffe, J; et al. 2009. Postnatal cadmium exposure, neurodevelopment, and blood
pressure in children at 2, 5, and 7 years of age. Environ Health Perspect 117(10):1580-1586.
Capar SG, Cunningham WC. 2000. Element and radionuclide concentrations in food: FDA total diet
study 1991-1996. J AOAC Int 83(1):157-177.
Capar SG, Yess NJ. 1996. U.S. Food and Drug Administration survey of cadmium, lead and other
elements in clams and oysters. Food Addit Contam 13(5):553-560.
Caravati EM, McGuigan MA, MacGregor Whyte I, et al. Cadmium fume pneumonitis. In: Medical
toxicology, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1411-1414/
Cardenas A, Bernard A, Lauwerys R. 1992a. Incorporation of [35S]sulfate into glomerular membranes of

rats chronically exposed to cadmium and its relation with urinary glycosaminoglycans and proteinuria.
Toxicology 76:219-231.
Cardenas A, Remis I, Hotter G, et al. 1992b. Human and experimental studies on renal eicosanoid
response to long term cadmium exposure. Toxicol Appl Pharmacol 116:155-160.
Caride A, Fernandez-Perez B, Cabaleiro T, et al. 2010b. Cadmium chronotoxicity at pituitary level:

effects on plasma ACTH, GH, and TSH daily pattern. J Physiol Biochem 66(3):213-22
Caride A, Fernandez Perez B, Cabaleiro T, et al. 2010a. Daily pattern of pituitary glutamine, glutamate,
and aspartate content disrupted by cadmium exposure. Amino Acids 38(4):1165-1172.
Carmignani N, Boscolo P. 1984. Cardiovascular responsiveness to physiological agonists of female rats

made hypertensive by long-term exposure to cadmium. Sci Total Environ 34:19-33.
*Carroll RE. 1966. The relationship of cadmium in the air to cardiovascular disease death rates. JAMA
198:267-269.
CADMIUM 362
9. REFERENCES
Carvalho FM, Silvany-Neto AM, Melo AM, et al. 1989. Cadmium in hair of children living near a lead
smelter in Brazil. Sci Total Environ 84:119-128.
Carvalho FM, Silvany-Neto AM, Lima MEC Atl, et al. 1986. Cadmium concentrations in blood of
children living near a lead smelter in Bahia, Brazil. Environ Res 40:437-449.
Casto BC, Meyers J, DiPaolo JA, et al. 1979. Enhancement of viral transformation for evaluation of the
carcinogenic or mutagenic potential of inorganic metal salts. Cancer Res 39:193-198.
CDC. 2005. Third national report on human exposure to environmental chemicals. Atlanta, GA: U.S.
Department of Health and Human Services, Centers for Disease Control and Prevention.
CDC. 2011. Fourth national report on human exposure to environmental chemicals, updated tables,
February 2011. http://www.cdc.gov/exposurereport/pdf/Updated_Tables.pdf. January 11, 2012.
CDC. 2012. Fourth national report on human exposure to environmental chemicals, updated tables,
February 2012. Atlanta, GA: Centers for Disease Control and Prevention.
http://www.cdc.gov/exposurereport/pdf/FourthReport_UpdatedTables_Feb2012.pdf. September 10,
2012.
Cerny EA, Bhattacharyya MH. 2003. Low-volume, high-sensitivity assay for cadmium in blood and
urine using conventional atomic absorption spectrophotometry. Anal Biochem 314(2):190-193.
Cha CW. 1987. A study on the effect of garlic to the heavy metal poisoning of rat. J Korean Med Sci
2:213-224.
Chan HM, Cherian MG. 1993. Mobilization of hepatic cadmium in pregnant rats. Toxicol Appl
Pharmacol 120:308-314.
Chan OY, Poh SC, Lee HS, et al. 1988. Respiratory function in cadmium battery workers: A follow-up
study. Ann Acad Med Singapore 17:283-287.
Chang PP, Robinson JW. 1993. Development of thermospray interfaced HPLC-FAAS system for studies
on cadmium speciation in human body fluid. Spectrosc Lett 26(10):2017-2035.
*Chatterjee MS, Abdel-Rahman M, Bhandal A, et al. 1988. Amniotic fluid cadmium and thiocyanate in
pregnant women who smoke. J Reprod Med 33:417-420.
*Chen WK, Chung C. 1989. In vivo and in vitro medical diagnoses of toxic cadmium in rats. J
Radioanal Nucl Chem 133(2):349-358.
Chen L, Jin T, Huang B, et al. 2006a. Plasma metallothionein antibody and cadmium-induced renal
dysfunction in an occupation population in China. Toxicol Sci 91(1):104-112.
Chen L, Jin T, Huang B, et al. 2006b. Critical exposure level of cadmium for elevated urinary
metallothionein: An occupational population study in China. Toxicol Appl Pharmacol 215(1):93-99.
Chen L, Lei L, Jin T, et al. 2006c. Plasma metallothionein antibody, urinary cadmium, and renal
dysfunction in a Chinese type 2 diabetic population. Diabetes Care 29:2682-2687.
CADMIUM 363
9. REFERENCES
Chen RW, Whanger PD, Weswig PH. 1975. Selenium induced redistribution of cadmium-binding to
tissue proteins: A possible mechanism of protection against cadmium toxicity. Bioinorg Chem 4:125.
Chen X, Zhu G, Jin T, et al. 2009. Effects of cadmium on forearm bone density after reduction of
exposure for 10 years in a Chinese population. Environ Int 35(8):1164-1168.
Chen X, Zhu G, Jin T, et al. 2011. Bone mineral density is related with previous renal dysfunction
caused by cadmium exposure. Environ Toxicol Pharmacol 32(1):46-53.
Cherian MG, Shaikh ZA. 1975. Metabolism of intravenously injected cadmium-binding protein.
Biochem Biophys Res Commun 65:863-869.
Chettle DR, Ellis KJ. 1992. Further scientific issues in determining an occupational standard for
cadmium. Am J Ind Med 22:117-124.
Chia KS, Ong CN, Ong HY, et al. 1989. Renal tubular function of workers exposed to low levels of
cadmium. Br J Ind Med 46:165-170.
Chia KS, Tan AL, Chia SE, et al. 1992. Renal tubular function of cadmium exposed workers. Ann Acad
Med Singapore 21(6):756-759.
*Chiarenza A, Elverdin JC, Espinal E, et al. 1989. Effects of cadmium on the function and structure of
the rat salivary glands. Arch Oral Biol 34:999-1002.
*Chmielnicka J, Halatek T, Jedlinska U. 1989. Correlation of cadmium-induced nephropathy and the

metabolism of endogenous copper and zinc in rats. Ecotoxicol Environ Saf 18:268-276.
Chopra RK, Prasad R, Sharma N, et al. 1984. Effect of dietary chronic cadmium exposure on cell-
mediated immune response in Rhesus monkeys (Macaca mulatta): Role of calcium deficiency. Arch
Toxicol 56:128-131.
Choudhury H, Harvey T, Thayer WC, et al. 2001. Urinary cadmium elimination as a biomarker of
exposure for evaluating a cadmium dietary exposure-biokinetics model. J Toxicol Environ Health A
63:321-350.
Christoffersson JO, Welinder H, Spang G, et al. 1987. Cadmium concentration in the kidney cortex of
occupationally exposed workers measured in vivo using X-ray fluorescence analysis. Environ Res
42:489-499.
Chung J, Nartey NO, Cherian MG. 1986. Metallothionein levels in liver and kidney of Canadians: A
potential indicator of environmental exposure to cadmium. Arch Environ Health 41:319-323.
Cifone MG, Alesse E, Di Egenio R, et al. 1989a. In vivo cadmium treatment alters natural killer activity
and large granular lymphocyte number in the rat. Immunopharmacology 18:149-156.
*Cifone MG, Alesse E, Procopio A, et al. 1989b. Effects of cadmium on lymphocyte activation.
Biochim Biophys Acta 1011:25-32.
*Clark DE, Nation JR, Bourgeois AJ, et al. 1985. The regional distribution of cadmium in the brains of
orally exposed adult rats. Neurotoxicology 6:109-114.
CADMIUM 364
9. REFERENCES
Clewell HJ, Andersen M. 1985. Risk assessment extrapolations and physiological modeling. Toxicol
Ind Health 1(4):111-131.
Cole RH, Frederick RE, Healy RP, et al. 1984. Preliminary findings of the Priority Pollutant Monitoring
Project of the Nationwide Urban Runoff Program. J Water Pollut Contr Fed 56:898-908.
Cordero MTS, de Torres AG, Pavon JMC. 1994. Solvent extraction of cadmium as a previous step for
its determination in biological samples by inductively coupled plasma atomic emission spectrometry.
Anal Lett 27(9):1689-1701.
Cortona G, Apostoli P, Toffoletto F, et al. 1992. Occupational exposure to cadmium and lung function.
In: Nordberg GF, Herber RFM, Alessio L, eds. Cadmium in the human environment: Toxicity and
carcinogenicity. IARC Scientific Publications No. 118. Lyon, France: International Agency for
Research on Cancer, 205-210.
Cousins RJ, Barber AK, Trout JR. 1973. Cadmium toxicity in growing swine. J Nutr 103:964-972.
Cresta L, Perdelli F, Franco Y, et al. 1989. [Possible correlations between urinary cadmium and fetal
growth retardation in pregnant women who smoke.] Minerva Genecol 41:85-88. (Italian)
Crews HM, Dean JR, Ebdon L, et al. 1989. Application of high-performance liquid chromatography-
inductively coupled plasma mass spectrometry to the investigation of cadmium speciation in pig kidney
following cooking and in vitro gastrointestinal digestion. Analyst 114:895-899.
Crews HM, Owen LM, Langford N, et al. 2000. Use of the stable isotope 106Cd for studying dietary
cadmium absorption in humans. Toxicol Lett 112-113:201-207.
Cummins PE, Dutton J, Evans CJ, et al. 1980. An in vivo study of renal cadmium and hypertension. Eur
J Clin Invest 10:459-461.
Dabeka RW. 1979. Graphite furnace atomic absorption spectrometric determination of lead and
cadmium in foods after solvent extraction and stripping. Anal Chem 51:902-907.
Daih B, Huang H. 1992. Determination of trace elements in sea water by flow-injection anodic stripping
voltammetry preceded by immobilized quinolin-8-ol silica gel preconcentration. Anal Chim Acta
258:245-252.
Daniels MJ, Menache MG, Burleson GR, et al. 1987. Effects of NiCl2 and CdCl2 on susceptibility to
murine cytomegalovirus and virus-augmented natural killer cell and interferon responses. Fundam Appl
Toxicol 8:443-453.
Davison AG, Fayers PM, Taylor AJ, et al. 1988. Cadmium fume inhalation and emphysema. Lancet
1(8587):663-667.
Deaven LL, Campbell EW. 1980. Factors affecting the induction of chromosomal aberrations by
cadmium in Chinese hamster cells. Cytogenet Cell Genet 26:251-260.
de Burbure C, Buchet JP, Leroyer A, et al. 2006. Renal and neurologic effects of cadmium, lead,
mercury, and arsenic in children: Evidence of early effects and multiple interactions at environmental
exposure levels. Environ Health Perspect 114(8):A458.
CADMIUM 365
9. REFERENCES
Debusk TA, Laughlin R B JR, Schwartz LN. 1996. Retention and compartmentalization of lead and
cadmium in wetland microcosms. Water Res 30 (11):2707-2716.
Decker LE, Byerrum RU, Decker CF, et al. 1958. Chronic toxicity studies. I. Cadmium administered in
drinking water to rats. AMA Arch Ind Health 18:228-231.
Deknudt G, Gerber GB. 1979. Chromosomal aberrations in bone marrow cells of mice given a normal or
a calcium-deficient diet supplemented with various heavy metals. Mutat Res 68:163-168.
Deknudt G, Deminatti M. 1978. Chromosome studies in human lymphocytes after in vitro exposure to
metal salts. Toxicology 10:67-75.
Deknudt G, Leonard A. 1975. Cytogenetic investigations on leucocytes of workers from a cadmium

plant. Environ Physiol Biochem 5:319-327.
Deknudt G, Leonard A, Ivanov B. 1973. Chromosome aberrations in male workers occupationally

exposed to lead. Environ Physiol Biochem 3:132-138.
de Kort WL, Verschoor MA, Wibowo AA, et al. 1987. Occupational exposure to lead and blood
pressure: A study in 105 workers. Am J Ind Med 11:145-156.
Denizeau F, Marion M. 1989. Genotoxic effects of heavy metals in rat hepatocytes. Cell Biol Toxicol
5:15-26.
Depault F, Cojocaru M, Fortin F, et al. 2006. Genotoxic effects of chromium(VI) and cadmium(II) in
human blood lymphocytes using the electron microscopy in situ end-labeling (EM-ISEL) assay. Toxicol
In Vitro 20(4):513-518.
Dervan PA, Hayes JA. 1979. Peribronchiolar fibrosis following acute experimental lung damage by
cadmium aerosol. J Pathol 128:143-149.
Desi I, Nagymajtenyi L, Schulz H. 1998. Behavioral and neurotoxicological changes caused by

cadmium treatment of rats during development. J Appl Toxicol 18(1):63-70.
Desi I, Nehez M, Siroki O, et al. 2000. Small subchronic doses of the pesticide dimethoate and/or
cadmium and lead treatment causes disturbances in the chromosomes of young rats. Cent Eur J Public
Health 8:59-60.
Devi KD, Banu BS, Mahboob M, et al. 2001. In vivo genotoxic effect of cadmium chloride in mice
leukocytes using comet assay. Teratog Carcinog Mutagen 21(5):325-333.
DHHS. September 1995. Report to Congress on workers' home contamination study conducted under
the workers' family protection act (29 U.S.C. 671a). Cincinnati, OH: U.S. Department of Health and
Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute
for Occupational Safety and Health.
Diamond GL, Thayer WC, Choudhury H. 2003. Pharmacokinetics/pharmacodynamics (PK/PD)

modeling of risks of kidney toxicity from exposure to cadmium: Estimates of dietary risks in the U.S.
population. J Toxicol Environ Health A 66:2141-2164.
CADMIUM 366
9. REFERENCES
*Diaz-Barriga F, Santos MA, Mejia JDJ, et al. 1993. Arsenic and cadmium exposure in children living
near a smelter complex in San Luis Potosi, Mexico. Environ Res 62(2):242-250.
Ding X, Jiang J, Wang Y, et al. 1994. Bioconcentration of cadmium in water hyacinth (Eichhornia
crassipes) in relation to thiol group content. Environ Pollut 84(1):93-96.
DiPaulo JA, Castro BC. 1979. Quantitative studies of in vitro morphological transformation of Syrian
hamster cells by inorganic metal salts. Cancer Res 39:1008-1013.
Dixon RL, Lee IP, Sherins RJ. 1976. Methods to assess reproductive effects of environmental
chemicals: Studies of cadmium and boron administered orally. Environ Health Perspect 13:59-67.
DOI. 1985. Cadmium hazards to fish, wildlife, and invertebrates: A synoptic view. U.S. Fish and
Wildlife Service Biological Report 85(1.2). Washington, DC: U.S. Department of the Interior.
Doll R. 1992. Is cadmium a human carcinogen? Ann Epidemiol 2:335-337.
Dorian C, Gattone VH, Klaasen CD. 1992a. Renal cadmium deposition and injury as a result of
accumulation of cadmium-metallothionein (CdMT) by the proximal convoluted tubules: A light
microscopic autoradiography study with 109CdMT. Toxicol Appl Pharmacol 114:173-181.
Dorian C, Gattone VH, Klaasen CD. 1992b. Accumulation and degradation of the protein moiety of
cadmium-metallothionein (CdMT) in the mouse kidney. Toxicol Appl Pharmacol 117:242-248.
Dorian C, Gattone VH, Klaasen CD. 1995. Discrepancy between the nephrotoxic potencies of cadmium
- metallothionein and cadmium chloride and the renal concentration of cadmium in the proximal
convoluted tubules. Toxicol Appl Pharmacol 130:161-168.
Dorian C, Klaassen CD. 1995. Protection by zinc-metallothionein (znmt) against cadmium-

metallothionein-induced nephrotoxicity. Fundam Appl Toxicol 26(1):99-106.
Doyle JJ, Pfander WH, Grebing SE, et al. 1974. Effect of dietary cadmium on growth, cadmium
absorption and cadmium tissue levels in growing lambs. J Nutr 104(2):160-166.
*Drasch GA, Kretschmer E, Neidlinger P, et al. 1989. Cadmium, zinc, copper and metallothionein in
human tissues (liver and kidney). Toxicol Environ Chem 23:207-214.
Driscoll KE, Maurer JK, Poynter J, et al. 1992. Stimulation of rat alveolar macrophage fibronectin
release in a cadmium chloride model of lung injury and fibrosis. Toxicol Appl Pharmacol 116:30-37.
Dudley RE, Gammal LM, Klaassen CD. 1985. Cadmium-induced hepatic and renal injury in chronically
exposed rats: Likely role of hepatic cadmium-metallothionein in nephrotoxicity. Toxicol Appl
Edling C, Elinder CG, Randma E. 1986. Lung function in workers using cadmium-containing solders.
Br J Ind Med 43:657-662.
*Eggert-Kruse W, Rohr G, Jochum R, et al. 1992. [The effect of heavy metals on the in vitro interaction
between human sperm and cervical mucus]. Dtsch Med Wochenschr 117(37):1383-1389. (German)
CADMIUM 367
9. REFERENCES
Egwuogu H, Shendell DG, Okosun IS, et al. 2009. The effect of urinary cadmium on cardiovascular
fitness as measured by VO2 max in white, black and Mexican Americans. Environ Res 109(3):292-300.
Eklund G, Grawe KP, Oskarsson A. 2001. Bioavailability of cadmium from infant diets in newborn rats.
Arch Toxicol 75:522-530.
Eklund G, Tallkvist J, Oskarsson A. 2004. A piglet model for studies of gastrointestinal uptake of
cadmium in neonates. Toxicol Lett 146(3):237-247.
Elinder CG. 1985a. Cadmium: Uses, occurrence and intake. In: Friberg L, Elinder CG, Kjellström T,
et al., eds. Cadmium and health: A toxicological and epidemiological appraisal. Vol. I. Exposure, dose,
and metabolism. Effects and response. Boca Raton, FL: CRC Press, 23-64.
Elinder CG. 1985b. Normal values for cadmium in human tissue, blood and urine in different countries.
In: Friberg L, Elinder CG, Kjellström T, et al., eds. Cadmium and health: A toxicological and
epidemiological appraisal. Vol. I. Exposure, dose, and metabolism. Effects and response. Boca Raton,
FL: CRC Press, 81-102.
Elinder CG. 1986b. Respiratory effects. In: Friberg L, Elinder CG, Kjellström T, et al., eds. Cadmium
and health: A toxicological and epidemiological appraisal. Vol. II. Effects and response. Boca Raton,
FL: CRC Press, 1-20.
Elinder CG. 1992. Cadmium as an environmental hazard. IARC Sci Publ 118:123-132.
Elinder CG, Lind B. 1985. Principles and problems of cadmium analysis. In: Friberg L, Elinder CG,
Kjellström T, et al., eds. Cadmium and health: A toxicological and epidemiological appraisal. Vol. I.
Boca Raton, FL: CRC Press, 7-22.
Elinder CG, Edling C, Lindberg E, et al. 1985a. Assessment of renal function in workers previously
exposed to cadmium. Br J Ind Med 42:754-760.
Elinder CG, Edling C, Lindberg E, et al. 1985b. β2-Microglobulinuria among workers previously
exposed to cadmium: Follow-up and dose-response analyses. Am J Ind Med 8:553-564.
Elinder CG, Kjellström T, Hogstedt C, et al. 1985c. Cancer mortality of cadmium workers. Br J Ind
Med 42:651-655.
Elinder CG, Kjellström T, Lind B, et al. 1978. Cadmium concentrations in human liver, blood, and bile:
Comparison with a metabolic model. Environ Res 17(2):236-241.
Ellenhorn MJ, Barceloux DJ. 1988. Medical toxicology: Diagnosis and treatment of human poisoning.
New York, NY: Elsevier, 1018-1020.
Ellis KJ. 1985. Dose-response analysis of heavy metal toxicants in man: Direct in vivo assessment of
body burden. Trace Subst Environ Health 19:149-159.
Ellis KJ, Cohn SH, Smith TJ. 1985. Cadmium inhalation exposure estimates: Their significance with
respect to kidney and liver cadmium burden. J Tox Environ Health 15:173-187.
Ellis KJ, Vartsky D, Zanzi I, et al. 1979. Cadmium: In vivo measurement in smokers and nonsmokers.
Science 205:323-325.
CADMIUM 368
9. REFERENCES
Ellis KJ, Yuen K, Yasumura S, et al. 1984. Dose-response analysis of cadmium in man: Body burden vs
kidney dysfunction. Environ Res 33:216-226.
Engström A, Skerving S, Lidfeldt J, et al. 2009. Cadmium-induced bone effect is not mediated via low
serum 1,25-dihydroxy vitamin D. Environ Res 109(2):188-192.
Engström B, Nordberg GF. 1979. Dose-dependence of gastrointestinal absorption and biological half-
time of cadmium in mice. Toxicology 13:215-222.
*Engström B, Norin H, Jawaid M, et al. 1980. Influence of different Cd-EDTA complexes on

distribution and toxicity of cadmium in mice after oral or parenteral administration. Acta Pharmacol
Toxicol (Copenh) 46:219-234.
EPA. 1979. Water-related fate of 129 priority pollutants. Washington, DC: U.S. Environmental
Protection Agency, Office of Water Planning and Standards. EPA 440479029a.
*EPA. 1980a. Ambient air quality criteria for cadmium. Washington, DC.: U.S. Environmental
Protection Agency, Office of Water Regulations and Standards. EPA440580025.
*EPA. 1980b. Land treatment waste analysis. U.S. Environmental Protection Agency. Code of Federal
Regulations. 40 CFR 265.273.
*EPA. 1980c. Land treatment: Food chain crops. U.S. Environmental Protection Agency. Code of
Federal Regulations. 40 CFR 265.276.
EPA. 1980d. Atmospheric cycles of cadmium and lead: Emissions, transport, transformation and
removal. U.S. Environmental Protection Agency, 1-6 to 1-17; 2-14 to 2-41.
EPA. 1981a. Health assessment document for cadmium. Research Triangle Park, NC: U.S.
Environmental Protection Agency. EPA600881023. PB82115163.
*EPA. 1981b. Electroplating pretreatment standards. U.S. Environmental Protection Agency. Code of
Federal Regulations. 40 CFR 413.14.
EPA. 1982a. Intermedia priority pollutant guidance documents. Cadmium. Washington, DC: U.S.
Environmental Protection Agency, Office of Toxics Integration.
*EPA. 1982b. Methods for chemical analysis of water and wastes. Method 200.7. Inductively coupled
plasma - atomic emission spectrometric method for trace element analysis of water and wastes.
Cincinnati, OH: U.S. Environmental Protection Agency, Environmental Monitoring and Support
Laboratory. EPA600479020.
EPA. 1983a. Methods for chemical analysis of water and wastes. Method 213.1 (Atomic absorption,
direct aspiration). Cincinnati, OH: U.S. Environmental Protection Agency, Office of Research and
Development, Environmental Monitoring and Support Laboratory. EPA600479020.
EPA. 1983b. Methods for chemical analysis of water and wastes. Method 213.2 (Atomic absorption,
furnace technique). Cincinnati, OH: U.S. Environmental Protection Agency, Office of Research and
Development, Environmental Monitoring and Support Laboratory. EPA600479020.
CADMIUM 369
9. REFERENCES
EPA. 1983c. Treatability manual. Vol. I. Treatability data. Washington, DC: U.S. Environmental
Protection Agency, Office of Research and Development. EPA600282001a.
EPA. 1985a. Cadmium contamination of the environment: An assessment of nationwide risk.

Washington, DC: U.S. Environmental Protection Agency, Office of Water Regulations and Standards.
EPA 440485023.
*EPA. 1985b. Summary of environmental profiles and hazard indices for constituents of municipal
sludge. Washington, DC: U.S. Environmental Protection Agency, Office of Water Regulations and
Standards, Wastewater Solids Criteria Branch.
*EPA. 1986a. Test methods for evaluating solid waste. 3rd ed. SW-846. U.S. Environmental
Protection Agency, Office of Solid Waste and Emergency Response.
*EPA. 1986b. Reportable quantity. U.S. Environmental Protection Agency. Code of Federal
*EPA. 1986c. Cadmium: Atomic absorption, furnace method. Method 7131. In: Test methods for
evaluating solid waste. Washington, DC: U.S. Environmental Protection Agency, Office of Solid Waste
and Emergency Response. SW-846, 206-209.
EPA. 1986d. General pretreatment regulations: 65 toxic pollutants. U.S. Environmental Protection
Agency. Code of Federal Regulations. 40 CFR 403, Appendix B.
EPA. 1986e. Method 7130. Cadmium (atomic absorption, direct aspiration). In: Test methods for
evaluating solid waste. Volume 1A: Laboratory manual physical/chemical methods. Washington, DC:
U.S. Environmental Protection Agency. SW-846.
*EPA. 1989a. . New source performance standards for sewage treatment plants: Test methods and
procedures. U.S. Environmental Protection Agency. Code of Federal Regulations. 40 CFR 60.154.
*EPA. 1989b. Reportable quantities. U.S. Environmental Protection Agency. Code of Federal
*EPA. 1989c. Interim methods for development of inhalation reference doses. Washington, DC: U.S.
Environmental Protection Agency, Office of Health and Environmental Assessment. EPA600888066F.
EPA. 1989d. Recognition and management of pesticide poisonings. Fourth edition. Washington, DC:
U.S. Environmental Protection Agency. EPA540988001, 109-111.
EPA. 1990a. National Pollutant Discharge Elimination System: Stormwater discharges. U.S.
Environmental Protection Agency. Code of Federal Regulations. 40 CFR 122.26.
*EPA. 1990b. Precision and recovery statements for methods for measuring metals. U.S. Environmental
Protection Agency. Code of Federal Regulations. 40 CFR 136, Appendix D.
*EPA. 1990c. Toxic Chemical Release Reporting Rule. U.S. Environmental Protection Agency. Code
of Federal Regulations. 40 CFR 372.65.
CADMIUM 370
9. REFERENCES
EPA. 1990d. Interim methods for development of inhalation reference concentrations. Washington, DC:
U.S. Environmental Protection Agency, Office of Health and Environmental Assessment, Office of
Research and Development, Environmental Criteria and Assessment Office. EPA600890066A.
*EPA. 1991a. .Criteria to classify solid waste and disposal facilities: Maximum contaminant levels.
U.S. Environmental Protection Agency. Code of Federal Regulations. 40 CFR 257, Appendix I.
*EPA. 1991b. Design criteria for municipal waste landfills. U.S. Environmental Protection Agency.
Code of Federal Regulations. 40 CFR 258.40.
EPA. 1991c. Constituents for detection monitoring. U.S. Environmental Protection Agency. Code of
Federal Regulations. 40 CFR 258, Appendix I.
EPA. 1993a. Effluent guidelines for offshore oil and gas extraction. U.S. Environmental Protection
Agency. Code of Federal Regulations. 40 CFR 435.13 and 15.
*EPA. 1993b. National listing of state fish and shellfish consumption advisories and bans. U.S.
Environmental Protection Agency. Research Triangle Institute, NC: Fish Contamination Section, Office
of Science and Technology, Office of Water, U.S. Environmental Protection Agency.
EPA. 1993c. Incineration pollutant limits. U.S. Environmental Protection Agency. Code of Federal
Regulations. 40 CFR 46-47.
EPA. 1994a. Methods for derivation of inhalation reference concentrations and application of inhalation
dosimetry. Washington, DC: U.S. Environmental Protection Agency, Office of Research and
Development. EPA600890066F.
EPA. 1994b. Method 200.7: Determination of metals and trace elements in water and wastes by
inductively coupled plasma-atomic emission spectrometry. Cincinnati, OH: U.S. Environmental
Protection Agency, Office of Research and Development.
EPA. 1996a. Method 1637: Determination of trace elements in ambient waters by off-line chelation
preconcentration and stabilized temperature graphite furnace atomic absorption. Washington, DC: U.S.
Environmental Protection Agency, Office of Water.
EPA. 1996b. Method 1638: Determination of trace elements in ambient waters by inductively coupled
plasma - mass spectrometry. Washington, DC: U.S. Environmental Protection Agency, Office of Water.
http://www.p2pays.org/ref%5C06/05111.pdf. May 13, 2008.
EPA. 1997a. Special report on environmental endocrine disruption: An effects assessment and analysis.
Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. EPA630R96012.
EPA. 1997b. Method 1640: Determination of trace elements in water by preconcentration and
inductively coupled plasma - mass spectrometry. Washington, DC: U.S. Environmental Protection
Agency, Office of Water. http://www.epa.gov/waterscience/methods/method/files/1640.pdf. May 14,
2008.
EPA. 1998. Notice of availability of draft RCRA waste minimization PBT chemical list. U.S.
Environmental Protection Agency. Fed Regist 63:60332. http://www.gpoaccess.gov/fr/index.html. May
05, 2008.
CADMIUM 371
9. REFERENCES
EPA. 2000. Method 6010C: Inductively coupled plasma-atomic emission spectrometry. Washington,
DC: U.S. Environmental Protection Agency. http://epa.gov/sw-846/pdfs/6010c.pdf. May 13, 2008.
*EPA. 2003a. National primary drinking water standards. Washington, DC: U.S. Environmental
Protection Agency, Office of Ground Water and Drinking Water. EPA816F03016.
http://www.epa.gov/safewater/mcl.html. March 07, 2006.
EPA. 2003b. Method 200.5: Determination of trace elements in drinking water by axially viewed
inductively coupled plasma - atomic emission spectrometry. Cincinnati, OH: U.S. Environmental
Protection Agency, Office of Research and Development. EPA600R06115.
http://www.epa.gov/nerlcwww/m_200_5.pdf. May 13, 2008.
EPA. 2005. Toxic chemical release inventory reporting forms and instructions: Revised 2004 version.
Section 313 of the Emergency Planning and Community Right-to-Know Act (Title III of the Superfund
Amendments and Reauthorization Act of 1986). Washington, DC: U.S. Environmental Protection
Agency. Office of Environmental Information. EPA260B05001.
EPA. 2006a. Consumer factsheet on: Cadmium. U.S. Environmental Protection Agency.
http://www.epa.gov/OGWDW/contaminants/dw_contamfs/cadmium.html. April 29, 2008.
EPA. 2006b. Technical factsheet on cadmium: Ground water and drinking water.
http://www.epa.gov/OGWDW/dwh/t-ioc/cadmium.html. July 28, 2008.
EPA. 2007. The Clean Air Act amendments of 1990 list of hazardous air pollutants. U.S. Environmental
Protection Agency. United States Code.42 USC 7412. http://www.epa.gov/ttn/atw/orig189.html. April
24, 2008.
*EPA. 2008a. Acute exposure guideline levels (AEGLs). Second AEGL Chemical Priority List.
Washington, DC: U.S. Environmental Protection Agency, Office of Pollution Prevention and Toxics.
http://www.epa.gov/oppt/aegl/pubs/priority_2.htm. April 24, 2008.
EPA. 2008b. Designation of hazardous substances. U.S. Environmental Protection Agency. Code of
Federal Regulations. 40 CFR 116.4. http://www.epa.gov/lawsregs/search/40cfr.html. April 24, 2008.
EPA. 2008c. Determination of reportable quantities. U.S. Environmental Protection Agency. Code of
Federal Regulations. 40 CFR 117.3. http://www.epa.gov/lawsregs/search/40cfr.html. April 24, 2008.
EPA. 2008d. Groundwater monitoring list. U.S. Environmental Protection Agency. Code of Federal
Regulations. 40 CFR 264, Appendix IX. http://www.epa.gov/lawsregs/search/40cfr.html. May 05, 2008.
EPA. 2008e. Designation of hazardous substances. U.S. Environmental Protection Agency. Code of
Federal Regulations. 40 CFR 302.4 http://www.epa.gov/lawsregs/search/40cfr.html.
EPA. 2008f. The list of extremely hazardous substances and their threshold planning quantities. U.S.
Environmental Protection Agency. Code of Federal Regulations. 40 CFR 355, Appendix A.
http://www.epa.gov/lawsregs/search/40cfr.html. April 24, 2008.
EPA. 2008g. Toxic chemical release reporting. Chemicals and chemical categories to which this part
applies. U.S. Environmental Protection Agency. Code of Federal Regulations. 40 CFR 372.65.
http://www.epa.gov/lawsregs/search/40cfr.html. April 24, 2008.
CADMIUM 372
9. REFERENCES
EPA. 2008h. Toxic pollutants. U.S. Environmental Protection Agency. Code of Federal Regulations.
40 CFR 401.15. http://www.epa.gov/lawsregs/search/40cfr.html. April 24, 2008.
EPA. 2009a. Targeted national sewage sludge survey sampling and analysis technical report.
Washington, DC: U.S. Environmental Protection Agency.
http://water.epa.gov/scitech/wastetech/biosolids/upload/2009_01_15_biosolids_tnsss-tech.pdf.
September 10, 2012.
EPA. 2009b. National primary drinking water regulations. U.S. Environmental Protection Agency,
Office of Ground Water. EPA816F090004. http://water.epa.gov/drink/contaminants/upload/mcl-2.pdf.
February 22, 2012.
EPA. 2011. Pollutant limits. U.S. Environmental Protection Agency. Code of Federal Regulations 40
CFR 503.13 http://www.gpo.gov/fdsys/pkg/CFR-2011-title40-vol30/pdf/CFR-2011-title40-vol30-
part503.pdf. September 10, 2012.
EPA. 2011b. 2011 Edition of the drinking water standards and health advisories. Washington, DC: U.S.
Environmental Protection Agency, Office of Water. EPA822R06013. PB2007101258.
http://www.epa.gov/waterscience/criteria/drinking/dwstandards.pdf. February 22, 2012.
Epstein SS, Arnold E, Andrea J, et al. 1972. Detection of chemical mutagens by the dominant lethal
assay in the mouse. Toxicol Appl Pharmacol 23:288-325.
Espinosa Almendro JM, Ojeda CB, de Torres AG, et al. 1992. Determination of cadmium in biological
samples by inductively coupled plasma atomic emission spectrometry after extraction with 1,5-bis(di-2-
pyridylmethylene) thiocarbonohydrazide. Analyst 117(11):1749-1751.
Eum, KD; Lee, MS; Paek, D. 2008. Cadmium in blood and hypertension. Sci Total Environ 407(1):147-
153.
European Chemicals Bureau. 2007. European union risk assessment report. Cadmium metal and
cadmium oxide. Luxembourg: European Chemicals Bureau, Institute for Health and Consumer
Protection.
*Evans J, Hastings L. 1992. Accumulation of Cd(II) in the CNS depending on the route of
administration: Intraperitoneal, intratracheal, or intranasal. Fundam Appl Toxicol 19:275-278.
Everett CJ, Frithsen IL. 2008. Association of urinary cadmium and myocardial infarction. Environ Res
106(2):284-286.
Ewers U, Brockhaus A, Dolgner R, et al. 1985. Environmental exposure to cadmium and renal function
of elderly women living in cadmium-polluted areas of the Federal Republic of Germany. Int Arch Occup
Exon JH, Koller LD, Kerkvliet NI. 1986. Tissue residues, pathology- and viral-induced mortality in
mice chronically exposed to different cadmium salts. J Environ Pathol Toxicol Oncol 7:109-114.
Eybl V, Kotyzova D, Koutensky J, et al. 1994. Effect of chelators, monoisoamyl meso-2,3-dimer-

captosuccinate and N-(4-methylbenzyl)-4-0-(B-D-galactopyranosyl)-D-glucamine-N-carbodithioate, on
cadmium and essential element levels in mice. Analyst 120:855-857.
CADMIUM 373
9. REFERENCES
Ezaki T, Tsukahara T, Moriguchi J, et al. 2003. No clear-cut evidence for cadmium-induced renal
tubular dysfunction among over 10,000 women in the Japanese general population: A nationwide large-
scale survey. Int Arch Occup Environ Health 76(3):186-196.
*Fagher U, Laudanski T, Schutz A, et al. 1993. The relationship between cadmium and lead burdens and
preterm labor. Int J Gynaecol Obstet 40(22):109-114.
Fahmy MA, Aly FA. 2000. In vivo and in vitro studies on the genotoxicity of cadmium chloride in mice.
J Appl Toxicol 20(3):231-238.
Falck FY, Fine LJ, Smith RG, et al. 1983. Occupational cadmium exposure and renal status. Am J Ind
Med 4:541-549.
Farnsworth M. 1980. Cadmium chemicals. 1st ed. New York, NY: International Lead Zinc Research
Organization, Inc.
Fatur T, Tusek M, Falnoga I, et al. 2002. DNA damage and metallothionein synthesis in human
hepatoma cells (HepG2) exposed to cadmium. Food Chem Toxicol 40(8):1069-1076.
*Favino A, Candura F, Chiappino G, et al. 1968. Study on the androgen function of men exposed to
cadmium. Med Lav 59:105-110.
FDA. 2007. Beverages. Bottled water. U.S. Food and Drug Administration. Code of Federal
Regulations. 21 CFR 165.110. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm.
April 24, 2008.
FDA. 2008. EAFUS: A food additive database. U.S. Food and Drug Administration.
http://vm.cfsan.fda.gov/~dms/eafus.html. April 24, 2008.
FDA. 2010. Total diet study statistics on elemental results. Market baskets 2006-1 through 2008-4.
College Park, MD: U.S. Food and Drug Administration.
http://www.fda.gov/downloads/Food/FoodSafety/FoodContaminantsAdulteration/TotalDietStudy/UCM1
84301.pdf. February 22, 2012.
FEDRIP. 2008. Cadmium. Federal Research in Progress database. Springfield, VA: National
Technical Information Service. April 27, 2008.
FEDRIP. 2012. Cadmium. Federal Research in Progress database. Springfield, VA: National
Technical Information Service. September 2012.
Feijtel TC, Delne RD, Patrick WH Jr. 1988. Biogeochemical control on metal distribution and
accumulation in Louisiana sediments. J Environ Qual 17:88-94.
Ferraro PM, Costanzi S, Naticchia A, et al. 2010. Low level exposure to cadmium increases the risk of
chronic kidney disease: Analysis of the NHANES 1999-2006. BMC Public Health 10:304.
Filipic M, Hei TK. 2004. Mutagenicity of cadmium in mammalian cells: Implication of oxidative DNA
damage. Mutat Res 546(1-2):81-91.
Fingerle H, Fischer G, Classen HG. 1982. Failure to produce hypertension in rats by chronic exposure to
cadmium. Food Chem Toxicol 20:301-306.
CADMIUM 374
9. REFERENCES
Flanagan PR, McLellan J, Haist J, et al. 1978. Increased dietary cadmium absorption in mice and human
subjects with iron deficiency. Gastroenterology 74:841-846.
Fomon SJ. 1966. Body composition of the infant. Part I. The male reference infant. In: Falkner F, ed.
Human development. Philadelphia, PA: WB Saunders, 239-246.
Fomon SJ, Haschke F, Ziegler EE, et al. 1982. Body composition of reference children from birth to age
10 years. Am J Clin Nutr 35:1169-1175.
Forbes GB, Bruining GJ. 1976. Urinary creatinine excretion and lean body mass. Am J Clin Nutr
29:1359-1366.
Forrester JW. 1968. Principles of systems. Cambridge: Wright-Allen Press.
Foulkes EC. 1978. Renal tubular transport of cadmium-metallothionein. Toxicol Appl Pharmacol
45:505-512.
Foulkes EC. 1980. Some determinants of intestinal cadmium transport in the rat. J Environ Pathol
Toxicol 3:471-481.
Foulkes EC. 1984. Intestinal absorption of heavy metals. In: Csaky TZ, ed. Handbook of experimental
pharmacology. Vol. 70/I. Pharmacology of intestinal permeation. Berlin: Springer Verlag, 543-565.
Foulkes EC. 1985. Interactions between metals in rat jejunum: Implications on the nature of cadmium
uptake. Toxicology 37:117-125.
Foulkes EC. 1989. On the mechanism of cellular cadmium uptake. Biol Trace Element Res 21:195-200.
Foulkes EC, Blanck S. 1990. Acute cadmium uptake by rabbit kidneys: Mechanism and effects.
Toxicol Appl Pharmacol 102:464-473.
*Foulkes EC, McMullen DM. 1986. Endogenous metallothionein as determinant of intestinal cadmium
absorption: A reevaluation. Toxicology 38:285-291.
Foulkes EC, Voner C. 1981. Effects of Zn status, bile and other endogenous factors on jejunal Cd
absorption. Toxicology 22:115-122.
Fox MR, Jacobs RM, Jones AO, et al. 1979. Effects of nutritional factors on metabolism of dietary
cadmium at levels similar to those of man. Environ Health Perspect 28:107-114.
Frant S, Kleeman I. 1941. Cadmium "food-poisoning." JAMA 117:86-89.
Frazier J. 1994. Need for physiologically based toxicokinetic models in estimating target organ dosage
following oral ingestion of cadmium. In: Wang RGM, ed. Water contamination and health. New York,
NY: Marcel Dekker, Inc., 281-304.
Frery N, Girard F, Moreau T, et al. 1993. Validity of hair cadmium in detecting chronic cadmium
exposure in general populations. Bull Environ Contam Toxicol 50:736-743.
CADMIUM 375
9. REFERENCES
Friberg L. 1950. Health hazards in the manufacture of alkaline accumulators with special reference to
chronic cadmium poisoning. Acta Med Scand 138(Suppl 240):1-124.
Friberg L, Piscator M, Nordberg GF, et al., eds. 1974. Cadmium in the environment. 2nd ed. Boca
Raton, FL: CRC Press, 23-91.
Fu JY, Huang XS, Zhu XQ. 1999. Study on peripheral blood lymphocytes chromosome abnormality of
people exposed to cadmium in environment. Biomed Environ Sci 12(1):15-19.
Galal-Gorchev H. 1993. Dietary intake, levels in food and estimated intake of lead, cadmium and
mercury. Food Addit Contam 10(1):115-128.
Galicia-García V, Rojas-Lopez M, Rios C. 1995. Cadmium levels in maternal, cord and newborn blood
in Mexico City newborns. Toxicologist 15(1):308.
Galicia-García V, Rojas-Lopez M, Rojas R, et al. 1997. Cadmium levels in maternal, cord and newborn
blood in Mexico City. Toxicol Lett 91(1):57-61.
Gallagher CM, Kovach JS, Meliker JR. 2008. Urinary cadmium and osteoporosis in U.S. Women
≥50 years of age: NHANES 1988-1994 and 1999-2004. Environ Health Perspect 116(10):1338-1343.
Gambrell RP. 1994. Trace and toxic metals in wetlands, a review. J Environ Qual 23:883-891.
Gamo M, Ono K, Nakanishi J. 2006. Meta-analysis for deriving age- and gender-specific dose-response
relationships between urinary cadmium concentration and β2-microglobulinuria under environmental
exposure. Environ Res 101(1):104-112.
Gartrell MJ, Craun JC, Podrebarac DS, et al. 1986. Pesticides, selected elements, and other chemicals in
adult total diet samples, October 1980 - March 1982. J Assoc Off Anal Chem 69:146-161.
Gasiorek K, Bauchinger M. 1981. Chromosome changes in human lymphocytes after separate and
combined treatment with divalent salts of lead, cadmium, and zinc. Environ Mutagen 3:513-518.
Gatta A, Bazzerla G, Amodio P, et al. 1989. Detection of the early steps of cadmium nephropathy-
comparison of light- and electron-microscopical patterns with the urinary enzymes excretion: An
experimental study. Nephron 51:20-24.
Geiger H, Bahner U, Anderes S, et al. 1989. Cadmium and renal hypertension. J Human Hypertension
3:23-27.
Gennart JP, Buchet JP, Roels H, et al. 1992. Fertility of male workers exposed to cadmium, lead, or
manganese. Am J Epidemiol 135(11):1208-1219.
Ghezzi I, Toffoletto F, Sesana G, et al. 1985. Behaviour of biological indicators of cadmium in relation
to occupational exposure. Int Arch Occup Environ Health 55:133-140.
Gibbs RJ. 1994. Metals in the sediments along the Hudson River estuary. Environ Int 20(4):507-516.
*Gill KD, Pal R, Nath R. 1989a. Effect of cadmium on lipid peroxidation and antioxidant enzymes in
undernourished weanling rat brain. Pharmacol Toxicol 65:73-77.
CADMIUM 376
9. REFERENCES
Gill KD, Pal R, Sandhir R, et al. 1989b. Effect of chronic cadmium exposure on lipid composition and
peroxidation in liver and kidneys in rats. Med Sci Res 17:921-924.
Gilliavod N, Leonard A. 1975. Mutagenicity tests with cadmium in the mouse. Toxicology 5:43-47.
Girolami JP, Bascands JL, Pecher C, et al. 1989. Renal kallikrein excretion as a distal nephrotoxicity
marker during cadmium exposure in rats. Toxicology 55:117-129.
Giwercman A, Carlsen E, Keiding N, et al. 1993. Evidence for increasing incidence of abnormalities of
the human testis: A review. Environ Health Perspect Suppl 101(2):65-71.
Glaser U, Hochrainer D, Otto FJ, et al. 1990. Carcinogenicity and toxicity of four cadmium compounds
inhaled by rats. Toxicol Environ Chem 27:153-162.
Glaser U, Kloppel H, Hochrainer D. 1986. Bioavailability indicators of inhaled cadmium compounds.

Ecotoxicol Environ Saf 11:261-271.
*Glauser SC, Bezlo CT, Glauser EM. 1976. Blood-cadmium levels in normotensive and untreated
hypertensive humans. Lancet 1:717-718.
Gochfeld M, Burger J. 1982. Biological concentrations of cadmium in estuarine birds of the New York
Bight. Colonial Waterbirds 5:116-123.
Goering PL, Klaassen CD. 1984a. Resistance to cadmium-induced hepatotoxicity in immature rats.
Goering PL, Klaassen CD. 1984b. Tolerance to cadmium-induced hepatotoxicity following cadmium
pretreatment. Toxicol Appl Pharmacol 74:308-313.
Goering PL, Klaassen CD. 1984c. Zinc-induced tolerance to cadmium hepatotoxicity. Toxicol Appl
Goering PL, Klaassen CD. 1985. Mechanism of manganese-induced tolerance to cadmium lethality and
hepatotoxicity. Biochem Pharmacol 34:1371-1379.
Goldfrank LR, Flomenbaum NE, Lewin NA, et al. 1990. Goldfrank's toxicologic emergencies. 4th ed.
Norwalk, CT: Appleton & Lange, 649-652.
Gompertz D, Chettle DR, Fletcher JG, et al. 1983. Renal dysfunction in cadmium smelters: Relation to
in vivo liver and kidney cadmium concentrations. Lancet 1:1185-1187.
Goon D, Klaassen CD. 1989. Dosage-dependent absorption of cadmium in the rat intestine measured in
situ. Toxicol Appl Pharmacol 100:41-50.
Goyer RA, Cherian MG. 1992. Role of metallothionein in human placenta and rats exposed to cadmium.
In: Nordberg GF, Herber RFM, Alessio L, eds. Cadmium in the Human Environment: Toxicity and
Carcinogenicity. Lyon: International Agency for Research on Cancer, 239-247.
Goyer RA, Miller CR, Zhu SY, et al. 1989. Non-metallothionein-bound cadmium in the pathogenesis of
cadmium nephrotoxicity in the rat. Toxicol Appl Pharmacol 101:232-244.
CADMIUM 377
9. REFERENCES
Graham JA, Miller FJ, Daniels MJ, et al. 1978. Influence of cadmium, nickel, and chromium on primary
immunity in mice. Environ Res16:77-87.
Greenberg RR, Gallorini M, Gills TE. 1979. Cadmium analysis by radiochemical neutron activation
analysis. Environ Health Perspect 28:1-4.
Greenspan BJ, Morrow PE, Ferin J. 1988. Effects of aerosol exposures to cadmium chloride on the
clearance of titanium dioxide from the lungs of rats. Exp Lung Res 14:491-500.
Grose EC, Richards JH, Jaskot RH, et al. 1987. A comparative study of the effects of inhaled cadmium
chloride and cadmium oxide: Pulmonary response. J Toxicol Environ Health 21:219-232.
Gross SB, Yeager DW, Middendorf MS. 1976. Cadmium in liver, kidney, and hair of humans, fetal
through old age. J Toxicol Environ Health 2:153-167.
Groten JP, Sinkeldam EJ, Luten JB, et al. 1990. Comparison of the toxicity of inorganic and liver-
incorporated cadmium: A 4-week feeding study in rats. Food Chem Toxicol 28:435-441.
Gruden N, Matausic S. 1989. Some factors influencing cadmium-manganese interaction in adult rats.
Bull Environ Contam Toxicol 43:101-106.
Guillard O, Lauwerys R. 1989. In vitro and in vivo effect of mercury, lead, and cadmium on the
generation of chemiluminescence by human whole blood. Biochem Pharmacol 38:2819-2824.
Gunn SA, Gould TC, Anderson WAD. 1968a. Mechanisms of zinc, cysteine and selenium protection
against cadmium-induced vascular injury to mouse testis. J Reprod Fertil 15:65-70.
Gunn SA, Gould TC, Anderson WAD. 1968b. Selectivity of organ response to cadmium and various
protective measures. J Pathol Bacteriol 96:89-96.
Gupta A, Gupta A, Murthy RC, et al. 1993. Neurochemical changes in developing rat brain after pre-
and postnatal cadmium exposure. Bull Environ Contam Toxicol 51:12-17.
Gutenmann WH, Rutzke M, Kuntz HT, et al. 1994. Elements and polychlorinated biphenyls in sewage
sludges of large cities in the United States. Chemosphere 28(4):725-728.
Guzelian PS, Henry CJ, Olin SS, eds. 1992. Similarities and differences between children and adults:
Implications for risk assessment. Washington, DC: International Life Sciences Institute Press.
Haddad LM, Winchester JF. 1990. Clinical management of poisoning and drug overdose. 2nd ed.
Philadelphia, PA: WB Sanders Company, 331-332, 1029-1030.
Hammer DI, Calocci AV, Hasselblad V, et al. 1973. Cadmium and lead in autopsy tissues. J Occup
Med 15:956-964.
Handy RD. 1992a. The assessment of episodic metal pollution. I. Uses and limitations of tissue
contaminant analysis in rainbow trout (Oncorhynchus mykiss) after short waterborne exposure to
cadmium or copper. Arch Environ Contam Toxicol 22(1):74-81.
CADMIUM 378
9. REFERENCES
Handy RD. 1992b. The assessment of episodic metal pollution. II. The effects of cadmium and copper
enriched diets on tissue contaminant analysis in rainbow trout (Oncorhynchus mykiss). Arch Environ
Contam Toxicol 22(1):82-87.
Hansen JC, Wulf HC, Kromann N, et al. 1985. Cadmium concentrations in blood samples from an East
Greenlandic population. Dan Med Bull 32:277-279.
Hardell L, Wing MA, Ljungberg B, et al. 1994. Levels of cadmium, zinc and copper in renal cell
carcinoma and normal kidney. Eur J Cancer Prev 3:45-48.
Harrison SE, Klaverkamp JF. 1990. Metal contamination in liver and muscle of northern pike (Esox
lucius) and white sucker (Catostomus commersoni) and in sediments from lakes near the smelter at Flin
Flon, Manitoba. Environ Toxicol Chem 9:941-956.
Hart BA. 1986. Cellular and biochemical response of the rat lung to repeated inhalation of cadmium.
Hart BA, Potts RJ, Watkin RD. 2001. Cadmium adaptation in the lung – a double-edged sword?
Toxicology 160(1-3):65-70.
Hart BA, Voss GW, Willean CL. 1989a. Pulmonary tolerance to cadmium following cadmium aerosol
pretreatment. Toxicol Appl Pharmacol 101:447-460.
Hart RP, Rose CS, Hamer RM. 1989b. Neuropsychological effects of occupational exposure to
cadmium. J Clin Exper Neuropsychol 11:933-943.
Hasselbach L, Ver Hoef JM, Ford J, et al. 2005. Spatial patterns of cadmium and lead deposition on and
adjacent to National Park Service lands in the vicinity of Red Dog Mine, Alaska. Sci Total Environ
348(1-3):223-229.
Haswell-Elkins M, Satarug S, O'Rourke P, et al. 2008. Striking association between urinary cadmium
level and albuminuria among Torres Strait Islander people with diabetes. Environ Res 106:379-383.
Hayano M, Nogawa K, Kido T, et al. 1996. Dose-response relationship between urinary cadmium
concentration and β2-microglobulinuria using logistic regression analysis. Arch Environ Health
51(2):162-167.
Hays ES, Margaretten N. 1985. Long-term oral cadmium produces bone marrow hypoplasia in mice.
Exp Hematol 13:229-234.
HazDat. 2007. Cadmium. HazDat Database: ATSDR’s Hazardous Substance Release and Health
Effects Database. Atlanta, GA: Agency for Toxic Substances and Disease Registry.
He QB, Singh BR. 1994. Crop uptake of cadmium from phosphorus fertilizers. I. Yield and cadmium
content. Water Air Soil Pollut 74:251-265.
Heinrich U, Peters L, Ernst H, et al. 1989. Investigation on the carcinogenic effects of various cadmium
compounds after inhalation exposure in hamsters and mice. Exp Pathol 37:253-258.
Hellström L, Elinder CG, Dahlberg B, et al. 2001. Cadmium exposure and end-stage renal disease. Am
J Kidney Dis 38(5): 1001-1008.
CADMIUM 379
9. REFERENCES
Henderson RF, Rebar AH, Pickrell JA, et al. 1979. Early damage indicators in the lung. III.
Biochemical and cytological response of the lung to inhaled metal salts. Toxicol Appl Pharmacol
50:123-136.
Herrero TC, Martin LFL. 1993. Evaluation of cadmium levels in fertilized soils. Bull Environ Contam
Toxicol 50:61-68.
Herron N. 2003. Cadmium compounds. Kirk-Othmer encyclopedia of chemical technology. Vol. 4.

John Wiley & Sons, Inc., 507-523.
http://mrw.interscience.wiley.com/emrw/9780471238966/kirk/article/cadmherr.a01/current/pdf. April 29,
2008.
*Hew KW, Ericson WA, Welsh MJ. 1993a. A single low cadmium dose causes failure of spermiation in
the rat. Toxicol Appl Pharmacol 121(1):15-21.
*Hew KW, Heath GL, Jiwa AH, et al. 1993b. Cadmium in vivo causes disruption of tight junction-
associated microfilaments in rat Sertoli cells. Biol Reprod 49(4):840-849.
Hirano S, Tsukamoto N, Higo S, et al. 1989a. Toxicity of cadmium oxide instilled into the rat lung. II.
Inflammatory in broncho-alveolar lavage fluid. Toxicology 55(1-2):25-35.
Hirano S, Tsukamoto N, Kobayashi E, et al. 1989b. Toxicity of cadmium oxide instilled into the rat
lung. I. Metabolism of cadmium oxide in the lung and its effects on essential elements. Toxicology
55(1-2):15-24.
*Hirano S, Tsukamoto N, Suzuki KT. 1990. Biochemical changes in the rat lung and liver following
intratracheal instillation of cadmium oxide. Toxicol Lett 50:97-105.
Hiratsuka H, Satoh S-i, Satoh M, et al. 1999. Tissue distribution of cadmium in rats given minimum
amounts of cadmium-polluted rice or cadmium chloride for 8 months. Toxicol Appl Pharmacol
160:183-191.
Hoadley JE, Cousins RJ. 1985. Effects of dietary zinc depletion and food restriction on intestinal
transport of cadmium in the rat. Proc Soc Exp Biol Med 180:296-302.
Hochi Y, Kido T, Nogawa K, et al. 1995. Dose-response relationship between total cadmium intake and
prevalence of renal dysfunction using general linear models. J Appl Toxicol 15:109-116.
Hoel DG, Davis DL, Miller AB, et al. 1992. Trends in cancer mortality in 15 industrialized countries,
1969-1986. J Natl Cancer Inst 84(5):313-320.
*Hoffmann L, Putzke HP, Kampehl HJ, et al. 1985. Carcinogenic effects of cadmium on the prostate of
the rat. J Cancer Res Clin Oncol 109:193-199.
*Holloway WR, Thor DH. 1988a. Cadmium exposure in infancy: Effects on activity and social
behaviors of juvenile rats. Neurotoxicol Teratol 10:135-142.
*Holloway WR, Thor DH. 1988b. Social memory deficits in adult male rats exposed to cadmium in
infancy. Neurotoxicol Teratol 10:193-197.
CADMIUM 380
9. REFERENCES
Holmgren GGS, Meyer MW, Chaney RL, et al. 1993. Cadmium, lead, zinc, copper, and nickel in
agricultural soils of the United States of America. J Environ Qual 22:335-348.
Holsen TM, Noll KE, Fang G, et al. 1993. Dry deposition and particle size distributions measured during
the Lake Michigan Urban Air Toxics Study. Environ Sci Technol 27(7):1327-1333.
Holt D, Webb M. 1987. Teratogenicity of ionic cadmium in the Wistar rat. Arch Toxicol 59:443-447.
Honda R, Swaddiwudhipong W, Nishijo M, et al. 2010. Cadmium induced renal dysfunction among
residents of rice farming area downstream from a zinc-mineralized belt in Thailand. Toxicol Lett
198(1):26-32.
Honma M, Hayashi M, Shimada H, et al. 1999. Evaluation of the mouse lymphoma tk assay (microwell
method) as an alternative to the in vitro chromosomal aberration test. Mutagenesis 14(1):5-22.
Hopf G, Bocker R, Bischoff, et al. 1990. Investigation of the combined effects of ethanol and cadmium
on rat liver and kidneys. Arch Toxicol 64:470-473.
Horiguchi H, Aoshima K, Oguma E, et al. 2010. Latest status of cadmium accumulation and its effects
on kidneys, bone, and erythropoiesis in inhabitants of the formerly cadmium-polluted Jinzu River Basin
in Toyama, Japan, after restoration of rice paddies. Int Arch Occup Environ Health 83(8):953-970.
Horiguchi H, Oguma E, Sasaki S, et al. 2004. Comprehensive study of the effects of age, iron
deficiency, diabetes mellitus, and cadmium burden on dietary cadmium absorption in cadmium-exposed
female Japanese farmers. Toxicol Appl Pharmacol 196:114-123.
Hotz P, Buchet JP, Bernard A, et al. 1999. Renal effects of low-level environmental cadmium exposure:
5-year follow-up of a subcohort from the Cadmibel study. Lancet 354:1508-1513.
HSDB. 2008. Cadmium and cadmium compounds. Hazardous Substance Data Bank. National Library
of Medicine, Bethesda, MD. May 28, 2008.
Huel G, Everson RB, Menger I. 1984. Increased hair cadmium in newborns of women occupationally
exposed to heavy metals. Environ Res 35:115-121.
Huel G, Ibrahim MA, Boudene C. 1981. Cadmium and lead content of maternal and newborn hair:
Relationship to parity, birth weight, and hypertension. Arch Environ Health 36:221-227.
Hwangbo Y, Weaver VM, Tellez-Plaza M, et al. 2011. Blood cadmium and estimated glomerular
filtration rate in Korean adults. Environ Health Perspect 119:1800-1805.
IARC. 1993. Cadmium and certain cadmium compounds. In: IARC monographs on the evaluation of
the carcinogenic risk of chemicals to humans. Beryllium, cadmium, mercury and exposures in the glass
manufacturing industry. IARC monographs, Vol. 58. Lyon, France: World Health Organization.
International Agency for Research on Cancer, 119-236.
IARC. 2008. Agents reviewed by the IARC monographs: Volumes 1-99. Lyon, France: International
Agency for Research on Cancer. http://monographs.iarc.fr/ENG/Classification/index.php. April 24,
2008.
CADMIUM 381
9. REFERENCES
ICRP. 1980. Metabolic data for cadmium. Limits for intakes of radionuclides by workers. Protection
Pergamon Press, NY: International Commission on Radiological, 42-44. ICRP Publication No. 30, Part
2.
ICRP. 1981. Report of the task group on reference man. Pergamon Press, NY: International
Commission on Radiological Protection, 40–45. ICRP Publication 23.
ICRP. 1994. Human respiratory tract model for radiological protection. Pergamon Press, Oxford:
International Commission on Radiological Protection. ICRP publication 66.
Iimura K. 1981. Heavy metal problems in paddy soils. In: Kitagishi K, Yamane I, eds. Heavy metal
problems in soils of Japan. Japan Scientific Societies Press, 37-50.
IJC. 1989. 1989 report on Great Lakes water quality. Windsor, Ontario: International Joint
Commission, Great Lakes Water Quality Board.
*Ijomah G, Corrigan FM, Holliday J, et al. 1993. Aluminum, cadmium, lipids and prevalence of
dementia in people living near an aluminum smelter. Trace Elements in Medicine 10(1):6-12.
Ikeda M, Ezaki T, Tsukahara T, et al. 2005a. Reproducibility of urinary cadmium, α-microglobulin, and
β2-microglobulin levels in health screening of the general population. Arch Environ Contam Toxicol
48(1):135-140.
Ikeda M, Ezaki T, Moriguchi J, et al. 2005b. The threshold cadmium level that causes a substantial
increase in β2-microglobulin in urine of general populations. Tohoku J Exp Med 205(3):247-261.
Ikeda M, Ezaki T, Tsukahara T, et al. 2003a. Bias induced by the use of creatinine-corrected values in
evaluation of B2-microgloblin levels. Toxicol Lett 145:197-207.
Ikeda M, Ezaki T, Tsukahara T, et al. 2003b. Threshold levels of urinary cadmium in relation to
increases in urinary β2-microglobulin among general Japanese populations. Toxicol Lett 137(3):135-141.
Ikeda M, Watanabe T, Zhang ZW, et al. 1997. The integrity of the liver among people environmentally
exposed to cadmium at various levels. Int Arch Occup Environ Health 69(6):379-385.
Ikeda M, Zhang ZW, Higashikawa K, et al. 1999. Background exposure of general women populations
in Japan to cadmium in the environment and possible health effects. Toxicol Lett 108(2-3):161-166.
Ikeda M, Zhang ZW, Moon CS, et al. 2000. Normal liver function in women in the general Japanese
population subjected to environmental exposure to cadmium at various levels. Int Arch Occup Environ
Health 73(2):86-90.
ILZRO. 1977. Biological availability of cadmium from cadmium pigments. New York, NY:
International Lead Zinc Research Organization, Inc.
Inoue Y, Watanabe TK. 1978. Toxicity and mutagenicity of cadmium and furylfuramide in Drosophila
melanogaster. Jpn J Genetics 53:183-189.
Inskip H, Beral V, McDowall M. 1982. Mortality of Shipham residents: 40-year follow-up.

Lancet:896-899.
CADMIUM 382
9. REFERENCES
IRIS. 2012. Cadmium. Integrated Risk Information System. Washington, DC: U.S. Environmental
Protection Agency. http://www.epa.gov/iris/subst/index.html. February 22, 2012.
Ishizaki M, Kido T, Honda R, et al. 1989. Dose-response relationship between urinary cadmium and β2-
microglobulin in Japanese environmentally cadmium exposed population. Toxicology 58:121-131.
Itoh H, Iwasaki M, Nakajima Y, et al. 2008. A case-control study of the association between urinary
cadmium concentration and endometriosis in infertile Japanese women. Sci Total Environ 402(2-3):171-
175.
Itokawa Y, Abe T, Tabei R, et al. 1974. Renal and skeletal lesions in experimental cadmium poisoning.
Arch Environ Health 28:149-154.
Iwata K, Katoh T, Morikawa Y, et al. 1988. Urinary trehalase activity as an indicator of kidney injury
due to environmental cadmium exposure. Arch Toxicol 62:435-439.
Iwata K, Saito H, Moriyama M, et al. 1993. Renal tubular function after reduction of environmental
cadmium exposure: A ten-year follow-up. Arch Environ Health 48(3):157-163.
Iwata K, Saito H, Moriyama M, et al. 1991a. Association between renal tubular dysfunction and
mortality among residents in a cadmium-polluted area, Nagasaki, Japan. Tohoku J Exp Med 164:93-102.
Iwata K, Saito H, Nakano A. 1991b. Association between cadmium-induced renal dysfunction and
mortality: Further evidence. Tohoku J Exp Med 164:319-330.
*Iwata K, Saito H, Moriyama M, et al. 1992. Follow up study of renal tubular dysfunction and mortality
in residents of an area polluted with cadmium. Br J Ind Med 49(10):737-737.
Izuno T, Sugita M, Arita S, et al. 2000. Validity of cadmium concentration in rice as the 'dose' of the
dose-response relationship between cadmium intake and renal dysfunction. Environ Res 84 Sect
A:275-281.
Jackson LW, Zullo MD, Goldberg JM. 2008. The association between heavy metals, endometriosis and
uterine myomas among premenopausal women: National Health and Nutrition Examination Survey
1999-2002. Hum Reprod 23(3):679-687.
Jacquillet G, Barbier O, Rubera I, et al. 2007. Cadmium causes delayed effects on renal function in the
offspring of cadmium-contaminated pregnant female rats. Am J Physiol Renal Physiol
293(5):F1450-1460.
Jaeger DE. 1990. Absorption interactions of zinc and cadmium in the isolated perfused rat intestine. J
Trace Elements Electrolytes Health Disease 4:101-105.
*Jahn F, Klinger W. 1989. Influence of prenatal administration of cadmium on postnatal development

and inducibility of hepatic monooxygenases in rats. Pharmacol Toxicol 64:291-292.
Jakubowski M, Razniewska G, Halatek T, et al. 1992. Integrated index of occupational exposure to

cadmium as a predictor of kidney dysfunction. Cadmium in the human environment: Toxicity and
carcinogenicity. IARC Sci Publ 118:319-324.
CADMIUM 383
9. REFERENCES
Jakubowski M, Trojanowska B, Kowalska G, et al. 1987. Occupational exposure to cadmium and kidney
dysfunction. Int Arch Occup Environ Health 59:567-577.
Jamall IS, Smith JC. 1985a. Effects of cadmium on glutathione peroxidose, superoxide dismutase and
lipid peroxidation in the rat heart: A possible mechanism of cadmium cardiotoxicity. Toxicol Appl
Pharmacol 80:33-42.
Jamall IS, Smith JC. 1985b. The effects of dietary selenium on cadmium binding in rat kidney and liver.
Arch Toxicol 56:252-255.
Jamall IS, Smith JC. 1985c. Effects of cadmium treatment on selenium dependent and selenium
independent glutathione peroxidase activities and lipid peroxidation in the kidney and liver of rats
maintained on various levels of dietary selenium. Arch Toxicol 58:102-105.
Jamall IS, Naik M, Sprowls JJ, et al. 1989. A comparison of the effects of dietary cadmium on heart and
kidney oxidant enzymes: Evidence for the greater vulnerability of the heart to cadmium toxicity. J Appl
Toxicol 9:339-345.
*Janecki A, Jakubowiak A, Steinberger A. 1992. Effect of cadmium chloride on transepithelial electrical

resistance of Sertoli cell monolayers in two-compartment cultures--a new model for toxicological
investigations of the "blood-testis" barrier in vitro. Toxicol Appl Pharmacol 112(1):51-57.
Jarrett JM, Xiao G, Caldwell KL, et al. 2008. Eliminating molybdenum oxide interference in urine
cadmium biomonitoring using ICP-DRC-MS. J Anal Atom Spectrom 23(7):962-967.
Järup L, Elinder CG. 1993. Incidence of renal stones among cadmium exposed battery workers. Br J Ind
Med 50:598-602.
Järup L, Elinder CG. 1994. Dose-response relations between urinary cadmium and tubular proteinuria in
cadmium-exposed workers. Am J Ind Med 26(6):759-769.
Järup L, Bellander T, Hogstedt C, et al. 1998a. Mortality and cancer incidence in Swedish battery
workers exposed to cadmium and nickel. Occup Environ Med 55(11):755-759.
Järup L, Berglund M, Elinder CG, et al. 1998b. Health effects of cadmium exposure - a review of the
literature and a risk estimate. Scand J Work Environ Health 24:1-52.
Järup L, Carlsson MD, Elinder CG, et al. 1995a. Enzymuria in a population living near a cadmium
battery plant. Occup Environ Med 52:770-772.
Järup L, Elinder CG, Spang G. 1988. Cumulative blood-cadmium and tubular proteinuria: A dose-
response relationship. Int Arch Occup Environ Health 60:223-229.
Järup L, Hellstrom L, Alfven T, et al. 2000. Low level exposure to cadmium and early kidney damage:
The OSCAR study. Occup Environ Med 57(10):668-672.
*Järup L, Persson B, Edling C, et al. 1993. Renal function impairment in workers previously exposed to
cadmium. Nephron 64:75-81.
Järup L, Persson B, Elinder CG. 1995b. Decreased glomerular filtration rate in solderers exposed to
cadmium. Occup Environ Med 52:818-822.
CADMIUM 384
9. REFERENCES
*Jaw S, Jeffery EH. 1988. The effect of dietary zinc status on biliary metal excretion of rats. J Nutr
118:1385-1390.
Jeng SL, Lee SJ, Lin SY. 1994. Determination of cadmium and lead in raw milk by graphite furnace
atomic absorption spectrophotometer. J Dairy Sci 77:945-949.
Jensen AA. 1983. Chemical contaminants in human milk. Residue Reviews 89:1-128.
Jianhua Z, Lian X, Shuanlai Z, et al. 2006. DNA lesion and Hprt mutant frequency in rat lymphocytes
and V79 Chinese hamster lung cells exposed to cadmium. J Occup Health 48(2):93-99.
Jin T, Nordberg M, Frech W, et al. 2002. Cadmium biomonitoring and renal dysfunction among a
population environmentally exposed to cadmium from smelting in China. Biometals 15:397-410.
Jin T, Nordberg G, Xunwei W, et al. 1999. Urinary N-acetyl-β-D-glucosaminidase isoenzyems as

biomarker of renal dysfunction caused by cadmium in general population. Environ Res 81(2):167-173.
Jin T, Kong Q, Ye T, et al. 2004a. Renal dysfunction of cadmium-exposed workers residing in a

cadmium-polluted environment. Biometals 17(5):513-518.
Jin T, Nordberg G, Ye T, et al. 2004c. Osteoporosis and renal dysfunction in a general population
exposed to cadmium in China. Environ Res 96(3):353-359.
Jin T, Wu X, Tang Y, et al. 2004b. Environmental epidemiological study and estimation of benchmark
dose for renal dysfunction in a cadmium-polluted area in China. Biometals 17(5):525-530.
Johanson CE. 1980. Permeability and vascularity of the developing brain: Cerebellum vs. cerebral
cortex. Brain Res 190(1):3-16.
Johansson A, Curstedt T, Robertson B, et al. 1984. Lung morphology and phospholipids after
experimental inhalation of soluble cadmium, copper, and cobalt. Environ Res 34:295-309.
John J, Gjessing ET, Grande M, et al. 1987. Influence of aquatic humus and pH on the uptake and
depuration of cadmium by the Atlantic salmon (Salmo salar L.). Sci Total Environ 62:253-265.
Jonah MM, Bhattacharyya MH. 1989. Early changes in the tissue distribution of cadmium after oral but
not intravenous cadmium exposure. Toxicology 58:325-338.
Jones MM, Cherian MG. 1990. The search for chelate antagonists for chronic cadmium intoxication.
Toxicology 62:1-25.
Jones MM, Singh PK, Basinger MA, et al. 1994. Cadmium mobilization by monoaralkyl- and
monoalkyl esters of meso-2,3-dimercaptosuccinic acid and by a dithiocarbamate. Pharmacol Toxicol
74:76-83.
Jones MM, Singh PK, Gale GR, et al. 1992. Cadmium mobilization in vivo by intraperitoneal or oral
administration of monoalkyl esters of meso-2,3-dimercaptosuccinic acid in the mouse. Pharmacol
Toxicol 70:336-343.
CADMIUM 385
9. REFERENCES
Jurasović J, Cvitkovic P, Pizent A, et al. 2004. Semen quality and reproductive endocrine function with
regard to blood cadmium in Croatian male subjects. Biometals 17(6):735-743.
Kagamimori S, Watanabe M, Nakagawa H, et al. 1986. Case-control study on cardiovascular function in

females with a history of heavy exposure to cadmium. Bull Environ Contam Toxicol 36:484-490.
*Kahan E, Derazne E, Rosenboim J, et al. 1992. Adverse health effects in workers exposed to cadmium.
Am J Ind Med 21:527-537.
Kalac P, Niznanska M, Bevilaqua D, et al. 1996. Concentrations of mercury, copper, cadmium and lead
in fruiting bodies of edible mushrooms in the vicinity of a mercury smelter and a copper smelter. Sci
Total Environ 177(1-3):251-258.
Kalahasthi RB, Rajmohan H, Rajan B, et al. 2007. Urinary N-acetyl-beta -D-glucosaminidase and its
isoenzymes A & B in workers exposed to cadmium at cadmium plating. J Occup Med Toxicol 2(5):1-7.
Kamenosono T, Shimada H, Funakoshi T, et al. 2002a. Involvement of active transport systems in the
mobilization of cadmium by dithiocarbamates in vivo. Toxicology 170(1-2):103-110.
*Kamenosono T, Shimada H, Funakoshi T, et al. 2002b. Structure-effect relationship in the mobilization

of cadmium in mice by several dithiocarbamates. Comp Biochem Physiol C 132(1):61-66.
Kanematsu N, Hara M, Kada T. 1980. Rec-assay and mutagenicity studies on metal compounds. Mutat
Res 77:109-116.
Kanisawa M, Schroeder HA. 1969. Life term studies on the effects of trace elements on spontaneous
tumors in mice and rats. Cancer Res 29:892-895.
Kaplan M, Atakan IH, Aydogdu N, et al. 2008. Influence of N-acetylcysteine on renal toxicity of
cadmium in rats. Pediatr Nephrol 23(2):233-241.
Kar AB, Das RP, Mukerji B. 1960. Prevention of cadmium induced changes in the gonads of rats by
zinc and selenium-A study in antagonism between metals in the biological system. Proc Natl Inst Sci
India. Part B. Biol Sci 26:40-50.
Karakaya A, Yucesoy B, Sardas OS. 1994. An immunological study on workers occupationally exposed
to cadmium. Human Exp Toxicol 13:73-75.
Karmakar R, Banik S, Bandyopadhyay S, et al. 1998. Cadmium-induced alterations of hepatic lipid

peroxidation, glutathione S-transferase activity and reduced glutathione level and their possible
correlation with chromosomal aberration in mice: A time course study. Mutat Res 397(2):183-190.
Kasuba V, Rozgaj R. 2002. Micronucleus distribution in human peripheral blood lymphocytes treated in
vitro with cadmium chloride in G0 and S phase of the cell cycle. Chemosphere 49(1):91-95.
Kasuba V, Rozgaj R, Saric MM, et al. 2002. Evaluation of genotoxic damage of cadmium chloride in
peripheral blood of suckling Wistar rats. J Appl Toxicol 22(4):271-277.
Katskov DA, Schwrzer R, Pieter JJG, et al. 1994. Use of a furnace with a graphite filter for
electrothermal atomic absorption spectrometry. J Anal Atom Spectrom 9:431-436.
CADMIUM 386
9. REFERENCES
Kawada T, Koyama H, Suzuki S. 1989. Cadmium, NAG activity, and B2-microglobulin in the urine of
cadmium pigment workers. Br J Ind Med 46:52-55.
Kawada T, Shinmyo RR, Suzuki S. 1992. Urinary cadmium and N-acetyl-β-D-glucosaminidase

excretion of inhabitants living in a cadmium-polluted area. Int Arch Occup Environ Health 63:541-546.
Kawada T, Tohyama C, Suzuki S. 1990. Significance of the excretion of urinary indicator proteins for a
low level of occupational exposure to cadmium. Int Arch Occup Environ Health 62:95-100.
Kawamura J, Yoshida O, Nishino K, et al. 1978. Disturbances in kidney functions and calcium and
phosphate metabolism in cadmium-poisoned rats. Nephron 20:101-110.
*Kawashima H, Nomiyama H, Nomiyama K. 1988. Chronic exposure to cadmium did not impair
vitamin D metabolism in monkeys. Environ Res 46:48-58.
Kazantzis G. 1979. Renal tubular dysfunction and abnormalities of calcium metabolism in cadmium
workers. Environ Health Perspect 28:155-159.
Kazantzis G, Blanks RG, Sullivan KR. 1992. Is cadmium a human carcinogen? In: Nordberg GF,
Herber RFM, Alessio L, eds. Cadmium in the human environment: Toxicity and carcinogenicity. IARC
Scientific Publications No. 118. Lyon, France: International Agency for Research on Cancer, 435-446.
Kazantzis G, Lam TH, Sullivan KR. 1988. Mortality of cadmium-exposed workers. A five-year update.
Scand J Work Environ Health 14:220-223.
Kelman BJ, Walter BK, Jarboe GE, et al. 1978. Effect of dietary cadmium on calcium metabolism in the
rat during late gestation. Proc Soc Exp Biol Med 158:614-617.
Kershaw WC, Iga T, Klaassen CD. 1990. Ethanol decreases cadmium hepatoxicity in rats: Possible role
of hepatic metallothionein induction. Toxicol Appl Pharmacol 106:448-455.
Kido T, Nogawa K. 1993. Dose-response relationship between total cadmium intake and
β2-microglobulinuria using logistic regression analysis. Toxicol Lett 69:113-120.
Kido T, Honda R, Tsuritani I, et al. 1988. Progress of renal dysfunction in inhabitants environmentally
exposed to cadmium. Arch Environ Health 43:213-217.
*Kido T, Honda R, Tsuritani I, et al. 1989a. High urinary cadmium concentration in a case of gastric
cancer. Br J Ind Med 46:288.
Kido T, Nogawa K, Honda R, et al. 1990a. The association between renal dysfunction and osteopenia in
environmental cadmium-exposed subjects. Environ Res 51:71-82.
Kido T, Nogawa K, Ishizaki M, et al. 1990b. Long-term observation of serum creatinine and arterial
blood pH in persons with cadmium-induced renal dysfunction. Arch Environ Health 45:35-41.
Kido T, Nogawa K, Yamada Y, et al. 1989b. Osteopenia in inhabitants with renal dysfunction induced
by exposure to environmental cadmium. Int Arch Occup Environ Health 61:271-276.
Kido T, Sunaga K, Nishijo M, et al. 2004. The relation of individual cadmium concentration in urine
with total cadmium intake in Kakehashi River basin, Japan. Toxicol Lett 152(1):57-61.
CADMIUM 387
9. REFERENCES
Kim DW, Kim KY, Choi BS, et al. 2007. Regulation of metal transporters by dietary iron, and the
relationship between body iron levels and cadmium uptake. Arch Toxicol 81:327-334.
Kimura M, Otaki N. 1972. Percutaneous absorption of cadmium in rabbit and hairless mouse. Ind
Health 10:7-10.
Kimura M, Otaki N, Yoshiki S, et al. 1974. The isolation of metallothionein and its protective role in
cadmium poisoning. Arch Biochem Biophys 165:340-348.
Kipling MD, Waterhouse JAH. 1967. Cadmium and prostatic carcinoma. Lancet 1(7492):730-731.
*Kjellström T. 1986a. Critical organs, critical concentrations, and whole-body dose-response

relationships. In: Friberg L, Elinder CG, Kjellström T, et al., eds. Cadmium and health: A toxicological
and epidemiological appraisal. Vol. II. Effects and response. Boca Raton, FL: CRC Press, 231-246.
*Kjellström T. 1986b. Effects on bone, on vitamin D, and calcium metabolism. In: Friberg L, Elinder
CG, Kjellström T, et al., eds. Cadmium and health: A toxicological and epidemiological appraisal. Vol.
II. Effects and response. Boca Raton, FL: CRC Press, 111-158.
Kjellström T. 1986c. Renal effects. In: Friberg L. Elinder CG, Kjellström T, et al., eds. Cadmium and
health: A toxicological and epidemiological appraisal. Vol. II. Effects and response. Boca Raton, FL:
CRC Press, 21-110.
Kjellström T, Nordberg GF. 1978. A kinetic model of cadmium metabolism in the human being.
Environ Res 16:248-269.
Kjellström T, Nordberg GF. 1985. Kinetic model of cadmium metabolism. In: Friberg L, Elinder CG,
Kjellström T, et al., eds. Cadmium and health: A toxicological and epidemiological appraisal. Vol. I.
Exposure, dose and metabolism. Boca Raton, FL: CRC Press, 179-197.
Kjellström T, Borg K, Lind B. 1978. Cadmium in feces as an estimator of daily cadmium intake in
Sweden. Environ Res 15:242-251.
Kjellström T, Evrin PE, Rahnster B. 1977a. Dose-response analysis of cadmium-induced tubular

proteinuria. A study of urinary beta-2-microglobulin excretion among workers in a battery factory.
Kjellström T, Fribert L, Rahnster B. 1979. Mortality and cancer morbidity among cadmium-exposed
workers. Environ Health Perspect 28:199-204.
*Kjellström T, Shiroisky K, Evrin PE. 1977b. Urinary β2-microglobulin excretion among people
exposed to cadmium in the general environment. An epidemiological study in cooperation between Japan
and Sweden. Environ Res 13:318-344.
Klaassen CD. 1978. Effect of metallothionein on hepatic disposition of metals. Am J Physiol 234-E47-
E53.
Klaassen CD, Kotsonis FN. 1977. Biliary excretion of cadmium in the rat, rabbit, and dog. Toxicol
Appl Pharmacol 41:101-112.
CADMIUM 388
9. REFERENCES
Klemm W, Bombach G. 1995. Trace element determination in contaminated sediments and soils by
ultrasonic slurry sampling and Zeeman graphite furnace atomic absorption spectrometry. Fresenius J
Anal Chem 353(1):12-15.
Klimisch HJ. 1993. Lung deposition, lung clearance and renal accumulation of inhaled cadmium
chloride and cadmium sulphide in rats. Toxicology 84:103-124.
Kobayashi E, Okubo Y, Suwazono Y, et al. 2002a. Association between urinary calcium excretion level
and mortality in inhabitants of the Jinzu River basin area of Japan. Biol Trace Elem Res 89:145-153.
Kobayashi E, OKubo Y, Suwazono Y, et al. 2002b. Dose-response relationship between total cadmium
intake calculated from the cadmium concentration in rice collected from each household of farmers and
renal dysfunction in inhabitants of the Jinzu River basin, Japan. J Appl Toxicol 22(6):431-436.
Kobayashi E, Suwazono Y, Dochi M, et al. 2008a. Estimation of benchmark doses as threshold levels of
urinary cadmium, based on excretion of beta2-microglobulin in cadmium-polluted and non-polluted
regions in Japan. Toxicol Lett 179(2):108-112.
Kobayashi E, Suwazono Y, Dochi M, et al. 2009a. Association of lifetime cadmium intake or drinking
Jinzu River water with the occurrence of renal tubular dysfunction. Environ Toxicol 24(5):421-428.
Kobayashi E, Suwazono Y, Dochi M, et al. 2009b. Influence of consumption of cadmium-polluted rice

or Jinzu River water on occurrence of renal tubular dysfunction and/or Itai-itai disease. Biol Trace Elem
Res 127(3):257-268.
Kobayashi E, Suwazono Y, Honda R, et al. 2008b. Serial changes in urinary cadmium concentrations
and degree of renal tubular injury after soil replacement in cadmium-polluted rice paddies. Toxicol Lett
176(2):124-130.
*Kobayashi E, Suwazono Y, Uetani M, et al. 2005. Association between lifetime cadmium intake and
cadmium concentration in individual urine. Bull Environ Contam Toxicol 74(5):817-821.
Kobayashi E, Suwazono Y, Uetani M, et al. 2006. Estimation of benchmark dose as the threshold levels
of urinary cadmium, based on excretion of total protein, β2-microglobulin and N-acetyl-β-D-
glucosaminidase in cadmium nonpolluted regions in Japan. Environ Res 101(3):401-406.
Koizumi N, Ohashi F, Ikeda M. 2010. Lack of correlation between cadmium level in local brown rice
and renal failure mortality among the residents: A nation-wide analysis in Japan. Int Arch Occup
Environ Health 83(3):333-339.
Komárek J, Slaninova M, Vrestal, et al. 1991. Determination of cadmium by electrothermal atomic

absorption spectrometry. Collect Czech Chem Commun 56:2083-2095.
Komori M, Nishio K, Kitada M, et al. 1990. Fetus-specific expression of a form of cytochrome P-450 in
human livers. Biochemistry 29(18):4430-4433.
Konig HP, Heinrich U, Kock H, et al. 1992. Effect of photocorrosion on cadmium sulfide suspensions
applied in animal inhalation studies with CDS particles. Arch Environ Contam Toxicol 22:30-35.
Kopp SJ, Glonek T, Perry HM, et al. 1982. Cardiovascular actions of cadmium at environmental
exposure levels. Science 217:837-839.
CADMIUM 389
9. REFERENCES
*Kostial K, Blanusa M, Maljkovic T, et al. 1989. Effect of a metal mixture in diet on the toxicokinetics
and toxicity of cadmium, mercury and manganese in rats. Toxicol Ind Health 5:686-698.
Kostial K, Blanusa M, Schonwald N, et al. 1993. Organ cadmium deposits in orally exposed female rats
and their pups and the depleting efficiency of sodium N-4-(methoxybenzyl)-d-glucamine-N-
carbodithioate monohydrate (MeOBDCG). Appl Toxicol 13(3):203-207.
Kostial K, Kello D, Jugo S, et al. 1978. Influence of age on metal metabolism and toxicity. Environ
Health Perspect 25:81-86.
Kostial K, Piasek M, Blanusa M, et al. 1996. Combined treatment with a new biscarbodithioate
C9G2DTC for mobilizing cadmium deposits in rats. J Appl Toxicol 16(2):157-158.
Kotsonis FN, Klaassen CD. 1977. Toxicity and distribution of cadmium administered to rats at sublethal
doses. Toxicol Appl Pharmacol 41:667-680.
Kotsonis FN, Klaassen CD. 1978. The relationship of metallothionein to the toxicity of cadmium after
prolonged administration to rats. Toxicol Appl Phamacol 46:39-54.
*Kowal NE. 1988. Urinary cadmium and B2-microglobulin: Correlation with nutrition and smoking
history. J Toxicol Environ Health 25:179-183.
Kozlowska D, Brzozowska A, Sulkowska J, et al. 1993. The effect of cadmium on iron metabolism in
rats. Nutr Res 13:1163-1172.
*Kreis IA, de Does M, Hoekstra JA, et al. 1993. Effects of cadmium on reproduction, an epizootologic
study. Teratology 48(3):189-196.
Krishnan K, Andersen ME. 1994. Physiologically based pharmacokinetic modeling in toxicology. In:
Hayes AW, ed. Principles and methods of toxicology. 3rd ed. New York, NY: Raven Press, Ltd.,
149-188.
Krishnan K, Andersen ME, Clewell HJ, et al. 1994. Physiologically based pharmacokinetic modeling of
chemical mixtures. In: Yang RSH, ed. Toxicology of chemical mixtures: Case studies, mechanisms,
and novel approaches. San Diego, CA: Academic Press, 399-437.
*Krishnan SS, Harrison JE, Jervis RE, et al. 1988. Studies of skeletal cadmium assay and toxicity. J
Radioanal Nucl Chem 124:79-84.
Krzystyniak K, Fournier M, Trottier B, et al. 1987. Immunosuppression in mice after inhalation of

cadmium aerosol. Toxicol Lett 38:1-12.
*Kucharz EJ. 1988. Effect of cadmium intoxication on collagen and elastin content in tissues of the rat.
*Kudo N, Nakagawa Y, Waku K. 1990. The effect of cadmium on the composition and metabolism of
hepatic fatty acids in zinc-adequate and zinc-deficient rats. Toxicol Lett 50:203-212.
Kuhnert PM, Kihnert BR, Bottoms SF, et al. 1982. Cadmium levels in maternal blood, fetal cord blood,
and placental tissues of pregnant women who smoke. Am J Obstet Gynecol 142:1021-1025.
CADMIUM 390
9. REFERENCES
Kurokawa Y, Takahashi M, Maekawa A, et al. 1989. Promoting effect of metal compounds on liver,
stomach, kidney, pancreas, and skin carcinogenesis. Am Coll Toxicol 8:1235-1239.
Kuroshima R. 1992. Cadmium accumulation in the mummichog, Fundulus heteroclitus, adapted to

various salinities. Bull Environ Contam Toxicol 49(5):680-685.
Kutzman RS, Drew RT, Shiotsuka RN, et al. 1986. Pulmonary changes resulting from subchronic
exposure to cadmium chloride aerosol. J Toxicol Environ Health 17:175-189.
Lagerkvist BJ, Lundstrom NG. 2004. Lead-and cadmium levels in children living close to a copper and
lead smelter in Sweden. Biometals 17(5):593-594.
*Lagerkvist BJ, Nordberg GF, Soderberg HA, et al. 1992. Placental transfer of cadmium. In: Nordberg
GF, Herber RFM, Alessio L, eds. Cadmium in the human environment: Toxicity and carcinogenicity.
IARC Scientific Publications No. 118. Lyon, France: International Agency for Research on Cancer,
287-291.
*Lagerkvist BJ, Soderberg H-A, Nordberg GF, et al. 1993. Biological monitoring of arsenic, lead and
cadmium in occupationally and environmentally exposed pregnant women. Scand J Work Environ
Health 19(Suppl. 1):50-53.
*Lai YL, Diamond L. 1992. Cigarette smoke exposure does not prevent cadmium-induced alterations in
rat lungs. J Toxicol Environ Health 35(1):63-76.
Lamm SH, Hall TA, Kutcher JS. 1994. Particulate exposure among cadmium workers: Is the risk due to
cigarette, cadmium or arsenic particulates? Ann Occup Hyg 38:873-878.
Lamm SH, Parkinson M, Anderson M, et al. 1992. Determinants of lung cancer risk among cadmium-
exposed workers. Ann Epidemiol 2:195-211.
Landsberger S, Wu D. 1993. Improvement of analytical sensitivities for the determination of antimony,

arsenic, cadmium, indium, iodine molybdenum, silicon and uranium in airborne particulate matter by
epithermal neutron activation analysis. J Radioanal Nucl Chem 167(2):219-225.
Lane RE, Campbell AC. 1954. Fatal emphysema in two men making a copper cadmium alloy. Br J Ind
Med 11:118-122.
Larregle EV, Varas SM, Oliveros LB, et al. 2008. Lipid metabolism in liver of rat exposed to cadmium.
Food Chem Toxicol 46(5):1786-1792.
Larsson SE, Piscator M. 1971. Effect of cadmium on skeletal tissue in normal and cadmium-deficient
rats. Isr J Med Sci 7:495-498.
*Laskey JW, Rehnberg GL, Favor MJ, et al. 1980. Chronic ingestion of cadmium and/or tritium. II.
Effects on growth, development, and reproductive function. Environ Res 22:466-475.
*Laskey JW, Rehnberg GL, Laws SC, et al. 1984. Reproductive effects of low acute doses of cadmium
chloride in adult male rats. Toxicol Appl Pharmacol 73:250-255.
CADMIUM 391
9. REFERENCES
Lauwerys R, De Wals PH. 1981. Environmental pollution by cadmium and mortality from renal
diseases. Lancet 1(8216):383.
Lauwerys R, Bernard A, Buchet JP, et al. 1991. Does environmental exposure to cadmium represent a
health risk? Conclusions from the Cadmibel study. Acta Clin Belg 46(44):219-225.
Lauwerys R, Buchet JP, Roels H, et al. 1978. Placental transfer of lead, mercury, cadmium, and carbon
monoxide in women. I. Comparison of the frequency distributions of the biological indices in maternal
and umbilical cord blood. Environ Res 15:278-289.
Lauwerys R, Hardey R, Job M, et al. 1984. Environmental pollution by cadmium and cadmium body
burden: An autopsy study. Toxicol Lett 23:287-289.
Lauwerys RR, Bernard AM, Roels HA, et al. 1994. Cadmium: Exposure markers as predictors of
nephrotoxic effects. Clin Chem 40(7):1391-1394.
Lazebnik N, Kuhnert BR, Kihnert PM. 1989. Zinc, cadmium, and hypertension in parturient women.
Am J Obstet Gynecol 161:437-440.
Leduc D, de Francquen P, Jacobovitz D, et al. 1993. Association of cadmium exposure with rapidly
progressive emphysema in a smoker. Thorax 48:570-571.
Lee, MS; Park, SK; Hu, H; et al. 2011. Cadmium exposure and cardiovascular disease in the 2005 Korea
National Health and Nutrition Examination Survey. Environ Res 111(1):171-176.
Leeder JS, Kearns GL. 1997. Pharmacogenetics in pediatrics: Implications for practice. Pediatr Clin
North Am 44(1):55-77.
Lehman LD, Klaassen CD. 1986. Dosage-dependent disposition of cadmium administered orally to rats.
*Lehotzky K, Ungvary G, Polinak D, et al. 1990. Behavioral deficits due to prenatal exposure to
cadmium chloride in CFY rat pups. Neurotoxicol Teratol 12:169-172.
Leikin JB, Paloucek FP. 2002. Cadmium. In: Poisoning and toxicology handbook. Hudson, OH: Lexi-
Comp, Inc., 309-310.
Lemen RA, Lee JS, Wagoner JK, et al. 1976. Cancer mortality among cadmium production workers.
Ann N Y Acad Sci 271:273-279.
Leroyer A, Hemon D, Nisse C, et al. 2001. Determinants of cadmium burden levels in a population of
children living in the vicinity of nonferrous smelters. Environ Res 87(3):147-159.
Leung HW. 1993. Physiologically-based pharmacokinetic modelling. In: Ballentyne B, Marrs T,

Turner P, eds. General and applied toxicology. Vol. 1. New York, NY: Stockton Press, 153-164.
Levy LS, Clack J. 1975. Further studies on the effect of cadmium on the prostate gland. I. Absence of
prostatic changes in rats given oral cadmium sulfate for two years. Ann Occup Hyg 17:205-211.
CADMIUM 392
9. REFERENCES
Levy LS, Clack J, Roe FJ. 1975. Further studies on the effect of cadmium on the prostate gland. II.
Absence of prostatic changes in mice given oral cadmium sulfate for eighteen months. Ann Occup Hyg
17:213-220.
Lewis GP, Coughlin L, Jusko W, et al. 1972a. Contribution of cigarette smoking to cadmium
accumulation in man. Lancet 1:291-292.
Lewis GP, Jusko WJ, Coughlin LL. 1972b. Cadmium accumulation in man: Influence of smoking,
occupation, alcoholic habit and disease. J Chronic Dis 25:717-726.
Lewis RJ, ed. 2000. In: Sax's dangerous properties of industrial materials. Vol. 2. 10th ed. New York,
NY: John Wiley & Sons, Inc., 667, 669, 673.
Lewis RJ, ed. 2001. In: Cadmium and cadmium compounds. Hawley's condensed chemical dictionary.
14th ed. New York, NY: John Wiley & Sons, Inc., 186-188.
Lide DR, ed. 2005. CRC handbook of chemistry and physics. 86th ed. Boca Raton, FL: Taylor &
Francis, 4-53, 4-54.
Lieberman KW, Kramer HH. 1970. Cadmium determination in biological tissue by neutron activation
analysis. Anal Chem 42:266-267.
Lind Y, Wicklund Glynn A, Engman J, et al. 1995. Bioavailability of cadmium from crab
hepatopancreas and mushroom in relation to inorganic cadmium: A 9-week feeding study in mice. Food
Chem Toxicol 33(8):667-673.
Lindqvist B, Nystrom K, Stegmayr B, et al. 1989. Cadmium concentration in human kidney biopsies.
Scand J Urol Nephrol 23:213-217.
Liu J, Klaassen CD. 1996. Absorption and distribution of cadmium in metallothionein-I transgenic mice.
Fundam Appl Toxicol 29:294-300.
Liu J, Liu Y, Habecbu SS, et al. 1998. Susceptibility of MT-null mice to chronic CdCl2-induced
nephrotoxicity indicates that renal injury is not mediated by the CdMT complex. Toxicol Sci
46(1):197-203.
Liu J, Liu Y, Michalska AE, et al. 1996. Distribution and retention of cadmium in metallothionein I and
II null mice. Toxicol Appl Pharmacol 136(2):260-268.
Liu YZ, Huang JX, Luo CM, et al. 1985. Effects of cadmium on cadmium smelter workers. Scand J
Work Environ Health 11(Suppl 4):29-32.
Livingston AL. 1978. Forage plant estrogens. J Toxicol Environ Health 4(2-3):301-324.
Loeser E, Lorke D. 1977a. Semichronic oral toxicity of cadmium. I. Studies on rats. Toxicology
7:215-224.
Loeser E, Lorke D. 1977b. Semichronic oral toxicity of cadmium. II. Studies on dogs. Toxicology
7:225-232.
CADMIUM 393
9. REFERENCES
Lopez-Ortal P, Souza V, Bucio L, et al. 1999. DNA damage produced by cadmium in a human fetal
hepatic cell line. Mutat Res 439(2):301-306.
Löser E. 1980. A two year oral carcinogenicity study with cadmium on rats. Cancer Lett 9(3):191-198.
Lu J, Jin T, Nordberg G, et al. 2001. Metallothionein gene expression in peripheral lymphocytes from
cadmium-exposed workers. Cell Stress Chaperones 6(2):97-104.
Lucas PA, Jariwalla AG, Jones JH, et al. 1980. Fatal cadmium fume inhalation. Lancet 2(8187):205.
Lutzen A, Liberti SE, Rasmussen LJ. 2004. Cadmium inhibits human DNA mismatch repair in vivo.
Biochem Biophys Res Commun 321(1):21-25.
Lynn S, Lai HT, Kao SM, et al. 1997. Cadmium inhibits DNA strand break rejoining in methyl
methanesulfonate-treated CHO-K1 cells. Toxicol Appl Pharmacol 144(1):171-176.
Ma R, Van Mol W, Adams F. 1994a. Determination of cadmium, copper and lead in environmental
samples. An evaluation of flow injection on-line sorbent extraction for flame atomic absorption
spectrometry. Anal Chim Acta 285:33-43.
Ma R, Van Mol W, Adams F. 1994b. Selective flow injection sorbent extraction for determination of
cadmium, copper and lead in biological and environmental samples by graphite furnace absorption
spectrometry. Anal Chim Acta 293:251-260.
Machemer L, Lorke D. 1981. Embryotoxic effect of cadmium on rats upon oral administration. Toxicol
Mailhes JB, Preston RJ, Yuan ZP, et al. 1988. Analysis of mouse metaphase II oocytes as an assay for
chemically induced aneuploidy. Mutat Res 198:145-152.
*Maitani T, Cuppage FE, Flaassen CD. 1988. Nephrotoxicity of intravenously injected cadmium-
metallothionein: Critical concentration and tolerance. Fundam Appl Toxicol 10:98-108.
Maitani T, Waalkes MP, Klaassen CD. 1984. Distribution of cadmium after oral administration of
cadmium-thionein to mice. Toxicol Appl Pharmacol 74:237-243.
Malave I, de Ruffino DT. 1984. Altered immune response during cadmium administration in mice.
*Manca D, Ricard AC, Tra HV et al. 1994. Relation between lipid peroxidation and inflammation in the
pulmonary toxicity of cadmium. Arch Toxicol 68(6):364-369.
Mandel R, Ryser HJP. 1984. Mutagenicity of cadmium in Salmonella typhimurium and its synergism
with two nitrosamines. Mutat Res 138:9-16.
Mangler B, Fischer G, Classen HG, et al. 1988. The induction and reversibility of cadmium-induced
nephropathy in rats: Quantitative analytical and histopathological studies. Trace Elem Med 5:143-149.
Mann SJ. 1973. Whole body retention and tissue distribution of intravenously administered 115m Cd in
goats, sheep, and dogs. M.S. Thesis, Purdue University.
CADMIUM 394
9. REFERENCES
Maravelias C, Hatzakis A, Katsouyanni, et al. 1989. Exposure to lead and cadmium of children living
near a lead smelter at Lavrion, Greece. Sci Total Environ 84:61-70.
Marlowe M, Cossairt A, Moon C, et al. 1985. Main and interaction effects of metallic toxins on
classroom behavior. J Abnorm Child Psychol 13:185-198.
Martin FM, Witschi HP. 1985. Cadmium-induced lung injury: Cell kinetics and long-term effects.
Masaoka T, Akahori F, Arai S, et al. 1994. A nine-year chronic toxicity study of cadmium ingestion in
monkeys. I. Effects of dietary cadmium on the general health of monkeys. Vet Hum Toxicol 36(3):189-
194.
Mason HJ. 1990. Occupational cadmium exposure and testicular endocrine function. Hum Exp Toxicol
9:91-94.
Mason HJ, Davison AG, Wright AL, et al. 1988. Relations between liver cadmium, cumulative
exposure, and renal function in cadmium alloy workers. Br J Ind Med 45:793-802.
Mason HJ, Stevenson AJ, Williams N, et al. 1999. Intra-individual variability in markers of proteinuria
for normal subjects and those with cadmium-induced renal dysfunction: Interpretation of results from
untimed, random urine samples. Biomarkers 4(2):118-128.
Mason HJ, Williams N, Armitage S, et al. 1999. Follow up of workers previously exposed to silver
solder containing cadmium. Occup Environ Med 56(8):553-558.
Mason RP, Laporte JM, Andres S. 2000. Factors controlling the bioaccumulation of mercury,
methylmercury, arsenic, selenium, and cadmium by freshwater invertebrates and fish. Arch Environ
Contam Toxicol 38:283-297.
Mathews TD. 1994. Contaminants in recreationally important estuarine finfish from South Carolina.
Matsubara-Khan J. 1974. Compartmental analysis for the evaluation of biological half lives of cadmium
and mercury in mouse organs. Environ Res 7:54-67.
Matsuda T, Kobayashi E, Okubo Y, et al. 2002. Association between renal dysfunction and mortality
among inhabitants in the region around the Jinzu River Basin polluted by cadmium. Environ Res
88:156-163.
Mayr U, Butsch A, Schneider S. 1992. Validation of two in vitro test systems for estrogenic activities
with zearalenone, phytoestrogens and cereal extracts. Toxicology 74(2-3):135-149.
McBride MB. 1995. Toxic metal accumulation from agricultural use of sludge: Are USEPA regulations
protective? J Environ Qual 24:5-18.
McComish MF, Ong JH. 1988. Cadmium. In: Bodek I, Lyman WJ, Reehl WF, et al., eds.
Environmental inorganic chemistry: Properties, processes, and estimation methods. New York, NY:
Pergamon Press, 7.5-1 to 7.5-12.
CADMIUM 395
9. REFERENCES
McDiarmid MA, Freeman CS, Grossman EA, et al. 1997. Follow-up of biologic monitoring results in
cadmium workers removed from exposure. Am J Ind Med 32:261-267.
McKelvey W, Gwynn RC, Jeffery N, et al. 2007. A biomonitoring study of lead, cadmium, and mercury
in the blood of New York City adults. Environ Health Perspect 115(10):1435-1441.
McKenzie-Parnell JM, Kjellström TE, Sharma RP, et al. 1988. Unusually high intake and fecal output of
cadmium, and fecal output of other trace elements in New Zealand adults consuming dredge oysters.
McLellan JS, Flanagan PR, Chamberlain MJ, et al. 1978. Measurement of dietary cadmium absorption
in humans. J Toxicol Environ Health 4:131-138.
Meltzer HM, Brantsaeter AL, Borch-Iohnsen B, et al. 2010. Low iron stores are related to higher blood
concentrations of manganese, cobalt and cadmium in non-smoking, Norwegian women in the HUNT 2
study. Environ Res 110(5):497-504.
Menke A, Guallar E, Shiels MS, et al. 2008. The association of urinary cadmium with sex steroid
hormone concentrations in a general population sample of U.S. adult men. BMC Publ Health 8:72-79.
Menke, A; Muntner, P; Silbergeld, EK; et al. 2009. Cadmium levels in urine and mortality among U.S.
adults. Environ Health Perspect 117(2):190-196.
Mielke HW, Adams JL, Chaney RL, et al. 1991. The pattern of cadmium in the environment of five
Minnesota cities. Environ Geochem Health 13:29-34.
Migliore L, Cocchi L, Nesti C, et al. 1999. Micronuclei assay and FISH analysis in human lymphocytes
treated with six metal salts. Environ Mol Mutagen 34(4):279-284.
Mikhailova MV, Littlefield NA, Hass BS, et al. 1997. Cadmium-induced δ-hydroxydeoxyguanosine
formation, DNA strand breaks and antioxidant enzyme activities in lymphoblastoid cells. Cancer Lett
115:141-148.
Miller ML, Murthy L, Basom CR, et al. 1974a. Alteration in hepatocytes after manipulation of the diet:
Copper, zinc and cadmium interactions. Am J Anat 141:23-40.
Miller ML, Murthy L, Sorenson JR. 1974b. Fine structure of connective tissue after ingestion of
cadmium: Observations on interstitium on male rat lung. Arch Pathol 98:386-392.
Miller WJ, Blackmon DM, Gentry RP, et al. 1969. Effect of dietary cadmium on tissue distribution of
109
cadmium following a single oral dose in young goats. J Diary Sci 32(12):2029-2033.
Milvy P, Kay K. 1978. Mutagenicity of 19 major graphic arts and printing dyes. J Toxicol Environ
Health 4:41-36.
Min KS, Ueda H, Tanaka K. 2008. Involvement of intestinal calcium transporter 1 and metallothionein
in cadmium accumulation in the liver and kidney of mice fed a low-calcium diet. Toxicol Lett 176:85-92.
Misra RR, Smith GT, Waalkes MP. 1998. Evaluation of the direct genotoxic potential of cadmium in
four different rodent cell lines. Toxicology 126:103-114.
CADMIUM 396
9. REFERENCES
Mokhtar G, Hossny E, el-Awady M, et al. 2002. In utero exposure to cadmium pollution in Cairo and
Giza governorates of Egypt. East Mediter Health J 8(2-3):254-260.
Monzawa K, Kido T, Yamaya H, et al. 1998. Urinary excretion levels of sodium and potassium in
environmental cadmium-exposed subjects. Toxicology 127:187-193.
Moore W, Stara JF, Crocker WC, et al. 1973. Comparison of 115Cd retention in rats following different
routes of administration. Environ Res 6:473-478.
Morgan H, Sherlock JC. 1984. Cadmium intake and cadmium in the human kidney. Food Addit Contam
1:45-51.
Morgan H, Simms DI. 1988. The Shipham Report: Discussion and conclusions. Sci Total Environ
75:135-143.
Moriguchi J, Ezaki T, Tsukahara T, et al. 2005a. α1-Microglobulin levels and correlation with cadmium
and other metals in urine of non-smoking women among general populations in Japan. Toxicol Environ
Chem 87(1):119-133.
Moriguchi J, Ezaki T, Tsukahara T, et al. 2005b. Decreases in urine specific gravity and urinary
creatinine in elderly women. Int Arch Occup Environ Health 78:438-445.
Morrow H. 2001. Cadmium and cadmium alloys. In: Kirk-Othmer encyclopedia of chemical
technology. John Wiley & Sons, Inc., 471-507.
http://www.mrw.interscience.wiley.com/emrw/9780471238966/kirk/article/cadmcarr.a01/current/pdf?hd=
All%2Ccadmium. April 29, 2008.
Morrow H. 2010. Cadmium and cadmium alloys. In: Kirk-Othmer encyclopedia of chemical
technology. John Wiley & Sons,
Inc.http://onlinelibrary.wiley.com/doi/10.1002/0471238961.0301041303011818.a01.pub3/abstract.
September 10 , 2012.
Morselli PL, Franco-Morselli R, Bossi L. 1980. Clinical pharmacokinetics in newborns and infants:
Age-related differences and therapeutic implications. Clin Pharmacokin 5(6):485-527.
*Mueller PW, Paschal DC, Hammel RR, et al. 1992. Chronic renal effects in three studies of men and
women occupationally exposed to cadmium. Arch Environ Contam Toxicol 23:125-136.
Mueller PW, Smith SJ, Steinberg KK, et al. 1989. Chronic renal tubular effects in relation to urine
cadmium levels. Nephron 52:45-54.
Mukherjee A, Giri AK, Sharma A, et al. 1988a. Relative efficacy of short-term tests in detecting
genotoxic effects of cadmium chloride in mice in vivo. Mutat Res 206:285-295.
Mukherjee A, Sharma A, Talukder G. 1988b. Effect of selenium on cadmium-induced chromosomal

aberrations in bone marrow cells of mice. Toxicol Lett 41:23-29.
*Muller L, Stacey NH. 1988. Subcellular toxicity of low level cadmium in rats: Effect on cytochrome C
oxidase. Toxicology 51:25-34.
CADMIUM 397
9. REFERENCES
Muller L, Abel J, Ohnesorge FK. 1986. Absorption and distribution of cadmium (Cd), copper and zinc
following oral subchronic low level administration to rats of different binding forms of cadmium (Cd-
acetate, Cd-metallothionein, Cd-glutathione). Toxicology 39:187-195.
Muller L, Craig G, Stacey NH. 1988. Dose response of rat liver to low level cadmium. Bull Environ
Contam Toxicol 40:301-308.
Munshower FF. 1977. Cadmium accumulation in plants and animals of polluted and nonpolluted
grasslands. J Environ Qual 6:411-413.
Muntau H, Baudo R. 1992. Sources of cadmium, its distribution and turnover in the freshwater
environment. IARC Sci Publ 118:133-148.
Murthy RC, Saxena DK, Lal B, et al. 1989. Chronic cadmium-ethanol administration alters metal
distribution and some biochemicals in rat brain. Biochem Int 19:135-143.
Muys T. 1984. Quantitative determination of lead and cadmium in foods by programmed dry ashing and
atomic absorption spectrophotometry with electrothermal atomization. Analyst 109:119-121.
Nagaraj M, Sunitha S, Varalakshmi P. 2000. Effect of lupeol, a pentacyclic triterpene, on the lipid
peroxidation and antioxidant status in rat kidney after chronic cadmium exposure. J Appl Toxicol
20(5):413-417.
Nagymajtenyi L, Schulz H, Desi I. 1997. Behavioural and functional neurotoxicological changes caused
by cadmium in a three-generational study in rats. Hum Exp Toxicol 16(12):691-699.
*Nagyova A, Galbavy S, Ginter E. 1994b. Histopathological evidence of vitamin C protection against

Cd-nephrotoxicity in guinea pigs. Exp Toxicol Pathol 46(1):11-14.
*Nagyova A, Ginter E, Stefek M. 1994a. Effect of cadmium on hepatic microsomal monooxygenase

activities in guinea pigs with low and high ascorbic acid intake. J Nutr Biochem 5(1):10-14.
Nakada T, Furuta H, Koike H, et al. 1989. Impaired urine concentrating ability in Itai-itai Ouch-ouch
disease. Int Urol Nephrol 21:201-210.
Nakadaira H, Nishi S. 2003. Effects of low-dose cadmium exposure on biological examinations. Sci
Total Environ 308(1-3):49-62.
Nakagawa H, Nishiojo M, Morikawa Y, et al. 1993. Urinary β2-microglobulin concentration and

mortality in a cadmium-polluted area. Arch Environ Health 48:428-435.
Nakagawa H, Sawano S, Okumura Y, et al. 1987. Mortality study of inhabitants in a cadmium-polluted

area. Bull Environ Contam Toxicol 38:553-560.
Nakashima K, Kobayashi E, Nogawa K, et al. 1997. Concentration of cadmium in rice and urinary
indicators of renal dysfunction. Occup Environ Med 54:750-755.
Nam DQ, Skacel F, Buryan P. 1994. Determination of airborne lead and cadmium collected on glass
fibre filters by differential-pulse anodic stripping voltammetry. Sci Total Environ 144:87-92.
CADMIUM 398
9. REFERENCES
Naqvi SM, Howell RD. 1993. Cadmium and lead uptake by red swamp crayfish (Procambarus clarkii)
of Louisiana. Bull Environ Contam Toxicol 51(2):296-302.
Naruse I, Hayashi Y. 1989. Amelioration of the teratogenicity of cadmium by the metallothionein

induced by bismuth nitrate. Teratology 40:459-465.
NAS/NRC. 1989. Report of the oversight committee. In: Biologic markers in reproductive toxicology.
Washington, DC: National Academy of Sciences, National Research Council, National Academy Press,
15-35.
Nation JR, Bourgeois AE, Clark DE, et al. 1984. The effects of oral cadmium exposure on passive
avoidance performance in the adult rat. Toxicol Lett 20:41-47.
Nation JR, Grover CA, Bratton GR, et al. 1990. Behavioral antagonism between lead and cadmium.
Neorotoxicol Teratol 12:99-104.
Nation JR, Pugh CK, Von Stutz J, et al. 1989. The effects of cadmium on the self-administration of
ethanol and an isocaloric/isohedonic equivalent. Neurotoxicol Teratol 11:509-514.
Navas-Acien A, Silbergeld EK, Sharrett AR, et al. 2005. Metals in urine and peripheral arterial disease.
Environ Health Perspect 113(2):164-169.
Nayak BN, Ray M, Persaud TV, et al. 1989. Embryotoxicity and in vivo cytogenetic changes following
maternal exposure to cadmium chloride in mice. Exp Pathol 36:75-80.
Newton D, Johnson P, Lally AE, et al. 1984. The uptake by man of cadmium ingested in crab meat.
Hum Toxicol 3:23-28.
Nilsson U, Skerfving S. 1993. In vivo X-ray fluorescence measurements of cadmium and lead. Scand J
Work Environ Health 19(Suppl 1):54-58.
Nimmo M, Fones G. 1994. Application of adsorptive cathodic stripping voltammetry for the
determination of Cu, Cd, Ni and Co in atmospheric samples. Anal Chim Acta 291:321-328.
NIOSH. 1989. Numbers of potentially exposed employees. Washington, DC: U.S. Department of
Health and Human Services, National Institute for Occupational Safety and Health.
NIOSH. 1990. Numbers of potentially exposed employees. National Occupational Exposure Survey.
U.S. Department of Health and Human Services, National Institute for Occupational Safety and Health.
http://www.cdc.gov/noes/. July 8, 2008.
*NIOSH. 1992a. NIOSH manual of analytical methods. Recommended exposure level. Washington,
DC: U.S. Department of Health and Human Services, National Institute for Occupational Safety and
Health.
NIOSH. 1992b. NIOSH recommendations for occupational safety and health. Compendium of policy
documents and statements. Categories of pesticides. Atlanta, GA: National Institute for Occupational
Safety and Health, Centers for Disease Control and Prevention. http://www.cdc.gov/niosh/92-100.html.
April 29, 2008.
CADMIUM 399
9. REFERENCES
NIOSH. 1994. Method 7048: Cadmium and compounds, as Cd. NIOSH Manual of Analytical Methods
(NMAM). 4th ed. National Institute for Occupational Safety and Health.
http://www.cdc.gov/niosh/nmam/pdfs/7048.pdf. May 13, 2008.
NIOSH. 2003. Method 7300: Elements by ICP (nitric/perchloric acid ashing). National Institute for
Occupational Safety and Health. http://www.cdc.gov/niosh/nmam/pdfs/7300.PDF. May 13, 2008.
NIOSH. 2005. Cadmium. NIOSH pocket guide to chemical hazards. Atlanta, GA: National Institute
for Occupational Safety and Health, Centers for Disease Control and Prevention.
http://www.cdc.gov/niosh/npg/ April 24, 2008.
Nishijo M, Morikawa Y, Nakagawa H, et al. 2006. Causes of death and renal tubular dysfunction in
residents exposed to cadmium in the environment. Occup Environ Med 63:545-550.
Nishijo M, Nakagawa H, Honda R, et al. 2002. Effects of maternal exposure to cadmium on pregnancy
outcome and breast milk. Occup Environ Med 59(6): 394-397.
Nishijo M, Nakagawa H, Morikawa Y, et al. 2004a. Mortality in a cadmium polluted area Japan.
Biometals 17(5):535-538.
Nishijo M, Nakagawa H, Morikawa Y, et al. 1995. Mortality of inhabitants in an area polluted by

cadmium: 15 year follow up. Occup Environ Med 52:181-184.
Nishijo M, Satarug S, Honda R, et al. 2004b. The gender differences in health effects of environmental
cadmium exposure and potential mechanisms. Mol Cell Biochem 255:87-92.
Nishino H, Shiroishi K, Kagamimori S, et al. 1988. Studies on the increase in serum concentrations of
urea cycle amino acids among subjects exposed to cadmium. Bull Environ Contam Toxicol 40:553-560.
Nishioka H. 1975. Mutagenic activities of metal compounds in bacteria. Mutat Res 311:185-189.
*Noack-Fuller G, DeBeer C, Seibert H. 1993. Cadmium, lead, selenium, and zinc in semen of
occupationally unexposed men. Andrologia 25(1):7-12.
*Nogawa K. 1984. Biological indicators of cadmium nephrotoxicity in persons with low-level cadmium
exposure. Environ Health Perspect 54:163-169.
Nogawa K, Honda R, Kido T, et al. 1989. A dose-response analysis of cadmium in the general
environment with special reference to total cadmium intake limit. Environ Res 48:7-16.
*Nogawa K, Kawano S, Nishi M. 1981a. Mortality study of inhabitants in a cadmium-polluted area with
special reference to low-molecular-weight proteinuria. In: Ernst WH, ed. Proceedings of the
International Conference on Heavy Metals in the Environment. Edinburgh: CEP Consultants, 538-540.
Nogawa K, Kobayashi E, Honda R, et al. 1980. Renal dysfunction of inhabitants in a cadmium-polluted

area. Environ Res 23:13-23.
Nogawa K, Kobayashi E, Konishi F. 1981b. Comparison of bone lesions in chronic cadmium

intoxication and vitamin D deficiency. Environ Res 23:233-249.
CADMIUM 400
9. REFERENCES
Nogawa K, Tsuritani I, Kido T, et al. 1987. Mechanism for bone disease found in inhabitants
environmentally exposed to cadmium: Decreased serum 1-alpha, 25-dihydroxy vitamin D level. Int Arch
Occup Environ Health 59:21-30.
Nogawa K, Tsuritani I, Kido T, et al. 1990. Serum vitamin D metabolites in cadmium-exposed persons
with renal damage. Int Arch Occup Environ Health 62:189-193.
Nomiyama K, Nomiyama H. 1986. Critical concentrations of 'unbound' cadmium in the rabbit renal
cortex. Experientia 42:149.
Nomiyama K, Sugata Y, Yamamoto A, et al. 1975. Effects of dietary cadmium on rabbits. I. Early
signs of cadmium intoxication. Toxicol Appl Pharmacol 31:4-12.
Noonan CW, Sarasua SM, Campagna D, et al. 2002. Effects of exposure to low levels of environmental
cadmium on renal biomarkers. Environ Health Perspect 110(2):151-155.
Nordberg GF. 2010. Biomarkers of exposure, effects and susceptibility in humans and their application
in studies of interactions among metals in China. Toxicol Lett 192(1):45-49.
Nordberg G, Jin T, Bernard A, et al. 2002. Low bone density and renal dysfunction following
environmental cadmium exposure in China. Ambio 31(6):478-481.
Nordberg GF, Kjellström T. 1979. Metabolic model for cadmium in man. Environ Health Perspective
28:211-217.
Nordberg GF, Jin T, Kong Q, et al. 1997. Biological monitoring of cadmium exposure and renal effects
in a population group residing in a polluted area in China. Sci Total Environ 199:111-114.
Nordberg GF, Kjellström T, Nordberg M. 1985. Kinetics and metabolism. In: Friberg L, Elinder CG,
Kjellström T, et al. eds. Cadmium and health: A toxicological and epidemiological appraisal. Vol. I.
Exposure, dose, and metabolism. Boca Raton, FL: CRC Press, 103-178.
Nordberg M, Nuottaniemi I, Cherian MG, et al. 1986. Characterization studies on the cadmium-binding
proteins from two species of New Zealand oysters. Environ Health Perspect 65:57-62.
Nordberg G, Slorach S, Steinstrom T. 1973. [Cadmium poisoning caused by a cooled-soft-drink

machine.] Lakartidingen 70:601-604. (Swedish)
NRC. 1993. Pesticides in the diets of infants and children. Washington, DC: National Research
Council. National Academy Press.
NRC. 2002. Biosolids applied to land: Advancing standards and practices. Washington, DC: National
Research Council. National Academy Press.
http://water.epa.gov/scitech/wastetech/biosolids/upload/complete.pdf. September 10, 2012.
NTP. 1994. Cadmium and certain cadmium compounds. In: Seventh annual report on carcinogens,
summary 1994. U.S. National Toxicology Program, U.S. Public Health Service, Department of Health
and Human Services, 111-116.
CADMIUM 401
9. REFERENCES
NTP. 1995. NTP technical report on toxicity studies of cadmium oxide (CAS No. 1306-19-0)
administered by inhalation to F344/N rats and B6C3F mice. Research Triangle Park, NC: National
Toxicology Program. Toxicity report series number 39.
NTP. 2005. Cadmium. Report on carcinogens. 11th ed. Research Triangle Park, NC: U.S. Department
of Health and Human Services, Public Health Service, National Toxicology Program. http://ntp-
server.niehs.nih.gov/ntp/roc/toc11.html. April 24, 2008.
NTP. 2011. Report on carcinogens. Twelfth edition. National Toxicology Program. U.S. Department
of Health and Human Services, Public Health. http://ntp-server.niehs.nih.gov/ntp/roc/twelfth/roc12.pdf
February 22, 2012.
Nwosu JU, Harding AK, Linder G. 1995. Cadmium and lead uptake by edible crops grown in a silt loam
soil. Bull Environ Contam Toxicol 54:570-578.
NYS Dept of Health. 2006. New York State heavy metals registry 2000 through 2005.
http://www.health.state.ny.us/environmental/workplace/heavy_metals_registry/docs/report_2005.pdf.
May 12, 2008.
*Oberdoerster G, Baumert H-P, Hochrainer D. 1979. The clearance of cadmium aerosols after inhalation
exposure. Am Ind Hyg Assoc J 40(6):443-450.
Oberdörster G. 1992. Pulmonary deposition, clearance and effects of inhaled soluble and insoluble
cadmium compounds. In: Nordberg GF, Herber RFM, Alessio L, eds. Cadmium in the human
environment: Toxicity and carcinogenicity. Lyon: International Agency for Research on Cancer,
189-204.
Oberdörster G, Cherian MG, Baggs RB. 1994. Importance of species differences in experimental
pulmonary carcinogenicity of inhaled cadmium for extrapolation to humans. Toxicol Lett 72:339-343.
Oberly TJ, Piper CE, McDonald DS. 1982. Mutagenicity of metal salts in the L5178Y mouse lymphoma
assay. J Toxicol Environ Health 9:367-376.
*O'Brien IG, King LJ. 1989. The effect of chronic parenteral administration of cadmium on isoenzyme
levels of alkaline phosphate in intestinal mucosa. Toxicology 56:87-94.
OECD. 1995. Risk reduction monograph No. 5: Cadmium. Background and national experience with
reducing risk. Paris, France: Organization for Economic Co-operation and Development.
OCDE/GD(94)97.
O'Flaherty EJ. 1993. Physiologically based models for bone-seeking elements. IV. Kinetics of lead
disposition in humans. Toxicol Appl Pharmacol 118:16-29.
Ogoshi K, Moriyama T, Nanzai Y. 1989. Decrease in the mechanical strength of bones of rats
administered cadmium. Arch Toxicol 63:320-324.
Ohba K, Okawa Y, Matsumoto Y, et al. 2007. A study of investigation of cadmium genotoxicity in rat
bone cells using DNA microarray. J Toxicol Sci 32(1):107-109.
Öhrvik H, Oskarsson A, Lundh T, et al. 2007. Impact of iron status on cadmium uptake in suckling
piglets. Toxicology 240:15-24.
CADMIUM 402
9. REFERENCES
Ohsawa M, Takahashi K, Otsuka F. 1988. Induction of anti-nuclear antibodies in mice orally exposed to
cadmium at low concentrations. Clin Exp Immunol 73:98-102.
*Ohta H, DeAngelis MV, Cherian MG. 1989. Uptake of cadmium and metallothionein by rat everted
intestinal sacs. Toxicol Appl Pharmacol 101:62-69.
*Ohta H, Yamauchi Y, Nakakita M, et al. 2000. Relationship between renal dysfunction and bone
metabolism disorder in male rats after long-term oral quantitative cadmium administration. Ind Health
38(4):339-355.
*Oldereid NB, Thomassen Y, Attramadal A, et al. 1993. Concentrations of lead, cadmium and zinc in
the tissues of reproductive organs of men. J Reprod Fertil 99:421-425.
Oldiges H, Glaser U. 1986. The inhalative toxicity of different cadmium compounds in rats. Trace Elem
Med 3:72-75.
Oldiges H, Hochrainer D, Glaser U. 1989. Long-term inhalation study with Wistar rats and four
cadmium compounds. Toxicol Environ Chem 19:217-222.
Olsson IM, Bensryd I, Lundh T, et al. 2002. Cadmium in blood and urine–impact of sex, age, dietary
intake, iron status, and former smoking–association of renal effects. Environ Health Perspect
110(12):1185-1190.
Omaye ST, Tappel AL. 1975. Effect of cadmium chloride on the rat testicular-soluble selenoenzyme,
glutathione peroxidase. Res Commun Chem Pathol Pharmacol 12:695-711.
O'Neil MJ, Heckelman PE, Koch CB, et al. 2006. Cadmium and cadmium compounds. Merck Index.
14th ed. Whitehouse Station, NJ: Merck & Co., Inc, 263, 264.
Oo YK, Kobayashi E, Nogawa K, et al. 2000. Renal effects of cadmium intake of a Japanese general
population in two areas unpolluted by cadmium. Arch Environ Health 55(2):98-103.
O'Riordan ML, Hughes EG, Evans HJ. 1978. Chromosomal studies on blood lymphocytes of men
occupationally exposed to cadmium. Mutat Res 58:305-311.
Orlowski C, Piotrowski JK, Subdys JK, et al. 1998. Urinary cadmium as indicator of renal cadmium in
humans: An autopsy study. Hum Exp Toxicol 17(6):302-306.
Ormos G, Cseh J, Groszmann M, et al. 1985. Urinary β2-microglobulin and retinol binding protein:
Individual fluctuations in cadmium-exposed workers. Toxicol Lett 27:59-64.
Ornes WH, Sajwan KS. 1993. Cadmium accumulation and bioavailability in coontail (Ceratophyllum
demersum L.) plants. Water Air Soil Pollut 69:291-300.
Osawa T, Kobayashi E, Okubo Y, et al. 2001. A retrospective study on the relation between renal
dysfunction and cadmium concentration in rice in individual hamlets in the Jinzu River basin, Toyama
Prefecture, Japan. Environ Res 86(Sect A):51-59.
OSHA. 1990. Occupational exposure to cadmium; proposed rule. Occupational Safety and Health
Administration. Code of Federal Regulations. 29 CFR 1910.
CADMIUM 403
9. REFERENCES
OSHA. 1991. ICP analysis of metal/metalloid particulates from solder operations. Occupational Safety
and Health Administration. http://www.osha.gov/dts/sltc/methods/inorganic/id206/id206.pdf. May 14,
2008.
OSHA. 2002a. Method ID-121: Metal and metalloid particulates in workplace atmospheres (atomic
absorption). Occupational Safety and Health Administration.
http://www.osha.gov/dts/sltc/methods/inorganic/id121/id121.pdf. May 14, 2008.
OSHA. 2002b. Method ID-125G: Metal and metalloid particulates in workplace atmospheres (ICP
analysis). Occupational Safety and Health Administration.
http://www.osha.gov/dts/sltc/methods/inorganic/id125g/id125g.html. May 14, 2008.
OSHA. 2004. Cadmium in workplace atmospheres. Occupational Safety and Health Administration.
http://www.osha.gov/dts/sltc/methods/inorganic/id189/id189.html. August 18, 2008.
OSHA. 2007a. Cadmium. Toxic and hazardous substances. Occupational Safety and Health
Administration. Code of Federal Regulations. 29 CFR 1910.1027. http://www.osha.gov/comp-
links.html. May 05, 2008.
OSHA. 2007b. Cadmium. Toxic and hazardous substances. Occupational Safety and Health
Administration. Code of Federal Regulations. 29 CFR 1915.1027. http://www.osha.gov/comp-
links.html. May 05, 2008.
OSHA. 2007c. Cadmium. Toxic and hazardous substances. Occupational Safety and Health
Administration. Code of Federal Regulations. 29 CFR 1926.1127.
http://www.osha.gov/comp-links.html. May 05, 2008.
Ostapczuk P. 1993. Present potentials and limitations in the determination of trace elements by
potentiometric stripping analysis. Anal Chim Acta 273:35-40.
OTA. 1990. Neurotoxicity: Identifying and controlling poisons of the nervous system. Washington,
DC: Office of Technology Assessment. OTABA438.
Owen GM, Brozek J. 1966. Influence of age, sex and nutrition on body composition during childhood
and adolescence. In: Falkner F, ed. Human development. Philadelphia, PA: WB Saunders, 222-238.
Pacyna JM, Pacyna EG. 2001. An assessment of global and regional emissions of trace metals to the
atmosphere from anthropogenic sources worldwide. Environ Rev 9(4):269-298.
Pal R, Nath R, Gill KD. 1993a. Influence of ethanol on cadmium accumulation and its impact on lipid
peroxidation and membrane bound functional enzymes(Na+, K+, -ATPase and acetylcholinesterase) in
various regions of adult rat brain. Neurochem Int 23(5):451-458.
Pal R, Nath R, Gill KD. 1993b. Lipid peroxidation and antioxidant defense enzymes in various regions
of adult rat brain after co-exposure to cadmium and ethanol. Pharmocol Toxicol 73:209-214.
Palus J, Rydzynski K, Dziubaltowska E, et al. 2003. Genotoxic effects of occupational exposure to lead
and cadmium. Mutat Res 540(1):19-28.
CADMIUM 404
9. REFERENCES
Palmer KC, Mari F, Malian MS. 1986. Cadmium-induced acute lung injury: Compromised repair
response following thyroidectomy. Environ Res 41:568-584.
*Parizek J. 1964. Vascular changes at sites of oestrogen biosynthesis produced by parenteral injection of
cadmium salts: The destruction of placenta by cadmium salts. J Reprod Fertil 7:263-265.
Park JD, Cherrington NJ, Klaassen CD. 2002. Intestinal absorption of cadmium is associated with
divalent metal transporter 1 in rats. Toxicol Sci 68(2):288-294.
Paton GR, Allison AC. 1972. Chromosome damage in human cell culture induced by metal salts. Mutat
Res 16:332-336.
Patwardhan JR, Finckh ES. 1976. Fatal cadmium-fume pneumonitis. Med J Aust 1:962-966.
Paulson A. 1997. The transport and fate of Fe, Mn, Cu, Zn, Cd, Pb and SO4 in a groundwater plume and
in downstream surface waters in the Coeur d'Alene mining district, Idaho, USA. Appl Geochem
12:447-464.
Pellizzari ED, Perritt RL, Clayton CA. 1999. National human exposure assessment survey (NHEXAS):
Exploratory survey of exposure among population subgroups in EPA Region V. J Expo Anal Environ
Epidemiol 9:49-55
Perry HM, Erlanger MW, Gustafsson TO, et al. 1989. Reversal of cadmium-induced hypertension by D-
myo-inositol-1,2,6-trisphosphate. J Toxicol Environ Health 28:151-159.
Petering HG, Choudhury H, Stemmer KL. 1979. Some effects of oral ingestion of cadmium on zinc,
copper and iron metabolism. Environ Health Perspect 28:97-106.
Peters JL, Perlstein TS, Perry MJ, et al. 2010. Cadmium exposure in association with history of stroke
and heart failure. Environ Res 110(2):199-206.
Peterson DP, Huff EA, Bhattacharyya MH. 1991. Determination of cadmium in blood, plasma, and
urine by electrothermal atomic absorption spectrophotometry after isolation by anion-exchange
chromatography. Anal Biochem 192(2):434-440.
Petersson Grawé K, Oskarsson A. 2000. Cadmium in milk and mammary gland in rats and mice. Arch
Toxicol 73(10-11):519-527.
*Pharikal K, Das PC, Dey CD, et al. 1988. Tissue ascorbate as a metabolic marker in cadmium toxicity.
Int J Vitam Nutr Res 58:306-311.
Pierce FJ, Dowdy RH, Grigel DF. 1982. Concentrations of six trace metals in some major Minnesota
Soil Series. J Environ Qual 11:416-422.
Pirrone N, Keeler GJ, Nriagu JO, et al. 1996. Historical trends of airborne trace metals in Detroit from
1971 to 1992. Water Air Soil Pollut 88:145-165.
Piscator M. 1966. Protenuria in chronic poisoning. III. Electrophoretic and immunoelectrophoretic

studies on urinary proteins from cadmium workers, with special reference to the excretion of low-
molecular-weight proteins. Arch Environ Health 12:335-344.
CADMIUM 405
9. REFERENCES
Piscator M. 1972. Cadmium toxicity industrial and environmental experience. In: Proceedings 17th
International Congress Occupational Health, Buenos Aires.
Piscator M. 1984. Long-term observations on tubular and glomerula function in cadmium-exposed

persons. Environ Health Perspect 54:175-179.
Pleasants EW, Sandow ME, DeCandido S, et al. 1992. The effect of vitamin D3 and 1,25-
dihydroxyvitamin D3 on the toxic symptoms of cadmium exposed rats. Nutr Res 12:1393-1403.
Pleasants WE, Waslien C, Naughton BA, et al. 1993. Dietary modulation of the symptoms of cadmium
toxicity in rats: Effects of vitamins A,C, D,DD hormone and fluoride. Nutr Res 13:839-850.
Pless-Mulloli T, Boettcher M, Steiner M, et al. 1998. α-1-Microglobulin: epidemiological indicator for

tubular dysfunction induced by cadmium? Occup Environ Med 55:440-445.
Poirier LA, Kasprzak KS, Hoover KL, et al. 1983. Effects of calcium and magnesium acetates on the
carcinogenicity of cadmium chloride in Wistar rats. Cancer Res 43:4575-4581.
*Pond WG, Walker EF. 1972. Cadmium-induced anemia in growing rats: Prevention by oral or
parenteral iron. Nutr Rep Int 5:365-370.
Pond WG, Walker EF. 1975. Effect of dietary Ca and Cd level of pregnant rats on reproduction and on
dam and progeny tissue mineral concentrations. Proc Soc Exp Biol Med 148:665-668.
Potts AM, Simon FP, Tobias JM, et al. 1950. Distribution and fate of cadmium in the animal body.
Arch Ind Hyg 2:175-188.
Prigge E. 1978a. Early signs of oral and inhalative cadmium uptake in rats. Arch Toxicol 40:231-247.
Prigge E. 1978b. Inhalative cadmium effects in pregnant and fetal rats. Toxicology 10:297-309.
Prodan L. 1932. Cadmium poisoning: II. Experimental cadmium poisoning. J Ind Hyg 14:174-196.
Putrament AH, Baranowska H, Ejchart A, et al. 1977. Manganese mutagenesis in yeast. VI. Mn2+
uptake, mitochondrial DNA replication and ER induction, comparison with other divalent cations. Mol
Gen Genet 151:69-76.
Racz P, Erdohelyi A. 1988. Cadmium, lead and copper concentrations in normal and senile cataractous
human lenses. Opthalmic Res 20:10-13.
Radisch B, Luck W, Nau H. 1987. Cadmium concentrations in milk and blood of smoking mothers.
Toxicol Lett 36:147-152.
Ragan HA. 1977. Effects of iron deficiency on the absorption and distribution of lead and cadmium in
rats. J Lab Clin Med 90(4):700-706.
Rahola T, Aaran R-K, Miettenen JK. 1973. Retention and elimination of 115mCd in man. In: Health
physics problems of internal contamination. Budapest: Akademia 213-218.
CADMIUM 406
9. REFERENCES
*Rajanna B, Hobson M, Boykin M, et al. 1990. Effects of chronic treatment with cadmium on ATPases,
uptake of catecholamines, and lipid peroxidation in rat brain synaptosomes. Ecotoxicol Environ Saf
20(1):36-41.
Ramel C, Magnusson J. 1979. Chemical induction of nondisjunction in Drosophila. Environ Health

Perspect 31:59-66.
Reeves PG, Chaney RL. 2001. Mineral status of female rats affects the absorption and organ distribution
of dietary cadmium derived from edible sunflower kernels (Helianthus annus L.). Environ Res 85(3):215-
225.
Reeves PG, Chaney RL. 2002. Nutritional status affects the absorption and whole-body and organ
retention of cadmium in rats fed rice-based diets. Environ Sci Technol 36:2684-2692.
Reeves PG, Vanderpool RA. 1997. Cadmium burden of men and women who report regular
consumption of confectionery sunflower kernels containing a natural abundance of cadmium. Environ
Health Perspect 105(10):1098-104.
*Rehm S, Waalkes MP. 1988. Cadmium-induced ovarian toxicity in hamsters, mice, and rats. Fundam
Appl Toxicol 10:635-647.
Reimann C, de Caritat P, Halleraker JH, et al. 1997. Regional atmospheric deposition patterns of Ag, As,
Bi, Cd, Hg, Mo, Sb and Ti in a 188,000 km2 area in the European Arctic as displayed by terrestrial moss
samples-long-range atmospheric transport vs. local impact. Atmos Environ 31(23):3887-3901.
Renugadevi J, Prabu SM. 2010. Cadmium-induced hepatotoxicity in rats and the protective effect of
naringenin. Exp Toxicol Pathol 62(2):171-181.
Roberts CA, Clark JM. 1986. Improved determination of cadmium in blood and plasma by flameless
atomic absorption spectroscopy. Bull Environ Contam Toxicol 36:496-499.
Roberts CA, Clark JM. 1988. In vivo depression of reserve albumin binding capacity by cadmium: A
preliminary evaluation. Life Sci 42:1369-1374.
Roels H, Bernard AM, Cardenas A, et al. 1993. Markers of early renal changes induced by industrial
pollutants. III. Application to workers exposed to cadmium. Brit J Ind Med 50:37-48.
Roels HA, Hubermont G, Buchet JP, et al. 1978. Placental transfer of lead, mercury, cadmium, and
carbon monoxide in women. III. Factors influencing the accumulation of heavy metals in the placenta,
and the relationship between maternal concentration in the placenta and in maternal and cord blood.
Roels HA, Lauwerys RR, Bernard AM, et al. 1991. Assessment of the filtration reserve capacity of the
kidney in workers exposed to cadmium. Br J Ind Med 48:365-374.
Roels HA, Lauwerys R, Buchet JB, et al. 1981a. Environmental exposure to cadmium and renal function
of aged women in three areas of Belgium. Environ Res 24:117-130.
Roels HA, Lauwerys R, Dardenne AN. 1983. The critical level of cadmium in human renal cortex: A
reevaluation. Toxicol Lett 15:357-360.
CADMIUM 407
9. REFERENCES
Roels HA, Lauwerys RR, Buchet JP, et al. 1981b. In vivo measurement of liver and kidney cadmium in
workers exposed to this metal: Its significance with respect to cadmium in blood and urine. Environ Res
26:217-240.
Roels HA, Lauwerys RR, Buchet JP, et al. 1989. Health significance of cadmium induced renal
dysfunction: A five year follow-up. Br J Ind Med 46:755-764.
Roels HA, Van Assche FJ, Oversteyns M, et al. 1997. Reversibility of microproteinuria in cadmium
workers with incipient tubular dysfunction after reduction of exposure. Am J Ind Med 31(5):645-652.
Rohr G, Bauchinger M. 1976. Chromosome analysis in cell cultures of the Chinese hamster after
application of cadmium sulfate. Mutat Res 40:125.
Rose CS, Heywood PG, Costanzo RM. 1992. Olfactory impairment after chronic occupational cadmium
exposure. J Occup Med 34(6):600-605.
Roseman EF, Mills EL, Rutszke M, et al. 1994. Absorption of cadmium from water by North American
zebra and quagga mussels (Bivalvia dreissenidae). Chemosphere 28(4):737-743.
Roy WR, Krapac IG, Steele JD. 1993. Soil processes and chemical transport. J Environ Qual
22:537-543.
Rozgaj R, Kasuba V, Fucic A. 2002. Genotoxicity of cadmium chloride in human lymphocytes

evaluated by the comet assay and cytogenetic tests. J Trace Elem Med Biol 16:187-192.
Rudzki E, Rebandel P, Stroinski J, et al. 1988. Reactions of cadmium. Contact Dermatitis 18:183-184.
Rule KL, Comber SDW, Ross D, et al. 2006. Diffuse sources of heavy metals entering an urban
wastewater catchment. Chemosphere 63:64-72.
Rusch GM, O'Grodnick JS, Rinehart WE. 1986. Acute inhalation study in rat of comparative uptake,
distribution and excretion of different cadmium containing materials. Am Ind Hyg Assoc 47:754-763.
Rutzke M, Gutenmann WH, Williams SD, et al. 1993. Cadmium and selenium absorption by swiss
chard grown in potted composted materials. Bull Environ Contam Toxicol 31:416-420.
Ryu DY, Lee SJ, Park DW, et al. 2004. Dietary iron regulates intestinal cadmium absorption through
iron transporters in mice. Toxicol Lett 152(1):19-25
Saaranen M, Kantola M, Saarikoski S, et al. 1989. Human seminal plasma cadmium: Comparison with
fertility and smoking habits. Andrologia 21:140-145.
Sakata S, Iwami K, Enoki Y, et al. 1988. Effects of cadmium on in vitro and in vivo erythropoiesis:
Erythroid progenitor cells (CFU-E) iron, and erythropoietin in cadmium-induced iron deficiency anemia.
Exp Hematol 16:581-587.
Saleh AI, Remail SW, Milad FM. 1993. Determination of cadmium in water samples by co-precipitation
and neutron activation analysis. J Radioanal Nucl Chem 168:23-27.
*Salovsky P, Shopova V, Dancheva V, et al. 1992. Changes in antioxidant lung protection after single
intratracheal cadmium acetate instillation in rats. Human Exp Toxicol 11:217-232.
CADMIUM 408
9. REFERENCES
Salpietro CD, Gangemi S, Minciullo PL, et al. 2002. Cadmium concentration in maternal and cord blood
and infant birth weight: A study in healthy non-smoking women. J Perinat Med 30 (5):395-399.
*Sanders CL, Mahaffey JA. 1984. Carcinogenicity of single and multiple intratracheal instillations of
cadmium oxide in the rat. Environ Res 33:227-233.
Saplakoglu U, Iscan M. 1998. Sister chromatid exchanges in human lymphocytes treated in vitro with
cadmium in Go and S phase of their cell cycles. Mutat Res 412:109-114.
Saplakoglu U, Iscan M, Iscan M. 1997. DNA single-strand breakage in rat lung, liver and kidney after
single and combined treatments of nickel and cadmium. Mutat Res 394(1-3):133-140.
*Sarhan MJ, Roels H, Lauwerys R, et al. 1986. Influence of manganese on the gastrointestinal
absorption of cadmium in rats. J Appl Toxicol 6:313-316.
Sasser LB, Jarboe GE. 1977. Intestinal absorption and retention of cadmium in neonatal rat. Toxicol
Sasser LB, Jarboe GE. 1980. Intestine absorption and retention of cadmium in neonatal pigs compared to
rats and guinea pigs. J Nutr 110:1641-1647.
Satarug S, Nishijo M, Ujjin P, et al. 2005. Cadmium-induced nephropathy in the development of high
blood pressure. Toxicol Lett 157(1):57-68.
Sato K, Iwamasa T, Tsuru T, et al. 1978. An ultrastructural study of chronic cadmium chloride induced
neuropathy. Acta Neuropathol 41:185-190.
Sato R, Kido T, Honda R, et al. 2010. Seventeen-year observation on urinary cadmium and
β2-microglobulin in inhabitants after cessation of cadmium-exposure in Japan. Bull Environ Contam
Toxicol 84(4):363-367.
Satzger RD, Bonnin E, Fricke FL. 1984. Development of a quality assurance program for determination
of ultratrace background levels and cadmium in raw agricultural crops by differential pulse anodic
stripping voltammetry. J Assoc Off Anal Chem 67:1138-1140.
Satzger RD, Clow CS, Bonnin E, et al. 1982. Determination of background levels of lead and cadmium
in raw agricultural crops by using differential pulse anodic stripping voltammetry. J Assoc Off Anal
Chem 65:987-991.
Saxena DK, Murthy RC, Chandra SV. 1986. Embryotoxic and teratogenic effects of interaction of
cadmium and lindane in rats. Acta Pharmacol Toxicol 59:175-178.
Saxena DK, Murthy RC, Singh C, et al. 1989. Zinc protects testicular injury induced by concurrent
exposure to cadmium and lead in rats. Res Commun Chem Pathol Pharmacol 64:317-329.
Schafer L, Andersen O, Nielsen JB. 1986. Effects of dietary factors on gastrointestinal Cd absorption in
mice. Acta Pharmacol Toxicol (Copenh) 59(Suppl 7):549-552.
CADMIUM 409
9. REFERENCES
Schafer SG, Schwegler U, Schumann K. 1990. Retention of cadmium in cadmium-naive normal and
iron-deficient rats as well as in cadmium-induced iron-deficient animals. Ecotoxicol Environ Saf
20:71-81.
Schiestl RH, Gietz RD, Mehta RD, et al. 1989. Carcinogens induce introchromosomal recombination in
yeast. Carcinogenesis 10:1445-1455.
Schmitt CJ, Brumbaugh WG. 1990. National contaminant biomonitoring program: Concentrations of
arsenic, cadmium, copper, lead, mercury, selenium, and zinc in U.S. freshwater fish, 1976-1984. Arch
Environ Contam Toxicol 19:731-747.
Schroeder HA, Mitchener M. 1971. Toxic effects of trace elements on the reproduction of mice and rats.
Arch Environ Health 23:102-106.
Schroeder HA, Balassa JJ, Vinton WH. 1964. Chromium, lead, cadmium, nickel, and titanium in mice:
Effect on mortality, tumors, and tissue levels. J Nutr 83:239-250.
Schroeder HA, Balassa JJ, Vinton WH. 1965. Chromium, cadmium, and lead in rats: Effects on life
span, tumors, and tissue levels. J Nutr 86:51-66.
*Schuhmacher M, Bosque MA, Domingo JL, et al. 1994. Effects of chronic lead and cadmium exposure
on blood pressure in occupationally exposed workers. Biol Trace Elem Res 41:269-278.
Schulte-Lobbert FJ, Bohn G. 1977. Determination of cadmium in human milk during lactation. Arch
Toxicol 37:155-157.
Schulte-Schrepping KH, Piscator M. 2002. Cadmium and cadmium compounds. Ullmann's

encyclopedia of industrial chemistry. Wiley-VCH Verlag GmbH & Co. KGaA.
http://www.mrw.interscience.wiley.com/emrw/9783527306732/ueic/article/a04_499/current/pdf. April
29, 2008.
Schutte R, Nawrot TS, Richart T, et al. 2008. Bone resorption and environmental exposure to cadmium
in women: A population study. Environ Health Perspect 116:777-783.
Schwartz GG, Il'yasova D, Ivanova A. 2003. Urinary cadmium, impaired fasting glucose, and diabetes
in the NHANES III. Diabetes Care 26(2):468-470.
Scott MC, Chettle DR. 1986. In vivo elemental analysis in occupational medicine. Scand J Work
Scott R, Haywood JK, Boddy K, et al. 1980. Whole body calcium deficit in cadmium-exposed workers
with hypercalciuria. Urology 15:356-359.
Scott R, Patterson PJ, Burns R, et al. 1978. Hypercalciuria related to cadmium exposure. Urology
11:462-465.
Seidal K, Jörgensen N, Elinder C. 1993. Fatal cadmium induced pneumonitis. Scand J Work Environ
Health 19:429-431.
Selypes A, Serenyi P, Boldog I, et al. 1992. Acute and ‘long term’ genotoxic effects of CdC12 on testes
of mice. J Toxicol Environ Health 36(4):401-409.
CADMIUM 410
9. REFERENCES
Sendelbach LE, Klaassen CD. 1988. Kidney synthesizes less metallothionein than liver in response to
cadmium chloride and cadmium-metallothionein. Toxicol Appl Pharmacol 92:95-102.
Seoane AI, Dulout FN. 2001. Genotoxic ability of cadmium, chromium and nickel salts studied by
kinetochore staining in the cytokinesis-blocked micronucleus assay. Mutat Res 490(2):99-106.
Setchell BP, Waites GMH. 1975. The blood-testis barrier. In: Creep RO, Astwood EB, Geiger SR, eds.
Handbook of physiology: Endocrinology V. Washington, DC: American Physiological Society, 143-
172.
Shaham J, Rosenboim J, Ophire D, et al. 1993. The correlation between blood and urine level of
cadmium and nasal and paranasal sinuses disorders. Int Arch Occup Environ Health 65:S91-S93.
Shaikh ZA. 1982. Metallothionein as a storage protein for cadmium: Its toxicological implications. Dev
Toxicol Environ Sci 9:69-76.
Shaikh ZA, Smith JC. 1976. The biosynthesis of metallothionein rat liver and kidney after
administration of cadmium. Chem Biol Interact 15:327-336.
Shaikh ZA, Smith JC. 1980. Metabolism of orally ingested cadmium in humans. In: Holmstedt B,
Lauwerys R, Mercier M, et al., eds. Mechanisms of toxicity and hazard evaluation. New York, NY:
Elservier/North-Holland Biomedical Press, 569-574.
Shaikh ZA, Smith LM. 1984. Biological indicators of cadmium exposure and toxicity. Experientia
40:36-43.
Shaikh ZA, Tang W. 1999. Protection against chronic cadmium toxicity by glycine. Toxicology
132(2-3):93-103.
Shaikh ZA, Harnett KM, Perlin SA, et al. 1989. Chronic cadmium intake results in dose-related
excretion of metallothionein in urine. Experientia 45:146-148.
Shaikh ZA, Jordan SA, Tang W. 1999a. Protection against chronic cadmium toxicity by calorie
restriction. Toxicology 133:93-103.
Shaikh ZA, Jordan SA, Tewari PC. 1993. Cadmium disposition and methallothionein induction in mice:
Strain, sex, age, and dose dependent differences. Toxicology 80:51-70.
Shaikh ZA, Tohyama C, Noland CV. 1987. Occupational exposure to cadmium: Effect on
metallothionein and other biological indices of exposure and renal function. Arch Toxicol 59:360-364.
Shaikh ZA, Vu TI, Zaman K. 1999b. Oxidative stress as a mechanism of chronic cadmium-induced
hepatoxicity and renal toxicity and protection by antioxidants. Toxicol Appl Pharmacol 154:256-263.
Shaikh ZA, Zaman K, Tang W, et al. 1999c. Treatment of chronic cadmium nephrotoxicity by N-acetyl
cystine. Toxicol Lett 104(1-2):137-142.
Shanbaky MM. 1973. A radiotracer distribution study of repeated administration of cadmium in the
Albino rat. M.S. Thesis, Purdue University.
CADMIUM 411
9. REFERENCES
Shank KE, Vetter RJ, Ziemer PL. 1977. A mathematical model of cadmium transport in a biological
system. Environ Res 13:209-214.
Sharma RP, Kjellström T, McKenzie JM. 1983. Cadmium in blood and urine among smokers and
nonsmokers with high cadmium intake via food. Toxicology 29:163-171.
Sharma RP, McKenzie JM, Kjellström T. 1982. Analysis of submicrogramme levels of cadmium in
whole blood, urine, and hair by graphite furnace atomic absorption spectroscopy. J Anal Toxicol
6:135-138.
Sharon IM. 1988. The significance of teeth in pollution detection. Perspect Biol Med 32:124-131.
Shevchenko V, Lisitzin A, Vinogradova A, et al. 2003. Heavy metals in aerosols over the seas of the
Russian Arctic. Sci Total Environ 306:11-25.
Shigematsu I. 1984. The epidemiological approach to cadmium pollution in Japan. Ann Acad Med
Singapore. 13:231-236.
Shimbo S, Zhang Z, Moon C, et al. 2000. Correlation between urine and blood concentrations, and
dietary intake of cadmium and lead among women in the general population of Japan. Int Arch Occup
Shimizu M, Morita S. 1990. Effects of fasting on cadmium toxicity, glutathione metabolism, and
metallothionein synthesis in rats. Toxicol Appl Pharmacol 103:28-39.
Shimizu A, Kobayashi E, Suwazono Y, et al. 2006. Estimation of benchmark doses for urinary cadmium
based on β2 -microglobulin excretion in cadmium-polluted regions of the Kakehashi River basin, Japan.
Int J Environ Health Res 16(5):329-337.
Shin M, Paek D, Yoon C. 2011. The relationship between the bone mineral density and urinary
cadmium concentration of residents in an industrial complex. Environ Res 111(1):101-109.
Shipman DL. 1986. Cadmium food poisoning in a Missouri school. J Environ Health 49:89.
Shiraishi Y, Yoshida TH. 1972. Chromosomal abnormalities in cultured beucocyte cells from Itai-itai
disease patients. Proc Japan Acad 48:248-251.
Shiraishi Y, Kurahashi H, Yoshida TH. 1972. Chromosomal aberrations in cultured human leucocytes
induced by cadmium sulfide. Proc Japan Acad 48:133-137.
Shiwen C, Lin Y, Zhineng H, et al. 1990. Cadmium exposure and health effects among residents in an
irrigation area with ore dressing wastewater. Sci Total Environ 90:67-73.
*Shukla GS, Hussain T, Srivastava RS, et al. 1988a. Diagnostic significance of erythrocyte antioxidative
enzymes in cadmium toxicity. Biochem Arch 4:429-436.
Sidhu M, Sharma M, Bhatia M, et al. 1993. Effect of chronic cadmium exposure on glutathione S-
transferase and glutathione peroxidase activities in Rhesus monkey the role of selenium. Toxicology
83:203-213.
CADMIUM 412
9. REFERENCES
SI/EPA. 2007. Cadmium. The Science Inventory. U.S. Environmental Protection Agency.
http://cfpub.epa.gov/si/sciencequery.cfm. April 23, 2008.
Sikorski R, Paszkowski T, Radomanski T, et al. 1989. Cadmium contamination of early human milk.
Gynecol Obstet Invest 27:91-93.
Sileo L, Beyer WN. 1985. Heavy metals in white-tailed deer living near a zinc smelter in Pennsylvania.
J Wildlife Diseases 21:289-296.
*Simmer K, Carlsson L, Thompson RPH. 1992. The effects of cadmium on zinc in the pregnant guinea
pig. Trace Elem Med 9(3):109-112.
Singh BR. 1994. Trace element availability to plants in agricultural soils, with special emphasis on
fertilizer inputs. Environ Rev 2:133-146.
Singh PK, Jones MM, Kostial K, et al. 1996. In vivo cadmium mobilization by three novel bis
(carbodithioates). Chem Res Toxicol 9(1):313-317.
*Singh PK, Jones SG, Gale GR, et al. 1990. Selective removal of cadmium from aged hepatic and renal
deposits: N-substituted talooctamine dithiocarbamates as cadmium mobilizing agents. Chem Biol
Interact 74:79-91.
Skerfving S, Nilsson U. 1992. Assessment of accumulated body burden of metals. Toxicol Lett
64/65:17-24.
Skog E, Wahlberg JE. 1964. A comparative investigation of the percutaneous absorption of metal
compounds in the guinea pig by means of the radioactive isotopes: 51Cr, 58Co, 65Zn, 110mAg,
115mCd, 203Hg. J Invest Dermatol 43:187-192.
Smith JP, Smith JC, McCall AJ. 1960. Chronic poisoning from cadmium fume. J Pathol Bacteriol
80:287-296.
*Smith NJ, Topping MD, Stewart JD, et al. 1986. Occupational cadmium exposure in jig solderers. Br J
Ind Med 43:663-666.
Smith SR. 1994. Effect of soil pH on availability to crops of metals in sewage sludge-treated soils. II.
Cadmium uptake by crops and implications for human dietary intake. Environ Pollut 86:5-13.
Smith TJ, Anderson RJ, Reading JC. 1980. Chronic cadmium exposures associated with kidney function
effects. Am J Ind Med 1:319-337.
Smith TJ, Petty TL, Reading JC, et al. 1976. Pulmonary effects of chronic exposure to airborne
cadmium. Am Rev Resp Dis 114:161-169.
Snider GL, Hayes JA, Korthy AL, et al. 1973. Centrilobular emphysema experimentally induced by
cadmium chloride aerosol. Am Rev Resp Dis 108:40-48.
*Snider GL, Lucey EC, Faris B, et al. 1988. Cadmium-chloride-induced air-space enlargement with
interstitial pulmonary fibrosis is not associated with destruction of lung elastin. Implications for the
pathogenesis of human emphysema. Am Rev Respir Dis 137:918-923.
CADMIUM 413
9. REFERENCES
Sorahan T. 1987. Mortality from lung cancer among a cohort of nickel cadmium battery workers: 1946-
1984. Br J Ind Med 44:803-809.
Sorahan T, Esmen NA. 2004. Lung cancer mortality in UK nickel-cadmium battery workers, 1947-2000.
Occup Environ Med 61(2):108-116.
Sorahan T, Lancashire R. 1994. Lung cancer findings from the NIOSH study of United States cadmium
recovery workers: A cautionary note. Occup Environ Med 51(2):139-140.
Sorahan T, Lancashire RJ. 1997. Lung cancer mortality in a cohort of workers employed at a cadmium
recovery plant in the United States: An analysis with detailed job histories. Occup Environ Med
54(3):194-201.
Sorahan T, Waterhouse JAH. 1983. Mortality study of nickel-cadmium battery workers by the method
of regression models in life tables. Br J Ind Med 40:293-300.
*Sorahan T, Waterhouse JAH. 1985. Cancer of prostate among nickel-cadmium battery workers. Lancet
1(8426):459.
Sorahan T, Lister A, Gilthorpe MS, et al. 1995. Mortality of copper cadmium alloy workers with special
reference to lung cancer and non-malignant diseases of the respiratory system, 1946-92. Occup Environ
Med 52(12):804-12.
Sorell TL, Graziano JH. 1990. Effect of oral cadmium exposure during pregnancy on maternal and fetal
zinc metabolism in the rat. Toxicol Appl Pharmacol 102:537-545.
Sporn A, Dinu I, Stoenescu L. 1970. Influence of cadmium administration on carbohydrate and cellular
energetic metabolism in the rat liver. Rev Roum Biochim 7:299-305.
Sprague JB. 1986. Toxicity and tissue concentrations of lead, zinc, and cadmium for marine molluscs
and crustaceans. Research Triangle Park, NC: International Lead Zinc Research Organization, Inc., 1-74.
Squibb KS, Pritchard JB, Fowler BA. 1984. Cadmium-metallothionein nephropathy: Relationships
between ultrastructural/biochemical alterations and intracellular cadmium binding. J Pharmacol Exp Ther
229:311-321.
SRI. 2007. Directory of chemical producers. United States of America. Menlo Park, CA: SRI
Consulting, 503; 799-800.
*Srivastava RC, Ahmad I, Kaur G, et al. 1988. Alterations in the metabolism of endogenous trace metals
due to cadmium, manganese and nickel effect of partial hepatectomy. J Environ Sci Health A23:95-101.
Stacey NH, Craig G, Muller L. 1988. Effects of cadmium on natural killer and killer cell functions in
vivo. Environ Res 45:71-77.
Staessen J, Bulpitt CJ, Roels H, et al. 1984. Urinary cadmium and lead and their relationship to blood
pressure in a population with low average exposure. Br J Ind Med 4:241-248.
Staessen J, Kuznetsova T, Roels HA, et al. 2000. Exposure to cadmium and conventional and
ambulatory blood pressures in a prospective population study. Am J Hypertens 13(2):146-156.
CADMIUM 414
9. REFERENCES
Staessen J, Lauwerys R. 1993. Health effects of environmental exposure to cadmium in a population

study. J Hum Hypertens 7:195-199.
Staessen JA, Roels HA, Emelianov D, et al. 1999. Environmental exposure to cadmium, forearm bone
density, and risk of fractures: Prospective population study. Lancet 353(9159):1140-1144.
Stayner L, Smith R, Schorr T, et al. 1993. Letter to the editor. Ann Epidemiol 3(1):114-116.
Stayner L, Smith R, Thun M, et al. 1992a. A dose-response analysis and quantitative assessment of lung
cancer risk and occupational cadmium exposure. Ann Epidemiol 2(3):177-194.
*Stayner L, Smith R, Thun M, et al. 1992b. A quantitative assessment of lung cancer risk and
occupational cadmium exposure. In: Nordberg GF, Herber RFM, Alessio L, eds. Cadmium in the
human environment: Toxicity and carcinogenicity. Lyon, France: International Agency for Research on
Cancer, 447-455.
Steenkamp PA, Coetzee PP. 1994. Simultaneous determination of toxic heavy metals in organic
matrices using reversed-phase high-performance liquid chromatography. S Afr J Chem 47(1):29-32.
Steibert E, Krol B, Sowa B, et al. 1984. Cadmium-induced changes in the histoenzymatic activity in
liver, kidney and duodenum of pregnant rats. Toxicol Lett 20:127-132.
Steinnes E, Friedland AJ. 2006. Metal contamination of natural surface soils from long-range
atmospheric transport: Existing and missing knowledge. Environ Rev 14:169-186.
Stowe HD, Wilson M, Goyer RA. 1972. Clinical and morphological effects of oral cadmium toxicity in
rabbits. Arch Pathol 94:389-405.
Stroh A. 1993. Determination of Pb and Cd in whole blood using isotope dilution ICP-MS. Atom
Spectrosc 14(5):141-143.
Struempler RE, Larson GE, Rimland B. 1985. Hair mineral analysis and disruptive behavior in clinically
normal young men. J Learn Disabil 18:609-612.
Stutz DR, Janusz SJ. 1988. Hazardous materials injuries: A handbook for pre-hospital care. 2nd
edition. Beltsville, MD: Bradford Communications Corporation, 21, 228-229.
Subramanian KS, Meranger JC. 1981. A rapid electrothermal atomic absorption spectrophotometric
method for cadmium and lead in human whole blood. Clin Chem 27:1866-1871.
Subramanian KS, Meranger JC, MacKeen JE. 1983. Graphite furnace atomic absorption spectrometry
with matrix modification for determination of cadmium and lead in human urine. Anal Chem
55:1064-1067.
*Sugawara N, Sugawara C. 1987. Role of mucosal metallothinein preinduced by oral Cd or Zn on the

intestinal absorption of a subsequent Cd dose. Bull Environ Contam Toxicol 38:295-299.
Sumino K, Hayakawa K, Shibata T, et al. 1975. Heavy metals in normal Japanese tissues. Arch Environ
Health 30:487-494.
CADMIUM 415
9. REFERENCES
Suresh A, Sivaramakrishna B, Radhakrishnaiah K. 1993. Patterns of cadmium accumulation in the

organs of fry and fingerlings of freshwater fish Cyprinus carpio following cadmium exposure.
Chemosphere 26(5):945-953.
Suter KE. 1975. Studies on the dominant-lethal and fertility effects of the heavy metal compounds
methylmercuric hydroxide, mercuric chloride, and cadmium chloride in male and female mice. Mutat
Res 30:365-374.
Sutou S, Yamamoto K, Sendota H, et al. 1980. Toxicity, fertility, teratogenicity, and dominant lethal
tests in rats administered cadmium subchronically. III. Fertility, teratogenicity, and dominant lethal tests.
Ecotoxicol Environ Saf 4:51-56.
Suwazono Y, Kobayashi E, Okubo Y, et al. 2000. Renal effects of cadmium exposure in cadmium
nonpolluted areas in Japan. Environ Res 84(Sect A):44-55.
Suwazono Y, Nogawa K, Uetani M, et al. 2011a. Application of the hybrid approach for estimating the
benchmark dose of urinary cadmium for adverse renal effects in the general population of Japan. J Appl
Toxicol 31(1):89-93.
Suwazono Y, Nogawa K, Uetani M, et al. 2011b. Application of the hybrid approach to the benchmark
dose of urinary cadmium as the reference level for renal effects in cadmium polluted and non-polluted
areas in Japan. Environ Res 111(2):312-314.
Suwazono Y, Nogawa K, Uetani M, et al. 2011c. Reassessment of the threshold of urinary cadmium by
using hybrid approach in a cadmium non-polluted area in Japan. Int J Hyg Environ Health 214(2):175-
178.
Suwazono Y, Saloman S, Vahter M, et al. 2006. Benchmark dose for cadmium-induced renal effects in
humans. Environ Health Perspect 114:1072-1076.
Suwazono Y, Uetani M, Akesson A, et al. 2010. Recent applications of benchmark dose method for
estimation of reference cadmium exposure for renal effects in man. Toxicol Lett 198(1):40-43.
Suzuki CAM, Cherian MG. 1987. Renal toxicity of cadmium-metallothionein and enzymuria in rats. J
Pharmacol Exp Ther 240:314-319.
Swaddiwudhipong, W; Mahasakpan, P; Limpatanachote, P; et al. 2010. Correlations of urinary cadmium

with hypertension and diabetes in persons living in cadmium-contaminated villages in northwestern
Thailand: A population study. Environ Res 110(6):612-616.
Swaddiwudhipong, W; Mahasakpan, P; Limpatanachote, P; et al. 2011. An association between urinary

cadmium and urinary stone disease in persons living in cadmium-contaminated villages in northwestern
Thailand: A population study. Environ Res 111(4):579-583.
Sweet CW, Vermette SJ, Landsberger S. 1993. Sources of toxic trace elements in urban air in Illinois.
Environ Sci Technol 27(12):2502-2510.
Sweet CW, Weiss A, Vermette SJ. 1998. Atmospheric deposition of trace metals at three sites near the
Great Lakes. Water Air Soil Pollut 103:423-439.
CADMIUM 416
9. REFERENCES
Swiergosz-Kowalewska R. 2001. Cadmium distribution and toxicity in tissues of small rodents.

Microsc Res Tech 55(3):208-222.
*Szymanska JA, Bem EM, Piotrowski JK, et al. 1989. Renal binding of cadmium in the rat following
intragastric exposure. Toxicology 55:339-348.
Takagi Y, Matsuda S, Imai S, et al. 1988. Survey of trace elements in human nails: An international
comparison. Bull Environ Contam Toxicol 41:690-695.
*Takebayashi S, Harada T, Kamura S, et al. 1987. Cadmium-induced osteopathy: Clinical and autopsy
findings of four patients. Appl Pathol 5:190-197.
Takenaka S, Karg E, Kreyling WG, et al. 2004. Fate and toxic effects of inhaled ultrafine cadmium
oxide particles in the rat lung. Inhal Toxicol 16:83-92.
Takenaka S, Oldiges H, Konig H, et al. 1983. Carcinogenicity of cadmium chloride aerosols in Wistar
rats. J Natl Cancer Inst 70:367-373.
Tandon L, Ni BF, Ding XX, et al. 1994. RNAA for arsenic, cadmium, copper, and molybdenum in CNS
tissues from subjects with age related neurodegenerative disease. J Radionanal Nucl Chem 179(2):331-
339.
Tang XM, Chen XQ, Zhang JX, et al. 1990. Cytogenetic investigation in lymphocytes of people living
in cadmium-polluted areas. Mutat Res 241:243-249.
Teeyakasem W, Nishijo M, Honda R, et al. 2007. Monitoring of cadmium toxicity in a Thai population
with high-level environmental exposure. Toxicol Lett 169:185-195.
Telišman S, Cvitkovic P, Jurasovic J, et al. 2000. Semen quality and reproductive endocrine function in
relation to biomarkers of lead, cadmium, zinc, and copper in men. Environ Health Perspect 108:45-53.
Tellez-Plaza M, Navas-Acien A, Crainiceanu CM, et al. 2008. Cadmium exposure and hypertension in
the 1999-2004 National Health and Nutrition Examination Survey (NHANES). Environ Health Perspect
116(1):51-56.
Tellez-Plaza, M; Navas-Acien, A; Crainiceanu, CM; et al. 2010. Cadmium and peripheral arterial
disease: Gender differences in the 1999-2004 US National Health and Nutrition Examination Survey.
Am J Epidemiol 172(6):671-681.
Terracio L, Nachtigal M. 1988. Oncogenicity of rat prostate cells transformed in vitro with cadmium
chloride. Arch Toxicol 61:450-456.
Tewari PC, Jain VK, Ashquin M, et al. 1986b. Influence of protein deficiency on cadmium toxicity in
rats. Arch Environ Contam Toxicol 15:409-415.
Thatcher RW, Lester ML, McAlaster R, et al. 1982. Effects of low levels of cadmium in lead on
cognitive functioning in children. Arch Environ Health 37:159-166.
Thomas K, Colborn T. 1992. Organochlorine endocrine disruptors in human tissue. In: Colborn T,
Clement C, eds. Chemically induced alterations in sexual and functional development: The
wildlife/human connection. Princeton, NJ: Princeton Scientific Publishing, 365-394.
CADMIUM 417
9. REFERENCES
Thomas, LD; Hodgson, S; Nieuwenhuijsen, M; et al. 2009. Early kidney damage in a population
exposed to cadmium and other heavy metals. Environ Health Perspect 117(2):181-184.
Thornton I. 1992. Sources and pathways of cadmium in the environment. In: Nordberg GF, Herber
RFM, Alessio L, eds. Cadmium in the human environment: Toxicity and carcinogenicity. IARC
Scientific Publications No. 118. Lyon, France: International Agency for Research on Cancer, 149-162.
Thun MJ, Osorio AM, Schober S, et al. 1989. Nephropathy in cadmium workers: Assessment of risk
from airborne occupational exposure to cadmium. Br J Ind Med 46:689-697.
Thun MJ, Schnorr TM, Smith A, et al. 1985. Mortality among a cohort of U.S. cadmium production
workers--an update. J Natl Cancer Inst 74:325-333.
Toffoletto F, Apostoli P, Ghezzi I, et al. 1992. Ten-year follow-up of biological monitoring of cadmium-
exposed workers. In: Nordgerg GF, Herber RFM, Alessio L, eds. Cadmium in the human environment:
Toxicity and carcinogenicity. Geneva: International Agency for Research on Cancer, 107-111
Tohyama C, Kobayashi E, Saito H, et al. 1986. Urinary microglobulin as an indicator protein or renal
tubular dysfunction caused by environmental cadmium exposure. J Appl Toxicol 6:171-178.
Tohyama C, Mitane Y, Kobayashi E, et al. 1988. The relationships of urinary metallothionein with other
indicators of renal dysfunction in people living in a cadmium-polluted area in Japan. J Appl Toxicol
8:15-21.
Tohyama C, Shaikh ZA, Ellis KJ, et al. 1981. Metallothionein excretion in urine upon cadmium
exposure: Its relationship with liver and kidney cadmium. Toxicology 22:181-191.
Tomera JF, Harakal C. 1988. Effects of cadmium ingestion on blood pressure and ventricular mass in
rabbits. Drug Nutr Interact 5:365-72.
Topping MD, Forster HW, Dolman C, et al. 1986. Measurement of urinary retinol-binding protein by
enzyme-linked immunosorbent assay, and its application to detection of tubular proteinuria. Clin Chem
32:1863-1866.
Townshend RH. 1982. Acute cadmium pneumonitis: A 17-year follow-up. Br J Ind Med 39:411-412.
Trevisan A, Gardin C. 2005. Nephrolithiasis in a worker with cadmium exposure in the past. Int Arch
Occup Environ Health 78(8):670-672.
TRI09. 2011. TRI explorer: Providing access to EPA’s toxics release inventory data. Washington, DC:
Office of Information Analysis and Access. Office of Environmental Information. U.S. Environmental
Protection Agency. Toxics Release Inventory. http://www.epa.gov/triexplorer/. September 19, 2011.
Truska P, Rosival L, Balazova G, et al. 1989. Blood and placental concentrations of cadmium, lead, and
mercury in mothers and their newborns. J Hyg Epidemiol Microbiol Immunol 33:141-147.
Trzcinka-Ochocka M, Jakubowski M, Halatek T, et al. 2002. Reversibility of microproteinuria in nickel-

cadmium battery workers after removal from exposure. Int Arch Occup Environ Health
75(Suppl):S101-S106.
CADMIUM 418
9. REFERENCES
Trzcinka-Ochocka M, Jakubowski M, Razniewska G, et al. 2004. The effects of environmental

cadmium exposure on kidney function: The possible influence of age. Environ Res 95(2):143-150.
Trzcinka-Ochocka, M; Jakubowski, M; Szymczak, W; et al. 2010. The effects of low environmental

cadmium exposure on bone density. Environ Res 110(3):286-293.
Tsukahara T, Ezaki T, Moriguchi J, et al. 2003. No significant effect of iron deficiency on cadmium
body burden or kidney dysfunction among women in the general population in Japan. Int Arch Occup
*Tsuritani I, Honda R, Ishizaki M, et al. 1994. Serum bone-type alkaline phosphatase activity in women
living in a cadmium-polluted area. Toxicol Lett 71:209-216.
Tsvetkova RP. 1970. [Materials on the study of the influence of cadmium compounds on the generative
function.] Gig Tr Prof Zabol 14:31-33. (Russian)
Tulley RT, Lehmann HP. 1982. Method for the simultaneous determination of cadmium and zinc in
whole blood by atomic absorption spectrophotometry and measurement in normotensive and hypertensive
humans. Clinica Chimica Acta 122:189-202.
UN. 1985. Treatment and disposal methods for waste chemicals. International Register of Potentially
Toxic Chemicals. Geneva, Switzerland: United Nations Environment Programme.
Uno T, Kobayashi E, Suwazono Y, et al. 2005. Health effects of cadmium exposure in the general
environment in Japan with special reference to the lower limit of the benchmark dose as the threshold
level of urinary cadmium. Scand J Work Environ Health 31(4):307-315.
U.S. Bureau of Mines. 1990. Mineral industry surveys. Cadmium in 1989. Washington, DC: U.S.
Bureau of Mines, 1-5.
USDA. 2012. Table 5. U.S. consumption of selected phosphate and potash fertilizers. Economic
research service. United States Department of Agriculture. http://www.ers.usda.gov/data-
products/fertilizer-use-and-price.aspx#26720. September 11, 2012.
USGS. 1985. Cadmium, atomic absorption spectrometric, direct. In: Fishman MJ, Friedman LC, eds.
Methods for the determination of inorganic substances in water and fluvial sediments, techniques of
water-resources investigations of the United States Geological Survey, Book 5, Chapter A1. U.S.
Geological Survey. infotrek.er.usgs.gov/pls/nemi_pdf/nemi_data.download_pdf?p_file=1333. May 14,
2008.
USGS. 1996. Methods of analysis by the U.S. Geological Survey National Water Quality Laboratory-
Preparation procedure for aquatic biological material determined for trace metals. Denver, CO: U.S.
Geological Survey. Open-File Report 96-362. http://pubs.er.usgs.gov/usgspubs/ofr/ofr96362. May 26,
2008.
USGS. 1997. Minerals yearbook: Cadmium. Reston, Virginia: U.S. Geological Survey.
USGS. 1998a. Methods of analysis by the U.S. Geological Survey National Water Quality Laboratory-
Determination of elements in whole-water digests using inductively coupled plasma-optical emission
spectrometry and inductively coupled plasma-mass spectrometry. Denver, CO: U.S. Geological Survey.
Open-File Report 98-165. http://pubs.er.usgs.gov/usgspubs/ofr/ofr98165. May 26, 2008.
CADMIUM 419
9. REFERENCES
USGS. 1998b. Water quality in the Hudson River basin. New York and adjacent states, 1992-1995.
U.S. Geological Survey. Circular 1165. http://ny.water.usgs.gov/projects/hdsn/report/Circular1165.pdf.
April 17, 2008.
USGS. 1999. Mineral commodity summary: Cadmium. Reston, Virginia: U.S. Geological Survey.
USGS. 2007. 2006 minerals yearbook. Cadmium. U.S. Geological Survey.

http://minerals.usgs.gov/minerals/pubs/commodity/cadmium/myb1-2006-cadmi.pdf. April 29, 2008.
USGS. 2008. Cadmium. Mineral commodity summaries. U.S. Geological Survey.

http://minerals.usgs.gov/minerals/pubs/commodity/cadmium/mcs-2008-cadmi.pdf. April 29, 2008.
Vahter M, Berglund M, Nermell B, et al. 1996. Bioavailability of cadmium from shellfish and mixed
diet in women. Toxicol Appl Pharmacol 136(2):332-341.
Valois AA, Webster WS. 1989. The choroid plexus as a target site for cadmium toxicity following
chronic exposure in the adult mouse: An ultrastructural study. Toxicology 55:193-205.
Valverde M, Fortoul TI, Diaz-Barriga F, et al. 2000. Induction of genotoxicity by cadmium chloride
inhalation in several organs of CD-1 mice. Mutagenesis 15(2):109-114.
Vanderpool RA, Reeves PG. 2001. Cadmium absorption in women fed processed edible sunflower
kernels labeled with a stable isotope of cadmium, 113Cd1. Environ Res 87:69-80.
Van Gestel CA, Adema DM, de Boer JL, et al. 1988. The influence of soil clean-up on the
bioavailability of metals. In: Wolf K, Van den Brink WJ, Colon FJ, eds. Contaminated soil '88. The
Netherlands: Kluser Academic Publishers, 63-66.
van Hattum B, de Voogt P, van den Bosch L, et al. 1989. Bioaccumulation of cadmium by the
freshwater isopod Asellus aquaticus (L.) from aqueous and dietary sources. Environ Pollut 62:129-152.
Vanhoe H, Dams R, Versieck J. 1994. Use of inductively coupled plasma mass spectrometry for the
determination of ultra-trace elements in human serum. J Anal Atom Spectrom 9:23-31.
van Sittert NJ, Ribbens PH, Huisman B, et al. 1993. A nine year follow-up study of renal effects in
workers exposed to cadmium in a zinc ore refinery. Br J Ind Med 50:603-612.
*Varga B, Zsolnai B, Paksy K, et al. 1993. Age dependent accumulation of cadmium in the human
ovary. Reprod Toxicol 7(3):225-228.
Vasudev V, Krishnamurthy NB. 1979. Dominant lethals induced by cadmium in Drosophila

melanogaster. Curr Sci 48:1007-1008.
Verschoor M, Herber R, van Hemmen, et al. 1987. Renal function of workers with low-level cadmium
exposure. Scand J Work Environ Health 13:232-238.
Vestergaard P, Shaikh ZA. 1994. The nephrotoxicity of intravenously administered cadmium-

metallothionein: Effect of dose, mode of administration, and preexisting renal cadmium burden. Toxicol
CADMIUM 420
9. REFERENCES
Viau C, Bernard A, Lauwerys R, et al. 1984. Cadmium compound analgesics, and the chronic
progressive nephrosis in the female Sprague-Dawley rat. Arch Toxicol 55:247-249.
Viccellio P. 1998. Cadmium, mercury, and arsenic. In: Emergency toxicology. 2nd ed. Philadelphia,
PA: Lippincott-Raven Publishers, 379-380.
Vidovic M, Sadibasic A, Cupic S, et al. 2005. Cd and Zn in atmospheric deposit, soil, wheat, and milk.
Vieira I, Sonnier M, Cresteil T. 1996. Developmental expression of CYP2E1 in the human liver:
Hypermethylation control of gene expression during the neonatal period. Eur J Biochem 238(2):476-483.
Vos G, Lammers H, Kan CA. 1990. Cadmium and lead in muscle tissue and organs of broilers, turkeys
and spent hens, and in mechanically deboned poultry meat. Food Addit Contam 7:83-92.
*Waalkes MP. 1986. Effect of dietary zinc deficiency on the accumulation of cadmium and
metallothionein and selected tissues of the rat. J Toxicol Environ Health 18:301-313.
Waalkes MP, Goering PL. 1990. Metallothionein and other cadmium-binding proteins: Recent
developments. Chem Res Toxicol 3:281-288.
Waalkes MP, Klaassen CD. 1985. Concentration of metallothionein in major organs of rats after
administration of various metals. Fundam Appl Toxicol 5:473-477.
Waalkes MP, Rehm S. 1992. Carcinogenicity or oral cadmium in the male Wistar (WF/NCr) rat: Effect
of chronic dietary zinc deficiency. Fundam Appl Toxicol 19:512-520.
Waalkes MP, Rehm S. 1994a. Chronic toxic and carcinogenic effects of cadmium chloride in male
DBA/2NCr and NFS/NCr mice: Strain dependent association with tumors of the hematopoietic system,
injection site, liver, and lung. Fundam Appl Toxicol 23:21-31.
Waalkes MP, Rehm S. 1994b. Carcinogenic and chronic toxic effects of single and multiple
subcutaneous doses of cadmium chloride in male BALB/c mice. Toxic Subst J 13:97-111.
Waalkes MP, Coogan TP, Barter RA. 1992. Toxicological principles of metal carcinogenesis with
special emphasis on cadmium. Crit Rev Toxicol 22(3,4):175-201.
Waalkes MP, Diwan BA, Weghorst CM, et al. 1993. Further evidence of the tumor suppressive effects
of cadmium in the B6C3F1 mouse liver and lung: Late stage vulnerability of tumors to cadmium and the
role of metallothionein. J Pharmacol Exp Ther 266(3):1656-1663.
Waalkes MP, Rehm S, Riggs CW, et al. 1989. Cadmium carcinogenesis in male Wistar [Crl:(WI)BR]
rats: Dose-response analysis of effects of zinc on tumor induction in the prostate, in the testes, and at the
injection site. Cancer Res 49:4282-4288.
Waalkes MP, Watkins JB, Klaassen CD. 1983. Minimal role of metallothionein in decreased chelator
efficacy for cadmium. Toxicol Appl Pharmacol 68:392-398.
*Wahba ZZ, Waalkes MP. 1990. Cadmium-induced route-specific alterations in essential trace element
homeostasis. Toxicol Lett 54:77-81.
CADMIUM 421
9. REFERENCES
Wahlberg JE, Boman A. 1979. Guinea pig maximization test method-cadmium chloride. Contact
Dermatitis 5:405.
Wahlberg JE. 1965. Percutaneous toxicity of metal compounds. Arch Environ Health 11:201-204.
Wahlberg JE. 1977. Routine patch testing with cadmium chloride. Contact Dermatitis 3:293-296.
Wang C, Bhattacharyya MH. 1993. Effect of cadmium on bone calcium and 45Ca in nonpregnant mice
on a calcium-deficient diet: evidence of direct effect of cadmium on bone. Toxicol Appl Pharmacol
120:228-239.
Wang XP, Foulkes EC. 1984. Specificity of acute effects of cadmium on renal function. Toxicology
30:243-247.
Wang C, Brown S, Bhattacharyya MH. 1994. Effect of cadmium on bone calcium and 45Ca in mouse
dams on a calcium-deficient diet: Evidence of itai-itai-like syndrome. Toxicol Appl Pharmacol
127:320-330.
Wang C, Fang Y, Peng S, et al. 1999. Synthesis of novel chelating agents and their effect on cadmium
decorporation. Chem Res Toxicol 12:331-334.
Wang H, Zhu G, Shi Y, et al. 2003. Influence of environmental cadmium exposure on forearm bone
density. J Bone Miner Res 18(3):553-560.
Watanabe M, Shiroishi K, Nishino H, et al. 1986. An experimental study on the long-term effect of
cadmium in mice fed cadmium-polluted rice with special reference to the effect of repeated reproductive
cycles. Environ Res 40:25-46.
Watanabe T, Endo A. 1982. Chromosome analysis of preimplantation embryos after cadmium

treatment of oocytes at meiosis. I. Environ Mutagen 4:563-567.
Watanabe T, Kasahara M, Nakatsuka H, et al. 1987. Cadmium and lead contents of cigarettes produced
in various areas of the world. Sci Total Environ 66:29-37.
*Watanabe T, Nakatsuka H, Seiji K, et al. 1989. Blood cadmium levels in the populations of Masan,
Korea, and Miyagi, Japan: An inter-regional comparison. Toxicol Lett 47:155-163.
Watanabe T, Shimada T, Endo A. 1979. Mutagenic effects of cadmium on mammalian occyte

chromosomes. Mutat Res 67:349-356.
Watanabe T, Shimbo S, Moon CS, et al. 1996. Cadmium contents in rice samples from various areas in
the world. Sci Total Environ 184(3):191-196.
Watanabe Y, Kobayashi E, Okubo Y, et al. 2002. Relationship between cadmium concentration in rice
and renal dysfunction in individual subjects of the Jinzu River basin determined using a logistic
regression analysis. Toxicology 172:93-101.
Webster WS. 1978. Cadmium-induced fetal growth retardation in the mouse. Arch Environ Health
33:36-42.
CADMIUM 422
9. REFERENCES
Weidenhamer JD, Miller J, Guinn D, et al. 2011. Bioavailability of cadmium in inexpensive jewelry.
Environ Health Perspect 119(7):1029-1033.
Weigel HJ, Jager HJ, Elmadfa I. 1984. Cadmium accumulation in rat organs after extended oral
administration with low concentrations of cadmium oxide. Arch Environ Contam Toxicol 13:279-287.
Welz B, Xu S, Sperling M. 1991. Flame atomic absorption spectrometric determination of cadmium,

cobalt, and nickel in biological samples using a flow injection system with on-line preconcentration by
co-precipitation without filtration. Appl Spectrosc 45(9):1433-1443.
Welz B, Yin X, Sperling M. 1992. Time-based and volume-based sampling for flow-injection on-line
sorbent extraction graphite furnace atomic absorption spectrometry. Anal Chim Acta 261:477-487.
West JR, Smith HW, Chasis H. 1948. Glomerular filtration rate, effective renal blood flow, and maximal
tubular excretory capacity in infancy. J Pediatr 32:10-18.
Wester RC, Maibach HI, Sedik L, et al. 1992. In vitro percutaneous absorption of cadmium from water
and soil into human skin. Fundam Appl Toxicol 19:1-5.
Whanger PD. 1992. Selenium in the treatment of heavy metal poisoning and chemical carcinogenesis. J
Trace Elem Electrolytes Health Dis 6:209-221.
Whelton BD, Bhattacharyya MH, Carnes BA, et al. 1988. Female reproduction and pup survival and
growth for mice fed a cadmium-containing purified diet through six consecutive rounds of gestation and
lactation. J Toxicol Environ Health 24:321-343.
WHO. 2000. Air quality guidelines. 2nd ed. Geneva, Switzerland: World Health Organization.
http://www.euro.who.int/Document/AIQ/AirQualRepMtg.pdf. March 08, 2006.
WHO. 2004. Guidelines for drinking-water quality. Vol. 1. Recommendations. 3rd ed. Geneva,
Switzerland: World Health Organization. http://www.who.int/water_sanitation_health/dwq/gdwq3/en/.
March 08, 2006.
Widdowson EM, Dickerson JWT. 1964. Chemical composition of the body. In: Comar CL, Bronner F,
eds. Mineral metabolism: An advanced treatise. Vol. II: The elements Part A. New York, NY:
Academic Press, 1-247.
Wilber GG, Smith L, Malanchuk JL. 1992. Emissions inventory of heavy metals and hydrophobic
organics in the Great Lakes basin. In: Schnoor JL, ed. Fate of pesticides and chemicals in the
environment. John Wiley and Sons, Inc., 27-50.
Wilhelm M, Eberwein G, Holzer J, et al. 2005. Human biomonitoring of cadmium and lead exposure of
child-mother pairs from Germany living in the vicinity of industrial sources (Hot Spot Study NRW). J
Trace Elem Med Biol 19:83-90.
Wilhelm M, Ohnesorge FK, Hotzel D. 1990. Cadmium, copper, lead, and zinc concentrations in human
scalp and pubic hair. Sci Total Environ 92:199-206.
Wills JH, Groblewski GE, Coulston F. 1981. Chronic and multigeneration toxicities of small
concentrations of cadmium in the diet of rats. Ecotoxicol Environ Saf 5:452-464.
CADMIUM 423
9. REFERENCES
Wilson RH, DeEds F, Cox AJ. 1941. Effects of continued cadmium feeding. J Pharmacol Exp Ther
71:222-235.
Wisniewska-Knypl JM, Jablonska J, Myslak Z. 1971. Binding of cadmium on metallothionein in man:

An analysis of a fatal poisoning by cadmium iodide. Arch Toxicol 28:46-55.
Woittiez JRW, Tangonan MD. 1992. Determination of Cd, Mo, Cr, and Co in biological materials by
RNAA. J Radioanal Nucl Chem 158(2):313-321.
Wong KL, Klaassen CD. 1980a. Tissue distribution and retention of cadmium in rats during postnatal
development: minimal role of hepatic metallothionein. Toxicol Appl Pharmacol 53:343-353.
*Wong KL, Klaassen CD. 1980b. Age difference in the susceptibility to cadmium-induced testicular
damage in rats. Toxicol Appl Pharmacol 55:456-466.
Wong KL, Klaassen CD. 1982. Neurotoxic effect of cadmium in young rats. Toxicol Appl Pharmacol
63:330-337.
Wong PK. 1988. Mutagenicity of heavy metals. Bull Environ Contam Toxicol 40(4):597-603.
Wronska-Nofer T, Wisniewska-Knypl J, Wyszynska K. 1999. Prooxidative and genotoxic effect of

transition metals (cadmium, nickel, chromium, and vanadium) in mice. Trace Elem Electrolytes
15(2):87-92.
Wu Q, Magnus JH, Hentz JG. 2010. Urinary cadmium, osteopenia, and osteoporosis in the US
population. Osteoporos Int 21(8):1449-1454.
Wu X, Jin T, Wang Z, et al. 2001. Urinary calcium as a biomarker of renal dysfunction in a general
population exposed to cadmium. J Occup Environ Med 43(10):898-904.
Wu X, Liang Y, Jin T, et al. 2008. Renal effects evolution in a Chinese population after reduction of
cadmium exposure in rice. Environ Res 108(2):233-238.
Xu B, Chia SE, Tsakok M, et al. 1993a. Trace elements blood and seminal plasma and their relationship
to sperm quality. Reprod Toxicol 7:613-618.
Xu B, Jin Y, Fen Z, et al. 1993b. Lipid peroxidation induced by maternal cadmium exposure in mouse
pups. Bull Environ Contam Toxicol 51:772-779.
Xu C, Holscher MA, Jones MM, et al. 1995. Effect of monoisoamyl meso-2,3-dimercaptosuccinate on

the pathology of acute cadmium intoxication. J Toxicol Environ Health 45:261-277.
Xu C, Johnson JE, Singh PK, et al. 1996. In vivo studies of cadmium-induced apoptosis in testicular
tissue of the rat and its modulation by a chelating agent. Toxicology 107:1-8.
Xue H, Sigg L, Gachter R. 2000. Transport of Cu, Zn and Cd in a small agricultural catchment. Water
Res 34(9):2558-2568.
Yamanaka O, Kobayashi EN K, Suwazono Y, et al. 1998. Association between renal effects and
cadmium exposure in cadmium-nonpolluted area in Japan. Environ Res 77(Sect A):1-8.
CADMIUM 424
9. REFERENCES
Yamane Y, Fukuchi M, Li CK, et al. 1990. Protective effect of sodium molybdate against the acute
toxicity of cadmium chloride. Toxicology 60:235-243.
Yokota H, Tonami H. 2008. Experimental studies on the bone metabolism of male rats chronically
exposed to cadmium intoxication using dual-energy X-ray absorptiometry. Toxicol Ind Health 24(3):161-
170.
Zeng X, Jin T, Buchet JP, et al. 2004a. Impact of cadmium exposure on male sex hormones: A
population-based study in China. Environ Res 2004:338-344.
Zeng X, Jin T, Jiang X, et al. 2004b. Effects on the prostrate of environmental cadmium exposure–a
cross-sectional population study in China. Biometals 17(5):559-565.
Zenick H, Hastings L, Goldsmith M, et al. 1982. Chronic cadmium exposure: Relation to male
reproductive toxicity and subsequent fetal outcome. J Toxicol Environ Health 9:377-387.
Zhang YL, Zhao YC, Wang JX, et al. 2004. Effect of environmental exposure to cadmium on pregnancy
outcome and fetal growth: A study on healthy pregnant women in China. J Environ Sci Health A
39(9):2507-2515.
Zhang ZQ, Chen SZ, Lin HM, et al. 1993. Simultaneous determination of copper, nickel, lead, cobalt
and cadmium by adsorptive voltammetry. Anal Chim Acta 272:227-232.
*Zhou D, Zhang L, Zhou J, et al. 2004a. Cellulose/chitin beads for adsorption of heavy metals in
aqueous solution. Water Res 38:2643-2650.
Zhou T, Jia X, Chapin RE, et al. 2004b. Cadmium at a non-toxic dose alters gene expression in mouse
testes. Toxicol Lett 154(3):191-200.
Zhu G, Wang H, Shi Y, et al. 2004. Environmental cadmium exposure and forearm bone density.
Biometals 17:499-503.
Ziegler EE, Edwards BB, Jensen RL, et al. 1978. Absorption and retention of lead by infants. Pediatr
Res 12(1):29-34.
CADMIUM 425
10. GLOSSARY
Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the

Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase)
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a
specified magnitude of changes in a specified adverse response. For example, a BMD10 would be the
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be
10%. The BMD is determined by modeling the dose response curve in the region of the dose response
relationship where biologically observable data are feasible.
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms

at a specific time or during a discrete time period of exposure divided by the concentration in the
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces
significant increases in the incidence of cancer (or tumors) between the exposed population and its
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study—A type of epidemiological study that examines the relationship between a
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic
chemicals). In a case-controlled study, a group of people with a specified and well-defined outcome is
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure. These may suggest
some potential topics for scientific research, but are not actual research studies.
Case Series—Describes the experience of a small number of individuals with the same disease or
exposure. These may suggest potential topics for scientific research, but are not actual research studies.
CADMIUM 426
10. GLOSSARY
Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are
followed forward from exposure to outcome. At least one exposed group is compared to one unexposed
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human
health assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result
from exposure to a chemical prior to conception (either parent), during prenatal development, or
postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a

toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to
a chemical; the distinguishing feature between the two terms is the stage of development during which the
insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information. A health advisory is not a legally
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of
disease or other health-related conditions within a defined human population during a specified period.
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a

contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or
irreversible health effects.
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals.
CADMIUM 427
10. GLOSSARY
Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of individuals in a population who develop a specified condition to the total
number of individuals in that population who could have developed that condition in a specified time
period.
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the

Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported
to have caused death in humans or animals.
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study,

or group of studies, that produces statistically or biologically significant increases in frequency or severity
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the

lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or

function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty
factors. The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific
population.
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified
interval of time.
CADMIUM 428
10. GLOSSARY
Mutagen—A substance that causes mutations. A mutation is a change in the DNA sequence of a cell’s
DNA. Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a

chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no

statistically or biologically significant increases in frequency or severity of adverse effects seen between
the exposed population and its appropriate control. Effects may be produced at this dose, but they are not
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical

in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not
exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound

and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA)
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control
of agricultural and public health pests.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate
(disposition) of an exogenous substance in an organism. Utilizing computational techniques, it provides
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent
chemical or metabolite in an animal system. There are two types of pharmacokinetic models: data-based
and physiologically-based. A data-based model divides the animal system into a series of compartments,
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-

response model that quantitatively describes the relationship between target tissue dose and toxic end
points. These models advance the importance of physiologically based models in that they clearly
describe the biological effect (response) produced by the system following exposure to an exogenous
substance.
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments

representing organs or tissue groups with realistic weights and blood flows. These models require a
CADMIUM 429
10. GLOSSARY
variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar
ventilation rates, and possibly membrane permeabilities. The models also utilize biochemical
information, such as air/blood partition coefficients, and metabolic parameters. PBPK models are also
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time.
Prospective Study—A type of cohort study in which the pertinent observations are made on events
occurring after the start of the study. A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the
multistage procedure. The q1* can be used to calculate an estimate of carcinogenic potency, the
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and
μg/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of

magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious
effects during a lifetime. The RfD is operationally derived from the no-observed-adverse-effect level
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect
various types of data used to estimate RfDs and an additional modifying factor, which is based on a
professional judgment of the entire database on the chemical. The RfDs are not applicable to
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). Reportable
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation
either under CERCLA or under Section 311 of the Clean Water Act. Quantities are measured over a
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result
from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related
endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior,
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of
this system.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed
at some time in the past. Data are collected from routinely recorded events, up to the time the study is
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing
records and/or examining survivors of the cohort.
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.
CADMIUM 430
10. GLOSSARY
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or

inherited characteristic that is associated with an increased occurrence of disease or other health-related
event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial

Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes
continually. No more than four excursions are allowed per day, and there must be at least 60 minutes
between exposure periods. The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may
not be exceeded.
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists

(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit
(STEL), or as a ceiling limit (CL).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour
workday or 40-hour workweek.
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation,
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data. UFs are intended to
account for (1) the variation in sensitivity among the members of the human population, (2) the
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used;
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic
average of 10 and 1.
Xenobiotic—Any chemical that is foreign to the biological system.

CADMIUM A-1
APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C.
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99–
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological
profiles for each substance included on the priority list of hazardous substances; and assure the initiation
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological
information and epidemiologic evaluations of a hazardous substance. During the development of
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are
used by ATSDR health assessors to identify contaminants and potential health effects that may be of
concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor
approach. They are below levels that might cause adverse health effects in the people most sensitive to
such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure. Currently,
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end
point considered to be of relevance to humans. Serious health effects (such as irreparable damage to the
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to
look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that
CADMIUM A-2
APPENDIX A
are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the
Division of Toxicology and Human Health Sciences (proposed), expert panel peer reviews, and agency-
wide MRL Workgroup reviews, with participation from other federal agencies and comments from the
public. They are subject to change as new information becomes available concomitant with updating the
toxicological profiles. Thus, MRLs in the most recent toxicological profiles supersede previously
published levels. For additional information regarding MRLs, please contact the Division of Toxicology
and Human Health Sciences (proposed), Agency for Toxic Substances and Disease Registry, 1600 Clifton
Road NE, Mailstop F-62, Atlanta, Georgia 30333.
CADMIUM A-3
APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: Cadmium
CAS Numbers: 7440-43-9
Date: September, 2012
Profile Status: Post-Public Comment Draft 2
Route: [X] Inhalation [ ] Oral
Duration: [X] Acute [ ] Intermediate [ ] Chronic
Graph Key: 16
Species: Rat
Minimal Risk Level: 0.03 [ ] mg/kg/day [X] μg Cd/m3
Reference: NTP. 1995. Cadmium oxide administered by inhalation to F344/N rats and B6C3F1 mice.
National Toxicology Program, U.S. Department of Health and Human Services, Research Triangle Park,
NC.
Experimental design: Groups of five male and five female F344 rats were exposed to 0, 0.1, 0.3, 1, 3, or
10 mg cadmium oxide/m3 (0, 0.088, 0.26, 0.88, 2.6, or 8.8 mg Cd/m3) 6.2 hours/day, 5 days/week for
2 weeks. The mean MMAD of the cadmium oxide particles was 1.5 μm with a geometric standard
deviation of 1.6–1.8. The animals were observed twice daily and weighed on days 1 and 8, and at
termination. Other parameters used to assess toxicity included organ weights (heart, kidney, liver, lungs,
spleen, testis, and thymus) and histopathological examination (gross lesions, heart, kidney, liver, lungs,
tracheobronchial lymph nodes, and nasal cavity and turbinates).
Effect noted in study and corresponding doses: All rats in the 8.8 mg Cd/m3 group died by day 6; no
other deaths occurred. A slight decrease in terminal body weights was observed at 2.6 mg Cd/m3;
however, the body weights were within 10% of control weights. Significant increases in relative and
absolute lung weights were observed at 0.26 (males only), 0.88, and 2.6 mg Cd/m3. Histological
alterations were limited to the respiratory tract and consisted of alveolar histiocytic infiltrate and focal
inflammation in alveolar septa in all rats exposed to ≥0.088 mg Cd/m3, necrosis of the epithelium lining
alveolar ducts in all rats exposed to ≥0.26 mg Cd/m3, tracheobronchiolar lymph node inflammation at
≥0.88 mg Cd/m3 (incidences in the 0, 0.088, 0.26, 0.88, 2.6, and 8.8 mg Cd/m3 groups were 0/3, 0/5, 5/5,
5/5, and 3/4 in males and 0/4, 1/5, 1/5, 3/5, 5/5, and 3/5 in females), degeneration of the nasal olfactory
epithelium at 0.88 mg Cd/m3 (0/5, 0/5, 0/5, 2/5, 5/5, and 5/5 in males and 0/5, 0/5, 0/5, 4/5, 4/5, and 4/4 in
females) and inflammation (0/5. 0/5. 0/5, 1/5, 5/5, and 3/5 in males and 0/5, 0/5, 0/5, 0/5, 4/5, and 3/4 in
females) and metaplasia (0/5. 0/5. 0/5, 1/5, 0/5, and 5/5 in males and 0/5, 0/5, 0/5, 0/5, 4/5, and 4/4 in
females)of the nasal respiratory epithelium at 2.6 mg Cd/m3.
Dose and end point used for MRL derivation: The LOAEL of 0.088 mg Cd/m3 was selected as the point
of departure for derivation of the MRL; benchmark dose analysis was considered; however, the data were
not suitable for benchmark dose analysis because the incidence data for alveolar histiocytic infiltration do
not provide sufficient information about the shape of the dose-response relationship below the 100%
response level.
[ ] NOAEL [X] LOAEL
Uncertainty Factors used in MRL derivation:
[X] 10 for use of a LOAEL

[X] 3 for extrapolation from animals to humans with dosimetric adjustment
CADMIUM A-4
APPENDIX A
[X] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose:
The LOAELHEC was calculated using the equations below.
LOAELHEC = LOAELADJ x RDDR
The duration-adjusted LOAEL (LOAELADJ) was calculated as follows:
LOAELADJ = 0.088 mg Cd/m3 x 6.2 hours/24 hours x 5 days/7 days

LOAELADJ = 0.016 mg Cd/m3
The regional deposited dose ratio (RDDR) for the pulmonary region of 0.617 was calculated with EPA’s
RDDR calculator (EPA 1994a) using the final body weight of 0.194 kg for the male rats exposed
0.088 mg Cd/m3, the reported MMAD of 1.5 μm and the midpoint of the reported range of geometric
standard deviations (1.7)
LOAELHEC = 0.016 mg Cd/m3 x 0.617

LOAELHEC = 0.01 mg Cd/m3
Was a conversion used from intermittent to continuous exposure? Yes (see above)
Other additional studies or pertinent information that lend support to this MRL: The acute toxicity of
airborne cadmium, particularly cadmium oxide fumes, was first recognized in the early 1920s and there
have been numerous case reports of cadmium workers dying after brief exposures to presumably high
concentrations of cadmium fumes (European Chemicals Bureau 2007). The initial symptoms, similar to
those observed in metal fume fever, are usually mild but rapidly progress to severe pulmonary edema and
chemical pneumonitis. Persistent respiratory effects (often lasting years after the exposure) have been
reported in workers surviving these initial effects. There are limited monitoring data for these human
reports; however, Elinder (1986b) estimated that an 8-hour exposure to 1–5 mg/m3 would be immediately
dangerous.
Animal studies support the findings in humans that acute exposure to cadmium results in lung damage.
Single exposures to approximately 1–10 mg Cd/m3 as cadmium chloride or cadmium oxide resulted in
interstitial pneumonitis, diffuse alveolitis with hemorrhage, focal interstitial thickening, and edema
(Boudreau et al. 1989; Buckley and Bassett 1987b; Bus et al. 1978; Grose et al. 1987; Hart 1986;
Henderson et al. 1979; Palmer et al. 1986). Repeated exposure to 6.1 mg Cd/m3 1 hour/day for 5, 10, or
15 days resulted in emphysema in rats (Snider et al. 1973). At lower concentrations of 0.4–0.5 mg Cd/m3
as cadmium oxide for 2–3 hours (Buckley and Bassett 1987b; Grose et al. 1987) or 0.17 mg Cd/m3 as
cadmium chloride 6 hours/day for 10 days (Klimisch 1993) resulted in mild hypercellularity and increases
in lung weight. Alveolar histiocytic infiltration and focal inflammation and minimal fibrosis in alveolar
septa were observed in rats exposed to 0.088 mg Cd/m3 as cadmium oxide 6.2 hours/day, 5 days/week for
2 weeks (NTP 1995); in similarly exposed mice, histiocytic infiltration was observed at 0.088 mg Cd/m3
(NTP 1995). At similar concentrations (0.19 or 0.88 mg Cd/m3as cadmium chloride), decreases in
humoral immune response were observed in mice exposed for 1–2 hours (Graham et al. 1978;
Krzystyniak et al. 1987). Other effects that have been reported in animals acutely exposed to cadmium
include erosion of the stomach, decreased body weight gain, and tremors in rats exposed to 132 mg Cd/m3
CADMIUM A-5
APPENDIX A
as cadmium carbonate for 2 hours (Rusch et al. 1986) and weight loss and reduced activity in rats exposed
to 112 mg Cd/m3 as cadmium oxide for 2 hours (Rusch et al. 1986).
Agency Contact (Chemical Manager): Obaid Faroon, DVM, Ph.D.

CADMIUM A-6
APPENDIX A

Route: [X] Inhalation [ ] Oral
Duration: [ ] Acute [ ] Intermediate [X] Chronic
Graph Key: 63
Species: Human
Minimal Risk Level: 0.01 [ ] mg/kg/day [X] μg Cd/m3
Reference: Buchet JP, Lauwerys R, Roels H, et al. 1990. Renal effects of cadmium body burden of the
general population. Lancet 336:699-702.
Suwazono Y, Sand S, Vahter M, et al. 2006. Benchmark dose for cadmium-induced renal effects in
Experimental design: As detailed in the chronic oral MRL worksheet, a meta-analysis of select
environmental exposure dose-response studies examining the relationship between urinary cadmium and
the prevalence of elevated levels of biomarkers of renal function in environmentally exposed populations
was conducted; for the inhalation MRL, the meta-analysis also included dose-response data from
three occupational exposure studies (Chen et al. 2006a, 2006b; Järup and Elinder 1994; Roels et al. 1993).
The meta-analysis was used to establish a point of departure for the urinary cadmium-response
relationship and pharmacokinetic models (ICRP 1994; Kjellström and Nordberg 1978) were used to
predict cadmium air concentrations.
Dose and end point used for MRL derivation: Analysis of the available environmental exposure studies
and occupational exposure studies resulted in an estimation of a urinary cadmium level that would result
in a 10% increase in the prevalence of β2-microglobulin proteinuria (UCD10). The lowest UCD10
(1.34 μg/g creatinine) was estimated from the European environmental exposure studies (Buchet et al.
1990; Järup et al. 2000; Suwazono et al. 2006); the UCD10 values from the occupational exposure studies
were 7.50 μg/g creatinine for the European cohorts (Järup and Elinder 1994; Roels et al. 1993) and
4.58 μg/g creatinine for the Chinese cohort (Chen et al. 2006a, 2006b). The UCD10 from the
environmental exposure studies was selected as the basis of the MRL. The 95% lower confidence limit
on this value (UCDL10) of 0.5 μg/g creatinine was used as the point of departure for the MRL.
[ ] NOAEL [ ] LOAEL [X] UCDL10
Deposition and clearance of inhaled cadmium oxide and cadmium sulfide particles were modeled using
the ICRP Human Respiratory Tract Model (ICRP 1994). The ICRP model simulates deposition,
retention, and absorption of inhaled cadmium particles of specific aerodynamic diameters, when specific
parameters for cadmium clearance are used in the model (ICRP 1980). Cadmium-specific parameters
represent categories of solubility and dissolution kinetics in the respiratory tract (e.g., slow, S; moderate,
M; or fast, F). Cadmium compounds are classified as follows: oxides and hydroxides, S; sulfides, halides
and nitrates, M; all other, including chloride salts, F.
CADMIUM A-7
APPENDIX A
Inhalation exposures (μg/m3) to cadmium oxide or cadmium sulfide aerosols having particle diameters of
1, 5, or 10 g (AMAD) were simulated using the ICRP model. Predicted mass transfers of cadmium
from the respiratory tract to the gastrointestinal tract (i.e., mucocilliary transport) and to blood (i.e.,
absorption) were used as inputs to the gastrointestinal and blood compartments of the Kjellström-
Nordberg pharmacokinetic model (1978) to simulate the kidney and urinary cadmium levels that
correspond to a given inhalation exposure.
An airborne cadmium concentration of 1.8–2.4 μg/m3 as cadmium oxide or 1.2–1.4 μg/m3 as cadmium
sulfide would result in a urinary cadmium level of 0.5 μg/g creatinine, assuming that the air was the only
source of cadmium. This assumption is not accurate because the diet is a significant contributor to the
cadmium body burden. Thus, inhalation exposures were combined with ingestion intakes to estimate an
internal dose in terms of urinary cadmium. The age-weighted average intakes of cadmium in nonsmoking
males and females in the United States are 0.35 and 0.30 μg Cd/kg/day, respectively (0.32 μg/kg/day for
males and females combined) (Choudhury et al. 2001).
Based on the relationship predicted between chronic inhalation exposures to cadmium sulfide
(AMAD=1 μm) and oral intakes that yield the same urinary cadmium level, exposure to an airborne
cadmium concentration of 0.1 μg/m3 and a dietary intake of 0.3 μg/kg/day would result in a urinary
cadmium level of 0.5 μg/g creatinine.
Uncertainty Factors and Modifying Factors used in MRL derivation:
[ ] 10 for use of a LOAEL

[ ] 10 for extrapolation from animals to humans with dosimetric adjustment
The uncertainty factor of 3 for human variability was used to account for the possible increased sensitivity
of diabetics (Åkesson et al. 2005; Buchet et al. 1990).
[X] modifying factor of 3
The modifying factor of 3 was used to account for the lack of adequate human data that could be used to
compare the relative sensitivities of the respiratory tract and kidneys.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not
applicable.
Was a conversion used from intermittent to continuous exposure? The pharmacokinetic model assumes
continuous exposure.
Other additional studies or pertinent information that lend support to this MRL: Numerous studies
examining the toxicity of cadmium in workers have identified the respiratory tract and the kidney as
sensitive targets of toxicity. A variety of respiratory tract effects have been observed in cadmium workers
including respiratory symptoms (e.g., dyspnea, coughing, wheezing), emphysema, and impaired lung
function. However, many of these studies did not control for smoking, and thus, the role of cadmium in
the induction of these effects is difficult to determine. Impaired lung function was reported in several
studies that controlled for smoking (Chan et al. 1988; Cortona et al. 1992; Davison et al. 1988; Smith et
al. 1976); other studies have not found significant alterations (Edling et al. 1986). The observed
alterations include an increase in residual volume in workers exposed to air concentrations of cadmium
CADMIUM A-8
APPENDIX A
fumes ranging from 0.008 (in 1990) to 1.53 mg/m3 (in 1975) (mean urinary cadmium level in the workers
was 4.3 μg/L) (Cortona et al. 1992); alterations in several lung function parameters (e.g., forced
expiratory volume, transfer factor, transfer coefficient) in workers exposed to 0.034–0.156 mg/m3
(Davison et al. 1988); and decreased force vital capacity in workers exposed to >0.2 mg/m3 (Smith et al.
1976). Additionally, Chan et al. (1988) found significant improvements in several parameters of lung
function of workers following reduction or cessation of cadmium exposure.
The renal toxicity of cadmium in workers chronically exposed to high levels of cadmium is well
established. Observed effects include tubular proteinuria (increased excretion of low molecular weight
proteins), decreased resorption of other solutes (increased excretion of enzymes such as N-acetyl-
β-glucosaminidase (NAG), amino acids, glucose, calcium, inorganic phosphate), evidence of increased
glomerular permeability (increased excretion of albumin), increased kidney stone formation, and
decreased glomerular filtration rate. The earliest sign of cadmium-induced kidney damage is an increase
in urinary levels of low molecular weight proteins (particularly, β2-microglobulin, retinol binding protein,
and human complex-forming glycoprotein [pHC]) in cadmium workers, as compared to levels found in a
reference group of workers or the general population (Bernard et al. 1990; Chen et al. 2006a, 2006b; Chia
et al. 1992; Elinder et al. 1985a; Falck et al. 1983; Jakubowski et al. 1987, 1992; Järup and Elinder 1994;
Järup et al. 1988; Shaikh et al. 1987; Toffoletto et al. 1992; Verschoor et al. 1987). Significant alterations
in the prevalence of low molecular weight proteinuria among cadmium workers has been observed at
urinary cadmium levels of 1.5 μg/g creatinine and higher (Chen et al. 2006a; Elinder et al. 1985a;
Jakubowski et al. 1987; Järup and Elinder 1994).

CADMIUM A-9
APPENDIX A

Route: [ ] Inhalation [X] Oral
Duration: [ ] Acute [X] Intermediate [ ] Chronic
Graph Key: 33
Species: Rat
Minimal Risk Level: 0.5 [X] μg Cd/kg/day [ ] ppm
Reference: Brzóska MM, Moniuszko-Jakoniuk J. 2005d. Disorders in bone metabolism of female rats
chronically exposed to cadmium. Toxicol Appl Pharmacol 202(1):68-83.
Brzóska MM, Majewska K, Moniuszko-Jakoniuk J. 2005a. Bone mineral density, chemical composition
and biomechanical properties of the tibia of female rats exposed to cadmium since weaning up to skeletal
maturity. Food Chem Toxicol 43(10):1507-1519.
Brzóska MM, Majewska K, Moniuszko-Jakoniuk J. 2005c. Weakness in the mechanical properties of

the femur of growing female rats exposed to cadmium. Arch Toxicol 79(5):277-288.
Experimental design: Groups of 40 3-week-old female Wistar rats were exposed to 0, 1, 5, or 50 mg

Cd/L as cadmium chloride in drinking water for 12 months. The investigators noted that cadmium
intakes were 0.059–0.219, 0.236–1.005, and 2.247–9.649 mg Cd/kg/day in the 1, 5, and 50 mg/L groups,
respectively. Using cadmium intake data presented in a figure, cadmium intakes of 0.2, 0.5, and 4 mg
Cd/kg/day were estimated. Bone mineral density, bone mineral concentration, and mineralization area of
the lumbar spine, femur and total skeleton (bone mineral density only) were assessed after 3, 6, 9, or
12 months of exposure. The mechanical properties of the femur and tibia were evaluated after 12 months
of exposure. Markers for bone resorption (urinary and serum levels of C-terminal cross-linking
telopeptide of type I collagen [CTX]) and bone formation (serum osteocalcin, total alkaline phosphatase,
and cortical bone and trabecular bone alkaline phosphatase), and serum and urinary levels of calcium
were also measured at 3, 6, 9, and 12 months.
Effect noted in study and corresponding doses: No significant alterations in body weight gain or food and
water consumption were observed. Significant decreases in total skeletal bone mineral density was
observed at ≥0.2 mg Cd/kg/day; the decrease was significant after 3 months in the 4 mg Cd/kg/day group,
after 6 months in the 0.5 mg Cd/kg/day group, and after 9 months in the 0.2 mg Cd/kg/day group.
Significant decreases in whole tibia and diaphysis bone mineral density were observed at ≥0.2 mg
Cd/kg/day after 12 months of exposure. At 0.2 mg Cd/kg/day, bone mineral density was decreased at the
proximal and distal ends of the femur after 6 months of exposure; diaphysis bone mineral density was not
affected. At 0.5 mg Cd/kg/day, bone mineral density was decreased at the femur proximal and distal ends
after 3 months of exposure and diaphysis bone mineral density after 6 months of exposure. At 4 mg
Cd/kg/day decreases in femoral proximal, distal, and diaphysis bone mineral density were decreased after
3 months of exposure. Similarly, bone mineral density was significantly decreased in the lumbar spine in
the 0.2 and 0.5 mg Cd/kg/day groups beginning at 6 months and at 3 months in the 4 mg Cd/kg/day
group. Significant decreases in the mineralization area were observed in the femur and lumbar spine of
rats exposed to 4 mg Cd/kg/day; lumbar spine bone mineral area was also affected at 0.5 mg Cd/kg/day.
Significant decreases in tibia weight and length were observed at 4 mg Cd/kg/day. In tests of the
mechanical properties of the tibia diaphysis, significant alterations in ultimate load, yield load, and
CADMIUM A-10
APPENDIX A
displacement at load were observed at ≥0.2 mg Cd/kg/day; work to fracture was also significantly altered
at 4 mg Cd/kg/day. In the mechanical properties compression tests of the tibia, significant alterations
were observed in ultimate load, ultimate load, and stiffness at 0.2 mg Cd/kg/day; displacement at yield
and work to fracture at ≥0.5 mg Cd/kg/day; and displacement at ultimate at 4 mg Cd/kg/day. Multiple
regression analysis showed that the cadmium-induced weakness in bone mechanical properties of the tibia
was primarily due to its effects on bone composition, particularly the non-organic components, organic
components, and the ratio of the ash weight to organic weight. The mechanical properties of the femur
were strongly influenced by the bone mineral density (at the whole bone and diaphysis). A significant
decrease in femur length was observed at 6 months of exposure to ≥0.2 mg Cd/kg/day; however,
decreases in length were not observed at other time points in the 0.2 or 0.5 mg Cd/kg/day groups. Femur
weight was significantly decreased at 4 mg Cd/kg/day. In tests of mechanical properties of the femoral
neck and distal, decreases in yield load, ultimate load, displacement at ultimate, work to fracture (neck
only), and stiffness (distal only) were observed at ≥0.2 mg Cd/kg/day. For the femoral diaphysis,
significant alterations were observed for yield load, displacement at yield, and stiffness at ≥0.2 mg
Cd/kg/day. Significant decreases in osteocalcin concentrations were observed in all cadmium groups
during the first 6 months of exposure, but not during the last 6 months. Decreases in total alkaline
phosphatase levels at 4 mg Cd/kg/day, trabecular bone alkaline phosphatase at 0.2 mg Cd/kg/day, and
cortical bone alkaline phosphatase at 4 mg Cd/kg/day were observed. CTX was decreased at ≥0.2 mg
Cd/kg/day. Total urinary calcium and fractional excretion of calcium were increased at ≥0.2 mg
Cd/kg/day.
Dose and end point used for MRL derivation:
[ ] NOAEL [ ] LOAEL [X] BMDLsd1
At the lowest dose tested, 0.2 mg Cd/kg/day, a number of skeletal alterations were observed including
decreases in bone mineral density in the lumbar spine, femur, and tibia, alterations in the mechanical
properties of the femur and tibia, decreases in osteocalcin levels, decreases in trabecular bone alkaline
phosphatase, and decreases in CTX. Of these skeletal end points, the decrease in bone mineral density
was selected as the critical effect because Brzóska et al. (2005a, 2005c) demonstrated that the bone
mineral density was a stronger predictor of femur and tibia strength and the risk of fractures.
Available continuous models in the EPA Benchmark Dose Software (version 1.4.1c) were fit to data
(Table A-1) for changes in bone mineral density of the femur and lumbar spine in female rats resulting
from exposure to cadmium in the drinking water for 6, 9, or 12 months (Brzóska and Moniuszko-
Jakoniuk 2005d). The BMD and the 95% lower confidence limit (BMDL) is an estimate of the doses
associated with a change of 1 standard deviation from the control. The model-fitting procedure for
continuous data is as follows. The simplest model (linear) is applied to the data while assuming constant
variance. If the data are consistent with the assumption of constant variance (p≥0.1), then the other
continuous models (polynomial, power, and Hill models) are applied to the data. Among the models
providing adequate fits to the means (p≥0.1), the one with the lowest Akaike’s information criterion
(AIC) for the fitted model is selected for BMD derivation. If the test for constant variance is negative, the
linear model is run again while applying the power model integrated into the benchmark dose software
(BMDS) to account for nonhomogenous variance. If the nonhomogenous variance model provides an
adequate fit (p≥0.1) to the variance data, then the other continuous models are applied to the data.
Among the models providing adequate fits to the means (p≥0.1), the one with the lowest AIC for the
fitted model is selected for BMD derivation. If the tests for both constant and non-constant variance are
negative, then the data set is considered not to be suitable for BMD modeling.
CADMIUM A-11
APPENDIX A
Table A-1. Data Sets for Changes in Mineral Bone Density of the Femur and
Lumbar Spine in Female Rats Exposed to Cadmium in
Drinking Water for 6, 9, or 12 Months
Dose (mg Cd/kg/day)

a
Dataset 0 0.2 0.5 4
b
Femur
c d e
6 month 329.7±3.6 317.6±2.7 308.5±3.4 303.4±3.4
d e e
9 month 343.8±3.1 328.2±2.9 322.8±3.0 310.4±3.4
d d e
12 month 354.3±3.7 338.0±1.9 330.9±3.1 318.7±3.4
b
Lumbar spine
c d e
6 month 272.0±2.4 263.4±2.6 258.3±2.7 249.5±2.9
d e e
9 month 282.4±2.3 271.8±1.6 267.8±1.8 259.5±2.7
d e e
12 month 286.1±2.3 275.5±1.9 269.1±1.9 257.1±3.0
a
n=10.
b
mean±SE; standard errors were transformed to standard deviations for benchmark dose modeling via a function in
the BMD software.
c
Significantly different (p≤0.05) from the control group.
d
e
Source: Brzóska and Moniuszko-Jakoniuk 2005d
The potential points of departures derived from the best fitting models for each dataset are summarized in
Table A-2.
CADMIUM A-12
APPENDIX A
Table A-2. Summary of BMDs and BMDLs From the Best Fitting Models
Predicting Changes in Bone Mineral Density in Female Rats After
Cadmium Exposure From Drinking Water
Exposure
Period Number of BMDsd1a BMDLsd1a
(months) Best-fitting model doses (mg Cd/kg/day) (mg Cd/kg/day)
Femur
6 Linear 3 0.24 0.17
9 Hill 4 0.11 0.05
12 Hill 4 0.09 0.05
Lumbar spine
6 Hill 4 0.19 0.08
9 Hill 4 0.11 0.05
12 Hill 4 0.12 0.07
a
BMDs and BMDLs from continuous data are associated with a 1 standard deviation change from the control.
The BMDLsd1 of 0.05 mg Cd/kg/day estimated from the 9-month lumbar spine data set was selected as the
point of departure for the MRL. In young female rats, the process of intense bone formation occurs
during the first 7 months of life (the first 6 months of exposure in this study); thereafter, the increase in
bone mineral density slows. In the lumbar spine of the control group, the changes in bone mineral density
at 3–6 months, 6–9 months, and 9–12 months were 15, 4, and 1%, respectively. Thus, the 9-month data
may best reflect the effect of cadmium on bone mineral density during the period of rapid skeletal growth.
The lumbar spine data was selected over the femur data set because trabecular bone, which is abundant in
the spine, appears to be more susceptible to cadmium toxicity than cortical bone.
For the 9-month lumbar spine data set, the simplest model (linear) was applied to the data first to test for a
fit for constant variance. The constant variance model did provide an adequate fit (as assessed by the
p-value for variance) to the data. The polynomial, power, and Hill models were then fit to the data with
constant variance assumed. The Hill model was the only model that provided an adequate fit to the data
(as assessed by the p-value for the means) (Table A-3). Using the constant-variance Hill model, the
BMDsd1 and BMDLsd1 are 0.11 mg/kg and 0.05 mg Cd/kg/day, respectively (Figure A-1).
CADMIUM A-13
APPENDIX A
Table A-3. Model Predictions for Changes in Bone Mineral Density of the Lumbar
Spine in Female Rats Exposed to Cd in Drinking Water for 9 Months
Variance p-Value for BMDsd1 BMDLsd1

Modela p-valueb the meansb AIC (mg Cd/kg/day) (mg Cd/kg/day)
c
Linear 0.36 0.00 211.92 1.93 1.42
c
Polynomial (1-degree) 0.36 0.00 211.92 1.93 1.42
c
c
Power 0.36 0.00 211.92 1.93 1.42
Hill 0.36 0.60 197.21 0.11 0.05
a
Constant variance assumed for all models.
b
Values <0.1 fail to meet conventional goodness-of-fit criteria.
c
Restriction = non-positive.
AIC = Akaike’s Information Criteria; BMD = benchmark dose; BMDL = lower confidence limit (95%) on the
benchmark dose; p = p value from the Chi-squared test; Std1 = a 1 standard deviation change from the control.
Source: Brzóska and Moniuszko-Jakoniuk 2005d
Figure A-1. Predicted and Observed Incidence of Changes in Lumbar Spine Bone
Mineral Density in Female Rats Exposed to Cadmium in Drinking Water for
9 Months (Brzóska and Moniuszko-Jakoniuk 2005d)*
Hill Model with 0.95 Confidence Level
290 Hill
285
280
275
Mean Response
270
265
260
255
BMDL BMD
250
0 0.5 1 1.5 2 2.5 3 3.5 4
dose
15:24 05/27 2008
*BMDs and BMDLs indicated are associated with a 1 standard deviation change from the control, and are in units of
mg Cd/kg/day.
CADMIUM A-14
APPENDIX A

[X] 10 for extrapolation from animals to humans
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Investigators
estimated doses based on body weight and water consumption.
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL: There are limited data on
the toxicity of cadmium in humans following intermediate-duration exposure. Numerous animal studies
have examined the systemic, immunological, neurological, reproductive, and developmental toxicity of
cadmium. The most sensitive systemic effect following intermediate-duration oral exposure to cadmium
appears to be damage to growing bone. Exposure to 0.2 mg Cd/kg/day as cadmium chloride in drinking
water for 3–12 months resulted decreases in bone mineral density, impaired mechanical strength of the
lumbar spine, tibia, and femur bones, increased bone turnover, and increased incidence of deformed or
fractured lumbar spine bone in young female rats (3 weeks of age at study initiation) (Brzóska and
Moniuszko-Jakoniuk 2005d; Brzóska et al. 2004b, 2005a, 2005b, 2005c, 2010); similar findings were
observed in young male rats exposed to 0.5 mg Cd/kg/day for up to 12 months (Brzóska and Moniuszko-
Jakoniuk 2005a, 2005b). Decreases in bone strength were also observed in young rats exposed to 0.8 mg
Cd/kg/day as cadmium chloride in drinking water for 4 weeks (Ogoshi et al. 1989); however, no skeletal
effects were observed in adult or elderly female rats exposed to doses >20 mg Cd/kg/day for 4 weeks
(Ogoshi et al. 1989).
Renal effects have been observed at higher doses than the skeletal effects. Vesiculation of the proximal
tubules was observed in rats exposed to 1.18 mg Cd/kg/day as cadmium chloride in drinking water for
40 weeks (Gatta et al. 1989). At approximately 3–8 mg Cd/kg/day, proteinuria, tubular necrosis, and
decreased renal clearance were observed in rats (Cha 1987; Itokawa et al. 1974; Kawamura et al. 1978;
Kotsonis and Klaassen 1978; Prigge 1978a). Liver necrosis and anemia (Cha 1987; Groten et al. 1990;
Kawamura et al. 1978) were observed at similar cadmium doses.
A number of developmental effects have been observed in the offspring of rats exposed to cadmium
during gestation and lactation. Decreases in glomerular filtration rates and increases in urinary fractional
excretion of phosphate, magnesium, potassium, sodium, and calcium were observed in 60-day-old
offspring of rats administered via gavage 0.5 mg Cd/kg/day on gestation days 1–21 (Jacquillet et al.
2007). Neurodevelopmental alterations have also been observed at the low maternal doses. Delays in the
development of sensory motor coordination reflexes and increased motor activity were observed at
0.706 mg Cd/kg/day (gestation days 1–21) (Ali et al. 1986), decreased motor activity at 0.04 mg
Cd/kg/day (5–8 weeks of pre-gestation exposure, gestation days 1–21) (Baranski et al. 1983), decreased
ambulation and rearing activity and altered ECG at 14 mg Cd/kg/day (gestation days 5–15, lactation
days 2–28, postnatal days 1–56) (Desi et al. 1998) or 7 mg Cd/kg/day (F2 and F3 generations)
(Nagymajtenyi et al. 1997) have been observed. Decreases in pup body weight were observed at ≥5 mg
Cd/kg/day (Baranski 1987; Gupta et al. 1993; Kostial et al. 1993; Pond and Walker 1975) and decreases
in fetal body weight or birth weight were observed at ≥2.4 mg Cd/kg/day (Petering et al. 1979; Sorell and
Graziano 1990; Webster 1978; Sutou et al. 1980). Another commonly reported developmental effect was
alterations in hematocrit levels or anemia in the offspring of animals exposed to ≥1.5 mg Cd/kg/day
CADMIUM A-15
APPENDIX A
(Kelman et al. 1978; Baranski 1987; Webster 1978). Increases in the occurrence of malformations or
anomalies is limited to a study by Sutou et al. (1980), which reported a significant delay in ossification in
rats exposed to 10 mg Cd/kg/day.
The animal studies identify several sensitive targets of toxicity following intermediate-duration exposure
to cadmium; these include skeletal mineralization in young female rats exposed for at least 3 months to
0.2 mg Cd/kg/day (Brzóska and Moniuszko-Jakoniuk 2005d; Brzóska et al. 2004b, 2005a, 2005b, 2005c),
decreased glomerular filtration in young rats exposed during gestation to maternal doses of 0.5 mg
Cd/kg/day (Jacquillet et al. 2007), and neurodevelopmental effects following gestational exposure to
0.04 mg Cd/kg/day (Baranski et al. 1983). Although the Baranski et al. (1983) study reported the lowest
LOAEL, it was not selected as the principal study for derivation of an intermediate-duration MRL. For
locomotor activity, a significant decrease in activity was observed in female offspring exposed to 0.04,
0.4, and 4 mg Cd/kg/day, as compared to controls; however, no significant differences were found
between the cadmium groups despite the 100-fold difference in doses. Locomotor activity was also
decreased in males exposed to 0.4 or 4 mg Cd/kg/day. For the rotorod test, a significant decrease in the
length of time the rat stayed on the rotorod was observed in males exposed to 0.04 and 0.4 mg Cd/kg/day,
but not to 4 mg Cd/kg/day and in females exposed to 0.4 and 4 mg Cd/kg/day; no differences between the
cadmium groups were observed in the males and females. The results were poorly reported and the
investigators did not explain the lack of dose-response of the effects or the discrepancy between genders.

CADMIUM A-16
APPENDIX A

Route: [ ] Inhalation [X] Oral
Duration: [ ] Acute [ ] Intermediate [X] Chronic
Graph Key: 106
Species: Human
Minimal Risk Level: 0.1 [X] μg Cd/kg/day [ ] μg Cd/m3
Reference: Buchet JP, Lauwerys R, Roels H, et al. 1990. Renal effects of cadmium body burden of the
general population. Lancet 336:699-702.
Suwazono Y, Sand S, Vahter M, et al. 2006. Benchmark dose for cadmium-induced renal effects in
Experimental design: ATSDR conducted a meta-analysis of select environmental exposure dose-response

studies examining the relationship between urinary cadmium and the prevalence of elevated levels of
biomarkers of renal function (Buchet et al. 1990; Järup et al. 2000; Jin et al. 2004c; Kobayashi et al. 2006;
Shimizu et al. 2006; Suwazono et al. 2006; Wu et al. 2001). The studies were selected based on the
following qualitative criteria: (1) the study measured an urinary cadmium as indicator of internal dose;
(2) the study measured reliable indicators of low molecular weight (LMW) proteinuria; (3) a dose-
response relationship was reported in sufficient detail so that the dose-response function could be
reproduced independently; (4) the study was of reasonable size to have provided statistical strength to the
estimates of dose-response model parameters (i.e., most studies selected included several hundred to
several thousand subjects); and (5) major co-variables that might affect the dose-response relationship
(e.g., age, gender) were measured or constrained by design and included in the dose-response analysis.
No attempt was made to weight selected studies for quality, statistical power, or statistical uncertainty in
dose-response parameters. Studies using a cut-off value for β2-microglobulin of ≥1,000 μg/g creatinine
were eliminated from the analysis based on the conclusions of Bernard et al. (1997) that urinary
β2-microglobulin levels of 1,000–10,000 μg/g creatinine were indicative of irreversible tubular
proteinuria, which may lead to an age-related decline in glomerular filtration rate. Additionally, an
attempt was made to avoid using multiple analyses of the same study population.
The individual dose-response functions from each study were implemented to arrive at estimates of the
internal dose (urinary cadmium expressed as μg/g creatinine) corresponding to probabilities of 10%
excess risk of low molecular weight proteinuria (urinary cadmium dose, UCD10). Estimates were derived
from the seven environmental exposure studies listed above. When available, male and female data were
treated separately; thus, 11 dose-response relationships were analyzed. For studies that did not report the
UCD10, the value was estimated by iteration of the reported dose response relationship for varying values
of urinary cadmium, until an excess risk of 10% was achieved. For studies that reported the dose-
response relationship graphically, but did not report the actual dose-response function, a function was
derived by least squares fitting based on data from a digitization of the graphic
CADMIUM A-17
APPENDIX A
Dose and end point used for MRL derivation: Aggregate UCD10 estimates and the estimates stratified by
location (i.e., Europe, Japan, China) are presented in Table A-4. The lowest UCD10 (1.34 μg/g creatinine)
was estimated from the European database; and the 95% lower confidence limit on this UCD10 (UCDL10)
of 0.5 μg/g creatinine was considered as the point of departure for the MRL.
Table A-4. Estimates of the UCD10 and Cadmium Intake from Environmental
Exposure Dose-Response Studies
Cadmium intakeb
UCD10a (μg/kg/day)
(μg Cd/g creatinine) Females Males
c
Europe (n=4)
Mean 1.34 0.97 2.24
Median — — —
95% CI 0.50, 2.18 0.33, 1.75 0.70, 3.94
d
Japan (n=4)
Mean 5.23 4.59 10.1
Median — — —
95% CI 4.24, 6.21 3.67, 5.49 8.07, 12.0
e
China (n=3)
Mean 9.55 8.60 18.8
Median — — —
95% CI 2.96, 16.1 2.48, 14.7 5.51, 31.9
All (n=11)
Mean 4.99 4.37 9.58
Median 4.20 3.63 7.99
95% CI 1.44, 6.60 1.06, 5.86 2.45, 12.8
a
Estimates of urinary cadmium level corresponding to probabilities of 10% excess risk of low molecular weight
proteinuria (UCD10).
b
UCD was transformed into estimates of chronic cadmium intake that would result in the UCD at age 55 using a
modification (Choudhury et al. 2001; Diamond et al. 2003) of the Kjellström and Nordberg (1978) model.
c
Dose-response function data from Buchet et al. (1990), Suwazono et al. (2006), and Järup et al. (2000); dose
response data from males and females in the Buchet et al. (1990) study were treated separately.
d
Dose-response function data from Kobayashi et al. (2006) and Shimizu et al. (2006); dose response data from
males and females were treated separately.
e
Dose-response function data from Jin et al. (2004c) and Wu et al. (2001); dose response data from males and
females in the Jin et al. (2004c) study were treated separately.
UCD = urinary cadmium dose
[ ] NOAEL [ ] LOAEL [X] UCDL10
The UCDL10 of 0.5 μg/g creatinine was transformed into estimates of chronic cadmium intake (expressed
as μg/kg/day) that would result in the UCDL10 at age 55 (approximate age of peak cadmium concentration
in the renal cortex associated with a constant chronic intake). The dose transformations were achieved by
simulation using a modification of the Kjellström and Nordberg (1978) model. The following
modifications (Choudhury et al. 2001; Diamond et al. 2003) were made to the model: (1) the equations
describing intercompartmental transfers of cadmium were implemented as differential equations in
Advanced Computer Simulation Language (acslXtreme, version 2.4.0.9); (2) growth algorithms for males
CADMIUM A-18
APPENDIX A
and females and corresponding organ weights (O’Flaherty 1993) were used to calculate age-specific
cadmium concentrations from tissue cadmium masses; (3) the cadmium concentration in renal cortex
(RC, μg/g) was calculated as follows:
K
RC = 1.5 ⋅
KW
where K is the age-specific renal cadmium burden (μg) and KW is the age-specific kidney wet
weight (g) (Friberg et al. 1974)
(4) the rate of creatinine excretion (e.g., Crur, g creatinine/day) was calculated from the relationship
between lean body mass (LBM) and Crur); and (5) absorption of ingested cadmium was assumed to be 5%
in males and 10% in females. The rate of creatinine excretion (e.g., Crur, g creatinine/day) was estimated
from the relationship between LBM (kg) and Crur:
LBM = 27.2 ⋅ Crur + 8.58
where the constants 27.2 and 8.58 are the sample size-weighted arithmetic mean of estimates of
these variables from eight studies reported in (Forbes and Bruining 1976). Lean body mass was
estimated as follows (ICRP 1981):
LBM = BW ⋅ 0.85,adult females

LBM = BW ⋅ 0.88,adult males
where the central tendency for adult body weight for males and females were assumed to be
70 and 58 kg for adult European/American males and females, respectively.
Dose units expressed as cadmium intake (μg/kg/day), urinary cadmium excretion (μg/g creatinine), or
kidney tissue cadmium (μg/g cortex) were interconverted by iterative pharmacokinetic model simulations
of constant intakes for the life-time to age 55 years, the age at which renal cortex cadmium concentrations
are predicted to reach their peak when the rate of intake (μg/kg/day) is constant.
The dietary cadmium intakes which would result in urinary cadmium levels of 1.34 and 0.5 μg/g
creatinine (UCD10 and UCDL10) are 0.97 and 0.33 μg/kg/day in females and 2.24 and 0.70 μg/kg/day in
males.

[ ] 10 for extrapolation from animals to humans
The UCD is based on several large-scale environmental exposure studies that likely included sensitive
subpopulations; however, there is concern that individuals with diabetes may be especially sensitive to the
renal toxicity of cadmium (Åkesson et al. 2005; Buchet et al. 1990) and diabetics were excluded from a
number of human studies, and thus, an uncertainty factor of 3 was used.
CADMIUM A-19
APPENDIX A
applicable.
Was a conversion used from intermittent to continuous exposure? No.
Other additional studies or pertinent information that lend support to this MRL: The results of numerous
studies of environmentally exposed populations provide strong evidence that the kidney, and possibly
bone, is the most sensitive target of toxicity following chronic exposure to cadmium. Most of the studies
have focused on subclinical alterations of kidney function, as measured by the urinary excretion of several
biomarkers including low molecular weight proteins (β2-microglobulin, pHC, retinol binding protein),
intracellular tubular enzymes (NAG), amino acids, high molecular weight proteins (albumin), and
electrolytes (potassium, sodium, calcium). Significant associations between urinary cadmium levels and
an increased prevalence of abnormal levels of these biomarkers have been found in populations living in
areas with moderate or high cadmium pollution or low cadmium pollution (Bandara et al. 2010; Buchet et
al. 1990; Cai et al. 1990, 1992, 1998, 2001; Ferraro et al. 2010; Hayano et al. 1996; Honda et al. 2010;
Horiguchi et al. 2004, 2010; Hwangbo et al. 2011; Ishizaki et al. 1989; Izuno et al. 2000; Järup et al.
2000; Jin et al. 2002, 2004a, 2004c; Kawada et al. 1992; Kido and Nogawa 1993; Kobayashi et al. 2002a,
2009b; Monzawa et al. 1998; Nakashima et al. 1997; Nogawa et al. 1989; Noonan et al. 2002; Nordberg
et al. 1997; Olsson et al. 2002; Oo et al. 2000; Osawa et al. 2001; Roels et al. 1981b; Suwazono et al.
2006; Teeyakasem et al. 2007; Trzcinka-Ochocka et al. 2004; Uno et al. 2005; Yamanaka et al. 1998; Wu
et al. 2001). Increases in the prevalence of abnormal biomarker levels appear to be the most sensitive
indicator of cadmium toxicity and alterations have been observed at urinary cadmium levels ranging from
1 μg/g creatinine (Järup et al. 2000) to 9.51 μg/g creatinine (Jin et al. 2004a).
Several studies have examined the possible association between exposure to cadmium and bone effects.
Significant associations between urinary cadmium levels and an increased risk of bone fractures at urinary
cadmium levels of ≥0.7 μg/g creatinine (Alfvén et al. 2004; Staessen et al. 1999; Wang et al. 2003),
increased risk of osteoporosis at urinary cadmium levels of ≥1.5 μg/g creatinine (Alfvén et al. 2000; Jin et
al. 2004b; Wang et al. 2003), and decreased bone mineral density at urinary cadmium levels of ≥0.6 μg/g
creatinine (Engström et al. 2009; Nordberg et al. 2002; Schutte et al. 2008; Trzcinka-Ochocka et al.
2010).
The adverse effect levels for renal effects were similar to those observed for skeletal effects. Because the
renal effects database is stronger, it was used for derivation of a chronic-duration oral MRL for cadmium.
Three approaches were considered for derivation of the MRL: (1) NOAEL/LOAEL approach using a
single environmental exposure study finding an increased prevalence of abnormal renal effect biomarker
levels, (2) selection of a point of departure from a published benchmark dose analysis, or (3) selection of
a point of departure on an analysis of the dose-response functions from a number of environmental
exposure studies.
In the first approach, all studies in which individual internal doses for subjects were estimated based on
urinary cadmium were considered. The Järup et al. (2000) study identified the lowest adverse effect
level; the investigators estimated that a urinary cadmium level of 1 μg/g creatinine would be associated
with a 10% increase in the prevalence of abnormal pHC levels above background prevalence
(approximately a 10% added risk). The European Chemicals Bureau (2007) recalculated the probability
of HC proteinuria because the reference population and the study population were not matched for age
(40 versus 53 years, respectively). They estimated that the probability of HC proteinuria (13%) would be
twice as high as the reference population at a urinary cadmium concentration of 0.5 μg/g creatinine. For
the second approach, eight published benchmark dose analyses were evaluated (Jin et al. 2004b;
Kobayashi et al. 2006, 2008a; Shimizu et al. 2006; Suwazono et al. 2006, 2011b, 2011c; Uno et al. 2005).
The lower 95% confidence interval of the benchmark dose (BMDL) for low molecular weight proteinuria
CADMIUM A-20
APPENDIX A
ranged from 0.7 μg/g creatinine (Uno et al. 2005) to 9.9 μg/g creatinine (Kobayashi et al. 2006). The
third approach involved a meta-analysis of selected environmental exposure dose-response studies. Using
individual dose-response functions from each study, estimates of the internal cadmium dose
corresponding to probabilities of 10% excess risk of low molecular weight proteinuria were calculated.
The lowest UCD10 (1.34 μg/g creatinine) was estimated from the European database; and the 95% lower
confidence limit on this UCD10 (UCDL10) of 0.5 μg/g creatinine was considered as a potential point of
departure for the MRL.
The points of departure selected using the three different approaches are similar: 0.5 μg/g creatinine from
the Järup et al. (2000) study (using the European Chemicals Bureau 2007 recalculation), 0.7 μg/g
creatinine from the Uno et al. (2005) benchmark dose analysis, and 0.5 μg/g creatinine from the dose-
response analysis. The third approach was selected for the derivation of the MRL because it uses the
whole dose-response curves from several studies rather than data from a single study.

CADMIUM B-1
APPENDIX B. USER'S GUIDE

Chapter 1
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language. Its intended
audience is the general public, especially people living in the vicinity of a hazardous waste site or
chemical release. If the Public Health Statement were removed from the rest of the document, it would
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The
topics are written in a question and answer format. The answer to each question includes a sentence that
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic,
epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight-
of-evidence discussions for human health end points by addressing the following questions:
1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human
data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic).
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also
considered in this chapter.
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral
routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not
meant to support regulatory action, but to acquaint health professionals with exposure levels at which
adverse health effects are not expected to occur in humans.
CADMIUM B-2
APPENDIX B
MRLs should help physicians and public health officials determine the safety of a community living near
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.
MRLs are based largely on toxicological studies in animals and on reports of human occupational
exposure.
MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2,
"Relevance to Public Health," contains basic information known about the substance. Other sections such
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology. MRLs are derived using a
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA)
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement,
represents the most sensitive human health effect for a given exposure route and duration. ATSDR
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available
for all potential systemic, neurological, and developmental effects. If this information and reliable
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive
species (when information from multiple species is available) with the highest no-observed-adverse-effect
level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor
(UF) of 10 must be employed. Additional uncertainty factors of 10 must be used both for human
variability to protect sensitive subpopulations (people who are most susceptible to the health effects
caused by the substance) and for interspecies variability (extrapolation from animals to humans). In
deriving an MRL, these individual uncertainty factors are multiplied together. The product is then
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used
in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure
(LSE) tables.
Chapter 3
Health Effects
Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure
associated with those effects. These levels cover health effects observed at increasing dose
concentrations and durations, differences in response by species, MRLs to humans for noncancer end
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to
locate data for a specific exposure scenario. The LSE tables and figures should always be used in
conjunction with the text. All entries in these tables and figures represent studies that provide reliable,
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures. Representative
examples of LSE Table 3-1 and Figure 3-1 are shown. The numbers in the left column of the legends
correspond to the numbers in the example table and figure.
CADMIUM B-3
APPENDIX B
LEGEND
See Sample LSE Table 3-1 (page B-6)
(1) Route of Exposure. One of the first considerations when reviewing the toxicity of a substance
using these tables and figures should be the relevant and appropriate route of exposure. Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral,
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes. Not all substances will have data on each
route of exposure and will not, therefore, have all five of the tables and figures.
(2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15–
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.
In this example, an inhalation study of intermediate exposure duration is reported. For quick
reference to health effects occurring from a known length of exposure, locate the applicable
exposure period within the LSE table and figure.
(3) Health Effect. The major categories of health effects included in LSE tables and figures are
death, systemic, immunological, neurological, developmental, reproductive, and cancer.
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.
Systemic effects are further defined in the "System" column of the LSE table (see key number
18).
(4) Key to Figure. Each key number in the LSE table links study information to one or more data
points using the same key number in the corresponding LSE figure. In this example, the study
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL
(also see the two "18r" data points in sample Figure 3-1).
(5) Species. The test species, whether animal or human, are identified in this column. Chapter 2,
"Relevance to Public Health," covers the relevance of animal data to human toxicity and
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent
human doses to derive an MRL.
(6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure
regimens are provided in this column. This permits comparison of NOAELs and LOAELs from
different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation
for 6 hours/day, 5 days/week, for 13 weeks. For a more complete review of the dosing regimen,
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al.
1981).
(7) System. This column further defines the systemic effects. These systems include respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered
in these systems. In the example of key number 18, one systemic effect (respiratory) was
investigated.
(8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the
organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system,
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see
footnote "b").
CADMIUM B-4
APPENDIX B
(9) LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect.
LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help
readers identify the levels of exposure at which adverse health effects first appear and the
gradation of effects with increasing dose. A brief description of the specific end point used to
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm. MRLs are not derived from
Serious LOAELs.
(10) Reference. The complete reference citation is given in Chapter 9 of the profile.
(11) CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in
experimental or epidemiologic studies. CELs are always considered serious effects. The LSE
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing
measurable cancer increases.
(12) Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found
in the footnotes. Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to
derive an MRL of 0.005 ppm.
LEGEND
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13) Exposure Period. The same exposure periods appear as in the LSE table. In this example, health
effects observed within the acute and intermediate exposure periods are illustrated.
(14) Health Effect. These are the categories of health effects for which reliable quantitative data
exists. The same health effects appear in the LSE table.
(15) Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are
graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log
scale "y" axis. Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in
mg/kg/day.
(16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in
the rat upon which an intermediate inhalation exposure MRL is based. The key number 18
corresponds to the entry in the LSE table. The dashed descending arrow indicates the
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17) CEL. Key number 38m is one of three studies for which CELs were derived. The diamond
symbol refers to a CEL for the test species-mouse. The number 38 corresponds to the entry in the
LSE table.
CADMIUM B-5
APPENDIX B
(18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the
cancer dose response curve at low dose levels (q1*).
(19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.
CADMIUM
SAMPLE
1 → Table 3-1. Levels of Significant Exposure to [Chemical x] – Inhalation
LOAEL (effect)
Exposure
Key to frequency/ NOAEL Less serious Serious (ppm)
figurea Species duration System (ppm) (ppm) Reference
2 → INTERMEDIATE EXPOSURE
5 6 7 8 9 10
3 → Systemic ↓ ↓ ↓ ↓ ↓ ↓
b
18 Rat 13 wk Resp 3 10 (hyperplasia)
4 → 5 d/wk Nitschke et al. 1981
6 hr/d
APPENDIX B
CHRONIC EXPOSURE
Cancer 11
↓
38 Rat 18 mo 20 (CEL, multiple Wong et al. 1982

5 d/wk organs)
7 hr/d
39 Rat 89–104 wk 10 (CEL, lung tumors, NTP 1982
5 d/wk nasal tumors)
6 hr/d
40 Mouse 79–103 wk 10 (CEL, lung tumors, NTP 1982
5 d/wk hemangiosarcomas)
6 hr/d
a
12 → The number corresponds to entries in Figure 3-1.
b -3
Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10 ppm; dose adjusted for intermittent exposure and divided
by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).
B-6
CADMIUM B-7
APPENDIX B
CADMIUM B-8
APPENDIX B

CADMIUM C-1
APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS

ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate of an adverse effect
BMDLX 95% lower confidence limit on the BMDX
BMDS Benchmark Dose Software
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor
CADMIUM C-2
APPENDIX C
DOT Department of Transportation

DOT/UN/ Department of Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F1 first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register
FSH follicle stimulating hormone
g gram
GC gas chromatography
gd gestational day
GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization
IRIS Integrated Risk Information System
Kd adsorption ratio
kg kilogram
kkg metric ton
Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill
LDLo lethal dose, low
LDH lactic dehydrogenase
LH luteinizing hormone
LOAEL lowest-observed-adverse-effect level
LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie
CADMIUM C-3
APPENDIX C
MCL maximum contaminant level

MCLG maximum contaminant level goal
MF modifying factor
MFO mixed function oxidase
mg milligram
mL milliliter
mm millimeter
mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System
NLM National Library of Medicine
nm nanometer
nmol nanomole
NOAEL no-observed-adverse-effect level
NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances
CADMIUM C-4
APPENDIX C
OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell
REL recommended exposure level/limit
RfC reference concentration
RfD reference dose
RNA ribonucleic acid
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory
TSCA Toxic Substances Control Act
TWA time-weighted average
UF uncertainty factor
U.S. United States
USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell
WHO World Health Organization
CADMIUM C-5
APPENDIX C
> greater than

≥ greater than or equal to
= equal to
< less than
≤ less than or equal to
% percent
α alpha
β beta
γ gamma
δ delta
μm micrometer
μg microgram
q1 * cancer slope factor
– negative
+ positive
(+) weakly positive result
(–) weakly negative result
CADMIUM C-6
APPENDIX C

CADMIUM D-1
APPENDIX D. INDEX
absorbed dose .................................................................................................................................... 231, 233
adenocarcinoma ........................................................................................................................................ 103
adenocarcinomas ....................................................................................................................... 103, 104, 181
adrenal gland ............................................................................................................................................. 167
adrenals ..................................................................................................................................................... 167
adsorbed ............................................................................................................................................ 280, 291
adsorption.................................................................................................................. 274, 291, 292, 293, 330
aerobic ....................................................................................................................................................... 275
alanine aminotransferase (see ALT) ................................................................................................... 85, 145
ALT (see alanine aminotransferase) ......................................................................................................... 146
ambient air .......................................................................................... 11, 280, 296, 305, 315, 317, 321, 326
anemia ....................................................................................................... 25, 26, 27, 84, 138, 139, 240, 249
aspartate aminotransferase (see AST) ....................................................................................................... 145
AST (see aspartate aminotransferase) ....................................................................................................... 146
bioaccumulation ........................................................................................................................................ 326
bioavailability ........................................................................... 292, 293, 301, 303, 323, 325, 329, 330, 343
bioconcentration factor ............................................................................................................................. 293
biokinetic .......................................................................................................................................... 232, 345
biological half-time ................................................................................................................................... 202
biomarker ..................... 13, 16, 21, 31, 32, 33, 35, 36, 37, 39, 86, 88, 89, 90, 136, 141, 143, 145, 147, 148,
149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 160, 161, 164, 165,
170, 230, 231, 232, 234, 235, 237, 240, 250, 254, 255, 258, 333
blood cell count ........................................................................................................................................... 84
body weight effects ............................................................................................................................. 93, 168
breast milk..................................................................................................................... 6, 228, 259, 319, 326
cancer ........................................ 5, 15, 46, 100, 101, 102, 104, 177, 178, 179, 226, 238, 246, 251, 256, 350
carcinogen ......................................................................................... 5, 13, 15, 100, 102, 104, 251, 256, 350
carcinogenic ................................................ 5, 15, 45, 46, 101, 102, 103, 104, 178, 180, 223, 251, 256, 350
carcinogenicity .......................................................................................................... 100, 102, 104, 251, 350
carcinoma ............................................................................................................ 73, 103, 104, 179, 181, 224
cardiovascular ....................................................................................................................... 82, 83, 136, 181
cardiovascular effects.......................................................................................................................... 82, 136
chromosomal aberrations .......................................................................................................... 184, 187, 252
clearance ........................................... 22, 26, 47, 49, 154, 166, 192, 198, 200, 206, 218, 229, 235, 249, 256
crustaceans ................................................................................................................................................ 301
death ........................................................ 4, 5, 45, 46, 47, 48, 49, 81, 89, 105, 136, 147, 177, 181, 234, 250
deoxyribonucleic acid (see DNA) ..................................................................................................... 186, 190
dermal effects .............................................................................................................................. 93, 167, 182
developmental effects ................................................. 14, 19, 25, 27, 99, 174, 177, 184, 248, 253, 256, 257
DNA (see deoxyribonucleic acid) ....... 81, 176, 184, 185, 186, 187, 188, 189, 190, 220, 231, 245, 252, 259
elimination half-time ................................................................................................................................... 16
endocrine ............................................................................................................................. 97, 167, 224, 225
endocrine effects ....................................................................................................................................... 167
fetus ................................................................................................................................................... 225, 258
follicle stimulating hormone ..................................................................................................................... 170
fractional absorption ......................................................................................................................... 105, 195
gastrointestinal effects ........................................................................................................................ 83, 139
general population............................... 13, 16, 20, 30, 47, 143, 169, 178, 184, 232, 240, 254, 305, 323, 326
genotoxic ..................................................................................................................................... 45, 184, 187
CADMIUM D-2
APPENDIX D
genotoxicity............................................................................................................................... 191, 246, 251

groundwater ................................................................................................................ 11, 280, 288, 298, 349
half-life.............................................................................................................................. 210, 215, 221, 231
hematological effects .................................................................................................................... 13, 84, 139
hematopoietic .................................................................................................................................... 174, 251
hepatic effects ....................................................................................................... 13, 85, 145, 146, 147, 237
hydrolysis .................................................................................................................................................. 146
immune system ......................................................................................................................... 169, 182, 228
immunological ............................................................................................ 13, 26, 45, 94, 95, 169, 182, 254
immunological effects ..................................................................................................... 13, 94, 95, 169, 182
Kow ............................................................................................................................................ 264, 265, 266
LD50................................................................................................................................................... 105, 181
leukemia .............................................................................................................................. 27, 106, 169, 180
menstrual ..................................................................................................................................................... 98
metabolic effects ....................................................................................................................................... 169
micronuclei ............................................................................................................................... 184, 187, 191
milk ................................................................................... 200, 228, 234, 242, 255, 297, 300, 319, 336, 338
mucociliary ..................................................................................... 23, 47, 49, 198, 200, 206, 217, 219, 229
musculoskeletal effects ................................................................................................................. 84, 85, 140
neonatal ..................................................................................................................................... 322, 327, 338
neurobehavioral............................................................................... 14, 19, 99, 100, 175, 225, 227, 253, 254
neurodevelopmental .............................................................................................................. 19, 27, 249, 257
neurological effects ....................................................................................... 95, 96, 169, 170, 184, 227, 237
nuclear ....................................................................................................................................................... 169
ocular effects ............................................................................................................................... 93, 167, 182
odds ratio................................................................................................... 137, 143, 156, 157, 158, 171, 178
partition coefficients ................................................................................................................................. 197
pharmacodynamic ..................................................................................................................................... 203
pharmacokinetic .......................................................................... 16, 22, 23, 43, 81, 203, 204, 205, 225, 345
photolysis .................................................................................................................................................. 103
placenta ............................................................................................. 199, 200, 229, 230, 234, 258, 322, 327
pulmonary fibrosis ...................................................................................................................................... 50
rate constant .............................................................................................................................. 211, 214, 216
renal effects ......................................................... 22, 31, 32, 85, 87, 147, 149, 160, 166, 181, 237, 250, 255
reproductive effects ................................................................. 97, 98, 99, 170, 172, 174, 184, 249, 252, 350
respiratory effects............................................................ 17, 21, 50, 73, 77, 79, 93, 106, 234, 248, 250, 345
retention .................................................... 22, 48, 49, 50, 192, 193, 197, 202, 211, 213, 218, 219, 228, 292
salivation ................................................................................................................................................... 139
sequestered ................................................................................................................................................ 220
solubility ..................................................................................... 12, 22, 45, 49, 50, 192, 218, 256, 275, 294
spermatozoa ...................................................................................................................................... 170, 186
systemic effects ............................................................................................................. 50, 94, 106, 181, 256
T3 ................................................................................................................................................ 51, 107, 183
thyroid ............................................................................................................................................... 155, 167
thyroid stimulating hormone ..................................................................................................................... 167
toxicokinetic.................................................................... 12, 16, 45, 202, 204, 219, 230, 250, 255, 256, 258
tremors .................................................................................................................................................. 17, 96
tumors ............................................................................................... 103, 104, 174, 179, 180, 181, 251, 256
vapor pressure ........................................................................................................................................... 290
volatility .................................................................................................................................................... 192

Cadmium

Uploaded by

Copyright:

Available Formats

Cadmium

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Cadmium

Uploaded by

Copyright:

Available Formats

TOXICOLOGICAL PROFILE FOR

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

This page is intentionally blank.

(A) Examines, summarizes, and interprets available toxicologic information and

Christopher J. Portier, Ph.D.

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Primary Chapters/Sections of Interest

Other Sections of Interest:

ATSDR Information Center

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene

Other Agencies and Organizations

The American College of Occupational and Environmental Medicine (ACOEM) is an association of

Obaid Faroon, Ph.D. DVM

Lisa Ingerman, Ph.D., DABT

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

This page is intentionally blank.

1. Maryka H. Bhattacharyya, Ph.D., Senior Biochemist, Biosciences Division (BIO), Argonne

This page is intentionally blank.

1. PUBLIC HEALTH STATEMENT .......................................................................................................... 1

2. RELEVANCE TO PUBLIC HEALTH ................................................................................................. 11

3. HEALTH EFFECTS .............................................................................................................................. 45

3.2.3 Dermal Exposure ................................................................................................................. 181

4. CHEMICAL AND PHYSICAL INFORMATION .............................................................................. 261

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL .......................................................... 267

6. POTENTIAL FOR HUMAN EXPOSURE ......................................................................................... 277

7. ANALYTICAL METHODS................................................................................................................ 333

8. REGULATIONS, ADVISORIES, AND GUIDELINES..................................................................... 345

9. REFERENCES .................................................................................................................................... 351

10. GLOSSARY ...................................................................................................................................... 425

This page is intentionally blank.

2-2. Estimates of the UCD10 from Environmental Exposure Dose-Response Studies............................... 40

3-1. Levels of Significant Exposure to Cadmium - Inhalation .................................................................. 69

3-2. Levels of Significant Exposure to Cadmium - Oral ......................................................................... 131

3-3. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a

3-4. A Schematic Representation of the Nordberg-Kjellström Model..................................................... 207

3-5. A Schematic Representation of the Shank Model ............................................................................ 212

3-6. Existing Information on Health Effects of Cadmium ....................................................................... 247

6-1. Frequency of NPL Sites with Cadmium Contamination .................................................................. 278

This page is intentionally blank.

2-1. Summary of Human Studies Finding Dose-Response Relationships Between Biomarkers of

3-1. Levels of Significant Exposure to Cadmium - Inhalation .................................................................. 51

3-2. Comparison of Lung Effects Across Intermediate-Duration Inhalation Studies ................................ 78

3-4. Summary of Occupational Exposure Studies Examining Renal Effects ............................................ 87

3-5. Guidelines for Interpreting β2-microglobulin Levels ......................................................................... 91

3-6. Levels of Significant Exposure to Cadmium - Oral ......................................................................... 107

3-7. Summary of Human Studies Examining Renal Effects .................................................................... 149

3-9. Levels of Significant Exposure to Cadmium - Dermal..................................................................... 183

3-10. Genotoxicity of Cadmium In Vivo.................................................................................................. 185

3-11. Genotoxicity of Cadmium In Vitro ................................................................................................. 188

3-14. Ongoing Studies on Cadmium ........................................................................................................ 259

4-1. Chemical Identity of Cadmium and Compounds ............................................................................. 262

5-1. Facilities that Produce, Process, or Use Cadmium ........................................................................... 268

6-10. Ongoing Studies on Cadmium ........................................................................................................ 329

7-3. Ongoing Analytical Methods Studies on Cadmium ......................................................................... 343

8-1. Regulations, Advisories, and Guidelines Applicable to Cadmium .................................................. 347

1. PUBLIC HEALTH STATEMENT

1. PUBLIC HEALTH STATEMENT